haloperidol has been researched along with Dementia Praecox in 2512 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Physically assaultive schizophrenia patients (N=99) were randomly assigned to receive clozapine, olanzapine, or haloperidol in a 12-week double-blind trial." | 9.41 | The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol. ( Czobor, P; Krakowski, M; Tural, U, 2021) |
| "The aim of this double-blind randomized study was to evaluate the response to antipsychotic treatment in schizophrenia patients with predicted high/low risk of nonresponse identified by applying a set of well-established scales and predictors of outcome and to compare efficacy between ziprasidone and haloperidol." | 9.30 | Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. ( Bottlender, R; Jäger, M; Laux, G; Möller, HJ; Musil, R; Obermeier, M; Riedel, M; Schennach, R; Schmauss, M; Spellmann, I, 2019) |
| "This Japanese, multicenter, randomized, double-blind trial, evaluating the efficacy and safety of blonanserin compared with haloperidol in patients with schizophrenia, was previously published by Murasaki in the Japanese language." | 9.30 | Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. ( Harvey, PD; Murasaki, M; Nakamura, H, 2019) |
| " Supplemental treatment with EPUFAs and vitamin E in schizophrenia patients treated with haloperidol is potentially beneficial and a larger independent study appears warranted." | 9.22 | Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol. ( Bošković, M; Grabnar, I; Koprivšek, J; Plesničar, BK; Vovk, T, 2016) |
| "To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year." | 9.22 | Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. ( Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M, 2016) |
| " Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)." | 9.20 | Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 9.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia." | 9.19 | A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. ( Gen, K; Suzuki, H; Takahashi, Y, 2014) |
| "In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate vs haloperidol decanoate did not result in a statistically significant difference in efficacy failure, but was associated with more weight gain and greater increases in serum prolactin, whereas haloperidol decanoate was associated with more akathisia." | 9.19 | Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. ( Buckley, PF; Byerly, M; Dominik, R; Hamer, RM; Lamberti, JS; McEvoy, JP; Ray, N; Rosenheck, RA; Stroup, TS; Swartz, MS; Wilkins, TM, 2014) |
| " Previous studies have demonstrated that IM ziprasidone is efficacious and safe for treatment of agitation in schizophrenia." | 9.17 | Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. ( Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J, 2013) |
| "gov identifier: NCT00395915) aimed to compare clinical efficacy and tolerability of haloperidol versus aripiprazole as combination treatment with clozapine in patients with resistant schizophrenia." | 9.17 | Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. ( Accordini, S; Barbui, C; Cipriani, A; Girlanda, F; Nosè, M; Purgato, M; Tansella, M, 2013) |
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 9.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "Haloperidol or trifluoperazine demonstrated similar efficacy as risperidone or olanzapine for patients with schizophrenia who had failed their first trial with a FGA." | 9.16 | Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. ( Chan, HY; Chen, CH; Chen, JJ; Gau, SS; Hwu, HG, 2012) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 9.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| "We applied 2D-CSI MR spectroscopy in 17 recurrent-episode schizophrenia patients off antipsychotics at baseline and at follow-up after 6 weeks, during which 7 patients were treated with haloperidol (10-16 mg/d) and 10 with risperidone (4-6 mg/d)." | 9.16 | Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients. ( Burmeister, HP; Gussew, A; Langbein, K; Reichenbach, JR; Rzanny, R; Sauer, H; Smesny, S, 2012) |
| "This study assessed the safety and tolerability of sertindole in the long-term treatment of schizophrenia." | 9.16 | Sertindole in the long-term treatment of schizophrenia. ( Azorin, JM; Hale, AS; Lemming, OM; Mæhlum, E, 2012) |
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 9.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 9.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "We conducted a secondary analysis of a completed study of the differential efficacy and side effects of aripiprazole versus haloperidol in early-stage schizophrenia (ESS), a subpopulation of patients which does not include first episode or chronic patients." | 9.15 | Aripiprazole versus haloperidol treatment in early-stage schizophrenia. ( Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M, 2011) |
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 9.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "This multisite study was conducted to compare the efficacy and tolerability of combination treatment with clozapine plus aripiprazole versus combination treatment with clozapine plus haloperidol in patients with schizophrenia who do not have an optimal response to clozapine." | 9.15 | Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. ( Accordini, S; Barbui, C; Cipriani, A; Esposito, E; Girlanda, F; Nosè, M; Purgato, M; Stroup, S; Tansella, M; Veronese, A, 2011) |
| "In this 8-week, multicenter, randomized, parallel-group, open-label, flexible-dose study, patients diagnosed with schizophrenia or schizoaffective disorder were randomized to aripiprazole 15-30 mg/day or haloperidol 10-15 mg/day." | 9.14 | Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. ( Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR, 2009) |
| " The goal of this study was to assess the effects of clozapine and olanzapine in comparison to the first-generation agent haloperidol on these metabolic parameters in aggressive patients with schizophrenia." | 9.14 | Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. ( Citrome, L; Czobor, P; Krakowski, M, 2009) |
| "Patients with refractory schizophrenia were assigned to clozapine (n=85) or haloperidol (n=96) and followed for 3 months." | 9.14 | The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. ( Charney, DS; Cramer, J; Gelernter, J; Krystal, JH; Luo, X; Zuo, L, 2009) |
| " We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole rather than with haloperidol, provides physicians with a solid evidence base to be directly applied in the routine care of patients with schizophrenia." | 9.14 | Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. ( Accordini, S; Artioli, P; Barale, F; Barbui, C; Beneduce, R; Berardi, D; Bertolazzi, G; Biancosino, B; Bisogno, A; Bivi, R; Bogetto, F; Boso, M; Bozzani, A; Bucolo, P; Casale, M; Cascone, L; Ciammella, L; Cicolini, A; Cipresso, G; Cipriani, A; Colombo, P; Dal Santo, B; De Francesco, M; Di Lorenzo, G; Di Munzio, W; Ducci, G; Erlicher, A; Esposito, E; Ferrannini, L; Ferrato, F; Ferro, A; Fragomeno, N; Frova, M; Gardellin, F; Garzotto, N; Giambartolomei, A; Giupponi, G; Grassi, L; Grazian, N; Grecu, L; Guerrini, G; Laddomada, F; Lazzarin, E; Lintas, C; Malchiodi, F; Malvini, L; Marchiaro, L; Marsilio, A; Mauri, MC; Mautone, A; Menchetti, M; Migliorini, G; Mollica, M; Moretti, D; Mulè, S; Nicholau, S; Nosè, F; Nosè, M; Occhionero, G; Pacilli, AM; Parise, VF; Pecchioli, S; Percudani, M; Piantato, E; Piazza, C; Pontarollo, F; Pycha, R; Quartesan, R; Rillosi, L; Risso, F; Rizzo, R; Rocca, P; Roma, S; Rossattini, M; Rossi, G; Sala, A; Santilli, C; Saraò, G; Sarnicola, A; Sartore, F; Scarone, S; Sciarma, T; Siracusano, A; Strizzolo, S; Tansella, M; Targa, G; Tasser, A; Tomasi, R; Travaglini, R; Veronese, A; Ziero, S, 2009) |
| "To determine the efficacy and safety of three doses of blonanserin compared with placebo and haloperidol in patients with acute-phase schizophrenia." | 9.14 | The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. ( Garcia, E; Nakamura, H; Peris, F; Robert, M; Sato, N; Terazawa, Y, 2009) |
| "This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS)." | 9.14 | Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. ( Bates, JA; Guo, Z; Kan, HJ; Kane, JM; Kim, E; Pikalov, A; Whitehead, R, 2009) |
| "To better understand the efficacy and tolerability of atypical antipsychotics among racial groups, we reviewed data from four short-term (4-6 weeks), fixed-dose, placebo-controlled trials of ziprasidone for black, white, and overall populations of patients with schizophrenia." | 9.14 | Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. ( Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M, 2009) |
| "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features." | 9.14 | Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010) |
| "In patients with early-episode schizophrenia, aripiprazole demonstrates greater improvement than haloperidol on PANSS items related to social functioning." | 9.14 | Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. ( Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD, 2010) |
| "To evaluate the therapeutic efficacy and tolerability of flunarizine compared to haloperidol in outpatients with stable and chronic DSM-IV-defined schizophrenia and schizoaffective disorder." | 9.13 | Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ( Bisol, LW; Borba, DL; Bressan, RA; Brunstein, MG; Daltio, CS; de Oliveira, RV; de Souza, SE; Lara, DR; Ottoni, GL; Paz, GE; Ramos, FL, 2008) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 9.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 9.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "This multicentre, parallel-group study compared the efficacy and tolerability of ziprasidone and chlorpromazine in treatment-resistant schizophrenia (at least three treatment periods of at least 6 weeks each with two or more antipsychotic agents during the past 5 years without significant response) that was unresponsive to 6 weeks of open-label haloperidol ( | 9.12 | Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. ( Giller, E; Kane, JM; Khanna, S; Rajadhyaksha, S, 2006) |
| "Thirty-one subjects with cocaine dependence and schizophrenia were randomized to olanzapine or haloperidol, underwent a cue-exposure procedure, and completed psychiatric and substance abuse ratings." | 9.12 | The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. ( Kaune, M; Losonczy, MF; Smelson, DA; Steinberg, ML; Williams, J; Ziedonis, D, 2006) |
| "A total of 572 inpatients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in a randomized, rater-blinded, 6-week, open-label study comparing sequential intramuscular and oral ziprasidone with haloperidol." | 9.12 | Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. ( Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J, 2006) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 9.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder." | 9.12 | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006) |
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 9.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "Intramuscular aripiprazole is effective in patients with acute agitation associated with schizophrenia, comparable to IM haloperidol, and enables convenient transfer to oral aripiprazole therapy." | 9.12 | Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. ( Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E, 2006) |
| "To determine if any of five second-generation antipsychotics or haloperidol is more effective in treating acutely ill patients with schizophrenia, schizoaffective disorder or schizophreniform disorder." | 9.12 | Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. ( Charles, R; Hasan, SM; Joseph, MD; McCue, RE; Orendain, G; Urcuyo, L; Waheed, R, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 9.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "Thirty-five patients with DSM-IV-TR schizophrenia and predominant negative symptoms were randomly assigned in a 12-week double-blind study to either olanzapine (15-20 mg/day) or haloperidol (15-20 mg/day)." | 9.12 | A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. ( Abad, MT; Iskander, A; Khan, A; Lindenmayer, JP; Parker, B, 2007) |
| "To contrast the effect of a typical antipsychotic (haloperidol) and an atypical antipsychotic (olanzapine) on neurocognitive functioning in schizophrenia when learning and practice (LP) effects are controlled." | 9.12 | Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol. ( Boulay, LJ; Bourget, D; Habib, R; Labelle, A; Milin, R; Robertson, S; Tessier, P; Tombaugh, T, 2007) |
| "This study aimed to assess the cost effectiveness of ziprasidone versus haloperidol in sequential intramuscular (IM)/oral treatment of patients with exacerbation of schizophrenia in Spain." | 9.12 | Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial. ( Cañas, F; Díaz, S; Pérez-Solá, V; Rejas, J, 2007) |
| "Fifty-six patients with hyperprolactinemia taking haloperidol were enrolled." | 9.12 | Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. ( Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH, 2007) |
| "To compare the impact of sertindole and haloperidol on cognitive function in patients suffering from schizophrenia." | 9.12 | Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. ( Gallhofer, B; Jaanson, P; Krieger, S; Lis, S; Mittoux, A; Tanghøj, P, 2007) |
| " Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested." | 9.12 | Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007) |
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 9.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 9.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| "We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia." | 9.11 | Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004) |
| "From April 1996 to August 1997, seventy-eight inpatients with a diagnosis of chronic schizophrenia (DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol." | 9.11 | Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2004) |
| "The objective of this study was to estimate the effects of intramuscular haloperidol and lorazepam on the QT interval in volunteers with schizophrenia." | 9.11 | Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. ( Burke, M; Flockhart, D; Gorski, JC; Greenblatt, DJ; Harvey, AT; Preskorn, SH; Werder, S, 2004) |
| "To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. ( Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J, 2005) |
| "Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks." | 9.11 | Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. ( Glick, ID; Marder, SR, 2005) |
| "As monotherapy, both olanzapine and risperidone were superior to haloperidol and clozapine in reducing aggression." | 9.11 | Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). ( Bitter, I; Czobor, P; Dossenbach, M; Volavka, J, 2005) |
| "The primary aim of this study was to compare the effectiveness of 12 months' treatment with olanzapine, risperidone, quetiapine, or haloperidol in preventing relapse of schizophrenia." | 9.11 | Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Aguilar, J; Arango-Dávila, C; Assunção, S; Caro, O; Dossenbach, M; Landa, E; Leadbetter, J; Silva Ibarra, H, 2005) |
| "To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol." | 9.11 | Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. ( Green, AI; Gu, H; Gur, RE; Kahn, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Sharma, T; Strakowski, SM; Tohen, MF; Tollefson, GD; Zipursky, RB, 2005) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 9.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| "We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked." | 9.10 | Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. ( Kamaraju, L; McEvoy, JP; Nelson, L; Wilson, W; Yang, YK, 2002) |
| " haloperidol for elderly chronic schizophrenia patients." | 9.10 | Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. ( Barak, Y; Mirecki, I; Shamir, E; Toren, P; Weizman, R; Zemishlani, H, 2002) |
| "The results of this study present a novel application for potassium channel openers/activators in the neuropsychiatric disorders and diazoxide may be an effective adjuvant agent in the management of schizophrenia." | 9.10 | Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. ( Akhondzadeh, S; Amini-Nooshabadi, H; Kamalipour, A; Mirsepassi, GR; Moin, M; Mojtahedzadeh, V, 2002) |
| "Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7." | 9.10 | Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "Thirty-nine subjects with early phase schizophrenia were randomly assigned to double blind treatment with haloperidol, risperidone, or olanzapine." | 9.10 | Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. ( Lindborg, SR; Purdon, SE; Stip, E; Woodward, N, 2003) |
| "This was a 2-year, randomized, double-blind comparison of 6 mg of risperidone versus haloperidol in 63 patients with stabilized DSM-IV schizophrenia." | 9.10 | Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. ( Blair, KE; Glynn, SM; Liberman, RP; Marder, SR; Mintz, J; Ross, D; Widmark, C; Wirshing, DA; Wirshing, WC, 2003) |
| "44 patients with chronic DSM-IV schizophrenia were treated with clozapine or haloperidol decanoate in an open prospective 6-month trial." | 9.10 | The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. ( Mester, R; Shabash, E; Sheitman, B; Spivak, B; Weizman, A, 2003) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 9.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "These results suggest that there is not a significant differential effect of olanzapine and haloperidol on the P50 sensory gating index in schizophrenia." | 9.10 | Olanzapine effects on auditory sensory gating in schizophrenia. ( Arango, C; Buchanan, RW; Summerfelt, A, 2003) |
| "Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia." | 9.10 | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. ( Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003) |
| "To compare the six-week clinical response and safety profile of schizophrenia patients, age > or =60 years, receiving olanzapine (OLZ) vs haloperidol (HAL) in a double blind, randomized trial." | 9.10 | Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. ( Breier, A; Bymaster, FP; Dossenbach, M; Gilmore, JA; Golshan, S; Jeste, D; Kaiser, CJ; Kennedy, JS; Kinon, BJ; Maguire, GA; Sanger, T; Tollefson, G, 2003) |
| "To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia." | 9.10 | Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003) |
| " haloperidol during the first 24 hours of treatment of acute schizophrenia." | 9.10 | Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. ( Alaka, K; Battaglia, J; Birkett, M; Bitter, I; Breier, A; Chouinard, G; Ferchland-Howe, I; Jones, B; Lindborg, SR; Meehan, K; Morris, PL; Pickard, A; Roth, J; Taylor, CC; Wright, P, 2003) |
| "Randomized controlled trial comparing risperidone and haloperidol regarding relapse in patients with schizophrenia treated with flexible doses during one year." | 9.10 | Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. ( de Sena, EP; Miranda-Scippa, A; Oliveira, IR; Quarantini, Lde C; Santos-Jesus, R, 2003) |
| " We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older, conventional neuroleptic drug, haloperidol, in terms of the rate of relapse in patients with schizophrenia and schizoaffective disorder." | 9.10 | A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. ( Brenner, R; Csernansky, JG; Mahmoud, R, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "A multicenter, double-blind study was conducted to determine rates of symptomatic exacerbation and adverse effects in 105 outpatients with schizophrenia randomly assigned to four different fixed doses of haloperidol decanoate and treated for 1 year or until relapse." | 9.10 | A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. ( Brauzer, B; Casey, D; Conley, R; Davis, JM; Kane, JM; Marder, S; Mintz, J; Schooler, N, 2002) |
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 9.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| "The association of clinical characteristics with a sustained response was investigated in 37 partially treatment-refractory outpatients with a DSM-III-R diagnosis of chronic schizophrenia who had been assigned to clozapine treatment in a double-blind, haloperidol-controlled, long-term (29-week) study of clozapine." | 9.10 | Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. ( Kane, JM; Marder, SR; McMeniman, M; Schooler, NR; Umbricht, DS; Wirshing, DA; Wirshing, WC, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 9.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 9.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| " This study compared ziprasidone with the conventional antipsychotic haloperidol in outpatients with stable schizophrenia." | 9.10 | A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. ( Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A, 2002) |
| "This study compared the effect of clozapine and haloperidol on positive and negative symptoms of schizophrenia and in patients with high levels of negative symptoms or the deficit syndrome." | 9.09 | Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Dunn, L; Peszke, M; Rosenheck, R; Thomas, J; Xu, W, 1999) |
| "Cyproheptadine is a relatively safe compound and may be of therapeutic benefit in treating negative symptoms of schizophrenia in combination with typical neuroleptics." | 9.09 | Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. ( Akhondzadeh, S; Amini-Nooshabadi, H; Davari-Ashtiani, R; Mohammadi, MR, 1999) |
| "Data from a 15-site randomized clinical trial were used to compare clozapine with haloperidol in hospitalized Veterans Affairs patients with refractory schizophrenia (n = 423)." | 9.09 | Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Allan, E; Charney, D; Cramer, J; Erdos, J; Frisman, LK; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 1999) |
| "The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia." | 9.09 | Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1999) |
| " A 6-week, double-blind randomized multicenter trial, with a long-term extension, was conducted to evaluate the clinical efficacy and QOL of olanzapine and haloperidol in treating schizophrenia and other psychotic disorders." | 9.09 | Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. ( Beasley, CM; Ganoczy, D; Genduso, LA; Hamilton, SH; Revicki, DA, 1999) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 9.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "We utilize data from a large, double-blind, randomized clinical trial of treatment for schizophrenia to compare the effect of therapy with the second generation antipsychotic olanzapine versus therapy with the conventional agent haloperidol on the perceived functioning and well-being of patients over 1 year as measured by the Medical Outcome Study Short Form (SF-36)." | 9.09 | Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. ( Dulisse, BK; Gibson, PJ; Johnstone, BM; Loosbrock, DL; Tunis, SL, 1999) |
| " The ketamine challenge study in schizophrenia subjects is at the vortex of the current debate." | 9.09 | The schizophrenia ketamine challenge study debate. ( Carpenter, WT, 1999) |
| "The purpose of this study was to compare, from the payor perspective, the clinical and economic outcomes of olanzapine to those of haloperidol for the treatment of schizophrenia." | 9.09 | Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. ( Edgell, ET; Genduso, LA; Hamilton, SH; Revicki, DA; Tollefson, G, 1999) |
| " A double-blind trial compared clozapine and haloperidol in patients with schizophrenia who were refractory to conventional antipsychotic medication and were hospitalized for 30 to 364 days at 15 Veteran Affairs medical centers during the year before study entry." | 9.09 | How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. ( Charney, D; Cramer, J; Evans, D; Henderson, W; Herz, L; Rosenheck, R; Thomas, J; Xu, W, 1999) |
| "To help determine whether sustained attention deficits as measured with the Continuous Performance Test (CPT) are stable vulnerability indicators of schizophrenia, we compared the CPT performance of schizophrenic patients before and after treatment with risperidone or haloperidol." | 9.09 | Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. ( Chang, CJ; Chen, WJ; Lin, HN; Liu, SK, 2000) |
| "This international, 6-week, multicentre, double-blind, randomized, parallel-group trial compared quetiapine with haloperidol (455 mg and 8 mg mean total daily doses, respectively) in 448 hospitalized patients with acute exacerbation of chronic or subchronic schizophrenia (DSM-III-R), in order to establish their equivalence in terms of efficacy, and the nature of their tolerability profiles, especially in terms of extrapyramidal symptoms (EPS) and serum prolactin levels." | 9.09 | A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. ( Copolov, DL; Kowalcyk, B; Link, CG, 2000) |
| "Dipyridamole may be of therapeutic benefit in treating schizophrenia in combination with neuroleptics." | 9.09 | Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. ( Akhondzadeh, S; Jamilian, H; Kamalipour, A; Shabestari, O; Shasavand, E, 2000) |
| "The primary aim of this study was to compare functional outcomes between patients with schizophrenia treated with olanzapine or haloperidol in Europe." | 9.09 | Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. ( Breier, A; Edgell, ET; Hamilton, SH; Revicki, DA, 2000) |
| "This study compares the effect of clozapine and haloperidol and identifies other factors related to family burden as experienced by relatives of patients with refractory schizophrenia (DSM-III-R)." | 9.09 | Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Henderson, W; Jurgis, G; Perlick, D; Rosenheck, R; Thomas, J; Xu, W, 2000) |
| "In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months." | 9.09 | Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). ( Bonhomme, D; Carrière, P; Lempérière, T, 2000) |
| "The purpose of the study was to evaluate the effect of the classic antipsychotic haloperidol plus extract of ginkgo biloba (EGb) on treatment-resistant chronic schizophrenia and on blood superoxide dismutase (SOD) levels." | 9.09 | The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. ( Su, JM; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "Previously, a double-blind, 6-week, parallel-group trial compared the therapeutic profiles of olanzapine (5-20 mg/day; N = 1,336) and haloperidol (5-20 mg/day; N = 660) in 1996 patients with DSM-III-R schizophrenia (83." | 9.09 | Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. ( Crawford, AM; Gomez, JC, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "After a 48-hour washout period, 25 patients with schizophrenia were randomly assigned to double-blind treatment with quetiapine or haloperidol for 6 months and evaluated with rating scales for psychotic symptoms, mood and extrapyramidal side effects, as well as standardized neuropsychological measures sensitive to 6 cognitive domains: fine motor skill, attention span, verbal reasoning and fluency, visuospatial construction and fluency, executive skills and visuomotor tracking, and immediate recall of verbal and nonverbal materials." | 9.09 | Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. ( Labelle, A; Lit, W; Malla, A; Purdon, SE, 2001) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 9.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Atypical antipsychotics, such as risperidone, have been shown to be more effective for the treatment of the symptoms of schizophrenia and have a greater beneficial effect on neurocognition compared to the conventional antipsychotics." | 9.09 | Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. ( Andreasen, NC; Boles Ponto, LL; Hichwa, RD; Miller, DD; O'Leary, DS; Watkins, GL, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 9.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 9.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "Despite the demonstrated efficacy of clozapine in severely refractory schizophrenia, questions remain regarding its efficacy for primary negative symptoms, comparison with a moderate dose of a first-generation antipsychotic, and adverse effects during a longer-term trial." | 9.09 | Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. ( Baker, RW; Borenstein, M; Ganguli, R; Kane, JM; Marder, SR; McMeniman, M; Safferman, A; Schooler, NR; Umbricht, D; Wirshing, DA; Wirshing, WC, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 9.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "In 54 patients with chronic refractory schizophrenia, 27 were treated with haloperidol plus EGb (group 1), and the rest received haloperidol plus placebo (group 2)." | 9.09 | The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. ( Cui, Y; Guan, Z; Liu, J; Nan, Z; Shen, Y; Su, J; Zhang, P; Zhang, X; Zhou, D, 1999) |
| "One hundred nine patients meeting DSM-III-R criteria for schizophrenia completed a double-blind, placebo-controlled, parallel-group study of EGb plus haloperidol." | 9.09 | A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. ( Cao, LY; Su, JM; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 9.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "Plasma haloperidol levels between 5 and 11 ng/mL may be clinically optimal for acutely exacerbated schizophrenia, but the evidence for this therapeutic window has been inconsistent." | 9.08 | Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. ( Cooper, TB; Czobor, P; Meisner, M; Volavka, J, 1995) |
| "Double-blind haloperidol was administered during two consecutive 3-week periods to 65 patients with acutely exacerbating schizophrenia or schizoaffective disorder." | 9.08 | Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. ( Cooper, TB; Czobor, P; Meisner, M; Volavka, J, 1996) |
| "The atypical antipsychotic zotepine was compared to haloperidol in 126 patients suffering from acute exacerbation of schizophrenia (DSM-III-R) in a randomized, double-blind study." | 9.08 | A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. ( Dollfus, S; Kelly, F; Leutenegger, E; Petit, M; Raniwalla, J; Tweed, J, 1996) |
| "Patients were investigated to gain more insight into the incidence and time course of clozapine induced weight gain (n = 81) and to compare weight gain in patients treated with clozapine (n = 31) with that of patients treated with standard antipsychotics (haloperidol, n = 11)." | 9.08 | Weight gain induced by clozapine. ( Fleischhacker, WW; Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H, 1995) |
| "Treatment-emergent eosinophilia occurred frequently in both haloperidol- and clozapine-treated patients." | 9.08 | Predictive value of eosinophilia for neutropenia during clozapine treatment. ( Ames, D; Baker, RW; Carter, J; Kane, JM; Marder, SR; Schooler, NR; Sun, AB; Umbricht, DS; Wirshing, WC, 1996) |
| "Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone." | 9.08 | Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. ( Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H, 1997) |
| "This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia." | 9.08 | Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997) |
| "In a large, multicenter, double-blind study of the effect of haloperidol and the atypical antipsychotic remoxipride on improvement of negative symptoms in schizophrenia, quality of life was also assessed using a modified version of the Sickness Impact Profile (SIP)." | 9.08 | Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. ( Angus, C; Awad, AG; Lapierre, YD; Rylander, A, 1997) |
| "For patients with refractory schizophrenia and high levels of hospital use, clozapine was somewhat more effective than haloperidol and had fewer side effects and similar overall costs." | 9.08 | A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Frisman, L; Fye, C; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 1997) |
| " This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia." | 9.08 | Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997) |
| "In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo." | 9.08 | The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 9.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 9.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| "Sertindole is an atypical antipsychotic that is efficacious in schizophrenia and is associated infrequently with extrapyramidal symptoms (EPS)." | 9.08 | Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. ( Daniel, DG; Mack, RJ; McCarthy, BG; Wozniak, P, 1998) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 9.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| "This study was conducted to determine whether the addition of naltrexone to ongoing neuroleptic treatment would facilitate the reduction in positive or negative symptoms in patients with schizophrenia." | 9.08 | Naltrexone augmentation of neuroleptics in schizophrenia. ( Charney, DS; Glazer, WM; Heninger, GR; Krystal, JH; Petrakis, IL; Price, LH; Sernyak, MJ; Woods, SW, 1998) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 9.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| "Subjects participated in a 12-month double-blind random-assignment trial comparing clozapine and haloperidol in patients hospitalized 30 to 364 days for refractory schizophrenia at 15 Department of Veterans Affairs medical centers." | 9.08 | Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Fontana, A; Henderson, W; Peters, J; Rosenheck, R; Tekell, J; Thomas, J; Xu, W, 1998) |
| "Data were from a 15-site randomized clinical trial comparing clozapine and haloperidol in hospitalized patients with refractory schizophrenia (n = 423)." | 9.08 | Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Crayton, J; Lawson, W; Rosenheck, R; Stolar, M; Thomas, J; Xu, W, 1998) |
| "We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol." | 9.08 | A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. ( Kim, YK; Lee, MS; Lee, SK; Suh, KY, 1998) |
| " Patients were recruited from a haloperidol-controlled, double-blind treatment study of clozapine in chronic schizophrenia." | 9.08 | Effects of clozapine on auditory event-related potentials in schizophrenia. ( Bates, J; Javitt, D; Kane, J; Lieberman, J; Novak, G; Pollack, S; Umbricht, D, 1998) |
| "A 12-month double-blind trial compared clozapine (n = 205) and haloperidol (n = 218) in the treatment of refractory schizophrenia." | 9.08 | Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Douyon, R; Grabowski, J; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 1998) |
| "Clinical improvement (20% reduction in total scores on the Positive and Negative Syndrome Scale for Schizophrenia) at the study end point was shown by 35% of the patients receiving 2 mg of risperidone, 57% receiving 6 mg, 40% receiving 10 mg, and 51% receiving 16 mg; and by 30% receiving haloperidol and 22% receiving placebo." | 9.07 | Risperidone in the treatment of schizophrenia. ( Marder, SR; Meibach, RC, 1994) |
| "This double-blind placebo controlled, parallel design clinical trial compared the therapeutic effects of the addition of lithium or placebo to haloperidol in 21 seriously ill state hospital patients with DSM-III-R schizophrenia, who did not have concurrent affective disorders and who had not responded to previous trials of conventional antipsychotic medication." | 9.07 | Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. ( Wilson, WH, 1993) |
| "Plasma clozapine and haloperidol concentrations were studied in adolescents being treated for childhood-onset schizophrenia." | 9.07 | Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. ( Albus, KE; Frazier, JA; Gordon, CT; Grothe, DR; McKenna, K; Piscitelli, SC; Rapoport, JL, 1994) |
| "Haloperidol levels in blood were measured in 55 acutely psychotic inpatients with schizophrenia, who were randomly assigned to three fixed doses of oral haloperidol." | 9.07 | Blood levels of haloperidol and clinical outcome in schizophrenia. ( Borenstein, M; Cooper, T; Doddi, S; Karajgi, B; Rifkin, A, 1994) |
| "Outpatients with schizophrenia who had histories of partial response to conventional neuroleptics and who had not responded to a prospective 6-week trial of fluphenazine participated in a 10-week, double-blind, parallel-groups comparison of clozapine and haloperidol." | 9.07 | Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. ( Breier, A; Buchanan, RW; Carpenter, WT; Davis, OR; Irish, D; Kirkpatrick, B; Summerfelt, A, 1994) |
| "Twenty-eight acutely psychotic patients with schizophrenia who were admitted to an emergency psychiatric service were randomly assigned to treatment with either haloperidol and alprazolam or haloperidol with placebo under double-blind conditions." | 9.07 | Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. ( Barbee, JG; Freed, CR; Mancuso, DM; Todorov, AA, 1992) |
| " Ninety-one patients with acute schizophrenia received either raclopride 2-8 mg twice daily or haloperidol 5-20 mg twice daily for 4 weeks." | 9.07 | A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. The British Isles Raclopride Study Group. ( , 1992) |
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 9.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| "After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3." | 9.07 | Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 9.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| "Eighty-seven newly admitted inpatients with schizophrenia were randomized to receive 10, 30, or 80 mg/d of oral haloperidol." | 9.07 | Dosage of haloperidol for schizophrenia. ( Borenstein, M; Doddi, S; Karajgi, B; Rifkin, A; Wachspress, M, 1991) |
| "Seventy-two patients fulfilling the DSM-III criteria for schizophrenia and schizophreniform psychosis were admitted to a multicentre, double-blind controlled study to evaluate the efficacy and safety of remoxipride in comparison to haloperidol." | 9.06 | A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. ( Andersen, J; Birket-Smith, M; Fensbo, C; Fogh, M; Hansen, NR; Kristensen, M; Kørner, A; Møller-Nielsen, EM; Ostergaard, P; Thiesen, S, 1990) |
| "Seventy-one patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder." | 9.06 | A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. ( den Boer, JA; Huisman, J; Ohrvik, J; Ravelli, DP; Verhoeven, WM; Westenberg, HG, 1990) |
| "The efficacy and safety of remoxipride in the treatment of schizophrenia were compared with those of haloperidol in a multicentre double-blind 6-week study which was randomized with a parallel group design and was preceded by a washout period." | 9.06 | Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. ( Chanas, A; Deo, R; Edwards, JG; Levine, S; Mitchell, M; Plant, I; Rastogi, SC; Soni, S, 1990) |
| "Ninety-two patients with schizophrenia were included in a double-blind multicentre parallel-group trial comparing remoxipride and haloperidol." | 9.06 | Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. ( Ahlfors, UG; Appelberg, B; Hagert, U; Harma, P; Katila, H; Mahlanen, A; Mehtonen, OP; Naukkarinen, H; Outakoski, J; Rimön, R, 1990) |
| "The efficacy of the use of moditen-depo and haloperidol decanoate as preventive anti-recurrence+ therapy was studied and compared in 2 groups of patients suffering from attack-like schizophrenia with frequent exacerbations." | 9.06 | [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. ( Kalugina, LI; Kopeĭko, GI; Kravchenko, NE; Mirzoian, MG; Ushakov, IuV, 1990) |
| "The impact of haloperidol treatment on the Wechsler Adult Intelligence Scale (WAIS) and the Thought Disorder Index was investigated in a group of 19 patients with schizophrenia tested both before and after 26 days of treatment with haloperidol." | 9.06 | The effects of haloperidol on thought disorder and IQ in schizophrenia. ( Gold, JM; Hurt, SW, 1990) |
| "Twenty-five inpatients with acute exacerbations of schizophrenia (by Research Diagnostic Criteria) or schizoaffective disorder underwent a prospective haloperidol dosing procedure and were assigned fixed doses chosen to yield a distribution of haloperidol plasma levels above and below a hypothesized upper therapeutic limit of 18 ng/ml." | 9.06 | Haloperidol plasma levels and acute clinical change in schizophrenia. ( Coryell, W; Kelly, M; Miller, DD; Perry, PJ, 1990) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 9.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "The antipsychotic effects of verapamil were tested in a double-blind, placebo-controlled, randomized study in 18 patients who met Research Diagnostic Criteria for acute schizophrenia." | 9.06 | Antipsychotic effects of verapamil in schizophrenia. ( Price, WA, 1987) |
| "The efficacy and safety of timiperone, a new butyrophenone derivative, in schizophrenia as compared with haloperidol were assessed in a multi-clinic double-blind controlled study in a total of 206 patients." | 9.05 | A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique. ( Itoh, H; Kariya, T; Mori, A; Murasaki, M; Shimazono, Y; Sugano, K; Toru, M; Yamashita, I, 1983) |
| "Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia." | 9.05 | Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. ( Dubini, A; Freeman, HL; Levine, S; Silverstone, T, 1984) |
| "To review the effects of haloperidol discontinuation in people with schizophrenia who are stable on haloperidol." | 9.01 | Haloperidol discontinuation for people with schizophrenia. ( AbouDamaah, A; Aboudamaah, S; AlMounayer, N; Diaa Aldeen, MR; Essali, A; Marwa, ME; Turkmani, K, 2019) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 8.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "A systematic literature survey (Cochrane Schizophrenia Group trial register) was applied to identify all RCTs that compared oral haloperidol with another oral FGA in schizophrenia." | 8.93 | Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. ( Dold, M; Kasper, S; Leucht, S; Li, C; Samara, MT; Tardy, M, 2016) |
| "To examine whether haloperidol alone, administered orally, intramuscularly or intravenously, is an effective treatment for long-term/persistent aggression in psychosis." | 8.93 | Haloperidol for long-term aggression in psychosis. ( Khushu, A; Powney, MJ, 2016) |
| "To compare the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotics in schizophrenia and schizophrenia-like psychosis." | 8.91 | Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. ( Dold, M; Leucht, S; Li, C; Samara, MT; Tardy, M, 2015) |
| "To review the effects in clinical response of haloperidol and low-potency antipsychotics for people with schizophrenia." | 8.90 | Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Kissling, W; Leucht, S; Tardy, M, 2014) |
| "To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia." | 8.89 | Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Donnelly, L; Rathbone, J, 2013) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo." | 8.89 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Bergman, H; Irving, CB; Lawrie, S, 2013) |
| "To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar conditions." | 8.88 | Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. ( Gibson, RC; Gunadasa, S; Jayakody, K; Kumar, A, 2012) |
| "The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo." | 8.86 | Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. ( Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV, 2010) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 8.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| "Pooled data from two 52-week, randomized, double-blind, multicenter, comparative trials of aripiprazole and haloperidol in acutely ill patients with schizophrenia were analyzed." | 8.84 | Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. ( Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W, 2007) |
| "To compare the effects of haloperidol and chlorpromazine for people with schizophrenia and schizophrenia-like psychoses." | 8.84 | Haloperidol versus chlorpromazine for schizophrenia. ( Chua, L; Kane, J; Kitzmantel, M; Leucht, C; Leucht, S, 2008) |
| "Consistent with prior research, haloperidol-treated patients with bipolar disorder appeared to be more vulnerable to the development of EPS than those with schizophrenia." | 8.83 | Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. ( Berg, PH; Briggs, SD; Cavazzoni, PA; Kane, JM; Kryzhanovskaya, LA; Roddy, TE; Tohen, M, 2006) |
| "To determine the doses of haloperidol as a comparator drug in randomized controlled trials (RCTs) with atypical antipsychotics in patients with schizophrenia and to compare these doses with the officially recommended doses for haloperidol in the United States and the United Kingdom." | 8.83 | Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. ( Egberts, AC; Heerdink, ER; Hugenholtz, GW; Meijer, WE; Nolen, WA; Stolker, JJ, 2006) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared to placebo." | 8.83 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Joy, CB; Lawrie, SM, 2006) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 8.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| "A total of 1476 patients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in 5 short-term, double-blind studies comparing aripiprazole with placebo; 3 of these studies also included a comparison with haloperidol." | 8.82 | Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. ( Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J, 2005) |
| "The primary goal of this review is to determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia." | 8.81 | Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Hamill, KM; Marti, J; Roque, M; Waraich, PS, 2002) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared to placebo." | 8.81 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Joy, CB; Lawrie, SM, 2001) |
| "Combined data on efficacy were available from 12 double-blind short-term (maximum 8 weeks) trials comparing risperidone and other antipsychotics in patients with chronic schizophrenia." | 8.81 | Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. ( Glick, ID; Lemmens, P; Vester-Blokland, E, 2001) |
| "Haloperidol is the most commonly used antipsychotic drug in the therapy of acute schizophrenia." | 8.80 | The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. ( Brosz, M; Meyer, FP; Ulrich, S; Wurthmann, C, 1998) |
| "To assess the effects of haloperidol decanoate versus oral anti-psychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes." | 8.80 | Depot haloperidol decanoate for schizophrenia. ( David, A; Quraishi, S, 2000) |
| "The effects of olanzapine, risperidone, and haloperidol on PRL were assessed in patients with schizophrenia or related psychoses participating in 3 double-blind clinical trials: (1) a 6-week acute trial comparing olanzapine 5 to 20 mg/d (n = 1,336) and haloperidol 5 to 20 mg/d (n = 660), with a 1-year, open-label olanzapine extension for responders; (2) a 54-week study comparing olanzapine 5 to 20 mg/d (n = 21), risperidone 4 to 10 mg/d (n = 21), and haloperidol 5 to 20 mg/d (n = 23) in early illness; and (3) a 28-week study comparing olanzapine 10 to 20 mg/d (n = 172) and risperidone 4 to 12 mg/d (n = 167)." | 8.80 | The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. ( Breier, A; David, SR; Kinon, BJ; Taylor, CC, 2000) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 8.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| "Our results highlight the importance of using both pharmacokinetic and pharmacodynamic genetic markers for predicting haloperidol treatment response to personalize schizophrenia spectrum disorders treatment." | 8.31 | The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders. ( Bure, IV; Kibitov, AA; Kibitov, AO; Kiryanova, EM; Salnikova, LI; Shmukler, AB, 2023) |
| "This study included 10 patients with schizophrenia who were originally treated with haloperidol alone." | 8.31 | Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study. ( Arai, Y; Kuraishi, K; Murata, S; Nakajima, Y; Sasayama, D; Tsuchida, M; Usuda, N; Washizuka, S, 2023) |
| "This study aimed to evaluate Haloperidol's (Hal) effects on the behavioral, neurotrophic factors, and epigenetic parameters in an animal model of schizophrenia (SCZ) induced by ketamine (Ket)." | 8.31 | Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine. ( da Rosa, RT; Dal-Pont, GC; Daminelli, T; Fries, GR; Mastella, GA; Quevedo, J; Valvassori, SS; Varela, RB; Zugno, AI, 2023) |
| "To study plasma adipokines (adiponectin, leptin, adipsin) in patients with the first episode of schizophrenia treated with haloperidol and risperidone." | 8.02 | [Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone]. ( Govorin, NV; Ozornin, AS; Sakharov, AV; Tereshkov, PP, 2021) |
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 8.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| "The present study aims to evaluate the effects of haloperidol, an important first-generation antipsychotic, on the antioxidant system parameters in the brain of animals subjected to a model of schizophrenia induced by ketamine." | 8.02 | Haloperidol elicits oxidative damage in the brain of rats submitted to the ketamine-induced model of schizophrenia. ( Aguiar-Geraldo, JM; Araujo, SL; Cararo, JH; Mastella, GA; Menegas, S; Possamai-Della, T; Quevedo, J; Valvassori, SS; Zugno, AI, 2021) |
| "Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult phenotype relevant to schizophrenia, including positive- and negative-like symptoms, cognitive deficits, dopaminergic dysfunction, structural and functional abnormalities." | 7.96 | Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. ( Babinska, Z; Bucolo, C; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Fedotova, J; Giurdanella, G; Iannotti, FA; Kratka, L; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Platania, CBM; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2020) |
| "Asenapine maleate (AM) is an atypical antipsychotic that, unlike many other antipsychotics, shows some efficacy in treating cognitive dysfunction in schizophrenia." | 7.91 | Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia. ( Foute Nelong, T; Manduca, JD; Perreault, ML; Zonneveld, PM, 2019) |
| "Clinical studies that focused on treating schizophrenia showed that Calculus Bovis Sativus (CBS), a substitute of Calculus Bovis, when used in combination with haloperidol could significantly lower the dosage of haloperidol compared with treatment with haloperidol alone, whereas efficacy was maintained." | 7.88 | Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. ( He, GF; He, GZ; Lei, K; Li, J; Li, XP; Liu, D; Liu, YN; Ren, XH; Zhang, CL, 2018) |
| "Prior work in animal models implicates abnormalities of adenosine metabolism in astrocytes as a possible pathophysiological mechanism underlying the symptoms of schizophrenia." | 7.88 | Cell-subtype-specific changes in adenosine pathways in schizophrenia. ( Devine, E; Hasselfeld, K; Koene, R; McCullumsmith, RE; Moody, CL; O'Donovan, SM; Sullivan, C, 2018) |
| "Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions." | 7.88 | Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 7.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| " He had relapse symptoms of schizophrenia and had recently received a single dose of parenteral haloperidol to manage his agitation." | 7.85 | Persistent oromandibular dystonia and angioedema secondary to haloperidol. ( Masiran, R, 2017) |
| "In this study, we investigated whether minocycline, a second-generation tetracycline proposed as an add-on to antipsychotics in treatment-resistant schizophrenia (TRS), may affect the expression of Homer and Arc postsynaptic density (PSD) transcripts, implicated in synaptic regulation." | 7.85 | Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. ( Avvisati, L; Buonaguro, EF; Chiodini, P; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Tomasetti, C, 2017) |
| "We thus propose the l-methionine treatment as an animal model recapitulating several symptoms of schizophrenia." | 7.81 | A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity. ( Alachkar, A; Belluzzi, JD; Civelli, O; Sanathara, N; Wang, L; Wang, Z, 2015) |
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 7.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| "The present study evaluated the association of the BDNF Val66Met polymorphism with treatment response to atypical antipsychotic olanzapine in schizophrenia and the possible predictive value of the BDNF Val66Met genotype status in treatment response to antipsychotic medication." | 7.80 | Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. ( Kozumplik, O; Mihaljevic-Peles, A; Muck-Seler, D; Nedic Erjavec, G; Nikolac Perkovic, M; Pivac, N; Sagud, M; Uzun, S; Zivkovic, M, 2014) |
| "Both aripiprazole and haloperidol have been used in the treatment of schizophrenia, and are metabolized by the cytochrome P450 (CYP) 2D6 and CYP3A4." | 7.80 | Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2014) |
| "The paper reports on a rare case of fulminant neuroleptic malignant syndrome (NMS) with several risk factors, typical manifestation and rapid death induced by low doses of haloperidol." | 7.80 | Death due to fulminant neuroleptic malignant syndrome induced by low doses of haloperidol: a rare case. ( Chen, Y; Huang, P; Li, Z; Liu, N; Qin, Z; Shao, Y; Zhang, J; Zou, D, 2014) |
| " Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 7.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
| "Differences in effectiveness between haloperidol injection and oral atypical antipsychotics in the acute-phase treatment of schizophrenia are not well examined." | 7.79 | Length of mechanical restraint following haloperidol injections versus oral atypical antipsychotics for the initial treatment of acute schizophrenia: a propensity-matched analysis from the Japanese diagnosis procedure combination database. ( Ando, S; Fushimi, K; Haraguchi, T; Horiguchi, H; Matsuda, S; Nakamura, M; Ohe, K; Sugihara, T; Yasunaga, H, 2013) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Aripiprazole (APZ) is considered a first-line medication for treating first and multiple episodes of schizophrenia, but its effect on preventing the progressive pathophysiology of schizophrenia remains unclear." | 7.77 | Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. ( Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y, 2011) |
| "Effect of haloperidol and risperidone on positive, negative, neurocognitive disorders, biological parameters and neurodestruction-neuroreparation processes have been studied in 23 patients with the first episode of paranoid schizophrenia." | 7.77 | [Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia]. ( Govorin, NV; Vasil'eva, AI, 2011) |
| "The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs." | 7.77 | A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. ( Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C, 2011) |
| "Valproic acid (VPA) has been suggested as a potential adjunct therapy in schizophrenia for the treatment of clinical symptoms and cognitive deficits." | 7.77 | Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. ( Babin, SL; Larrison, AL; Patel, SS; Sereno, AB; Wassef, AA; Xing, Y, 2011) |
| "This naturalistic retrospective study aims to compare effectiveness of a second-generation antipsychotic medication, risperidone, with first-generation antipsychotic medications (haloperidol and trifluoperazine) in an Asian population with first-episode schizophrenia-spectrum disorders." | 7.76 | Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. ( Edimansyah, A; Liew, A; Subramaniam, M; Vaingankar, J; Verma, S, 2010) |
| "This study aimed to investigate the effects of treatment with haloperidol, olanzapine and risperidone on cardiovascular variability in patients with recent-onset schizophrenia by means of spectral analysis." | 7.75 | Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. ( Hempel, RJ; Hengeveld, MW; Röder, CH; Tulen, JH; van Beveren, NJ, 2009) |
| "The ketamine (ket) model reflects features of schizophrenia as well as secondary symptoms such as altered pain sensitivity." | 7.75 | Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ( Becker, A; Grecksch, G; Hiemke, C; Ladstaetter, E; Schmitt, U; Zernig, G, 2009) |
| "Outpatients initiating or changing antipsychotic therapy for DSM-IV- or ICD-10-defined schizophrenia (N = 7658) were allocated to olanzapine or nonolanzapine cohorts (November 2000 to December 2001)." | 7.74 | Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. ( Anders, M; Dossenbach, M; Irimia, V; Kotler, M; Logozar-Perkovic, D; Lowry, AJ; Pecenak, J; Peciukaitiene, D; Smulevich, AB; Szulc, A; Treuer, T; West, TM, 2008) |
| "This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR)." | 7.74 | Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. ( Ascher-Svanum, H; Marcus, SC; Olfson, M, 2007) |
| "To evaluate the cost-effectiveness of three antipsychotic medications (olanzapine, risperidone and haloperidol) in the treatment of schizophrenia using the Positive and Negative Symptom Scale." | 7.74 | Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. ( Bounthavong, M; Okamoto, MP, 2007) |
| "To comparatively assess the incidence of tardive dyskinesia in patients with schizophrenia receiving either aripiprazole or haloperidol." | 7.74 | Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. ( Eudicone, JM; Kim, E; Miller, DD; Pikalov, A, 2007) |
| "Clozapine may alleviate hyperactivity in the limbic system in schizophrenia and may facilitate activation of the regions involved in cognitive tasks to a greater degree than risperidone, as well as eliciting greater inhibition of the PF region." | 7.74 | Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. ( De Luxán, A; Domínguez-Gil, A; Martin, C; Molina, V; Montes, C; Rivas, N; Sancho, C; Tamayo, P, 2008) |
| "These results show that haloperidol and clozapine produce different patterns of metabolic changes in schizophrenia." | 7.73 | Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. ( Desco, M; Gispert, JD; Molina, V; Palomo, T; Pascau, J; Reig, S; Santos, A; Sanz, J, 2005) |
| "This post hoc analysis used data from a multinational, double-blind, randomized, placebo-controlled study comparing the efficacy of olanzapine, haloperidol, and placebo in acutely agitated inpatients aged > or =18 years with schizophrenia conducted at hospitals in 13 countries." | 7.73 | A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. ( Ahl, J; Battaglia, J; Houston, JP; Kaiser, CJ; Meyers, AL, 2005) |
| "This reanalysis of a previously reported pivotal clinical trial assessed whether quetiapine or haloperidol has benefits for the treatment of hostility and agitation among patients experiencing an acute exacerbation of schizophrenia." | 7.72 | A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. ( Chengappa, KN; Goldstein, JM; Greenwood, M; John, V; Levine, J, 2003) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 7.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 7.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| "This analysis models the cost-effectiveness of quetiapine compared with haloperidol in partial responders with schizophrenia." | 7.71 | An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. ( Aristides, M; Burns, T; Meddis, D; Tilden, D, 2002) |
| "To report a case of neuroleptic malignant syndrome (NMS) in a patient whose therapy was being switched from haloperidol to risperidone." | 7.71 | Neuroleptic malignant syndrome during a change from haloperidol to risperidone. ( Mack, JE; Reeves, RR; Torres, RA, 2001) |
| "PET scans were performed on 6 controls and 18 patients with schizophrenia treated with haloperidol or with risperidone, clozapine, amisulpride or olanzapine." | 7.71 | Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. ( Artiges, E; Loc'H, C; Mallet, L; Martinot, JL; Mazière, B; Paillère-Martinot, ML; Xiberas, X, 2001) |
| "The impact of genetic polymorphism of CYP1A2 that are related to the induction of the isozyme on the plasma levels of haloperidol (HAL) in 40 male smokers with schizophrenia was investigated." | 7.71 | Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. ( Hirokane, G; Morita, S; Okawa, M; Shimoda, K; Someya, T; Takahashi, S; Yokono, A, 2002) |
| "The aim of the present study is to determine the effect of the atypical antipsychotic drug, risperidone on sleep measures in patients with schizophrenia by polysomnography." | 7.71 | Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. ( Horiguchi, J; Morinobu, S; Nagao, M; Yamashita, H; Yamawaki, S, 2002) |
| "G protein functional measurements coupled to beta-adrenergic, muscarinic, and dopamine receptors were undertaken through bacterial toxin sensitive, agonist enhanced [3H]-Gpp(NH)p binding capacity, substantiated by quantitative measures of Gs alpha, Gi alpha, and G beta subunit proteins through immunoblot analysis in mononuclear leukocytes obtained from patients with schizophrenia under haloperidol, or clozapine treatments in comparison with untreated patients with schizophrenia and healthy volunteers." | 7.71 | Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. ( Avissar, S; Roitman, G; Schreiber, G, 2001) |
| "A decision-tree simulation model is used to examine the costs associated with olanzapine versus haloperidol in the treatment of patients with schizophrenia in the UK." | 7.70 | Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol. ( Almond, S; O'Donnell, O, 1998) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 7.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "The aim of this study was to evaluate the frequency and course of sexual disturbances associated with clozapine and haloperidol and their potential influence on compliance with medication regimens in patients with schizophrenia." | 7.70 | Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. ( Fleischhacker, WW; Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H, 1999) |
| "To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia." | 7.70 | Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. ( Almond, S; O'Donnell, O, 2000) |
| "A 40-year-old patient being treated for schizophrenia developed elevated plasma levels of haloperidol (HAL) in combination with chlorpromazine (CPZ) and during overlap treatment with clozapine." | 7.70 | Effect of chlorpromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia. ( Allen, SA, 2000) |
| "Plasma homovanillic acid concentration was assessed in 60 young schizophrenic patients, with and without first-degree relatives with schizophrenia, before treatment, and 3 days after starting haloperidol treatment." | 7.69 | Schizophrenia: gender, family risk, and plasma homovanillic acid. ( Andía, I; Basterreche, E; Dávila, R; Friedhoff, AJ; González-Torres, MA; Guimón, J; Zamalloa, MI; Zumárraga, M, 1995) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 7.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 7.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| " negative symptoms show different tonic electrodermal patterns, 26 patients with Type I schizophrenia and 19 patients with Type II schizophrenia were evaluated before and after 2 weeks of haloperidol treatment (standard daily dose = 4." | 7.69 | Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. ( Barzega, G; Bellino, S; Bogetto, F; Maina, G; Ravizza, L, 1995) |
| "Ten patients with schizophrenia participated in 120-min free-smoking sessions when actively psychotic and free of antipsychotic medications, and again after the initiation of haloperidol treatment." | 7.69 | Haloperidol increases smoking in patients with schizophrenia. ( Freudenreich, O; Levin, ED; McEvoy, JP; Rose, JE, 1995) |
| "A patient with chronic schizophrenia, who had been treated for a long time with chlorpromazine, haloperidol, levodopa, benserazide hydrochloride, diazepam and biperiden, developed extreme hypothermia (about 32 degrees C) when the dose of haloperidol was increased because of a deterioration of the patient's mental symptoms." | 7.69 | A schizophrenic patient who developed extreme hypothermia after an increase in the dose of haloperidol: a case report. ( Harada, H; Igarashi, M; Nakajima, T; Okamoto, K; Sugae, S; Tsuji, M, 1994) |
| "The dopamine hypotheses of schizophrenia and antipsychotic drug action suggest that the dopamine metabolite homovanillic acid (HVA) should change with drug withdrawal and change in clinical state." | 7.69 | Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies. ( Beuger, M; Kelley, ME; van Kammen, DP; Yao, J, 1996) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 7.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "This study examined the time-course of treatment response to haloperidol in chronic schizophrenia." | 7.68 | Early response to haloperidol treatment in chronic schizophrenia. ( Amin, F; Apter, SH; Harvey, PD; Hirschowitz, J; Kahn, RS; Stern, RG, 1993) |
| "Measurement of plasma prolactin (PRL) concentration and plasma homovanillic acid (HVA) concentration was performed in 24 patients with schizophrenia during maintenance haloperidol treatment." | 7.68 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| "Twenty-nine hospitalized patients suffering acute exacerbations of schizophrenia were treated for 2 weeks with fixed daily oral doses of haloperidol prospectively calculated to achieve a haloperidol plasma concentration of either 8-18 ng/ml or 25-35 ng/ml." | 7.68 | Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. ( Arndt, SV; Coryell, WH; Kelly, MW; Miller, DD; Perry, PJ, 1990) |
| "Forty-four male, neuroleptic-free, acutely psychotic patients with at least one diagnosis of schizophrenia among 11 diagnostic systems, and 28 healthy controls, underwent measurement of prolactin (PRL) concentrations before and after intravenous administration of haloperidol (0." | 7.68 | Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. ( Copolov, DL; Hassett, A; Keks, NA; Kulkarni, J; Mackie, B; McGorry, P; McLaughlin, M; Rubin, RT; Singh, BS; van Riel, R, 1990) |
| "In an open study, 18 patients suffering from an acute episode of schizophrenia and 18 patients with severe mania were given haloperidol at different dosage levels." | 7.67 | Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. ( Balant, L; Balant-Gorgia, AE; Eisele, R; Garrone, G, 1984) |
| " Haloperidol concentrations were determined by radioreceptor assay (RRA) and prolactin concentrations were measured in 20 patients diagnosed as schizophrenia (DSM-III)." | 7.67 | Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility. ( Almoguera, I; Cabranes, JA; Prieto, P; Ramos, JA; Rubio, ME; Santos, JL; Vazquez, C, 1989) |
| "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 7.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
| " A case of recurrent thrombocytopenia due to the repeated exposure to chlorpromazine (twice), haloperidol (four times) and thiothixene (twice) in a 59 year old female treated for schizophrenia is reported." | 7.67 | Thrombocytopenia associated with chlorpromazine, haloperidol and thiothixene: a case report. ( Balon, R; Berchou, R; Zethelius, M, 1987) |
| " Both groups reported insomnia as the most common treatment-emergent adverse event, and no serious adverse event was reported." | 6.79 | A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. ( Chan, HY; Chen, CK; Chen, JJ; Chen, YS; Chou, SY; Ree, SC; Su, LW, 2014) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 6.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Schizophrenia is a persistent, lifelong illness such that enduring functional improvements may only occur over the course of years [corrected]." | 6.75 | A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. ( Harvey, PD; Loebel, A; Malla, A; Newcomer, JW; Potkin, SG; Romano, S; Siu, CO; Stahl, SM; Watsky, E; Weiden, PJ, 2010) |
| "Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day." | 6.73 | The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. ( Gursoy, B; Kirli, S; Sarandöl, E; Sipahioglu, D; Sivrioglu, EY, 2007) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 6.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 6.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "Haloperidol-treated patients improved only on domains of learning/memory." | 6.72 | One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. ( Breier, A; Gold, JM; Keefe, RS; Purdon, SE; Rock, SL; Young, CA, 2006) |
| "Olanzapine has been shown to be better tolerated in comparison with conventional antipsychotics in a large unselected sample of acutely psychotic schizophrenic in-patients." | 6.71 | Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. ( Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M; Sacristán, JA, 2003) |
| "Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine, occur commonly in patients with schizophrenia and are associated with increased morbidity and mortality." | 6.71 | First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. ( Clark, WS; Glick, I; Green, AI; Hamer, RM; Lieberman, JA; Strakowski, SM; Tohen, MF, 2004) |
| "Comorbid cocaine abuse adversely affects clinical outcomes in schizophrenia." | 6.71 | Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. ( Campbell, EC; Caroff, SN; Cornish, J; Kondrich, J; Mann, SC; O'Brien, C; Sayers, SL, 2005) |
| " Patients were initiated with quetiapine to 400 mg/day over 7 days, and then flexibly dosed (300-750 mg/day) for 11 weeks." | 6.71 | Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. ( Altman, C; de Nayer, A; Jones, AM; Larmo, I; Lindenbauer, B; Platz, T; Rittmannsberger, H; Windhager, E, 2005) |
| "Risperidone was immediately effective against positive and negative symptoms in untreated patients; however, in the previously treated groups, it was initially effective against negative symptoms only; after a 2-week interval, positive symptoms also improved." | 6.71 | Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. ( Himei, A; Okamura, T, 2005) |
| " Using either a slower dose-titration or a high, single loading dose followed by a low maintenance dosing may have offered the possibility to obtain a good antipsychotic effect together with low incidence of EPS." | 6.70 | Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. ( Bischoff, S; Gerebtzoff, A; Möller, HJ; Volz, HP, 2002) |
| "Its usefulness in schizophrenia has yet to be adequately assessed." | 6.70 | Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. ( Hafiz, NG; Hampton, D; Molloy, M; Wassef, AA, 2001) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 6.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| "Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects." | 6.70 | Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Berk, M; Brook, S; Ichim, C, 2001) |
| "Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor." | 6.70 | Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. ( Berk, M; Schutz, G, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 6.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "D-fenfluramine has been identified as a highly selective serotonin (5-HT) releaser and re-uptake inhibitor." | 6.69 | Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1998) |
| "Olanzapine has been reported as less likely to cause EPS and may improve some negative signs." | 6.69 | The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998) |
| "Risperidone treatment produced a greater effect on patients' ability to perceive emotion compared with haloperidol treatment." | 6.69 | Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. ( Green, MF; Kee, KS; Kern, RS; Marshall, BD, 1998) |
| "Haloperidol was associated with a sustained hyperprolactinemia, unlike ziprasidone, where only transient elevations in prolactin that returned to normal within the dosing interval were observed." | 6.69 | An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. ( Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD, 1998) |
| "This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia." | 6.69 | Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998) |
| " A simulation of this dependence of clinical improvement on serum levels, mediated by the variable dose design, can be excluded because of the results of a retrospective analysis of dosing behavior." | 6.69 | Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1998) |
| "D-Fenfluramine was administered to 22 young, acutely ill schizophrenics (11 females and 11 males) after 4 weeks of haloperidol treatment." | 6.69 | Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1999) |
| "The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients." | 6.69 | No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A, 2000) |
| "Risperidone treatment had a greater beneficial effect on verbal working memory than haloperidol treatment across testing conditions (with and without distraction) and study phases (fixed and flexible dose)." | 6.68 | Does risperidone improve verbal working memory in treatment-resistant schizophrenia? ( Ames, D; Green, MF; Kern, RS; Marder, SR; Marshall, BD; McGurk, S; Mintz, J; Wirshing, WC, 1997) |
| "Five fixed doses of the atypical antipsychotic "Seroquel" (quetiapine) were evaluated to delineate a dose-response relationship, as measured by changes from baseline in Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores, and to compare efficacy and tolerability opposite placebo and haloperidol." | 6.68 | Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. ( Arvanitis, LA; Miller, BG, 1997) |
| "Risperidone 6 mg was the lowest dose that produced substantial change in negative symptoms and no increase in extrapyramidal symptoms and antiparkinsonian medication use." | 6.67 | Negative symptoms in schizophrenia: assessment of the effect of risperidone. ( Schooler, NR, 1994) |
| " Dosage of these two drugs were 450 = 133 mg and 32 +/- 9." | 6.67 | [A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin]. ( Gu, SF, 1992) |
| "Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients." | 6.67 | A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990) |
| " The total incidence of serious adverse events in the short-term double-blind programme was approximately 2% for both remoxipride and haloperidol." | 6.67 | Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. ( Englund, A; Lawrie, V; Lewander, T; Morrison, D; Schlachet, A; Westerbergh, SE, 1990) |
| " Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections." | 6.67 | Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ( McCreadie, RG; Whitehead, A; Wiles, DH, 1990) |
| " The dosage equivalency of haloperidol decanoate (1." | 6.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| " The dosage calculation was made from the haloperidol doses previously received by the patients, adjusted in each particular case, with a mean of 73 mg per application (range, 50 to 200 mg)." | 6.66 | [Chronic treatment of schizophrenia with injectable bromperidol decanoate]. ( Suárez Richards, M, 1985) |
| " It was concluded that 4-week intramuscular administration of haloperidol decanoate provides appropriate control of schizophrenic symptoms, but that flupenthixol decanoate should be dosed at shorter intervals." | 6.66 | Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. ( Eberhard, G; Hellbom, E, 1986) |
| "Haloperidol was also significantly superior to thiothixene in Cognitive Disturbance on the HPRSD." | 6.65 | Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. ( Abuzzahab, FS; Zimmerman, RL, 1982) |
| "In a double blind chlorpromazine-controlled trial, high dosage haloperidol (100 mg daily) given for three months, appreciably improved the mental state of male chronic 'drug resistant' schizophrenic inpatients in the rehabilitation/long-stay unit of one psychiatric hospital." | 6.64 | High dosage haloperidol in chronic schizophrenia. ( MacDonald, IM; McCreadie, RG, 1977) |
| "When bromperidol decanoate was compared with fluphenazine depot, we found no important change on global outcome (n = 30, RR no clinical important improvement 1." | 6.48 | Bromperidol decanoate (depot) for schizophrenia. ( Adams, CE; Purgato, M, 2012) |
| "When bromperidol decanoate was compared with fluphenazine depot, we found no important change on global outcome (n = 30, RR no clinical important improvement 1." | 6.47 | Bromperidol decanoate (depot) for schizophrenia. ( Adams, CE; Purgato, M, 2011) |
| "Aripiprazole is a novel antipsychotic with a unique mechanism of action." | 6.42 | Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. ( Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003) |
| "When bromperidol decanoate was compared with fluphenazine depot we found no important change on global outcome (n=30, RR no clinical important improvement 1." | 6.42 | Depot bromperidol decanoate for schizophrenia. ( Adams, CE; David, A; Quraishi, SN; Wong, D, 2004) |
| "Anti-psychotic drugs are the mainstay treatment for schizophrenia." | 6.41 | Depot bromperidol decanoate for schizophrenia. ( Adams, CE; David, A; Quraishi, S, 2000) |
| " The proportion of patients failing to reach at least 20% improvement on the positive and negative syndrome scale (PANSS) or brief psychiatric rating scale (BPRS), the proportion of patients discontinuing treatment because of adverse effects and the number of patients who needed antiparkinsonian medication were abstracted for use as outcome measures." | 6.39 | Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. ( Bacaltchuk, J; de Castro-e-Silva, E; de Oliveira, IR; de Sena, EP; Miranda-Scippa, AM; Pereira, EL; Ribeiro, MG, 1996) |
| "Patients with schizophrenia were randomized to monotherapy with risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, perphenazine or haloperidol in a 6-week pharmacological trial." | 6.23 | The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia. ( Chen, Q; Coid, J; Deng, W; Guo, W; Li, K; Li, L; Li, T; Lu, T; Lv, L; Ma, X; Tan, L; Tan, Q; Tao, S; Wang, C; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L, 2024) |
| "A total of 3010 patients with schizophrenia enrolled in a randomized controlled trial (RCT) and received a 6-week treatment with one antipsychotic drug randomly chosen from five atypical antipsychotics (risperidone 2-6 mg/d, olanzapine 5-20 mg/d, quetiapine 400-750 mg/d, aripiprazole 10-30 mg/d, and ziprasidone 80-160 mg/d) and two typical antipsychotics (perphenazine 20-60 mg/d and haloperidol 6-20 mg/d)." | 5.69 | Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. ( Chen, Q; Deng, W; Du, X; Hao, Q; Hu, X; Li, C; Li, K; Li, L; Li, T; Li, X; Lu, T; Lv, L; Ma, X; Ren, H; Tan, L; Tan, Q; Tang, Y; Wang, C; Wang, L; Wang, Q; Wang, Y; Wu, Y; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, Y; Zhao, L, 2023) |
| "Physically assaultive schizophrenia patients (N=99) were randomly assigned to receive clozapine, olanzapine, or haloperidol in a 12-week double-blind trial." | 5.41 | The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol. ( Czobor, P; Krakowski, M; Tural, U, 2021) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 5.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| "Co-occurring substance use disorders (SUD), including alcohol, are common in schizophrenia (SZ) and are associated with poor outcome." | 5.40 | Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. ( Gibson, LE; Green, AI; Mesholam-Gately, RI; Seidman, LJ, 2014) |
| "Here, we treated schizophrenia rat models with a systematic injection of MK-801 (0." | 5.40 | Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. ( Fang, Y; Xu, L; Zhang, C, 2014) |
| "Haloperidol dose was positively correlated with plasma protein carbonyls." | 5.39 | Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. ( Bošković, M; Grabnar, I; Kores Plesničar, B; Terzič, T; Vovk, T, 2013) |
| " Subsequently, the developed model was utilized to characterize an effective dosing strategy for using haloperidol as a comparator drug in future antipsychotic drug trials." | 5.39 | Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale. ( Danhof, M; de Greef, R; Groothuis, GM; Johnson, M; Kozielska, M; Liu, J; Mafirakureva, N; Pilla Reddy, V; Proost, JH; Rujescu, D; Vermeulen, A, 2013) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 5.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 5.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 5.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 5.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Treatment with haloperidol and clozapine attenuated the detrimental performance effects of these challenges, with clozapine exhibiting more robust attenuation." | 5.35 | Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. ( Martinez, V; Sarter, M, 2008) |
| " Results of the sensitivity analysis confirmed that the results were robust to a wide variation of different input variables (effectiveness, dosing distribution, patient status according to healthcare system)." | 5.33 | Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. ( Caleo, S; De Graeve, D; Lecompte, D; Mehnert, A; Miadi-Fargier, H; Mosqueda, GJ; Peuskens, J; Smet, A, 2005) |
| "(-)Stepholidine (SPD) is an active ingredient of the Chinese herb Stephania intermedia, which binds to the dopamine D(1) and D(2) like receptors." | 5.33 | Effects of (-)stepholidine in animal models for schizophrenia. ( Ellenbroek, BA; Jin, GZ; Zhang, XX, 2006) |
| "With the background of a number of meta-analyses on the optimal neuroleptic dosages [1,2] the average daily dosage for the treatment of acute schizophrenic episodes recommended in the internal treatment guidelines of our psychiatric clinic was reduced from 24 mg to 15 mg haloperidol equivalent." | 5.31 | ["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. ( Kissling, W; Kockott, G; Müller, R, 2000) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 5.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "The haloperidol-treated group had significantly lower CSF-uncorrected and CSF-corrected left frontal NAA than the normal controls, with the clozapine group having intermediate concentrations." | 5.31 | Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. ( Blanchard, J; Brooks, WM; Bustillo, JR; Hart, BL; Jung, RE; Keith, SJ; Lauriello, J; Petropoulos, H; Rowland, LM, 2001) |
| "Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients." | 5.31 | Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001) |
| "The aim of this double-blind randomized study was to evaluate the response to antipsychotic treatment in schizophrenia patients with predicted high/low risk of nonresponse identified by applying a set of well-established scales and predictors of outcome and to compare efficacy between ziprasidone and haloperidol." | 5.30 | Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. ( Bottlender, R; Jäger, M; Laux, G; Möller, HJ; Musil, R; Obermeier, M; Riedel, M; Schennach, R; Schmauss, M; Spellmann, I, 2019) |
| "This Japanese, multicenter, randomized, double-blind trial, evaluating the efficacy and safety of blonanserin compared with haloperidol in patients with schizophrenia, was previously published by Murasaki in the Japanese language." | 5.30 | Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. ( Harvey, PD; Murasaki, M; Nakamura, H, 2019) |
| "Thirty-seven newly admitted schizophrenic patients were treated with an open and flexible dosage of chlorpromazine for 3 months after receiving a test dose." | 5.30 | Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine. ( Minami, H; Miyahara, A; Nakahara, T; Nakane, Y, 1997) |
| "Haloperidol and clozapine were tested in rats after daily administration for 3 and 21 days in combination with vehicle or PCP (2." | 5.30 | A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. ( Sams-Dodd, F, 1998) |
| " The recommended initial dosage was 150 mg bromperidol (one 3 ml ampoule), and this did not in fact have to be increased during the trial." | 5.29 | [Bromperidol decanoate in the residual phase of schizophrenia]. ( Canova, L; Cocconcelli, C; Faravelli, C; Marchetti, FP; Mariani, G; Rapisarda, V; Smeraldi, E, 1996) |
| "The pharmacokinetic interaction between buspirone and haloperidol was evaluated in schizophrenic patients in two different groups." | 5.29 | Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ( Chang, TP; Chang, WH; Chen, JS; Chien, CP; Huang, HF; Jann, MW; Juang, DJ; Lam, YW; Lin, SK; Wei, FC, 1996) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 5.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| " In neither patient, the increase in haloperidol dosage affected paranoid symptoms." | 5.26 | [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. ( Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982) |
| "Chronic schizophrenic patients were maintained for six months on a dosage of haloperidol adjusted to give optimum clinical effect." | 5.26 | Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. ( Bishop, M; Coppen, A; Rao, VA, 1980) |
| "Cyproheptadine pretreatment was associated with erratic increases or decreases in the hGH response to apomorphine, but did not alter PRL levels or apomorphine-induced PRL suppression." | 5.26 | Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research. ( Angrist, B; Branchey, L; Gershon, S; Halpern, F; Oleshansky, M; Paquin, J; Rotrosen, J; Sachar, EJ, 1979) |
| " Supplemental treatment with EPUFAs and vitamin E in schizophrenia patients treated with haloperidol is potentially beneficial and a larger independent study appears warranted." | 5.22 | Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol. ( Bošković, M; Grabnar, I; Koprivšek, J; Plesničar, BK; Vovk, T, 2016) |
| "To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year." | 5.22 | Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. ( Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M, 2016) |
| "To assess the benefit of short-term treatment with the atypical antipsychotic asenapine versus placebo on depressive symptoms in patients with acute schizophrenia in an exacerbated state." | 5.20 | Management of depressive symptoms in schizophrenia. ( Castle, DJ; Slott Jensen, JK, 2015) |
| " Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)." | 5.20 | Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015) |
| "Physically aggressive inpatients with schizophrenia who received an evaluation of depression and impulsivity at baseline were randomly assigned in a double-blind, parallel group, 12-week trial to clozapine, olanzapine, or haloperidol." | 5.19 | Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. ( Czobor, P; Krakowski, MI, 2014) |
| "Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride." | 5.19 | Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. ( Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J, 2014) |
| "Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders." | 5.19 | Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014) |
| "This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia." | 5.19 | A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. ( Gen, K; Suzuki, H; Takahashi, Y, 2014) |
| "In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate vs haloperidol decanoate did not result in a statistically significant difference in efficacy failure, but was associated with more weight gain and greater increases in serum prolactin, whereas haloperidol decanoate was associated with more akathisia." | 5.19 | Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. ( Buckley, PF; Byerly, M; Dominik, R; Hamer, RM; Lamberti, JS; McEvoy, JP; Ray, N; Rosenheck, RA; Stroup, TS; Swartz, MS; Wilkins, TM, 2014) |
| " Previous studies have demonstrated that IM ziprasidone is efficacious and safe for treatment of agitation in schizophrenia." | 5.17 | Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. ( Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J, 2013) |
| "A prospective, randomized, open-label study was carried out to compare the long-term neurocognitive effectiveness of haloperidol, olanzapine, and risperidone in the first episode of schizophrenia spectrum disorders." | 5.17 | Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. ( Ayesa-Arriola, R; Crespo-Facorro, B; Martínez-García, O; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Sánchez-Moreno, J; Tabarés-Seisdedos, R; Vázquez-Barquero, JL, 2013) |
| "gov identifier: NCT00395915) aimed to compare clinical efficacy and tolerability of haloperidol versus aripiprazole as combination treatment with clozapine in patients with resistant schizophrenia." | 5.17 | Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. ( Accordini, S; Barbui, C; Cipriani, A; Girlanda, F; Nosè, M; Purgato, M; Tansella, M, 2013) |
| "To evaluate depressive symptoms regarding their association with the acute outcome in first-episode schizophrenia comparing risperidone and haloperidol." | 5.16 | Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "Haloperidol or trifluoperazine demonstrated similar efficacy as risperidone or olanzapine for patients with schizophrenia who had failed their first trial with a FGA." | 5.16 | Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. ( Chan, HY; Chen, CH; Chen, JJ; Gau, SS; Hwu, HG, 2012) |
| "Ninety-nine physically aggressive inpatients (aged 18-60 years) with schizophrenia or schizoaffective disorder (diagnosed according to DSM-IV) who completed tests of executive function were randomly assigned in a double-blind, parallel-group, 12-week trial to clozapine (n = 32), olanzapine (n = 32), or haloperidol (n = 35)." | 5.16 | Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. ( Czobor, P; Krakowski, MI, 2012) |
| "The ITT population included both schizoaffective and schizophrenia patients (N = 2401): n = 370, n = 494, and n = 424 for iloperidone 4-8, 10-16, and 20-24 mg/day, respectively; n = 294 for risperidone; n = 114 for haloperidol; n = 144 for ziprasidone; and n = 561 for placebo." | 5.16 | Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. ( Citrome, L; Hochfeld, M; Meng, X; Stahl, SM, 2012) |
| "This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS." | 5.16 | Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012) |
| " The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs)." | 5.16 | Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs. ( Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A, 2012) |
| "From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up." | 5.16 | Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012) |
| "We applied 2D-CSI MR spectroscopy in 17 recurrent-episode schizophrenia patients off antipsychotics at baseline and at follow-up after 6 weeks, during which 7 patients were treated with haloperidol (10-16 mg/d) and 10 with risperidone (4-6 mg/d)." | 5.16 | Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients. ( Burmeister, HP; Gussew, A; Langbein, K; Reichenbach, JR; Rzanny, R; Sauer, H; Smesny, S, 2012) |
| "This study assessed the safety and tolerability of sertindole in the long-term treatment of schizophrenia." | 5.16 | Sertindole in the long-term treatment of schizophrenia. ( Azorin, JM; Hale, AS; Lemming, OM; Mæhlum, E, 2012) |
| "We investigated the effects of risperidone (N=16), olanzapine (N=18) and low doses of haloperidol (N=18) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients." | 5.16 | Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. ( Ayesa-Arriola, R; Crespo-Facorro, B; Gutiérrez, A; Ortíz-García de la Foz, V; Roiz-Santiáñez, R; Tabarés-Seisdedos, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL, 2012) |
| "This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot." | 5.16 | The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. ( Gen, K; Suzuki, H, 2012) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 5.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "We conducted a secondary analysis of a completed study of the differential efficacy and side effects of aripiprazole versus haloperidol in early-stage schizophrenia (ESS), a subpopulation of patients which does not include first episode or chronic patients." | 5.15 | Aripiprazole versus haloperidol treatment in early-stage schizophrenia. ( Girgis, RR; Lieberman, JA; Merrill, DB; Pikalov, A; Vorel, SR; Whitehead, R; You, M, 2011) |
| "We examined data on 420 patients with schizophrenia treated for 6 weeks in two double-blind placebo-controlled trials using haloperidol and olanzapine." | 5.15 | The different trajectories of antipsychotic response: antipsychotics versus placebo. ( Agid, O; Arenovich, T; Chen, L; Kapur, S; Kinon, BJ; Marques, TR; Muthén, B; Sajeev, G, 2011) |
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 5.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "This multisite study was conducted to compare the efficacy and tolerability of combination treatment with clozapine plus aripiprazole versus combination treatment with clozapine plus haloperidol in patients with schizophrenia who do not have an optimal response to clozapine." | 5.15 | Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. ( Accordini, S; Barbui, C; Cipriani, A; Esposito, E; Girlanda, F; Nosè, M; Purgato, M; Stroup, S; Tansella, M; Veronese, A, 2011) |
| "To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder." | 5.15 | Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). ( Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J, 2011) |
| "Eighty hospitalized patients suffering from Schizophrenia or Schizoaffective disorder (male 54, female 26) were first treated with Haloperidol (N=60) or Fluphenazine (N=20), and then were switched to Risperidone." | 5.15 | First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011) |
| "Community dwelling patients with schizophrenia were randomized to treatment with haloperidol (n=47) or ziprasidone dosed either once or twice daily (n=139)." | 5.14 | Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. ( Harvey, PD; Kremer, CM; Lombardo, I; Pappadopulos, E, 2009) |
| "In this 8-week, multicenter, randomized, parallel-group, open-label, flexible-dose study, patients diagnosed with schizophrenia or schizoaffective disorder were randomized to aripiprazole 15-30 mg/day or haloperidol 10-15 mg/day." | 5.14 | Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. ( Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR, 2009) |
| " The goal of this study was to assess the effects of clozapine and olanzapine in comparison to the first-generation agent haloperidol on these metabolic parameters in aggressive patients with schizophrenia." | 5.14 | Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. ( Citrome, L; Czobor, P; Krakowski, M, 2009) |
| "Patients with refractory schizophrenia were assigned to clozapine (n=85) or haloperidol (n=96) and followed for 3 months." | 5.14 | The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. ( Charney, DS; Cramer, J; Gelernter, J; Krystal, JH; Luo, X; Zuo, L, 2009) |
| " We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole rather than with haloperidol, provides physicians with a solid evidence base to be directly applied in the routine care of patients with schizophrenia." | 5.14 | Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. ( Accordini, S; Artioli, P; Barale, F; Barbui, C; Beneduce, R; Berardi, D; Bertolazzi, G; Biancosino, B; Bisogno, A; Bivi, R; Bogetto, F; Boso, M; Bozzani, A; Bucolo, P; Casale, M; Cascone, L; Ciammella, L; Cicolini, A; Cipresso, G; Cipriani, A; Colombo, P; Dal Santo, B; De Francesco, M; Di Lorenzo, G; Di Munzio, W; Ducci, G; Erlicher, A; Esposito, E; Ferrannini, L; Ferrato, F; Ferro, A; Fragomeno, N; Frova, M; Gardellin, F; Garzotto, N; Giambartolomei, A; Giupponi, G; Grassi, L; Grazian, N; Grecu, L; Guerrini, G; Laddomada, F; Lazzarin, E; Lintas, C; Malchiodi, F; Malvini, L; Marchiaro, L; Marsilio, A; Mauri, MC; Mautone, A; Menchetti, M; Migliorini, G; Mollica, M; Moretti, D; Mulè, S; Nicholau, S; Nosè, F; Nosè, M; Occhionero, G; Pacilli, AM; Parise, VF; Pecchioli, S; Percudani, M; Piantato, E; Piazza, C; Pontarollo, F; Pycha, R; Quartesan, R; Rillosi, L; Risso, F; Rizzo, R; Rocca, P; Roma, S; Rossattini, M; Rossi, G; Sala, A; Santilli, C; Saraò, G; Sarnicola, A; Sartore, F; Scarone, S; Sciarma, T; Siracusano, A; Strizzolo, S; Tansella, M; Targa, G; Tasser, A; Tomasi, R; Travaglini, R; Veronese, A; Ziero, S, 2009) |
| "To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder." | 5.14 | Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. ( Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A, 2009) |
| "To determine the efficacy and safety of three doses of blonanserin compared with placebo and haloperidol in patients with acute-phase schizophrenia." | 5.14 | The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. ( Garcia, E; Nakamura, H; Peris, F; Robert, M; Sato, N; Terazawa, Y, 2009) |
| " Using PET with 15O, we evaluated the time course of regional cerebral blood flow (rCBF) patterns generated by a first (haloperidol) and a second (olanzapine) generation antipsychotic drug in patients with schizophrenia during a 6-week treatment trial." | 5.14 | Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. ( Cropsey, KL; Holcomb, HH; Lahti, AC; Tamminga, CA; Weiler, MA, 2009) |
| "This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS)." | 5.14 | Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. ( Bates, JA; Guo, Z; Kan, HJ; Kane, JM; Kim, E; Pikalov, A; Whitehead, R, 2009) |
| "To better understand the efficacy and tolerability of atypical antipsychotics among racial groups, we reviewed data from four short-term (4-6 weeks), fixed-dose, placebo-controlled trials of ziprasidone for black, white, and overall populations of patients with schizophrenia." | 5.14 | Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. ( Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M, 2009) |
| "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features." | 5.14 | Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010) |
| "In patients with early-episode schizophrenia, aripiprazole demonstrates greater improvement than haloperidol on PANSS items related to social functioning." | 5.14 | Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. ( Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD, 2010) |
| "Prodromal subjects and unmedicated patients with first-episode schizophrenia showed significant PPI deficits, whereas schizophrenia patients treated with risperidone had almost normal PPI." | 5.13 | Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. ( Berning, J; Frommann, I; Kühn, KU; Maier, W; Quednow, BB; Wagner, M, 2008) |
| " Fifty-one patients diagnosed with paranoid schizophrenia received haloperidol in combination with nifedipine (25 patients) or haloperidol only (26 patients) during 26 weeks." | 5.13 | [The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics]. ( Popov, MIu, 2008) |
| "The purpose of this study was to compare the effects of olanzapine, clozapine, and haloperidol on neurocognitive function in schizophrenic patients who present with documented episodes of physical aggression and to determine whether change in cognitive function is related to aggression." | 5.13 | Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. ( Czobor, P; Krakowski, MI; Nolan, KA, 2008) |
| "To evaluate the therapeutic efficacy and tolerability of flunarizine compared to haloperidol in outpatients with stable and chronic DSM-IV-defined schizophrenia and schizoaffective disorder." | 5.13 | Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ( Bisol, LW; Borba, DL; Bressan, RA; Brunstein, MG; Daltio, CS; de Oliveira, RV; de Souza, SE; Lara, DR; Ottoni, GL; Paz, GE; Ramos, FL, 2008) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 5.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| "Medication-naïve patients with schizophrenia (n = 99) underwent baseline fasting and 2 h post-prandial plasma glucose measurements repeated after 6 weeks after randomization to receive olanzapine, risperidone or haloperidol." | 5.13 | Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2008) |
| " This network meta-analysis aims to evaluate the efficacy of short-acting IM second-generation antipsychotic drugs, haloperidol and placebo in patients with diagnosis of schizophrenia and schizophrenia-like disorders that present acute agitation." | 5.12 | Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. ( Bighelli, I; Davis, JM; Deste, G; Leucht, S; Paris, G; Schneider-Thoma, J; Siafis, S; Vita, A; Zhu, Y, 2021) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 5.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "This multicentre, parallel-group study compared the efficacy and tolerability of ziprasidone and chlorpromazine in treatment-resistant schizophrenia (at least three treatment periods of at least 6 weeks each with two or more antipsychotic agents during the past 5 years without significant response) that was unresponsive to 6 weeks of open-label haloperidol ( | 5.12 | Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. ( Giller, E; Kane, JM; Khanna, S; Rajadhyaksha, S, 2006) |
| "Thirty-one subjects with cocaine dependence and schizophrenia were randomized to olanzapine or haloperidol, underwent a cue-exposure procedure, and completed psychiatric and substance abuse ratings." | 5.12 | The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. ( Kaune, M; Losonczy, MF; Smelson, DA; Steinberg, ML; Williams, J; Ziedonis, D, 2006) |
| "Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N=2638), risperidone (N=860), quetiapine (N=142) or haloperidol (N=188)." | 5.12 | Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Akram, A; Anders, M; Araszkiewicz, A; Dossenbach, M; Dyachkova, Y; Khalil, A; McBride, M; Pecenak, J; Pirildar, S; Shakhnovich, T; Treuer, T, 2006) |
| "A total of 572 inpatients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in a randomized, rater-blinded, 6-week, open-label study comparing sequential intramuscular and oral ziprasidone with haloperidol." | 5.12 | Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. ( Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J, 2006) |
| "Clozapine was superior to both olanzapine and haloperidol in reducing the number and severity of physical assaults as assessed by the MOAS physical aggression score and in reducing overall aggression as measured by the MOAS total score." | 5.12 | Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. ( Bark, N; Citrome, L; Cooper, TB; Czobor, P; Krakowski, MI, 2006) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 5.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder." | 5.12 | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006) |
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 5.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "Intramuscular aripiprazole is effective in patients with acute agitation associated with schizophrenia, comparable to IM haloperidol, and enables convenient transfer to oral aripiprazole therapy." | 5.12 | Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. ( Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E, 2006) |
| "To determine if any of five second-generation antipsychotics or haloperidol is more effective in treating acutely ill patients with schizophrenia, schizoaffective disorder or schizophreniform disorder." | 5.12 | Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. ( Charles, R; Hasan, SM; Joseph, MD; McCue, RE; Orendain, G; Urcuyo, L; Waheed, R, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 5.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "Thirty-five patients with DSM-IV-TR schizophrenia and predominant negative symptoms were randomly assigned in a 12-week double-blind study to either olanzapine (15-20 mg/day) or haloperidol (15-20 mg/day)." | 5.12 | A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. ( Abad, MT; Iskander, A; Khan, A; Lindenmayer, JP; Parker, B, 2007) |
| "Acutely agitated patients with schizophrenia or schizoaffective disorder treated with aripiprazole IM or haloperidol IM demonstrated similar effective and safe transition to their respective oral formulations." | 5.12 | Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. ( Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007) |
| "To contrast the effect of a typical antipsychotic (haloperidol) and an atypical antipsychotic (olanzapine) on neurocognitive functioning in schizophrenia when learning and practice (LP) effects are controlled." | 5.12 | Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol. ( Boulay, LJ; Bourget, D; Habib, R; Labelle, A; Milin, R; Robertson, S; Tessier, P; Tombaugh, T, 2007) |
| "This study aimed to assess the cost effectiveness of ziprasidone versus haloperidol in sequential intramuscular (IM)/oral treatment of patients with exacerbation of schizophrenia in Spain." | 5.12 | Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial. ( Cañas, F; Díaz, S; Pérez-Solá, V; Rejas, J, 2007) |
| "Fifty-six patients with hyperprolactinemia taking haloperidol were enrolled." | 5.12 | Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. ( Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH, 2007) |
| " The objective of this study was to examine the antipsychotic effect and side effect profile of amoxapine versus haloperidol in a double-blind study for 6 weeks in patients with schizophrenia." | 5.12 | Amoxapine as an antipsychotic: comparative study versus haloperidol. ( Badshah, S; Chaudhry, IB; Deakin, B; Husain, N; Kapur, S; Khan, S, 2007) |
| "To compare the impact of sertindole and haloperidol on cognitive function in patients suffering from schizophrenia." | 5.12 | Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. ( Gallhofer, B; Jaanson, P; Krieger, S; Lis, S; Mittoux, A; Tanghøj, P, 2007) |
| " Accordingly, the hypothesis of whether 1-year relapse rate in first-episode schizophrenia under maintenance treatment with risperidone is lower compared to haloperidol in low dose was tested." | 5.12 | Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W, 2007) |
| " Although clozapine generates substantially fewer side effects than haloperidol, its impact on psychiatric aspects of schizophrenia is less robust and primarily involves positive symptoms." | 5.11 | Discrete state analysis for interpretation of data from clinical trials. ( James, GM; Lenert, LA; Rosenheck, RA; Sugar, CA, 2004) |
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 5.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| "Over 3 months, 41 patients with schizophrenia were randomized to treatment with risperidone 1-12 mg (n=21) or haloperidol 2-20 mg (n=20) daily." | 5.11 | Adverse effects of risperidone and haloperidol treatment in schizophrenia. ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| "While haloperidol is still widely used in the treatment of psychoses, the optimal daily dose remains a topic of controversy, particularly in first-episode psychosis." | 5.11 | A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. ( Emsley, R; Jadri Turner, H; Keyter, N; Oosthuizen, P, 2004) |
| "307 schizophrenia subjects in their first episode of illness were recruited to participate in a clinical trial comparing the long-term efficacy of haloperidol and risperidone." | 5.11 | Correlates of cognitive deficits in first episode schizophrenia. ( Csernansky, JG; DeLisi, LE; Heydebrand, G; Hoff, AL; Rabinowitz, J; Weiser, M, 2004) |
| "We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia." | 5.11 | Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004) |
| "This 12-month, randomized, investigator-blinded study compared the efficacy of quetiapine (N = 22) and haloperidol (N = 23) in treating patients with DSM-IV schizophrenia or schizoaffective disorder and established tardive dyskinesia." | 5.11 | A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. ( Botha, K; Emsley, R; Oosthuizen, PP; Schronen, J; Smit, R; Turner, HJ, 2004) |
| "Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned in a 3:1:1 ratio to receive fixed doses of investigational drug, placebo, or haloperidol for 6 weeks." | 5.11 | Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. ( Arvanitis, L; Bauer, D; Meltzer, HY; Rein, W, 2004) |
| "Patients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment with olanzapine (mean modal dose= 9." | 5.11 | Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. ( Christensen, BK; Gur, RC; Hamer, RM; Keefe, RS; Lewine, RR; Lieberman, JA; Sanger, TM; Seidman, LJ; Sharma, T; Sitskoorn, MM; Tohen, M; Tollefson, GD; Yurgelun-Todd, DA, 2004) |
| "Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone." | 5.11 | Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. ( Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004) |
| "The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia." | 5.11 | Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2005) |
| "From April 1996 to August 1997, seventy-eight inpatients with a diagnosis of chronic schizophrenia (DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol." | 5.11 | Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2004) |
| "The objective of this study was to estimate the effects of intramuscular haloperidol and lorazepam on the QT interval in volunteers with schizophrenia." | 5.11 | Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. ( Burke, M; Flockhart, D; Gorski, JC; Greenblatt, DJ; Harvey, AT; Preskorn, SH; Werder, S, 2004) |
| "Sixty-three outpatients with schizophrenia who met retrospective and prospective criteria for either residual positive or residual negative symptoms entered a 16-week double-blind, parallel-groups comparison of olanzapine and haloperidol." | 5.11 | Olanzapine treatment of residual positive and negative symptoms. ( Ball, MP; Buchanan, RW; Carpenter, WT; Gold, JM; Kirkpatrick, B; McMahon, RP; Weiner, E, 2005) |
| " This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)." | 5.11 | Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. ( Ascher-Svanum, H; Kinon, BJ; Stensland, M; Zhao, Z, 2005) |
| "To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. ( Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J, 2005) |
| " We evaluated the long-term effects of a new-generation antipsychotic, quetiapine and a conventional antipsychotic, haloperidol on body mass index (BMI) and glycaemic control in patients with schizophrenia previously treated with conventional antipsychotics." | 5.11 | Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. ( Botha, K; Emsley, R; Oosthuizen, PP; Schronen, J; Smit, R; Turner, HJ, 2005) |
| "Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks." | 5.11 | Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. ( Glick, ID; Marder, SR, 2005) |
| "This study investigated safety and effectiveness of olanzapine in monotherapy compared with conventional antipsychotics in treatment of acute inpatients with schizophrenia." | 5.11 | Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. ( Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Ciudad, A; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M, 2005) |
| "Cerebral cortical gray was examined volumetrically in 19 patients with schizophrenia before and following 28 days of treatment with two SGAs (risperidone and ziprasidone; n = 13) or a FGA (haloperidol; n = 6)." | 5.11 | Cerebral cortical gray expansion associated with two second-generation antipsychotics. ( Christensen, JD; Garver, DL; Holcomb, JA, 2005) |
| "As monotherapy, both olanzapine and risperidone were superior to haloperidol and clozapine in reducing aggression." | 5.11 | Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). ( Bitter, I; Czobor, P; Dossenbach, M; Volavka, J, 2005) |
| "The primary aim of this study was to compare the effectiveness of 12 months' treatment with olanzapine, risperidone, quetiapine, or haloperidol in preventing relapse of schizophrenia." | 5.11 | Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Aguilar, J; Arango-Dávila, C; Assunção, S; Caro, O; Dossenbach, M; Landa, E; Leadbetter, J; Silva Ibarra, H, 2005) |
| "Cognitive assessments were conducted in 533 patients experiencing their first episode of schizophrenia or a related psychosis who had been randomly assigned to receive low doses of risperidone or haloperidol." | 5.11 | Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. ( Davidson, M; Eerdekens, M; Harvey, PD; Rabinowitz, J, 2005) |
| "To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol." | 5.11 | Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. ( Green, AI; Gu, H; Gur, RE; Kahn, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Sharma, T; Strakowski, SM; Tohen, MF; Tollefson, GD; Zipursky, RB, 2005) |
| "Both haloperidol and risperidone have been widely used in the treatment of schizophrenia." | 5.10 | Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. ( De Vries, R; Inoue, Y; Kaneko, S; Kondo, T; Mihara, K; Suzuki, A; Yasui-Furukori, N, 2002) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 5.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| "We applied nicotine 21 mg and matching placebo transdermal patches to thirty haloperidol-treated patients with schizophrenia who smoked." | 5.10 | Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. ( Kamaraju, L; McEvoy, JP; Nelson, L; Wilson, W; Yang, YK, 2002) |
| " Fifty subjects met the DSM-III-R criteria for schizophrenia or schizoaffective disorder, participated in a 10-week, double-blind comparison of haloperidol and clozapine and a 1-year, open-label clozapine trial, and had available serum glucose and lipid levels." | 5.10 | Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. ( Ball, P; Baymiller, SP; Buchanan, RW; McMahon, RP, 2003) |
| " haloperidol for elderly chronic schizophrenia patients." | 5.10 | Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. ( Barak, Y; Mirecki, I; Shamir, E; Toren, P; Weizman, R; Zemishlani, H, 2002) |
| "The results of this study present a novel application for potassium channel openers/activators in the neuropsychiatric disorders and diazoxide may be an effective adjuvant agent in the management of schizophrenia." | 5.10 | Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. ( Akhondzadeh, S; Amini-Nooshabadi, H; Kamalipour, A; Mirsepassi, GR; Moin, M; Mojtahedzadeh, V, 2002) |
| "Haloperidol decanoate is widely used in the maintenance treatment of schizophrenia and other psychotic disorders, but knowledge concerning its pharmacokinetics at the injected region is very limited." | 5.10 | 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. ( Girard, F; Ikehira, H; Obata, T; Okubo, Y; Sassa, T; Suhara, T; Tanada, S, 2002) |
| "The superiority of olanzapine to haloperidol with respect to a decreased incidence of treatment-emergent extrapyramidal syndromes (EPS) in patients with schizophrenia was demonstrated in studies conducted in both Japan and Western countries." | 5.10 | Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. ( Beasley, CM; Inada, T; Tanaka, Y; Walker, DJ, 2003) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7." | 5.10 | Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| " In 3 double-blind studies, acutely agitated patients with schizophrenia (N = 311), bipolar mania (N = 201), or dementia (N = 206) were treated with intramuscular (1-3 injections/24 hrs) olanzapine (2." | 5.10 | Calming versus sedative effects of intramuscular olanzapine in agitated patients. ( Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P, 2003) |
| "Thirty-nine subjects with early phase schizophrenia were randomly assigned to double blind treatment with haloperidol, risperidone, or olanzapine." | 5.10 | Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. ( Lindborg, SR; Purdon, SE; Stip, E; Woodward, N, 2003) |
| " Databases included: placebo-controlled [two schizophrenia, one bipolar mania trials (n=565)]; haloperidol-controlled [two schizophrenia trials (n=482)]; geriatric placebo-controlled [1 dementia trial (n=204)]." | 5.10 | Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. ( Alaka, K; Beasley, CM; Lindborg, SR; Taylor, CC, 2003) |
| " Acutely agitated inpatients with schizophrenia were treated with 1 to 3 IM injections to olanzapine 10 mg or haloperidol 7." | 5.10 | A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. ( Birkett, M; Breier, A; Lindborg, SR; Meehan, K; Morris, P; Taylor, CC; Wright, P, 2003) |
| "This was a 2-year, randomized, double-blind comparison of 6 mg of risperidone versus haloperidol in 63 patients with stabilized DSM-IV schizophrenia." | 5.10 | Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. ( Blair, KE; Glynn, SM; Liberman, RP; Marder, SR; Mintz, J; Ross, D; Widmark, C; Wirshing, DA; Wirshing, WC, 2003) |
| "Partially responsive outpatients with schizophrenia who participated in a 10-week, parallel-group, double-blind comparison of clozapine and haloperidol and who had an available magnetic resonance imaging scan were included in the current study." | 5.10 | The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. ( Arango, C; Breier, A; Buchanan, RW; Carpenter, WT; McMahon, R, 2003) |
| "44 patients with chronic DSM-IV schizophrenia were treated with clozapine or haloperidol decanoate in an open prospective 6-month trial." | 5.10 | The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. ( Mester, R; Shabash, E; Sheitman, B; Spivak, B; Weizman, A, 2003) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 5.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "These results suggest that there is not a significant differential effect of olanzapine and haloperidol on the P50 sensory gating index in schizophrenia." | 5.10 | Olanzapine effects on auditory sensory gating in schizophrenia. ( Arango, C; Buchanan, RW; Summerfelt, A, 2003) |
| "Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia." | 5.10 | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. ( Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A, 2003) |
| "To compare the six-week clinical response and safety profile of schizophrenia patients, age > or =60 years, receiving olanzapine (OLZ) vs haloperidol (HAL) in a double blind, randomized trial." | 5.10 | Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. ( Breier, A; Bymaster, FP; Dossenbach, M; Gilmore, JA; Golshan, S; Jeste, D; Kaiser, CJ; Kennedy, JS; Kinon, BJ; Maguire, GA; Sanger, T; Tollefson, G, 2003) |
| "To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia." | 5.10 | Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003) |
| " haloperidol during the first 24 hours of treatment of acute schizophrenia." | 5.10 | Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. ( Alaka, K; Battaglia, J; Birkett, M; Bitter, I; Breier, A; Chouinard, G; Ferchland-Howe, I; Jones, B; Lindborg, SR; Meehan, K; Morris, PL; Pickard, A; Roth, J; Taylor, CC; Wright, P, 2003) |
| "Randomized controlled trial comparing risperidone and haloperidol regarding relapse in patients with schizophrenia treated with flexible doses during one year." | 5.10 | Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. ( de Sena, EP; Miranda-Scippa, A; Oliveira, IR; Quarantini, Lde C; Santos-Jesus, R, 2003) |
| " We performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older, conventional neuroleptic drug, haloperidol, in terms of the rate of relapse in patients with schizophrenia and schizoaffective disorder." | 5.10 | A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. ( Brenner, R; Csernansky, JG; Mahmoud, R, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "To more clearly clarify the efficacy of the atypical antipsychotics compared to conventional antipsychotics, we add data on the outcome of patients diagnosed with schizophrenia from two large, international clinical trials comparing olanzapine with haloperidol (n = 1996) and olanzapine with risperidone (n = 339)." | 5.10 | Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. ( Berg, PH; Glick, ID, 2002) |
| "The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial." | 5.10 | The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. ( Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002) |
| "A multicenter, double-blind study was conducted to determine rates of symptomatic exacerbation and adverse effects in 105 outpatients with schizophrenia randomly assigned to four different fixed doses of haloperidol decanoate and treated for 1 year or until relapse." | 5.10 | A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. ( Brauzer, B; Casey, D; Conley, R; Davis, JM; Kane, JM; Marder, S; Mintz, J; Schooler, N, 2002) |
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 5.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| "The association of clinical characteristics with a sustained response was investigated in 37 partially treatment-refractory outpatients with a DSM-III-R diagnosis of chronic schizophrenia who had been assigned to clozapine treatment in a double-blind, haloperidol-controlled, long-term (29-week) study of clozapine." | 5.10 | Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. ( Kane, JM; Marder, SR; McMeniman, M; Schooler, NR; Umbricht, DS; Wirshing, DA; Wirshing, WC, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 5.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 5.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| " This study compared ziprasidone with the conventional antipsychotic haloperidol in outpatients with stable schizophrenia." | 5.10 | A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. ( Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A, 2002) |
| "This study compared the effect of clozapine and haloperidol on positive and negative symptoms of schizophrenia and in patients with high levels of negative symptoms or the deficit syndrome." | 5.09 | Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Dunn, L; Peszke, M; Rosenheck, R; Thomas, J; Xu, W, 1999) |
| " In this post hoc analysis of the Brief Psychiatric Rating Scale anxiety-depression cluster, olanzapine therapy was associated with a significantly greater baseline-to-end-point improvement in the cluster compared with haloperidol therapy among 1996 randomized, double-blind subjects." | 5.09 | Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? ( Sanger, TM; Tollefson, GD, 1999) |
| "Cyproheptadine is a relatively safe compound and may be of therapeutic benefit in treating negative symptoms of schizophrenia in combination with typical neuroleptics." | 5.09 | Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. ( Akhondzadeh, S; Amini-Nooshabadi, H; Davari-Ashtiani, R; Mohammadi, MR, 1999) |
| "Data from a 15-site randomized clinical trial were used to compare clozapine with haloperidol in hospitalized Veterans Affairs patients with refractory schizophrenia (n = 423)." | 5.09 | Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Allan, E; Charney, D; Cramer, J; Erdos, J; Frisman, LK; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 1999) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| "The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia." | 5.09 | Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1999) |
| " A 6-week, double-blind randomized multicenter trial, with a long-term extension, was conducted to evaluate the clinical efficacy and QOL of olanzapine and haloperidol in treating schizophrenia and other psychotic disorders." | 5.09 | Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. ( Beasley, CM; Ganoczy, D; Genduso, LA; Hamilton, SH; Revicki, DA, 1999) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 5.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "We utilize data from a large, double-blind, randomized clinical trial of treatment for schizophrenia to compare the effect of therapy with the second generation antipsychotic olanzapine versus therapy with the conventional agent haloperidol on the perceived functioning and well-being of patients over 1 year as measured by the Medical Outcome Study Short Form (SF-36)." | 5.09 | Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. ( Dulisse, BK; Gibson, PJ; Johnstone, BM; Loosbrock, DL; Tunis, SL, 1999) |
| " The ketamine challenge study in schizophrenia subjects is at the vortex of the current debate." | 5.09 | The schizophrenia ketamine challenge study debate. ( Carpenter, WT, 1999) |
| "The purpose of this study was to compare, from the payor perspective, the clinical and economic outcomes of olanzapine to those of haloperidol for the treatment of schizophrenia." | 5.09 | Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. ( Edgell, ET; Genduso, LA; Hamilton, SH; Revicki, DA; Tollefson, G, 1999) |
| " A double-blind trial compared clozapine and haloperidol in patients with schizophrenia who were refractory to conventional antipsychotic medication and were hospitalized for 30 to 364 days at 15 Veteran Affairs medical centers during the year before study entry." | 5.09 | How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. ( Charney, D; Cramer, J; Evans, D; Henderson, W; Herz, L; Rosenheck, R; Thomas, J; Xu, W, 1999) |
| "To help determine whether sustained attention deficits as measured with the Continuous Performance Test (CPT) are stable vulnerability indicators of schizophrenia, we compared the CPT performance of schizophrenic patients before and after treatment with risperidone or haloperidol." | 5.09 | Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. ( Chang, CJ; Chen, WJ; Lin, HN; Liu, SK, 2000) |
| "The aim of the study was to examine effects of haloperidol on the relationships between neuropsychological measures of frontal lobe functioning and the schizophrenia syndromes of psychomotor poverty and disorganization." | 5.09 | Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes. ( Allen, DN; Anastasiou, A; Gilbertson, M; Goldstein, G; van Kammen, DP, 2000) |
| "This international, 6-week, multicentre, double-blind, randomized, parallel-group trial compared quetiapine with haloperidol (455 mg and 8 mg mean total daily doses, respectively) in 448 hospitalized patients with acute exacerbation of chronic or subchronic schizophrenia (DSM-III-R), in order to establish their equivalence in terms of efficacy, and the nature of their tolerability profiles, especially in terms of extrapyramidal symptoms (EPS) and serum prolactin levels." | 5.09 | A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. ( Copolov, DL; Kowalcyk, B; Link, CG, 2000) |
| " In this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months." | 5.09 | Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. ( Colonna, L; Dondey-Nouvel, L; Rein, W; Saleem, P, 2000) |
| "Data from a 15-site double-blind, randomized clinical trial (N = 423) were used to compare patients with DSM-III-R schizophrenia assigned to clozapine or haloperidol in terms of duration of participation while taking the randomly assigned study drug (continuation) and the proportion of prescribed pills that were taken (compliance)." | 5.09 | Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. ( Chang, S; Charney, D; Choe, Y; Cramer, J; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 2000) |
| "Dipyridamole may be of therapeutic benefit in treating schizophrenia in combination with neuroleptics." | 5.09 | Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. ( Akhondzadeh, S; Jamilian, H; Kamalipour, A; Shabestari, O; Shasavand, E, 2000) |
| "The primary aim of this study was to compare functional outcomes between patients with schizophrenia treated with olanzapine or haloperidol in Europe." | 5.09 | Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. ( Breier, A; Edgell, ET; Hamilton, SH; Revicki, DA, 2000) |
| "Long-stay patients with schizophrenia in a state hospital were randomly assigned to begin open-label clozapine (n = 138) or to continue receiving conventional antipsychotic medications (n = 89)." | 5.09 | Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. ( Covell, NH; Essock, SM; Frisman, LK; Hargreaves, WA, 2000) |
| "This study compares the effect of clozapine and haloperidol and identifies other factors related to family burden as experienced by relatives of patients with refractory schizophrenia (DSM-III-R)." | 5.09 | Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Henderson, W; Jurgis, G; Perlick, D; Rosenheck, R; Thomas, J; Xu, W, 2000) |
| "In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months." | 5.09 | Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). ( Bonhomme, D; Carrière, P; Lempérière, T, 2000) |
| "Effects of flexible doses of risperidone and haloperidol were compared in 77 psychotic patients (83% with chronic schizophrenia) with disturbing neuroleptic-induced EPS (risperidone 40 patients, haloperidol 37)." | 5.09 | Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. ( de Groot, IW; Haffmans, PM; Heck, AH; Hoencamp, E, 2000) |
| "The purpose of the study was to evaluate the effect of the classic antipsychotic haloperidol plus extract of ginkgo biloba (EGb) on treatment-resistant chronic schizophrenia and on blood superoxide dismutase (SOD) levels." | 5.09 | The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. ( Su, JM; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "Previously, a double-blind, 6-week, parallel-group trial compared the therapeutic profiles of olanzapine (5-20 mg/day; N = 1,336) and haloperidol (5-20 mg/day; N = 660) in 1996 patients with DSM-III-R schizophrenia (83." | 5.09 | Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. ( Crawford, AM; Gomez, JC, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "After a 48-hour washout period, 25 patients with schizophrenia were randomly assigned to double-blind treatment with quetiapine or haloperidol for 6 months and evaluated with rating scales for psychotic symptoms, mood and extrapyramidal side effects, as well as standardized neuropsychological measures sensitive to 6 cognitive domains: fine motor skill, attention span, verbal reasoning and fluency, visuospatial construction and fluency, executive skills and visuomotor tracking, and immediate recall of verbal and nonverbal materials." | 5.09 | Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. ( Labelle, A; Lit, W; Malla, A; Purdon, SE, 2001) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 5.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Atypical antipsychotics, such as risperidone, have been shown to be more effective for the treatment of the symptoms of schizophrenia and have a greater beneficial effect on neurocognition compared to the conventional antipsychotics." | 5.09 | Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. ( Andreasen, NC; Boles Ponto, LL; Hichwa, RD; Miller, DD; O'Leary, DS; Watkins, GL, 2001) |
| " The Veterans Affairs (VA) Cooperative Study of Clozapine in Refractory Schizophrenia evaluated 423 patients on clozapine or haloperidol." | 5.09 | Detecting improvement in quality of life and symptomatology in schizophrenia. ( Charney, D; Cramer, J; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "During an 8-week period, 227 patients with DSM-III chronic schizophrenia received 4 mg/day of risperidone and 226 patients received 10 mg/day of haloperidol." | 5.09 | Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. ( Davidson, M; Hornik, T; Rabinowitz, J, 2001) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 5.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 5.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| " Patients with schizophrenia and related disorders (ICD-10) who were taking haloperidol (N = 94; mean dose = 12." | 5.09 | Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. ( Alvarez, N; Costa e Silva, JA; Cousins, L; Gattaz, WF; Larach, V; Mazzotti, G; Oliva, D; Ospina, J; Starkstein, S; Taylor, CC; Tohen, M; Tran, PV; Wang, J, 2001) |
| "Despite the demonstrated efficacy of clozapine in severely refractory schizophrenia, questions remain regarding its efficacy for primary negative symptoms, comparison with a moderate dose of a first-generation antipsychotic, and adverse effects during a longer-term trial." | 5.09 | Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. ( Baker, RW; Borenstein, M; Ganguli, R; Kane, JM; Marder, SR; McMeniman, M; Safferman, A; Schooler, NR; Umbricht, D; Wirshing, DA; Wirshing, WC, 2001) |
| "Neurocognition and clinical symptomatology were evaluated in 27 patients with schizophrenia during a double-blind, placebo-controlled, cross-over study involving clozapine, an atypical antipsychotic agent, and haloperidol, a conventional neuroleptic." | 5.09 | Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. ( Fleming, K; Gulasekaram, B; Jin, Y; Potkin, SG, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 5.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "In 54 patients with chronic refractory schizophrenia, 27 were treated with haloperidol plus EGb (group 1), and the rest received haloperidol plus placebo (group 2)." | 5.09 | The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. ( Cui, Y; Guan, Z; Liu, J; Nan, Z; Shen, Y; Su, J; Zhang, P; Zhang, X; Zhou, D, 1999) |
| "One hundred nine patients meeting DSM-III-R criteria for schizophrenia completed a double-blind, placebo-controlled, parallel-group study of EGb plus haloperidol." | 5.09 | A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. ( Cao, LY; Su, JM; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| " The purpose of this study was to compare the efficacy and safety of zotepine and haloperidol in Taiwanese patients with schizophrenia." | 5.09 | Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. ( Hwang, TJ; Lin, HN; Lin, SK, 2001) |
| "The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients." | 5.08 | A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. ( Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR, 1995) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 5.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "Plasma haloperidol levels between 5 and 11 ng/mL may be clinically optimal for acutely exacerbated schizophrenia, but the evidence for this therapeutic window has been inconsistent." | 5.08 | Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. ( Cooper, TB; Czobor, P; Meisner, M; Volavka, J, 1995) |
| "Alosetron is under clinical development for the treatment of schizophrenia." | 5.08 | Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. ( Gupta, SK; Kunka, RL; Lloyd, T; Metz, A; Perel, JM; Rudolph, G, 1995) |
| "The weight and symptoms of 39 outpatients with schizophrenia who were randomly assigned to double-blind treatment with either clozapine or haloperidol were assessed." | 5.08 | Differential effect of clozapine on weight: a controlled study. ( Breier, A; Buchanan, RW; Bustillo, JR; Irish, D, 1996) |
| "Seven patients with schizophrenia were treated with 2 mg/day of haloperidol for 2 weeks, and D2 receptor occupancy was measured by [11C]raclopride and positron emission tomography." | 5.08 | High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. ( DaSilva, J; Houle, S; Jones, C; Kapur, S; Remington, G; Wilson, A; Zipursky, R, 1996) |
| "5 mg/day [Olz-H]) to a dosage range of haloperidol (15 +/- 5 mg/day [Hal]) and to placebo in the treatment of 335 patients who met the DSM-III-R criteria for schizophrenia." | 5.08 | Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. ( Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P, 1996) |
| "The subjects were 62 patients hospitalized for acute exacerbations of schizophrenia and were randomly assigned to receive risperidone (mean dose, 7." | 5.08 | Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. ( Azorin, JM; Blin, O; Bouhours, P, 1996) |
| " Nicotine has a variety of pharmacologic effects that may both counteract some of the cognitive deficits of schizophrenia and counteract some of the adverse side effects of antipsychotic drugs." | 5.08 | Nicotine-haloperidol interactions and cognitive performance in schizophrenics. ( Levin, ED; McEvoy, J; Rose, JE; Wilson, W, 1996) |
| "Double-blind haloperidol was administered during two consecutive 3-week periods to 65 patients with acutely exacerbating schizophrenia or schizoaffective disorder." | 5.08 | Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. ( Cooper, TB; Czobor, P; Meisner, M; Volavka, J, 1996) |
| "The atypical antipsychotic zotepine was compared to haloperidol in 126 patients suffering from acute exacerbation of schizophrenia (DSM-III-R) in a randomized, double-blind study." | 5.08 | A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. ( Dollfus, S; Kelly, F; Leutenegger, E; Petit, M; Raniwalla, J; Tweed, J, 1996) |
| "Patients were investigated to gain more insight into the incidence and time course of clozapine induced weight gain (n = 81) and to compare weight gain in patients treated with clozapine (n = 31) with that of patients treated with standard antipsychotics (haloperidol, n = 11)." | 5.08 | Weight gain induced by clozapine. ( Fleischhacker, WW; Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H, 1995) |
| "Treatment-emergent eosinophilia occurred frequently in both haloperidol- and clozapine-treated patients." | 5.08 | Predictive value of eosinophilia for neutropenia during clozapine treatment. ( Ames, D; Baker, RW; Carter, J; Kane, JM; Marder, SR; Schooler, NR; Sun, AB; Umbricht, DS; Wirshing, WC, 1996) |
| "Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone." | 5.08 | Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. ( Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H, 1997) |
| "This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia." | 5.08 | Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997) |
| "0 mg/day) and with a dose range of haloperidol (15 +/- 5 mg/day) in the treatment of 431 patients with schizophrenia." | 5.08 | Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. ( Beasley, CM; Beuzen, JN; Blin, O; Crawford, AM; Dellva, MA; Hamilton, SH; Tollefson, GD; Tran, PV, 1997) |
| "The current study uses utility analysis to assess economic and quality-of-life benefits of risperidone in patients with chronic schizophrenia." | 5.08 | Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. ( Albright, PS; Chouinard, G, 1997) |
| "In a large, multicenter, double-blind study of the effect of haloperidol and the atypical antipsychotic remoxipride on improvement of negative symptoms in schizophrenia, quality of life was also assessed using a modified version of the Sickness Impact Profile (SIP)." | 5.08 | Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. ( Angus, C; Awad, AG; Lapierre, YD; Rylander, A, 1997) |
| "In line with the autoimmune hypothesis of schizophrenia we have tested in this study whether the commonly used neuroleptics, clozapine and haloperidol can also act as systemic immunosuppressants." | 5.08 | Short and long-term immunosuppressive effects of clozapine and haloperidol. ( Leykin, I; Mayer, R; Shinitzky, M, 1997) |
| "Data were analyzed from three actively controlled and blind long-term responder studies of subjects meeting DSM-III-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 707, up to 20 mg/day, 237 median days of exposure) or haloperidol (N = 197, up to 20 mg/day, 203 median days of exposure) who did not have evidence of tardive dyskinesia at baseline." | 5.08 | Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. ( Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV, 1997) |
| "For patients with refractory schizophrenia and high levels of hospital use, clozapine was somewhat more effective than haloperidol and had fewer side effects and similar overall costs." | 5.08 | A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Frisman, L; Fye, C; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 1997) |
| " This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia." | 5.08 | Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997) |
| "This double-blind study evaluated the impact of treatment with olanzapine compared with haloperidol, and placebo on improvements in symptomatology and quality of life in patients with a DSM-III-R diagnosis of schizophrenia." | 5.08 | Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. ( Beasley, CM; Genduso, LA; Hamilton, SH; Revicki, DA, 1998) |
| "Inpatients with acute exacerbations of DSM-III schizophrenia (N = 66) were randomly assigned to receive fixed haloperidol doses intended to achieve plasma levels of 8-18 ng/ml or of 25-35 ng/ml." | 5.08 | Haloperidol plasma levels and dose optimization. ( Coryell, W; Miller, DD; Perry, PJ, 1998) |
| "In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo." | 5.08 | The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. ( Chouinard, G; Davis, JM; Marder, SR, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 5.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 5.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| "Sertindole is an atypical antipsychotic that is efficacious in schizophrenia and is associated infrequently with extrapyramidal symptoms (EPS)." | 5.08 | Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. ( Daniel, DG; Mack, RJ; McCarthy, BG; Wozniak, P, 1998) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 5.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| "This study was conducted to determine whether the addition of naltrexone to ongoing neuroleptic treatment would facilitate the reduction in positive or negative symptoms in patients with schizophrenia." | 5.08 | Naltrexone augmentation of neuroleptics in schizophrenia. ( Charney, DS; Glazer, WM; Heninger, GR; Krystal, JH; Petrakis, IL; Price, LH; Sernyak, MJ; Woods, SW, 1998) |
| "In a preliminary report, the authors observed that clozapine was superior to haloperidol in the treatment of positive and negative symptoms in stable outpatients with schizophrenia." | 5.08 | Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. ( Ball, P; Breier, A; Buchanan, RW; Carpenter, WT; Kirkpatrick, B, 1998) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 5.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| "Subjects participated in a 12-month double-blind random-assignment trial comparing clozapine and haloperidol in patients hospitalized 30 to 364 days for refractory schizophrenia at 15 Department of Veterans Affairs medical centers." | 5.08 | Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Fontana, A; Henderson, W; Peters, J; Rosenheck, R; Tekell, J; Thomas, J; Xu, W, 1998) |
| "Data were from a 15-site randomized clinical trial comparing clozapine and haloperidol in hospitalized patients with refractory schizophrenia (n = 423)." | 5.08 | Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Crayton, J; Lawson, W; Rosenheck, R; Stolar, M; Thomas, J; Xu, W, 1998) |
| "We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol." | 5.08 | A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. ( Kim, YK; Lee, MS; Lee, SK; Suh, KY, 1998) |
| " Patients were recruited from a haloperidol-controlled, double-blind treatment study of clozapine in chronic schizophrenia." | 5.08 | Effects of clozapine on auditory event-related potentials in schizophrenia. ( Bates, J; Javitt, D; Kane, J; Lieberman, J; Novak, G; Pollack, S; Umbricht, D, 1998) |
| "A 12-month double-blind trial compared clozapine (n = 205) and haloperidol (n = 218) in the treatment of refractory schizophrenia." | 5.08 | Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. ( Charney, D; Cramer, J; Douyon, R; Grabowski, J; Henderson, W; Rosenheck, R; Thomas, J; Xu, W, 1998) |
| "Clinical improvement (20% reduction in total scores on the Positive and Negative Syndrome Scale for Schizophrenia) at the study end point was shown by 35% of the patients receiving 2 mg of risperidone, 57% receiving 6 mg, 40% receiving 10 mg, and 51% receiving 16 mg; and by 30% receiving haloperidol and 22% receiving placebo." | 5.07 | Risperidone in the treatment of schizophrenia. ( Marder, SR; Meibach, RC, 1994) |
| "In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, after a single-blind placebo washout period." | 5.07 | A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. ( Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G, 1993) |
| "Four patients with chronic schizophrenia were treated with a combination of fluvoxamine, haloperidol, and benztropine." | 5.07 | Coadministration of fluvoxamine increases serum concentrations of haloperidol. ( Abi-Dargham, A; Daniel, DG; Egan, M; Elkashef, A; Handel, S; Jaskiw, G; Liboff, S; Randolph, C; Shoaf, S; Williams, T, 1994) |
| "This double-blind placebo controlled, parallel design clinical trial compared the therapeutic effects of the addition of lithium or placebo to haloperidol in 21 seriously ill state hospital patients with DSM-III-R schizophrenia, who did not have concurrent affective disorders and who had not responded to previous trials of conventional antipsychotic medication." | 5.07 | Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. ( Wilson, WH, 1993) |
| "Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia." | 5.07 | Clozapine in tardive dyskinesia: observations from human and animal model studies. ( Gao, XM; Kakigi, T; Moran, M; Tamminga, CA; Thaker, GK, 1994) |
| "Plasma clozapine and haloperidol concentrations were studied in adolescents being treated for childhood-onset schizophrenia." | 5.07 | Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. ( Albus, KE; Frazier, JA; Gordon, CT; Grothe, DR; McKenna, K; Piscitelli, SC; Rapoport, JL, 1994) |
| "Sixty-two first-episode psychotic patients who were neuroleptic-naive were studied to examine predictors of acute dystonia after treatment with haloperidol." | 5.07 | Predictors of acute dystonia in first-episode psychotic patients. ( Aguilar, EJ; Gómez-Beneyto, M; Hernández, J; Keshavan, MS; Martínez-Quiles, MD; Schooler, NR, 1994) |
| "Haloperidol levels in blood were measured in 55 acutely psychotic inpatients with schizophrenia, who were randomly assigned to three fixed doses of oral haloperidol." | 5.07 | Blood levels of haloperidol and clinical outcome in schizophrenia. ( Borenstein, M; Cooper, T; Doddi, S; Karajgi, B; Rifkin, A, 1994) |
| "Clozapine is an atypical neuroleptic medication with superior efficacy to conventional antipsychotic agents for patients with chronic, symptomatic schizophrenia." | 5.07 | The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. ( Breier, A; Buchanan, RW; Goldstein, DS; Holmes, C; Listwak, S; Waltrip, RW, 1994) |
| "Outpatients with schizophrenia who had histories of partial response to conventional neuroleptics and who had not responded to a prospective 6-week trial of fluphenazine participated in a 10-week, double-blind, parallel-groups comparison of clozapine and haloperidol." | 5.07 | Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. ( Breier, A; Buchanan, RW; Carpenter, WT; Davis, OR; Irish, D; Kirkpatrick, B; Summerfelt, A, 1994) |
| "Twenty-eight acutely psychotic patients with schizophrenia who were admitted to an emergency psychiatric service were randomly assigned to treatment with either haloperidol and alprazolam or haloperidol with placebo under double-blind conditions." | 5.07 | Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. ( Barbee, JG; Freed, CR; Mancuso, DM; Todorov, AA, 1992) |
| " The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol." | 5.07 | Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. ( Aizenberg, D; Hermesh, H; Lapidot, M; Mayor, C; Munitz, H; Weizman, A, 1992) |
| "Two hundred and forty-two patients with acute schizophrenia were enrolled in a double-blind, comparative, dose-finding study of a novel antipsychotic, remoxipride." | 5.07 | A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. ( Ancill, R; Awad, G; Bakish, D; Beaudry, P; Bloom, D; Chandrasena, R; Das, M; Durand, C; Elliott, D; Lapierre, YD, 1992) |
| " Ninety-one patients with acute schizophrenia received either raclopride 2-8 mg twice daily or haloperidol 5-20 mg twice daily for 4 weeks." | 5.07 | A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. The British Isles Raclopride Study Group. ( , 1992) |
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 5.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| "Plasma prolactin concentration (pPRL), plasma homovanillic acid concentration (pHVA), and symptomatology were measured in 24 male subjects with schizophrenia during maintenance haloperidol treatment." | 5.07 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| "In an open label study, two fixed doses of nifedipine (30 mg and 60 mg daily) were added to the usual antipsychotic drug treatments of 10 patients suffering from chronic schizophrenia." | 5.07 | Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. ( Eyles, D; Pond, SM; Stedman, TJ; Welham, JL; Whiteford, HA, 1991) |
| "Plasma concentrations of remoxipride and haloperidol as well as prolactin (PRL) were determined in 20 patients with acute symptoms of schizophrenia." | 5.07 | Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients. ( Appelberg, B; Katila, H; Kuoppasalmi, K; Lahdelma, RL; Rimón, R, 1991) |
| "Patients with an index diagnosis of schizophrenia were compared to patients with an index diagnosis of schizophreniform disorder to determine if they differed in latency to therapeutic response to haloperidol." | 5.07 | Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. ( Garver, DL; McDermott, BE; Sautter, FJ, 1991) |
| "After individual determination of neuroleptic threshold (NT) doses of haloperidol, 106 patients with schizophrenia or schizoaffective disorder (Research Diagnostic Criteria) were treated openly at such doses (mean, 3." | 5.07 | Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. ( Hogarty, GE; McEvoy, JP; Steingard, S, 1991) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 5.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| "Eighty-seven newly admitted inpatients with schizophrenia were randomized to receive 10, 30, or 80 mg/d of oral haloperidol." | 5.07 | Dosage of haloperidol for schizophrenia. ( Borenstein, M; Doddi, S; Karajgi, B; Rifkin, A; Wachspress, M, 1991) |
| "Seventy-two patients fulfilling the DSM-III criteria for schizophrenia and schizophreniform psychosis were admitted to a multicentre, double-blind controlled study to evaluate the efficacy and safety of remoxipride in comparison to haloperidol." | 5.06 | A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. ( Andersen, J; Birket-Smith, M; Fensbo, C; Fogh, M; Hansen, NR; Kristensen, M; Kørner, A; Møller-Nielsen, EM; Ostergaard, P; Thiesen, S, 1990) |
| "Seventy-one patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder." | 5.06 | A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. ( den Boer, JA; Huisman, J; Ohrvik, J; Ravelli, DP; Verhoeven, WM; Westenberg, HG, 1990) |
| "The efficacy and safety of remoxipride in the treatment of schizophrenia were compared with those of haloperidol in a multicentre double-blind 6-week study which was randomized with a parallel group design and was preceded by a washout period." | 5.06 | Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. ( Chanas, A; Deo, R; Edwards, JG; Levine, S; Mitchell, M; Plant, I; Rastogi, SC; Soni, S, 1990) |
| "The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double-blind study with parallel group design comprising 98 patients with schizophrenia or schizophreniform disorder according to DSM-III." | 5.06 | A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. ( Cosyns, P; de Bleeker, E; Deleu, G; Lotstra, F; Masson, A; Mendlewicz, J; Mertens, C; Parent, M; Peuskens, J; Suy, E, 1990) |
| "Eighteen patients (7 men, 11 women) from one of the centres taking part in a multicentre comparative study of remoxipride and haloperidol in the treatment of acute schizophrenia were investigated separately to study the effect of the two neuroleptic drugs on cognitive abilities." | 5.06 | Cognitive disturbances in neuroleptic therapy. ( Klieser, E; Strauss, WH, 1990) |
| "A total of 186 patients who met the DSM-III criteria for schizophrenia were admitted to a double-blind randomized multicentre trial in which the efficacy and safety of remoxipride at two dose levels was compared with those of haloperidol." | 5.06 | A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. ( Agussol, P; Alby, JM; Brion, S; Burnat, G; Castelnau, D; Deluermoz, S; Dufour, H; Ferreri, M; Goudemand, M; Patris, M, 1990) |
| "Nine double-blind studies comparing remoxipride to haloperidol in the treatment of acute schizophrenia formed the basis of this analysis." | 5.06 | Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme. ( Lewander, T; Morrison, D; Westerbergh, SE, 1990) |
| "Ninety-two patients with schizophrenia were included in a double-blind multicentre parallel-group trial comparing remoxipride and haloperidol." | 5.06 | Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. ( Ahlfors, UG; Appelberg, B; Hagert, U; Harma, P; Katila, H; Mahlanen, A; Mehtonen, OP; Naukkarinen, H; Outakoski, J; Rimön, R, 1990) |
| "The efficacy of the use of moditen-depo and haloperidol decanoate as preventive anti-recurrence+ therapy was studied and compared in 2 groups of patients suffering from attack-like schizophrenia with frequent exacerbations." | 5.06 | [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. ( Kalugina, LI; Kopeĭko, GI; Kravchenko, NE; Mirzoian, MG; Ushakov, IuV, 1990) |
| "The impact of haloperidol treatment on the Wechsler Adult Intelligence Scale (WAIS) and the Thought Disorder Index was investigated in a group of 19 patients with schizophrenia tested both before and after 26 days of treatment with haloperidol." | 5.06 | The effects of haloperidol on thought disorder and IQ in schizophrenia. ( Gold, JM; Hurt, SW, 1990) |
| "Twenty-five inpatients with acute exacerbations of schizophrenia (by Research Diagnostic Criteria) or schizoaffective disorder underwent a prospective haloperidol dosing procedure and were assigned fixed doses chosen to yield a distribution of haloperidol plasma levels above and below a hypothesized upper therapeutic limit of 18 ng/ml." | 5.06 | Haloperidol plasma levels and acute clinical change in schizophrenia. ( Coryell, W; Kelly, M; Miller, DD; Perry, PJ, 1990) |
| "Eighty newly admitted or readmitted men with DSM-III schizophrenia were assigned to receive 5, 10, or 20 mg/d of haloperidol for 4 weeks." | 5.06 | A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. ( Marder, SR; Mintz, J; Van Putten, T, 1990) |
| "To establish the differential indication of trazodone and to find the predictors of its efficacy, we conducted a study in which 45 patients with major depressive disorder and 75 patients with acute schizophrenia were randomly assigned under double-blind conditions to either 400 mg trazodone daily, 150 mg amitriptyline daily, 20 mg haloperidol daily, or placebo daily." | 5.06 | Experimental examination of trazodone. ( Klieser, E; Lehmann, E, 1989) |
| "Twelve male patients suffering from acute paranoid schizophrenia, randomly receiving fluperlapine - a new dibenzodiazepine very similar to clozapine - or haloperidol were included in a double blind study." | 5.06 | Fluperlapine vs haloperidol: a comparison of their neuroendocrinological profiles and the influence on serum lipids. ( Fleischhacker, WW; Hinterhuber, H; Moser, C; Schubert, H; Stuppäck, C, 1986) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 5.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "The antipsychotic effects of verapamil were tested in a double-blind, placebo-controlled, randomized study in 18 patients who met Research Diagnostic Criteria for acute schizophrenia." | 5.06 | Antipsychotic effects of verapamil in schizophrenia. ( Price, WA, 1987) |
| "Thirty patients with chronic schizophrenia received oral haloperidol and haloperidol decanoate in a two-phase open study." | 5.06 | A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. ( Achim, A; Lizondo, E; Nayak, R; Schwartz, G; Suranyi-Cadotte, B; Thavundayil, JX; Vasavan Nair, NP, 1986) |
| "A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms." | 5.05 | Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. ( Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020) |
| "The efficacy and safety of timiperone, a new butyrophenone derivative, in schizophrenia as compared with haloperidol were assessed in a multi-clinic double-blind controlled study in a total of 206 patients." | 5.05 | A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique. ( Itoh, H; Kariya, T; Mori, A; Murasaki, M; Shimazono, Y; Sugano, K; Toru, M; Yamashita, I, 1983) |
| "Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia." | 5.05 | Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. ( Dubini, A; Freeman, HL; Levine, S; Silverstone, T, 1984) |
| "Pimozide and haloperidol were found to be equally effective in the treatment of acute schizophrenia in a double-blind clinical trial involving 22 patients." | 5.05 | The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. ( Ball, R; Chin, CN; Cookson, J; Gould, S; Jacobs, D; Lader, S; Silverstone, T, 1984) |
| "Two investigators have recently suggested therapeutic ranges for plasma haloperidol in the treatment of schizophrenia." | 5.05 | Haloperidol plasma and red blood cell levels and clinical antipsychotic response. ( Garver, DL; Glicksteen, GA; Hirschowitz, J; Kanter, DR; Mavroidis, ML, 1984) |
| "To review the effects of haloperidol discontinuation in people with schizophrenia who are stable on haloperidol." | 5.01 | Haloperidol discontinuation for people with schizophrenia. ( AbouDamaah, A; Aboudamaah, S; AlMounayer, N; Diaa Aldeen, MR; Essali, A; Marwa, ME; Turkmani, K, 2019) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 4.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "PubMed/Medline and EBSCO databases were searched using the keywords: diabetic ketoacidosis, antipsychotics, atypical antipsychotics, second generation antipsychotics, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, paliperidone, amisulpride and haloperidol." | 4.95 | Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. ( Baretic, M; Kuzman, MR; Osvatic, MM; Vuk, A, 2017) |
| "In treatment-resistant schizophrenia, clozapine is considered the standard treatment." | 4.93 | Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. ( Dold, M; Gianatsi, M; Helfer, B; Leucht, S; Nikolakopoulou, A; Salanti, G; Samara, MT, 2016) |
| "A systematic literature survey (Cochrane Schizophrenia Group trial register) was applied to identify all RCTs that compared oral haloperidol with another oral FGA in schizophrenia." | 4.93 | Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. ( Dold, M; Kasper, S; Leucht, S; Li, C; Samara, MT; Tardy, M, 2016) |
| "To examine whether haloperidol alone, administered orally, intramuscularly or intravenously, is an effective treatment for long-term/persistent aggression in psychosis." | 4.93 | Haloperidol for long-term aggression in psychosis. ( Khushu, A; Powney, MJ, 2016) |
| "To compare the efficacy, acceptability, and tolerability of haloperidol with other first-generation antipsychotics in schizophrenia and schizophrenia-like psychosis." | 4.91 | Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. ( Dold, M; Leucht, S; Li, C; Samara, MT; Tardy, M, 2015) |
| "To review the effects in clinical response of haloperidol and low-potency antipsychotics for people with schizophrenia." | 4.90 | Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Kissling, W; Leucht, S; Tardy, M, 2014) |
| "To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia." | 4.89 | Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Donnelly, L; Rathbone, J, 2013) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo." | 4.89 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Bergman, H; Irving, CB; Lawrie, S, 2013) |
| " Second, we review the studies that have examined latent inhibition in populations with schizophrenia and in healthy populations after administration of amphetamine or haloperidol." | 4.88 | The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)? ( Le Pelley, M; Schmidt-Hansen, M, 2012) |
| "To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar conditions." | 4.88 | Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. ( Gibson, RC; Gunadasa, S; Jayakody, K; Kumar, A, 2012) |
| " When the risk of adverse effects is analyzed, olanzapine and clozapine are afflicted with the highest risk of inducing weight gain and haloperidol with extrapyramidal symptoms." | 4.87 | A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. ( Aursnes, I; Gaasemyr, J; Klemp, M; Natvig, B; Skomedal, T; Tvete, IF, 2011) |
| "The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo." | 4.86 | Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. ( Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV, 2010) |
| "Pooled data were analyzed from 5 short-term, double-blind, multicenter studies (published between 1997 and 2007) involving patients hospitalized with acute exacerbation of schizophrenia (5 studies) or schizoaffective disorder (2 studies) and randomly assigned to aripiprazole (N = 875), haloperidol (N = 193), risperidone (N = 95), or placebo (N = 406)." | 4.85 | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. ( Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD, 2009) |
| " This report describes a case of drug-induced dysphagia in a 53-year-old man receiving haloperidol for treatment of schizophrenia." | 4.84 | Neuroleptic-induced dysphagia: case report and literature review. ( Dziewas, R; Nabavi, DG; Reker, T; Ringelstein, EB; Ritter, M; Schilling, M; Schnabel, M; Warnecke, T, 2007) |
| "Prospective, double-blind, randomized trials comparing atypical antipsychotic drugs (APDs) to typical APDs, such as haloperidol, indicate that atypical APDs provide a modest benefit to cognitive function in schizophrenia." | 4.84 | A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. ( Meltzer, HY; Purdon, SE; Woodward, ND; Zald, DH, 2007) |
| "Pooled data from two 52-week, randomized, double-blind, multicenter, comparative trials of aripiprazole and haloperidol in acutely ill patients with schizophrenia were analyzed." | 4.84 | Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. ( Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W, 2007) |
| "To compare the effects of haloperidol and chlorpromazine for people with schizophrenia and schizophrenia-like psychoses." | 4.84 | Haloperidol versus chlorpromazine for schizophrenia. ( Chua, L; Kane, J; Kitzmantel, M; Leucht, C; Leucht, S, 2008) |
| "This research compared the long-term efficacy and safety of iloperidone with those of haloperidol in individuals with schizophrenia." | 4.84 | Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. ( Di Marino, M; Kane, JM; Laska, E; Lauriello, J; Wolfgang, CD, 2008) |
| " The three case studies are (1) bupropion versus nicotine replacement therapy for smoking cessation, (2) risperidone versus haloperidol for schizophrenia, and (3) fluoxetine versus imipramine for depressive disorders." | 4.84 | Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. ( Harvey, I; Lilford, R; Song, F, 2008) |
| "Consistent with prior research, haloperidol-treated patients with bipolar disorder appeared to be more vulnerable to the development of EPS than those with schizophrenia." | 4.83 | Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. ( Berg, PH; Briggs, SD; Cavazzoni, PA; Kane, JM; Kryzhanovskaya, LA; Roddy, TE; Tohen, M, 2006) |
| "To determine the doses of haloperidol as a comparator drug in randomized controlled trials (RCTs) with atypical antipsychotics in patients with schizophrenia and to compare these doses with the officially recommended doses for haloperidol in the United States and the United Kingdom." | 4.83 | Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. ( Egberts, AC; Heerdink, ER; Hugenholtz, GW; Meijer, WE; Nolen, WA; Stolker, JJ, 2006) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared to placebo." | 4.83 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Joy, CB; Lawrie, SM, 2006) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 4.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| "Randomised clinical trials comparing new generation antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, sulpiride, ziprasidone, zotepine) with conventional antipsychotics for people with a first episode of schizophrenia or schizophrenia-like psychoses." | 4.82 | New generation antipsychotics for first episode schizophrenia. ( Hamann, J; Kissling, W; Leucht, S; Rummel, C, 2003) |
| " In phase III comparative clinical studies, aripiprazole 15-30 mg/day was at least as effective as haloperidol and risperidone in short term treatment of acute exacerbation of schizophrenia but superior to haloperidol in long term maintenance therapy." | 4.82 | Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. ( Lambert, M; Naber, D, 2004) |
| "A total of 1476 patients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in 5 short-term, double-blind studies comparing aripiprazole with placebo; 3 of these studies also included a comparison with haloperidol." | 4.82 | Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. ( Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J, 2005) |
| "The primary goal of this review is to determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia." | 4.81 | Haloperidol dose for the acute phase of schizophrenia. ( Adams, CE; Hamill, KM; Marti, J; Roque, M; Waraich, PS, 2002) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared to placebo." | 4.81 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Joy, CB; Lawrie, SM, 2001) |
| "Combined data on efficacy were available from 12 double-blind short-term (maximum 8 weeks) trials comparing risperidone and other antipsychotics in patients with chronic schizophrenia." | 4.81 | Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. ( Glick, ID; Lemmens, P; Vester-Blokland, E, 2001) |
| " We outline how the synaptic changes induced by the antipsychotic drug haloperidol may help our understanding of the mechanism of action of antipsychotic drugs in general, and how they may help to elucidate the neurobiology of schizophrenia." | 4.81 | Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. ( Heckers, S; Konradi, C, 2001) |
| "Haloperidol is the most commonly used antipsychotic drug in the therapy of acute schizophrenia." | 4.80 | The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. ( Brosz, M; Meyer, FP; Ulrich, S; Wurthmann, C, 1998) |
| "The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics." | 4.80 | Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. ( Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G, 1999) |
| " Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenia, particularly its negative symptoms, with a substantially more favorable safety profile than conventional antipsychotic agents (e." | 4.80 | [Clinical efficacy of olanzapine]. ( Yui, K, 1999) |
| "To assess the effects of haloperidol decanoate versus oral anti-psychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes." | 4.80 | Depot haloperidol decanoate for schizophrenia. ( David, A; Quraishi, S, 2000) |
| "The effects of olanzapine, risperidone, and haloperidol on PRL were assessed in patients with schizophrenia or related psychoses participating in 3 double-blind clinical trials: (1) a 6-week acute trial comparing olanzapine 5 to 20 mg/d (n = 1,336) and haloperidol 5 to 20 mg/d (n = 660), with a 1-year, open-label olanzapine extension for responders; (2) a 54-week study comparing olanzapine 5 to 20 mg/d (n = 21), risperidone 4 to 10 mg/d (n = 21), and haloperidol 5 to 20 mg/d (n = 23) in early illness; and (3) a 28-week study comparing olanzapine 10 to 20 mg/d (n = 172) and risperidone 4 to 12 mg/d (n = 167)." | 4.80 | The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. ( Breier, A; David, SR; Kinon, BJ; Taylor, CC, 2000) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 4.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| " Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol." | 4.79 | Dosing the antipsychotic medication olanzapine. ( Nemeroff, CB, 1997) |
| "The studies of relationship between haloperidol plasma levels and clinical response in schizophrenia have yielded variable results." | 4.77 | Review of haloperidol blood level and clinical response: looking through the window. ( Cooper, TB; Volavka, J, 1987) |
| " In the field of antipsychotics, the first clinical trial on haloperidol decanoate in the treatment of schizophrenia was performed and the daily changes of blood concentrations of haloperidol were also observed." | 4.76 | [Recent advances in clinical psychopharmacology]. ( Mori, A, 1984) |
| "Loxapine is a dibenzoxazepine, tricyclic compound recommended for the treatment of acute and chronic schizophrenia." | 4.75 | Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978) |
| "Our results highlight the importance of using both pharmacokinetic and pharmacodynamic genetic markers for predicting haloperidol treatment response to personalize schizophrenia spectrum disorders treatment." | 4.31 | The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders. ( Bure, IV; Kibitov, AA; Kibitov, AO; Kiryanova, EM; Salnikova, LI; Shmukler, AB, 2023) |
| "This study included 10 patients with schizophrenia who were originally treated with haloperidol alone." | 4.31 | Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study. ( Arai, Y; Kuraishi, K; Murata, S; Nakajima, Y; Sasayama, D; Tsuchida, M; Usuda, N; Washizuka, S, 2023) |
| "To compare the effectiveness of different long-acting injectable antipsychotics (LAIs) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in Japan." | 4.31 | Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. ( Akazawa, M; Inada, K; Okada, Y, 2023) |
| "This study aimed to evaluate Haloperidol's (Hal) effects on the behavioral, neurotrophic factors, and epigenetic parameters in an animal model of schizophrenia (SCZ) induced by ketamine (Ket)." | 4.31 | Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine. ( da Rosa, RT; Dal-Pont, GC; Daminelli, T; Fries, GR; Mastella, GA; Quevedo, J; Valvassori, SS; Varela, RB; Zugno, AI, 2023) |
| "To study the efficacy and safety of intranasal administration of 5 mg haloperidol on mild-moderate agitated patients with schizophrenia or schizoaffective disorder in an acute psychiatry unit setting." | 4.02 | Efficacy and safety of intranasal haloperidol in an acute Psychiatry Unit: a pilot study on schizophrenic patients with mild-modedate agitation. ( Duñó Ambròs, R; Iglesias-Lepine, ML; Labad Arias, J; Monreal Ortiz, JAMO; Oliva Morera, JC; Palao Vidal, D, 2021) |
| "To study plasma adipokines (adiponectin, leptin, adipsin) in patients with the first episode of schizophrenia treated with haloperidol and risperidone." | 4.02 | [Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone]. ( Govorin, NV; Ozornin, AS; Sakharov, AV; Tereshkov, PP, 2021) |
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 4.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| "The present study aims to evaluate the effects of haloperidol, an important first-generation antipsychotic, on the antioxidant system parameters in the brain of animals subjected to a model of schizophrenia induced by ketamine." | 4.02 | Haloperidol elicits oxidative damage in the brain of rats submitted to the ketamine-induced model of schizophrenia. ( Aguiar-Geraldo, JM; Araujo, SL; Cararo, JH; Mastella, GA; Menegas, S; Possamai-Della, T; Quevedo, J; Valvassori, SS; Zugno, AI, 2021) |
| "Here, we tested whether amphetamine would similarly improve 5C-CPT performance in the presence of dopamine D2 receptor blockade, since pro-cognitive treatments in schizophrenia would virtually always be used in conjunction with D2 receptor antagonists." | 3.96 | Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment. ( Breier, M; Roberts, BZ; Swerdlow, NR; Young, JW, 2020) |
| "Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult phenotype relevant to schizophrenia, including positive- and negative-like symptoms, cognitive deficits, dopaminergic dysfunction, structural and functional abnormalities." | 3.96 | Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. ( Babinska, Z; Bucolo, C; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Fedotova, J; Giurdanella, G; Iannotti, FA; Kratka, L; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Platania, CBM; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2020) |
| " It is probably no accident that a sequence from the SARS-CoV-2 orf1b gene is found in the human NTNG1 gene, implicated in schizophrenia, and that haloperidol, used to treat schizophrenia, may also be a treatment for COVID-19." | 3.96 | SARS-CoV-2 ( Lehrer, S; Rheinstein, PH, 2020) |
| "Over 67 days, 1,461 patients were screened in the ED, 269 had bipolar I or schizophrenia, 194 of whom had a contraindication to inhaled loxapine leaving 75 eligible patients; preconsent was obtained in 43 patients." | 3.91 | Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. ( Cole, JB; Driver, BE; Klein, LR; Mullinax, SZ; Nordstrom, KD; Wilson, MP, 2019) |
| "Asenapine maleate (AM) is an atypical antipsychotic that, unlike many other antipsychotics, shows some efficacy in treating cognitive dysfunction in schizophrenia." | 3.91 | Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia. ( Foute Nelong, T; Manduca, JD; Perreault, ML; Zonneveld, PM, 2019) |
| "The methionine-folate cycle-dependent one-carbon metabolism is implicated in the pathophysiology of schizophrenia." | 3.88 | Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits. ( Abbott, GW; Alachkar, A; Civelli, O; Hamzeh, AR; Lee, SM; Sanathara, N; Wang, L; Wang, Z; Xu, X; Yoshimura, R, 2018) |
| "Clinical studies that focused on treating schizophrenia showed that Calculus Bovis Sativus (CBS), a substitute of Calculus Bovis, when used in combination with haloperidol could significantly lower the dosage of haloperidol compared with treatment with haloperidol alone, whereas efficacy was maintained." | 3.88 | Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. ( He, GF; He, GZ; Lei, K; Li, J; Li, XP; Liu, D; Liu, YN; Ren, XH; Zhang, CL, 2018) |
| "Caffeine and nicotine are widely used by schizophrenia patients and may worsen psychosis and affect antipsychotic therapies." | 3.88 | Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. ( Avvisati, L; Buonaguro, EF; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Tomasetti, C, 2018) |
| "Prior work in animal models implicates abnormalities of adenosine metabolism in astrocytes as a possible pathophysiological mechanism underlying the symptoms of schizophrenia." | 3.88 | Cell-subtype-specific changes in adenosine pathways in schizophrenia. ( Devine, E; Hasselfeld, K; Koene, R; McCullumsmith, RE; Moody, CL; O'Donovan, SM; Sullivan, C, 2018) |
| "Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions." | 3.88 | Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018) |
| "We describe a case of clozapine toxicity in a patient with schizophrenia treated with the combination of clozapine, valproate and haloperidol." | 3.88 | Clozapine toxicity in a CYP2D6 poor metaboliser: Additive effects of haloperidol and valproate on clozapine metabolism. ( Chen, RYY; Reznik, R; Stanford, P, 2018) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 3.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| "Clinical studies indicate a reciprocal impact between nicotine use and antipsychotic medications in patients with schizophrenia." | 3.85 | A drug-drug conditioning paradigm reveals multiple antipsychotic-nicotine interactions. ( Feng, M; Li, M; Sparkman, NL; Sui, N, 2017) |
| "Haloperidol decanoate is a typical antipsychotic drug used as maintenance therapy for schizophrenia and mood disorders formulated as an ester for intramuscular injection." | 3.85 | An acute oral intoxication with haloperidol decanoate. ( Dekkers, BGJ; Eck, RJ; Ter Maaten, JC; Touw, DJ, 2017) |
| "To determine the cost-effectiveness of PP3M compared with once-monthly paliperidone (PP1M), haloperidol long-acting therapy (HAL-LAT), risperidone microspheres (RIS-LAT), and oral olanzapine (oral-OLZ) for treating chronic schizophrenia in The Netherlands." | 3.85 | Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. ( Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K, 2017) |
| "Successful treatment of acute periodic catatonia was achieved with a lorazepam-diazepam protocol, and the patient remained in remission for a longer duration under clozapine treatment." | 3.85 | Periodic catatonia with long-term treatment: a case report. ( Chen, RA; Huang, TL, 2017) |
| " He had relapse symptoms of schizophrenia and had recently received a single dose of parenteral haloperidol to manage his agitation." | 3.85 | Persistent oromandibular dystonia and angioedema secondary to haloperidol. ( Masiran, R, 2017) |
| "In this study, we investigated whether minocycline, a second-generation tetracycline proposed as an add-on to antipsychotics in treatment-resistant schizophrenia (TRS), may affect the expression of Homer and Arc postsynaptic density (PSD) transcripts, implicated in synaptic regulation." | 3.85 | Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. ( Avvisati, L; Buonaguro, EF; Chiodini, P; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Tomasetti, C, 2017) |
| "We performed quantitative PCR and western blot analysis to measure PSD-95 expression in schizophrenia vs control subjects, rodent haloperidol treatment studies, rodent postmortem interval studies, and GluN1 knockdown (KD) mice vs controls." | 3.85 | Postsynaptic Density-95 Isoform Abnormalities in Schizophrenia. ( Funk, AJ; Koene, R; Lipska, BK; McCullumsmith, RE; Mielnik, CA; Newburn, E; Ramsey, AJ, 2017) |
| " Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol." | 3.83 | Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. ( Cheng, J; Giguere, PM; Huang, XP; Kozikowski, AP; McCorvy, JD; Pogorelov, VM; Rodriguiz, RM; Roth, BL; Schmerberg, CM; Wetsel, WC; Zhu, H, 2016) |
| " This idea was first implemented in the clinical trial, the Neuroleptic Strategy Study, with a randomised design comparing efficacy and safety of two different strategies: either to use first-generation antipsychotics (haloperidol and flupentixol) or second-generation antipsychotics (olanzapine, aripiprazole and quetiapine) in patients suffering from schizophrenia." | 3.83 | Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. ( Cordes, J; Gründer, G; Heinze, M; Mühlbauer, B; Rüther, E; Schulz, C; Timm, J, 2016) |
| " phencyclidine (PCP), produces prolonged impairment of novel object recognition (NOR), suggesting they constitute a hypoglutamate-based model of cognitive impairment in schizophrenia (CIS)." | 3.81 | Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. ( Horiguchi, M; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L, 2015) |
| " A meta-analysis of haloperidol versus placebo for schizophrenia is used to illustrate the model." | 3.81 | A Bayesian framework to account for uncertainty due to missing binary outcome data in pairwise meta-analysis. ( Ades, AE; Dias, S; Turner, NL; Welton, NJ, 2015) |
| "When choosing between first-generation antipsychotics, clinicians should consider haloperidol as the first-line agent for schizophrenia." | 3.81 | A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. ( Babigumira, JB; Lubinga, SJ; Mutamba, BB; Nganizi, A, 2015) |
| "We thus propose the l-methionine treatment as an animal model recapitulating several symptoms of schizophrenia." | 3.81 | A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity. ( Alachkar, A; Belluzzi, JD; Civelli, O; Sanathara, N; Wang, L; Wang, Z, 2015) |
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 3.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| "We included 39 men with schizophrenia (10 who were taking clozapine, 16 who were taking haloperidol and 13 who were antipsychotic-free) and 29 controls in our study." | 3.80 | Cerebellar motor learning deficits in medicated and medication-free men with recent-onset schizophrenia. ( Coesmans, M; De Zeeuw, CI; Frens, MA; Koekkoek, SK; Röder, CH; Smit, AE; van der Geest, JN, 2014) |
| "The present study evaluated the association of the BDNF Val66Met polymorphism with treatment response to atypical antipsychotic olanzapine in schizophrenia and the possible predictive value of the BDNF Val66Met genotype status in treatment response to antipsychotic medication." | 3.80 | Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. ( Kozumplik, O; Mihaljevic-Peles, A; Muck-Seler, D; Nedic Erjavec, G; Nikolac Perkovic, M; Pivac, N; Sagud, M; Uzun, S; Zivkovic, M, 2014) |
| " First, he received 15 mg per day of haloperidol, and seven days later he developed priapism." | 3.80 | [Antipsychotic-induced priapism and management challenges: a case report]. ( Doufik, J; Ghanmi, J; Khalili, L; Otheman, Y; Ouanass, A, 2014) |
| "Both aripiprazole and haloperidol have been used in the treatment of schizophrenia, and are metabolized by the cytochrome P450 (CYP) 2D6 and CYP3A4." | 3.80 | Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2014) |
| "Haloperidol is a benchmark drug for the pharmacological treatment of schizophrenia, but the genetics of its efficacy is yet to be elucidated." | 3.80 | Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. ( Drago, A; Friedl, M; Giegling, I; Hartmann, AM; Konte, B; Rujescu, D; Schäfer, M; Serretti, A, 2014) |
| "The paper reports on a rare case of fulminant neuroleptic malignant syndrome (NMS) with several risk factors, typical manifestation and rapid death induced by low doses of haloperidol." | 3.80 | Death due to fulminant neuroleptic malignant syndrome induced by low doses of haloperidol: a rare case. ( Chen, Y; Huang, P; Li, Z; Liu, N; Qin, Z; Shao, Y; Zhang, J; Zou, D, 2014) |
| " Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 3.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
| "Differences in effectiveness between haloperidol injection and oral atypical antipsychotics in the acute-phase treatment of schizophrenia are not well examined." | 3.79 | Length of mechanical restraint following haloperidol injections versus oral atypical antipsychotics for the initial treatment of acute schizophrenia: a propensity-matched analysis from the Japanese diagnosis procedure combination database. ( Ando, S; Fushimi, K; Haraguchi, T; Horiguchi, H; Matsuda, S; Nakamura, M; Ohe, K; Sugihara, T; Yasunaga, H, 2013) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| " TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation." | 3.79 | A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. ( Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG, 2013) |
| "We compared the effects of subchronic clozapine and haloperidol administration on the expression of SNAP-25 and synaptophysin in an animal model of schizophrenia based on the glutamatergic hypothesis." | 3.78 | Differential effects of antipsychotics on hippocampal presynaptic protein expressions and recognition memory in a schizophrenia model in mice. ( Basar, K; Ertugrul, A; Ozdemir, H; Saka, E, 2012) |
| " He had a history of schizophrenia that had been controlled with propericiazine 10 mg and bromperidol 3 mg daily for 34 years." | 3.78 | [Severe hypotension and ventricular fibrillation during combined general and epidural anesthesia in a patient on major tranquilizers]. ( Abe, R; Fujita, K; Futsukaichi, K; Matsumoto, K; Noguchi, T, 2012) |
| "Aripiprazole (APZ) is considered a first-line medication for treating first and multiple episodes of schizophrenia, but its effect on preventing the progressive pathophysiology of schizophrenia remains unclear." | 3.77 | Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. ( Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y, 2011) |
| "Since oxidative stress observed in schizophrenia may be caused partially by the treatment of patients with various antipsychotics, the aim of the study was to establish the effects of beta-d-glucan, polysaccharide derived from the yeast cell walls of species such as Saccharomyces cerevisiae, and the antipsychotics (the first generation antipsychotic (FGA) - haloperidol and the second generation antipsychotic (SGA) - amisulpride) action on plasma lipid peroxidation in vitro." | 3.77 | Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol. ( Dietrich-Muszalska, A; Kontek, B; Olas, B; Rabe-Jabłońska, J, 2011) |
| "Effect of haloperidol and risperidone on positive, negative, neurocognitive disorders, biological parameters and neurodestruction-neuroreparation processes have been studied in 23 patients with the first episode of paranoid schizophrenia." | 3.77 | [Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia]. ( Govorin, NV; Vasil'eva, AI, 2011) |
| "The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs." | 3.77 | A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. ( Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C, 2011) |
| "We recruited 109 patients with schizophrenia treated with clozapine or haloperidol and evaluated their body mass index (BMI), waist circumference, blood pressure, and fasting triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), fasting plasma glucose, insulin, RBP4, total adiponectin, and HMW adiponectin levels." | 3.77 | Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Liu, HC; Lu, ML, 2011) |
| "Valproic acid (VPA) has been suggested as a potential adjunct therapy in schizophrenia for the treatment of clinical symptoms and cognitive deficits." | 3.77 | Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. ( Babin, SL; Larrison, AL; Patel, SS; Sereno, AB; Wassef, AA; Xing, Y, 2011) |
| "Analysis of certain aspects of quality of life in patients with schizophrenia treated with depot formulations of a typical antipsychotic (haloperidol) and injection preparation of a long-acting atypical antipsychotic (risperidone)." | 3.77 | Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone. ( Djukić-Dejanović, S; Janjić, V; Janković, S; Jovanović-Mihajlović, N; Mihajlović, G; Milovanović, N; Petrović, D; Radmanović, B; Radonjić, K; Tomić, K, 2011) |
| "We described herein the design, synthesis, and pharmacological evaluation of N-phenylpiperazine heterocyclic derivatives as multi-target compounds potentially useful for the treatment of schizophrenia." | 3.76 | Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. ( Antonio, CB; Barreiro, EJ; Fraga, CA; Grazziottin, LR; Menegatti, R; Neves, G; Noël, F; Rates, SM; Vieira, RO, 2010) |
| "This naturalistic retrospective study aims to compare effectiveness of a second-generation antipsychotic medication, risperidone, with first-generation antipsychotic medications (haloperidol and trifluoperazine) in an Asian population with first-episode schizophrenia-spectrum disorders." | 3.76 | Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. ( Edimansyah, A; Liew, A; Subramaniam, M; Vaingankar, J; Verma, S, 2010) |
| "In this study, 11 healthy male subjects taking different doses of sulpiride and 24 male patients with DSM-IV-diagnosed schizophrenia taking different antipsychotic drugs (risperidone, olanzapine, haloperidol, and sulpiride) participated." | 3.76 | Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. ( Arakawa, R; Ito, H; Maeda, J; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H, 2010) |
| " To complete our understanding, here we studied neurogenesis and its sensitivity to the classical neuroleptic haloperidol in a developmental model of schizophrenia (maternal vitamin D deficiency)." | 3.76 | Haloperidol normalized prenatal vitamin D depletion-induced reduction of hippocampal cell proliferation in adult rats. ( Becker, A; Grecksch, G; Keilhoff, G, 2010) |
| "Single-photon emission-computed tomography (SPECT) ligand [(123)I]epidepride was used to determine dopamine D(2/3) apparent binding potential in 13 antipsychotic-treated (seven with clozapine, four with olanzapine and two with haloperidol) patients with schizophrenia." | 3.76 | Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra. ( Husso, M; Kuikka, JT; Tiihonen, J; Tuppurainen, H; Viinamäki, H, 2010) |
| "Haloperidol is a potent dopamine receptor antagonist and used to treat psychotic disorders, such as schizophrenia." | 3.76 | Neonatal ventral hippocampus lesion induces increase in nitric oxide [NO] levels which is attenuated by subchronic haloperidol treatment. ( Aguilar-Alonso, P; Baltazar-Gaytán, E; Bringas, ME; Flores, G; León-Chávez, BA; Negrete-Díaz, JV; Newton, S; Vazquez-Roque, RA, 2010) |
| "Asenapine is a novel psychopharmacologic agent under development for the treatment of schizophrenia and bipolar disorder." | 3.75 | Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. ( Shahid, M; Walker, GB; Wong, EH; Zorn, SH, 2009) |
| "This study aimed to investigate the effects of treatment with haloperidol, olanzapine and risperidone on cardiovascular variability in patients with recent-onset schizophrenia by means of spectral analysis." | 3.75 | Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. ( Hempel, RJ; Hengeveld, MW; Röder, CH; Tulen, JH; van Beveren, NJ, 2009) |
| "The ketamine (ket) model reflects features of schizophrenia as well as secondary symptoms such as altered pain sensitivity." | 3.75 | Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ( Becker, A; Grecksch, G; Hiemke, C; Ladstaetter, E; Schmitt, U; Zernig, G, 2009) |
| "Ketamine-induced alterations in EEG power spectra are consistent with abnormalities in the theta and gamma frequency ranges reported in patients with schizophrenia." | 3.75 | N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. ( Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI, 2009) |
| "To compare the effectiveness of intramuscular (IM) olanzapine and typical IM antipsychotics in naturalistically treated acutely agitated patients with schizophrenia or acute mania." | 3.75 | Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. ( Castle, DJ; Isik, T; Karagianis, J; Kim, CY; Melamed, Y; Omar, AN; Pidrman, V; Rosales, JI; Sarosi, A; Treuer, T; Udristoiu, T, 2009) |
| "Dopamine D(2/3) binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with clozapine), six drug-naïve patients and seven healthy controls." | 3.75 | Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. ( Husso, M; Kuikka, JT; Tiihonen, J; Tuppurainen, H; Viinamäki, H, 2009) |
| " We describe several choices for weighting studies in the meta-analysis, and illustrate methods using a meta-analysis of trials of haloperidol for schizophrenia." | 3.74 | Imputation methods for missing outcome data in meta-analysis of clinical trials. ( Higgins, JP; White, IR; Wood, AM, 2008) |
| "In total 56 patients acutely treated with haloperidol or risperidone either for the first episode of schizophrenia, schizophreniform or schizoaffective disorders, or for the relapse of these psychotic disorders after tapering their maintenance treatment, were genotyped for the 5-HTTLPR L and S alleles and for the new A/G functional variant within the L alelle (La/g)." | 3.74 | Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. ( Dolzan, V; Kastelic, M; Koprivsek, J; Mandelli, L; Plesnicar, BK; Serretti, A, 2008) |
| "A man with schizophrenia received regular haloperidol ester therapy, but his psychotic symptoms were not mitigated." | 3.74 | Zotepine-induced spontaneous ejaculation. ( Huang, CJ; Wang, PW; Wang, SY, 2008) |
| "Outpatients initiating or changing antipsychotic therapy for DSM-IV- or ICD-10-defined schizophrenia (N = 7658) were allocated to olanzapine or nonolanzapine cohorts (November 2000 to December 2001)." | 3.74 | Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. ( Anders, M; Dossenbach, M; Irimia, V; Kotler, M; Logozar-Perkovic, D; Lowry, AJ; Pecenak, J; Peciukaitiene, D; Smulevich, AB; Szulc, A; Treuer, T; West, TM, 2008) |
| "The psychotomimetic drug, phencyclidine, induces schizophrenia-like behavioural changes in both humans and animals." | 3.74 | The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. ( Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C, 2007) |
| " Given that atypical antipsychotics have been shown to ameliorate negative symptoms of schizophrenia more effectively than typical neuroleptics, this effect should be reversed by clozapine but not haloperidol." | 3.74 | Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats. ( Hulick, VC; Turgeon, SM, 2007) |
| " The subjects consisted of 49 acutely exacerbated inpatients with schizophrenia treated with bromperidol (30 cases, 6-18 mg/day) or nemonapride (19 cases, 18 mg/day) for 3 weeks." | 3.74 | Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia. ( Kondo, T; Mihara, K; Sakumoto, N; Suzuki, A; Yasui-Furukori, N, 2007) |
| "This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR)." | 3.74 | Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. ( Ascher-Svanum, H; Marcus, SC; Olfson, M, 2007) |
| "Disruptions in 5-CSRTT performance induced by repeated PCP administration are prevented by chronic clozapine treatment and may constitute a useful animal model of some cognitive symptoms of schizophrenia." | 3.74 | Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. ( Amitai, N; Markou, A; Semenova, S, 2007) |
| "To evaluate the cost-effectiveness of three antipsychotic medications (olanzapine, risperidone and haloperidol) in the treatment of schizophrenia using the Positive and Negative Symptom Scale." | 3.74 | Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. ( Bounthavong, M; Okamoto, MP, 2007) |
| "Analysis 1 found that nonsedated patients with bipolar I disorder and schizophrenia showed significant decreases in PEC scores following treatment with aripiprazole IM (p < 0." | 3.74 | Intramuscular aripiprazole in the control of agitation. ( Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007) |
| "Nineteen unmedicated male schizophrenia patients were treated prospectively with haloperidol for six weeks." | 3.74 | Relation of neurological soft signs to psychiatric symptoms in schizophrenia. ( Angrist, B; Duncan, EJ; Hasenkamp, W; Mittal, VA; Rotrosen, J; Sanfilipo, M; Wieland, S, 2007) |
| " We previously reported that baclofen, the prototypical GABA(B) agonist, elicits antipsychotic-like effects in the rat paradigm of prepulse inhibition (PPI) of the startle, a highly validated animal model of schizophrenia." | 3.74 | Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice. ( Bortolato, M; Castelli, MP; Fà, M; Frau, R; Gessa, GL; Marrosu, F; Mereu, G; Orrù, M; Piras, AP; Puligheddu, M; Tuveri, A, 2007) |
| "Sixty-seven outpatients with schizophrenia receiving stable doses of risperidone or haloperidol were evaluated for akathisia and other extrapyramidal side effects." | 3.74 | Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. ( Byun, HJ; Kim, JH, 2007) |
| "One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol." | 3.74 | Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. ( Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C, 2007) |
| "Sub-chronic phencyclidine (PCP) treatment mimics certain aspects of schizophrenia symptomology in rats." | 3.74 | Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation. ( Neill, JC; Snigdha, S, 2008) |
| "(1) For patients with schizophrenia, risperidone is one of many available neuroleptics." | 3.74 | Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent. ( , 2007) |
| "To comparatively assess the incidence of tardive dyskinesia in patients with schizophrenia receiving either aripiprazole or haloperidol." | 3.74 | Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. ( Eudicone, JM; Kim, E; Miller, DD; Pikalov, A, 2007) |
| "Clozapine may alleviate hyperactivity in the limbic system in schizophrenia and may facilitate activation of the regions involved in cognitive tasks to a greater degree than risperidone, as well as eliciting greater inhibition of the PF region." | 3.74 | Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. ( De Luxán, A; Domínguez-Gil, A; Martin, C; Molina, V; Montes, C; Rivas, N; Sancho, C; Tamayo, P, 2008) |
| "A sample included 61 patients, 53 men and 8 women, with ICD-10 episodic schizophrenia in the remission after treatment with atypical neuroleptics (risperidon, olanzapine, clozapine)." | 3.74 | [Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics]. ( Danilov, DS; Tiul'pin, IuG, 2007) |
| " The initial doses varied widely, ranging from 1 to 30 mg, with a maximum total daily dosage of 100 mg." | 3.74 | Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. ( Donlon, PT; Hopkin, J; Tupin, JP, 1979) |
| "These results show that haloperidol and clozapine produce different patterns of metabolic changes in schizophrenia." | 3.73 | Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. ( Desco, M; Gispert, JD; Molina, V; Palomo, T; Pascau, J; Reig, S; Santos, A; Sanz, J, 2005) |
| "Bupropion reduced the amplitude and gating of the N40 evoked potential in mice, similar to the P50 and N100 endophenotypes associated with sensory encoding deficits in schizophrenia." | 3.73 | Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. ( Gur, RE; Kanes, SJ; Lerman, C; Liang, Y; Majumdar, S; Maxwell, CR; Siegel, SJ; Trief, DF, 2005) |
| " Volunteers with schizophrenia were scanned while drug-free (baseline) and after single dose administration of haloperidol (n=6) or olanzapine (n=6) during a time course adapted to their plasma kinetics." | 3.73 | Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia. ( Holcomb, HH; Lahti, AC; Medoff, DR; Tamminga, CA; Weiler, MA, 2005) |
| "A 26-year-old woman with schizophrenia gained 7 kg over the course of 1 year after starting treatment with olanzapine." | 3.73 | Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. ( Koga, M; Nakayama, K, 2005) |
| " Using a microarray approach, we here demonstrate that the antipsychotic drugs clozapine and haloperidol upregulate several genes involved in cholesterol and fatty acid biosynthesis in cultured human glioma cells, including HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase), HMGCS1 (3-hydroxy-3-methylglutaryl-coenzyme A synthase-1), FASN (fatty acid synthase) and SCD (stearoyl-CoA desaturase)." | 3.73 | Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? ( Berge, RK; Breilid, H; Fernø, J; Glambek, M; Løvlie, R; Raeder, MB; Skrede, S; Stansberg, C; Steen, VM; Tronstad, KJ; Vik-Mo, AO, 2005) |
| " Data from a randomized, double-blind trial comparing treatment of schizophrenia with placebo and olanzapine were used to correlate weight change and change in psychopathology." | 3.73 | Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. ( Ascher-Svanum, H; Kinon, BJ; Stensland, MD; Tollefson, GD, 2005) |
| "This post hoc analysis used data from a multinational, double-blind, randomized, placebo-controlled study comparing the efficacy of olanzapine, haloperidol, and placebo in acutely agitated inpatients aged > or =18 years with schizophrenia conducted at hospitals in 13 countries." | 3.73 | A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. ( Ahl, J; Battaglia, J; Houston, JP; Kaiser, CJ; Meyers, AL, 2005) |
| "The psychotomimetic drug phencyclidine (PCP) induces symptoms closely related to those of schizophrenia in humans." | 3.73 | Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. ( Morris, BJ; Ohashi, Y; Paterson, GJ; Pratt, JA; Reynolds, GP, 2006) |
| "Plasma prolactin concentration was measured in patients with schizophrenia and schizoaffective disorders receiving therapy with risperidone, olanzapine, and quetiapine and compared with the corresponding parameter in patient receiving typical neuroleptic drug haloperidol." | 3.73 | Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders. ( Gorobets, LN, 2005) |
| "Clozapine (CLZ) can improve both the positive and negative symptoms of treatment-resistant schizophrenia (TRS), which does not respond to typical antipsychotics." | 3.73 | Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. ( Abekawa, T; Ito, K; Koyama, T, 2006) |
| "Factors that influenced the risk of hyperprolactinemia included gender, with females appearing to be more sensitive than males, and drug treatment, with risperidone and conventional antipsychotic agents increasing prolactin more than olanzapine." | 3.72 | Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "Texas Medicaid claims were retrieved for persons aged 21-65 years, diagnosed with schizophrenia or schizoaffective disorder, after initiating treatment with olanzapine (n = 1875), risperidone (n = 982), or haloperidol (n = 726) between January 1997 and August 1998." | 3.72 | Role of ethnicity in predicting antipsychotic medication adherence. ( Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL, 2003) |
| " Because reduced glutamatergic function represents a major feature of schizophrenia, we investigated the effects of the concomitant administration of haloperidol or olanzapine with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 on BDNF expression." | 3.72 | Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. ( Bedogni, F; Fossati, C; Fumagalli, F; Gennarelli, M; Molteni, R; Racagni, G; Riva, MA; Roceri, M; Santero, R, 2003) |
| "This reanalysis of a previously reported pivotal clinical trial assessed whether quetiapine or haloperidol has benefits for the treatment of hostility and agitation among patients experiencing an acute exacerbation of schizophrenia." | 3.72 | A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. ( Chengappa, KN; Goldstein, JM; Greenwood, M; John, V; Levine, J, 2003) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 3.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "Twenty-five haloperidol-treated subjects with chronic schizophrenia and twenty-five healthy control subjects participated in the study." | 3.72 | Elevated cerebrospinal fluid SNAP-25 in schizophrenia. ( Kelley, M; Thompson, PM; Tsai, G; van Kammen, DP; Yao, J, 2003) |
| "Gains from earning rates for employed persons with schizophrenia, savings in informal caregiver costs and other human benefits could justify an incremental cost of 19,609 US dollars for each additional employable person prescribed risperidone." | 3.72 | Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. ( Ganguly, R; Martin, BC; Miller, LS, 2003) |
| "This study investigated the effectiveness and tolerability of a switching strategy using quetiapine in 16 women with schizophrenia who were suffering from haloperidol- or risperidone-induced amenorrhea." | 3.72 | Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. ( Higuchi, H; Kamata, M; Naitoh, S; Shimizu, T; Sugita, T; Takahashi, H; Yoshida, K, 2003) |
| "Fifty-seven subjects with first-episode psychosis and a DSM-IV diagnosis of schizophreniform disorder, schizophrenia, or schizoaffective disorder were treated according to a fixed protocol with a mean dose of haloperidol of 1." | 3.72 | Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. ( Emsley, RA; Keyter, N; Maritz, JS; Oosthuizen, PP; Turner, JA, 2003) |
| "Most antipsychotic drugs act equivalently and potently on the symptoms of schizophrenia, with clozapine as the notable exception." | 3.72 | Similarities and differences among antipsychotics. ( Tamminga, CA, 2003) |
| "Texas Medicaid claims were analyzed for persons aged 21 to 65 years with a diagnosis of schizophrenia or schizoaffective disorder who started treatment with olanzapine (N=1875), risperidone (N=982), or haloperidol (N= 726) between January 1, 1997 and August 31, 1998." | 3.72 | Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. ( Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL, 2004) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| " In a first genome scan on obesity under antipsychotics in SZ and BP, we analyzed 21 multigenerational kindreds (508 family members) including several patients treated for a minimum of 3 years mainly with haloperidol or chlopromazine." | 3.72 | A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. ( Bouchard, RH; Chagnon, YC; Emond, C; Maziade, M; Mérette, C; Roy, MA, 2004) |
| " We then illustrate our findings in a study examining the efficacy of clozapine versus haloperidol in the treatment of refractory schizophrenia." | 3.72 | Covariate adjustment in clinical trials with non-ignorable missing data and non-compliance. ( Levy, DE; Normand, SL; O'Malley, AJ, 2004) |
| "Augmentation strategy in the treatment of schizophrenia with the NMDA receptor co-agonist glycine has demonstrated significant improvement in patient symptoms." | 3.72 | Effects of typical and atypical antipsychotics on human glycine transporters. ( Conn, PJ; Mallorga, PJ; Pettibone, DJ; Sur, C; Williams, JB, 2004) |
| "We followed up our initial results by in situ hybridization in subjects with schizophrenia, major depression, and a chronic haloperidol-treated nonhuman primate model." | 3.72 | Heat shock protein 12A shows reduced expression in the prefrontal cortex of subjects with schizophrenia. ( Levitt, P; Lewis, DA; Middleton, FA; Mirnics, K; Peng, L; Pongrac, JL, 2004) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 3.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| "Patients with a Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) diagnosis of schizophrenia or psychotic disorder not otherwise specified with onset of psychosis before the age of 13 participated in 6- to 8-week open or double-blind trials of haloperidol (n = 15, mean dose 15." | 3.71 | Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. ( Alfaro, CL; Gochman, P; Lenane, M; Nicolson, R; Rapoport, JL; Sporn, A; Wudarsky, M, 2002) |
| "We examined the effect of age on psychopharmacological management in a naturalistic study of a group of 165 patients with a clinical diagnosis of schizophrenia or a related psychotic disorder (age range = 21-84 years; subjects > or = 1;45 years n = 86) treated with either haloperidol decanoate or fluphenazine decanoate." | 3.71 | The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. ( Chengappa, KN; Jeste, DV; Mamo, DC; Reddy, RR; Sweet, RA, 2002) |
| "Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis." | 3.71 | Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. ( Bilker, WB; Glasser, DB; Hennessy, S; Kimmel, SE; Knauss, JS; Margolis, DJ; Morrison, MF; Reynolds, RF; Strom, BL, 2002) |
| "This analysis models the cost-effectiveness of quetiapine compared with haloperidol in partial responders with schizophrenia." | 3.71 | An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. ( Aristides, M; Burns, T; Meddis, D; Tilden, D, 2002) |
| "The authors added haloperidol, a potent D(2) blocker, to ongoing treatment with clozapine in patients with schizophrenia to determine the effects of this combination on dopamine D(2) receptor blockade, prolactin level, and extrapyramidal side effects." | 3.71 | Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. ( Daskalakis, J; Kapur, S; Remington, G; Roy, P; Zipursky, R, 2001) |
| " In the present study, JL13 was compared with clozapine and haloperidol in several animal models for schizophrenia." | 3.71 | Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. ( Bruhwyler, J; Cools, AR; Ellenbroek, BA; Liégeois, JF, 2001) |
| "To report a case of neuroleptic malignant syndrome (NMS) in a patient whose therapy was being switched from haloperidol to risperidone." | 3.71 | Neuroleptic malignant syndrome during a change from haloperidol to risperidone. ( Mack, JE; Reeves, RR; Torres, RA, 2001) |
| "Our data suggest that at least one drug commonly used to treat schizophrenia (haloperidol) can interfere with the vasodilatory response to NA." | 3.71 | An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. ( Ross, BM; Seeman, M; Turenne, SD, 2001) |
| " In order to determine the specificity of these observations, similar studies were conducted in subjects with major depressive disorder and in monkeys after 9-12 months of haloperidol treatment." | 3.71 | Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. ( Cruz, DA; Lewis, DA; Melchitzky, DS; Pierri, JN, 2001) |
| "The data demonstrate an impairment of brain kynurenine pathway metabolism in schizophrenia, resulting in elevated kynurenate levels and suggesting a possible concomitant reduction in glutamate receptor function." | 3.71 | Increased cortical kynurenate content in schizophrenia. ( Medoff, D; Rassoulpour, A; Roberts, RC; Schwarcz, R; Tamminga, CA; Wu, HQ, 2001) |
| "PET scans were performed on 6 controls and 18 patients with schizophrenia treated with haloperidol or with risperidone, clozapine, amisulpride or olanzapine." | 3.71 | Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. ( Artiges, E; Loc'H, C; Mallet, L; Martinot, JL; Mazière, B; Paillère-Martinot, ML; Xiberas, X, 2001) |
| "The impact of genetic polymorphism of CYP1A2 that are related to the induction of the isozyme on the plasma levels of haloperidol (HAL) in 40 male smokers with schizophrenia was investigated." | 3.71 | Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. ( Hirokane, G; Morita, S; Okawa, M; Shimoda, K; Someya, T; Takahashi, S; Yokono, A, 2002) |
| "The aim of the present study is to determine the effect of the atypical antipsychotic drug, risperidone on sleep measures in patients with schizophrenia by polysomnography." | 3.71 | Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. ( Horiguchi, J; Morinobu, S; Nagao, M; Yamashita, H; Yamawaki, S, 2002) |
| " Patients with schizophrenia according to DSM-IV treated with olanzapine (n =10) or haloperidol (n=10) were compared to healthy controls (n =10) and untreated patients (n=10)." | 3.71 | Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study. ( Klein, HE; Müller, JL; Röder, C; Schuierer, G, 2002) |
| "G protein functional measurements coupled to beta-adrenergic, muscarinic, and dopamine receptors were undertaken through bacterial toxin sensitive, agonist enhanced [3H]-Gpp(NH)p binding capacity, substantiated by quantitative measures of Gs alpha, Gi alpha, and G beta subunit proteins through immunoblot analysis in mononuclear leukocytes obtained from patients with schizophrenia under haloperidol, or clozapine treatments in comparison with untreated patients with schizophrenia and healthy volunteers." | 3.71 | Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. ( Avissar, S; Roitman, G; Schreiber, G, 2001) |
| "A decision-tree simulation model is used to examine the costs associated with olanzapine versus haloperidol in the treatment of patients with schizophrenia in the UK." | 3.70 | Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol. ( Almond, S; O'Donnell, O, 1998) |
| "To clarify the implication of antagonism of serotonin (5-HT)2 receptors in the treatment of schizophrenia, the effects of ritanserin (RIT) on the development of reverse tolerance in rats repeatedly administered methamphetamine (MAP) were investigated and compared with those of low doses of haloperidol (HPD)." | 3.70 | Partial inhibition of reverse tolerance by a high dose of ritanserin or low dose of haloperidol in methamphetamine-sensitized rat. ( Ishigooka, J; Miura, S; Nagata, E; Tanaka, T; Watanabe, S, 1998) |
| "In 20 patients with schizophrenia [Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised)] treated with mean daily doses of risperidone ranging from 0." | 3.70 | Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. ( Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K, 1998) |
| "We summarise preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone." | 3.70 | Research and treatment strategies in first-episode psychoses. The Pittsburgh experience. ( Haas, GL; Keshavan, MS; Pettegrew, JW; Schooler, NR; Sweeney, JA, 1998) |
| "Fourteen medication-free patients with schizophrenia underwent 2 nights of sleep EEG monitoring before and after 3-4 weeks of treatment with clinically determined doses of haloperidol or thiothixene." | 3.70 | Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension. ( DeQuardo, JR; Eiser, A; Maixner, S; Shipley, J; Tandon, R; Taylor, S, 1998) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 3.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "A model was developed to estimate the medical costs and effectiveness outcomes of three antipsychotic treatments (olanzapine, haloperidol, and risperidone) for patients with schizophrenia." | 3.70 | A cost-effectiveness clinical decision analysis model for schizophrenia. ( Brown, RE; Genduso, LA; Hamilton, SH; Palmer, CS; Revicki, DA, 1998) |
| "The aim of this study was to evaluate the frequency and course of sexual disturbances associated with clozapine and haloperidol and their potential influence on compliance with medication regimens in patients with schizophrenia." | 3.70 | Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. ( Fleischhacker, WW; Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H, 1999) |
| "Haloperidol concentrations in the human brain tissue were 10-30 times higher than optimal serum concentrations used in the treatment of schizophrenia." | 3.70 | Persistence of haloperidol in human brain tissue. ( Boissl, KW; Gleiter, CH; Kornhuber, J; Leblhuber, F; Meineke, I; Riederer, P; Schultz, A; Wiltfang, J; Zöchling, R, 1999) |
| "Olanzapine (Zyprexa), a neuroleptic, has obtained marketing authorization for treatment of schizophrenia." | 3.70 | Olanzapine. Keep an eye on this neuroleptic. ( , 2000) |
| "Elevated cerebrospinal fluid (CSF) angiotensin I-converting enzyme (ACE) levels have been evidenced in patients with schizophrenia who have been treated with antipsychotics." | 3.70 | Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients. ( Ahokas, A; Nikkilä, H; Rimón, R; Wahlbeck, K, 2000) |
| "Plasma concentrations of bromperidol (BRP) and reduced bromperidol (RBRP) were determined in 31 patients with schizophrenia who were administered BRP for their psychiatric symptoms." | 3.70 | Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. ( Hirokane, G; Muratake, T; Shibasaki, M; Shimoda, K; Someya, T; Takahashi, S, 2000) |
| " Phencyclidine (PCP), a non-competitive NMDA-receptor antagonist, is able to induce schizophrenia-like symptoms in animals and in humans." | 3.70 | Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. ( Sabel, BA; Schroeder, H; Schroeder, U; Schwegler, H, 2000) |
| "The objectives of this study were to determine the doses of olanzapine (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in outpatients with schizophrenia and the rates of occurrence of extrapyramidal symptoms (EPS) and other adverse events, clinical response, and use of concomitant medications." | 3.70 | Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. ( Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E, 2000) |
| "To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia." | 3.70 | Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. ( Almond, S; O'Donnell, O, 2000) |
| "A 40-year-old patient being treated for schizophrenia developed elevated plasma levels of haloperidol (HAL) in combination with chlorpromazine (CPZ) and during overlap treatment with clozapine." | 3.70 | Effect of chlorpromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia. ( Allen, SA, 2000) |
| "The enhancement of immobility in a forced swimming test of mice induced by repeated treatment with phencyclidine and amphetamine swimming "normalization" test of mice were used as animal models of negative and positive symptoms of schizophrenia, respectively." | 3.70 | Atypical antipsychotic effects of quetiapine fumarate in animal models. ( Dai, J; Guan, HJ; Zhu, XZ, 2000) |
| "The dopamine hypothesis of schizophrenia received strong support when a two- to three-fold elevation of D2 receptor densities was demonstrated by positron emission tomography (PET) and [11C]N-methylspiperone ([11C]NMSP)." | 3.69 | No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. ( Eriksson, L; Farde, L; Halldin, C; Nordström, AL, 1995) |
| "Plasma homovanillic acid concentration was assessed in 60 young schizophrenic patients, with and without first-degree relatives with schizophrenia, before treatment, and 3 days after starting haloperidol treatment." | 3.69 | Schizophrenia: gender, family risk, and plasma homovanillic acid. ( Andía, I; Basterreche, E; Dávila, R; Friedhoff, AJ; González-Torres, MA; Guimón, J; Zamalloa, MI; Zumárraga, M, 1995) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 3.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 3.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| " negative symptoms show different tonic electrodermal patterns, 26 patients with Type I schizophrenia and 19 patients with Type II schizophrenia were evaluated before and after 2 weeks of haloperidol treatment (standard daily dose = 4." | 3.69 | Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. ( Barzega, G; Bellino, S; Bogetto, F; Maina, G; Ravizza, L, 1995) |
| "Ten patients with schizophrenia participated in 120-min free-smoking sessions when actively psychotic and free of antipsychotic medications, and again after the initiation of haloperidol treatment." | 3.69 | Haloperidol increases smoking in patients with schizophrenia. ( Freudenreich, O; Levin, ED; McEvoy, JP; Rose, JE, 1995) |
| "A patient with chronic schizophrenia, who had been treated for a long time with chlorpromazine, haloperidol, levodopa, benserazide hydrochloride, diazepam and biperiden, developed extreme hypothermia (about 32 degrees C) when the dose of haloperidol was increased because of a deterioration of the patient's mental symptoms." | 3.69 | A schizophrenic patient who developed extreme hypothermia after an increase in the dose of haloperidol: a case report. ( Harada, H; Igarashi, M; Nakajima, T; Okamoto, K; Sugae, S; Tsuji, M, 1994) |
| "We report a fulminant case of Neuroleptic Malignant Syndrome in a 31-year-old male schizophrenic on haloperidol, thioridazine, benzhexol and flurazepam who presented with rigidity, fever, stupor and autonomic instability." | 3.69 | A fulminant case of neuroleptic malignant syndrome. ( Chew, WL; Lam, KN; Teo, SK, 1994) |
| "The potencies of the major neuroleptics used in the treatment of schizophrenia, including haloperidol and remoxipride, correlate with their ability to bind D2-dopaminergic receptors in subcortical structures." | 3.69 | A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. ( Goldman-Rakic, PS; Lidow, MS, 1994) |
| "Regional cerebral glucose metabolism was studied in 12 subjects with schizophrenia while they were receiving a fixed dose of haloperidol, again 5 days after withdrawal of the drug, and a third time 30 days after withdrawal." | 3.69 | Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. ( Cascella, NG; Dannals, RF; Holcomb, HH; Medoff, DR; Tamminga, CA; Thaker, GK, 1996) |
| "Plasma concentrations of clozapine and its metabolites desmethylclozapine and clozapine N-oxide were measured in 61 patients with refractory schizophrenia." | 3.69 | Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. ( Chang, WH; Jann, MW; Lin, SK; Liu, HC; Wei, FC, 1996) |
| " There is an ongoing controversy, if increased binding of 3H-spiperone to lymphocytes might discriminate between schizophrenia and other psychiatric diseases or even be a genetic vulnerability marker for schizophrenia, or predict the response to neuroleptic treatment." | 3.69 | 3H-spiperone binding to peripheral mononuclear cells in psychiatric in-patients. ( Fritze, J; Riederer, P; Wodarz, N, 1996) |
| "The dopamine hypotheses of schizophrenia and antipsychotic drug action suggest that the dopamine metabolite homovanillic acid (HVA) should change with drug withdrawal and change in clinical state." | 3.69 | Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies. ( Beuger, M; Kelley, ME; van Kammen, DP; Yao, J, 1996) |
| " The methods are illustrated on a data set involving alternative dosage regimens for the treatment of schizophrenia using haloperidol and on a regression example." | 3.69 | Pattern-mixture models for multivariate incomplete data with covariates. ( Little, RJ; Wang, Y, 1996) |
| "Haloperidol is unlikely to confound the results of studies investigating disease-related alterations in the levels of a broad range of cytokines and soluble cytokine receptors in schizophrenia." | 3.69 | Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. ( Fenzel, T; Hinze-Selch, D; Kraus, T; Mullington, J; Pollmächer, T; Schuld, A, 1997) |
| "A haloperidol-treated patient with chronic schizophrenia had a near-arrhythmic circadian rest-activity cycle, whereas rhythms of 6-sulphatoxy-melatonin and core body temperature were of normal amplitude and phase-advanced." | 3.69 | A schizophrenic patient with an arrhythmic circadian rest-activity cycle. ( Cajochen, C; Nussbaum, P; Wirz-Justice, A, 1997) |
| "The patient was a 24-year-old man with recently diagnosed schizophrenia who presented twice to a general hospital with difficulty speaking within 72 hours of increasing his dose of haloperidol." | 3.69 | Neuroleptic-induced laryngeal dystonia can mimic anaphylaxis. ( Ilchef, R, 1997) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 3.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "A radioreceptor assay (RRA) was used to determine the neuroleptic plasma levels of 32 outpatients with schizophrenia receiving a high dose of neuroleptics (the equivalent of 18 mg or more of oral haloperidol per day) and undergoing a 50% partial and progressive reduction (ten percent each month for five months) in their medication." | 3.68 | Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics. ( Cormier, H; Di Paolo, T; Gagné, MA; Leblanc, G; Lévesque, D, 1993) |
| "Eleven acutely psychotic patients with schizophrenia or schizoaffective disorder underwent a 5-7 day drug-washout period (with lorazepam allowed) prior to participating in a 6-week controlled dose haloperidol trial." | 3.68 | Haloperidol response and plasma catecholamines and their metabolites. ( Alam, MY; Boshes, RA; Fitzgibbon, ME; Green, AI; Pappalardo, KM; Schildkraut, JJ; Tsuang, MT; Waternaux, C, 1993) |
| "This study examined the time-course of treatment response to haloperidol in chronic schizophrenia." | 3.68 | Early response to haloperidol treatment in chronic schizophrenia. ( Amin, F; Apter, SH; Harvey, PD; Hirschowitz, J; Kahn, RS; Stern, RG, 1993) |
| " Thirty-six acutely psychotic patients receiving parenteral haloperidol were evaluated by the Brief Psychiatric Rating Scale, the Schedule for Affective Disorders and Schizophrenia-Change Version, and the Nurses' Observation Scale for Inpatient Evaluation, as well as by drug levels in plasma." | 3.68 | Acutely psychotic patients receiving high-dose haloperidol therapy. ( Coulter, K; Pollock, B; Reed, K; Remington, G; Voineskos, G, 1993) |
| "Institutionalized persons with a deteriorating form of schizophrenia that was refractory to neuroleptic medication were titrated downward in their haloperidol dose." | 3.68 | Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics. ( Bowen, L; Kuehnel, TG; Liberman, RP; Marshall, BD, 1992) |
| "Measurement of plasma prolactin (PRL) concentration and plasma homovanillic acid (HVA) concentration was performed in 24 patients with schizophrenia during maintenance haloperidol treatment." | 3.68 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| "Twenty recently admitted patients with mood-incongruent psychoses underwent 1) interviews with the Schedule for Affective Disorders and Schizophrenia for diagnostic evaluation and symptom profiles, 2) drug-free baseline measurements of CSF neurotensin and homovanillic acid, and 3) close monitoring of a therapeutic trial of haloperidol to determine latency of antipsychotic response." | 3.68 | Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. ( Bissette, G; Garver, DL; Nemeroff, CB; Yao, JK, 1991) |
| "Twenty-nine hospitalized patients suffering acute exacerbations of schizophrenia were treated for 2 weeks with fixed daily oral doses of haloperidol prospectively calculated to achieve a haloperidol plasma concentration of either 8-18 ng/ml or 25-35 ng/ml." | 3.68 | Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. ( Arndt, SV; Coryell, WH; Kelly, MW; Miller, DD; Perry, PJ, 1990) |
| "Forty-four male, neuroleptic-free, acutely psychotic patients with at least one diagnosis of schizophrenia among 11 diagnostic systems, and 28 healthy controls, underwent measurement of prolactin (PRL) concentrations before and after intravenous administration of haloperidol (0." | 3.68 | Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. ( Copolov, DL; Hassett, A; Keks, NA; Kulkarni, J; Mackie, B; McGorry, P; McLaughlin, M; Rubin, RT; Singh, BS; van Riel, R, 1990) |
| "A patient had torsades de pointes ventricular tachycardia related to psychotherapy with haloperidol in conventional doses." | 3.68 | Haloperidol-induced torsades de pointes. ( Gutman, Y; Kishon, Y; Kriwisky, M; Perry, GY; Tarchitsky, D, 1990) |
| "In an open study, 18 patients suffering from an acute episode of schizophrenia and 18 patients with severe mania were given haloperidol at different dosage levels." | 3.67 | Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. ( Balant, L; Balant-Gorgia, AE; Eisele, R; Garrone, G, 1984) |
| "Nineteen male patients, under 35 years of age, newly admitted with a diagnosis of schizophrenia, were treated with either chlorpromazine or haloperidol at a fixed dosage for 25 days." | 3.67 | Total and free plasma neuroleptic levels in schizophrenic patients. ( Davidson, L; Glaister, J; Jeffries, JJ; Seeman, P; Tang, SW; Toth, R, 1984) |
| "The relationship of haloperidol dose and plasma concentration to psychotic symptoms of schizophrenia is described." | 3.67 | Beyond the therapeutic window: a case presentation. ( Butterfield, L; Friedel, RO; Garicano, M; Narasimhachari, N; Schulz, SC, 1984) |
| " We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy." | 3.67 | Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. ( Barak, Y; Sexson, WR, 1989) |
| " Haloperidol concentrations were determined by radioreceptor assay (RRA) and prolactin concentrations were measured in 20 patients diagnosed as schizophrenia (DSM-III)." | 3.67 | Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility. ( Almoguera, I; Cabranes, JA; Prieto, P; Ramos, JA; Rubio, ME; Santos, JL; Vazquez, C, 1989) |
| " Many such patients respond to a trial of lithium therapy; responders are usually better able to work or attend school and to live independently, and they less often show the degree of personality deterioration present in classical schizophrenia." | 3.67 | Acutely psychotic patients: a treatment approach. ( Cade, JR; Lippmann, S; Wagemaker, H, 1985) |
| "To study a correlation between anxiety and delirium, 50 schizophrenic patients with the anxiety-delirious syndrome were treated with anxiolytics (leponex and phenazepam)." | 3.67 | [Structure of the anxious-delusional syndrome of schizophrenic patients during treatment with anxiolytics]. ( Nuller, IuL; Vasil'ev, AA, 1986) |
| "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 3.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
| "A case history was presented of a 49-year-old female patient, who had developed paranoid-hallucinatory schizophrenia for the first time and suffered from an acute functional bladder obstruction while receiving haloperidol." | 3.67 | Urinary retention in the course of neuroleptic therapy with haloperidol. ( Kober, C; Schunck, H; Ulmar, G, 1988) |
| "The case of a 47-year old schizophrenic patient, who developed priapism on the fourth day of treatment with 40 mg Haloperidol and 50 mg Levomepromazin daily, is presented." | 3.67 | [Priapism in neuroleptic therapy]. ( Eikmeier, G, 1987) |
| " To evaluate the effects of antipsychotic drugs on plasma vasopressin, we measured vasopressin response to a single dose of intramuscular chlorpromazine or intravenous haloperidol in normal individuals and to 2 weeks of oral antipsychotics in patients with acute schizophrenia." | 3.67 | Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. ( Backus, FI; Bokan, JA; Courtney, N; Dorsa, DM; Murburg, MM; Raskind, MA; Ries, RK; Weitzman, RE, 1987) |
| " A case of recurrent thrombocytopenia due to the repeated exposure to chlorpromazine (twice), haloperidol (four times) and thiothixene (twice) in a 59 year old female treated for schizophrenia is reported." | 3.67 | Thrombocytopenia associated with chlorpromazine, haloperidol and thiothixene: a case report. ( Balon, R; Berchou, R; Zethelius, M, 1987) |
| "Thirty-nine patients with chronic schizophrenia for whom hospitalization was clinically indicated received haloperidol for 4 to 6 weeks in a standardized dose schedule." | 3.67 | Familial schizophrenia and treatment response. ( Breitner, JC; Davidson, M; Davis, KL; Keefe, RS; Losonczy, MF; Mohs, RC; Silverman, JM; Sorokin, JE, 1987) |
| "In a four-segment long-term (greater than or equal to 6 mo) study, patients with schizophrenia received oral haloperidol in single daily doses and subsequently depot intramuscular (IM) haloperidol decanoate q28d." | 3.67 | The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. ( Doose, DR; Nair, NP; Nayak, RK, 1987) |
| "The indications for administering clozapine to 21 adolescent inpatients with schizophrenia were insufficient response to other neuroleptic agents, likelihood of psychotic symptoms becoming chronic and extensive extrapyramidal side-effects from other neuroleptic agents." | 3.67 | [Results of treatment with clozapine in schizophrenic adolescents]. ( Remschmidt, H; Siefen, G, 1986) |
| "The relationship between enlargement of the lateral ventricles in the brains of schizophrenic patients and clinical response to neuroleptic treatment, as assessed by the ventricle-brain ratio (VBR) and psychopathology scores, was studied in a sample of 39 patients with schizophrenia or schizoaffective psychosis during a drug-free washout and after 3 1/2 weeks of treatment with either haloperidol or thioridazine." | 3.67 | Lateral ventricular enlargement and clinical response in schizophrenia. ( Baumgartner, R; Burd, A; Calderon, M; Gordon, J; Mauldin, M; Ravichandran, GK; Smith, RC; Vroulis, G, 1985) |
| "To test the dopamine hypothesis of schizophrenia the authors measured specific 3H-neuroleptic/dopamine binding sites in three dopamin-rich regions of 59 postmortem normal human brains and 50 postmortem brains from schizophrenic patients using 3H-haloperidol and 3H-spiperone." | 3.66 | Elevation of brain neuroleptic/dopamine receptors in schizophrenia. ( Lee, T; Seeman, P, 1980) |
| "In order to test the dopamine hypothesis of schizophrenia, the neuroleptic/dopamine receptors in three dopamine-rich regions of 53 postmortem normal human brains and 42 schizophrenic brains were measured using 3H-haloperidol and 3H-spiperone." | 3.66 | Abnormal neuroleptic/dopamine receptors in schizophrenia. ( Lee, T; Seeman, P, 1980) |
| " Muscle rigidity was not affected by etybenzatropine or diazepam, but dantrolene, a direct-acting skeletal muscle relaxant, provided muscle relaxation with a concomitant decrease of fever and serum creatine kinase." | 3.66 | Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. ( Bismuth, C; Conso, F; de Rohan-Chabot, P; Elkharrat, D; Gajdos, P; Goulon, M, 1983) |
| "The authors treated 16 outpatients and 1 inpatient who had diagnoses of schizophrenia in exacerbation with haloperidol as the sole neuroleptic agent and obtained ratings of psychopathology and serum levels of haloperidol." | 3.66 | Relationship of serum haloperidol levels to clinical response in schizophrenic patients. ( Arnold, KV; Earle, GM; Hollister, LE; Magliozzi, JR, 1981) |
| "26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol." | 3.65 | Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. ( Ackenheil, M; Eben, E; Hippius, H; Rüther, E; Schilkrut, R, 1976) |
| "Three patients, aged 23-33 years, with the diagnosis of schizophrenia, developed symptoms of tardive dyskinesia while receiving neuroleptic treatment, mostly with haloperidol." | 3.65 | Diazepam in the treatment of tardive dyskinesia. Preliminary observations. ( Singh, MM, 1976) |
| "While antipsychotic-induced extrapyramidal symptoms (EPS) and akathisia remain important concerns in the treatment of patients with schizophrenia, the relationship between movement disorder rating scales and spontaneously reported EPS-related adverse events (EPS-AEs) remains unexplored." | 2.80 | Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales. ( Fleischhacker, WW; Karayal, ON; Kemmler, G; Kolluri, S; Vanderburg, D; Widschwendter, CG, 2015) |
| "Diagnosis, cannabis use, duration of untreated psychosis (DUP), smoking and antipsychotic class were examined as possible predictive variables." | 2.79 | Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. ( Crespo-Facorro, B; de León, J; Diaz, FJ; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R, 2014) |
| " Both groups reported insomnia as the most common treatment-emergent adverse event, and no serious adverse event was reported." | 2.79 | A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. ( Chan, HY; Chen, CK; Chen, JJ; Chen, YS; Chou, SY; Ree, SC; Su, LW, 2014) |
| " The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia." | 2.77 | The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012) |
| "Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol." | 2.77 | Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012) |
| "risperidone (RIS), produce more extensive blockade of brain serotonin (5-HT)(2A) than dopamine (DA) D(2) receptors." | 2.77 | Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. ( Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM, 2012) |
| "112 patients were treated with a mean dosage of 4." | 2.76 | Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Kühn, KU; Mayr, A; Meyer, S; Möller, HJ; Riedel, M; Schennach-Wolff, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2011) |
| "Schizophrenia is a persistent, lifelong illness such that enduring functional improvements may only occur over the course of years [corrected]." | 2.75 | A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. ( Harvey, PD; Loebel, A; Malla, A; Newcomer, JW; Potkin, SG; Romano, S; Siu, CO; Stahl, SM; Watsky, E; Weiden, PJ, 2010) |
| " Sample size was reduced from 311 to 156 patients, thereby decreasing the number of patients exposed to placebo from 54 to 30 and the number exposed to the active control with a known side effect from 126 to 60." | 2.74 | Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach. ( Baker, R; Breier, A; Dunayevich, E; Lindborg, S; Seaman, J; Spann, M, 2009) |
| "Dynamic, 4-dimensional models of disease progression were created from 4 repeated high-resolution brain magnetic resonance imaging scans of 36 first-episode schizophrenia patients (30 men/6 women; mean age: 24." | 2.74 | Time-lapse mapping of cortical changes in schizophrenia with different treatments. ( Bartzokis, G; Charles, C; Edwards, N; Geaga, JA; Hamer, RM; Hayashi, KM; Hong, MS; Klunder, AD; Lieberman, JA; Lu, PH; McEvoy, J; Perkins, DO; Thompson, PM; Toga, AW; Tohen, M; Tollefson, GD; Yu, M, 2009) |
| "Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels." | 2.74 | Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. ( Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2009) |
| "Auditory hallucinations are a characteristic symptom of schizophrenia and are usually resistant to treatment." | 2.74 | Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. ( Bagati, D; Nizamie, SH; Prakash, R, 2009) |
| " Therefore, if flupentixol's efficacy on negative symptoms is based on its interaction with 5-HT(2A) and/or D(1) receptors, it should be highly dependent on serum concentration and thus on dosage and metabolism." | 2.73 | Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. ( Bares, R; Bartels, M; Beneke, M; Glaser, T; Machulla, HJ; Noda, S; Reimold, M; Schaefer, JE; Solbach, C; Wormstall, H, 2007) |
| "Treatment with haloperidol could significantly increase the PI than the treatment with risperidone (p<0." | 2.73 | Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients. ( Chou, YH; Lee, SM; Li, MH; Wan, FJ; Yen, MH, 2008) |
| "Patients with schizophrenia are characterized by emotional symptoms such as flattened affect which are accompanied by cerebral dysfunctions." | 2.73 | Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia. ( Backes, V; Gaebel, W; Habel, U; Jon Shah, N; Kellermann, T; Reske, M; Schneider, F; Stöcker, T; von Wilmsdorff, M, 2007) |
| "Haloperidol was also associated with a significant increase of peripheral blood mononuclear cell membrane peroxidation." | 2.73 | Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. ( Bernardo, M; Cardellach, F; Casademont, J; Garrabou, G; López, S; Miró, O; Pons, A, 2007) |
| "Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day." | 2.73 | The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. ( Gursoy, B; Kirli, S; Sarandöl, E; Sipahioglu, D; Sivrioglu, EY, 2007) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 2.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| "We studied 32 minimally treated schizophrenia patients and 21 healthy subjects with single-voxel proton magnetic resonance spectroscopy ((1)H-MRS) of the frontal and occipital lobes, caudate nucleus, and cerebellum." | 2.73 | Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. ( Brooks, WM; Bustillo, JR; Hammond, R; Hart, B; Jung, R; Lauriello, J; Qualls, C; Rowland, LM, 2008) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 2.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "Weight gain has become one of the most common and concerning side effects of antipsychotic treatment." | 2.73 | Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. ( Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2008) |
| "Aripiprazole was significantly inferior to olanzapine (SMD = 1." | 2.72 | Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. ( Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S, 2021) |
| "Haloperidol-treated patients improved only on domains of learning/memory." | 2.72 | One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. ( Breier, A; Gold, JM; Keefe, RS; Purdon, SE; Rock, SL; Young, CA, 2006) |
| "Olanzapine-treated patients had significantly more weight gain compared with the haloperidol and risperidone groups (p < ." | 2.72 | A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. ( Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M, 2006) |
| "Clinical trials for the treatment of schizophrenia now often include cognitive assessments in addition to clinical ratings of symptoms." | 2.71 | Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study. ( Artiola i Fortuny, L; De Smedt, G; Harvey, PD; Vester-Blockland, E, 2003) |
| "Olanzapine has been shown to be better tolerated in comparison with conventional antipsychotics in a large unselected sample of acutely psychotic schizophrenic in-patients." | 2.71 | Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. ( Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M; Sacristán, JA, 2003) |
| "Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients." | 2.71 | Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. ( Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R, 2003) |
| "In schizophrenia and Parkinson's disease, cortical and subcortical motor organization is influenced by primary disease conditions and neuroleptic treatment." | 2.71 | Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study. ( Deuticke, C; Hajak, G; Müller, JL; Putzhammer, A; Röder, CH; Winkler, J, 2003) |
| "625 mg/day) were added to a fixed dosage of haloperidol (5 mg daily)." | 2.71 | Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. ( Bassitt, D; Diegoli, M; Elkis, H; Gattaz, WF; Louzã, MR; Marques, AP, 2004) |
| "Co-occurring substance use disorders, mostly involving alcohol, cannabis or cocaine, occur commonly in patients with schizophrenia and are associated with increased morbidity and mortality." | 2.71 | First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. ( Clark, WS; Glick, I; Green, AI; Hamer, RM; Lieberman, JA; Strakowski, SM; Tohen, MF, 2004) |
| "Duration of untreated psychosis (DUP) may contribute to the observed heterogeneity of the treatment response in first-episode schizophrenia." | 2.71 | Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. ( Green, A; Gu, H; Gur, R; Kahn, R; Lieberman, J; McEvoy, J; Perkins, D; Sharma, T; Strakowski, S; Tohen, M; Tollefson, G; Zipursky, R, 2004) |
| "Haloperidol plasma levels were measured weekly for at least 2 months after discontinuation." | 2.71 | Haloperidol half-life after chronic dosing. ( Cooper, TB; de Leon, J; Diaz, FJ; Josiassen, RC; Simpson, GM; Wedlund, P, 2004) |
| "Risperidone treatment reduced this deficit, suggesting a facilitation of attentional function, but haloperidol treatment did not." | 2.71 | Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia. ( Harris, MS; Keshavan, MS; Reilly, JL; Sweeney, JA, 2005) |
| "Haloperidol-treated patients exhibited significant decreases in gray matter volume, whereas olanzapine-treated patients did not." | 2.71 | Antipsychotic drug effects on brain morphology in first-episode psychosis. ( Charles, C; Green, AI; Gu, H; Gur, RE; Hamer, RM; Kahn, RS; Keefe, RS; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, GD; Zipursky, R, 2005) |
| "Comorbid cocaine abuse adversely affects clinical outcomes in schizophrenia." | 2.71 | Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. ( Campbell, EC; Caroff, SN; Cornish, J; Kondrich, J; Mann, SC; O'Brien, C; Sayers, SL, 2005) |
| " According to response, dosage was then adjusted to a maximum dosage of 20 mg daily of either drug." | 2.71 | Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. ( Christensen, BK; Daskalakis, Z; Epstein, I; Furimsky, I; Kapur, S; Roy, P; Sanger, T; Zipursky, RB, 2005) |
| "Risperidone treatment, however, was more effective in the reduction of negative symptoms." | 2.71 | The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. ( Cohen, H; Pourcher, E; Rémillard, S, 2005) |
| " Patients were initiated with quetiapine to 400 mg/day over 7 days, and then flexibly dosed (300-750 mg/day) for 11 weeks." | 2.71 | Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. ( Altman, C; de Nayer, A; Jones, AM; Larmo, I; Lindenbauer, B; Platz, T; Rittmannsberger, H; Windhager, E, 2005) |
| "Risperidone was immediately effective against positive and negative symptoms in untreated patients; however, in the previously treated groups, it was initially effective against negative symptoms only; after a 2-week interval, positive symptoms also improved." | 2.71 | Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. ( Himei, A; Okamura, T, 2005) |
| " Using either a slower dose-titration or a high, single loading dose followed by a low maintenance dosing may have offered the possibility to obtain a good antipsychotic effect together with low incidence of EPS." | 2.70 | Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. ( Bischoff, S; Gerebtzoff, A; Möller, HJ; Volz, HP, 2002) |
| "The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients." | 2.70 | Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. ( Benkert, O; Eich, FX; Müller, MJ; Puech, A; Rein, W; Wetzel, H, 2002) |
| "Its usefulness in schizophrenia has yet to be adequately assessed." | 2.70 | Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. ( Hafiz, NG; Hampton, D; Molloy, M; Wassef, AA, 2001) |
| " The present study aims to investigate the relationship between the -141C Ins/Del polymorphism and extrapyramidal adverse effects of bromperidol and nemonapride, antipsychotic drugs with a selective and potent DRD2 antagonistic property, in schizophrenic inpatients." | 2.70 | No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Ono, S; Otani, K; Suzuki, A; Yasui, N, 2001) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 2.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| "Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects." | 2.70 | Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Berk, M; Brook, S; Ichim, C, 2001) |
| "Olanzapine induced a lower striatal D2 occupancy than haloperidol." | 2.70 | Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. ( Bernardo, M; Catafau, AM; Font, M; Gómez, JC; Gutiérrez, F; Lomeña, F; López-Carrero, C; Parellada, E; Pavía, J; Salamero, M, 2001) |
| "Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor." | 2.70 | Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. ( Berk, M; Schutz, G, 2001) |
| "m." | 2.70 | Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. ( Hatzimanolis, J; Lykouras, L; Markianos, M, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 2.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "D-fenfluramine has been identified as a highly selective serotonin (5-HT) releaser and re-uptake inhibitor." | 2.69 | Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1998) |
| "Olanzapine has been reported as less likely to cause EPS and may improve some negative signs." | 2.69 | The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998) |
| "Risperidone treatment produced a greater effect on patients' ability to perceive emotion compared with haloperidol treatment." | 2.69 | Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. ( Green, MF; Kee, KS; Kern, RS; Marshall, BD, 1998) |
| "Haloperidol was associated with a sustained hyperprolactinemia, unlike ziprasidone, where only transient elevations in prolactin that returned to normal within the dosing interval were observed." | 2.69 | An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. ( Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD, 1998) |
| "This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia." | 2.69 | Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998) |
| " A simulation of this dependence of clinical improvement on serum levels, mediated by the variable dose design, can be excluded because of the results of a retrospective analysis of dosing behavior." | 2.69 | Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. ( Braun, V; Meyer, FP; Neuhof, S; Ulrich, S, 1998) |
| "Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients." | 2.69 | Olanzapine versus haloperidol treatment in first-episode psychosis. ( Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD, 1999) |
| "Haloperidol treatment did not alter glutamate concentrations." | 2.69 | Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. ( Bardgett, M; Csernansky, JG; Faull, KF; Faustman, WO; Pfefferbaum, A, 1999) |
| " Sixteen patients who did not respond to the traditional antipsychotics after 2 weeks of treatment with a certain dosage of haloperidol were administered with 50 mg of sertraline for a period of 2 weeks." | 2.69 | Co-administration of sertraline and haloperidol. ( Han, CS; Kim, SH; Lee, MS; You, YW, 1998) |
| "Haloperidol-treated patients showed dose-dependently (Pearson r = 0." | 2.69 | In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. ( Asenbaum, S; Barnas, C; Brücke, T; Fischer, P; Kasper, S; Küfferle, B; Pezawas, L; Tauscher, J; Tauscher-Wisniewski, S, 1999) |
| "D-Fenfluramine was administered to 22 young, acutely ill schizophrenics (11 females and 11 males) after 4 weeks of haloperidol treatment." | 2.69 | Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1999) |
| "Olanzapine-treated patients improved in 5 of 8 domains to a significantly greater degree than did haloperidol patients." | 2.69 | Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. ( Croghan, TW; Heilman, DK; Johnstone, BM; Obenchain, RL; Tunis, SL, 1999) |
| "The relationship between Taq1 A polymorphism of dopamine D(2) receptor (DRD(2)) gene and extrapyramidal adverse effects of bromperidol and nemonapride, which are both antipsychotic drugs with selective and potent DRD(2) antagonistic property, was investigated in Japanese schizophrenic inpatients." | 2.69 | No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. ( Kaneko, S; Kondo, T; Mihara, K; Nagashima, U; Ono, S; Otani, K; Suzuki, A, 2000) |
| "Zuclopenthixol acetate was effective in the management of the acutely disturbed schizophrenic." | 2.69 | A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. ( Chandramohan, P; Cheah, YC; Chin, CN; Hamid, AR; Leonard, AO; Loh, CC; Mahmud, M; Norhamidah, MS; Philip, G; Ramlee, T; Roslan, KA; Suraya, Y; Zakariah, MS; Zulkifli, G, 1998) |
| "biperiden was studied in an open clinical trial in twenty-three (12 male and 11 female) patients who developed antipsychotic-induced acute akathisia as defined by the research criteria of the DSM-IV." | 2.69 | Intravenous biperiden in akathisia: an open pilot study. ( Ashby, CR; Hirose, S, 2000) |
| "Risperidone (6 to 16 mg)-treated patients showed significantly (p < 0." | 2.68 | Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. ( Chouinard, G, 1995) |
| "Haloperidol decanoate is a long-acting depot antipsychotic agent used for the treatment of schizophrenic patients." | 2.68 | A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. ( Chang, WH; Jann, MW; Lin, HN; Piao-Chien, C; Wei, FC, 1996) |
| "Risperidone was compared in 2 double blind studies with haloperidol and perphenazine in schizophrenic psychoses." | 2.68 | [Efficacy and tolerance of risperidone in various doses (report of a study)]. ( Cesková, E; Svestka, J, 1996) |
| "Desipramine 50 mg/day was coadministered for 1 week, and blood samplings and clinical ratings were performed before and after the coadministration." | 2.68 | No interaction between desipramine and bromperidol. ( Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui, N, 1996) |
| "Haloperidol dose was negatively associated with improvement in positive symptoms (r = -." | 2.68 | Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics. ( Pardo, M; Pollack, S; Weisbard, JJ, 1997) |
| "Risperidone is a novel and clinically effective atypical antipsychotic medication with a unique biochemical profile." | 2.68 | Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. ( Bauer, KS; Haas, GL; Keshavan, MS; Kroboth, PD; Schooler, NR; Sweeney, JA, 1997) |
| "Risperidone treatment had a greater beneficial effect on verbal working memory than haloperidol treatment across testing conditions (with and without distraction) and study phases (fixed and flexible dose)." | 2.68 | Does risperidone improve verbal working memory in treatment-resistant schizophrenia? ( Ames, D; Green, MF; Kern, RS; Marder, SR; Marshall, BD; McGurk, S; Mintz, J; Wirshing, WC, 1997) |
| " Eighteen patients were treated for at least 4 weeks with a fixed dose of orally administered haloperidol for at least 4 weeks (mean daily dosage ranging from 0." | 2.68 | D2-dopamine-receptor occupancy during treatment with haloperidol decanoate. ( Albus, M; Mager, T; Oertel, WH; Scherer, J; Schwarz, J; Tatsch, K, 1997) |
| "Bromperidol is a close structural analog of haloperidol." | 2.68 | Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. ( Ikeda, K; Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Shibata, M; Suzuki, A; Yasui, N, 1997) |
| "As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol." | 2.68 | Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. ( Avenoso, A; Campo, G; Caputi, AP; Facciolă, G; Ferlito, M; Perucca, E; Spinà, E; Zuccaro, P, 1997) |
| "Five fixed doses of the atypical antipsychotic "Seroquel" (quetiapine) were evaluated to delineate a dose-response relationship, as measured by changes from baseline in Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores, and to compare efficacy and tolerability opposite placebo and haloperidol." | 2.68 | Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. ( Arvanitis, LA; Miller, BG, 1997) |
| "Risperidone 6 mg was the lowest dose that produced substantial change in negative symptoms and no increase in extrapyramidal symptoms and antiparkinsonian medication use." | 2.67 | Negative symptoms in schizophrenia: assessment of the effect of risperidone. ( Schooler, NR, 1994) |
| "Risperidone was found to have a curvilinear dose-response curve with an optimum effect of 4 mg day on the negative, anxious/depressive and cognitive factors and with an optimum effect of 8 mg day on the positive and excited factors." | 2.67 | Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. ( Lindström, E; von Knorring, L, 1994) |
| "Nine haloperidol patients were selected from a separate treatment study that had a similar design and selection criteria and used identical EEG methods." | 2.67 | Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. ( Czobor, P; Volavka, J, 1993) |
| "The purpose of the study was to investigate clinical and pharmacokinetic parameters concerning perphenazine decanoate (PD) and haloperidol decanoate (HD) with an interval of 3 weeks during a study period of 51 weeks." | 2.67 | A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. ( Dencker, SJ; Giös, I; Mårtensson, E; Nordén, T; Nyberg, G; Persson, R; Roman, G; Stockman, O; Svärd, KO, 1994) |
| "Treatment with haloperidol caused initial increases in urinary homovanillic acid (HVA) output that returned toward baseline by the 5th week." | 2.67 | Studies of catecholamine metabolism in schizophrenia/psychosis--II. ( Berman, N; Bowden, CL; Contreras, SA; Javors, MA; Maas, JW; Miller, AL; Seleshi, E; Weintraub, SE, 1993) |
| " Dosage of these two drugs were 450 = 133 mg and 32 +/- 9." | 2.67 | [A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin]. ( Gu, SF, 1992) |
| " Mean daily lorazepam dosage was 0." | 2.67 | Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. ( Gaertner, HJ; Mahal, A; Stevens, A; Stevens, I, 1992) |
| "Haloperidol was superior to placebo for reduction of target symptoms with optimal haloperidol dose of 0." | 2.67 | Haloperidol in schizophrenic children: early findings from a study in progress. ( Campbell, M; Kafantaris, V; Padron-Gayol, MV; Rosenberg, CR; Spencer, EK, 1992) |
| "Haloperidol was assayed by a sensitive and specific radioimmunoassay." | 2.67 | Haloperidol plasma levels and clinical response: a therapeutic window relationship. ( Marder, SR; Mintz, J; Poland, RE; Van Putten, T, 1992) |
| "During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue." | 2.67 | Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991) |
| "Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients." | 2.67 | A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. ( Beckmann, H; Bunse, J; Dittmann, V; Klieser, E; König, P; Laux, G; Schöny, HW; Schröder, HG; Schubert, H; Unterweger, B, 1990) |
| " The total incidence of serious adverse events in the short-term double-blind programme was approximately 2% for both remoxipride and haloperidol." | 2.67 | Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. ( Englund, A; Lawrie, V; Lewander, T; Morrison, D; Schlachet, A; Westerbergh, SE, 1990) |
| "Haloperidol disposition has been associated with reversible metabolism: it is reversibly reduced to its metabolite, reduced haloperidol, which has less pharmacologic activity than the parent compound." | 2.67 | Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. ( Chang, WH; Jann, MW; Lam, YW, 1990) |
| " Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections." | 2.67 | Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ( McCreadie, RG; Whitehead, A; Wiles, DH, 1990) |
| " The dosage equivalency of haloperidol decanoate (1." | 2.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| " The plasma RHAL:HAL ratios on days 6 and 7 were higher than and positively correlated with those at Tmax after a single dose of HAL and were negatively correlated with the HAL:RHAL ratios at Tmax after a single dose of RHAL." | 2.66 | Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. ( Chang, WH; Chen, CT; Chen, TY; Hu, WH; Jann, MW; Lam, YW; Lin, SK; Yeh, EK, 1989) |
| "Haloperidol treatment masked withdrawal-exacerbated tardive dyskinesia more than molindone did; this difference (measured by percent change in AIMS scores) was significant (p = ." | 2.66 | Molindone and haloperidol in tardive dyskinesia. ( Benarroche, CL; Glazer, WM; Hafez, HM, 1985) |
| " Therefore, it is critical to establish dosing strategies for long-term therapy that emphasize a minimal effective dose." | 2.66 | Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. ( Kane, JM, 1986) |
| " The dosage calculation was made from the haloperidol doses previously received by the patients, adjusted in each particular case, with a mean of 73 mg per application (range, 50 to 200 mg)." | 2.66 | [Chronic treatment of schizophrenia with injectable bromperidol decanoate]. ( Suárez Richards, M, 1985) |
| "Fluperlapine (NB-106-689) was tested on 26 schizophrenic patients in an open and crossover study." | 2.66 | Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study. ( Bartels, M; Gärtner, HJ; Heimann, H; Mann, K; Schied, HW; Wagner, W, 1987) |
| "Bromperidol has a potent antipsychotic action, and some stimulating properties on activity which make it very useful when increasing patients' motivation, and resocialization is at stake." | 2.66 | [Treatment with bromperidol in schizophrenic patients]. ( Ellerman, LA, 1988) |
| "Haloperidol appeared to produce lower levels of psychopathology than flupenthixol but similar levels of side effects." | 2.66 | Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol. ( Beninger, RJ; Delva, NJ; Ehmann, TS, 1987) |
| " Dosage ratios of loxapine to haloperidol ranged from a minimum of 2." | 2.66 | A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. ( Tuason, VB, 1986) |
| " It was concluded that 4-week intramuscular administration of haloperidol decanoate provides appropriate control of schizophrenic symptoms, but that flupenthixol decanoate should be dosed at shorter intervals." | 2.66 | Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. ( Eberhard, G; Hellbom, E, 1986) |
| " The dosage was adjusted to the clinical response of the patients and the mean dose was 21." | 2.65 | A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients. ( Bechelli, LP; Hetem, G; Ruffino-Netto, A, 1983) |
| " It appears that propericiazine shows an inverted U-shaped dose-response curve." | 2.65 | Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine. ( Hoaki, Y; Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y, 1984) |
| "Using a double-blind experimental design, two dosage regimens of haloperidol were compared in acutely decompensated, newly admitted schizophrenic patients." | 2.65 | Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens. ( Greub, E; Modestin, J; Pia, M; Toffler, G, 1983) |
| "In a double-blind controlled study, 20 acutely psychotic inpatients were treated with different haloperidol dosage regimens." | 2.65 | Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. ( Depry, D; Janowsky, DS; Munson, E; Neborsky, RJ; Perel, JM, 1984) |
| "Carbamazepine has recently been reported to have therapeutic potential in mania." | 2.65 | Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. ( Belmaker, RH; Bental, E; Klein, E; Lerer, B, 1984) |
| "We studied the incidence of akathisia in two populations of newly admitted schizophrenic patients: one group was treated with haloperidol and the other group was treated with thiothixene hydrochloride." | 2.65 | Akathisia with haloperidol and thiothixene. ( Marder, SR; May, PR; Van Putten, T, 1984) |
| "The drug difference between a low and a high dosage of haloperidol was investigated in 40 acutely ill schizophrenic patients." | 2.65 | Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder. ( Lehmann, E; Scholz, OB; Winter, M, 1984) |
| "Treatment with sulpiride was associated with a significant rise in plasma prolactin level, but paradoxically these patients had significantly reduced extrapyramidal symptoms." | 2.65 | A clinical and pharmacodynamic evaluation of sulpiride. ( Bailey, J; Bishop, M; Coppen, A; Rao, VA, 1981) |
| " Mean daily dosage was approximately 112 mg flupenthixol and 18 mg haloperidol." | 2.65 | Flupenthixol versus haloperidol in acute psychosis. ( Parent, M; Toussaint, C, 1983) |
| " There appeared to be no difference between the viloxazine-treated group and the placebo-treated group, although the study raised some question as to the adequacies of the dosage utilized since there was an absence of any apparent side effects." | 2.65 | Viloxazine and the depressed schizophrenic--methodological issues. ( Kurland, AA; Nagaraju, A, 1981) |
| "Haloperidol was also significantly superior to thiothixene in Cognitive Disturbance on the HPRSD." | 2.65 | Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. ( Abuzzahab, FS; Zimmerman, RL, 1982) |
| "Haloperidol was well tolerated by the patients; there were no serious adverse reactions." | 2.65 | Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. ( Donlon, PT; Hopkin, JT; Meadow, A; Tupin, JP; Wahba, M; Wicks, JJ, 1980) |
| "An eleven-fold increase in dystonia was found in patients who received no prophylactic medication." | 2.65 | Benztropine prophylaxis of dystonic reactions. ( Anderson, WH; Stern, TA, 1979) |
| "In a double blind chlorpromazine-controlled trial, high dosage haloperidol (100 mg daily) given for three months, appreciably improved the mental state of male chronic 'drug resistant' schizophrenic inpatients in the rehabilitation/long-stay unit of one psychiatric hospital." | 2.64 | High dosage haloperidol in chronic schizophrenia. ( MacDonald, IM; McCreadie, RG, 1977) |
| " The employed dosage caused no strong sedation." | 2.64 | Double-blind comparison of bromperidol and perphenazine. ( Angst, J; Woggon, B, 1978) |
| " In the 1-day dosage group the amount of anticholinergics were significantly reduced (2." | 2.64 | [Extrapyamidal side-effects with 1-day dosage of haloperidol (author's transl)]. ( Matzner, G; Rüther, E; Uriarte, V, 1978) |
| "Haloperidol has proved to be remarkably safe in this high dose regimen." | 2.64 | Higher than usual dosage of haloperidol: a pilot study in 'back ward' schizophrenics. ( Declercq, H; Tanghe, A, 1976) |
| "The long-term treatment of schizophrenia is one of the most challenging tasks for practicing physicians." | 2.48 | [The long-term treatment of schizophrenia]. ( Herold, R, 2012) |
| "Schizophrenia has been found to be a disease of progressive reductions in grey matter, and the more lost, the worse the outcome." | 2.48 | The differences between typical and atypical antipsychotics: the effects on neurogenesis. ( Agius, M; Nandra, KS, 2012) |
| "Influential protocols in the treatment of schizophrenia recommend the use of antipsychotics in monotherapy." | 2.48 | [Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature]. ( Bitter, I; Gazdag, G; Tolna, J, 2012) |
| "When bromperidol decanoate was compared with fluphenazine depot, we found no important change on global outcome (n = 30, RR no clinical important improvement 1." | 2.48 | Bromperidol decanoate (depot) for schizophrenia. ( Adams, CE; Purgato, M, 2012) |
| "When bromperidol decanoate was compared with fluphenazine depot, we found no important change on global outcome (n = 30, RR no clinical important improvement 1." | 2.47 | Bromperidol decanoate (depot) for schizophrenia. ( Adams, CE; Purgato, M, 2011) |
| "Ten acute trials in mania, 3 in bipolar depression, and 8 in schizophrenia were identified, along with 2 maintenance studies in bipolar disorder and 2 in schizophrenia." | 2.44 | A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. ( Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ, 2008) |
| " Antipsychotic-induced laryngeal dystonia has been reported predominantly in young males, but does not correlate to the dosage or the category of the drug." | 2.43 | Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. ( Christodoulou, C; Kalaitzi, C, 2005) |
| "Tardive Tourette syndrome is an extrapyramidal symptom which appears after long-term neuroleptic use." | 2.43 | [Two cases of tardive Tourette syndrome]. ( Ohmori, T; Yamauchi, K, 2006) |
| "Aripiprazole is a novel antipsychotic with a unique mechanism of action." | 2.42 | Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. ( Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E, 2003) |
| " We performed (1) a meta-analysis of randomized efficacy trials comparing SGAs and FGAs, (2) comparisons between SGAs, (3) a dose-response analysis of FGAs and SGAs, and (4) an analysis of the effect on efficacy of an overly high dose of an FGA comparator." | 2.42 | A meta-analysis of the efficacy of second-generation antipsychotics. ( Chen, N; Davis, JM; Glick, ID, 2003) |
| "When bromperidol decanoate was compared with fluphenazine depot we found no important change on global outcome (n=30, RR no clinical important improvement 1." | 2.42 | Depot bromperidol decanoate for schizophrenia. ( Adams, CE; David, A; Quraishi, SN; Wong, D, 2004) |
| " We exemplify how this dosing confounder could lead to inappropriate conclusions." | 2.41 | Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. ( Kapur, S; Remington, G; Wadenberg, ML, 2000) |
| "Anti-psychotic drugs are the mainstay treatment for schizophrenia." | 2.41 | Depot bromperidol decanoate for schizophrenia. ( Adams, CE; David, A; Quraishi, S, 2000) |
| "A diagnosis of neuroleptic malignant syndrome was made and the patient continued to receive aggressive supportive care." | 2.41 | Neuroleptic malignant syndrome and severe thrombocytopenia: case report and literature review. ( Ahmed, W; Ghani, SO; Marco, LA, 2000) |
| " Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale." | 2.41 | Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000) |
| "Risperidone is a relatively new antipsychotic available world-wide since the early 1990s." | 2.41 | Focus on risperidone. ( Green, B, 2000) |
| "Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class." | 2.40 | Efficacy of olanzapine: an overview of pivotal clinical trials. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| "Sertindole is a novel antipsychotic which has been tested in large clinical trials in North America and Europe; the results showed that this drug has efficacy against both the positive and negative symptoms of schizophrenia, while causing adverse neurological events at a similar level to that observed in patients taking placebo." | 2.40 | Sertindole: a review of clinical efficacy. ( Kane, JM, 1998) |
| "Risperidone has these pharmacologic properties." | 2.39 | Extrapyramidal side effects and tolerability of risperidone: a review. ( Owens, DG, 1994) |
| " Three notions have been utilized conceptually to explain the distinction between atypical versus typical antipsychotic drugs: 1) dose-response separation between particular pharmacologic functions; 2) anatomic specificity of particular pharmacologic activities; 3) neurotransmitter receptor interactions and pharmacodynamics." | 2.39 | Mechanisms of action of atypical antipsychotic drugs: a critical analysis. ( Kinon, BJ; Lieberman, JA, 1996) |
| " The proportion of patients failing to reach at least 20% improvement on the positive and negative syndrome scale (PANSS) or brief psychiatric rating scale (BPRS), the proportion of patients discontinuing treatment because of adverse effects and the number of patients who needed antiparkinsonian medication were abstracted for use as outcome measures." | 2.39 | Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. ( Bacaltchuk, J; de Castro-e-Silva, E; de Oliveira, IR; de Sena, EP; Miranda-Scippa, AM; Pereira, EL; Ribeiro, MG, 1996) |
| "Sydenham's chorea is a symptom of rheumatic fever and results from an autoimmune attack on the CNS." | 2.39 | Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. ( Moore, DP, 1996) |
| " To deal with pharmacokinetic aspects two main topics are discussed in this paper: (A) the interindividual differences in bioavailability and metabolism and (B) the plasma level-clinical response relationship." | 2.38 | A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance. ( Altamura, AC, 1993) |
| " In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance." | 2.38 | Dose response of prophylactic antipsychotics. ( Brauzer, B; Casey, DE; Davis, JM; Gierl, B; Hassan, M; Kane, JM; Marder, SR; Schooler, N, 1993) |
| " In chronic unresponsive schizophrenic patients, poor drug bioavailability is not the major factor for the lack of response, and the possibility that these patients constitute a nosological subgroup is suggested." | 2.36 | Haloperidol plasma level monitoring in neuropsychiatric patients. ( Bianchetti, G; Dugas, M; Morselli, PL, 1982) |
| "Expert consensus-based clinically equivalent dose estimates and dosing recommendations can provide valuable support for the use of drugs for psychosis in clinical practice and research." | 1.91 | Second International Consensus Study of Antipsychotic Dosing (ICSAD-2). ( Baldessarini, RJ; Gardner, DM; McAdam, MK; Murphy, AL, 2023) |
| "Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials." | 1.72 | Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. ( Byeon, SJ; Chung, SJ; Oh, S, 2022) |
| "Schizophrenia is analysed as one of the diseases with the highest rate of Disability-Adjusted Life Years - DALY." | 1.72 | Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund. ( Anczewska, M; Balicki, M; Droździkowska, A; Gorczyca, P; Janus, J; Paciorek, S; Plisko, R; Zięba, M, 2022) |
| "Schizophrenia is a severe neuropsychiatric disease associated with substantially higher mortality." | 1.62 | Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. ( Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J, 2021) |
| "Some individuals with schizophrenia present with a dopamine supersensitivity state (DSS) induced by a long-term administration of excessive antipsychotics; this is recognized as dopamine supersensitivity psychosis (DSP)." | 1.62 | Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol. ( Hashimoto, K; Hirose, Y; Iyo, M; Kanahara, N; Kimura, H; Kimura, M; Nangaku, M; Niitsu, T; Oda, Y; Shirayama, Y, 2021) |
| "Schizophrenia is a serious, chronic psychiatric disorder requiring lifelong treatment." | 1.56 | ( Grubor, M; Mihaljevic-Peles, A; Muck-Seler, D; Nikolac Perkovic, M; Pivac, N; Sagud, M; Svob Strac, D; Zivkovic, M, 2020) |
| "Schizophrenia is a chronic, severe and disabling psychiatric disorder, whose treatment is based on psychosocial interventions and the use of antipsychotic drugs." | 1.56 | Ubiquitin-proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia. ( Antunes, ASLM; Crunfli, F; de Almeida, V; Martins-de-Souza, D; Reis-de-Oliveira, G; Seabra, G, 2020) |
| " The duration of each adequate antipsychotic treatment at an optimal dosage was 4 weeks or more." | 1.51 | Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study. ( Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B, 2019) |
| " The current report presents adverse events in an infant exposed to a combination of risperidone and haloperidol through breast milk." | 1.51 | Adverse Events in a Breastfed Infant Exposed to Risperidone and Haloperidol. ( Uguz, F, 2019) |
| "This study examined the effects of chronic administration of haloperidol in female C57BL/6 mice." | 1.51 | Effects of haloperidol on cognitive function and behavioural flexibility in the IntelliCage social home cage environment. ( Dawe, GS; Marwari, S, 2019) |
| "Polydipsia was the most prevalent (24, 60." | 1.51 | Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. ( Chikowe, I; Domingo, M; Kampira, E; Mafuta, C; Mwakaswaya, V; Parveen, S, 2019) |
| "Schizophrenia is one of the most serious and common mental disorders, which is characterized by high levels of pathogenic heterogeneity as well as neuroimmune abnormalities, which require treatment with antipsychotic drugs." | 1.48 | [The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: affinity linked mechanism]. ( Ershov, EE; Grunina, MN; Krupitsky, EM; Nasyrova, RF; Sosin, DN; Sosina, KA; Taraskina, AE; Zabotina, AM, 2018) |
| "Haloperidol-treated rats did not have altered expression of these subunits, suggesting the changes we observed in schizophrenia are likely not due to chronic antipsychotic treatment." | 1.43 | Protein Expression of Proteasome Subunits in Elderly Patients with Schizophrenia. ( Haroutunian, V; Meador-Woodruff, JH; Rubio, MD; Scott, MR, 2016) |
| " Generally, the antipsychotics significantly enhanced NRG1/ErbB signaling with increased expression of NRG1 and phosphorylation of ErbB4 and ErbB2 in the brain and myocardium, except that clozapine partly blocked the cardiac NRG1/ErbB2 activation, which could be associated with its more severe cardiac adverse actions." | 1.43 | Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect. ( Cai, H; Dang, R; Guo, Y; Jiang, P; Liang, D; Lv, C; Yang, R, 2016) |
| "Treating schizophrenia is costly for health systems." | 1.43 | Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. ( Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K, 2016) |
| "Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition." | 1.43 | Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. ( Bauer, M; Broccoli, L; Falkai, P; Frodl, T; Hansson, AC; Hirth, N; Malchow, B; Schmitt, A; Sommer, C; Spanagel, R; Steiner, J; Uhrig, S; von Wilmsdorff, M; Zink, M, 2016) |
| "haloperidol-treated SIR animals." | 1.43 | The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol. ( Cockeran, M; Dreyer, W; Harvey, BH; Sallinen, J; Shahid, M; Uys, M, 2016) |
| "Haloperidol and biperiden was the most common drug pair of 232 pairs evaluated." | 1.43 | Potential drug-drug interaction in Mexican patients with schizophrenia. ( de la O de la O, ME; Genis, A; González-Castro, TB; Juárez-Rojop, IE; Lilia López-Narváez, M; Nicolini, H; Ocaña-Zurita, MC; Tovilla-Zárate, CA, 2016) |
| "If hallucinations are experienced during or after a period of alcohol abuse, the diagnosis of alcohol hallucinosis should be considered." | 1.42 | [Alcohol hallucinosis]. ( Blom, JD; Bouritius, EM; Neven, A, 2015) |
| "Haloperidol decanoate-treated animals, acting as controls for possible antipsychotic effects, did not have significantly altered neuronal EAAT2b mRNA levels." | 1.42 | Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia. ( Bauer, D; Haroutunian, V; Hasselfeld, K; McCullumsmith, RE; Meador-Woodruff, JH; O'Donovan, SM; Roussos, P; Simmons, M, 2015) |
| "Previous studies in schizophrenia have found altered glycan biosynthesis and abnormal glycan levels in cerebrospinal fluid (CSF) and plasma, as well as altered expression in frontal cortex of glycosyltransferase transcripts encoding proteins associated with both N- and O-linked glycosylation." | 1.42 | Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia. ( Haroutunian, V; Kippe, JM; Meador-Woodruff, JH; Mueller, TM, 2015) |
| " This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo." | 1.40 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. ( Beard, JD; Davis, RE; Hendrick, JP; Lee, T; Li, P; Mates, S; Peng, Y; Robichaud, AJ; Snyder, GL; Tomesch, J; Vanover, KE; Wennogle, LP; Yao, W; Zhang, Q; Zhu, H, 2014) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 1.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| "Co-occurring substance use disorders (SUD), including alcohol, are common in schizophrenia (SZ) and are associated with poor outcome." | 1.40 | Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. ( Gibson, LE; Green, AI; Mesholam-Gately, RI; Seidman, LJ, 2014) |
| "Current pharmacological treatments for schizophrenia target G protein-coupled receptors (GPCRs), including dopamine receptors." | 1.40 | Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia. ( Funk, AJ; Haroutunian, V; McCullumsmith, RE; Meador-Woodruff, JH, 2014) |
| "Here, we treated schizophrenia rat models with a systematic injection of MK-801 (0." | 1.40 | Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. ( Fang, Y; Xu, L; Zhang, C, 2014) |
| "Schizophrenia is a severe, persistent, and fairly common mental illness." | 1.39 | Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. ( Basu, AC; Bolo, NR; Coyle, JT; Konopaske, GT; Renshaw, PF, 2013) |
| "9% of the total antipsychotic dosage on average." | 1.39 | Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. ( Den, R; Mimura, M; Sakurai, H; Suzuki, T; Tsutsumi, C; Uchida, H; Uchida, T, 2013) |
| "Extrapyramidal symptoms (EPSs) are common adverse effects of antipsychotics." | 1.39 | The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. ( Bozina, N; Mihaljević-Peles, A; Muck-Seler, D; Nikolac-Perkovic, M; Sagud, M; Vuksan-Cusa, B; Zivković, M, 2013) |
| "Haloperidol dose was positively correlated with plasma protein carbonyls." | 1.39 | Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. ( Bošković, M; Grabnar, I; Kores Plesničar, B; Terzič, T; Vovk, T, 2013) |
| " Subsequently, the developed model was utilized to characterize an effective dosing strategy for using haloperidol as a comparator drug in future antipsychotic drug trials." | 1.39 | Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale. ( Danhof, M; de Greef, R; Groothuis, GM; Johnson, M; Kozielska, M; Liu, J; Mafirakureva, N; Pilla Reddy, V; Proost, JH; Rujescu, D; Vermeulen, A, 2013) |
| "Schizophrenia is thought to be the psychiatric diagnosis the most frequently associated with TD." | 1.39 | [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics]. ( Bellaaj, R; Bouguerra, C; Gallali, S; Mehdi, F; Oumaya, A; Sejil, I, 2013) |
| "Haloperidol treatment of primary astrocytes resulted in coordinated increases in QKI7 and GFAP expression." | 1.39 | RNA-binding protein QKI regulates Glial fibrillary acidic protein expression in human astrocytes. ( Emilsson, L; Feuk, L; Halvardson, J; Jazin, E; Lindholm Carlström, E; Radomska, KJ; Reinius, B, 2013) |
| "We describe the discovery of potent and orally bioavailable tetrahydropyridopyrimidine inhibitors of phosphodiesterase 10A by systematic optimization of a novel HTS lead." | 1.38 | Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. ( Breslin, MJ; Coleman, PJ; Cox, CD; Fandozzi, C; Fuerst, J; Hill, N; Huszar, S; Kandebo, M; Kim, SH; Ma, B; McGaughey, G; Raheem, IT; Renger, JJ; Schreier, JD; Sharma, S; Smith, S; Uslaner, J; Yan, Y, 2012) |
| "Long-term treatment of schizophrenia with antipsychotics is crucial for relapse prevention, but a prolonged blockade of D(2) dopamine receptors may lead to the development of supersensitivity psychosis." | 1.38 | Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. ( Hashimoto, K; Iyo, M; Kanahara, N; Okamura, N; Sekine, Y; Tadokoro, S, 2012) |
| "Rodent models offer a tractable system to test this hypothesis, and we therefore examined the effect of chronic treatment (8 weeks) and subsequent withdrawal (8 weeks) with clinically relevant dosing of an antipsychotic (haloperidol, HAL) or lithium (Li) on brain volume using longitudinal in vivo structural MRI and confirmed the findings postmortem using unbiased stereology." | 1.38 | Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. ( Cooper, JD; Crum, WR; Kapur, S; Modo, M; Natesan, S; Vernon, AC; Williams, SC, 2012) |
| "Even though schizophrenia has a strong hereditary component, departures from simple genetic transmission are prominent." | 1.38 | Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. ( Ekström, TJ; Lavebratt, C; Melas, PA; Ösby, U; Rogdaki, M; Schalling, M, 2012) |
| "JNJ-37822681 induced catalepsy and inhibited avoidance behavior, but with a specificity margin relative to apomorphine antagonism that was larger than that obtained for haloperidol and similar to that obtained for olanzapine." | 1.38 | Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. ( Atack, J; Cik, M; De Bruyn, M; Hendrickx, H; Langlois, X; Lavreysen, H; Macdonald, G; Megens, A; Peeters, L; te Riele, P; Vermeire, J; Wouters, R, 2012) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 1.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| "Schizophrenia is associated with perceptual and physiological auditory processing impairments that may result from primary auditory cortex excitatory and inhibitory circuit pathology." | 1.38 | Reduced glutamate decarboxylase 65 protein within primary auditory cortex inhibitory boutons in schizophrenia. ( Asafu-Adjei, JK; Delevich, KM; Dorph-Petersen, KA; Fish, KN; Lewis, DA; Moyer, CE; Sampson, AR; Sweet, RA, 2012) |
| " Further study is needed to determine whether these results concerning mechanism and dosage can be the basis for prevention of the development of CIS in at risk populations." | 1.38 | Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. ( Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY, 2012) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 1.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 1.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| "Schizophrenia has been proposed to be associated with abnormal glutamatergic neurotransmission." | 1.38 | Upregulation of cornichon transcripts in the dorsolateral prefrontal cortex in schizophrenia. ( Drummond, JB; Haroutunian, V; Meador-Woodruff, JH; Simmons, M, 2012) |
| "Ziprasidone was associated with a shorter LOS compared with olanzapine, 13." | 1.37 | Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost. ( Benedetti, AM; Frazee, LA; Leung, JG; Myers, N, 2011) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| "Haloperidol is an antipsychotic drug associated with the development of movement disorders." | 1.37 | Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. ( Barcelos, RC; Beck, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Ourique, AF; Pase, CS; Reckziegel, P, 2011) |
| " Chronic administration of olanzapine and aripiprazole significantly attenuated the decreased expression of these proteins in the hippocampus of rats caused by immobilization stress, and significantly increased the levels of these proteins even without the immobilization stress." | 1.37 | Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress. ( Cho, HY; Fang, ZH; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Phuong, VT; Seo, MK, 2011) |
| "A 64-year-old woman developed catatonia after experiencing persecutory delusions." | 1.37 | Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment. ( Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T, 2011) |
| "Oral haloperidol was started." | 1.37 | Case report: increased patient response to intramuscular haloperidol decanoate following a change in needle length. ( Brahm, NC; Washington, NB, 2011) |
| "Haloperidol treatment of rats increased levels of SNAP-25 (mean 24%, P=0." | 1.36 | A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. ( Barakauskas, VE; Barr, AM; Beasley, CL; Davceva, N; Dwork, AJ; Falkai, P; Honer, WG; Ilievski, B; Jakovski, Z; Li, HY; Mancevski, B; Mann, JJ; Rosokilja, G; Thornton, AE; Wong, H; Ypsilanti, AR, 2010) |
| "treated with haloperidol (1." | 1.35 | Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. ( Alvarez, Jdo N; Carvalho, Rde C; Frussa-Filho, R; Fukushiro, DF; Ribeiro, LT; Ricardo, VP, 2008) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 1.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "The structure of depressive syndrome was influenced by the number of previous psychotic episodes The combination of antipsychotics and antidepressants was effective in the treatment of depressive symptoms in schizophrenic patients during the postpsychotic phase." | 1.35 | [Depression in schizophrenia]. ( Ivanets, NN; Kinkul'kina, MA, 2008) |
| "Haloperidol has been included in the World Health Organisation's list of essential medicines." | 1.35 | The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. ( Alamo, C; López-Muñoz, F, 2009) |
| "Risperidone is proven to be an efficient product." | 1.35 | [Complex therapy of schizophrenia]. ( Gaszner, P, 2009) |
| "Haloperidol and clozapine were given intraperitoneally (IP) to animals that had received vehicle or a competitive NMDA receptor antagonist, 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP), directly into the medial prefrontal cortex." | 1.35 | Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. ( Baviera, M; Carli, M; Invernizzi, RW, 2008) |
| "Treatment with haloperidol and clozapine attenuated the detrimental performance effects of these challenges, with clozapine exhibiting more robust attenuation." | 1.35 | Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. ( Martinez, V; Sarter, M, 2008) |
| "Schizophrenia is a chronic, severe mental illness with profound emotional and economic burdens for those afflicted and their families." | 1.35 | Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. ( Haroutunian, V; Kristiansen, LV; McCullumsmith, RE; Meador-Woodruff, JH; Oni-Orisan, A, 2008) |
| "Schizophrenia is a neurodevelopmental disorder associated with persistent symptomatology, severe functional disability, and residual morbidity characteristic of neurodegenerative brain diseases." | 1.34 | Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. ( Jarskog, LF; Lieberman, JA; Perkins, DO, 2007) |
| "Risperidone has been reported to decrease the reduction of MRI volume during the clinical course of schizophrenia." | 1.34 | Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. ( Hashioka, S; Kanba, S; Kato, T; Monji, A, 2007) |
| "Schizophrenia Care and Assessment Program, a large, prospective study of treatment for schizophrenia conducted July 1997 through September 2003." | 1.34 | Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. ( Ascher-Svanum, H; Faries, D; Marder, SR; Montgomery, W; Shi, L; Zhu, B, 2007) |
| "(1) The first-line drug for the treatment of schizophrenic disorders is a neuroleptic such as haloperidol." | 1.34 | Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation. ( , 2007) |
| " Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits." | 1.34 | The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. ( Feifel, D; Melendez, G; Priebe, K; Shilling, PD, 2007) |
| "Constipation is a frequent adverse effect of antipsychotics and adjunctive psychotropics, which can be severe and may lead to life-threatening paralytic ileus." | 1.34 | Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. ( Kashima, H; Suzuki, T; Uchida, H; Watanabe, K, 2007) |
| " In addition, adverse events were also evaluated." | 1.34 | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| "Schizophrenia is a chronic, debilitating psychotic illness of unknown etiology that has been the subject of many genetic studies." | 1.33 | Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. ( Boffa, E; Kennedy, JL; Likhodi, O; Lipska, BK; Van Tol, HH; Weinberger, DR; Wong, AH, 2005) |
| " As ciproxifan and thioperamide are inhibitors of cytochrome P450 enzymes, responsible for metabolizing risperidone and haloperidol, the possibility that the augmentation of antipsychotics by imidazoles resulted from drug-drug interactions was tested." | 1.33 | Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. ( Ballard, ME; Cowart, M; Decker, MW; Esbenshade, TA; Faghih, R; Fox, GB; Hancock, AA; Pan, L; Roberts, S; Rueter, LE; Zhang, M, 2005) |
| "Haloperidol was provided at a moderate dose (10 mg/day)." | 1.33 | Aripiprazole: new drug. Just another neuroleptic. ( , 2005) |
| "According to zero hypothesis in the treatment of schizophrenia at University hospitals in FBiH new antipsychotic drugs are in use, small doses are proscribed (up to 20 mg), not more then one antipsychotic drug is used simultaneously, antipsychotics are administrated once a day and alongside with antipsychotics other medicaments are not co-administrated, especially antiparkinsons." | 1.33 | Models of treatment with antipsychotics of the schizophrenic patients. ( Fiseković, S; Kusturica, J; Loga, S; Loga-Zec, S; Mulabegović, N; Zulić, I, 2005) |
| "The drug-transporting P-glycoprotein transports drugs against a concentration gradient across the blood-brain barrier back into the plasma and thereby reduces the bioavailability in the brain." | 1.33 | Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. ( Kaneda, A; Kaneko, S; Nakagami, T; Saito, M; Tateishi, T; Yasui-Furukori, N, 2006) |
| "Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse." | 1.33 | Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. ( Heeg, B; Laux, G; Mehnert, A; van Hout, BA, 2005) |
| " Results of the sensitivity analysis confirmed that the results were robust to a wide variation of different input variables (effectiveness, dosing distribution, patient status according to healthcare system)." | 1.33 | Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. ( Caleo, S; De Graeve, D; Lecompte, D; Mehnert, A; Miadi-Fargier, H; Mosqueda, GJ; Peuskens, J; Smet, A, 2005) |
| "Schizophrenia is a chronic, relapsing disease that requires more healthcare resources to manage than any other single psychiatric illness." | 1.33 | Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. ( Buskens, E; Chue, PS; Heeg, B; van Hout, BA, 2005) |
| "Catalepsy was induced by haloperidol (2 mg/kg p." | 1.33 | Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. ( Akhtar, M; Ali, A; Pillai, KK; Uma Devi, P; Vohora, D, 2006) |
| "(-)Stepholidine (SPD) is an active ingredient of the Chinese herb Stephania intermedia, which binds to the dopamine D(1) and D(2) like receptors." | 1.33 | Effects of (-)stepholidine in animal models for schizophrenia. ( Ellenbroek, BA; Jin, GZ; Zhang, XX, 2006) |
| " The main effect of the long-term administration of haloperidol seems to be an increase of cerebellar, basal ganglia and motor area metabolism." | 1.32 | Cerebral metabolic patterns in chronic and recent-onset schizophrenia. ( Benito, C; Desco, M; Gispert, JD; Molina, V; Palomo, T; Pascau, J; Reig, S; Santos, A; Sanz, J; Sarramea, F, 2003) |
| " Controlled released transdermal dosage form (TDDS) of the drug was designed for maintenance therapy." | 1.32 | Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome. ( Dube, R; Samanta, MK; Suresh, B, 2003) |
| "A clear double dissociation of Wisconsin Card Sorting Test and Gambling Task performances was found, with SKZ patients performing the Wisconsin Card Sorting test significantly worse than OCD patients and control subjects and OCD patients performing the Gambling Task significantly worse than SKZ and control subjects." | 1.32 | Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study. ( Angelone, SM; Bassi, T; Bellodi, L; Cavallaro, R; Cavedini, P; Mistretta, P; Ubbiali, A, 2003) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Haloperidol was considered as the first choice for the treatment of positive symptoms." | 1.32 | Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. ( Apiquian, R; de la Fuente-Sandoval, C; Fresán, A; Nicolini, H; Ulloa, RE, 2004) |
| " Moreover, chronic administration of haloperidol failed to decrease serum BDNF levels in adult rats." | 1.31 | Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. ( Asama, K; Muratake, T; Nawa, H; Someya, T; Takahashi, M; Toyooka, K; Watanabe, Y, 2002) |
| "Nicotine has been shown in a variety of studies to improve memory performance." | 1.31 | Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. ( Addy, N; Levin, ED, 2002) |
| "Treatment with haloperidol should be avoided in extremely slow and extremely rapid metabolizers of CYP2D6 substrates." | 1.31 | The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. ( Brockmöller, J; Kirchheiner, J; Müller-Oerlinghausen, B; Roots, I; Sachse, C; Schmider, J; Walter, S, 2002) |
| "With the background of a number of meta-analyses on the optimal neuroleptic dosages [1,2] the average daily dosage for the treatment of acute schizophrenic episodes recommended in the internal treatment guidelines of our psychiatric clinic was reduced from 24 mg to 15 mg haloperidol equivalent." | 1.31 | ["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. ( Kissling, W; Kockott, G; Müller, R, 2000) |
| "Haloperidol is a typical neuroleptic giving extrapyramidal side effects (EPS), whereas the atypical compound clozapine does not." | 1.31 | Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine. ( Brené, S; Olson, L; Ringholm, A; Werme, M, 2000) |
| " Neither withdrawal of drug treatment in patients nor chronic administration of haloperidol to rats altered levels of BDNF." | 1.31 | Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. ( Hashimoto, T; Kitamura, N; Koizumi, S; Maeda, K; Nawa, H; Shirakawa, O; Someya, T; Takahashi, H; Takahashi, M; Toyooka, K; Wakabayashi, K, 2000) |
| "In addition to the diagnosis of chronic pseudoakathisia, five patients (62." | 1.31 | Prevalence and characteristics of patients with pseudoakathisia. ( Christodoulou, GN; Havaki-Kontaxaki, BJ; Kontaxakis, VP, 2000) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 1.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "The steady-state trough concentrations of haloperidol were studied to clarify the role of the characteristics of Japanese patients in estimating haloperidol dosing regimens by using routine therapeutic drug-monitoring data." | 1.31 | Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. ( Anai, M; Funakoshi, A; Goto, Y; Higuchi, S; Hokazono, T; Ichimaru, R; Makit, T; Matsunaga, K; Ohdo, S; Yukawa, E; Yukawa, M, 2000) |
| "Two cases of schizophrenia are reported in which insomnia developed after biperiden withdrawal or reduction." | 1.31 | Insomnia related to biperiden withdrawal in two schizophrenic patients. ( Hirose, S, 2000) |
| " We also provide evidence of deficient NT neurotransmission as well as a left-shifted antipsychotic drug dose-response curve in isolation-reared rats." | 1.31 | Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. ( Binder, EB; Kilts, CD; Kinkead, B; Nemeroff, CB; Owens, MJ, 2001) |
| "Haloperidol and clozapine have been widely used to alleviate schizophrenic symptoms, but their physiological effects in the prefrontal cortex (PFC) are not known." | 1.31 | Haloperidol and clozapine increase neural activity in the rat prefrontal cortex. ( Baeg, EH; Chung, Y; Chung, YK; Jang, J; Jung, MW; Kim, HT; Kim, SU; Kim, YB; Mook-Jung, I, 2001) |
| "After treatment of neurosyphilis, steady improvements were noted in psychotic and cognitive symptoms." | 1.31 | Neurosyphilis presenting as schizophrenialike psychosis. ( Ballas, C; Kohler, CG; Pickholtz, J, 2000) |
| "The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms." | 1.31 | Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000) |
| "1." | 1.31 | Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine. ( Hatzimanolis, J; Lykouras, L; Markianos, M; Oulis, P, 2001) |
| "Treatment with risperidone, though, results in considerably elevated plasma prolactin (PRL) levels which are not observed with other atypical neuroleptics, such as clozapine, indicating a differentiated action on receptors that are involved in PRL release, mainly dopaminergic and serotonergic." | 1.31 | Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. ( Hatzimanolis, J; Lykouras, L; Markianos, M, 2001) |
| "The haloperidol-treated group had significantly lower CSF-uncorrected and CSF-corrected left frontal NAA than the normal controls, with the clozapine group having intermediate concentrations." | 1.31 | Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. ( Blanchard, J; Brooks, WM; Bustillo, JR; Hart, BL; Jung, RE; Keith, SJ; Lauriello, J; Petropoulos, H; Rowland, LM, 2001) |
| " We conducted a survey of Spanish psychiatrists in mental health centers and outpatient treatment units to assess the severity scores that they would assign to a list of the most common adverse events (AEs) that usually occur with antipsychotic treatment." | 1.31 | Global index of safety (GIS): a new instrument to assess drug safety. ( Badía, X; Gómez, JC; Kind, P; Sacristán, JA, 2001) |
| "This suggests that schizophrenia is associated with elevated rCBF in the hippocampus, which "normalizes" with antipsychotic drug treatment." | 1.31 | Probing the human hippocampus using rCBF: contrasts in schizophrenia. ( Holcomb, HH; Lahti, AC; Medoff, DR; Tamminga, CA, 2001) |
| "Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients." | 1.31 | Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). ( Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA, 2001) |
| " These findings suggest that acute dystonia is affected by age factor, and that daily dosage or monitoring of drug concentration is unlikely to be a useful marker for the prediction of side-effects during bromperidol treatment." | 1.31 | The characteristics of side-effects of bromperidol in schizophrenic patients. ( Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Tanaka, O; Yasui-Furukori, N, 2002) |
| "The novel antipsychotic medications offer a more favorable extrapyramidal side effect profile than conventional agents." | 1.31 | Sexual side effects of novel antipsychotic medications. ( Marder, SR; Pierre, JM; Saunders, CS; Wirshing, DA; Wirshing, WC, 2002) |
| " Chronic administration of haloperidol upregulated fos and jun family mRNA expression that was detectable 24 h and 6 d after cessation of the treatment mainly in the cortex." | 1.31 | Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. ( Castrén, E; Kontkanen, O; Lakso, M; Wong, G, 2002) |
| " Chronic administration of many DA antagonists alters dopaminergic function, causing a supersensitivity to DA agonists." | 1.30 | Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats. ( Kosten, TA, 1997) |
| "Carbamazepine 400 mg." | 1.30 | Interaction between carbamazepine and bromperidol. ( Furukori, H; Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui, N, 1997) |
| "Thirty-seven newly admitted schizophrenic patients were treated with an open and flexible dosage of chlorpromazine for 3 months after receiving a test dose." | 1.30 | Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine. ( Minami, H; Miyahara, A; Nakahara, T; Nakane, Y, 1997) |
| " In addition, the polymorphic distribution of RH/HL ratios, suggested by previous investigators, was further tested in each dosage group (for controlling the potential dosage effect on RH/HL ratios)." | 1.30 | Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. ( Chang, WH; Chang, YC; Hu, OY; Hu, WH; Jann, MW; Lane, HY; Lin, HN, 1997) |
| "Haloperidol and clozapine were tested in rats after daily administration for 3 and 21 days in combination with vehicle or PCP (2." | 1.30 | A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. ( Sams-Dodd, F, 1998) |
| "Bromperidol treatment significantly (P < 0." | 1.30 | Prolactin response to bromperidol treatment in schizophrenic patients. ( Inoue, Y; Ishida, M; Kaneko, S; Kondo, T; Mihara, K; Otani, K; Suzuki, A; Yasui, N, 1998) |
| "In order to study the putative monoamine oxidase (MAO) inhibitory side effect of neuroleptics and simultaneous changes in platelet serotonin content both MAO-B activity and serotonin (5-HT) content in platelets of 30 healthy volunteers and 50 schizophrenic patients treated with neuroleptics were investigated." | 1.30 | MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients. ( Borcsiczky, D; Magyar, K; Máté, M; Mészáros, Z; Tarcali, J; Tekes, K, 1998) |
| "Sertindole-treated patients exhibited significantly (P < 0." | 1.30 | Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. ( Asenbaum, S; Barnas, C; Brücke, T; Hesselmann, B; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J, 1998) |
| "1." | 1.30 | Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol. ( Furukori, H; Inoue, Y; Kaneko, S; Kondo, T; Otani, K; Suzuki, A; Yasui, N, 1998) |
| " In this case, NMS seemed to be induced by bacterial pneumonia after long term administration of LPZ 5 mg per day." | 1.30 | [A study of neuroleptic malignant syndrome in the presenium and senium]. ( Honma, H; Koyama, T; Matsubara, S; Suzuki, I; Watanabe, N, 1998) |
| "Tardive dystonia is a difficult condition to treat." | 1.30 | Treatment of tardive dystonia with an antispastic agent. ( Ishiguro, T; Nisijima, K; Shimizu, M, 1998) |
| "The objective of this study was to examine neuroleptic effectiveness among Asians and Caucasians, and to investigate inter-ethnic pharmacodynamic differences." | 1.30 | An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. ( Bean, G; Beiser, M; Zhang-Wong, J; Zipursky, RB, 1998) |
| "To compare the side effect profile of risperidone with that of oral haloperidol in patients with no previous exposure to antipsychotic drugs (APDs)." | 1.30 | Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. ( Mazurek, MF; Rosebush, PI, 1999) |
| "We report five cases of neuroleptic malignant syndrome (NMS) with psychotic symptoms treated with electroconvulsive therapy (ECT)." | 1.30 | Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. ( Ishiguro, T; Nisijima, K, 1999) |
| "Treatment of schizophrenia is often complicated by substance abuse." | 1.30 | Alcohol dependence and hospitalization in schizophrenia. ( Arana, GW; Gerding, LB; Labbate, LA; Measom, MO; Santos, AB, 1999) |
| "Risperidone is a dopaminergic as well as a 5-HT2 antagonist." | 1.30 | Some behavioural effects of risperidone in rats: comparison with haloperidol. ( Chodera, A; Kus, K; Nowakowska, E; Rybakowski, J, 1999) |
| "Haloperidol treatment was withdrawn for up to 6 weeks and patients were evaluated for symptom recurrence." | 1.29 | Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. ( Gurklis, J; Kelley, ME; McAllister, CG; Miller, AL; Peters, JL; Rehn, TJ; van Kammen, DP; Yao, J, 1995) |
| " However, when neuronal sampling was performed in unanesthetized rats, chronic administration of haloperidol (daily for 21-28 days) failed to reduce the incidence of active dopaminergic neurons." | 1.29 | Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats. ( Diana, M; Gessa, GL; Lilliu, V; Mereu, G; Muntoni, AL; Vargiu, P, 1994) |
| " In 53 patients who were treated with two or more haloperidol dosage regimens, steady-state haloperidol and reduced haloperidol drug concentrations obtained from the different regimens were positively correlated with the haloperidol dose (R = ." | 1.29 | Intra- and interethnic variability in reduced haloperidol to haloperidol ratios. ( Chang, WH; Chen, H; Davis, CM; Jann, MW; Lam, YW; Lin, SK; Yu, HS, 1995) |
| "Pretreatment with haloperidol (13 to 130 nmol/kg sc), but not equimolar doses of UH 232, prevented the disruption of PPI produced by the highest dose (0." | 1.29 | Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. ( Caine, SB; Geyer, MA; Swerdlow, NR, 1995) |
| "During a 4-week interval of haloperidol decanoate dosage (dose range = 30-50 mg), the patients' D2 receptor occupancy was determined with positron emission tomography on two occasions." | 1.29 | D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. ( Bertilsson, L; Dahl, ML; Farde, L; Halldin, C; Nyberg, S, 1995) |
| " In this case, it seems necessary to diminish the interval between injections than to give higher dosage in order to maintain plasma concentrations." | 1.29 | Do enzyme inducers modify haloperidol decanoate rate of release? ( Agenet, C; Barges-Bertocchio, MH; Levron, JC; Pupeschi, G, 1994) |
| "There is a trend in clinical psychiatric practice to make the dosing schedules of psychotropic medications as simple as possible." | 1.29 | Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients. ( Chang, WH; Chen, CH; Lin, SK, 1993) |
| "Haloperidol decanoate was initiated using the loading-dose regimen in 16 chronically ill patients." | 1.29 | A loading-dose strategy for converting from oral to depot haloperidol. ( Anderson, C; Ereshefsky, L; Saklad, SR; Seidel, D; Toney, G, 1993) |
| "We report a case of neuroleptic malignant syndrome where the catatonia clearly followed the administration of neuroleptics and where the neurovegetative disturbance was remarkably severe, including episodes of tracheal spasm, apnoea and episodes of bradycardia, and sinus arrest requiring insertion of a temporary external pacing wire." | 1.29 | Recurrent sinus arrest in association with neuroleptic malignant syndrome. ( Hamlin, GW; Ormerod, LP; Parry, AK; Saleem, PT, 1994) |
| "Doctors' prescription and dosing behaviour was investigated using data from 9 clinical trials in 550 patients treated with psychotropics." | 1.29 | Correct titration of non-drugs and some other methodological issues. ( Beneke, M; Fritze, J; Rasmus, W; Rød, IS, 1994) |
| " After single doses, haloperidol appeared rapidly in serum, achieving peak concentration at a mean of 4." | 1.29 | The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. ( Bigelow, LB; DeVane, CL; Khot, V; Kirch, DG; Korpi, ER; Venable, D; Wyatt, RJ, 1993) |
| "Previous data suggest the possibility that haloperidol daily dosing requirements may be confounded by smoking and, at higher doses, capacity-limited metabolism." | 1.29 | Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. ( Arndt, SV; Holman, TL; Miller, DD; Perry, PJ; Smith, DA, 1993) |
| "When schizophrenia is first diagnosed antipsychotic therapy should be started quickly as the longer the initial psychosis remains untreated the worse the final outcome will be." | 1.29 | Managing the first episode of schizophrenia: the role of new therapies. ( McCreadie, RG, 1996) |
| " Gross toxic side effects (seizures, catatonia, confusion) and Neuroleptic Induced Deficit Syndrome in conjunction with blood levels over 30 ng/ml were identified in 13 of our 43 patients." | 1.29 | Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. ( Clark, L; Dabiri, L; Darby, JK; Mosbacher, D; Pasta, DJ, 1995) |
| " Patients were maintained on monthly depot treatment for 40 weeks after the loading dose regimen and only one patient relapsed during treatment despite dosage increases." | 1.29 | Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. ( Chang, WH; Jann, MW; Lin, HN; Piao-Chien, C; Wei, FC, 1996) |
| " Parallel analyses of rat brain tissue showed no changes in 5-HT1A or 5-HT2A receptor mRNAs or binding site densities after chronic administration of haloperidol." | 1.29 | 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. ( Burnet, PW; Eastwood, SL; Harrison, PJ, 1996) |
| " The recommended initial dosage was 150 mg bromperidol (one 3 ml ampoule), and this did not in fact have to be increased during the trial." | 1.29 | [Bromperidol decanoate in the residual phase of schizophrenia]. ( Canova, L; Cocconcelli, C; Faravelli, C; Marchetti, FP; Mariani, G; Rapisarda, V; Smeraldi, E, 1996) |
| "The pharmacokinetic interaction between buspirone and haloperidol was evaluated in schizophrenic patients in two different groups." | 1.29 | Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ( Chang, TP; Chang, WH; Chen, JS; Chien, CP; Huang, HF; Jann, MW; Juang, DJ; Lam, YW; Lin, SK; Wei, FC, 1996) |
| "Perphenazine levels were more variable (46%) than haloperidol (25%) and flupenthixol (12." | 1.29 | Large variations of plasma levels during maintenance treatment with depot neuroleptics. ( Levander, S; Tuninger, E, 1996) |
| "Olanzapine treated patients had similar levels of striatal D2 binding in vivo (1." | 1.29 | Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study. ( Busatto, GF; Costa, DC; Ell, PJ; Kerwin, RW; Nohria, V; Pilowsky, LS; Sharma, T; Sigmundsson, T; Taylor, M, 1996) |
| " Patients were treated with risperidone in two different dosage groups (3 mg and 8 mg) and haloperidol (10-20 mg) and compared with eight healthy control subjects." | 1.29 | Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. ( Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C, 1996) |
| " These data were used to determine the pharmacokinetic factor(s) that correlate best with HL and RHL concentrations in hair." | 1.28 | Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair. ( Hasegawa, K; Hirayama, H; Matsuno, H; Nakashima, M; Sato, H; Uematsu, T, 1992) |
| " The mean elimination half-life of 54." | 1.28 | Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. ( Chang, WH; Chen, H; Jann, MW; Lam, YW, 1992) |
| "Pharmacotherapy of schizophrenia is a complex matter." | 1.28 | [Drug treatment of schizophrenic patients]. ( Finzen, A, 1991) |
| " The study indicates that haloperidol decanoate even in low dosage is effective maintenance therapy is preventing relapse." | 1.28 | Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. ( Youssef, HA, 1991) |
| " Interpatient variation in plasma HAL levels at a given dosage was up to sixfold." | 1.28 | Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients. ( Chang, WH; Chen, H; Chen, TY; Hwu, HG; Lane, HY; Lin, HN; Lin, SK; Lin, WL; Wei, HL, 1991) |
| "Haloperidol and clozapine were rapidly withdrawn from a schizophrenic patient on separate occasions several months apart." | 1.28 | Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. ( Alphs, LD; Lee, HS, 1991) |
| "1." | 1.28 | Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. ( Beinfeld, MC; Garver, DL, 1991) |
| "The management of the neuroleptic malignant syndrome and its complications is discussed." | 1.28 | Neuroleptic malignant syndrome with renal and respiratory complications--a case report. ( Liam, CK; Ong, SB, 1990) |
| "Fluoxetine (20 mg/day) was added for 7-10 days to stable doses of haloperidol given to eight psychotic patients." | 1.28 | Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. ( Baldessarini, RJ; Brotman, AW; Goff, DC; Midha, KK; Waites, M, 1991) |
| "Haloperidol was administered IV to 46 male psychotic inpatients and 28 male control subjects." | 1.28 | Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. ( Copolov, DL; Hill, C; Keks, NA; Kulkarni, J; McGorry, P; McKenzie, D; Singh, BS, 1990) |
| "The authors review the literature on tactile hallucinations." | 1.28 | A case study: schizophrenia and tactile hallucinations, treated with electroconvulsive therapy. ( England, RD; Salama, AA, 1990) |
| " Prediction of steady-state concentrations on the basis of a mg/kg/day dosage (dose method), although equally precise, generated significantly less information concerning the variance between observed and predicted haloperidol plasma concentrations." | 1.28 | Pharmacokinetic protocol for predicting plasma haloperidol concentrations. ( Arndt, SV; Coryell, WH; Kelly, MW; Miller, DD; Perry, PJ, 1990) |
| " The authors examined the possibilities of a pharmacokinetic effect of alprazolam on neuroleptic plasma levels and of a clinical effect of alprazolam." | 1.28 | Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. ( Angrist, B; Cooper, T; Douyon, R; Peselow, E; Rotrosen, J, 1989) |
| "RBC choline concentration was significantly lower in patients medicated with neuroleptics and cogentin." | 1.28 | RBC and plasma choline in neuroleptic-treated schizophrenic patients. ( Hanin, I; Jeste, DV; Kopp, U; Lawson, WB; Wyatt, RJ, 1989) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 1.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| "Sulpiride is a substituted benzamide which blocks selectively D-2 receptors." | 1.28 | [Sulpiride in psychiatric practice]. ( Faltus, F; Jirák, R; Pavlovský, P, 1989) |
| "A positive FH-NIDDM was significantly associated with the presence of TD and with higher drug-free FBS." | 1.28 | Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. ( Mukherjee, S; Roth, SD; Sandyk, R; Schnur, DB, 1989) |
| " The dosage schema can be adapted individually whenever necessary." | 1.27 | [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate]. ( Roncoroni, D, 1984) |
| "The authors studied high-potency versus low-potency neuroleptic dosing practices for 110 Boston-area psychiatric inpatients and compared the findings with the dosing practices reported in surveys of nearly 16,000 Veterans Administration patients." | 1.27 | Dissimilar dosing with high-potency and low-potency neuroleptics. ( Baldessarini, RJ; Cotton, P; Katz, B, 1984) |
| "Oral haloperidol was given before and after each drug." | 1.27 | Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. ( Hansen, V; Jorgensen, A; Mackie, M; McCreadie, RG; Menzies, C; Wiles, DH, 1984) |
| " Four to 5 Cmin were monitored just before the morning valproic acid dose for 3 to 4 days preceding the kinetic study." | 1.27 | The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ( Chiba, K; Iizuka, R; Ishizaki, T; Kobayashi, K; Saito, M, 1984) |
| "The bromperidol serum values were not correlated with the therapeutic response but, at more than 5 ng per ml, there might be a positive correlation between the bromperidol levels and clinical efficacy in the newly admitted schizophrenics." | 1.27 | Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations. ( Fujii, Y; Itoh, H; Kamisada, M; Nakajima, S; Takamiya, M; Tanoue, A; Tateyama, M, 1984) |
| "Twenty-nine patients were treated with haloperidol decanoate, the dosage ranging from 100 to 300 mg i." | 1.27 | The use of depot neuroleptic haloperidol decanoate. ( Fernando, J; Jones, GG; Krishna Raju, R; Stanley, RO, 1984) |
| " Patients were selected based on poor response or the need for high dosage and were rated with the Clinical Global Impression Scale." | 1.27 | Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. ( Browning, JL; Burch, NR; Davis, CM; Ereshefsky, L; Harrington, CA; Jann, MW; Saklad, SR, 1984) |
| "Haloperidol blood levels were not correlated with the age of the patient." | 1.27 | Blood levels of haloperidol in schizophrenic patients. ( Dekirmenjian, H; Shvartsburd, A; Smith, RC, 1983) |
| "Treatment with haloperidol normalized the low ratio." | 1.27 | Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. ( Bigelow, LB; Karoum, F; Karson, CN; Lawson, WB; Wyatt, RJ, 1987) |
| "[3H]Haloperidol binding was saturable and of high affinity with comparable KD values in human PBL (0." | 1.27 | Initial identification and characterization of sigma receptors on human peripheral blood leukocytes. ( Battaglia, G; De Souza, EB; Jaffe, JH; Kulsakdinun, C; Wolfe, SA, 1988) |
| " In these six cases it was demonstrated that the neuroleptics dosage was inappropriate, being either too high or too low as judged from the plasma concentrations." | 1.27 | [Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]. ( Balant-Gorgia, AE; Eisele, R; Garrone, G, 1985) |
| " Moreover pharmacokinetic data increasingly have been clinically applied." | 1.27 | Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. ( Knudsen, P, 1985) |
| " Data were analyzed to determine the effect of anticholinergic prophylaxis, age, sex, and type and dosage of neuroleptic on the incidence of dystonic reactions." | 1.27 | Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. ( Heiser, JF; Morrison, RL; Simpson, GM; Sramek, JJ, 1986) |
| "In a sulpiride-treated patient, the dosage was reduced in four steps over a nine-week period and a curvilinear relationship was demonstrated between central D2-dopamine receptor occupancy and serum drug concentrations." | 1.27 | Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. ( Farde, L; Halldin, C; Sedvall, G; Wiesel, FA, 1988) |
| "Haloperidol was given to 8 patients for 10 days (group A: 0." | 1.27 | Effects of neuroleptic treatments on peripheral opioid secretion. ( Bellodi, L; Brambilla, F; Brancato, V; Facchinetti, F; Genazzani, AR; Petraglia, F; Smeraldi, E, 1987) |
| "Debrisoquin is a drug that suppresses the peripheral formation of homovanillic acid without affecting the central formation." | 1.27 | Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. ( Davidson, M; Davis, BM; Davis, KL; Freed, LB; Lesser, JC; Losonczy, MF; Mohs, RC; Mykytyn, VV; Powchik, P, 1987) |
| " Within each interval between doses, haloperidol plasma levels were maximal within the first week after each dose, decaying with an average half-life of three weeks." | 1.27 | Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate. ( Gelders, YG, 1986) |
| "This suggests that the depressive syndrome among schizophrenics is not manifested as a result of pharmaceutical action." | 1.27 | [Depressive syndromes within the scope of schizophrenic diseases]. ( Heim, M, 1986) |
| "Haloperidol activity was determined by the radioreceptor assay for neuroleptics on weeks 2 and 4 serum samples." | 1.27 | Neuroleptic radioreceptor activity and clinical outcome in schizophrenia. ( Alexander, H; Bowden, C; Contreras, S; Faber, R, 1987) |
| " Serum haloperidol levels in these patients decreased to about 60% of the levels seen just prior to the usual morning dosing during the drug holiday." | 1.27 | Drug holidays and serum haloperidol levels in schizophrenic patients. ( Couch, L; Fody, EP; Harrison, RH; McMillan, DE; Newton, JE; Reese, WG, 1986) |
| "Eighteen chronic schizophrenic subjects treated with a uniform dosage (4-6 mg/day p." | 1.27 | Computed tomography and pattern reversal visual evoked potentials in chronic schizophrenic patients. ( Callieco, R; Cosi, V; Mariotti, G; Romani, A; Zerbi, F, 1986) |
| "Polydipsia and polyuria have a long association with schizophrenia." | 1.27 | Increased urine volume in chronic schizophrenic patients. ( Bigelow, LB; Karson, CN; Lawson, WB, 1985) |
| "Haloperidol was administered orally to 6 male schizophrenic patients and intravenously to 3." | 1.27 | Elimination half-life and bioavailability of haloperidol in schizophrenic patients. ( Hollister, LE; Magliozzi, JR, 1985) |
| "Neuroleptic treatment of schizophrenia reduces CSF cyclic AMP in clinical responders after a mean of 8 weeks of treatment." | 1.26 | Does neuroleptic blocking of dopamine receptors continue after chronic treatment? ( Belmaker, RH; Dasberg, H; Ebstein, RP, 1980) |
| "Thioridazine levels were substantially higher than those of other neuroleptics." | 1.26 | Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients. ( Creese, I; DePaulo, JR; Slavney, PR; Snyder, SH; Tune, LE, 1981) |
| "In recent years, the complex treatment of schizophrenia has been extended by the neuroleptic large-dose therapy." | 1.26 | [Neuroleptic large dose therapy of schizophrenias]. ( Pethö, B; Ungvári, G, 1981) |
| "The determinants of relapse have been elusive." | 1.26 | Low serum neuroleptic levels predict relapse in schizophrenic patients. ( Brown, WA; Chisholm, E; Laughren, T; Williams, BW, 1982) |
| "Treatment with thioridazine or butaperazine also tended to decrease platelet MAO activity." | 1.26 | Effects of neuroleptics on platelet monoamine oxidase activity. ( Allen, R; DeJohn, C; Ho, BT; Khan, M; Kralik, P; Schoolar, J; Smith, RC, 1982) |
| " In neither patient, the increase in haloperidol dosage affected paranoid symptoms." | 1.26 | [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. ( Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982) |
| "Chronic schizophrenic patients were maintained for six months on a dosage of haloperidol adjusted to give optimum clinical effect." | 1.26 | Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. ( Bishop, M; Coppen, A; Rao, VA, 1980) |
| "A comparison of a chemical analytic technique (gas chromatography/mass spectrometry) with that of the dopamine receptor blocking assay in a study involving seven schizophrenic patients being administered a fixed dosage of haloperidol (20 mg) demonstrated a high degree of correspondence in the quantification of the plasma levels of the neuroleptic." | 1.26 | A comparison of dopamine receptor blocking assay with plasma drug levels of haloperidol in schizophrenic patients. ( Hanlon, TE; Kurland, AA; Nagaraju, A; Ng, KT; Wilkinson, EH, 1981) |
| "Haloperidol levels were measured by radioreceptor assay in 12 schizophrenic patients during gradual dosage reduction (at 10-day) intervals) from 60 to 0 mg/day." | 1.26 | Haloperidol blood levels during dosage reduction in chronic schizophrenic patients. ( Belmaker, RH; Ebstein, RP; Goldman, Z; Hermoni, M; Lerer, B; Zohar, J, 1981) |
| "The chlorpromazine therapy was then begun and continued for three months." | 1.26 | Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients. ( Ikenaga, H; Nakahara, T; Sakurai, Y; Takahashi, R, 1980) |
| ") every 4 weeks with haloperidol decanoate using different dosage schedules which were calculated from the previously prescribed daily oral dose of haloperidol multiplied by a factor of 30, 20 or 10." | 1.26 | Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. ( Berghmans, W; Deberdt, R; Driesens, F; Elens, P; Heykants, J; Reyntjens, A; van Wijngaarden, I; Woestenborghs, R, 1980) |
| "These episodes are differentiated from nocturnal wanderings and epileptic attacks during sleep; they occurred within two to three hours after sleep onset and were characterized by the patients appearing confused and walking about in a quiet, detached and clumsy manner." | 1.26 | Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment. ( Charney, DS; Kales, A; Nelson, JC; Soldatos, CR, 1979) |
| " Data in adult patients illustrate on the one hand possible causes of variability in plasma levels of haloperidol and, on the other hand, the fact that poor bioavailability is not the cause of lack of response in 'resistant' schizophrenic patients." | 1.26 | Clinical significance of monitoring plasma levels of psychotropic drugs. ( Morselli, PL; Zarifian, E, 1979) |
| "Cyproheptadine pretreatment was associated with erratic increases or decreases in the hGH response to apomorphine, but did not alter PRL levels or apomorphine-induced PRL suppression." | 1.26 | Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research. ( Angrist, B; Branchey, L; Gershon, S; Halpern, F; Oleshansky, M; Paquin, J; Rotrosen, J; Sachar, EJ, 1979) |
| " A long-term use of the preparation leads to development of habituation, while its cessation--to symptoms similar to withdrawal." | 1.26 | [Influence of extrapyramidal disorders induced by haloperidol on phenamine stereotypy and the effects of schizophrenic patients' serum (experimental study)]. ( Bobritskaia, ZM; Gorbatko, LG; Litvinova, NM; Stoliarov, GV, 1977) |
| "Histamine and serotonin were ineffective." | 1.25 | Dopamine-sensitive adenylyl cyclase in human caudate nucleus. A study in control subjects and schizophrenic patients. ( Carenzi, A; Gillin, JC; Guidotti, A; Schwartz, MA; Trabucchi, M; Wyatt, RJ, 1975) |
| "Haloperidol was given for 30 days, at a daily dose of 6 mg i." | 1.25 | Growth hormone secretion in chronic schizophrenia. ( Brambilla, F; Guastalla, A; Guerrini, A; Recchia, M; Riggi, F; Rovere, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 711 (28.30) | 18.7374 |
| 1990's | 670 (26.67) | 18.2507 |
| 2000's | 716 (28.50) | 29.6817 |
| 2010's | 361 (14.37) | 24.3611 |
| 2020's | 54 (2.15) | 2.80 |
| Authors | Studies |
|---|---|
| Hrib, NJ | 1 |
| Jurcak, JG | 1 |
| Bregna, DE | 1 |
| Dunn, RW | 1 |
| Geyer, HM | 1 |
| Hartman, HB | 1 |
| Roehr, JE | 1 |
| Rogers, KL | 1 |
| Rush, DK | 1 |
| Szczepanik, AM | 1 |
| Shahid, M | 2 |
| Walker, GB | 1 |
| Zorn, SH | 1 |
| Wong, EH | 1 |
| Rotella, DP | 2 |
| McFarlane, GR | 1 |
| Greenfield, A | 1 |
| Grosanu, C | 1 |
| Robichaud, AJ | 3 |
| Denny, RA | 1 |
| Feenstra, RW | 1 |
| Núñez-García, S | 1 |
| Reinders, JH | 2 |
| Neut, Mv | 1 |
| McCreary, A | 1 |
| Kruse, CG | 2 |
| Sullivan, K | 1 |
| Pruthi, F | 1 |
| Lai, M | 2 |
| Zhang, J | 4 |
| Kowal, DM | 2 |
| Carrick, T | 2 |
| Grauer, SM | 1 |
| Navarra, RL | 1 |
| Graf, R | 1 |
| Brennan, J | 1 |
| Marquis, KL | 2 |
| Pausch, MH | 2 |
| Carro, L | 1 |
| Raviña, E | 1 |
| Domínguez, E | 1 |
| Brea, J | 1 |
| Loza, MI | 1 |
| Masaguer, CF | 1 |
| Neves, G | 1 |
| Menegatti, R | 1 |
| Antonio, CB | 3 |
| Grazziottin, LR | 1 |
| Vieira, RO | 1 |
| Rates, SM | 3 |
| Noël, F | 2 |
| Barreiro, EJ | 3 |
| Fraga, CA | 3 |
| Yan, Y | 2 |
| Zhou, P | 1 |
| Feenstra, R | 1 |
| van der Neut, M | 1 |
| Raheem, IT | 1 |
| Breslin, MJ | 1 |
| Fandozzi, C | 1 |
| Fuerst, J | 1 |
| Hill, N | 1 |
| Huszar, S | 1 |
| Kandebo, M | 1 |
| Kim, SH | 3 |
| Ma, B | 1 |
| McGaughey, G | 1 |
| Renger, JJ | 1 |
| Schreier, JD | 1 |
| Sharma, S | 2 |
| Smith, S | 1 |
| Uslaner, J | 1 |
| Coleman, PJ | 1 |
| Cox, CD | 1 |
| Sun, H | 2 |
| Zhu, L | 1 |
| Yang, H | 1 |
| Qian, W | 1 |
| Guo, L | 1 |
| Zhou, S | 1 |
| Gao, B | 1 |
| Li, Z | 2 |
| Zhou, Y | 2 |
| Jiang, H | 1 |
| Chen, K | 1 |
| Zhen, X | 1 |
| Liu, H | 2 |
| Pompeu, TE | 1 |
| Alves, FR | 1 |
| Figueiredo, CD | 1 |
| Herzfeldt, V | 2 |
| Moura, BC | 1 |
| Li, P | 1 |
| Zhang, Q | 2 |
| Lee, T | 6 |
| Tomesch, J | 1 |
| Yao, W | 1 |
| Beard, JD | 1 |
| Snyder, GL | 1 |
| Zhu, H | 3 |
| Peng, Y | 1 |
| Hendrick, JP | 1 |
| Vanover, KE | 1 |
| Davis, RE | 1 |
| Mates, S | 1 |
| Wennogle, LP | 1 |
| Brindisi, M | 1 |
| Butini, S | 1 |
| Franceschini, S | 1 |
| Brogi, S | 1 |
| Trotta, F | 1 |
| Ros, S | 1 |
| Cagnotto, A | 1 |
| Salmona, M | 1 |
| Casagni, A | 1 |
| Andreassi, M | 1 |
| Saponara, S | 1 |
| Gorelli, B | 1 |
| Weikop, P | 1 |
| Mikkelsen, JD | 1 |
| Scheel-Kruger, J | 1 |
| Sandager-Nielsen, K | 1 |
| Novellino, E | 1 |
| Campiani, G | 1 |
| Gemma, S | 1 |
| Huang, L | 2 |
| Zhang, W | 2 |
| Zhang, X | 3 |
| Yin, L | 2 |
| Chen, B | 1 |
| Song, J | 1 |
| Cheng, J | 1 |
| Giguere, PM | 1 |
| Schmerberg, CM | 1 |
| Pogorelov, VM | 1 |
| Rodriguiz, RM | 1 |
| Huang, XP | 1 |
| McCorvy, JD | 1 |
| Wetsel, WC | 1 |
| Roth, BL | 1 |
| Kozikowski, AP | 1 |
| Schwalbe, T | 1 |
| Kaindl, J | 1 |
| Hübner, H | 1 |
| Gmeiner, P | 1 |
| Cao, X | 1 |
| Zhang, Y | 6 |
| Chen, Y | 3 |
| Qiu, Y | 1 |
| Yu, M | 2 |
| Xu, X | 3 |
| Liu, X | 1 |
| Liu, BF | 1 |
| Zhang, L | 2 |
| Zhang, G | 4 |
| Gao, L | 1 |
| Hu, J | 1 |
| Song, T | 1 |
| Kurimoto, E | 1 |
| Yamada, R | 1 |
| Hirakawa, T | 1 |
| Kimura, H | 2 |
| Duñó Ambròs, R | 1 |
| Oliva Morera, JC | 1 |
| Iglesias-Lepine, ML | 1 |
| Palao Vidal, D | 1 |
| Monreal Ortiz, JAMO | 1 |
| Labad Arias, J | 1 |
| Ishikawa, S | 1 |
| Yamamura, R | 1 |
| Hashimoto, N | 1 |
| Okubo, R | 1 |
| Sawagashira, R | 1 |
| Ito, YM | 1 |
| Sato, N | 2 |
| Kusumi, I | 1 |
| Ozornin, AS | 1 |
| Govorin, NV | 2 |
| Sakharov, AV | 1 |
| Tereshkov, PP | 1 |
| Takahashi, K | 2 |
| Yokotsuka-Ishida, S | 1 |
| Nakamura, T | 1 |
| Sasayama, D | 3 |
| Washizuka, S | 2 |
| Hakami, T | 1 |
| Oh, S | 1 |
| Byeon, SJ | 1 |
| Chung, SJ | 1 |
| Lopez-Morinigo, JD | 1 |
| Leucht, S | 17 |
| Arango, C | 4 |
| Misawa, F | 1 |
| Fujii, Y | 3 |
| Takeuchi, H | 1 |
| Bogers, JPAM | 1 |
| Hambarian, G | 1 |
| Walburgh Schmidt, N | 1 |
| Vermeulen, JM | 1 |
| de Haan, L | 6 |
| Moya, NA | 3 |
| Yun, S | 3 |
| Fleps, SW | 3 |
| Martin, MM | 3 |
| Nadel, JA | 3 |
| Beutler, LR | 3 |
| Zweifel, LS | 3 |
| Parker, JG | 3 |
| Tang, Y | 3 |
| Wu, Y | 4 |
| Li, X | 3 |
| Hao, Q | 3 |
| Deng, W | 5 |
| Yue, W | 4 |
| Yan, H | 4 |
| Tan, L | 4 |
| Chen, Q | 4 |
| Yang, G | 4 |
| Lu, T | 4 |
| Wang, L | 6 |
| Yang, F | 4 |
| Zhang, F | 4 |
| Yang, J | 4 |
| Li, K | 5 |
| Lv, L | 4 |
| Tan, Q | 5 |
| Zhang, H | 6 |
| Ma, X | 9 |
| Li, L | 5 |
| Wang, C | 4 |
| Zhang, D | 5 |
| Yu, H | 3 |
| Zhao, L | 4 |
| Ren, H | 3 |
| Wang, Y | 5 |
| Li, C | 6 |
| Du, X | 3 |
| Hu, X | 3 |
| Li, T | 5 |
| Wang, Q | 5 |
| Kibitov, AA | 3 |
| Kiryanova, EM | 3 |
| Salnikova, LI | 3 |
| Bure, IV | 3 |
| Shmukler, AB | 3 |
| Kibitov, AO | 3 |
| Spoov, J | 2 |
| Tao, S | 1 |
| Coid, J | 1 |
| Wei, W | 1 |
| Guo, W | 1 |
| Arai, Y | 1 |
| Kuraishi, K | 1 |
| Murata, S | 1 |
| Usuda, N | 1 |
| Tsuchida, M | 1 |
| Nakajima, Y | 1 |
| Ghanbarzehi, A | 1 |
| Sepehrinezhad, A | 1 |
| Hashemi, N | 1 |
| Karimi, M | 1 |
| Shahbazi, A | 1 |
| Okada, Y | 1 |
| Inada, K | 2 |
| Akazawa, M | 1 |
| Yu, CL | 1 |
| Carvalho, AF | 2 |
| Thompson, T | 1 |
| Tsai, TC | 2 |
| Tseng, PT | 1 |
| Hsu, CW | 1 |
| Hsu, TW | 1 |
| Liang, CS | 1 |
| Langova, V | 1 |
| Horka, P | 1 |
| Hubeny, J | 1 |
| Novak, T | 1 |
| Vales, K | 1 |
| Adamek, P | 1 |
| Holubova, K | 1 |
| Horacek, J | 4 |
| Szocsics, P | 1 |
| Papp, P | 1 |
| Havas, L | 1 |
| Lőke, J | 1 |
| Maglóczky, Z | 1 |
| Anczewska, M | 1 |
| Balicki, M | 1 |
| Droździkowska, A | 1 |
| Gorczyca, P | 1 |
| Janus, J | 1 |
| Paciorek, S | 1 |
| Plisko, R | 1 |
| Zięba, M | 1 |
| Liao, J | 1 |
| Dong, G | 1 |
| Zhu, W | 1 |
| Wulaer, B | 1 |
| Mizoguchi, H | 1 |
| Sawahata, M | 1 |
| Liu, Y | 2 |
| Kaibuchi, K | 1 |
| Ozaki, N | 2 |
| Nabeshima, T | 3 |
| Nagai, T | 3 |
| Yamada, K | 4 |
| Valvassori, SS | 2 |
| da Rosa, RT | 1 |
| Dal-Pont, GC | 1 |
| Varela, RB | 1 |
| Mastella, GA | 2 |
| Daminelli, T | 1 |
| Fries, GR | 1 |
| Quevedo, J | 2 |
| Zugno, AI | 2 |
| McAdam, MK | 1 |
| Baldessarini, RJ | 4 |
| Murphy, AL | 1 |
| Gardner, DM | 1 |
| Kitagawa, K | 1 |
| Krzystanek, M | 1 |
| Krysta, K | 1 |
| Janas-Kozik, M | 1 |
| Martyniak, E | 1 |
| Rybakowski, J | 3 |
| Crippa, A | 1 |
| Siafis, S | 2 |
| Patel, MX | 1 |
| Orsini, N | 1 |
| Davis, JM | 19 |
| Gómez-Revuelta, M | 1 |
| Pelayo-Terán, JM | 8 |
| Juncal-Ruiz, M | 2 |
| Vázquez-Bourgon, J | 1 |
| Suárez-Pinilla, P | 4 |
| Romero-Jiménez, R | 1 |
| Setién Suero, E | 1 |
| Ayesa-Arriola, R | 3 |
| Crespo-Facorro, B | 12 |
| Grubor, M | 1 |
| Zivkovic, M | 3 |
| Sagud, M | 3 |
| Nikolac Perkovic, M | 2 |
| Mihaljevic-Peles, A | 3 |
| Pivac, N | 2 |
| Muck-Seler, D | 3 |
| Svob Strac, D | 1 |
| Young, JW | 1 |
| Roberts, BZ | 1 |
| Breier, M | 1 |
| Swerdlow, NR | 2 |
| Stark, T | 2 |
| Di Bartolomeo, M | 1 |
| Di Marco, R | 1 |
| Drazanova, E | 1 |
| Platania, CBM | 1 |
| Iannotti, FA | 1 |
| Ruda-Kucerova, J | 3 |
| D'Addario, C | 1 |
| Kratka, L | 1 |
| Pekarik, V | 1 |
| Piscitelli, F | 1 |
| Babinska, Z | 2 |
| Fedotova, J | 1 |
| Giurdanella, G | 1 |
| Salomone, S | 1 |
| Sulcova, A | 1 |
| Bucolo, C | 1 |
| Wotjak, CT | 1 |
| Starcuk, Z | 1 |
| Drago, F | 1 |
| Mechoulam, R | 2 |
| Di Marzo, V | 1 |
| Micale, V | 3 |
| Kajani, R | 1 |
| Apramian, A | 1 |
| Vega, A | 1 |
| Ubhayakar, N | 1 |
| Xu, P | 1 |
| Liu, A | 1 |
| Lehrer, S | 1 |
| Rheinstein, PH | 1 |
| Strube, W | 1 |
| Marshall, L | 1 |
| Quattrocchi, G | 1 |
| Little, S | 1 |
| Cimpianu, CL | 1 |
| Ulbrich, M | 1 |
| Schneider-Axmann, T | 3 |
| Falkai, P | 10 |
| Hasan, A | 1 |
| Bestmann, S | 1 |
| Chipps, J | 1 |
| Seabra, G | 1 |
| de Almeida, V | 1 |
| Reis-de-Oliveira, G | 1 |
| Crunfli, F | 1 |
| Antunes, ASLM | 1 |
| Martins-de-Souza, D | 1 |
| Horska, K | 2 |
| Kotolova, H | 1 |
| Karpisek, M | 1 |
| Hammer, T | 1 |
| Prochazka, J | 1 |
| Zemba Cilic, A | 1 |
| Zemba, M | 1 |
| Cilic, M | 1 |
| Balenovic, I | 1 |
| Strbe, S | 1 |
| Ilic, S | 1 |
| Vukojevic, J | 1 |
| Zoricic, Z | 1 |
| Filipcic, I | 1 |
| Kokot, A | 1 |
| Drmic, D | 1 |
| Blagaic, AB | 1 |
| Tvrdeic, A | 1 |
| Seiwerth, S | 1 |
| Sikiric, P | 1 |
| Noh, S | 1 |
| Na, E | 1 |
| Park, SJ | 1 |
| Evins, AE | 1 |
| Roh, S | 1 |
| Crosta, CM | 1 |
| Hernandez, K | 1 |
| Bhattiprolu, AK | 1 |
| Fu, AY | 1 |
| Moore, JC | 1 |
| Clarke, SG | 1 |
| Dudzinski, NR | 1 |
| Brzustowicz, LM | 1 |
| Paradiso, KG | 1 |
| Firestein, BL | 1 |
| Nani, JV | 2 |
| Lee, RS | 1 |
| Yonamine, CM | 1 |
| Sant'Anna, OA | 1 |
| Juliano, MA | 1 |
| Gadelha, A | 2 |
| Mari, JJ | 1 |
| Hayashi, MAF | 2 |
| Kucera, J | 1 |
| Hruska, P | 1 |
| Kuruczova, D | 1 |
| Bienertova-Vasku, J | 1 |
| Srisurapanont, M | 1 |
| Likhitsathian, S | 1 |
| Suttajit, S | 1 |
| Maneeton, N | 1 |
| Maneeton, B | 1 |
| Oon-Arom, A | 1 |
| Suradom, C | 1 |
| Krakowski, M | 5 |
| Tural, U | 1 |
| Czobor, P | 41 |
| Kimura, M | 1 |
| Oda, Y | 1 |
| Nangaku, M | 1 |
| Hirose, Y | 1 |
| Niitsu, T | 1 |
| Kanahara, N | 2 |
| Shirayama, Y | 1 |
| Hashimoto, K | 2 |
| Iyo, M | 3 |
| Cararo, JH | 1 |
| Menegas, S | 1 |
| Possamai-Della, T | 1 |
| Aguiar-Geraldo, JM | 1 |
| Araujo, SL | 1 |
| Ostuzzi, G | 2 |
| Bertolini, F | 1 |
| Del Giovane, C | 1 |
| Tedeschi, F | 1 |
| Bovo, C | 1 |
| Gastaldon, C | 1 |
| Nosé, M | 4 |
| Ogheri, F | 1 |
| Papola, D | 1 |
| Purgato, M | 5 |
| Turrini, G | 1 |
| Correll, CU | 4 |
| Barbui, C | 5 |
| Paris, G | 1 |
| Bighelli, I | 1 |
| Deste, G | 1 |
| Schneider-Thoma, J | 2 |
| Zhu, Y | 1 |
| Vita, A | 3 |
| Faay, MDM | 1 |
| Sommer, IE | 1 |
| Arranz, B | 1 |
| Garriga, M | 1 |
| Bernardo, M | 9 |
| González-Pinto, A | 2 |
| Arrojo, M | 1 |
| Torrens, M | 1 |
| Tirado-Muñoz, J | 1 |
| Fonseca, F | 1 |
| Sáiz, PA | 1 |
| Flórez, G | 1 |
| Goikolea, JM | 1 |
| Zorrilla, I | 1 |
| Cunill, R | 1 |
| Castells, X | 1 |
| Becoña, E | 1 |
| López, A | 1 |
| San, L | 3 |
| Varga, TG | 1 |
| de Toledo Simões, JG | 1 |
| Siena, A | 1 |
| Henrique, E | 1 |
| da Silva, RCB | 1 |
| Dos Santos Bioni, V | 1 |
| Ramos, AC | 1 |
| Rosenstock, TR | 1 |
| Montague-Cardoso, K | 1 |
| Veraart, JKE | 1 |
| Smith-Apeldoorn, SY | 1 |
| Bakker, IM | 1 |
| Visser, BAE | 1 |
| Kamphuis, J | 1 |
| Schoevers, RA | 1 |
| Touw, DJ | 2 |
| Barber, S | 1 |
| Olotu, U | 1 |
| Corsi, M | 1 |
| Cipriani, A | 4 |
| Feng, M | 1 |
| Sparkman, NL | 2 |
| Sui, N | 1 |
| Li, M | 3 |
| Einoch, R | 1 |
| Weinreb, O | 2 |
| Mandiuk, N | 1 |
| Youdim, MBH | 1 |
| Bilker, W | 1 |
| Silver, H | 4 |
| Swathy, B | 2 |
| Saradalekshmi, KR | 2 |
| Nair, IV | 2 |
| Nair, C | 3 |
| Banerjee, M | 2 |
| Bou Khalil, R | 1 |
| Kim, Y | 1 |
| Giusti-Rodriguez, P | 1 |
| Crowley, JJ | 1 |
| Bryois, J | 1 |
| Nonneman, RJ | 1 |
| Ryan, AK | 1 |
| Quackenbush, CR | 1 |
| Iglesias-Ussel, MD | 1 |
| Lee, PH | 1 |
| Sun, W | 1 |
| de Villena, FP | 1 |
| Sullivan, PF | 1 |
| Ramirez-Bonilla, M | 3 |
| Gomez-Arnau, J | 1 |
| Ortiz-Garcia de la Foz, V | 2 |
| Martinez-Garcia, O | 6 |
| Neergaard, KD | 1 |
| Tabares-Seisdedos, R | 5 |
| Onaolapo, OJ | 1 |
| Ademakinwa, OQ | 1 |
| Olalekan, TO | 1 |
| Onaolapo, AY | 1 |
| Decuypere, F | 1 |
| Sermon, J | 1 |
| Geerts, P | 1 |
| Denee, TR | 2 |
| De Vos, C | 1 |
| Malfait, B | 1 |
| Lamotte, M | 1 |
| Mulder, CL | 1 |
| Vuk, A | 1 |
| Kuzman, MR | 1 |
| Baretic, M | 1 |
| Osvatic, MM | 1 |
| Dekkers, BGJ | 1 |
| Eck, RJ | 1 |
| Ter Maaten, JC | 1 |
| Einarson, TR | 4 |
| Bereza, BG | 2 |
| Tedouri, F | 1 |
| Van Impe, K | 2 |
| Dries, PJT | 1 |
| Alachkar, A | 2 |
| Yoshimura, R | 1 |
| Hamzeh, AR | 1 |
| Wang, Z | 3 |
| Sanathara, N | 2 |
| Lee, SM | 3 |
| Abbott, GW | 1 |
| Civelli, O | 2 |
| Ning, H | 1 |
| Cao, D | 1 |
| Wang, H | 1 |
| Kang, B | 1 |
| Xie, S | 2 |
| Meng, Y | 1 |
| Franza, F | 1 |
| Solomita, B | 1 |
| Aldi, G | 1 |
| Del Buono, G | 1 |
| Chen, RA | 1 |
| Huang, TL | 1 |
| Masiran, R | 1 |
| Nikolić, T | 1 |
| Petronijević, M | 1 |
| Sopta, J | 1 |
| Velimirović, M | 1 |
| Stojković, T | 1 |
| Jevtić Dožudić, G | 1 |
| Aksić, M | 1 |
| Radonjić, NV | 1 |
| Petronijević, N | 1 |
| Kathirvel, N | 1 |
| Ghosh, AK | 1 |
| Aly El-Gabry, DM | 1 |
| Abdel Aziz, K | 1 |
| Okasha, T | 1 |
| Azzam, H | 1 |
| Okasha, A | 1 |
| Lei, K | 1 |
| He, GF | 1 |
| Zhang, CL | 1 |
| Liu, YN | 1 |
| Li, J | 1 |
| He, GZ | 1 |
| Li, XP | 1 |
| Ren, XH | 1 |
| Liu, D | 1 |
| Kim, DD | 1 |
| Lang, DJ | 1 |
| Procyshyn, RM | 1 |
| Woodward, ML | 1 |
| Kaufman, K | 1 |
| White, RF | 1 |
| Honer, WG | 6 |
| Warburton, DER | 1 |
| de Bartolomeis, A | 3 |
| Iasevoli, F | 3 |
| Marmo, F | 3 |
| Buonaguro, EF | 3 |
| Avvisati, L | 2 |
| Latte, G | 3 |
| Tomasetti, C | 3 |
| O'Donovan, SM | 2 |
| Sullivan, C | 1 |
| Koene, R | 2 |
| Devine, E | 1 |
| Hasselfeld, K | 2 |
| Moody, CL | 1 |
| McCullumsmith, RE | 10 |
| Yoshimura, B | 1 |
| Sakamoto, S | 1 |
| Sato, K | 2 |
| Takaki, M | 1 |
| Yamada, N | 1 |
| Ben-Azu, B | 1 |
| Aderibigbe, AO | 1 |
| Ajayi, AM | 1 |
| Eneni, AO | 1 |
| Umukoro, S | 1 |
| Iwalewa, EO | 1 |
| Mizoguchi, T | 1 |
| Minakuchi, H | 1 |
| Tanaka, M | 4 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Edlinger, M | 1 |
| Welte, AS | 1 |
| Yalcin-Siedentopf, N | 1 |
| Kemmler, G | 6 |
| Neymeyer, F | 1 |
| Fleischhacker, WW | 15 |
| Hofer, A | 1 |
| Tagne Nouemssi, AB | 1 |
| Taraskina, AE | 1 |
| Zabotina, AM | 1 |
| Nasyrova, RF | 1 |
| Sosin, DN | 1 |
| Sosina, KA | 1 |
| Ershov, EE | 1 |
| Grunina, MN | 1 |
| Krupitsky, EM | 1 |
| Reznik, R | 1 |
| Chen, RYY | 1 |
| Stanford, P | 1 |
| Samara, MT | 4 |
| Klupp, E | 1 |
| Helfer, B | 2 |
| Rothe, PH | 1 |
| Stiefelhagen, P | 1 |
| Kumbol, VW | 1 |
| Abotsi, WKM | 1 |
| Ekuadzi, E | 1 |
| Woode, E | 1 |
| Alonso, A | 2 |
| Van der Elst, W | 2 |
| Molenberghs, G | 1 |
| Schennach, R | 5 |
| Riedel, M | 11 |
| Spellmann, I | 3 |
| Musil, R | 5 |
| Obermeier, M | 1 |
| Jäger, M | 8 |
| Bottlender, R | 1 |
| Schmauss, M | 1 |
| Laux, G | 8 |
| Möller, HJ | 43 |
| Uzuneser, TC | 1 |
| Schindehütte, M | 1 |
| Dere, E | 1 |
| von Hörsten, S | 1 |
| Kornhuber, J | 4 |
| Grömer, TW | 1 |
| Müller, CP | 1 |
| Cole, JB | 1 |
| Klein, LR | 1 |
| Mullinax, SZ | 1 |
| Nordstrom, KD | 1 |
| Driver, BE | 1 |
| Wilson, MP | 1 |
| Stroup, TS | 4 |
| Bareis, NA | 1 |
| Rosenheck, RA | 7 |
| Swartz, MS | 3 |
| McEvoy, JP | 23 |
| Monte, GG | 1 |
| de Almeida Campos, MR | 1 |
| Dal Mas, C | 1 |
| Marins, LAN | 1 |
| Martins, LG | 1 |
| Tasic, L | 1 |
| Mori, MA | 1 |
| Nakagawasai, O | 2 |
| Sakuma, W | 1 |
| Nemoto, W | 1 |
| Odaira, T | 1 |
| Lin, JR | 1 |
| Onogi, H | 2 |
| Srivastava, LK | 1 |
| Tan-No, K | 1 |
| Mavridis, D | 1 |
| White, IR | 2 |
| Essali, A | 1 |
| Turkmani, K | 1 |
| Aboudamaah, S | 1 |
| AbouDamaah, A | 1 |
| Diaa Aldeen, MR | 1 |
| Marwa, ME | 1 |
| AlMounayer, N | 1 |
| Harvey, PD | 16 |
| Nakamura, H | 2 |
| Murasaki, M | 2 |
| Nucifora, LG | 1 |
| MacDonald, ML | 1 |
| Lee, BJ | 3 |
| Peters, ME | 1 |
| Norris, AL | 1 |
| Orsburn, BC | 1 |
| Yang, K | 1 |
| Gleason, K | 1 |
| Margolis, RL | 1 |
| Pevsner, J | 2 |
| Tamminga, CA | 21 |
| Sweet, RA | 5 |
| Ross, CA | 2 |
| Sawa, A | 3 |
| Nucifora, FC | 1 |
| Guma, E | 1 |
| Rocchetti, J | 1 |
| Devenyi, GA | 1 |
| Tanti, A | 1 |
| Mathieu, AP | 1 |
| Lerch, JP | 1 |
| Elgbeili, G | 1 |
| Courcot, B | 1 |
| Mechawar, N | 1 |
| Chakravarty, MM | 1 |
| Giros, B | 2 |
| Uguz, F | 1 |
| Marwari, S | 1 |
| Dawe, GS | 2 |
| Guillon, P | 1 |
| Harmand, S | 1 |
| Ansolabehere, X | 1 |
| Chikowe, I | 1 |
| Domingo, M | 1 |
| Mwakaswaya, V | 1 |
| Parveen, S | 1 |
| Mafuta, C | 1 |
| Kampira, E | 1 |
| Foute Nelong, T | 1 |
| Manduca, JD | 1 |
| Zonneveld, PM | 1 |
| Perreault, ML | 1 |
| Joo, SW | 1 |
| Shon, SH | 1 |
| Choi, G | 1 |
| Koh, M | 1 |
| Cho, SW | 1 |
| Lee, J | 2 |
| Wang, G | 2 |
| Zhao, J | 3 |
| Shi, J | 1 |
| Deng, H | 1 |
| Gao, C | 1 |
| Wang, X | 1 |
| Vanderburg, D | 2 |
| Pan, S | 1 |
| Tang, H | 1 |
| Shu, L | 4 |
| Karayal, ON | 3 |
| Suzuki, H | 4 |
| Gen, K | 3 |
| Inoue, Y | 26 |
| Chervenkov, T | 1 |
| Shishkov, R | 1 |
| Tonchev, AB | 1 |
| Cheung, C | 1 |
| Huang, C | 1 |
| Jiang, L | 1 |
| Sham, PC | 1 |
| Collier, DA | 2 |
| Gong, Q | 1 |
| Chua, SE | 1 |
| McAlonan, GM | 1 |
| Rodríguez-Sánchez, JM | 2 |
| Pérez-Iglesias, R | 9 |
| Roiz-Santiáñez, R | 2 |
| Sánchez-Moreno, J | 1 |
| Vázquez-Barquero, JL | 8 |
| Diaz, FJ | 3 |
| de León, J | 4 |
| Tsuchie, K | 1 |
| Miyaoka, T | 1 |
| Furuya, M | 1 |
| Liaury, K | 1 |
| Ieda, M | 1 |
| Wake, R | 1 |
| Horiguchi, J | 2 |
| Takechi, M | 1 |
| Nakamura, M | 3 |
| Yasunaga, H | 1 |
| Haraguchi, T | 1 |
| Ando, S | 1 |
| Sugihara, T | 1 |
| Horiguchi, H | 1 |
| Ohe, K | 1 |
| Matsuda, S | 1 |
| Fushimi, K | 1 |
| Kirk Morton, N | 1 |
| Zubek, D | 1 |
| Kondo, MA | 1 |
| Tajinda, K | 1 |
| Colantuoni, C | 1 |
| Hiyama, H | 1 |
| Seshadri, S | 1 |
| Huang, B | 1 |
| Pou, S | 1 |
| Furukori, K | 1 |
| Hookway, C | 1 |
| Jaaro-Peled, H | 2 |
| Kano, SI | 1 |
| Matsuoka, N | 2 |
| Harada, K | 2 |
| Ni, K | 1 |
| Volk, DW | 6 |
| Siegel, BI | 2 |
| Verrico, CD | 2 |
| Lewis, DA | 19 |
| Drummond, JB | 3 |
| Tucholski, J | 2 |
| Haroutunian, V | 16 |
| Meador-Woodruff, JH | 15 |
| Rubio, MD | 2 |
| Wood, K | 1 |
| Müller-Spahn, F | 3 |
| Yanagi, M | 1 |
| Joho, RH | 1 |
| Southcott, SA | 1 |
| Shukla, AA | 1 |
| Ghose, S | 3 |
| Konopaske, GT | 2 |
| Bolo, NR | 1 |
| Basu, AC | 1 |
| Renshaw, PF | 1 |
| Coyle, JT | 2 |
| Andreou, C | 2 |
| Moritz, S | 2 |
| Veith, K | 1 |
| Veckenstedt, R | 1 |
| Naber, D | 5 |
| Stadlbauer, U | 1 |
| Langhans, W | 1 |
| Meyer, U | 2 |
| Accordini, S | 3 |
| Girlanda, F | 2 |
| Tansella, M | 3 |
| Uchida, T | 2 |
| Suzuki, T | 4 |
| Sakurai, H | 1 |
| Tsutsumi, C | 1 |
| Den, R | 1 |
| Mimura, M | 1 |
| Uchida, H | 2 |
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 2 |
| Lykouras, L | 8 |
| Bharadwaj, R | 1 |
| Jiang, Y | 1 |
| Mao, W | 1 |
| Jakovcevski, M | 1 |
| Dincer, A | 1 |
| Krueger, W | 1 |
| Garbett, K | 1 |
| Whittle, C | 1 |
| Tushir, JS | 1 |
| Liu, J | 3 |
| Sequeira, A | 1 |
| Vawter, MP | 1 |
| Gardner, PD | 1 |
| Casaccia, P | 1 |
| Rasmussen, T | 1 |
| Bunney, WE | 3 |
| Mirnics, K | 5 |
| Futai, K | 1 |
| Akbarian, S | 1 |
| Genius, J | 5 |
| Geiger, J | 1 |
| Dölzer, AL | 1 |
| Benninghoff, J | 2 |
| Giegling, I | 9 |
| Hartmann, AM | 5 |
| Rujescu, D | 13 |
| Kishi, T | 1 |
| Mukai, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Reifsnyder, JW | 1 |
| Tettambel, MA | 1 |
| Krakowski, MI | 5 |
| Bozina, N | 1 |
| Nikolac-Perkovic, M | 1 |
| Vuksan-Cusa, B | 1 |
| Fang, F | 1 |
| Xu, H | 1 |
| Huang, Q | 1 |
| Adilijiang, A | 1 |
| Wang, J | 3 |
| Zhang, Z | 1 |
| He, J | 1 |
| Kong, L | 1 |
| Li, XM | 1 |
| Donnelly, L | 1 |
| Rathbone, J | 1 |
| Adams, CE | 11 |
| Bošković, M | 2 |
| Grabnar, I | 2 |
| Terzič, T | 1 |
| Kores Plesničar, B | 1 |
| Vovk, T | 2 |
| Dietz, DM | 1 |
| Kennedy, PJ | 1 |
| Maze, I | 1 |
| Gancarz, AM | 1 |
| Vialou, V | 1 |
| Koo, JW | 1 |
| Mouzon, E | 1 |
| Nestler, EJ | 2 |
| Coesmans, M | 1 |
| Röder, CH | 4 |
| Smit, AE | 1 |
| Koekkoek, SK | 1 |
| De Zeeuw, CI | 1 |
| Frens, MA | 1 |
| van der Geest, JN | 1 |
| Pilla Reddy, V | 1 |
| Kozielska, M | 1 |
| Johnson, M | 1 |
| Mafirakureva, N | 1 |
| Vermeulen, A | 1 |
| de Greef, R | 1 |
| Groothuis, GM | 1 |
| Danhof, M | 1 |
| Proost, JH | 1 |
| Sengupta, EJ | 2 |
| Edelson, JR | 2 |
| Bergman, H | 1 |
| Irving, CB | 1 |
| Lawrie, S | 4 |
| Hsu, CY | 1 |
| Lin, YH | 1 |
| Shen, YC | 8 |
| Vicente, C | 1 |
| Zilbershtein, R | 1 |
| Piwko, C | 1 |
| Bø, CN | 1 |
| Pudas, H | 1 |
| Jensen, R | 1 |
| Hemels, ME | 1 |
| Volavka, J | 35 |
| Citrome, L | 20 |
| Van Dorn, RA | 1 |
| Walther, S | 1 |
| Moggi, F | 1 |
| Horn, H | 1 |
| Moskvitin, K | 1 |
| Abderhalden, C | 1 |
| Maier, N | 1 |
| Strik, W | 1 |
| Müller, TJ | 1 |
| Takahashi, Y | 1 |
| Sajatovic, M | 1 |
| Levin, J | 1 |
| Ramirez, LF | 1 |
| Hahn, DY | 1 |
| Tatsuoka, C | 1 |
| Bialko, CS | 1 |
| Cassidy, KA | 1 |
| Fuentes-Casiano, E | 1 |
| Williams, TD | 1 |
| Gill, KM | 1 |
| Cook, JM | 1 |
| Poe, MM | 1 |
| Grace, AA | 1 |
| Alaqeel, B | 1 |
| Piazza, J | 1 |
| Hoare, T | 1 |
| Molinaro, L | 1 |
| Terpstra, K | 1 |
| Bhandari, J | 1 |
| Selvaganapathy, PR | 1 |
| Gupta, B | 1 |
| Mishra, RK | 2 |
| Pinner, AL | 2 |
| Meyerwas, S | 1 |
| Zill, P | 3 |
| Dehning, S | 2 |
| Cerovecki, A | 2 |
| Seemüller, F | 6 |
| Schäfer, M | 8 |
| Müller, N | 2 |
| Nedic Erjavec, G | 1 |
| Uzun, S | 1 |
| Kozumplik, O | 1 |
| Mesholam-Gately, RI | 1 |
| Gibson, LE | 1 |
| Seidman, LJ | 2 |
| Green, AI | 8 |
| Doufik, J | 1 |
| Otheman, Y | 1 |
| Khalili, L | 1 |
| Ghanmi, J | 1 |
| Ouanass, A | 1 |
| Díez, Á | 1 |
| Suazo, V | 1 |
| Casado, P | 2 |
| Martín-Loeches, M | 2 |
| Molina, V | 5 |
| Nakamura, A | 1 |
| Mihara, K | 26 |
| Nemoto, K | 1 |
| Nagai, G | 1 |
| Kagawa, S | 1 |
| Kondo, T | 28 |
| Chan, HY | 3 |
| Ree, SC | 1 |
| Su, LW | 1 |
| Chen, JJ | 3 |
| Chou, SY | 1 |
| Chen, CK | 1 |
| Chen, YS | 1 |
| Drago, A | 2 |
| Konte, B | 2 |
| Friedl, M | 2 |
| Serretti, A | 6 |
| Bianchini, O | 1 |
| Porcelli, S | 3 |
| Nespeca, C | 1 |
| Cannavò, D | 1 |
| Trappoli, A | 1 |
| Aguglia, E | 4 |
| De Ronchi, D | 2 |
| Zou, D | 1 |
| Shao, Y | 1 |
| Qin, Z | 1 |
| Liu, N | 1 |
| Huang, P | 1 |
| Byerly, M | 1 |
| Hamer, RM | 9 |
| Dominik, R | 1 |
| Ray, N | 1 |
| Lamberti, JS | 1 |
| Buckley, PF | 3 |
| Wilkins, TM | 1 |
| Meyer, JM | 1 |
| Santoro, ML | 2 |
| Ota, VK | 2 |
| Stilhano, RS | 1 |
| Silva, PN | 1 |
| Santos, CM | 2 |
| Diana, MC | 2 |
| Bressan, RA | 3 |
| Melaragno, MI | 1 |
| Han, SW | 1 |
| Abílio, VC | 2 |
| Belangero, SI | 2 |
| Tardy, M | 3 |
| Huhn, M | 1 |
| Kissling, W | 13 |
| Engel, RR | 2 |
| Sarappa, C | 1 |
| Rossi, R | 2 |
| Eramo, A | 1 |
| Föcking, M | 3 |
| Lopez, LM | 2 |
| English, JA | 3 |
| Dicker, P | 3 |
| Wolff, A | 1 |
| Brindley, E | 1 |
| Wynne, K | 1 |
| Cagney, G | 1 |
| Cotter, DR | 3 |
| Koprivšek, J | 2 |
| Plesničar, BK | 2 |
| Funk, AJ | 2 |
| Zanatta, G | 1 |
| Nunes, G | 1 |
| Bezerra, EM | 1 |
| da Costa, RF | 1 |
| Martins, A | 1 |
| Caetano, EW | 1 |
| Freire, VN | 1 |
| Gottfried, C | 2 |
| Zhang, C | 1 |
| Fang, Y | 1 |
| Xu, L | 1 |
| Lange, N | 1 |
| Benes, FM | 1 |
| Ouhaz, Z | 1 |
| Ba-M'hamed, S | 1 |
| Bennis, M | 1 |
| Kawaura, K | 1 |
| Koike, H | 1 |
| Kinoshita, K | 1 |
| Kambe, D | 1 |
| Kaku, A | 1 |
| Karasawa, J | 1 |
| Chaki, S | 2 |
| Hikichi, H | 1 |
| Castle, DJ | 2 |
| Slott Jensen, JK | 1 |
| Oyamada, Y | 1 |
| Horiguchi, M | 2 |
| Rajagopal, L | 1 |
| Miyauchi, M | 1 |
| Meltzer, HY | 14 |
| Mondal, G | 1 |
| Nizamie, SH | 2 |
| Mukherjee, N | 1 |
| Tikka, SK | 1 |
| Jaiswal, B | 1 |
| Deng, C | 1 |
| Pan, B | 1 |
| Hu, CH | 1 |
| Han, M | 1 |
| Huang, XF | 3 |
| Dold, M | 3 |
| Bouritius, EM | 1 |
| Neven, A | 1 |
| Blom, JD | 1 |
| Ran, MS | 1 |
| Chan, CL | 1 |
| Ng, SM | 1 |
| Guo, LT | 1 |
| Xiang, MZ | 1 |
| Huang, CL | 1 |
| Hwang, TJ | 2 |
| Chen, YH | 2 |
| Huang, GH | 1 |
| Hsieh, MH | 1 |
| Chen, HH | 1 |
| Hwu, HG | 6 |
| Turner, NL | 1 |
| Dias, S | 1 |
| Ades, AE | 1 |
| Welton, NJ | 1 |
| Foote, M | 1 |
| Qiao, H | 2 |
| Graham, K | 1 |
| van der Weide, K | 1 |
| van der Weide, J | 1 |
| Lubinga, SJ | 1 |
| Mutamba, BB | 1 |
| Nganizi, A | 1 |
| Babigumira, JB | 1 |
| Datta, D | 1 |
| Arion, D | 1 |
| Corradi, JP | 1 |
| Belluzzi, JD | 1 |
| Frau, R | 2 |
| Abbiati, F | 1 |
| Bini, V | 1 |
| Casti, A | 1 |
| Caruso, D | 1 |
| Devoto, P | 1 |
| Bortolato, M | 2 |
| Matosin, N | 1 |
| Fernandez-Enright, F | 1 |
| Lum, JS | 1 |
| Andrews, JL | 1 |
| Engel, M | 1 |
| Newell, KA | 1 |
| Bauer, D | 2 |
| Simmons, M | 2 |
| Roussos, P | 2 |
| Kippe, JM | 1 |
| Mueller, TM | 1 |
| Bryan, TL | 1 |
| Widschwendter, CG | 1 |
| Kolluri, S | 1 |
| Rubio, G | 1 |
| López-Muñoz, F | 2 |
| Jurado-Barba, R | 1 |
| Martínez-Gras, I | 1 |
| Rodríguez-Jiménez, R | 1 |
| Espinosa, R | 1 |
| Pérez-Nieto, MÁ | 1 |
| Moratti, S | 1 |
| Jiménez-Arriero, MÁ | 1 |
| Carlos Leza, J | 1 |
| Scott, MR | 1 |
| Peltola, MA | 1 |
| Kuja-Panula, J | 1 |
| Liuhanen, J | 1 |
| Võikar, V | 1 |
| Piepponen, P | 1 |
| Hiekkalinna, T | 1 |
| Taira, T | 1 |
| Lauri, SE | 1 |
| Suvisaari, J | 1 |
| Kulesskaya, N | 1 |
| Paunio, T | 1 |
| Rauvala, H | 1 |
| Udawela, M | 1 |
| Money, TT | 1 |
| Neo, J | 1 |
| Seo, MS | 1 |
| Scarr, E | 3 |
| Dean, B | 6 |
| Everall, IP | 1 |
| Parabiaghi, A | 2 |
| Tettamanti, M | 2 |
| D'Avanzo, B | 2 |
| Barbato, A | 2 |
| Liang, Y | 4 |
| Su, YA | 1 |
| Zhao, ZG | 1 |
| Gao, N | 1 |
| Huang, JZ | 1 |
| Tang, MQ | 1 |
| Li, KQ | 1 |
| Yang, FD | 1 |
| Yu, X | 1 |
| Si, TM | 1 |
| Xavier, G | 1 |
| Spindola, LN | 1 |
| Moretti, PN | 1 |
| Fabrazzo, M | 1 |
| Monteleone, P | 3 |
| Prisco, V | 1 |
| Perris, F | 1 |
| Catapano, F | 1 |
| Tortorella, A | 1 |
| Monteleone, AM | 1 |
| Steardo, L | 1 |
| Maj, M | 8 |
| Yu, HY | 1 |
| Hsiao, CY | 1 |
| Chen, KC | 1 |
| Lee, LT | 1 |
| Chang, WH | 29 |
| Chi, MH | 1 |
| Hui Lee, I | 1 |
| Chen, PS | 1 |
| Yang, YK | 3 |
| Betti, AH | 1 |
| Górska, A | 1 |
| Marszałł, M | 1 |
| Sloderbach, A | 1 |
| Shoja Shafti, S | 1 |
| Akbari, S | 1 |
| Melkersson, K | 1 |
| Lewitt, M | 1 |
| Hall, K | 1 |
| McCollum, LA | 1 |
| Roberts, RC | 2 |
| Gianatsi, M | 1 |
| Nikolakopoulou, A | 1 |
| Salanti, G | 1 |
| Yamamoto, S | 1 |
| Ohta, N | 1 |
| Matsumoto, A | 1 |
| Horiguchi, Y | 1 |
| Koide, M | 1 |
| Fujino, Y | 1 |
| Kasper, S | 10 |
| Karbownik, MS | 1 |
| Szemraj, J | 1 |
| Wieteska, Ł | 1 |
| Antczak, A | 1 |
| Górski, P | 1 |
| Kowalczyk, E | 1 |
| Pietras, T | 1 |
| Dang, R | 1 |
| Guo, Y | 1 |
| Cai, H | 1 |
| Yang, R | 1 |
| Liang, D | 1 |
| Lv, C | 1 |
| Jiang, P | 1 |
| Barakauskas, VE | 2 |
| Moradian, A | 1 |
| Barr, AM | 3 |
| Beasley, CL | 2 |
| Rosoklija, G | 1 |
| Mann, JJ | 3 |
| Ilievski, B | 2 |
| Stankov, A | 1 |
| Dwork, AJ | 3 |
| Morin, GB | 1 |
| Potanin, SS | 1 |
| Burminskiy, DS | 1 |
| Morozova, MA | 1 |
| Platova, AI | 1 |
| Baymeeva, NV | 1 |
| Miroshnichenko, II | 1 |
| Schulz, C | 1 |
| Timm, J | 1 |
| Cordes, J | 1 |
| Gründer, G | 2 |
| Mühlbauer, B | 1 |
| Rüther, E | 6 |
| Heinze, M | 1 |
| Scangos, KW | 1 |
| Caton, M | 1 |
| Newman, WJ | 1 |
| Hudson, MR | 1 |
| Rind, G | 1 |
| O'Brien, TJ | 1 |
| Jones, NC | 1 |
| Maia-Lopes, S | 1 |
| Goswami, P | 1 |
| Uhrig, S | 1 |
| Hirth, N | 1 |
| Broccoli, L | 1 |
| von Wilmsdorff, M | 6 |
| Bauer, M | 3 |
| Sommer, C | 1 |
| Zink, M | 4 |
| Steiner, J | 5 |
| Frodl, T | 2 |
| Malchow, B | 1 |
| Spanagel, R | 1 |
| Hansson, AC | 1 |
| Schmitt, A | 16 |
| Pinacho, R | 1 |
| Vila, E | 1 |
| Prades, R | 1 |
| Tarragó, T | 1 |
| Castro, E | 1 |
| Ferrer, I | 1 |
| Ramos, B | 1 |
| Kolbeck, K | 1 |
| Leslie, DL | 1 |
| Sint, KJ | 1 |
| Lin, H | 1 |
| Li, Y | 2 |
| Byerly, MJ | 1 |
| Bauer, JØ | 1 |
| Stenborg, D | 1 |
| Lodahl, T | 1 |
| Mønsted, MM | 1 |
| Buoli, M | 2 |
| Kahn, RS | 14 |
| Serati, M | 1 |
| Altamura, AC | 10 |
| Cahn, W | 1 |
| Uys, M | 1 |
| Sallinen, J | 1 |
| Dreyer, W | 1 |
| Cockeran, M | 1 |
| Harvey, BH | 2 |
| Chiodini, P | 1 |
| Mutică, M | 1 |
| Marinescu, I | 1 |
| Militaru, F | 1 |
| Pîrlog, MC | 1 |
| Udriştoiu, I | 1 |
| Ocaña-Zurita, MC | 1 |
| Juárez-Rojop, IE | 1 |
| Genis, A | 1 |
| Tovilla-Zárate, CA | 1 |
| González-Castro, TB | 1 |
| Lilia López-Narváez, M | 1 |
| de la O de la O, ME | 1 |
| Nicolini, H | 3 |
| Gottschling, C | 1 |
| Geissler, M | 1 |
| Springer, G | 1 |
| Wolf, R | 1 |
| Juckel, G | 3 |
| Faissner, A | 1 |
| Kim, E | 3 |
| Mao, L | 1 |
| Starr, HL | 1 |
| Alphs, L | 2 |
| Khushu, A | 1 |
| Powney, MJ | 1 |
| Khan, AY | 1 |
| Salaria, S | 1 |
| Ovais, M | 1 |
| Ide, GD | 1 |
| Zehtabchi, S | 1 |
| Meyvisch, P | 1 |
| Pan, YJ | 1 |
| Chen, CH | 5 |
| Mielnik, CA | 1 |
| Newburn, E | 1 |
| Ramsey, AJ | 1 |
| Lipska, BK | 7 |
| Oliveras, I | 1 |
| Sánchez-González, A | 1 |
| Sampedro-Viana, D | 1 |
| Piludu, MA | 1 |
| Río-Alamos, C | 1 |
| Giorgi, O | 1 |
| Corda, MG | 1 |
| Aznar, S | 1 |
| González-Maeso, J | 1 |
| Gerbolés, C | 1 |
| Blázquez, G | 1 |
| Cañete, T | 1 |
| Tobeña, A | 1 |
| Fernández-Teruel, A | 1 |
| Benmessaoud, D | 1 |
| Hamdani, N | 1 |
| Boni, C | 1 |
| Ramoz, N | 1 |
| Hamon, M | 1 |
| Kacha, F | 1 |
| Gorwood, P | 1 |
| Quednow, BB | 2 |
| Frommann, I | 1 |
| Berning, J | 1 |
| Kühn, KU | 5 |
| Maier, W | 10 |
| Wagner, M | 3 |
| Rossi, A | 2 |
| Tiradritti, P | 1 |
| Romeo, F | 2 |
| Higgins, JP | 1 |
| Wood, AM | 1 |
| Hempel, RJ | 1 |
| Tulen, JH | 1 |
| van Beveren, NJ | 1 |
| Hengeveld, MW | 1 |
| Dankert, ME | 1 |
| Brensinger, CM | 1 |
| Metzger, KL | 1 |
| Koleva, SG | 1 |
| Mesén, A | 1 |
| Laprade, B | 1 |
| Wiguna, T | 1 |
| Han, C | 1 |
| Farooq, S | 1 |
| Severus, WE | 1 |
| Gayares, JG | 1 |
| Langosch, JM | 2 |
| Lallart, X | 1 |
| Tateno, M | 1 |
| Mihai, A | 1 |
| Nair, SR | 1 |
| Belmaker, R | 1 |
| Owe-Larsson, B | 1 |
| Kane, JM | 20 |
| Johnstone, EC | 2 |
| MacIntyre, DJ | 1 |
| Malhotra, S | 1 |
| Mosquera, F | 1 |
| Babb, SM | 1 |
| Habib pour, E | 1 |
| Fatemi, SS | 1 |
| Swanson, C | 1 |
| Adler, C | 1 |
| Young, A | 1 |
| Hoeft, F | 1 |
| Sivakumar, K | 1 |
| Radoeva, PD | 1 |
| Lallart, EA | 1 |
| Bilker, WB | 3 |
| Siegel, SJ | 6 |
| Vargas, HE | 1 |
| Gama, CS | 2 |
| Andreazza, AC | 2 |
| Medeiros, D | 1 |
| Stertz, L | 1 |
| Fries, G | 1 |
| Palha, J | 1 |
| Cereser, KM | 1 |
| Berk, M | 4 |
| Kapczinski, F | 2 |
| Belmonte-de-Abreu, PS | 1 |
| Dolzan, V | 1 |
| Mandelli, L | 1 |
| Kastelic, M | 1 |
| Fakra, E | 2 |
| Khalfa, S | 1 |
| Da Fonseca, D | 1 |
| Besnier, N | 2 |
| Delaveau, P | 1 |
| Azorin, JM | 5 |
| Blin, O | 4 |
| Popov, MIu | 1 |
| Kelley, ME | 11 |
| Haas, GL | 3 |
| van Kammen, DP | 40 |
| Leucht, C | 2 |
| Kitzmantel, M | 2 |
| Chua, L | 2 |
| Kane, J | 7 |
| Bonham, C | 1 |
| Abbott, C | 1 |
| Barak, S | 2 |
| Weiner, I | 8 |
| Black, MD | 1 |
| Varty, GB | 1 |
| Arad, M | 4 |
| De Levie, A | 1 |
| Boulay, D | 1 |
| Pichat, P | 1 |
| Griebel, G | 1 |
| Fukushiro, DF | 1 |
| Carvalho, Rde C | 1 |
| Ricardo, VP | 1 |
| Alvarez, Jdo N | 1 |
| Ribeiro, LT | 1 |
| Frussa-Filho, R | 1 |
| Funatogawa, T | 1 |
| Funatogawa, I | 1 |
| Takeuchi, M | 1 |
| Nolan, KA | 2 |
| Spann, M | 1 |
| Lindborg, S | 2 |
| Seaman, J | 1 |
| Baker, R | 1 |
| Dunayevich, E | 1 |
| Breier, A | 22 |
| Malkoff, A | 1 |
| Weizman, A | 11 |
| Gozes, I | 1 |
| Rehavi, M | 2 |
| Becker, A | 3 |
| Grecksch, G | 3 |
| Zernig, G | 1 |
| Ladstaetter, E | 1 |
| Hiemke, C | 1 |
| Schmitt, U | 1 |
| Thompson, PM | 2 |
| Bartzokis, G | 1 |
| Hayashi, KM | 1 |
| Klunder, AD | 1 |
| Lu, PH | 1 |
| Edwards, N | 1 |
| Hong, MS | 1 |
| Geaga, JA | 1 |
| Toga, AW | 1 |
| Charles, C | 2 |
| Perkins, DO | 4 |
| McEvoy, J | 10 |
| Tohen, M | 10 |
| Tollefson, GD | 22 |
| Lieberman, JA | 24 |
| Spoerri, E | 1 |
| Yee, BK | 2 |
| Schwarz, MJ | 1 |
| Feldon, J | 3 |
| Levine, SZ | 2 |
| Rabinowitz, J | 14 |
| Mössner, R | 1 |
| Schuhmacher, A | 1 |
| Cvetanovska, G | 1 |
| Rietschel, M | 2 |
| Wölwer, W | 7 |
| Gaebel, W | 17 |
| Brinkmeyer, J | 1 |
| Riesbeck, M | 7 |
| Freimüller, L | 1 |
| Klimke, A | 5 |
| Klingberg, S | 7 |
| Mata, I | 4 |
| Amado, JA | 2 |
| Garcia-Unzueta, MT | 2 |
| Berja, A | 2 |
| Wang, PW | 1 |
| Wang, SY | 1 |
| Huang, CJ | 1 |
| Dossenbach, M | 7 |
| Pecenak, J | 2 |
| Szulc, A | 1 |
| Irimia, V | 1 |
| Anders, M | 2 |
| Logozar-Perkovic, D | 1 |
| Peciukaitiene, D | 1 |
| Kotler, M | 2 |
| Smulevich, AB | 2 |
| West, TM | 1 |
| Lowry, AJ | 2 |
| Treuer, T | 3 |
| Ehrlichman, RS | 1 |
| Gandal, MJ | 1 |
| Maxwell, CR | 3 |
| Lazarewicz, MT | 1 |
| Finkel, LH | 1 |
| Contreras, D | 1 |
| Turetsky, BI | 1 |
| Bastiampillai, T | 1 |
| Dhillon, R | 1 |
| Mohindra, R | 1 |
| Reske, M | 2 |
| Habel, U | 2 |
| Kellermann, T | 2 |
| Backes, V | 2 |
| Jon Shah, N | 2 |
| Zilles, K | 1 |
| Schneider, F | 10 |
| González-Blanch, C | 1 |
| Alvarez-Jiménez, M | 1 |
| Peuskens, J | 9 |
| Gillain, B | 1 |
| De Graeve, D | 2 |
| Van Vleymen, B | 1 |
| Albert, A | 1 |
| Udristoiu, T | 1 |
| Kim, CY | 1 |
| Sarosi, A | 1 |
| Pidrman, V | 1 |
| Omar, AN | 1 |
| Rosales, JI | 1 |
| Melamed, Y | 2 |
| Isik, T | 1 |
| Karagianis, J | 1 |
| Zhang, XY | 10 |
| Zhou, DF | 12 |
| Qi, LY | 1 |
| Chen, S | 1 |
| Cao, LY | 8 |
| Chen, DC | 2 |
| Xiu, MH | 2 |
| Wang, F | 1 |
| Wu, GY | 8 |
| Lu, L | 1 |
| Kosten, TA | 3 |
| Kosten, TR | 2 |
| Danilov, DS | 2 |
| Ivanets, NN | 1 |
| Kinkul'kina, MA | 1 |
| Emsley, R | 8 |
| Oosthuizen, P | 4 |
| Koen, L | 2 |
| Niehaus, DJ | 2 |
| Medori, R | 3 |
| Seeman, P | 12 |
| Alamo, C | 1 |
| Pappadopulos, E | 1 |
| Lombardo, I | 1 |
| Kremer, CM | 1 |
| Iwata, K | 1 |
| Masuda, M | 1 |
| Soejima, K | 1 |
| Ohashi, M | 1 |
| Bisol, LW | 1 |
| Brunstein, MG | 1 |
| Ottoni, GL | 1 |
| Ramos, FL | 1 |
| Borba, DL | 1 |
| Daltio, CS | 1 |
| de Oliveira, RV | 1 |
| Paz, GE | 1 |
| de Souza, SE | 1 |
| Lara, DR | 1 |
| Janicak, PG | 4 |
| Glick, ID | 6 |
| Marder, SR | 37 |
| Crandall, DT | 4 |
| McQuade, RD | 7 |
| Marcus, RN | 5 |
| Eudicone, JM | 2 |
| Assunção-Talbott, S | 2 |
| Wobrock, T | 1 |
| Gruber, O | 4 |
| Klosterkötter, J | 7 |
| Buchkremer, G | 3 |
| Bender, S | 2 |
| Schlösser, R | 6 |
| de Oliveira, IR | 4 |
| Elkis, H | 4 |
| Gattaz, WF | 12 |
| Chaves, A | 1 |
| de Sena, EP | 5 |
| de Matos E Souza, FG | 1 |
| Campos, JA | 1 |
| Bueno, JR | 1 |
| E Silva, JA | 1 |
| Louzã, MR | 2 |
| de Abreu, PB | 1 |
| Bagati, D | 1 |
| Prakash, R | 3 |
| Zuo, L | 1 |
| Luo, X | 1 |
| Krystal, JH | 3 |
| Cramer, J | 11 |
| Charney, DS | 4 |
| Gelernter, J | 1 |
| Bernstein, HG | 5 |
| Ernst, T | 1 |
| Lendeckel, U | 4 |
| Bukowska, A | 2 |
| Ansorge, S | 1 |
| Stauch, R | 2 |
| Have, ST | 1 |
| Dobrowolny, H | 3 |
| Bogerts, B | 5 |
| Potkin, SG | 11 |
| Weiden, PJ | 3 |
| Loebel, AD | 1 |
| Warrington, LE | 1 |
| Watsky, EJ | 1 |
| Siu, CO | 3 |
| Kähne, T | 1 |
| Ten Have, S | 1 |
| Wolke, C | 1 |
| Keilhoff, G | 3 |
| Artioli, P | 1 |
| Barale, F | 1 |
| Beneduce, R | 1 |
| Berardi, D | 1 |
| Bertolazzi, G | 1 |
| Biancosino, B | 1 |
| Bisogno, A | 1 |
| Bivi, R | 1 |
| Bogetto, F | 3 |
| Boso, M | 1 |
| Bozzani, A | 1 |
| Bucolo, P | 1 |
| Casale, M | 1 |
| Cascone, L | 1 |
| Ciammella, L | 1 |
| Cicolini, A | 1 |
| Cipresso, G | 1 |
| Colombo, P | 1 |
| Dal Santo, B | 1 |
| De Francesco, M | 1 |
| Di Lorenzo, G | 2 |
| Di Munzio, W | 1 |
| Ducci, G | 1 |
| Erlicher, A | 1 |
| Esposito, E | 2 |
| Ferrannini, L | 1 |
| Ferrato, F | 1 |
| Ferro, A | 1 |
| Fragomeno, N | 1 |
| Parise, VF | 1 |
| Frova, M | 1 |
| Gardellin, F | 1 |
| Garzotto, N | 1 |
| Giambartolomei, A | 1 |
| Giupponi, G | 1 |
| Grassi, L | 1 |
| Grazian, N | 1 |
| Grecu, L | 1 |
| Guerrini, G | 1 |
| Laddomada, F | 1 |
| Lazzarin, E | 1 |
| Lintas, C | 1 |
| Malchiodi, F | 1 |
| Malvini, L | 1 |
| Marchiaro, L | 1 |
| Marsilio, A | 1 |
| Mauri, MC | 8 |
| Mautone, A | 1 |
| Menchetti, M | 1 |
| Migliorini, G | 1 |
| Mollica, M | 1 |
| Moretti, D | 1 |
| Mulè, S | 1 |
| Nicholau, S | 1 |
| Nosè, F | 1 |
| Occhionero, G | 1 |
| Pacilli, AM | 1 |
| Pecchioli, S | 1 |
| Percudani, M | 2 |
| Piantato, E | 1 |
| Piazza, C | 1 |
| Pontarollo, F | 1 |
| Pycha, R | 1 |
| Quartesan, R | 2 |
| Rillosi, L | 1 |
| Risso, F | 1 |
| Rizzo, R | 1 |
| Rocca, P | 2 |
| Roma, S | 1 |
| Rossattini, M | 1 |
| Rossi, G | 2 |
| Sala, A | 1 |
| Santilli, C | 1 |
| Saraò, G | 1 |
| Sarnicola, A | 1 |
| Sartore, F | 1 |
| Scarone, S | 3 |
| Sciarma, T | 1 |
| Siracusano, A | 2 |
| Strizzolo, S | 1 |
| Targa, G | 1 |
| Tasser, A | 1 |
| Tomasi, R | 1 |
| Travaglini, R | 1 |
| Veronese, A | 2 |
| Ziero, S | 1 |
| Goldberg, TE | 3 |
| Gomar, JJ | 1 |
| Gleason, KA | 1 |
| Potts, BW | 1 |
| Lewis-Amezcua, K | 1 |
| Rajarethinam, R | 2 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 2 |
| Tuppurainen, H | 2 |
| Kuikka, JT | 2 |
| Viinamäki, H | 2 |
| Husso, M | 2 |
| Tiihonen, J | 2 |
| Alptekin, K | 1 |
| Hafez, J | 1 |
| Brook, S | 5 |
| Akkaya, C | 2 |
| Ucok, A | 1 |
| El Tallawy, H | 1 |
| Danaci, AE | 1 |
| Lowe, W | 1 |
| Ravanic, DB | 1 |
| Dejanovic, SM | 1 |
| Janjic, V | 2 |
| Jovic, SD | 1 |
| Milovanovic, DR | 1 |
| Jakovljevic, V | 1 |
| Pantovic, V | 1 |
| Ravanic, B | 1 |
| Pantovic, M | 1 |
| Pantovic, MM | 1 |
| Garcia, E | 1 |
| Robert, M | 1 |
| Peris, F | 1 |
| Terazawa, Y | 1 |
| Dunn, MJ | 2 |
| Lipkovich, IA | 1 |
| Deberdt, W | 1 |
| Csernansky, JG | 9 |
| Sabbe, B | 1 |
| Keefe, RS | 9 |
| Kollack-Walker, S | 2 |
| Lindner, LM | 1 |
| Marasciulo, AC | 1 |
| Farias, MR | 1 |
| Grohs, GE | 1 |
| Lahti, AC | 5 |
| Weiler, MA | 3 |
| Holcomb, HH | 5 |
| Cropsey, KL | 1 |
| Buchsbaum, MS | 3 |
| Haznedar, M | 1 |
| Newmark, RE | 1 |
| Chu, KW | 1 |
| Dusi, N | 1 |
| Entis, JJ | 1 |
| Goldstein, KE | 1 |
| Goodman, CR | 1 |
| Gupta, A | 1 |
| Hazlett, E | 2 |
| Iannuzzi, J | 1 |
| Torosjan, Y | 1 |
| Wolkin, A | 8 |
| Gaszner, P | 3 |
| Kan, HJ | 1 |
| Guo, Z | 1 |
| Bates, JA | 1 |
| Whitehead, R | 2 |
| Pikalov, A | 5 |
| Dzhuga, NP | 1 |
| Kozlovskiĭ, VL | 1 |
| Uezato, A | 1 |
| Toua, C | 1 |
| Brand, L | 1 |
| Möller, M | 1 |
| Emsley, RA | 7 |
| Rock, W | 1 |
| Elias, M | 1 |
| Lev, A | 1 |
| Saliba, WR | 1 |
| Lawson, WB | 6 |
| Herman, BK | 1 |
| Loebel, A | 3 |
| Lazariciu, I | 1 |
| Malik, M | 1 |
| Liew, A | 1 |
| Verma, S | 1 |
| Edimansyah, A | 1 |
| Subramaniam, M | 1 |
| Vaingankar, J | 1 |
| Barnes, TR | 2 |
| Sachs, G | 1 |
| Buckley, P | 2 |
| Eudicone, J | 3 |
| McQuade, R | 3 |
| Tran, QV | 1 |
| Quincozes-Santos, A | 1 |
| Bobermin, LD | 1 |
| Tonial, RP | 1 |
| Bambini-Junior, V | 1 |
| Riesgo, R | 1 |
| De Hert, M | 1 |
| Cohen, D | 1 |
| Ypsilanti, AR | 1 |
| Li, HY | 1 |
| Thornton, AE | 1 |
| Wong, H | 1 |
| Rosokilja, G | 1 |
| Mancevski, B | 1 |
| Jakovski, Z | 1 |
| Davceva, N | 1 |
| Syu, A | 1 |
| Ishiguro, H | 1 |
| Inada, T | 4 |
| Horiuchi, Y | 1 |
| Tanaka, S | 1 |
| Ishikawa, M | 1 |
| Arai, M | 1 |
| Itokawa, M | 1 |
| Niizato, K | 2 |
| Iritani, S | 2 |
| Takahashi, M | 3 |
| Kakita, A | 2 |
| Takahashi, H | 6 |
| Nawa, H | 5 |
| Keino-Masu, K | 1 |
| Arikawa-Hirasawa, E | 1 |
| Arinami, T | 1 |
| Miceli, JJ | 2 |
| Tensfeldt, TG | 2 |
| Shiovitz, T | 2 |
| Anziano, R | 1 |
| O'Gorman, C | 2 |
| Harrigan, RH | 2 |
| Shariati, GR | 1 |
| Ahangari, G | 1 |
| Hossein-nezhad, A | 1 |
| Asadi, SM | 1 |
| Pooyafard, F | 1 |
| Ahmadkhaniha, HR | 1 |
| Dyer, C | 1 |
| Danovich, L | 1 |
| Youdim, MB | 1 |
| Burns, T | 2 |
| Derks, EM | 2 |
| Rössler, W | 1 |
| Rizos, EN | 1 |
| Papadopoulou, A | 1 |
| Laskos, E | 1 |
| Michalopoulou, PG | 1 |
| Kastania, A | 1 |
| Vasilopoulos, D | 1 |
| Katsafouros, K | 1 |
| Wang, CK | 1 |
| Wang, WY | 1 |
| Meyer, RF | 1 |
| Winey, KI | 2 |
| Leung, JG | 1 |
| Benedetti, AM | 1 |
| Frazee, LA | 1 |
| Myers, N | 1 |
| Jaffe, A | 2 |
| Levine, J | 3 |
| Kristiansen, LV | 2 |
| Bakir, B | 1 |
| Arakawa, R | 1 |
| Okumura, M | 1 |
| Ito, H | 1 |
| Takano, A | 1 |
| Takano, H | 2 |
| Maeda, J | 1 |
| Okubo, Y | 2 |
| Suhara, T | 2 |
| Anziano, RJ | 1 |
| Pekkan, G | 1 |
| Kilicoglu, A | 1 |
| Algin, DI | 1 |
| Yagmur, F | 1 |
| Ulusoy, HB | 1 |
| Buyukoglan, H | 1 |
| Kaya, MG | 1 |
| Oshibuchi, H | 1 |
| Ishigooka, J | 3 |
| Schennach-Wolff, R | 3 |
| Seemüller, FH | 1 |
| Mayr, A | 6 |
| Heuser, I | 7 |
| Gastpar, M | 7 |
| Häfner, H | 3 |
| Sauer, H | 5 |
| Cohen, M | 1 |
| Panagides, J | 1 |
| Shibuya, M | 1 |
| Komi, E | 1 |
| Wang, R | 1 |
| Kato, T | 5 |
| Watanabe, Y | 2 |
| Sakai, M | 1 |
| Ozaki, M | 1 |
| Someya, T | 14 |
| Docherty, JP | 1 |
| Baker, RA | 1 |
| Mathew, S | 1 |
| Mankoski, R | 1 |
| Eggan, SM | 3 |
| Stoyak, SR | 1 |
| Bech, P | 1 |
| Tanghøj, P | 2 |
| Andreasson, K | 1 |
| Overø, KF | 1 |
| Padurariu, M | 1 |
| Ciobica, A | 1 |
| Dobrin, I | 1 |
| Stefanescu, C | 1 |
| Stahl, SM | 2 |
| Malla, A | 2 |
| Newcomer, JW | 4 |
| Watsky, E | 1 |
| Romano, S | 1 |
| Opgen-Rhein, M | 1 |
| Bondy, B | 2 |
| Lipina, TV | 1 |
| Niwa, M | 1 |
| Fletcher, PJ | 2 |
| Roder, JC | 1 |
| De Carolis, L | 1 |
| Stasi, MA | 1 |
| Serlupi-Crescenzi, O | 1 |
| Borsini, F | 1 |
| Nencini, P | 1 |
| Negrete-Díaz, JV | 1 |
| Baltazar-Gaytán, E | 1 |
| Bringas, ME | 1 |
| Vazquez-Roque, RA | 1 |
| Newton, S | 1 |
| Aguilar-Alonso, P | 1 |
| León-Chávez, BA | 1 |
| Flores, G | 1 |
| Daniel, DG | 8 |
| Eickhoff, M | 2 |
| Lemke, M | 2 |
| Huff, W | 1 |
| Köpcke, W | 2 |
| Ohmann, C | 4 |
| Bubenikova-Valesova, V | 1 |
| Svoboda, J | 1 |
| Sumiyoshi, T | 2 |
| Chatterjee, M | 1 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 1 |
| Masana, M | 1 |
| Bortolozzi, A | 1 |
| Artigas, F | 2 |
| Wadenberg, ML | 3 |
| Fjällström, AK | 1 |
| Federley, M | 1 |
| Persson, P | 1 |
| Stenqvist, P | 1 |
| Goetghebeur, PJ | 1 |
| Lerdrup, L | 1 |
| Sylvest, A | 1 |
| Dias, R | 1 |
| Lin, CH | 1 |
| Kuo, CC | 1 |
| Chou, LS | 1 |
| Chen, CC | 2 |
| Huang, KH | 1 |
| Lane, HY | 5 |
| Abekawa, T | 2 |
| Ito, K | 2 |
| Nakagawa, S | 1 |
| Nakato, Y | 1 |
| Koyama, T | 3 |
| Girgis, RR | 1 |
| Merrill, DB | 1 |
| Vorel, SR | 1 |
| You, M | 1 |
| Marques, TR | 1 |
| Arenovich, T | 2 |
| Agid, O | 2 |
| Sajeev, G | 1 |
| Muthén, B | 1 |
| Chen, L | 1 |
| Kinon, BJ | 13 |
| Kapur, S | 17 |
| Carli, M | 2 |
| Calcagno, E | 1 |
| Mainolfi, P | 1 |
| Mainini, E | 1 |
| Invernizzi, RW | 2 |
| Furukawa, TA | 1 |
| Akechi, T | 1 |
| Wagenpfeil, S | 1 |
| Benvegnú, DM | 1 |
| Barcelos, RC | 1 |
| Boufleur, N | 1 |
| Reckziegel, P | 1 |
| Pase, CS | 1 |
| Ourique, AF | 1 |
| Beck, RC | 1 |
| Bürger, ME | 1 |
| Hughes, L | 1 |
| Fuller, G | 1 |
| Lataster, J | 1 |
| van Os, J | 1 |
| Thewissen, V | 1 |
| Bak, M | 1 |
| Lataster, T | 1 |
| Lardinois, M | 1 |
| Delespaul, PA | 1 |
| Myin-Germeys, I | 1 |
| Meyer, S | 2 |
| Weng, SH | 1 |
| Wang, GH | 1 |
| Wang, XP | 1 |
| Goodwin, DG | 1 |
| Strobl, JS | 1 |
| Lindsay, DS | 1 |
| Tadokoro, S | 1 |
| Okamura, N | 1 |
| Sekine, Y | 1 |
| Ghaleiha, A | 1 |
| Honarbakhsh, N | 1 |
| Boroumand, MA | 1 |
| Jafarinia, M | 1 |
| Tabrizi, M | 1 |
| Rezaei, F | 1 |
| Raznahan, M | 1 |
| Akhondzadeh, S | 7 |
| Dietrich-Muszalska, A | 1 |
| Olas, B | 1 |
| Kontek, B | 1 |
| Rabe-Jabłońska, J | 1 |
| Vasil'eva, AI | 1 |
| Jain, T | 1 |
| Bhandari, A | 1 |
| Ram, V | 1 |
| Parakh, M | 1 |
| Parakh, MC | 1 |
| Fukuda, T | 1 |
| Hashimoto, H | 1 |
| Okayasu, N | 1 |
| Kameyama, A | 1 |
| Nakazawa, T | 1 |
| Kurosawa, T | 1 |
| Hao, Y | 1 |
| Isaji, T | 1 |
| Tadano, T | 1 |
| Narimatsu, H | 1 |
| Taniguchi, N | 1 |
| Gu, J | 1 |
| Stroup, S | 2 |
| Vasil'eva, EF | 1 |
| Koliaskina, GI | 1 |
| Brusov, OS | 1 |
| Faktor, MI | 1 |
| Kaleda, VG | 1 |
| Barkhatova, NA | 1 |
| Bogdanova, ED | 1 |
| Schubert, KO | 1 |
| Babin, SL | 2 |
| Hood, AJ | 1 |
| Wassef, AA | 5 |
| Williams, NG | 2 |
| Patel, SS | 2 |
| Sereno, AB | 2 |
| de Araújo, FY | 1 |
| de Oliveira, GV | 1 |
| Gomes, PX | 1 |
| Soares, MA | 1 |
| Silva, MI | 1 |
| de Moraes, MO | 1 |
| de Moraes, ME | 1 |
| Vasconcelos, SM | 1 |
| Viana, GS | 1 |
| de Sousa, FC | 1 |
| Macêdo, DS | 1 |
| De Silva, PN | 1 |
| Raposo, NR | 1 |
| Ferreira, AS | 1 |
| Charlier, P | 1 |
| Chaillot, PF | 1 |
| Alvarez, JC | 1 |
| Lorin de la Grandmaison, G | 1 |
| Chen, ML | 1 |
| Lin, YY | 1 |
| Tsai, YM | 1 |
| Wang, LK | 1 |
| Lee, MC | 1 |
| Tsai, FM | 1 |
| Lindström, E | 4 |
| Eberhard, J | 1 |
| Fors, BM | 1 |
| Hansen, K | 1 |
| Sapin, C | 1 |
| Yeganeh-Doost, P | 1 |
| Radchenkova, PV | 1 |
| Walker, EM | 1 |
| Bitter, I | 9 |
| Libiger, J | 6 |
| Chen, PY | 1 |
| Huang, MC | 2 |
| Chiu, CC | 1 |
| Liu, HC | 4 |
| Lu, ML | 1 |
| Makkos, Z | 2 |
| Fejes, L | 1 |
| Inczédy-Farkas, G | 1 |
| Kassai-Farkas, A | 1 |
| Faludi, G | 1 |
| Lazáry, J | 1 |
| Tanahashi, S | 1 |
| Yamamura, S | 1 |
| Nakagawa, M | 1 |
| Motomura, E | 1 |
| Okada, M | 1 |
| Park, SW | 1 |
| Phuong, VT | 1 |
| Lee, CH | 1 |
| Lee, JG | 2 |
| Seo, MK | 1 |
| Cho, HY | 1 |
| Fang, ZH | 1 |
| Kim, YH | 4 |
| Katsel, P | 1 |
| Davis, KL | 14 |
| Bitsios, P | 1 |
| Giakoumaki, SG | 1 |
| Jogia, J | 1 |
| Rozsnyai, K | 1 |
| Collier, D | 1 |
| Frangou, S | 1 |
| Siever, LJ | 1 |
| Tsujino, N | 1 |
| Nemoto, T | 1 |
| Yamaguchi, T | 1 |
| Katagiri, N | 1 |
| Tohgi, N | 1 |
| Ikeda, R | 1 |
| Shiraga, N | 1 |
| Mizumura, S | 1 |
| Mizuno, M | 1 |
| Klemp, M | 1 |
| Tvete, IF | 1 |
| Skomedal, T | 1 |
| Gaasemyr, J | 1 |
| Natvig, B | 1 |
| Aursnes, I | 1 |
| Larrison, AL | 1 |
| Xing, Y | 1 |
| Brahm, NC | 1 |
| Washington, NB | 1 |
| Popović, I | 1 |
| Ravanić, D | 1 |
| Popović, V | 1 |
| Vladejić, S | 1 |
| Stanojević, A | 1 |
| Stojanović, M | 1 |
| Schmitt, GJ | 1 |
| Dresel, S | 2 |
| la Fougère, C | 1 |
| Boerner, R | 1 |
| Hahn, K | 2 |
| Meisenzahl, EM | 1 |
| Gau, SS | 2 |
| Meng, X | 1 |
| Hochfeld, M | 1 |
| Zedkova, I | 1 |
| Dudova, I | 1 |
| Urbanek, T | 1 |
| Hrdlicka, M | 1 |
| Kucharska-Pietura, K | 2 |
| Tylec, A | 2 |
| Czernikiewicz, A | 2 |
| Mortimer, A | 2 |
| Zhang, PY | 6 |
| Zhang, WF | 1 |
| Liang, J | 1 |
| Satake, S | 1 |
| Melo, LL | 1 |
| Barbosa Silva, R | 1 |
| Fang, M | 1 |
| Chen, H | 7 |
| Li, LH | 1 |
| Wu, R | 1 |
| Liu, L | 1 |
| Ye, M | 1 |
| Huang, J | 1 |
| Zhu, S | 1 |
| Zheng, H | 1 |
| Wang, B | 1 |
| Zhou, J | 1 |
| Zhao, JP | 1 |
| Vernon, AC | 1 |
| Natesan, S | 1 |
| Crum, WR | 1 |
| Cooper, JD | 1 |
| Modo, M | 1 |
| Williams, SC | 1 |
| Lai, EC | 1 |
| Chang, CH | 1 |
| Kao Yang, YH | 1 |
| Lin, SJ | 1 |
| Lin, CY | 1 |
| Mahmood, D | 1 |
| Khanam, R | 1 |
| Pillai, KK | 2 |
| Akhtar, M | 2 |
| Mihajlović, G | 1 |
| Jovanović-Mihajlović, N | 1 |
| Radmanović, B | 1 |
| Radonjić, K | 1 |
| Djukić-Dejanović, S | 1 |
| Janković, S | 1 |
| Milovanović, N | 1 |
| Petrović, D | 1 |
| Tomić, K | 1 |
| Kroken, RA | 1 |
| Johnsen, E | 1 |
| Wilmsdorff, MV | 1 |
| Blaich, C | 1 |
| Treutlein, J | 1 |
| Schulze, T | 1 |
| Melas, PA | 1 |
| Rogdaki, M | 1 |
| Ösby, U | 1 |
| Schalling, M | 1 |
| Lavebratt, C | 1 |
| Ekström, TJ | 1 |
| Schmidt-Hansen, M | 1 |
| Le Pelley, M | 1 |
| Suzuki, Y | 3 |
| Watanabe, J | 1 |
| Sugai, T | 1 |
| Fukui, N | 1 |
| Ono, S | 5 |
| Tsuneyama, N | 1 |
| Saito, M | 7 |
| Huang, WL | 1 |
| Chang, LR | 1 |
| Covell, NH | 2 |
| Schooler, NR | 10 |
| Jackson, CT | 1 |
| Rojas, IA | 1 |
| Essock, SM | 2 |
| Langlois, X | 1 |
| Megens, A | 1 |
| Lavreysen, H | 1 |
| Atack, J | 1 |
| Cik, M | 1 |
| te Riele, P | 1 |
| Peeters, L | 1 |
| Wouters, R | 1 |
| Vermeire, J | 1 |
| Hendrickx, H | 1 |
| Macdonald, G | 1 |
| De Bruyn, M | 1 |
| Jayakody, K | 1 |
| Gibson, RC | 1 |
| Kumar, A | 2 |
| Gunadasa, S | 1 |
| Smesny, S | 1 |
| Langbein, K | 1 |
| Rzanny, R | 1 |
| Gussew, A | 1 |
| Burmeister, HP | 1 |
| Reichenbach, JR | 1 |
| Reuter, N | 1 |
| Braun, I | 2 |
| Hartmann, A | 1 |
| Stauffer, V | 1 |
| Liu-Seifert, H | 1 |
| Chindo, BA | 1 |
| Adzu, B | 1 |
| Yahaya, TA | 1 |
| Gamaniel, KS | 1 |
| Hale, AS | 1 |
| Lemming, OM | 1 |
| Mæhlum, E | 1 |
| Lewitzka, U | 2 |
| Doucette, S | 1 |
| Moyer, CE | 1 |
| Delevich, KM | 1 |
| Fish, KN | 1 |
| Asafu-Adjei, JK | 1 |
| Sampson, AR | 6 |
| Dorph-Petersen, KA | 1 |
| Ozdemir, H | 1 |
| Ertugrul, A | 1 |
| Basar, K | 1 |
| Saka, E | 1 |
| Revel, FG | 1 |
| Moreau, JL | 2 |
| Pouzet, B | 1 |
| Mory, R | 1 |
| Bradaia, A | 1 |
| Buchy, D | 1 |
| Metzler, V | 1 |
| Chaboz, S | 1 |
| Groebke Zbinden, K | 1 |
| Galley, G | 1 |
| Norcross, RD | 1 |
| Tuerck, D | 1 |
| Bruns, A | 1 |
| Morairty, SR | 1 |
| Kilduff, TS | 1 |
| Wallace, TL | 1 |
| Risterucci, C | 1 |
| Wettstein, JG | 1 |
| Hoener, MC | 1 |
| Detke, HC | 1 |
| Zhao, F | 1 |
| Witte, MM | 1 |
| Galderisi, S | 6 |
| Mucci, A | 5 |
| Bucci, P | 4 |
| Wilkinson, J | 1 |
| Smalla, KH | 1 |
| Dürrschmidt, D | 1 |
| Kreutz, MR | 1 |
| Herold, R | 1 |
| Hannaway, KE | 1 |
| Adelekun, AE | 1 |
| Jayathilake, K | 2 |
| Morag, A | 1 |
| Oved, K | 1 |
| Gurwitz, D | 1 |
| Rizig, MA | 1 |
| McQuillin, A | 1 |
| Ng, A | 1 |
| Robinson, M | 1 |
| Harrison, A | 1 |
| Zvelebil, M | 1 |
| Hunt, SP | 1 |
| Gurling, HM | 1 |
| Balzarro, B | 2 |
| Andrisano, C | 1 |
| Teraishi, T | 1 |
| Ozeki, Y | 1 |
| Hori, H | 2 |
| Chiba, S | 1 |
| Yamamoto, N | 1 |
| Tanaka, H | 1 |
| Iijima, Y | 1 |
| Matsuo, J | 1 |
| Kawamoto, Y | 1 |
| Kinoshita, Y | 1 |
| Hattori, K | 1 |
| Ota, M | 1 |
| Kajiwara, M | 1 |
| Terada, S | 1 |
| Higuchi, T | 3 |
| Kunugi, H | 1 |
| Caputo, GB | 1 |
| Ferrucci, R | 1 |
| Bortolomasi, M | 1 |
| Giacopuzzi, M | 1 |
| Priori, A | 1 |
| Zago, S | 1 |
| Tordesillas-Gutiérrez, D | 1 |
| Gutiérrez, A | 1 |
| Krämer, P | 1 |
| Stassen, HH | 1 |
| Minutolo, G | 1 |
| Petralia, A | 1 |
| Dipasquale, S | 1 |
| Klingenberg, S | 1 |
| Bédard, AM | 1 |
| Maheux, J | 1 |
| Lévesque, D | 3 |
| Samaha, AN | 1 |
| Nandra, KS | 1 |
| Agius, M | 1 |
| Vanover, K | 1 |
| Weiner, DM | 1 |
| Peters, P | 1 |
| Hacksell, U | 1 |
| Gazdag, G | 1 |
| Tolna, J | 1 |
| McClure, RK | 1 |
| Styner, M | 1 |
| Maltbie, E | 1 |
| Gouttard, S | 1 |
| Gerig, G | 1 |
| Shi, X | 1 |
| Futsukaichi, K | 1 |
| Matsumoto, K | 1 |
| Fujita, K | 2 |
| Abe, R | 1 |
| Noguchi, T | 5 |
| Díaz, I | 1 |
| Sejil, I | 1 |
| Oumaya, A | 1 |
| Bouguerra, C | 1 |
| Mehdi, F | 1 |
| Bellaaj, R | 1 |
| Gallali, S | 1 |
| Radomska, KJ | 1 |
| Halvardson, J | 1 |
| Reinius, B | 1 |
| Lindholm Carlström, E | 1 |
| Emilsson, L | 1 |
| Feuk, L | 1 |
| Jazin, E | 1 |
| Madras, BK | 1 |
| Gonzalez, D | 1 |
| Bienroth, M | 1 |
| Curtis, V | 1 |
| Debenham, M | 1 |
| Jones, S | 1 |
| Pitsi, D | 1 |
| George, M | 1 |
| Shan, D | 1 |
| Lucas, EK | 1 |
| Crosby, D | 1 |
| Peterson, J | 1 |
| Carroll, BT | 1 |
| Volz, HP | 3 |
| Gerebtzoff, A | 1 |
| Bischoff, S | 1 |
| Puech, A | 3 |
| Toyooka, K | 3 |
| Asama, K | 1 |
| Muratake, T | 2 |
| Waraich, PS | 1 |
| Roque, M | 1 |
| Hamill, KM | 1 |
| Marti, J | 1 |
| Alfaro, CL | 1 |
| Wudarsky, M | 1 |
| Nicolson, R | 1 |
| Gochman, P | 1 |
| Sporn, A | 1 |
| Lenane, M | 1 |
| Rapoport, JL | 2 |
| Breese, GR | 1 |
| Knapp, DJ | 1 |
| Moy, SS | 1 |
| Yagi, G | 8 |
| Miura, S | 4 |
| Cohen, CI | 1 |
| Schoos, R | 1 |
| Yasui-Furukori, N | 15 |
| Suzuki, A | 25 |
| De Vries, R | 1 |
| Kaneko, S | 31 |
| Carson, WH | 6 |
| Saha, AR | 1 |
| Ingenito, GG | 1 |
| Zimbroff, DL | 4 |
| Ali, MW | 1 |
| Addy, N | 1 |
| Levin, ED | 4 |
| Nelson, L | 1 |
| Kamaraju, L | 1 |
| Wilson, W | 2 |
| Ohye, C | 1 |
| Shibazaki, T | 1 |
| Brockmöller, J | 1 |
| Kirchheiner, J | 1 |
| Schmider, J | 1 |
| Walter, S | 1 |
| Sachse, C | 1 |
| Müller-Oerlinghausen, B | 4 |
| Roots, I | 1 |
| Goto, Y | 2 |
| O'Donnell, P | 1 |
| Oranje, B | 1 |
| Gispen-de Wied, CC | 1 |
| Verbaten, MN | 1 |
| Mamo, DC | 2 |
| Chengappa, KN | 2 |
| Reddy, RR | 1 |
| Jeste, DV | 2 |
| Roberts, MC | 1 |
| Turner, J | 2 |
| Keyter, L | 1 |
| Keyter, N | 4 |
| Torreman, M | 1 |
| Hermida, T | 1 |
| Franco, K | 1 |
| Hadi, F | 1 |
| Douyon, K | 1 |
| Baymiller, SP | 1 |
| Ball, P | 2 |
| McMahon, RP | 4 |
| Buchanan, RW | 13 |
| Su, KP | 1 |
| Shen, WW | 1 |
| Chuang, CL | 1 |
| Chen, KP | 1 |
| Artiola i Fortuny, L | 1 |
| Vester-Blockland, E | 1 |
| De Smedt, G | 2 |
| Makifuchi, T | 1 |
| Shirakawa, O | 2 |
| Kitamura, N | 2 |
| Maeda, K | 4 |
| Nakamura, R | 1 |
| Watanabe, M | 1 |
| Hennessy, S | 1 |
| Knauss, JS | 1 |
| Margolis, DJ | 1 |
| Kimmel, SE | 1 |
| Reynolds, RF | 1 |
| Glasser, DB | 1 |
| Morrison, MF | 1 |
| Strom, BL | 1 |
| Bilici, M | 1 |
| Cakirbay, H | 1 |
| Guler, M | 1 |
| Tosun, M | 1 |
| Ulgen, M | 1 |
| Tan, U | 1 |
| van Amelsvoort, T | 1 |
| Barak, Y | 3 |
| Shamir, E | 1 |
| Zemishlani, H | 1 |
| Mirecki, I | 1 |
| Toren, P | 1 |
| Weizman, R | 4 |
| Müller, MJ | 2 |
| Wetzel, H | 1 |
| Eich, FX | 1 |
| Rein, W | 6 |
| Benkert, O | 1 |
| Tilden, D | 1 |
| Aristides, M | 1 |
| Meddis, D | 1 |
| Mojtahedzadeh, V | 1 |
| Mirsepassi, GR | 1 |
| Moin, M | 1 |
| Amini-Nooshabadi, H | 3 |
| Kamalipour, A | 3 |
| Alvarez, E | 2 |
| Bobes, J | 3 |
| Gómez, JC | 7 |
| Sacristán, JA | 4 |
| Cañas, F | 3 |
| Carrasco, JL | 2 |
| Gascón, J | 2 |
| Gibert, J | 2 |
| Gutiérrez, M | 2 |
| Sassa, T | 1 |
| Ikehira, H | 1 |
| Obata, T | 1 |
| Girard, F | 1 |
| Tanada, S | 1 |
| Beasley, CM | 17 |
| Tanaka, Y | 1 |
| Walker, DJ | 2 |
| De Vanna, M | 1 |
| Onor, ML | 1 |
| Ferrara, D | 1 |
| Wilson, WH | 6 |
| Rose, JE | 3 |
| Gilani, S | 1 |
| Tancer, M | 1 |
| DeQuardo, J | 1 |
| Atmaca, M | 1 |
| Kuloglu, M | 1 |
| Tezcan, E | 1 |
| Gecici, O | 1 |
| Ustundag, B | 1 |
| Lindenmayer, JP | 13 |
| Sheitman, B | 10 |
| Cooper, TB | 24 |
| Chakos, M | 5 |
| van Bruggen, M | 1 |
| Lavalaye, J | 1 |
| Booij, J | 1 |
| Dingemans, PM | 1 |
| Linszen, D | 1 |
| Rudolf, S | 1 |
| Peters, M | 1 |
| Rothermundt, M | 1 |
| Arolt, V | 1 |
| Kirchner, H | 1 |
| Gaisler-Salomon, I | 1 |
| Kowalski, J | 2 |
| Blada, P | 2 |
| Kucia, K | 2 |
| Lawniczek, T | 1 |
| Madej, A | 2 |
| Belowski, D | 1 |
| Herman, ZS | 2 |
| Meibach, RC | 4 |
| Osser, DN | 1 |
| Akhter, A | 1 |
| Messori, A | 1 |
| Gupta, S | 1 |
| Koh, PO | 1 |
| Bergson, C | 1 |
| Undie, AS | 2 |
| Goldman-Rakic, PS | 2 |
| Lidow, MS | 3 |
| Spivak, M | 1 |
| Adams, B | 1 |
| Crockford, D | 1 |
| Ninan, I | 1 |
| Jardemark, KE | 1 |
| Wang, RY | 1 |
| Gilmore, JA | 4 |
| Halbreich, UM | 1 |
| Vernaleken, I | 1 |
| Davids, E | 1 |
| Heydari, N | 1 |
| Buchholz, HG | 1 |
| Bartenstein, P | 1 |
| Munk, OL | 1 |
| Stoeter, P | 1 |
| Wong, DF | 5 |
| Gjedde, A | 5 |
| Cumming, P | 1 |
| Furukori, H | 14 |
| Otani, K | 24 |
| Opolka, JL | 3 |
| Rascati, KL | 3 |
| Brown, CM | 3 |
| Gibson, PJ | 4 |
| Desco, M | 2 |
| Gispert, JD | 2 |
| Reig, S | 2 |
| Sanz, J | 3 |
| Pascau, J | 2 |
| Sarramea, F | 1 |
| Benito, C | 1 |
| Santos, A | 2 |
| Palomo, T | 3 |
| Montgomery, JH | 1 |
| Tekell, JL | 2 |
| Gothelf, D | 2 |
| Apter, A | 2 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 6 |
| Ratzoni, G | 1 |
| Stock, E | 3 |
| Kaplita, S | 1 |
| Marcus, R | 3 |
| Safferman, AZ | 1 |
| Saha, A | 2 |
| Ali, M | 2 |
| Iwamoto, T | 2 |
| Bromet, EJ | 1 |
| Davidson, M | 23 |
| Samanta, MK | 1 |
| Dube, R | 1 |
| Suresh, B | 1 |
| Fumagalli, F | 1 |
| Molteni, R | 1 |
| Roceri, M | 1 |
| Bedogni, F | 1 |
| Santero, R | 1 |
| Fossati, C | 1 |
| Gennarelli, M | 1 |
| Racagni, G | 1 |
| Riva, MA | 1 |
| Goldstein, JM | 4 |
| Greenwood, M | 1 |
| John, V | 1 |
| Schulz, SC | 3 |
| Thomson, R | 1 |
| Brecher, M | 1 |
| Rejas, J | 2 |
| Garcia-Garcia, M | 1 |
| Rico-Villademoros, F | 1 |
| García-Portilla, MP | 1 |
| Fernández, I | 1 |
| Hernández, G | 1 |
| Wynchank, D | 1 |
| Chen, N | 2 |
| Battaglia, J | 3 |
| Lindborg, SR | 5 |
| Alaka, K | 3 |
| Meehan, K | 6 |
| Wright, P | 5 |
| Kelley, M | 1 |
| Yao, J | 8 |
| Tsai, G | 1 |
| Reeves, D | 1 |
| Mills, MJ | 2 |
| Billick, SB | 1 |
| Brodie, JD | 8 |
| Barner, JC | 1 |
| Johnsrud, MT | 1 |
| Woods, SW | 2 |
| Kagerer, S | 2 |
| Winter, C | 3 |
| Soyka, M | 3 |
| Purdon, SE | 6 |
| Woodward, N | 1 |
| Stip, E | 6 |
| Conley, RR | 6 |
| Kelly, DL | 6 |
| Love, RC | 2 |
| Linn, GS | 1 |
| Negi, SS | 1 |
| Gerum, SV | 1 |
| Javitt, DC | 1 |
| Taylor, CC | 8 |
| Zuckerman, L | 2 |
| Nachman, R | 1 |
| Birkett, M | 4 |
| Morris, P | 1 |
| Hashimoto, T | 3 |
| Pierri, JN | 7 |
| Sun, Z | 3 |
| Jones, AM | 3 |
| Greenwood, MR | 1 |
| Morishita, S | 1 |
| Lerman, DN | 1 |
| Khaing, ZZ | 2 |
| Weickert, CS | 2 |
| Weinberger, DR | 14 |
| Ganguly, R | 1 |
| Miller, LS | 2 |
| Martin, BC | 1 |
| Tollefson, G | 6 |
| Gur, RE | 5 |
| Kahn, R | 2 |
| Perkins, D | 3 |
| Sharma, T | 7 |
| Zipursky, R | 8 |
| Wei, H | 2 |
| Glynn, SM | 3 |
| Wirshing, WC | 11 |
| Wirshing, DA | 8 |
| Ross, D | 3 |
| Widmark, C | 3 |
| Mintz, J | 18 |
| Liberman, RP | 6 |
| Blair, KE | 1 |
| McMahon, R | 1 |
| Carpenter, WT | 10 |
| Rosenheck, R | 13 |
| Doyle, J | 1 |
| Leslie, D | 2 |
| Fontana, A | 2 |
| Gefvert, O | 1 |
| Lindström, LH | 3 |
| Waters, N | 1 |
| Waters, S | 1 |
| Carlsson, A | 4 |
| Tedroff, J | 1 |
| Cavallaro, R | 5 |
| Cavedini, P | 1 |
| Mistretta, P | 1 |
| Bassi, T | 1 |
| Angelone, SM | 1 |
| Ubbiali, A | 1 |
| Bellodi, L | 3 |
| Carlson, CD | 1 |
| Cavazzoni, PA | 2 |
| Berg, PH | 4 |
| Higuchi, H | 2 |
| Kamata, M | 1 |
| Naitoh, S | 1 |
| Yoshida, K | 1 |
| Shimizu, T | 3 |
| Sugita, T | 1 |
| Spivak, B | 5 |
| Shabash, E | 1 |
| Mester, R | 2 |
| Torner, C | 1 |
| Herrera-Estrella, M | 1 |
| Gutiérrez, JA | 1 |
| Aguilar-Roblero, R | 1 |
| Laws, SM | 1 |
| Hone, E | 1 |
| Taddei, K | 1 |
| Thomas, EA | 1 |
| Harper, C | 1 |
| McClean, C | 1 |
| Masters, C | 1 |
| Lautenschlager, N | 1 |
| Gandy, SE | 1 |
| Martins, RN | 1 |
| ENOCH, MD | 1 |
| ROBIN, AA | 1 |
| LINDQVIST, R | 1 |
| BUFFARDI, R | 1 |
| GARRY, JW | 1 |
| LEONARD, TJ | 1 |
| PAQUAY, J | 2 |
| ARNOULD, F | 1 |
| BURTON, P | 1 |
| TINANT, M | 1 |
| GOLDWURM, GF | 1 |
| MAZZA, M | 1 |
| GONZALO GONZALEZ, M | 1 |
| PACHECO, A | 1 |
| HOLLISTER, LE | 7 |
| OVERALL, JE | 1 |
| CAFFEY, E | 1 |
| BENNETT, JL | 1 |
| MEYER, F | 1 |
| KIMBELL, I | 1 |
| HONIGFELD, G | 2 |
| AVRUTSKII, GIa | 2 |
| COURT, JH | 1 |
| CAMERON, IA | 1 |
| MOTZENBECKER, FP | 1 |
| BOBON, J | 1 |
| COLLARD, J | 1 |
| DELREE, C | 1 |
| GERNAY, JM | 1 |
| LEHMANN, HE | 4 |
| BAN, TA | 9 |
| KATO, G | 1 |
| GOZSY, B | 1 |
| KATO, L | 1 |
| GERLE, B | 3 |
| ALEKSANDROVSKII, IuA | 2 |
| BUIS, C | 1 |
| FLOHIL, JM | 1 |
| NEUMANN, H | 2 |
| KURLAND, AA | 3 |
| FERRO-DIAZ, P | 1 |
| MCCUSKER, K | 1 |
| VOLMAT, R | 1 |
| BEAUDOUIN, JL | 1 |
| COLLIN, J | 1 |
| NICOLAS-CHARLES, PJ | 1 |
| ALLERS, G | 1 |
| SCHWARZ, H | 3 |
| KRUEGER, HJ | 1 |
| JUENEMANN, HJ | 1 |
| LURIA, E | 1 |
| RIZZUTO, N | 1 |
| LUNA, NE | 1 |
| FOX, W | 1 |
| GOBBLE, IF | 1 |
| CLOS, M | 1 |
| DENISON, E | 1 |
| PRATT, JP | 2 |
| BISHOP, MP | 2 |
| GALLANT, DM | 5 |
| Faurbye, A | 1 |
| Clausen, J | 1 |
| KAMENSKAIA, VM | 1 |
| WEIDTMANN, W | 1 |
| BORGHESI, R | 1 |
| BISTER, W | 1 |
| CIANI, N | 2 |
| DONINI, G | 1 |
| CIBELLI, S | 1 |
| SABBATINI, F | 1 |
| Nejatisafa, AA | 1 |
| Amini, H | 2 |
| Mohammadi, MR | 2 |
| Larijani, B | 1 |
| Kashani, L | 1 |
| Raisi, F | 1 |
| Duncan, E | 3 |
| Szilagyi, S | 1 |
| Schwartz, M | 1 |
| Kunzova, A | 1 |
| Negi, S | 1 |
| Efferen, T | 1 |
| Peselow, E | 2 |
| Chakravorty, S | 1 |
| Stephanides, M | 1 |
| Harmon, J | 1 |
| Bugarski-Kirola, D | 1 |
| Gonzenbach, S | 1 |
| Rotrosen, J | 8 |
| Williams, LM | 1 |
| Loughland, CM | 1 |
| Green, MJ | 1 |
| Harris, AW | 1 |
| Gordon, E | 1 |
| Brunnauer, A | 1 |
| Geiger, E | 1 |
| Dalal, MA | 1 |
| Schuld, A | 2 |
| Pollmächer, T | 3 |
| Shim, JC | 4 |
| Yoon, YR | 2 |
| Park, JH | 2 |
| Shin, JG | 3 |
| Medoff, DR | 4 |
| Frey, KN | 1 |
| Hardin, M | 1 |
| Sernyak, MJ | 2 |
| Sielk, M | 1 |
| Rummel, C | 1 |
| Hamann, J | 2 |
| Summerfelt, A | 2 |
| Apiquian, R | 2 |
| Fresán, A | 2 |
| Herrera, K | 1 |
| Ulloa, RE | 2 |
| Lóyzaga, C | 1 |
| de la Fuente-Sandoval, C | 2 |
| Gutiérrez, D | 1 |
| Lerman, MN | 1 |
| Archibald, D | 1 |
| Ingenito, G | 1 |
| Pigott, T | 1 |
| Kennedy, JS | 1 |
| Jeste, D | 1 |
| Kaiser, CJ | 2 |
| Golshan, S | 1 |
| Maguire, GA | 1 |
| Sanger, T | 3 |
| Bymaster, FP | 1 |
| Yao, JK | 21 |
| Sistilli, CG | 1 |
| Oosthuizen, PP | 4 |
| Maritz, JS | 1 |
| Turner, JA | 1 |
| Müller, JL | 4 |
| Deuticke, C | 1 |
| Putzhammer, A | 4 |
| Hajak, G | 2 |
| Winkler, J | 1 |
| Sungur, MZ | 1 |
| Guner, P | 1 |
| Ustun, B | 1 |
| Cetin, I | 1 |
| Soygur, H | 1 |
| Perlick, D | 2 |
| Bingham, S | 2 |
| Liu-Mares, W | 1 |
| Collins, J | 2 |
| Warren, S | 1 |
| Allan, E | 2 |
| Campbell, EC | 2 |
| Caroff, S | 1 |
| Corwin, J | 1 |
| Davis, L | 1 |
| Douyon, R | 5 |
| Dunn, L | 2 |
| Evans, D | 2 |
| Frecska, E | 5 |
| Grabowski, J | 2 |
| Graeber, D | 1 |
| Herz, L | 3 |
| Kwon, K | 1 |
| Lawson, W | 2 |
| Mena, F | 1 |
| Sheikh, J | 1 |
| Smelson, D | 1 |
| Smith-Gamble, V | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Puri, BK | 1 |
| Davey, NJ | 1 |
| Zaman, R | 1 |
| Jarskog, LF | 2 |
| Selinger, ES | 1 |
| Gilmore, JH | 1 |
| May, B | 2 |
| Müller, B | 2 |
| Braus, DF | 4 |
| Henn, FA | 4 |
| Jones, B | 9 |
| Ferchland-Howe, I | 1 |
| Pickard, A | 1 |
| Roth, J | 1 |
| Chouinard, G | 14 |
| Morris, PL | 1 |
| Sugar, CA | 1 |
| James, GM | 1 |
| Lenert, LA | 1 |
| Emamian, ES | 1 |
| Hall, D | 1 |
| Birnbaum, MJ | 1 |
| Karayiorgou, M | 1 |
| Gogos, JA | 1 |
| Yen, YC | 1 |
| Lung, FW | 5 |
| Chong, MY | 1 |
| Feifel, D | 2 |
| Melendez, G | 2 |
| Shilling, PD | 2 |
| Abe, K | 1 |
| Paquet, F | 1 |
| Soucy, JP | 2 |
| Lévesque, M | 1 |
| Elie, A | 1 |
| Bédard, MA | 2 |
| Glazer, WM | 7 |
| Amin, M | 1 |
| Shukla, VS | 1 |
| Kunz, M | 3 |
| van Beveren, N | 2 |
| Jadri Turner, H | 1 |
| Heydebrand, G | 1 |
| Weiser, M | 1 |
| Hoff, AL | 2 |
| DeLisi, LE | 2 |
| Good, KP | 1 |
| Whitehorn, D | 1 |
| DeSmedt, G | 1 |
| Kopala, LC | 3 |
| Marques, AP | 1 |
| Bassitt, D | 1 |
| Diegoli, M | 1 |
| Tohen, MF | 2 |
| Strakowski, SM | 2 |
| Glick, I | 2 |
| Clark, WS | 1 |
| Demirakca, T | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Mutoh, S | 2 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Kennedy, JL | 2 |
| Ni, X | 1 |
| Nolan, K | 2 |
| Gaszner, G | 1 |
| Kosza, P | 1 |
| Henkel, V | 1 |
| Mergl, R | 1 |
| Hegerl, U | 2 |
| Ahl, J | 2 |
| Rotelli, MD | 1 |
| McMullen, E | 1 |
| Kudoh, A | 2 |
| Katagai, H | 1 |
| Takase, H | 1 |
| Takazawa, T | 1 |
| van den Buuse, M | 1 |
| Morris, M | 2 |
| Chavez, C | 1 |
| Martin, S | 1 |
| Molloy, MS | 1 |
| Turner, HJ | 3 |
| Schronen, J | 2 |
| Botha, K | 2 |
| Smit, R | 2 |
| Shimoda, K | 7 |
| Tateishi, T | 2 |
| Arvanitis, L | 1 |
| Christensen, BK | 4 |
| Sitskoorn, MM | 1 |
| Lewine, RR | 2 |
| Yurgelun-Todd, DA | 1 |
| Gur, RC | 1 |
| Sanger, TM | 6 |
| Turner, M | 1 |
| Eerdekens, E | 1 |
| Jacko, M | 1 |
| Eerdekens, M | 4 |
| Chagnon, YC | 1 |
| Mérette, C | 1 |
| Bouchard, RH | 1 |
| Emond, C | 1 |
| Roy, MA | 1 |
| Maziade, M | 1 |
| Lieberman, J | 3 |
| Gu, H | 3 |
| Green, A | 2 |
| Strakowski, S | 1 |
| Gur, R | 1 |
| Matsumoto, C | 1 |
| Shinkai, T | 1 |
| Ohmori, O | 1 |
| Nakamura, J | 1 |
| Wong, D | 1 |
| David, A | 3 |
| Quraishi, SN | 1 |
| Levy, DE | 1 |
| O'Malley, AJ | 2 |
| Normand, SL | 2 |
| Nilsson, M | 1 |
| Markinhuhta, KR | 1 |
| Sonesson, C | 1 |
| Pettersson, F | 1 |
| Gullme, M | 1 |
| Carlsson, ML | 1 |
| Grigor'eva, EA | 1 |
| Ritskov, AS | 1 |
| Muñoz, F | 1 |
| Hinojosa, JA | 1 |
| Iglesias, A | 1 |
| Matsumoto, M | 1 |
| Konno, T | 1 |
| Tamba, K | 1 |
| Abe, T | 1 |
| Kato, S | 1 |
| Kajii, E | 1 |
| Kurland, BF | 1 |
| Heagerty, PJ | 1 |
| Santos-Jesus, R | 1 |
| Miranda-Scippa, A | 1 |
| Quarantini, Lde C | 1 |
| Oliveira, IR | 1 |
| Harvey, AT | 1 |
| Flockhart, D | 1 |
| Gorski, JC | 1 |
| Greenblatt, DJ | 1 |
| Burke, M | 1 |
| Werder, S | 1 |
| Preskorn, SH | 1 |
| Higashima, M | 1 |
| Takeda, T | 1 |
| Nagasawa, T | 1 |
| Hirao, N | 1 |
| Oka, T | 1 |
| Kitamura, M | 1 |
| Koshino, Y | 1 |
| Bai, J | 1 |
| He, F | 1 |
| Novikova, SI | 1 |
| Dracheva, S | 2 |
| Williams, JB | 1 |
| Mallorga, PJ | 1 |
| Conn, PJ | 1 |
| Pettibone, DJ | 1 |
| Sur, C | 1 |
| Fear, C | 1 |
| Tebartz van Elst, L | 1 |
| Bäumer, D | 1 |
| Ebert, D | 1 |
| Trimble, MR | 1 |
| Zipursky, RB | 8 |
| Mikulis, DJ | 1 |
| Brunnauer, M | 1 |
| Wedlund, P | 1 |
| Josiassen, RC | 4 |
| Simpson, GM | 10 |
| Mackin, P | 1 |
| Young, AH | 1 |
| Pogarell, O | 1 |
| Mulert, C | 1 |
| Amann, B | 1 |
| Nadeem, Z | 2 |
| McIntosh, A | 3 |
| Perfahl, M | 2 |
| Pfeiff, L | 2 |
| Broll, K | 1 |
| Hess, L | 1 |
| Ibach, B | 2 |
| Lambert, M | 1 |
| Pongrac, JL | 1 |
| Middleton, FA | 3 |
| Peng, L | 1 |
| Levitt, P | 3 |
| Ball, MP | 1 |
| Weiner, E | 1 |
| Kirkpatrick, B | 6 |
| Gold, JM | 3 |
| Bergen, SE | 2 |
| Nguyen, QL | 1 |
| Xu, B | 1 |
| Monteggia, LM | 1 |
| Ascher-Svanum, H | 5 |
| Stensland, M | 1 |
| Zhao, Z | 1 |
| Walden, J | 2 |
| Benattia, I | 1 |
| Romano, SJ | 1 |
| Reilly, JL | 2 |
| Harris, MS | 2 |
| Keshavan, MS | 7 |
| Sweeney, JA | 4 |
| Safarcherati, A | 1 |
| Gabriele, JP | 1 |
| Chong, VZ | 1 |
| Pontoriero, GF | 1 |
| Bergemann, N | 1 |
| Mundt, C | 1 |
| Parzer, P | 1 |
| Pakrasi, M | 1 |
| Eckstein-Mannsperger, U | 1 |
| Haisch, S | 1 |
| Salbach, B | 1 |
| Klinga, K | 1 |
| Runnebaum, B | 1 |
| Resch, F | 2 |
| Sawada, K | 1 |
| Arima, K | 1 |
| Young, CE | 1 |
| Phillips, AG | 1 |
| Tenn, CC | 1 |
| Kato, R | 1 |
| Sato, J | 1 |
| Sirota, P | 2 |
| Meiman, M | 1 |
| Herschko, R | 1 |
| Bessler, H | 1 |
| Cosi, C | 1 |
| Waget, A | 1 |
| Rollet, K | 1 |
| Tesori, V | 1 |
| Newman-Tancredi, A | 1 |
| Schooler, N | 3 |
| Kopala, L | 1 |
| McGorry, PD | 3 |
| Van Hove, I | 1 |
| Swyzen, W | 2 |
| Schiller, D | 1 |
| Christodoulou, C | 1 |
| Kalaitzi, C | 1 |
| Wong, AH | 1 |
| Likhodi, O | 1 |
| Boffa, E | 1 |
| Van Tol, HH | 1 |
| Majumdar, S | 1 |
| Trief, DF | 1 |
| Lerman, C | 1 |
| Kanes, SJ | 2 |
| Zhang, M | 1 |
| Ballard, ME | 1 |
| Pan, L | 2 |
| Roberts, S | 1 |
| Faghih, R | 1 |
| Cowart, M | 1 |
| Esbenshade, TA | 1 |
| Fox, GB | 1 |
| Decker, MW | 1 |
| Hancock, AA | 1 |
| Rueter, LE | 1 |
| Sayers, SL | 1 |
| Kondrich, J | 1 |
| Mann, SC | 1 |
| Cornish, J | 1 |
| O'Brien, C | 1 |
| Caroff, SN | 1 |
| Taskapan, C | 1 |
| Sahin, I | 1 |
| Taskapan, H | 1 |
| Kaya, B | 1 |
| Kosar, F | 1 |
| Kline, L | 1 |
| Kaye, NS | 1 |
| Ciudad, A | 1 |
| Koga, M | 1 |
| Nakayama, K | 1 |
| Vieweg, WV | 1 |
| Bertsch, T | 1 |
| Henning, U | 1 |
| Tost, H | 1 |
| Lenders, MW | 1 |
| Buschman, HP | 1 |
| Vergouwen, MD | 1 |
| Steur, EN | 1 |
| Kölling, P | 1 |
| Hariz, M | 1 |
| Johann, M | 1 |
| Zitzelsberger, U | 1 |
| Matsui-Sakata, A | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Garver, DL | 13 |
| Holcomb, JA | 1 |
| Christensen, JD | 2 |
| Bersani, G | 3 |
| Gherardelli, S | 1 |
| Clemente, R | 1 |
| Di Giannantonio, M | 1 |
| Grilli, A | 1 |
| Conti, CM | 1 |
| Exton, MS | 1 |
| Conti, P | 1 |
| Doyle, R | 1 |
| Pancheri, P | 1 |
| Fernø, J | 1 |
| Raeder, MB | 1 |
| Vik-Mo, AO | 1 |
| Skrede, S | 1 |
| Glambek, M | 1 |
| Tronstad, KJ | 1 |
| Breilid, H | 1 |
| Løvlie, R | 1 |
| Berge, RK | 1 |
| Stansberg, C | 1 |
| Steen, VM | 1 |
| Park, S | 1 |
| Ross-Degnan, D | 1 |
| Adams, AS | 1 |
| Sabin, J | 1 |
| Kanavos, P | 1 |
| Soumerai, SB | 1 |
| Arango-Dávila, C | 1 |
| Silva Ibarra, H | 1 |
| Landa, E | 1 |
| Aguilar, J | 1 |
| Caro, O | 1 |
| Leadbetter, J | 1 |
| Assunção, S | 1 |
| Kessler, RM | 2 |
| Ansari, MS | 1 |
| Riccardi, P | 1 |
| Li, R | 1 |
| Dawant, B | 1 |
| Daskalakis, Z | 1 |
| Epstein, I | 1 |
| Roy, P | 3 |
| Furimsky, I | 1 |
| Machida, N | 1 |
| Shiotsuka, S | 1 |
| Semba, J | 1 |
| Rémillard, S | 2 |
| Pourcher, E | 2 |
| Cohen, H | 3 |
| Mendhekar, DN | 2 |
| Jiloha, RC | 1 |
| Larmo, I | 1 |
| de Nayer, A | 1 |
| Windhager, E | 1 |
| Lindenbauer, B | 1 |
| Rittmannsberger, H | 1 |
| Platz, T | 1 |
| Altman, C | 1 |
| Swartz, M | 1 |
| Plopsky, I | 1 |
| Perquin, LN | 1 |
| Himei, A | 1 |
| Okamura, T | 1 |
| Young, CA | 1 |
| Rock, SL | 1 |
| Basu, A | 1 |
| Dukic, V | 1 |
| Stensland, MD | 1 |
| Jung, DU | 2 |
| Seo, YS | 2 |
| Jeong, CY | 1 |
| Keist, R | 1 |
| von Boehmer, L | 1 |
| Studer, R | 1 |
| Benke, D | 1 |
| Hagenbuch, N | 1 |
| Dong, Y | 1 |
| Malenka, RC | 1 |
| Fritschy, JM | 1 |
| Bluethmann, H | 1 |
| Möhler, H | 1 |
| Rudolph, U | 1 |
| Lauriat, TL | 1 |
| Chin, B | 1 |
| Schmeidler, J | 2 |
| McInnes, LA | 1 |
| Khanna, S | 1 |
| Rajadhyaksha, S | 1 |
| Giller, E | 1 |
| Kragh, J | 1 |
| Houston, JP | 1 |
| Meyers, AL | 1 |
| Loga-Zec, S | 1 |
| Zulić, I | 1 |
| Mulabegović, N | 1 |
| Loga, S | 1 |
| Fiseković, S | 1 |
| Kusturica, J | 1 |
| Nakagami, T | 1 |
| Kaneda, A | 1 |
| Smelson, DA | 1 |
| Ziedonis, D | 1 |
| Williams, J | 2 |
| Losonczy, MF | 6 |
| Steinberg, ML | 1 |
| Kaune, M | 1 |
| Heeg, B | 2 |
| van Hout, BA | 2 |
| Mehnert, A | 2 |
| Smet, A | 1 |
| Caleo, S | 1 |
| Miadi-Fargier, H | 1 |
| Mosqueda, GJ | 1 |
| Lecompte, D | 1 |
| Chue, PS | 1 |
| Buskens, E | 1 |
| Kostic, D | 1 |
| Hardy, S | 1 |
| Kryzhanovskaya, LA | 1 |
| Briggs, SD | 1 |
| Roddy, TE | 1 |
| Salvador, M | 1 |
| Silva Belmonte-de-Abreu, P | 1 |
| Paterson, GJ | 1 |
| Ohashi, Y | 1 |
| Reynolds, GP | 3 |
| Pratt, JA | 1 |
| Morris, BJ | 1 |
| Huerta, I | 1 |
| Giménez-Amaya, JM | 1 |
| Charra, B | 1 |
| Nejmi, H | 1 |
| Hachimi, A | 1 |
| Benslama, A | 1 |
| Motaouakkil, S | 1 |
| Artaloytia, JF | 1 |
| Lahti, A | 1 |
| Pascual, A | 1 |
| Cubero, P | 1 |
| Prieto, D | 1 |
| Johnson, JL | 1 |
| Centorrhino, F | 1 |
| Glick, IB | 1 |
| Dyachkova, Y | 1 |
| Pirildar, S | 1 |
| Khalil, A | 1 |
| Araszkiewicz, A | 1 |
| Shakhnovich, T | 1 |
| Akram, A | 1 |
| McBride, M | 1 |
| Kongsakon, R | 2 |
| Leelahanaj, T | 1 |
| Price, N | 1 |
| Birinyi-Strachan, L | 1 |
| Davey, P | 1 |
| Pillai, A | 1 |
| Parikh, V | 1 |
| Terry, AV | 1 |
| Mahadik, SP | 2 |
| Adetunji, B | 1 |
| Basil, B | 1 |
| Mathews, M | 1 |
| Williams, A | 1 |
| Osinowo, T | 1 |
| Mandel, FS | 1 |
| Saeedi, H | 1 |
| Remington, G | 13 |
| Kesby, JP | 1 |
| Burne, TH | 1 |
| McGrath, JJ | 3 |
| Eyles, DW | 5 |
| Ko, F | 1 |
| Tallerico, T | 1 |
| Stone, JM | 1 |
| Arstad, E | 1 |
| Erlandsson, K | 1 |
| Waterhouse, RN | 1 |
| Ell, PJ | 2 |
| Pilowsky, LS | 2 |
| Kelly, MP | 1 |
| Abel, T | 1 |
| Bark, N | 2 |
| Pardo-García, G | 1 |
| Guha, P | 1 |
| Roy, K | 1 |
| Sanyal, D | 1 |
| Dasgupta, T | 1 |
| Bhattacharya, K | 1 |
| Gorobets, LN | 1 |
| Hugenholtz, GW | 1 |
| Heerdink, ER | 1 |
| Stolker, JJ | 1 |
| Meijer, WE | 1 |
| Egberts, AC | 1 |
| Nolen, WA | 1 |
| Uma Devi, P | 1 |
| Ali, A | 1 |
| Vohora, D | 1 |
| Yamauchi, K | 1 |
| Ohmori, T | 1 |
| Duggal, HS | 1 |
| Shkedy, Z | 1 |
| Schreiner, A | 1 |
| Memis, D | 1 |
| Bayrak, F | 1 |
| Tokatlioglu, D | 1 |
| Gorman, JM | 5 |
| Bäuml, J | 4 |
| Carrasco-Marín, E | 2 |
| Arranz, MJ | 1 |
| Leyva-Cobían, F | 1 |
| Ellenbroek, BA | 3 |
| Zhang, XX | 1 |
| Jin, GZ | 1 |
| Andrezina, R | 2 |
| Oren, DA | 2 |
| Manos, G | 4 |
| Kishikawa, N | 1 |
| Hamachi, C | 1 |
| Imamura, Y | 1 |
| Ohba, Y | 1 |
| Nakashima, K | 1 |
| Tagawa, Y | 1 |
| Kuroda, N | 1 |
| Zhang, ZJ | 1 |
| Kang, WH | 1 |
| Li, Q | 1 |
| Wang, XY | 1 |
| Yao, SM | 1 |
| Ma, AQ | 1 |
| Aziz, MA | 1 |
| Pepler, A | 1 |
| McNeely, C | 1 |
| Schmidt, P | 1 |
| Clouth, J | 1 |
| Haggenmüller, L | 1 |
| Reitberger, U | 1 |
| Dziewas, R | 1 |
| Warnecke, T | 1 |
| Schnabel, M | 1 |
| Ritter, M | 1 |
| Nabavi, DG | 1 |
| Schilling, M | 1 |
| Ringelstein, EB | 1 |
| Reker, T | 1 |
| Trinidad-Oñate, P | 1 |
| Chaudhry, HR | 1 |
| Raza, SB | 1 |
| Leynes, CR | 1 |
| Khan, IU | 1 |
| Ismail, HC | 1 |
| Chan, B | 1 |
| Ignacio, JC | 1 |
| Rodriguez, SC | 1 |
| Brnabic, AJ | 1 |
| Buenaventura, R | 1 |
| Joy, CB | 2 |
| Lawrie, SM | 2 |
| Woodward, ND | 2 |
| Zald, DH | 1 |
| McCue, RE | 1 |
| Waheed, R | 1 |
| Urcuyo, L | 1 |
| Orendain, G | 1 |
| Joseph, MD | 1 |
| Charles, R | 1 |
| Hasan, SM | 1 |
| Walloch, JE | 1 |
| Klauwer, C | 1 |
| Lanczik, M | 1 |
| Brockington, IF | 1 |
| Llorca, J | 1 |
| Luis Vázquez-Barquero, J | 1 |
| Reimold, M | 1 |
| Solbach, C | 1 |
| Noda, S | 1 |
| Schaefer, JE | 1 |
| Bartels, M | 3 |
| Beneke, M | 2 |
| Machulla, HJ | 1 |
| Bares, R | 1 |
| Glaser, T | 1 |
| Wormstall, H | 1 |
| Marcsisin, MJ | 1 |
| O'Connor, JA | 1 |
| Muly, EC | 1 |
| Arnold, SE | 1 |
| Hemby, SE | 1 |
| Almond, S | 2 |
| O'Donnell, O | 2 |
| Kidd, M | 1 |
| Skilbeck, KJ | 2 |
| O'Reilly, JN | 2 |
| Johnston, GA | 2 |
| Hinton, T | 2 |
| Fejgin, K | 1 |
| Safonov, S | 1 |
| Pålsson, E | 1 |
| Wass, C | 1 |
| Engel, JA | 1 |
| Svensson, L | 1 |
| Klamer, D | 1 |
| Thomsen, M | 1 |
| Wörtwein, G | 1 |
| Fink-Jensen, A | 1 |
| Woldbye, DP | 1 |
| Wess, J | 1 |
| Caine, SB | 2 |
| Paulson, L | 1 |
| Martin, P | 2 |
| Ljung, E | 1 |
| Blennow, K | 1 |
| Davidsson, P | 1 |
| Turgeon, SM | 1 |
| Hulick, VC | 1 |
| Potvin, S | 1 |
| Mancini-Marïe, A | 1 |
| Fahim, C | 1 |
| Mensour, B | 1 |
| Lévesque, J | 1 |
| Karama, S | 1 |
| Beauregard, M | 1 |
| Rompré, PP | 1 |
| Morice, E | 1 |
| Billard, JM | 1 |
| Denis, C | 1 |
| Mathieu, F | 1 |
| Betancur, C | 1 |
| Epelbaum, J | 1 |
| Nosten-Bertrand, M | 1 |
| Limosin, F | 1 |
| López-Gil, X | 1 |
| Babot, Z | 1 |
| Amargós-Bosch, M | 1 |
| Suñol, C | 1 |
| Adell, A | 1 |
| Sakumoto, N | 1 |
| Monji, A | 1 |
| Hashioka, S | 1 |
| Kanba, S | 4 |
| Khan, A | 1 |
| Iskander, A | 1 |
| Abad, MT | 1 |
| Parker, B | 1 |
| Chou, YH | 2 |
| Li, MH | 2 |
| Wan, FJ | 2 |
| Yen, MH | 2 |
| Shi, L | 2 |
| Zhu, B | 2 |
| Faries, D | 2 |
| Montgomery, W | 2 |
| Dávila, R | 6 |
| Zumárraga, M | 6 |
| Basterreche, N | 1 |
| Arrúe, A | 1 |
| Anguiano, JB | 1 |
| Stöcker, T | 1 |
| Olfson, M | 1 |
| Marcus, SC | 1 |
| Strassnig, M | 1 |
| Miewald, J | 1 |
| Ganguli, R | 3 |
| Amitai, N | 1 |
| Semenova, S | 1 |
| Markou, A | 1 |
| Casademont, J | 1 |
| Garrabou, G | 1 |
| Miró, O | 1 |
| López, S | 1 |
| Pons, A | 1 |
| Cardellach, F | 1 |
| Bounthavong, M | 1 |
| Okamoto, MP | 1 |
| Currier, GW | 2 |
| Citrome, LL | 2 |
| Oren, D | 2 |
| Pikalov, AA | 2 |
| Allen, MH | 1 |
| Timdahl, K | 1 |
| Stening, G | 1 |
| Mittal, VA | 1 |
| Hasenkamp, W | 1 |
| Sanfilipo, M | 4 |
| Wieland, S | 2 |
| Angrist, B | 7 |
| Duncan, EJ | 1 |
| Boulay, LJ | 1 |
| Labelle, A | 5 |
| Bourget, D | 1 |
| Robertson, S | 1 |
| Habib, R | 1 |
| Tessier, P | 1 |
| Tombaugh, T | 1 |
| Milin, R | 1 |
| Priebe, K | 1 |
| Cilia, J | 1 |
| Hatcher, P | 1 |
| Reavill, C | 1 |
| Jones, DN | 1 |
| Grunze, H | 1 |
| Bender, A | 1 |
| Orrù, M | 1 |
| Piras, AP | 1 |
| Fà, M | 1 |
| Tuveri, A | 1 |
| Puligheddu, M | 1 |
| Gessa, GL | 5 |
| Castelli, MP | 1 |
| Mereu, G | 2 |
| Marrosu, F | 1 |
| Sinn, DI | 1 |
| Chu, K | 1 |
| Jung, KH | 1 |
| Park, KI | 1 |
| Nam, H | 1 |
| Lee, SK | 2 |
| Wynn, JK | 1 |
| Green, MF | 8 |
| Sprock, J | 1 |
| Light, GA | 1 |
| Reist, C | 2 |
| Erhart, S | 2 |
| Braff, DL | 2 |
| Panagiotidis, G | 1 |
| Arthur, HW | 1 |
| Lindh, JD | 1 |
| Dahl, ML | 3 |
| Sjöqvist, F | 1 |
| Kennedy, E | 1 |
| Datta, SS | 1 |
| Heres, S | 1 |
| Amar, S | 1 |
| Shaltiel, G | 1 |
| Mann, L | 1 |
| Shamir, A | 1 |
| Bersudsky, Y | 1 |
| Belmaker, RH | 15 |
| Agam, G | 2 |
| Sivrioglu, EY | 1 |
| Kirli, S | 2 |
| Sipahioglu, D | 1 |
| Gursoy, B | 1 |
| Sarandöl, E | 1 |
| Koh, HY | 1 |
| Kim, D | 1 |
| Lee, S | 2 |
| Shin, HS | 1 |
| Pérez-Solá, V | 1 |
| Díaz, S | 1 |
| Praharaj, SK | 1 |
| Arora, M | 1 |
| Liu, KH | 1 |
| Shon, JH | 1 |
| Perlick, DA | 1 |
| Kaczynski, R | 1 |
| Salgado-Pineda, P | 1 |
| Sarandol, A | 1 |
| Cangur, S | 1 |
| Kantrowitz, JT | 1 |
| Srihari, VH | 1 |
| Tek, C | 1 |
| Kim, JH | 2 |
| Byun, HJ | 1 |
| Watanabe, K | 1 |
| Kashima, H | 1 |
| Verrall, L | 1 |
| Walker, M | 1 |
| Rawlings, N | 1 |
| Benzel, I | 1 |
| Kew, JN | 1 |
| Harrison, PJ | 4 |
| Burnet, PW | 4 |
| Castro, AP | 1 |
| Reschke, RW | 1 |
| Sergi, MJ | 1 |
| Kee, KS | 2 |
| Villari, V | 1 |
| Fonzo, V | 1 |
| Montemagni, C | 1 |
| Pandullo, P | 1 |
| Lin, CC | 1 |
| Bai, YM | 1 |
| Chen, JY | 1 |
| Wang, YC | 1 |
| Liou, YJ | 1 |
| Baviera, M | 1 |
| Bhatia, MS | 1 |
| Gupta, R | 1 |
| Dhawan, J | 1 |
| Chaudhry, IB | 1 |
| Husain, N | 1 |
| Khan, S | 1 |
| Badshah, S | 1 |
| Deakin, B | 1 |
| Gallhofer, B | 3 |
| Jaanson, P | 1 |
| Mittoux, A | 1 |
| Lis, S | 2 |
| Krieger, S | 2 |
| Snigdha, S | 1 |
| Neill, JC | 1 |
| McLeod, MC | 1 |
| Sundram, S | 1 |
| Jockers-Scherübl, MC | 1 |
| Bechdolf, A | 1 |
| Degner, D | 1 |
| Schmidt, LG | 3 |
| Salize, HJ | 1 |
| Saddichha, S | 3 |
| Manjunatha, N | 2 |
| Ameen, S | 3 |
| Akhtar, S | 3 |
| Cheng, WJ | 1 |
| Martinez, V | 1 |
| Sarter, M | 1 |
| Bustillo, JR | 3 |
| Rowland, LM | 2 |
| Jung, R | 1 |
| Brooks, WM | 2 |
| Qualls, C | 1 |
| Hammond, R | 1 |
| Hart, B | 1 |
| Lauriello, J | 3 |
| Schlagenhauf, F | 1 |
| Koslowski, M | 1 |
| Kahnt, T | 1 |
| Knutson, B | 1 |
| Dembler, T | 1 |
| Kienast, T | 1 |
| Gallinat, J | 1 |
| Wrase, J | 1 |
| Heinz, A | 2 |
| Oni-Orisan, A | 1 |
| Miller, DD | 9 |
| Verma, V | 1 |
| Tan, CH | 1 |
| Ong, WY | 1 |
| Grigoryan, GA | 1 |
| Jones, CA | 1 |
| Stolzberg, D | 1 |
| Salvi, R | 1 |
| Gross, KW | 1 |
| Ratty, AK | 1 |
| Halim, ND | 1 |
| Hyde, TM | 3 |
| Deep-Soboslay, A | 1 |
| Saylor, EM | 1 |
| Herman, MM | 1 |
| Thakar, J | 1 |
| Verma, A | 1 |
| Kleinman, JE | 8 |
| Boggs, DL | 1 |
| Hu, Q | 1 |
| Jirikowski, GF | 1 |
| Konopelska, S | 1 |
| Quinkler, M | 1 |
| Strasburger, CJ | 1 |
| Ventz, M | 1 |
| Gao, K | 1 |
| Ganocy, SJ | 1 |
| Gajwani, P | 1 |
| Muzina, DJ | 1 |
| Kemp, DE | 1 |
| Calabrese, JR | 1 |
| Demily, C | 1 |
| Franck, N | 1 |
| Tamayo, P | 1 |
| Montes, C | 1 |
| De Luxán, A | 1 |
| Martin, C | 1 |
| Rivas, N | 1 |
| Sancho, C | 1 |
| Domínguez-Gil, A | 1 |
| Zbytovský, J | 4 |
| Shamsi, SA | 1 |
| Busch, R | 1 |
| Hazra, M | 1 |
| Laska, E | 3 |
| Di Marino, M | 1 |
| Wolfgang, CD | 1 |
| Leo, R | 1 |
| Razzini, C | 1 |
| Bianchi, F | 1 |
| Tesauro, M | 1 |
| Zanasi, M | 1 |
| Boter, H | 1 |
| Vergouwe, Y | 1 |
| Keet, IP | 1 |
| Gheorghe, MD | 1 |
| Rybakowski, JK | 1 |
| Hummer, M | 4 |
| Dollfus, S | 2 |
| López-Ibor, JJ | 1 |
| Hranov, LG | 1 |
| Lindefors, N | 1 |
| Riecher-Rössler, A | 1 |
| Grobbee, DE | 1 |
| Stanković, Z | 1 |
| Britvić, D | 1 |
| Vuković, O | 1 |
| Ille, T | 1 |
| Tiul'pin, IuG | 1 |
| Song, F | 1 |
| Harvey, I | 1 |
| Lilford, R | 1 |
| István, S | 1 |
| Agoston, T | 1 |
| Tamás, T | 1 |
| Zoltán, J | 1 |
| Martello, D | 1 |
| Allingham, B | 1 |
| Owens, DC | 1 |
| Henteleff, RA | 1 |
| Wickelmaier, F | 1 |
| Chung, CH | 1 |
| Gau, CS | 1 |
| Johnson, PC | 1 |
| Charalampous, KD | 1 |
| Braun, GA | 2 |
| Lapolla, A | 2 |
| Hirschowitz, J | 12 |
| Fleishmann, R | 1 |
| Djuric, PE | 1 |
| Luchins, DJ | 1 |
| Neckers, L | 1 |
| Rosenblatt, JE | 2 |
| Bigelow, LB | 12 |
| Wyatt, RJ | 19 |
| Creese, I | 3 |
| Rubin, RT | 5 |
| Hays, SE | 2 |
| Lideman, RR | 1 |
| Zlobina, GP | 1 |
| Mukhin, AG | 1 |
| Rovinskaia, SA | 1 |
| Revva, LI | 1 |
| Lechin, F | 1 |
| Gômez, F | 1 |
| van der Dijs, B | 1 |
| Lechin, E | 1 |
| Dasberg, H | 3 |
| Ebstein, RP | 3 |
| Tune, LE | 3 |
| DePaulo, JR | 1 |
| Slavney, PR | 1 |
| Snyder, SH | 6 |
| Gershon, S | 4 |
| Ringwald, E | 1 |
| Lustig, A | 1 |
| Moscovici, M | 1 |
| Spiegel, R | 1 |
| Vamos, E | 1 |
| Wise, CD | 1 |
| Bridge, TP | 1 |
| Wagner, RL | 3 |
| Morihisa, J | 1 |
| Karson, C | 2 |
| Chojnacki, M | 2 |
| Kralik, P | 2 |
| Allen, RH | 1 |
| Ho, BT | 4 |
| Schoolar, JC | 2 |
| Smith, RC | 15 |
| Ungvári, G | 2 |
| Pethö, B | 2 |
| Bowers, MB | 5 |
| Heninger, GR | 3 |
| Brannen, JO | 2 |
| Petrie, WM | 1 |
| Berney, SA | 2 |
| Schaffer, JD | 1 |
| White, K | 2 |
| Busk, J | 2 |
| Eaton, E | 1 |
| Gomez, G | 1 |
| Razani, J | 1 |
| Sloane, RB | 2 |
| Nedopil, N | 2 |
| Brown, WA | 8 |
| Laughren, TP | 3 |
| Kolakowska, T | 1 |
| Braddock, L | 1 |
| Wiles, D | 1 |
| Franklin, M | 1 |
| Gelder, M | 1 |
| Braddock, LE | 1 |
| Blake, IM | 1 |
| Dikiĭ, NT | 1 |
| Moss, HB | 2 |
| Bochkarev, VK | 1 |
| Paniushkina, SV | 1 |
| Vitrai, J | 1 |
| Smirnov, VK | 1 |
| Rollin, HR | 1 |
| Laughren, T | 2 |
| Chisholm, E | 1 |
| Williams, BW | 2 |
| Allen, R | 2 |
| Schoolar, J | 2 |
| Khan, M | 1 |
| DeJohn, C | 3 |
| Tyrer, SP | 1 |
| Schüssler, G | 1 |
| Kappes, CV | 1 |
| Nishikawa, T | 3 |
| Tsuda, A | 2 |
| Koga, I | 2 |
| Uchida, Y | 2 |
| Baron, M | 3 |
| Gruen, R | 3 |
| Levitt, M | 3 |
| Fog, R | 2 |
| Pakkenberg, H | 1 |
| Regeur, L | 1 |
| Pakkenberg, B | 1 |
| Greenberg, JS | 1 |
| Krantz, J | 1 |
| Kariya, T | 1 |
| Shimazono, Y | 1 |
| Itoh, H | 6 |
| Mori, A | 2 |
| Sugano, K | 1 |
| Toru, M | 2 |
| Yamashita, I | 1 |
| Bjørndal, N | 2 |
| Remvig, J | 1 |
| Gottlieb, P | 1 |
| Stoudemire, A | 1 |
| Nelson, A | 1 |
| Houpt, JL | 1 |
| Pi, EH | 1 |
| Goodnick, PJ | 1 |
| Tong, C | 1 |
| Duncavage, MB | 1 |
| Bechelli, LP | 1 |
| Ruffino-Netto, A | 1 |
| Hetem, G | 1 |
| Roncoroni, D | 1 |
| Hoaki, Y | 2 |
| Planche, R | 1 |
| Wagner, HN | 3 |
| Gramsch, C | 1 |
| Emrich, HM | 4 |
| John, S | 1 |
| Haas, S | 4 |
| Beckmann, H | 6 |
| Zaudig, M | 1 |
| von Zerssen, D | 5 |
| Kelwala, S | 1 |
| Katz, B | 1 |
| Cotton, P | 1 |
| McCreadie, RG | 5 |
| Mackie, M | 1 |
| Wiles, DH | 3 |
| Jorgensen, A | 1 |
| Hansen, V | 1 |
| Menzies, C | 1 |
| Eben, E | 3 |
| Silverstone, T | 4 |
| Levine, S | 3 |
| Freeman, HL | 1 |
| Dubini, A | 1 |
| Ishizaki, T | 1 |
| Chiba, K | 1 |
| Kobayashi, K | 1 |
| Iizuka, R | 1 |
| Asarnow, RF | 1 |
| Van Putten, T | 16 |
| Tateyama, M | 1 |
| Kamisada, M | 1 |
| Tanoue, A | 1 |
| Takamiya, M | 1 |
| Nakajima, S | 1 |
| arap Mengech, HN | 1 |
| Wazome, EG | 1 |
| Rastogi, RB | 1 |
| Singhal, RL | 1 |
| Lapierre, YD | 7 |
| Allen, RM | 1 |
| Brambilla, F | 8 |
| Genazzani, AR | 2 |
| Facchinetti, F | 2 |
| Parrini, D | 1 |
| Petraglia, F | 2 |
| Sacchetti, E | 1 |
| Gustalla, A | 1 |
| D'Antona, N | 1 |
| Modestin, J | 2 |
| Toffler, G | 1 |
| Pia, M | 1 |
| Greub, E | 1 |
| Neborsky, RJ | 1 |
| Janowsky, DS | 1 |
| Perel, JM | 5 |
| Munson, E | 3 |
| Depry, D | 3 |
| Klein, E | 2 |
| Bental, E | 1 |
| Lerer, B | 4 |
| Munk-Andersen, E | 1 |
| Behnke, K | 2 |
| Heltberg, J | 2 |
| Nielsen, H | 2 |
| Gerlach, J | 8 |
| Annable, L | 2 |
| Campbell, W | 2 |
| Boisvert, D | 1 |
| Bradwejn, J | 1 |
| Cookson, J | 1 |
| Ball, R | 1 |
| Chin, CN | 2 |
| Jacobs, D | 1 |
| Lader, S | 1 |
| Gould, S | 1 |
| Mavroidis, ML | 3 |
| Kanter, DR | 3 |
| Langer, G | 6 |
| Aschauer, H | 1 |
| Koinig, G | 1 |
| Schönbeck, G | 2 |
| Dittrich, R | 1 |
| Lehmann, E | 7 |
| Lienert, GA | 3 |
| Shvartsburd, A | 6 |
| Sajadi, C | 1 |
| Morton, V | 1 |
| Mirabi, M | 1 |
| Gordon, J | 2 |
| Balant-Gorgia, AE | 2 |
| Eisele, R | 2 |
| Balant, L | 1 |
| Garrone, G | 2 |
| May, PR | 3 |
| Baumgartner, R | 5 |
| Misra, CH | 3 |
| Mauldin, M | 5 |
| Gangadhar, BN | 1 |
| Desai, NG | 1 |
| Channabasavanna, SM | 1 |
| Korpi, ER | 8 |
| Ko, GN | 4 |
| Phelps, BH | 2 |
| Reed, RM | 1 |
| Bass, AD | 1 |
| Lemperiere, T | 2 |
| Ropert, R | 1 |
| Leger, JM | 1 |
| Alexandre, JY | 1 |
| Clerc, G | 1 |
| Darondel, A | 1 |
| Delaunay, J | 1 |
| Delteil, P | 1 |
| Malauzat, D | 1 |
| Raynaud, J | 1 |
| Winter, M | 1 |
| Scholz, OB | 1 |
| Iwamura, K | 2 |
| Ichikawa, K | 2 |
| Kim, JS | 1 |
| Kornhuber, ME | 1 |
| Kornhuber, HH | 5 |
| Yonekawa, M | 1 |
| Kanaya, T | 1 |
| Sera, H | 1 |
| Sarai, K | 1 |
| Pugnetti, L | 1 |
| Massironi, R | 1 |
| Penati, G | 2 |
| Nobile, P | 1 |
| Sternberg, DE | 1 |
| Ravichandran, GK | 5 |
| Lu, RB | 1 |
| Kahn, M | 1 |
| Costakos, DT | 1 |
| Linnoila, M | 4 |
| Shen, Y | 2 |
| Pardes, H | 2 |
| Zhou, D | 2 |
| Korpi, E | 1 |
| Tang, SW | 1 |
| Glaister, J | 1 |
| Davidson, L | 1 |
| Toth, R | 1 |
| Jeffries, JJ | 1 |
| Levy, DL | 1 |
| Lipton, RB | 1 |
| Holzman, PS | 1 |
| Aoba, A | 2 |
| Kakita, Y | 2 |
| Yamaguchi, N | 6 |
| Shido, M | 2 |
| Shibata, M | 4 |
| Kitani, K | 2 |
| Hasegawa, K | 3 |
| Kita, N | 1 |
| Goulon, M | 1 |
| de Rohan-Chabot, P | 1 |
| Elkharrat, D | 1 |
| Gajdos, P | 1 |
| Bismuth, C | 1 |
| Conso, F | 1 |
| Dubach, MF | 1 |
| Bowden, DM | 1 |
| Fernando, J | 1 |
| Krishna Raju, R | 1 |
| Jones, GG | 1 |
| Stanley, RO | 1 |
| Barbaro, AC | 1 |
| Butterfield, L | 1 |
| Garicano, M | 1 |
| Narasimhachari, N | 1 |
| Friedel, RO | 1 |
| Swigar, ME | 1 |
| Jatlow, PI | 3 |
| Goicoechea, N | 1 |
| Tischio, J | 1 |
| Hetyei, N | 1 |
| Patrick, J | 1 |
| Mosketi, KV | 2 |
| Mokhovikov, AN | 2 |
| Aksent'ev, SB | 1 |
| Goĭkhberg, IG | 1 |
| Kryzhanovskiĭ, GN | 3 |
| Glicksteen, GA | 1 |
| Ereshefsky, L | 7 |
| Davis, CM | 8 |
| Harrington, CA | 3 |
| Jann, MW | 26 |
| Browning, JL | 2 |
| Saklad, SR | 6 |
| Burch, NR | 2 |
| Kaminer, Y | 1 |
| Munitz, H | 5 |
| McBurney, A | 1 |
| George, S | 1 |
| Ariano, MG | 1 |
| Pirozzi, R | 1 |
| Salvati, A | 1 |
| Kemali, D | 6 |
| Svestka, J | 4 |
| Náhunek, K | 1 |
| Cesková, E | 5 |
| Rysánek, R | 2 |
| Bjerre, M | 1 |
| Kristjansen, P | 2 |
| Magelund, G | 3 |
| Oestrich, IH | 1 |
| Waehrens, J | 1 |
| Nair, NP | 4 |
| Lal, S | 3 |
| Schwartz, G | 2 |
| Thavundayil, JX | 2 |
| Gil-Ad, I | 1 |
| Dickerman, Z | 1 |
| Laron, Z | 1 |
| Rao, VA | 2 |
| Bailey, J | 1 |
| Bishop, M | 3 |
| Coppen, A | 2 |
| Rimón, R | 6 |
| Averbuch, I | 3 |
| Rozick, P | 1 |
| Fijman-Danilovich, L | 1 |
| Kara, T | 1 |
| Moulin, MA | 1 |
| Davy, JP | 1 |
| Debruyne, D | 2 |
| Andersson, JC | 1 |
| Bigot, MC | 1 |
| Camsonne, R | 1 |
| Poilpré, E | 1 |
| Rotman, A | 1 |
| Zemishlany, Z | 2 |
| Wijsenbeek, H | 1 |
| Terenius, L | 1 |
| Dekirmenjian, H | 3 |
| Dosani, RA | 1 |
| Parent, M | 5 |
| Toussaint, C | 3 |
| Jerussi, TP | 1 |
| Taylor, CA | 1 |
| Kita, S | 1 |
| Kagono, Y | 1 |
| Suitsu, N | 1 |
| Honda, Y | 1 |
| Neborsky, R | 2 |
| Janowsky, D | 2 |
| Nagaraju, A | 2 |
| Abuzzahab, FS | 1 |
| Zimmerman, RL | 1 |
| Snider, SR | 1 |
| Morselli, PL | 3 |
| Bianchetti, G | 2 |
| Dugas, M | 1 |
| Heikkilä, L | 1 |
| Laitinen, J | 1 |
| Vartiainen, H | 1 |
| Rapisarda, V | 3 |
| Poma, A | 1 |
| Sheard, MH | 1 |
| Hornbeck, C | 1 |
| Wolf, ME | 1 |
| Bowie, L | 1 |
| Keener, S | 1 |
| Mosnaim, AD | 1 |
| Vroulis, G | 4 |
| Lewis, N | 1 |
| Johnson, R | 1 |
| Scatton, B | 1 |
| Zarifian, E | 3 |
| Cuche, H | 1 |
| Loo, H | 3 |
| Tower, BB | 1 |
| Poland, RE | 7 |
| Berney, S | 1 |
| Dixon, PA | 1 |
| Oforah, E | 1 |
| Makanjuola, R | 1 |
| Karson, CN | 5 |
| Schaffer, CB | 2 |
| Shahid, A | 1 |
| Javaid, JI | 4 |
| Dysken, MW | 1 |
| Castellani, S | 1 |
| Ziegler, MG | 1 |
| Alexander, PE | 1 |
| Siris, SG | 1 |
| Lake, CR | 2 |
| Kim, DY | 1 |
| Fishbain, DA | 1 |
| Lang, C | 1 |
| Doerr, P | 1 |
| Pirke, KM | 1 |
| Extein, I | 1 |
| Augusthy, KA | 1 |
| Gold, MS | 1 |
| Pottash, AL | 1 |
| Martin, D | 1 |
| Potter, WZ | 1 |
| Reyntigens, AJ | 1 |
| Heykants, JJ | 1 |
| Woestenborghs, RJ | 1 |
| Gelders, YG | 3 |
| Aerts, TJ | 2 |
| Reyntijens, AJ | 1 |
| Ash, CW | 1 |
| Antelman, SM | 1 |
| Eichler, AJ | 1 |
| Black, CA | 1 |
| Kocan, D | 1 |
| Waddington, JL | 1 |
| Gamble, SJ | 1 |
| Solomon, PR | 1 |
| Crider, A | 1 |
| Winkelman, JW | 1 |
| Turi, A | 1 |
| Kamer, RM | 1 |
| Kaplan, LJ | 1 |
| Binder, R | 1 |
| Rice, M | 1 |
| Hanlon, TE | 1 |
| Wilkinson, EH | 1 |
| Ng, KT | 1 |
| Elizur, A | 2 |
| Segal, Z | 2 |
| Yeret, A | 2 |
| Ben-David, M | 2 |
| Psaras, M | 1 |
| Zissis, NP | 1 |
| Mouzakis, D | 1 |
| Lyketsos, G | 1 |
| Rowell, FJ | 1 |
| Hui, SM | 1 |
| Fairbairn, AF | 1 |
| Eccleston, D | 1 |
| Wahba, M | 2 |
| Donlon, PT | 4 |
| Meadow, A | 2 |
| Cohen, BM | 1 |
| Korivi, P | 1 |
| Leelavathi, DE | 1 |
| Arzu, D | 1 |
| Goldman, Z | 1 |
| Zohar, J | 1 |
| Hermoni, M | 1 |
| Tasman, A | 1 |
| Hale, MS | 2 |
| Simon, RH | 1 |
| Ida, Y | 1 |
| Kohno, Y | 1 |
| Marconi Tassara, J | 1 |
| Diaz, JP | 1 |
| Mourgues, C | 1 |
| Shopsin, B | 1 |
| Kline, N | 1 |
| Stevens, JR | 1 |
| Slotnick, VB | 1 |
| Hopkin, JT | 1 |
| Tupin, JP | 2 |
| Wicks, JJ | 1 |
| Ohtsuka, N | 2 |
| Sakurai, Y | 1 |
| Takahashi, R | 1 |
| Nakahara, T | 2 |
| Ikenaga, H | 1 |
| Forsman, A | 2 |
| Heykants, J | 2 |
| Ohman, R | 1 |
| Tower, B | 1 |
| Michiels, M | 1 |
| Deberdt, R | 1 |
| Elens, P | 1 |
| Berghmans, W | 1 |
| Woestenborghs, R | 1 |
| Driesens, F | 1 |
| Reyntjens, A | 1 |
| van Wijngaarden, I | 1 |
| Magliozzi, JR | 3 |
| Arnold, KV | 1 |
| Earle, GM | 1 |
| Eastwood, SL | 2 |
| Huang, HF | 2 |
| Tseng, YT | 1 |
| Chung, MC | 1 |
| Chien, CP | 8 |
| Bergman, A | 1 |
| O'Brien, J | 1 |
| Osgood, G | 1 |
| Cornblatt, B | 1 |
| Nordström, AL | 2 |
| Farde, L | 7 |
| Eriksson, L | 1 |
| Halldin, C | 6 |
| González-Torres, MA | 1 |
| Andía, I | 5 |
| Zamalloa, MI | 1 |
| Basterreche, E | 1 |
| Guimón, J | 2 |
| Friedhoff, AJ | 4 |
| Condray, R | 3 |
| Steinhauer, SR | 3 |
| Kasparek, A | 2 |
| Brown, AS | 2 |
| Hembree, WC | 1 |
| Friedman, JH | 1 |
| Kaufmann, CA | 2 |
| Lacombe, S | 1 |
| Agren, H | 1 |
| O'Connor, DT | 2 |
| Gurklis, J | 8 |
| Peters, JL | 11 |
| Janssen, PA | 2 |
| Awouters, FH | 1 |
| Breslin, NA | 1 |
| Suddath, RL | 3 |
| Bissette, G | 3 |
| Nemeroff, CB | 7 |
| Lowrimore, P | 1 |
| von Knorring, L | 3 |
| Owens, DG | 1 |
| Bennett, JA | 1 |
| Keck, PE | 1 |
| Wallhausser, LJ | 1 |
| Vainer, JL | 1 |
| Bélanger, MC | 2 |
| Turnier, L | 1 |
| Beaudry, P | 2 |
| Roy, JY | 1 |
| Miller, R | 1 |
| Kitaichi, K | 1 |
| Hasegawa, T | 1 |
| Furukawa, H | 2 |
| Perry, PJ | 9 |
| Müller, H | 2 |
| Borison, RL | 4 |
| Gurklis, JA | 5 |
| Gilbertson, MW | 8 |
| Musser, WS | 1 |
| Kirisci, L | 1 |
| Labarca, R | 2 |
| Silva, H | 2 |
| Jerez, S | 2 |
| Ruiz, A | 2 |
| Renterías, P | 1 |
| Ogalde, C | 1 |
| Bustos, G | 2 |
| Zuardi, AW | 1 |
| Morais, SL | 1 |
| Guimarães, FS | 1 |
| Maina, G | 1 |
| Barzega, G | 1 |
| Bellino, S | 1 |
| Ravizza, L | 1 |
| Marsh, SJ | 1 |
| Dolson, GM | 1 |
| Meisner, M | 4 |
| Hinze-Selch, D | 2 |
| Mullington, J | 2 |
| Holsboer, F | 1 |
| Jaffe, E | 1 |
| Trémeau, F | 1 |
| Sharif, Z | 2 |
| Reider, R | 1 |
| Levinson, I | 1 |
| Greenberg, WM | 1 |
| Goff, DC | 4 |
| Midha, KK | 4 |
| Sarid-Segal, O | 1 |
| Hubbard, JW | 2 |
| Amico, E | 1 |
| Kuhs, H | 1 |
| Folkerts, H | 1 |
| Lambert, PD | 1 |
| Gross, R | 1 |
| Kilts, CD | 2 |
| Fang, J | 1 |
| Yu, PH | 1 |
| Gorrod, JW | 1 |
| Boulton, AA | 1 |
| Freudenreich, O | 2 |
| McGee, M | 1 |
| VanderZwaag, C | 1 |
| Levin, E | 1 |
| Rose, J | 1 |
| Stone, CK | 1 |
| Garve, DL | 1 |
| Griffith, J | 1 |
| Bennett, J | 1 |
| Shader, RI | 3 |
| Oesterheld, JR | 1 |
| McAllister, CG | 2 |
| Rehn, TJ | 1 |
| Miller, AL | 6 |
| Schmidt, M | 1 |
| Blanz, B | 1 |
| Dippe, A | 1 |
| Koppe, T | 1 |
| Lay, B | 1 |
| Lee, HS | 3 |
| Song, DH | 1 |
| Lee, YM | 1 |
| Han, ES | 1 |
| Yoo, KJ | 1 |
| Bloom, D | 2 |
| Addington, D | 3 |
| MacEwan, GW | 1 |
| Beauclair, L | 2 |
| Arnott, W | 1 |
| Knott, P | 2 |
| Stern, RG | 2 |
| Apter, S | 2 |
| Min, SK | 1 |
| Rhee, CS | 1 |
| Kim, CE | 2 |
| Kang, DY | 2 |
| Lilliu, V | 1 |
| Vargiu, P | 1 |
| Muntoni, AL | 1 |
| Diana, M | 1 |
| Yousef, KA | 1 |
| Volkow, ND | 2 |
| Schlyer, DJ | 2 |
| Fowler, JS | 4 |
| Wolf, AP | 7 |
| Wang, GJ | 1 |
| Smith, MR | 1 |
| Warner, D | 1 |
| Ulrich, S | 5 |
| Meyer, FP | 4 |
| Neuhof, S | 4 |
| Knorr, W | 3 |
| Lam, YW | 10 |
| Yu, HS | 1 |
| Lin, SK | 16 |
| Gupta, SK | 1 |
| Kunka, RL | 1 |
| Metz, A | 1 |
| Lloyd, T | 1 |
| Rudolph, G | 1 |
| Sower, AC | 1 |
| Bird, ED | 2 |
| Perrone-Bizzozero, NI | 1 |
| Bravin, S | 1 |
| Mantero, M | 1 |
| Invernizzi, G | 1 |
| Pearlson, GD | 2 |
| Chase, GA | 1 |
| Links, JM | 2 |
| Dannals, RF | 3 |
| Wilson, AA | 2 |
| Ravert, HT | 2 |
| Geyer, MA | 1 |
| Whiteford, HA | 4 |
| Stedman, TJ | 5 |
| Welham, J | 1 |
| Pond, S | 1 |
| Egan, MF | 2 |
| Brown, RJ | 1 |
| Olbrich, HM | 1 |
| Piccolo, A | 1 |
| Martino, M | 1 |
| Mackert, A | 1 |
| Diefenbacher, A | 1 |
| Friedrich, A | 1 |
| Stock, G | 1 |
| Palao, DJ | 4 |
| Arauxo, A | 4 |
| Brunet, M | 4 |
| Haro, JM | 2 |
| Ferrer, J | 2 |
| Gonzalez-Monclus, E | 2 |
| Randolph, C | 1 |
| Jaskiw, G | 1 |
| Handel, S | 2 |
| Williams, T | 1 |
| Abi-Dargham, A | 3 |
| Shoaf, S | 1 |
| Egan, M | 1 |
| Elkashef, A | 1 |
| Liboff, S | 1 |
| D'Souza, DC | 1 |
| Bennett, A | 1 |
| Oretti, RG | 1 |
| Spurlock, G | 1 |
| Buckland, PR | 1 |
| McGuffin, P | 1 |
| Siever, L | 1 |
| Greenwald, C | 1 |
| Moore, C | 1 |
| Scherer, J | 5 |
| Tatsch, K | 4 |
| Schwarz, J | 3 |
| Oertel, WH | 2 |
| Konjarczyk, M | 1 |
| Albus, M | 4 |
| Oertel, W | 1 |
| Kirsch, MC | 1 |
| Brunner, J | 1 |
| Maras, A | 2 |
| Nyberg, S | 4 |
| Bertilsson, L | 2 |
| Welker, JA | 1 |
| Dencker, SJ | 1 |
| Giös, I | 1 |
| Mårtensson, E | 1 |
| Nordén, T | 1 |
| Nyberg, G | 1 |
| Persson, R | 1 |
| Roman, G | 1 |
| Stockman, O | 1 |
| Svärd, KO | 1 |
| Sarkar, P | 1 |
| Andrade, C | 1 |
| Kapur, B | 1 |
| Das, P | 1 |
| Sivaramakrishna, Y | 1 |
| Harihar, C | 1 |
| Pandey, A | 1 |
| Anand, A | 1 |
| Dharmendra, MS | 1 |
| Henneberg, A | 1 |
| Ruffert, S | 1 |
| Horter, S | 1 |
| Holstein, C | 1 |
| Pond, SM | 5 |
| Pupeschi, G | 1 |
| Agenet, C | 1 |
| Levron, JC | 1 |
| Barges-Bertocchio, MH | 1 |
| Thara, R | 1 |
| Henrietta, M | 1 |
| Joseph, A | 1 |
| Rajkumar, S | 1 |
| Eaton, WW | 1 |
| Safadi, G | 1 |
| Guidotti, A | 3 |
| Neylan, T | 3 |
| Guarneri, P | 2 |
| Costa, E | 2 |
| Fitzgerald, LW | 1 |
| Deutch, AY | 1 |
| Gasic, G | 1 |
| Heinemann, SF | 1 |
| Harada, H | 1 |
| Igarashi, M | 1 |
| Sugae, S | 1 |
| Okamoto, K | 1 |
| Tsuji, M | 1 |
| Nakajima, T | 1 |
| Markianos, M | 9 |
| Hatzimanolis, J | 9 |
| Stefanis, C | 2 |
| Gewirtz, GR | 1 |
| Cadet, JL | 1 |
| Sarti, P | 1 |
| Awad, AG | 8 |
| Kubota, T | 2 |
| Ishikura, T | 1 |
| Jibiki, I | 7 |
| Gagné, MA | 1 |
| Cormier, H | 1 |
| Leblanc, G | 1 |
| Di Paolo, T | 1 |
| Baruah, S | 2 |
| Waziri, R | 2 |
| Sherman, A | 1 |
| Toney, G | 1 |
| Anderson, C | 1 |
| Seidel, D | 1 |
| Nisijima, K | 3 |
| Matoba, M | 1 |
| Ishiguro, T | 3 |
| Marshall, BD | 9 |
| Shieh, YS | 1 |
| Parry, AK | 1 |
| Ormerod, LP | 1 |
| Hamlin, GW | 1 |
| Saleem, PT | 1 |
| Serper, MR | 3 |
| Ford, JM | 1 |
| White, PM | 1 |
| Faustman, WO | 4 |
| Roth, WT | 1 |
| Pfefferbaum, A | 2 |
| Koeppl, P | 1 |
| Wetzel, MW | 1 |
| Vogler, GP | 1 |
| McLennan, HR | 1 |
| Jones, A | 1 |
| Thaker, GK | 5 |
| Moran, M | 1 |
| Kakigi, T | 1 |
| Gao, XM | 1 |
| Kinkead, B | 2 |
| Piscitelli, SC | 1 |
| Frazier, JA | 1 |
| McKenna, K | 1 |
| Albus, KE | 1 |
| Grothe, DR | 1 |
| Gordon, CT | 1 |
| Sakai, T | 2 |
| Ishihara, H | 1 |
| Matsuki, A | 1 |
| Rasmus, W | 1 |
| Rød, IS | 1 |
| Fritze, J | 3 |
| Aguilar, EJ | 1 |
| Martínez-Quiles, MD | 1 |
| Hernández, J | 1 |
| Gómez-Beneyto, M | 1 |
| Conley, R | 3 |
| Nguyen, JA | 1 |
| Aravagiri, M | 3 |
| Issa, F | 2 |
| Gerhardt, GA | 2 |
| Bartko, JJ | 3 |
| Lynch, M | 1 |
| Gamache, PH | 1 |
| Freedman, R | 2 |
| Kirch, DG | 11 |
| Teo, SK | 1 |
| Lam, KN | 1 |
| Chew, WL | 1 |
| Forman, SD | 1 |
| Khanna, R | 1 |
| Damodaran, SS | 2 |
| Chakraborty, SP | 1 |
| Doddi, S | 3 |
| Rifkin, A | 3 |
| Karajgi, B | 3 |
| Cooper, T | 4 |
| Borenstein, M | 3 |
| Klieser, E | 10 |
| Strauss, WH | 3 |
| Lemmer, W | 2 |
| Sandyk, R | 3 |
| Kanofsky, JD | 1 |
| LaPorta, LD | 1 |
| Brauzer, B | 2 |
| Gierl, B | 1 |
| Casey, DE | 3 |
| Hassan, M | 1 |
| Schellenberg, R | 2 |
| Schwarz, A | 2 |
| Miele, L | 1 |
| Maas, JW | 5 |
| Contreras, S | 2 |
| Seleshi, E | 4 |
| True, JE | 1 |
| Bowden, C | 2 |
| Castiglioni, J | 1 |
| Marquez, M | 2 |
| Irish, D | 3 |
| Barbieri, NB | 1 |
| Dubé, JM | 1 |
| Bowen, L | 3 |
| Kuehnel, TG | 4 |
| Elkashef, AM | 1 |
| Frank, JA | 1 |
| Lewis, BK | 1 |
| Burke, MA | 1 |
| Ritchie, JC | 1 |
| Lévy-Soussan, P | 1 |
| Barbouche, R | 1 |
| Poirier, MF | 2 |
| Galinowski, A | 2 |
| Avrameas, S | 1 |
| Waltrip, RW | 1 |
| Listwak, S | 1 |
| Holmes, C | 1 |
| Goldstein, DS | 1 |
| Rasmussen, K | 1 |
| Giobbio, GM | 1 |
| Ferrara, A | 1 |
| Dieci, M | 1 |
| Bitetto, A | 1 |
| Seno, H | 1 |
| Kumazawa, T | 1 |
| Ishii, A | 1 |
| Suzuki, O | 1 |
| Chen, TY | 9 |
| Lin, WL | 3 |
| Hu, WH | 9 |
| Lin, HN | 10 |
| Dixon, L | 1 |
| Thaker, G | 1 |
| Cascella, N | 1 |
| Tamminga, C | 1 |
| Davis, OR | 1 |
| Convit, A | 2 |
| de Asis, J | 1 |
| Evangelista, C | 1 |
| Peters, J | 6 |
| Cassady, SL | 1 |
| Kastrup, O | 1 |
| Schwarz, M | 1 |
| Fujimoto, K | 1 |
| Sakamoto, H | 1 |
| Hasegawa, M | 1 |
| Furuta, H | 1 |
| Adler, G | 1 |
| Radwan, M | 4 |
| Brandon, J | 3 |
| Baruch, Y | 1 |
| Stawski, M | 1 |
| Doran, AR | 1 |
| Gietzen, DW | 1 |
| Olson, AM | 1 |
| Maclin, EL | 1 |
| Tuason, VB | 2 |
| Hayden, JL | 2 |
| Wodarz, N | 2 |
| Riederer, P | 3 |
| Laruelle, M | 1 |
| Lipska, B | 1 |
| Jaskiw, GE | 2 |
| Wong, DT | 1 |
| Robertson, DW | 1 |
| Alam, MY | 1 |
| Boshes, RA | 1 |
| Waternaux, C | 1 |
| Pappalardo, KM | 1 |
| Fitzgibbon, ME | 1 |
| Tsuang, MT | 2 |
| Schildkraut, JJ | 1 |
| Glenthøj, B | 1 |
| Mogensen, J | 1 |
| Laursen, H | 1 |
| Holm, S | 1 |
| Hemmingsen, R | 1 |
| Amin, F | 1 |
| Apter, SH | 1 |
| Kurokawa, K | 2 |
| Fukushima, T | 1 |
| Juang, DJ | 4 |
| Chen, LC | 3 |
| Yang, CH | 3 |
| Lam, YF | 1 |
| Monfort, JC | 1 |
| Escobar, R | 1 |
| Stone, AM | 1 |
| Greenstein, RA | 1 |
| Gamble, G | 2 |
| McLellan, AT | 1 |
| Forray, MI | 1 |
| Gysling, K | 1 |
| Andres, ME | 1 |
| Castillo, Y | 1 |
| Hono, J | 1 |
| Khot, V | 1 |
| DeVane, CL | 2 |
| Venable, D | 1 |
| Contreras, SA | 3 |
| Berman, N | 2 |
| Bowden, CL | 5 |
| Javors, MA | 1 |
| Weintraub, SE | 1 |
| Pollock, B | 2 |
| Voineskos, G | 2 |
| Reed, K | 2 |
| Coulter, K | 2 |
| Arndt, SV | 3 |
| Smith, DA | 1 |
| Holman, TL | 1 |
| Koffel, B | 1 |
| LaPorte, D | 1 |
| Iwahashi, K | 4 |
| Nakamura, K | 2 |
| Miyatake, R | 2 |
| Suwaki, H | 2 |
| Hosokawa, K | 2 |
| Cascella, NG | 1 |
| Gonzalez, MA | 1 |
| Silva, RR | 1 |
| Akiyama, K | 1 |
| Tsuchida, K | 1 |
| Kanzaki, A | 1 |
| Ujike, H | 1 |
| Hamamura, T | 1 |
| Kondo, K | 1 |
| Miyanagi, K | 1 |
| Kuroda, S | 1 |
| Otsuki, S | 1 |
| Rotrosen, JP | 1 |
| Dardennes, RM | 2 |
| Amorim, ES | 1 |
| Diquet, B | 1 |
| Moreira, EC | 1 |
| de Castro-e-Silva, EJ | 1 |
| Payan, C | 1 |
| Fermanian, J | 1 |
| Marcílio, C | 2 |
| Ichikawa, Y | 1 |
| Jones, C | 3 |
| Wilson, A | 1 |
| DaSilva, J | 1 |
| Houle, S | 2 |
| Wei, FC | 4 |
| Piao-Chien, C | 2 |
| Abraham, D | 2 |
| Lauter, H | 1 |
| Smith, M | 3 |
| de Souza, MA | 1 |
| Pugliese, S | 1 |
| Mari, Jde J | 1 |
| Streit, M | 1 |
| Polzer, U | 1 |
| Banerjee, SP | 1 |
| Zuck, LG | 1 |
| Yablonsky-Alter, E | 1 |
| Lidsky, TI | 1 |
| Ha, KS | 1 |
| Jeong, SH | 1 |
| Kim, YS | 1 |
| Griffon, N | 1 |
| Sokoloff, P | 1 |
| Diaz, J | 1 |
| Sautel, F | 1 |
| Schwartz, JC | 1 |
| Simon, P | 1 |
| Costentin, J | 1 |
| Garrido, F | 1 |
| Mann, A | 1 |
| Tacchini, GL | 1 |
| Maes, M | 3 |
| Cha, IJ | 1 |
| Kim, YK | 3 |
| Kim, JI | 1 |
| Park, GH | 1 |
| Jang, IJ | 1 |
| Woo, JI | 1 |
| Shin, SG | 1 |
| Mahmood, T | 1 |
| Aymard, N | 2 |
| Viala, A | 1 |
| Stein, I | 1 |
| Caroli, F | 1 |
| Bauer, U | 1 |
| Gruppe, H | 1 |
| Beuger, M | 2 |
| Bilsker, D | 1 |
| Chiang, TS | 1 |
| Tran, P | 1 |
| Satterlee, W | 1 |
| Hamilton, S | 1 |
| Darby, JK | 1 |
| Pasta, DJ | 1 |
| Dabiri, L | 1 |
| Clark, L | 1 |
| Mosbacher, D | 1 |
| Funderburg, L | 1 |
| Silva, JA | 1 |
| True, J | 1 |
| Velligan, D | 1 |
| Schwarzkopf, SB | 1 |
| Bruno, JP | 1 |
| Mitra, T | 1 |
| Ison, JR | 1 |
| Bouhours, P | 1 |
| Sharma, RP | 2 |
| Leach, AM | 1 |
| Naylor, L | 1 |
| Opeskin, K | 2 |
| Pavey, G | 1 |
| Hill, C | 3 |
| Keks, N | 1 |
| Copolov, D | 2 |
| Raleigh, F | 1 |
| Odou, P | 1 |
| Vaiva, G | 1 |
| Luyckx, M | 1 |
| Brunet, C | 1 |
| Dine, T | 1 |
| Gressier, B | 1 |
| Cazin, M | 1 |
| Cazin, JC | 1 |
| Bartur, P | 2 |
| Raja, M | 1 |
| Maisto, G | 1 |
| Altavista, MC | 1 |
| Albanese, A | 1 |
| Sokulski, DE | 1 |
| Damask, SP | 1 |
| Bovenkerk, KA | 1 |
| de la Pena, G | 1 |
| Hoversten, KM | 1 |
| Peters, DB | 1 |
| Valentine, AM | 1 |
| Scherer, H | 1 |
| Delorimier, J | 1 |
| Lalonde, P | 1 |
| Goldman, RG | 1 |
| Alexander, GE | 1 |
| Mukherjee, S | 3 |
| Sackeim, H | 1 |
| Prohovnik, I | 1 |
| Cola, PA | 1 |
| Parsa, M | 1 |
| Inosaka, T | 1 |
| Saito, H | 1 |
| Sato, M | 1 |
| White, L | 1 |
| Mohs, RC | 8 |
| De Meester, I | 1 |
| Scharpe, S | 1 |
| Desnyder, R | 1 |
| Ranjan, R | 1 |
| Huttunen, MO | 1 |
| Tuhkanen, H | 1 |
| Haavisto, E | 1 |
| Nyholm, R | 1 |
| Pitkänen, M | 1 |
| Raitasuo, V | 1 |
| Romanov, M | 1 |
| Smeraldi, E | 3 |
| Cocconcelli, C | 1 |
| Canova, L | 1 |
| Faravelli, C | 1 |
| Marchetti, FP | 1 |
| Mariani, G | 1 |
| Petit, M | 1 |
| Raniwalla, J | 2 |
| Tweed, J | 1 |
| Leutenegger, E | 1 |
| Kelly, F | 1 |
| Reynolds, CF | 1 |
| Miewald, JM | 1 |
| Montrose, DM | 1 |
| Chang, TP | 1 |
| Chen, JS | 1 |
| Tuninger, E | 2 |
| Levander, S | 2 |
| Pereira, EL | 2 |
| Miranda, AM | 1 |
| de Oliveira, NF | 1 |
| Ribeiro, MG | 2 |
| de Castro-e-Silva, E | 2 |
| Samuel-Lajeunesse, B | 1 |
| Little, RJ | 1 |
| Suzuki, E | 3 |
| Koshikawa, H | 2 |
| Nibuya, M | 3 |
| Asai, M | 2 |
| Busatto, GF | 1 |
| Taylor, M | 1 |
| Costa, DC | 1 |
| Sigmundsson, T | 1 |
| Nohria, V | 1 |
| Kerwin, RW | 1 |
| Sperner-Unterweger, B | 3 |
| Falk, M | 1 |
| Kurz, M | 3 |
| Oberbauer, H | 3 |
| Ishida, M | 9 |
| Yasui, N | 15 |
| Vanelle, JM | 1 |
| Amorim, P | 1 |
| Piketti, ML | 1 |
| Bourdel, MC | 2 |
| Poirier-Littré, MF | 1 |
| Higaki, J | 1 |
| Murphy, GM | 1 |
| Cordell, B | 1 |
| Weatherspoon, JK | 2 |
| Gonzalez-Alvear, GM | 1 |
| Frank, AR | 1 |
| Werling, LL | 1 |
| Kurzthaler, I | 2 |
| Karniel, E | 1 |
| Szor, H | 1 |
| Ames, D | 2 |
| Baker, RW | 2 |
| Umbricht, DS | 2 |
| Sun, AB | 1 |
| Carter, J | 1 |
| Liu, KL | 1 |
| Vallabhajosula, S | 2 |
| Machac, J | 1 |
| Küfferle, B | 8 |
| Brücke, T | 4 |
| Topitz-Schratzberger, A | 1 |
| Tauscher, J | 5 |
| Gössler, R | 1 |
| Vesely, C | 2 |
| Asenbaum, S | 4 |
| Podreka, I | 3 |
| Rezai, K | 1 |
| Alliger, R | 1 |
| Andreasen, NC | 3 |
| Hitzemann, R | 4 |
| Piscani, K | 1 |
| Burr, G | 2 |
| Culliton, D | 1 |
| Mann, M | 1 |
| Curtis, C | 1 |
| Barnas, C | 6 |
| Heiden, A | 1 |
| Laakmann, G | 1 |
| Zeit, H | 1 |
| Pfolz, H | 1 |
| Tran, PV | 9 |
| Street, JS | 1 |
| Krueger, JA | 1 |
| Tamura, RN | 3 |
| Graffeo, KA | 1 |
| Thieme, ME | 2 |
| Nagaoka, S | 1 |
| Iwamoto, N | 1 |
| Arai, H | 2 |
| Ikeda, K | 2 |
| Hu, OY | 2 |
| Deng, HC | 2 |
| Dhopesh, V | 1 |
| Macfadden, A | 1 |
| Maany, I | 1 |
| Young, D | 1 |
| Wilson, PD | 1 |
| Meltzer, CC | 1 |
| Miranda-Scippa, AM | 1 |
| Bacaltchuk, J | 1 |
| Weisbard, JJ | 1 |
| Pardo, M | 1 |
| Pollack, S | 2 |
| Bauer, KS | 1 |
| Kroboth, PD | 1 |
| Leach, A | 1 |
| Dowd, S | 1 |
| Mack, RJ | 2 |
| Wozniak, PJ | 1 |
| Sebree, TB | 1 |
| Wallin, BA | 1 |
| Kashkin, KB | 1 |
| McGurk, S | 1 |
| Kern, RS | 3 |
| Hamilton, SH | 7 |
| Crawford, AM | 4 |
| Dellva, MA | 5 |
| Beuzen, JN | 1 |
| Allen, DN | 3 |
| Barry, EJ | 1 |
| Mager, T | 2 |
| Potvin, JH | 2 |
| Kiesler, GM | 1 |
| Wahlbeck, K | 2 |
| Ahokas, A | 2 |
| Nikkilä, H | 2 |
| Miettinen, K | 1 |
| Crabtree, BL | 1 |
| Pitts, WM | 1 |
| Carter, JG | 1 |
| Bobba, R | 1 |
| Albright, PS | 1 |
| Angus, C | 2 |
| Rylander, A | 1 |
| Avenoso, A | 1 |
| Spinà, E | 1 |
| Campo, G | 1 |
| Facciolă, G | 1 |
| Ferlito, M | 1 |
| Zuccaro, P | 1 |
| Perucca, E | 1 |
| Caputi, AP | 1 |
| Johnstone, BM | 3 |
| Meszaros, K | 1 |
| Lenzinger, E | 1 |
| Hornik, K | 1 |
| Hatzinger, R | 1 |
| Sieghart, W | 1 |
| Aschauer, HN | 1 |
| Aloe, L | 1 |
| Iannitelli, A | 1 |
| Alleva, E | 1 |
| Angelucci, F | 1 |
| Maselli, P | 1 |
| Manni, L | 1 |
| Arvanitis, LA | 2 |
| Miller, BG | 1 |
| Leykin, I | 1 |
| Mayer, R | 1 |
| Shinitzky, M | 1 |
| Xu, W | 10 |
| Thomas, J | 10 |
| Henderson, W | 8 |
| Frisman, L | 1 |
| Fye, C | 1 |
| Charney, D | 10 |
| Boyer, P | 2 |
| Fleurot, O | 2 |
| Robertson, MJ | 1 |
| Minami, H | 1 |
| Miyahara, A | 1 |
| Nakane, Y | 1 |
| Chang, YC | 1 |
| Gewirtz, G | 1 |
| Harkavy-Friedman, J | 1 |
| Brébion, G | 1 |
| Amador, XF | 1 |
| Malaspina, D | 1 |
| Hayashi, K | 2 |
| Patel, JK | 1 |
| Kalinowski, A | 1 |
| Fenzel, T | 1 |
| Kraus, T | 1 |
| Fogelson, DL | 1 |
| Sternbach, H | 1 |
| Payne, D | 1 |
| Revicki, DA | 5 |
| Genduso, LA | 4 |
| Lynch, MR | 1 |
| Addington, J | 1 |
| Coryell, W | 2 |
| Mattes, JA | 2 |
| Birkett, DP | 1 |
| Zabalo, MJ | 1 |
| Bulbena, A | 1 |
| Wirz-Justice, A | 1 |
| Cajochen, C | 1 |
| Nussbaum, P | 1 |
| Regenthal, R | 1 |
| Künstler, U | 1 |
| Junhold, U | 1 |
| Preiss, R | 1 |
| Ferrero, F | 1 |
| Fuger, J | 1 |
| Geretsegger, C | 2 |
| Schubert, H | 4 |
| Ilchef, R | 1 |
| Stevens, KE | 2 |
| Nagamoto, H | 1 |
| Johnson, RG | 1 |
| Rose, GM | 1 |
| Bartlett, EJ | 2 |
| Simkowitz, P | 1 |
| Dewey, SL | 2 |
| Rusinek, H | 1 |
| Cancro, R | 1 |
| Schiffer, W | 1 |
| Aparicio-Legarza, MI | 1 |
| Davis, B | 1 |
| Hutson, PH | 1 |
| Sams-Dodd, F | 1 |
| Lu, Y | 1 |
| Wurthmann, C | 1 |
| Brosz, M | 1 |
| Tokinaga, N | 3 |
| Mohr, P | 3 |
| Motlová, L | 2 |
| Wozniak, P | 1 |
| McCarthy, BG | 1 |
| Allan, ER | 1 |
| Sison, CE | 1 |
| Alpert, M | 1 |
| Connolly, B | 1 |
| Crichton, J | 1 |
| Mészáros, Z | 1 |
| Borcsiczky, D | 1 |
| Máté, M | 1 |
| Tarcali, J | 1 |
| Tekes, K | 1 |
| Magyar, K | 1 |
| Jin, Y | 2 |
| Sandman, CA | 1 |
| Rudelli, R | 1 |
| Vanni, S | 1 |
| Panza, G | 2 |
| Sicaro, A | 1 |
| Audisio, D | 1 |
| Sacerdote, P | 2 |
| Panerai, AE | 2 |
| Tanaka, T | 1 |
| Watanabe, S | 1 |
| Nagata, E | 1 |
| Hesselmann, B | 1 |
| Petrakis, IL | 1 |
| Price, LH | 1 |
| Ryding, E | 1 |
| Ohlsson, T | 1 |
| Sjöholm, H | 1 |
| Freccero-Rosman, K | 1 |
| Rosén, I | 1 |
| Jentsch, JD | 1 |
| Taylor, JR | 1 |
| Roth, RH | 1 |
| Knable, MB | 1 |
| Coppola, R | 2 |
| Gorey, JG | 1 |
| Jones, DW | 2 |
| Lee, KS | 1 |
| Richardson, C | 1 |
| Peszke, M | 2 |
| Lingle, J | 1 |
| Hegerty, J | 1 |
| Love, R | 1 |
| Gounaris, C | 1 |
| Zaremba, S | 1 |
| Dähne, I | 1 |
| Leyris, A | 1 |
| Beauverie, P | 1 |
| Tekell, J | 1 |
| Reddy, R | 4 |
| McElhinny, LG | 1 |
| Posever, T | 1 |
| Simmons, J | 1 |
| Kletti, N | 1 |
| Lapierre, K | 1 |
| Wilner, KD | 1 |
| Law, CG | 1 |
| Feinberg, I | 1 |
| Campbell, IG | 1 |
| Licht, RW | 1 |
| Agelink, MW | 1 |
| Malessa, R | 1 |
| Kamcili, E | 1 |
| Zeit, T | 1 |
| Bertling, R | 1 |
| Almeida, OP | 1 |
| Balon, R | 2 |
| Breggin, PR | 1 |
| Suzuki, I | 1 |
| Honma, H | 1 |
| Watanabe, N | 1 |
| Matsubara, S | 1 |
| Moore, DP | 1 |
| Dose, M | 3 |
| Hellweg, R | 1 |
| Yassouridis, A | 1 |
| Theison, M | 1 |
| Pettegrew, JW | 1 |
| Crayton, J | 2 |
| Stolar, M | 1 |
| Lee, MS | 3 |
| Suh, KY | 1 |
| Umbricht, D | 2 |
| Javitt, D | 1 |
| Novak, G | 1 |
| Bates, J | 1 |
| Maixner, S | 1 |
| Tandon, R | 4 |
| Eiser, A | 1 |
| Taylor, S | 1 |
| DeQuardo, JR | 1 |
| Shipley, J | 1 |
| Shimizu, M | 1 |
| Wentley, AL | 1 |
| Chou, JC | 2 |
| Braun, V | 3 |
| Moore, DB | 1 |
| Sherr, JD | 1 |
| Grundy, S | 2 |
| Beasley, C | 1 |
| Bardgett, M | 2 |
| Faull, KF | 1 |
| Han, CS | 1 |
| You, YW | 1 |
| Zhang-Wong, J | 1 |
| Beiser, M | 1 |
| Bean, G | 1 |
| Storosum, JG | 1 |
| Elferink, AJ | 1 |
| van Zwieten, BJ | 1 |
| Fischer, P | 1 |
| Pezawas, L | 1 |
| Tauscher-Wisniewski, S | 2 |
| Pitschel-Walz, G | 1 |
| Hirokane, G | 6 |
| Takahashi, S | 9 |
| Morita, S | 5 |
| Rosebush, PI | 1 |
| Mazurek, MF | 1 |
| Nagashima, U | 4 |
| Palmer, CS | 1 |
| Brown, RE | 1 |
| Morgenstern, H | 1 |
| Ferguson, K | 1 |
| Saxena, BM | 2 |
| Williamson, P | 1 |
| Vincent, P | 1 |
| Carle, R | 1 |
| Lavallee, YJ | 1 |
| Manchanda, R | 3 |
| Gauthier, B | 1 |
| Wolf, MA | 1 |
| Teehan, MD | 1 |
| Denis, JF | 1 |
| Malla, AK | 1 |
| Oyewumi, LK | 1 |
| Busse, E | 1 |
| Claesson, L | 1 |
| Grafford, K | 1 |
| Hoffmann-Richter, U | 1 |
| Sperling, W | 1 |
| Vieth, J | 1 |
| Martus, M | 1 |
| Demling, J | 1 |
| Barocka, A | 1 |
| Davari-Ashtiani, R | 2 |
| Cohen, JD | 1 |
| Reddy, RD | 1 |
| Erdos, J | 1 |
| Frisman, LK | 2 |
| Schultz, A | 1 |
| Wiltfang, J | 1 |
| Meineke, I | 1 |
| Gleiter, CH | 1 |
| Zöchling, R | 1 |
| Boissl, KW | 1 |
| Leblhuber, F | 1 |
| Yokono, A | 4 |
| Shibasaki, M | 4 |
| See, RE | 1 |
| Fido, AA | 1 |
| Maurice, M | 1 |
| Ibrahim, MM | 1 |
| Salama, GM | 1 |
| Nair, TR | 1 |
| Holcomb, J | 1 |
| Ramberg, J | 1 |
| Kingsbury, S | 1 |
| Prinssen, EP | 2 |
| Kleven, MS | 2 |
| Koek, W | 2 |
| Taylor, G | 1 |
| Csernansky, J | 2 |
| Early, T | 1 |
| Haller, J | 1 |
| Scherrer, J | 1 |
| Womack, S | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Wu, SM | 1 |
| Ko, WK | 1 |
| Wu, HL | 1 |
| Chen, SH | 1 |
| Tunis, SL | 2 |
| Croghan, TW | 1 |
| Heilman, DK | 1 |
| Obenchain, RL | 1 |
| Gerding, LB | 1 |
| Labbate, LA | 1 |
| Measom, MO | 1 |
| Santos, AB | 1 |
| Arana, GW | 1 |
| Japha, K | 1 |
| Koch, M | 2 |
| Hesslinger, B | 1 |
| Normann, C | 1 |
| Klose, P | 1 |
| Berger, M | 1 |
| Funakoshi, T | 1 |
| Yoshikawa, R | 1 |
| Okuyama, S | 1 |
| Kumagai, T | 1 |
| Nakazato, A | 1 |
| Nagamine, M | 1 |
| Tomisawa, K | 1 |
| Ganoczy, D | 1 |
| Fukuzako, H | 1 |
| Fukuzako, T | 1 |
| Kodama, S | 1 |
| Hashiguchi, T | 1 |
| Takigawa, M | 1 |
| Fujimoto, T | 2 |
| König, P | 2 |
| Conca, A | 1 |
| Lugmayer, B | 1 |
| Yui, K | 1 |
| Ricard, N | 2 |
| Sauriol, L | 2 |
| Loosbrock, DL | 1 |
| Dulisse, BK | 1 |
| Akil, M | 2 |
| Whitehead, RE | 1 |
| Edgar, CL | 2 |
| Mohila, C | 1 |
| Vander Stichele, R | 1 |
| Rosseel, MT | 1 |
| Berlo, JA | 1 |
| De Schepper, N | 1 |
| Belpaire, FM | 1 |
| Grube, M | 1 |
| Kurzweg, A | 1 |
| Nowakowska, E | 1 |
| Chodera, A | 1 |
| Kus, K | 1 |
| Edgell, ET | 2 |
| Shibata, N | 1 |
| Ohnuma, T | 1 |
| Baba, H | 1 |
| Shimada, H | 1 |
| Takahashi, T | 1 |
| Chaudry, AS | 1 |
| Woo, TU | 1 |
| Stanilla, JK | 1 |
| Abraham, G | 1 |
| Odom-White, A | 1 |
| Turner, RM | 1 |
| Noorbala, AA | 1 |
| Dittert, S | 1 |
| Velligan, DI | 2 |
| Fitzgerald, PB | 2 |
| Caligiuri, MP | 1 |
| Silvestri, S | 1 |
| Hermesh, H | 3 |
| Manor, I | 1 |
| Gracey, DJ | 1 |
| Bell, R | 1 |
| King, DJ | 2 |
| Liu, SK | 1 |
| Chen, WJ | 1 |
| Chang, CJ | 1 |
| Northoff, G | 1 |
| Pflug, B | 3 |
| Anastasiou, A | 1 |
| Goldstein, G | 1 |
| Gilbertson, M | 1 |
| Casali, S | 1 |
| Jones, BD | 1 |
| David, SR | 3 |
| Copolov, DL | 6 |
| Link, CG | 1 |
| Kowalcyk, B | 1 |
| Müller, R | 1 |
| Kockott, G | 1 |
| Song, C | 1 |
| Lin, Ah | 1 |
| Kenis, G | 1 |
| Bosmans, E | 1 |
| Windhaber, J | 1 |
| Urbanits, S | 1 |
| Grisold, W | 1 |
| Begić, D | 1 |
| Hotujac, L | 1 |
| Jokić-Begić, N | 1 |
| Watanabe, E | 1 |
| Danos, P | 1 |
| Pester, U | 1 |
| Hoy, L | 1 |
| Werme, M | 1 |
| Ringholm, A | 1 |
| Olson, L | 1 |
| Brené, S | 1 |
| Schroeder, U | 1 |
| Schroeder, H | 1 |
| Schwegler, H | 1 |
| Sabel, BA | 1 |
| Quraishi, S | 2 |
| Ghani, SO | 1 |
| Ahmed, W | 1 |
| Marco, LA | 1 |
| Coulouvrat, C | 1 |
| Dondey-Nouvel, L | 2 |
| Dott, SG | 1 |
| Harris, A | 1 |
| Brown, A | 1 |
| O'Boyle, M | 1 |
| Meyer, WJ | 1 |
| Rose, RM | 1 |
| Colonna, L | 1 |
| Saleem, P | 1 |
| Chang, S | 2 |
| Choe, Y | 1 |
| Liddle, PF | 1 |
| Shasavand, E | 1 |
| Jamilian, H | 1 |
| Shabestari, O | 1 |
| Fendt, M | 1 |
| Schwienbacher, I | 1 |
| Pralong, D | 1 |
| Tomaskovic-Crook, E | 1 |
| Montejo, AL | 1 |
| Vieta, E | 1 |
| Gregor, KJ | 1 |
| Bailey, PJ | 1 |
| Koizumi, S | 1 |
| Wakabayashi, K | 1 |
| Kyosseva, SV | 1 |
| Elbein, AD | 1 |
| Hutton, TL | 1 |
| Griffin, ST | 1 |
| Mrak, RE | 1 |
| Sturner, WQ | 1 |
| Eichhammer, P | 1 |
| Borrmann-Hassenbach, M | 1 |
| Schoeler, A | 1 |
| Frick, U | 1 |
| Klein, HE | 3 |
| Rohrmeier, T | 1 |
| Green, B | 1 |
| Miwa, T | 1 |
| Horikomi, K | 1 |
| Reznik, I | 1 |
| Aleman, A | 1 |
| de Haan, EH | 1 |
| Kim, L | 1 |
| Hamid, AR | 1 |
| Philip, G | 1 |
| Ramlee, T | 1 |
| Mahmud, M | 1 |
| Zulkifli, G | 1 |
| Loh, CC | 1 |
| Zakariah, MS | 1 |
| Norhamidah, MS | 1 |
| Suraya, Y | 1 |
| Roslan, KA | 1 |
| Chandramohan, P | 1 |
| Cheah, YC | 1 |
| Leonard, AO | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Kontaxakis, VP | 1 |
| Christodoulou, GN | 2 |
| Breese, CR | 2 |
| Lee, MJ | 2 |
| Sullivan, B | 1 |
| Logel, J | 1 |
| Gillen, KM | 1 |
| Marks, MJ | 1 |
| Collins, AC | 1 |
| Leonard, S | 2 |
| Bareggi, SR | 3 |
| Hirose, S | 2 |
| Ashby, CR | 1 |
| Grinshpoon, A | 1 |
| Valevski, A | 1 |
| Moskowitz, M | 1 |
| Dean, CE | 1 |
| Hargreaves, WA | 1 |
| Jurgis, G | 1 |
| Carrière, P | 1 |
| Bonhomme, D | 1 |
| Shapiro, J | 1 |
| Biegon, A | 1 |
| Seker, A | 1 |
| Allen, SA | 1 |
| Colpaert, FC | 1 |
| Stockmeyer, M | 1 |
| Yukawa, E | 1 |
| Hokazono, T | 1 |
| Funakoshi, A | 1 |
| Yukawa, M | 1 |
| Ohdo, S | 1 |
| Higuchi, S | 1 |
| Ichimaru, R | 1 |
| Makit, T | 1 |
| Matsunaga, K | 1 |
| Anai, M | 1 |
| Van Baelen, B | 2 |
| De Smedt, C | 1 |
| Lemmens, P | 3 |
| Shiloh, R | 1 |
| Weizer, N | 1 |
| Dorfman-Etrog, P | 1 |
| Heck, AH | 1 |
| Haffmans, PM | 1 |
| de Groot, IW | 1 |
| Hoencamp, E | 2 |
| Shulman, RW | 1 |
| Volk, D | 1 |
| Austin, M | 1 |
| Pierri, J | 1 |
| Sampson, A | 1 |
| Lewis, D | 1 |
| Daskalakis, J | 1 |
| Binder, EB | 1 |
| Owens, MJ | 1 |
| Strook, ML | 1 |
| Kim, YB | 1 |
| Jang, J | 1 |
| Chung, Y | 1 |
| Baeg, EH | 1 |
| Kim, HT | 1 |
| Mook-Jung, I | 1 |
| Kim, SU | 1 |
| Jung, MW | 1 |
| Chung, YK | 1 |
| Rodríguez, JJ | 1 |
| Garcia, DR | 1 |
| Nakabeppu, Y | 1 |
| Pickel, VM | 1 |
| Thankamma, JK | 1 |
| Kohler, CG | 1 |
| Pickholtz, J | 1 |
| Ballas, C | 1 |
| Hafiz, NG | 1 |
| Hampton, D | 1 |
| Molloy, M | 1 |
| Su, JM | 2 |
| Noda, Y | 1 |
| Kamei, H | 1 |
| Miura, H | 1 |
| Kayukawa, Y | 1 |
| Ohta, T | 1 |
| Hilger, E | 1 |
| Bhana, N | 1 |
| Foster, RH | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Roychowdhury, SM | 1 |
| Milton, DR | 1 |
| Hill, AL | 1 |
| Basson, BR | 3 |
| Ichim, C | 1 |
| Bast, T | 1 |
| Zhang, WN | 1 |
| Heidbreder, C | 1 |
| Gaertner, I | 1 |
| Altendorf, K | 1 |
| Batra, A | 1 |
| Gaertner, HJ | 4 |
| Fehr, C | 1 |
| Dahmen, N | 1 |
| Klawe, C | 1 |
| Eicke, M | 1 |
| Szegedi, A | 1 |
| Myers, CS | 1 |
| Contreras, MA | 1 |
| Chang, MC | 1 |
| Rapoport, SI | 1 |
| Appel, NM | 1 |
| Mujica, R | 1 |
| Weiden, P | 1 |
| Lit, W | 1 |
| Drybcák, P | 1 |
| Hrobar, P | 1 |
| Lorenc, M | 1 |
| Spacek, J | 1 |
| Czekalla, J | 1 |
| Bergiannaki, JD | 1 |
| Liappas, J | 1 |
| Sakkas, PN | 1 |
| Stefanis, CN | 1 |
| O'Leary, DS | 1 |
| Watkins, GL | 1 |
| Boles Ponto, LL | 1 |
| Hichwa, RD | 1 |
| Guan, HJ | 1 |
| Dai, J | 1 |
| Zhu, XZ | 1 |
| Stanwood, GD | 1 |
| Guntermann, A | 1 |
| Erfurth, A | 1 |
| Mullen, B | 1 |
| Brar, JS | 1 |
| Vagnucci, AH | 1 |
| Oulis, P | 1 |
| Szymanski, KA | 1 |
| Talvik, M | 1 |
| Olsson, H | 1 |
| Esel, E | 1 |
| Basturk, M | 1 |
| Saffet Gonul, A | 1 |
| Kula, M | 1 |
| Tayfun Turan, M | 1 |
| Yabanoglu, I | 1 |
| Sofuoglu, S | 1 |
| Liégeois, JF | 1 |
| Bruhwyler, J | 1 |
| Cools, AR | 2 |
| Reeves, RR | 1 |
| Mack, JE | 1 |
| Torres, RA | 1 |
| Hornik, T | 1 |
| Ferchland, I | 2 |
| Alaka, KJ | 1 |
| Saunders, JC | 1 |
| Krueger, J | 1 |
| Bradley, P | 1 |
| Reinstein, M | 1 |
| Turenne, SD | 1 |
| Seeman, M | 1 |
| Ross, BM | 1 |
| Laporta, M | 1 |
| Edwardes, MD | 1 |
| Deslandes, M | 1 |
| Suissa, S | 1 |
| Flor-Henry, P | 1 |
| Costa e Silva, JA | 1 |
| Alvarez, N | 1 |
| Mazzotti, G | 1 |
| Ospina, J | 1 |
| Larach, V | 1 |
| Starkstein, S | 1 |
| Oliva, D | 1 |
| Cousins, L | 1 |
| Wang, HC | 1 |
| Hsieh, Y | 1 |
| de Bruin, NM | 1 |
| van Luijtelaar, EL | 1 |
| Parellada, E | 1 |
| Lomeña, F | 1 |
| Catafau, AM | 1 |
| Font, M | 1 |
| López-Carrero, C | 1 |
| Gutiérrez, F | 1 |
| Pavía, J | 1 |
| Salamero, M | 1 |
| Cruz, DA | 1 |
| Melchitzky, DS | 1 |
| Vester-Blokland, E | 1 |
| Schutz, G | 1 |
| Roh, HK | 1 |
| Chung, JY | 1 |
| Oh, DY | 1 |
| Park, CS | 1 |
| Svensson, JO | 1 |
| Jung, RE | 1 |
| Petropoulos, H | 1 |
| Hart, BL | 1 |
| Blanchard, J | 1 |
| Keith, SJ | 1 |
| Safferman, A | 1 |
| McMeniman, M | 2 |
| Anemo, K | 1 |
| Fukunishi, I | 1 |
| Igarashi, K | 1 |
| Fleming, K | 1 |
| Gulasekaram, B | 2 |
| Schwarcz, R | 1 |
| Rassoulpour, A | 1 |
| Wu, HQ | 1 |
| Medoff, D | 1 |
| Infante, M | 1 |
| Singh, A | 1 |
| Khandat, A | 1 |
| Badía, X | 1 |
| Kind, P | 1 |
| Petroianu, G | 1 |
| Scheuer, L | 1 |
| Konradi, C | 1 |
| Heckers, S | 1 |
| Su, J | 1 |
| Nan, Z | 1 |
| Cui, Y | 1 |
| Guan, Z | 1 |
| Zhang, P | 1 |
| Varner, RV | 1 |
| Hays, JR | 1 |
| Wagner, AL | 1 |
| Averill, P | 1 |
| Xiberas, X | 1 |
| Martinot, JL | 1 |
| Mallet, L | 1 |
| Artiges, E | 1 |
| Loc'H, C | 2 |
| Mazière, B | 2 |
| Paillère-Martinot, ML | 1 |
| Newcomer, J | 1 |
| Pultz, J | 1 |
| Mahurin, R | 1 |
| Oh, PI | 1 |
| Iskedjian, M | 1 |
| Addis, A | 1 |
| Lanctôt, K | 1 |
| Hardy-Baylé, MC | 1 |
| Mahmoud, R | 1 |
| Brenner, R | 1 |
| Geddes, J | 1 |
| Loewenthal, U | 1 |
| Matar, M | 1 |
| Okawa, M | 1 |
| García-Cabeza, I | 1 |
| Edgell, E | 1 |
| González de Chavez, M | 1 |
| Inoue, M | 1 |
| Thyrum, PT | 1 |
| Alva, G | 1 |
| Bera, R | 1 |
| Yeh, C | 1 |
| Marder, S | 1 |
| Casey, D | 1 |
| Yamashita, H | 1 |
| Morinobu, S | 1 |
| Yamawaki, S | 1 |
| Nagao, M | 1 |
| Zavitsanou, K | 1 |
| Röder, C | 1 |
| Schuierer, G | 2 |
| Tanaka, O | 1 |
| Løberg, EM | 1 |
| Jørgensen, HA | 2 |
| Hugdahl, K | 1 |
| David, S | 1 |
| Sutton, V | 1 |
| Palmer, R | 1 |
| Kiesler, G | 1 |
| Blair, K | 1 |
| Curtin, F | 1 |
| Stalman, SL | 1 |
| Schneider, L | 1 |
| McClelland, RA | 1 |
| VanderSpek, SC | 1 |
| Baker, G | 1 |
| Nobrega, J | 1 |
| Klein, H | 1 |
| Cohen, LS | 1 |
| Horton, NJ | 1 |
| Lee, H | 1 |
| Andersen, S | 1 |
| Crawford, A | 1 |
| Lenox, RH | 1 |
| Ikeda, D | 1 |
| Gandhi, N | 1 |
| Zhang, WX | 1 |
| Bilder, RM | 1 |
| Goldman, RS | 3 |
| Hoptman, M | 1 |
| Horowitz, TL | 1 |
| Falk, B | 1 |
| Singer, P | 1 |
| Kairi, M | 1 |
| Phillip, M | 1 |
| Zigel, L | 1 |
| Poraz, I | 1 |
| Frishman, S | 1 |
| Constantini, N | 1 |
| Zalsman, G | 1 |
| Avissar, S | 1 |
| Roitman, G | 1 |
| Schreiber, G | 2 |
| Weiss, E | 1 |
| Yagdiran, O | 1 |
| Haasen, C | 1 |
| Nika, E | 1 |
| Krausz, M | 1 |
| McGurk, SR | 1 |
| Le Pen, G | 1 |
| Pierre, JM | 1 |
| Saunders, CS | 1 |
| Hirsch, SR | 3 |
| Power, A | 1 |
| O'Connor, R | 1 |
| Andersson, C | 1 |
| Lawler, CP | 1 |
| Mailman, RB | 1 |
| Kontkanen, O | 1 |
| Lakso, M | 1 |
| Wong, G | 1 |
| Castrén, E | 1 |
| Carlsson, VA | 1 |
| Burt, DR | 1 |
| Ericksen, SE | 3 |
| Hurt, SW | 3 |
| Howard, JS | 2 |
| Paprocki, J | 2 |
| Versiani, M | 1 |
| Cassano, GB | 2 |
| Castrogiovanni, P | 2 |
| Conti, L | 2 |
| Bonollo, L | 1 |
| Corsini, GU | 3 |
| Del Zompo, M | 3 |
| Manconi, S | 2 |
| Cianchetti, C | 1 |
| Mangoni, A | 3 |
| Gruen, PH | 2 |
| Sachar, EJ | 5 |
| Altman, N | 1 |
| Leifer, M | 1 |
| Frantz, A | 1 |
| Halpern, FS | 4 |
| Malick, JB | 1 |
| Billingsley, ML | 1 |
| Kubena, RK | 1 |
| Firling, RJ | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Sim, M | 1 |
| Jus, A | 2 |
| Jus, K | 2 |
| Fontaine, P | 1 |
| Ziemba, T | 1 |
| Singh, MM | 13 |
| Kay, SR | 8 |
| Klass, D | 1 |
| Nurnberg, HG | 1 |
| Ambrosini, PJ | 1 |
| Stern, TA | 1 |
| Anderson, WH | 1 |
| Ackenheil, M | 2 |
| Doss, FW | 1 |
| Asnis, GM | 1 |
| Fink, M | 1 |
| Kales, A | 1 |
| Soldatos, CR | 1 |
| Nelson, JC | 3 |
| Aboo-Shach, M | 1 |
| Spissu, A | 1 |
| Nathan, RS | 2 |
| Tabrizi, MA | 1 |
| Guerrini, A | 4 |
| Guastalla, A | 4 |
| Rovere, C | 4 |
| Riggi, F | 4 |
| Linn, MW | 1 |
| Caffey, EM | 1 |
| Klett, CJ | 1 |
| Hogarty, GE | 2 |
| Lamb, HR | 1 |
| Hole, K | 1 |
| Bergslien, H | 1 |
| Berge, OG | 1 |
| Reichelt, KL | 1 |
| Trygstad, OE | 1 |
| Martin, IC | 1 |
| Wald, D | 1 |
| Gagrat, D | 1 |
| Maggiano, J | 1 |
| Eaton, EM | 1 |
| Maloney, MP | 1 |
| Whipple, K | 1 |
| Zapletálek, M | 3 |
| van Leeuwen, AM | 1 |
| Molders, J | 1 |
| Sterkmans, P | 1 |
| Mielants, P | 1 |
| Martens, C | 1 |
| Hovent, AM | 1 |
| Desseilles, MF | 1 |
| Koch, H | 1 |
| Devroye, A | 1 |
| MacDonald, IM | 1 |
| Fruensgaard, K | 1 |
| Korsgaard, S | 1 |
| Jorgensen, H | 1 |
| Jensen, K | 1 |
| Rompel, H | 1 |
| Segal, H | 1 |
| Lonowski, DJ | 1 |
| Sterling, FE | 1 |
| Kennedy, JC | 1 |
| Woggon, B | 2 |
| Angst, J | 2 |
| Hopkin, J | 2 |
| Biederman, J | 1 |
| Lerner, Y | 3 |
| Walls, P | 1 |
| Gillin, JC | 2 |
| Koukkou, M | 1 |
| Zimmer, D | 1 |
| Lwow, E | 1 |
| Levitin, A | 1 |
| Matzner, G | 1 |
| Uriarte, V | 1 |
| Gillis, JS | 1 |
| Tarsy, D | 1 |
| Granacher, R | 1 |
| Bralower, M | 1 |
| Blaha, L | 1 |
| Zenglein, R | 1 |
| Wiedmayer, J | 1 |
| Raskind, M | 1 |
| Alvarez, C | 1 |
| Herlin, S | 1 |
| Ruskin, P | 1 |
| Averbukh, I | 1 |
| Dohan, FC | 1 |
| Dudley, DL | 1 |
| Rowlett, DB | 1 |
| Loebel, PJ | 1 |
| Negri, F | 1 |
| Malagoli, G | 1 |
| Paquin, J | 1 |
| Branchey, L | 1 |
| Oleshansky, M | 1 |
| Halpern, F | 1 |
| Bobritskaia, ZM | 1 |
| Gorbatko, LG | 1 |
| Litvinova, NM | 1 |
| Stoliarov, GV | 2 |
| Havdala, HS | 1 |
| Diamond, BI | 3 |
| Aliev, MN | 1 |
| Haase, HJ | 1 |
| Kaumeier, S | 1 |
| Gundel, A | 1 |
| Linde, OK | 1 |
| Maetz, H | 1 |
| Scheel, R | 1 |
| Stripf, A | 1 |
| Stripf, L | 1 |
| Kalman, T | 1 |
| Warner, GM | 1 |
| Ito, T | 1 |
| Maruta, K | 1 |
| Teradaira, R | 1 |
| Beppu, H | 1 |
| Nakagami, Y | 1 |
| Kato, Y | 1 |
| Nagatsu, T | 1 |
| Tourtellotte, WW | 1 |
| Farley, IJ | 1 |
| Hornykeiwicz, O | 1 |
| Storrie, MC | 1 |
| Scher, M | 1 |
| McGuire, J | 1 |
| Bokan, J | 1 |
| Engelhardt, DM | 1 |
| Rudorfer, L | 1 |
| Rosen, B | 1 |
| Ayd, FJ | 4 |
| Amsterdam, E | 1 |
| Barcala Peixoto, MP | 1 |
| Andrade, NM | 1 |
| Frangos, E | 1 |
| Christodoulides, H | 1 |
| Mattke, DJ | 2 |
| Mombour, W | 1 |
| Glötzner, FL | 1 |
| Pecknold, JC | 1 |
| Tanghe, A | 1 |
| Declercq, H | 1 |
| Pacquay, M | 1 |
| Brasseur, F | 2 |
| Pool, D | 1 |
| Bloom, W | 1 |
| Mielke, DH | 2 |
| Roniger, JJ | 1 |
| Selman, FB | 1 |
| McClure, RF | 1 |
| Helwig, H | 1 |
| Levenson, AJ | 1 |
| Burnett, GB | 1 |
| Nottingham, JD | 1 |
| Sermas, CE | 1 |
| Thornby, JI | 1 |
| Markianos, ES | 1 |
| Nyström, I | 1 |
| Reichel, H | 1 |
| Matussek, N | 1 |
| Jackson, AH | 1 |
| Harmatz, JS | 1 |
| Appelbaum, PS | 1 |
| Cutler, NR | 1 |
| Anderson, DJ | 1 |
| Carter, RG | 1 |
| Wallace, ER | 1 |
| Staton, MA | 1 |
| Sakurai, S | 1 |
| Gautier, J | 1 |
| Villeneuve, A | 1 |
| Pires, P | 1 |
| Villeneuve, R | 1 |
| Krishna, NR | 1 |
| Abrams, R | 1 |
| Taylor, MA | 2 |
| Behar, D | 1 |
| Pöldinger, W | 1 |
| Bures, E | 1 |
| Haage, H | 1 |
| Piccardi, MP | 1 |
| Onali, PL | 1 |
| König, L | 2 |
| Gelenberg, AJ | 1 |
| Mandel, MR | 1 |
| Bellak, L | 1 |
| Bódog, G | 2 |
| Lange, E | 1 |
| Chau-Wong, M | 2 |
| Wong, K | 2 |
| Schilkrut, R | 1 |
| Hippius, H | 1 |
| Lavagna, J | 1 |
| Lafont, A | 1 |
| Darcourt, G | 1 |
| Zurabashvilli, A | 1 |
| Butchukuri, DA | 1 |
| Kakimoto, Y | 1 |
| Baastrup, PC | 1 |
| Hollnagel, P | 1 |
| Sorensen, R | 1 |
| Schou, M | 1 |
| Tedesco, J | 1 |
| Itil, TM | 3 |
| Marasa, J | 2 |
| Saletu, B | 4 |
| Davis, S | 1 |
| Mucciardi, AN | 1 |
| Wray, SR | 1 |
| Thorsen, K | 1 |
| Solan, GM | 1 |
| Swett, C | 1 |
| Moline, RA | 1 |
| Carenzi, A | 1 |
| Schwartz, MA | 1 |
| Trabucchi, M | 1 |
| Cookson, IB | 1 |
| Owen, F | 1 |
| Ridges, AP | 1 |
| Corbett, L | 1 |
| Zanoboni, A | 2 |
| Zanoboni-Muciaccia, W | 2 |
| Recchia, M | 1 |
| Stimmel, GL | 1 |
| Zhang, XL | 1 |
| Gu, SF | 1 |
| Shintani, F | 2 |
| Kinoshita, N | 2 |
| Eitan, N | 1 |
| Levin, Y | 1 |
| Ben-Artzi, E | 1 |
| Levy, A | 1 |
| Neumann, M | 1 |
| Barbee, JG | 1 |
| Mancuso, DM | 1 |
| Freed, CR | 1 |
| Todorov, AA | 1 |
| Haffmans, PJ | 1 |
| Jansen, GS | 1 |
| Stuppäck, CH | 3 |
| Miller, C | 3 |
| Haring, C | 2 |
| Yasaei, P | 1 |
| Aizenberg, D | 1 |
| Lapidot, M | 1 |
| Mayor, C | 1 |
| Haufe, C | 1 |
| Sachdev, P | 1 |
| Tang, WM | 1 |
| Oke, AF | 1 |
| Putz, C | 1 |
| Adams, RN | 1 |
| Claus, A | 2 |
| Bollen, J | 2 |
| De Cuyper, H | 2 |
| Eneman, M | 2 |
| Malfroid, M | 2 |
| Heylen, S | 2 |
| Wilms, G | 1 |
| Van Ongeval, C | 1 |
| Baert, AL | 1 |
| van den Bosch, RJ | 1 |
| van Asma, MJ | 1 |
| Rombouts, R | 1 |
| Louwerens, JW | 1 |
| Stevens, A | 2 |
| Mahal, A | 2 |
| Uematsu, T | 1 |
| Matsuno, H | 1 |
| Sato, H | 1 |
| Hirayama, H | 1 |
| Nakashima, M | 1 |
| Rigdon, GC | 1 |
| Colbert, K | 1 |
| Zubin, J | 1 |
| Siegel, BV | 1 |
| Lohr, J | 1 |
| Katz, M | 1 |
| Gottschalk, LA | 1 |
| Marshall, JF | 1 |
| Lottenberg, S | 1 |
| Teng, CY | 1 |
| Ancill, R | 1 |
| Awad, G | 1 |
| Bakish, D | 2 |
| Chandrasena, R | 1 |
| Das, M | 1 |
| Durand, C | 1 |
| Elliott, D | 1 |
| Moran, MJ | 1 |
| Smith, D | 1 |
| Cassady, S | 1 |
| Layne-Gedge, J | 1 |
| Matsuda, H | 2 |
| Hisada, K | 2 |
| Di Gregorio, M | 1 |
| Warner, MD | 2 |
| Gillespie, H | 1 |
| Pavlou, SN | 1 |
| Nader, S | 2 |
| Peabody, CA | 3 |
| Uehlinger, C | 1 |
| Barrelet, L | 1 |
| Touabi, M | 1 |
| Baumann, P | 1 |
| Keks, NA | 5 |
| McKenzie, DP | 1 |
| Low, LH | 1 |
| Kulkarni, J | 4 |
| Singh, BS | 5 |
| McLaren, S | 1 |
| Cookson, JC | 3 |
| Stevens, I | 1 |
| O'Connor, D | 1 |
| Nofzinger, E | 1 |
| Spencer, EK | 1 |
| Kafantaris, V | 1 |
| Padron-Gayol, MV | 1 |
| Rosenberg, CR | 1 |
| Campbell, M | 1 |
| More, J | 1 |
| Velamoor, VR | 1 |
| Warkentin, S | 1 |
| Nilsson, A | 1 |
| Karlson, S | 1 |
| Risberg, J | 1 |
| Franze'n, G | 1 |
| Gustafson, L | 1 |
| Roy, S | 2 |
| Herrera, J | 2 |
| Bigelow, L | 1 |
| Monzani, E | 1 |
| Janssen, P | 1 |
| Mazure, CM | 2 |
| Gastanaga, P | 1 |
| Crowner, M | 1 |
| Bagne, CA | 1 |
| Lewis, RF | 1 |
| Riney, SJ | 2 |
| Vinogradov, S | 2 |
| Griffin, M | 1 |
| Boutros, NN | 1 |
| Worsley, IG | 1 |
| Friesen, HG | 1 |
| Johnson, G | 1 |
| Brane, D | 1 |
| Ghanbari, HA | 1 |
| Merril, CR | 1 |
| Shiue, CY | 3 |
| Bendriem, B | 1 |
| Logan, J | 1 |
| Raulli, R | 1 |
| Hogan, TP | 3 |
| Ghodhbane, T | 1 |
| Neylan, TC | 1 |
| Jolkkonen, J | 1 |
| Pitkänen, A | 1 |
| Riekkinen, PJ | 1 |
| Glovinsky, D | 1 |
| Ruskin, PE | 1 |
| Nyman, G | 1 |
| Sherman, AD | 1 |
| Davidson, AT | 1 |
| Hegwood, TS | 1 |
| Eyles, D | 1 |
| Welham, JL | 1 |
| Finzen, A | 1 |
| Chabert, N | 1 |
| Ishizuki, T | 1 |
| Kohno, H | 1 |
| Nakaki, T | 1 |
| Valente, B | 1 |
| Wang, JM | 1 |
| Richards, AL | 3 |
| Wistedt, B | 2 |
| Koskinen, T | 1 |
| Thelander, S | 1 |
| Nerdrum, T | 1 |
| Pedersen, V | 1 |
| Mølbjerg, C | 1 |
| Tegeler, J | 1 |
| Youssef, HA | 1 |
| Eklund, K | 1 |
| Edwards, JG | 4 |
| Goldie, A | 1 |
| Fukushima, Y | 1 |
| Sato, T | 2 |
| Putnam, KM | 1 |
| Powchik, P | 5 |
| McQueeney, R | 2 |
| Hebenstreit, GF | 1 |
| Amman, J | 1 |
| Bunse, J | 3 |
| Eikmeier, G | 2 |
| Kanitz, RD | 1 |
| Kanzow, WT | 2 |
| Lahdelma, RL | 1 |
| Appelberg, B | 2 |
| Kuoppasalmi, K | 1 |
| Katila, H | 2 |
| van Kammen, WB | 2 |
| Shaw, D | 1 |
| Rapaport, MH | 1 |
| Pickar, D | 1 |
| Pontius, E | 1 |
| Behrens, S | 1 |
| De Vry, J | 1 |
| Wei, HL | 1 |
| Liberzon, I | 1 |
| Goodson, J | 3 |
| Greden, JF | 2 |
| Subramanyam, B | 1 |
| Fouda, HG | 1 |
| Castagnoli, N | 1 |
| Laska, EM | 1 |
| Alexander, B | 1 |
| Mignone, ML | 1 |
| Fux, M | 1 |
| Takizawa, Y | 1 |
| Schwartz, A | 1 |
| Karbe, H | 1 |
| Wienhard, K | 1 |
| Hamacher, K | 1 |
| Huber, M | 1 |
| Herholz, K | 1 |
| Coenen, HH | 1 |
| Stöcklin, G | 1 |
| Lövenich, A | 1 |
| Heiss, WD | 1 |
| Earle-Boyer, EA | 1 |
| McDermott, BE | 1 |
| Sautter, FJ | 1 |
| Alphs, LD | 2 |
| Ishida, N | 2 |
| Steingard, S | 1 |
| Laev, H | 1 |
| Schnur, DB | 2 |
| Molcho, A | 1 |
| Ohring, R | 1 |
| Taylor, SF | 1 |
| Shipley, JE | 1 |
| Eiser, AS | 1 |
| Lin, KM | 2 |
| Miller, MH | 1 |
| Nuccio, I | 2 |
| Yamaguchi, M | 1 |
| Kaminsky, R | 3 |
| Cooper, M | 1 |
| DuMont, K | 1 |
| Blacker, M | 2 |
| Weller, MP | 2 |
| Kinuya, K | 1 |
| Kinuya, S | 1 |
| Shuke, N | 1 |
| Sumiya, H | 1 |
| Tonami, N | 1 |
| Robinson, S | 1 |
| Rosca, P | 1 |
| Durst, R | 1 |
| Shai, U | 1 |
| Ghinea, C | 1 |
| Schmidt, U | 1 |
| Nir, I | 1 |
| Beinfeld, MC | 2 |
| Altamura, CA | 1 |
| Colacurcio, F | 3 |
| Moro, AR | 2 |
| De Novellis, F | 2 |
| Brotman, AW | 3 |
| McCormick, S | 2 |
| Lecrubier, Y | 1 |
| Puech, AJ | 1 |
| Nimgaonkar, VL | 1 |
| Rajendran, MY | 1 |
| Whatley, SA | 1 |
| Liam, CK | 1 |
| Ong, SB | 1 |
| den Boer, JA | 3 |
| Westenberg, HG | 3 |
| Delcker, A | 1 |
| Schoon, ML | 1 |
| Oczkowski, B | 1 |
| Remington, GJ | 1 |
| Decina, P | 1 |
| Caracci, G | 1 |
| Scapicchio, PL | 1 |
| Ravelli, DP | 2 |
| Huisman, J | 2 |
| Ohrvik, J | 2 |
| Verhoeven, WM | 2 |
| Andersen, J | 1 |
| Kørner, A | 1 |
| Ostergaard, P | 1 |
| Fensbo, C | 1 |
| Birket-Smith, M | 1 |
| Thiesen, S | 1 |
| Hansen, NR | 1 |
| Fogh, M | 1 |
| Kristensen, M | 1 |
| Møller-Nielsen, EM | 1 |
| Deo, R | 1 |
| Soni, S | 1 |
| Rastogi, SC | 1 |
| Plant, I | 1 |
| Mitchell, M | 1 |
| Chanas, A | 1 |
| Schröder, HG | 1 |
| Dittmann, V | 1 |
| Unterweger, B | 2 |
| Schöny, HW | 1 |
| Wieselgren, IM | 1 |
| Struwe, G | 1 |
| Kristjansson, E | 1 |
| Akselson, S | 1 |
| Arthur, H | 1 |
| Andersen, T | 1 |
| Lindgren, S | 1 |
| Norman, O | 1 |
| Naimell, L | 1 |
| Mendlewicz, J | 1 |
| de Bleeker, E | 1 |
| Cosyns, P | 1 |
| Deleu, G | 1 |
| Lotstra, F | 1 |
| Masson, A | 1 |
| Mertens, C | 1 |
| Suy, E | 1 |
| Bauer, H | 1 |
| Stein, D | 1 |
| Wålinder, J | 1 |
| Holm, AC | 1 |
| Morrison, D | 2 |
| Englund, A | 1 |
| Lawrie, V | 1 |
| Lewander, T | 2 |
| Schlachet, A | 1 |
| Westerbergh, SE | 2 |
| Jostell, KG | 2 |
| Saxena, B | 1 |
| McClure, DJ | 1 |
| Max, P | 1 |
| Patris, M | 1 |
| Agussol, P | 1 |
| Alby, JM | 1 |
| Brion, S | 1 |
| Burnat, G | 1 |
| Castelnau, D | 1 |
| Deluermoz, S | 1 |
| Dufour, H | 1 |
| Ferreri, M | 1 |
| Goudemand, M | 1 |
| Ahlfors, UG | 1 |
| Hagert, U | 1 |
| Harma, P | 1 |
| Mahlanen, A | 1 |
| Mehtonen, OP | 1 |
| Naukkarinen, H | 1 |
| Outakoski, J | 1 |
| Ushakov, IuV | 1 |
| Kravchenko, NE | 1 |
| Kopeĭko, GI | 1 |
| Kalugina, LI | 1 |
| Mirzoian, MG | 1 |
| Bartkó, G | 4 |
| Horváth, S | 1 |
| Zádor, G | 2 |
| Arató, M | 2 |
| Anderer, P | 2 |
| Grünberger, J | 2 |
| Steinberger, K | 1 |
| Wachspress, M | 2 |
| Sakellariou, G | 1 |
| Bistolaki, E | 1 |
| Waites, M | 2 |
| Brown, JE | 1 |
| Middlemiss, DN | 1 |
| Amico, ET | 1 |
| Kwon, KY | 1 |
| Zigun, JR | 1 |
| Berman, KF | 1 |
| Tan, ST | 1 |
| Boniface, PJ | 1 |
| Kelly, MW | 4 |
| Coryell, WH | 3 |
| Kahn, EM | 1 |
| Alexander, JE | 1 |
| Roca, RP | 1 |
| Blackman, MR | 1 |
| Ackerley, MB | 1 |
| Harman, SM | 1 |
| Gregerman, RI | 1 |
| LaFleur, P | 1 |
| Van Norman, J | 1 |
| Shapiro, L | 1 |
| Di Gregorio, MR | 1 |
| Itoh, T | 1 |
| Yamasaki, T | 1 |
| Fukui, S | 1 |
| Raptis, C | 1 |
| Garcia-Borreguero, D | 1 |
| Weber, MM | 1 |
| Bremer, D | 1 |
| Takeichi, M | 1 |
| Petrie, EC | 1 |
| Moses, JA | 1 |
| Lombrozo, L | 1 |
| McKenzie, D | 1 |
| McGorry, P | 2 |
| deCataldo, S | 1 |
| Bolino, F | 1 |
| Pacitti, F | 1 |
| Stratta, P | 1 |
| Casacchia, M | 2 |
| Stuart, G | 1 |
| Mackie, B | 2 |
| Minas, IH | 1 |
| Jolley, AG | 1 |
| Morrison, E | 1 |
| McRink, A | 1 |
| Wilson, L | 1 |
| Kelly, M | 1 |
| Kaplan, MJ | 1 |
| Lazoff, M | 1 |
| Kelly, K | 2 |
| Lukin, R | 1 |
| Herczeg, I | 3 |
| Zemlan, FP | 1 |
| Thienhaus, OJ | 1 |
| Yeh, EK | 4 |
| Salama, AA | 1 |
| England, RD | 1 |
| Westphal, KP | 2 |
| Grözinger, B | 1 |
| Diekmann, V | 2 |
| Scherb, W | 2 |
| Reess, J | 1 |
| Leibing, U | 2 |
| Alexander, RC | 1 |
| Coggiano, M | 1 |
| Whitehead, A | 1 |
| Hassett, A | 1 |
| McLaughlin, M | 1 |
| van Riel, R | 1 |
| Nevalainen, TJ | 1 |
| Kinnunen, PK | 2 |
| Wyant, M | 1 |
| O'Neal, E | 1 |
| Sloan, A | 1 |
| Jaeger, J | 2 |
| Kriwisky, M | 1 |
| Perry, GY | 1 |
| Tarchitsky, D | 1 |
| Gutman, Y | 1 |
| Kishon, Y | 1 |
| Mauri, M | 3 |
| Regazzetti, MG | 2 |
| Bergman, RL | 2 |
| Bergman, LR | 1 |
| Karoum, F | 1 |
| Lee, TH | 1 |
| Tang, LM | 1 |
| Nugent, A | 1 |
| Goetz, KL | 1 |
| Rinieris, P | 1 |
| Diedrich, U | 1 |
| Müller, P | 1 |
| Lundberg, T | 1 |
| Hartvig, P | 1 |
| Eckernâs, SA | 1 |
| Ekblom, B | 1 |
| Lundqvist, H | 1 |
| Fasth, KJ | 1 |
| Gullberg, P | 1 |
| Långström, B | 1 |
| Inderbitzin, LB | 1 |
| Gloersen, BA | 1 |
| Rosen, PB | 1 |
| McDonald, SC | 1 |
| Vidanagama, BP | 1 |
| Wagman, AM | 1 |
| Straw, GM | 1 |
| Jauch, D | 1 |
| Motomura, N | 1 |
| Asaba, H | 1 |
| Barouche, F | 3 |
| Perényi, A | 2 |
| Goswami, U | 1 |
| Majláth, E | 1 |
| Barcs, G | 1 |
| Kassay-Farkas, A | 1 |
| Fidone, GS | 1 |
| Hernandez, JM | 1 |
| Amrung, S | 1 |
| Saran, A | 1 |
| Addy, O | 1 |
| Foliart, RH | 1 |
| Schubert, DS | 1 |
| Halaris, A | 1 |
| Hanin, I | 1 |
| Kopp, U | 1 |
| Hinterhuber, H | 2 |
| Alda, M | 1 |
| Pavlovsky, P | 2 |
| Kristofikova, Z | 1 |
| Dufkova, D | 1 |
| Young, AS | 1 |
| Faraone, SV | 2 |
| Korínková, V | 1 |
| Stárková, L | 1 |
| Mrna, B | 1 |
| Sinha, D | 1 |
| Haverstock, S | 1 |
| McLarnon, MC | 1 |
| Classen, W | 2 |
| Valeri, M | 1 |
| Bersani, I | 1 |
| Piazza, A | 1 |
| Adorno, D | 1 |
| Casciani, CU | 1 |
| Bagdy, G | 1 |
| Révai, K | 1 |
| Papp, Z | 1 |
| Fekete, MI | 1 |
| Groezinger, B | 1 |
| Rees, J | 1 |
| Rosse, RB | 1 |
| Theut, SK | 1 |
| Banay-Schwartz, M | 1 |
| Leighton, M | 1 |
| Scarcella, E | 1 |
| Cohen, CG | 1 |
| Deutsch, SI | 1 |
| Vampini, V | 1 |
| Rost, W | 2 |
| Hübner, CK | 1 |
| Bauer, K | 2 |
| Merriam, A | 1 |
| Kim, TS | 1 |
| Liebling, M | 1 |
| Dickson, DW | 1 |
| Moore, GR | 1 |
| Riehl, T | 1 |
| Binz, U | 1 |
| Wendt, G | 1 |
| Santos, JL | 3 |
| Cabranes, JA | 3 |
| Vazquez, C | 3 |
| Fuentenebro, F | 1 |
| Almoguera, I | 3 |
| Ramos, JA | 3 |
| Kramer, MS | 1 |
| Vogel, WH | 1 |
| DiJohnson, C | 1 |
| Dewey, DA | 1 |
| Sheves, P | 1 |
| Cavicchia, S | 1 |
| Little, P | 1 |
| Schmidt, R | 1 |
| Kimes, I | 1 |
| Gram, LF | 2 |
| Caillard, V | 1 |
| Boulenger, JP | 1 |
| Lacotte, J | 1 |
| Moulin, M | 1 |
| Kahne, GJ | 1 |
| Angeles, F | 1 |
| Sexson, WR | 1 |
| Chen, CT | 1 |
| Straube, ER | 1 |
| Wagner, W | 2 |
| Foerster, K | 1 |
| Heimann, H | 3 |
| Faltus, F | 2 |
| Jirák, R | 1 |
| Roth, SD | 1 |
| Matsuda, K | 1 |
| Hathuc, N | 1 |
| Su, TP | 1 |
| Fu, P | 1 |
| Fowler, J | 1 |
| Kishimoto, T | 1 |
| Hirai, M | 1 |
| Ohsawa, H | 1 |
| Terada, M | 1 |
| Matsuoka, I | 1 |
| Ikawa, G | 1 |
| Nasser, J | 1 |
| Thomas, B | 1 |
| Prieto, P | 1 |
| Rubio, ME | 1 |
| Tanne, Z | 1 |
| Karp, L | 1 |
| Katz, Y | 1 |
| Gavish, M | 1 |
| Wolfe, SA | 1 |
| Kulsakdinun, C | 1 |
| Battaglia, G | 1 |
| Jaffe, JH | 1 |
| De Souza, EB | 1 |
| Goldney, R | 1 |
| Bowes, J | 1 |
| Spence, N | 1 |
| Czechowicz, A | 1 |
| Hurley, R | 1 |
| Wagemaker, H | 1 |
| Lippmann, S | 1 |
| Cade, JR | 1 |
| Eastwood, MR | 1 |
| Hafez, HM | 1 |
| Benarroche, CL | 1 |
| Igarashi, Y | 1 |
| Toyoshima, R | 1 |
| Moroji, T | 1 |
| Curry, SH | 1 |
| Lazarus, A | 1 |
| Scharl, W | 1 |
| Knudsen, P | 1 |
| Suárez Richards, M | 1 |
| Crow, TJ | 1 |
| MacMillan, JF | 1 |
| Johnson, AL | 1 |
| Krska, J | 1 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Soni, SD | 1 |
| Sramek, JJ | 2 |
| Morrison, RL | 1 |
| Heiser, JF | 1 |
| Stuppäck, C | 1 |
| Moser, C | 1 |
| Linden, M | 1 |
| Krebs, E | 1 |
| Schied, HW | 2 |
| Vasil'ev, AA | 1 |
| Nuller, IuL | 1 |
| Heim, M | 5 |
| Broussolle, EP | 1 |
| Toung, JK | 1 |
| Malat, J | 1 |
| Williams, JA | 1 |
| O'Tuama, LA | 1 |
| Kuhar, MJ | 1 |
| Meya, U | 1 |
| Renfordt, E | 1 |
| Curran, JP | 1 |
| Johnston, R | 1 |
| Gorni, A | 2 |
| Urbanchek, MS | 1 |
| Largen, J | 1 |
| Calderon, M | 2 |
| Burd, A | 3 |
| Mann, K | 1 |
| Gärtner, HJ | 1 |
| Morgner, J | 2 |
| Rao, ML | 1 |
| Wiesel, FA | 2 |
| Sedvall, G | 3 |
| Mayláth, E | 1 |
| Dinan, TG | 1 |
| Brancato, V | 1 |
| Boppana, V | 1 |
| Amore, M | 1 |
| Cerisoli, M | 1 |
| Campanile, S | 1 |
| Campanile, A | 1 |
| Komoda, T | 1 |
| Sugishita, M | 1 |
| Yamazaki, J | 1 |
| Miura, M | 1 |
| Sakagishi, Y | 1 |
| Yamauchi, T | 1 |
| Siemetzki, H | 1 |
| Luethcke, H | 1 |
| Rueda-Vasquez, E | 1 |
| Ellerman, LA | 1 |
| Silverman, JM | 2 |
| Horvath, TB | 4 |
| Newton, JE | 2 |
| Cannon, DJ | 1 |
| Couch, L | 2 |
| Fody, EP | 2 |
| McMillan, DE | 2 |
| Metzer, WS | 1 |
| Paige, SR | 1 |
| Reid, GM | 1 |
| Summers, BN | 1 |
| Bulens, C | 1 |
| Meerwaldt, JD | 1 |
| van der Wildt, GJ | 1 |
| Keemink, CJ | 1 |
| Zeeberg, BR | 1 |
| Gibson, RE | 1 |
| Reba, RC | 1 |
| Arnett, CD | 1 |
| Russell, JA | 1 |
| MacGregor, RR | 1 |
| Carson, R | 1 |
| Diksic, M | 1 |
| Evans, A | 1 |
| Hakim, A | 1 |
| Nair, N | 1 |
| Kadysheva, NM | 1 |
| Singer, J | 1 |
| Meltzer, H | 1 |
| Bellomo, LE | 1 |
| Rosset, N | 1 |
| Tellarini, L | 1 |
| Forconesi, N | 1 |
| Wang, SB | 1 |
| Shafique, M | 1 |
| Khan, IA | 1 |
| Akhtar, MH | 1 |
| Hussain, I | 1 |
| Mintzer, Y | 1 |
| Schestatzky, M | 1 |
| Huff, FJ | 1 |
| Reiter, CT | 1 |
| Rosen, J | 1 |
| Fisher, H | 1 |
| Chaloupková, L | 1 |
| Komzák, F | 2 |
| Kolomazník, M | 2 |
| Seidl, J | 1 |
| Hronek, J | 2 |
| Sefrna, F | 1 |
| Zalcman, S | 2 |
| Ulmar, G | 1 |
| Schunck, H | 1 |
| Kober, C | 1 |
| Soloff, PH | 1 |
| George, A | 1 |
| Schulz, P | 1 |
| Cornelius, J | 1 |
| Kohlmeyer, K | 1 |
| Hübner, C | 1 |
| Gasser, T | 1 |
| Chaturvedi, SK | 1 |
| Altamura, C | 1 |
| Bareggi, S | 1 |
| Thompson, TR | 1 |
| Yassa, R | 1 |
| Gerstein, W | 1 |
| Louza Neto, MR | 1 |
| Heh, CW | 2 |
| DeMet, E | 1 |
| Potkin, S | 1 |
| Costa, J | 1 |
| Sramek, J | 1 |
| Fried, KA | 1 |
| Magnusson, M | 1 |
| Ehmann, TS | 1 |
| Delva, NJ | 1 |
| Beninger, RJ | 1 |
| McKane, JP | 1 |
| Robinson, AD | 1 |
| Stirling, GS | 1 |
| Price, WA | 2 |
| Apelt, S | 1 |
| Pfohl, BM | 1 |
| Manero, E | 1 |
| Schweitzer, JW | 1 |
| Lee, CF | 2 |
| Hung, JC | 1 |
| Haloupková, L | 1 |
| Seidl, I | 1 |
| Herrera, JN | 1 |
| Costa, JF | 1 |
| Nguyen, BN | 1 |
| Nakano, T | 1 |
| Fujii, M | 1 |
| Okada, A | 1 |
| Yokoyama, Y | 1 |
| Tsuji, T | 1 |
| Igata, A | 1 |
| Asakura, T | 1 |
| Lesser, JC | 1 |
| Freed, LB | 1 |
| Davis, BM | 4 |
| Mykytyn, VV | 1 |
| Vasavan Nair, NP | 1 |
| Suranyi-Cadotte, B | 1 |
| Achim, A | 1 |
| Lizondo, E | 1 |
| Nayak, R | 1 |
| Song, IS | 1 |
| Small, NA | 1 |
| Johns, CA | 2 |
| Kennedy, NM | 1 |
| Gribbon, D | 1 |
| Leff, JP | 1 |
| Tress, KH | 1 |
| Kahn, JP | 1 |
| Puertollano, M | 1 |
| Schane, MD | 1 |
| Klein, DF | 1 |
| Köllisch, M | 1 |
| Thuren, T | 1 |
| Virtanen, JA | 1 |
| Raskind, MA | 1 |
| Courtney, N | 1 |
| Murburg, MM | 1 |
| Backus, FI | 1 |
| Bokan, JA | 1 |
| Ries, RK | 1 |
| Dorsa, DM | 1 |
| Weitzman, RE | 1 |
| Berchou, R | 1 |
| Zethelius, M | 1 |
| Opler, LA | 1 |
| Alexander, H | 1 |
| Faber, R | 1 |
| Beaubrun, MH | 1 |
| Patrick, AL | 1 |
| Zito, JM | 1 |
| Craig, TJ | 1 |
| Wanderling, J | 1 |
| Siegel, C | 1 |
| Devaney, NM | 1 |
| Cooper, SJ | 1 |
| Schmajuk, NA | 1 |
| Yang, ZJ | 1 |
| Békésy, M | 1 |
| Bloom, DM | 1 |
| Tourjman, SV | 1 |
| Perea, K | 1 |
| Small, JG | 1 |
| Milstein, V | 1 |
| Small, IF | 1 |
| Miller, MJ | 1 |
| Kellams, JJ | 1 |
| Corsaro, CJ | 1 |
| Breitner, JC | 1 |
| Sorokin, JE | 1 |
| von Kirchbach, A | 1 |
| Fischer, EG | 1 |
| Nayak, RK | 1 |
| Doose, DR | 1 |
| Pascarzi, GA | 1 |
| Stiller, RL | 2 |
| Everett, GR | 1 |
| Nemes, ZC | 1 |
| O'Donnell, J | 1 |
| Farr, R | 1 |
| Harrison, RH | 1 |
| Reese, WG | 1 |
| Takeda, M | 1 |
| Nishinuma, K | 1 |
| Yamashita, S | 1 |
| Matsubayashi, T | 1 |
| Tanino, S | 1 |
| Nishimura, T | 1 |
| Harell, M | 1 |
| Englender, M | 1 |
| Demer, M | 1 |
| Kimhi, R | 1 |
| Zohar, M | 1 |
| Cabrera, JF | 1 |
| Körner, W | 1 |
| Romani, A | 1 |
| Zerbi, F | 1 |
| Mariotti, G | 1 |
| Callieco, R | 1 |
| Cosi, V | 1 |
| Siefen, G | 1 |
| Remschmidt, H | 1 |
| Eberhard, G | 1 |
| Hellbom, E | 1 |
| Fuller, AK | 1 |
| Tingle, D | 1 |
| Scott, JA | 1 |
| Stewart, RB | 1 |
| Giordani, AB | 1 |
| Kendler, KS | 2 |
| Hoshino, Y | 1 |
| Kaneko, M | 1 |
| Kumashiro, H | 1 |
| Tachibana, R | 1 |
| Baron, JC | 1 |
| Sgouropoulos, P | 1 |
| Duquesnoy, N | 1 |
| D'Antona, R | 1 |
| Cambon, H | 1 |
| Escobar, JI | 1 |
| Keller, J | 1 |
| Wilkins, J | 1 |
| Mason, B | 1 |
| Claghorn, JL | 1 |
| Munk-Anderson, E | 1 |
| O'Brien, RP | 1 |
| Buccio, M | 1 |
| Colombo, G | 1 |
| Terzi, A | 1 |
| Morihisa, JM | 1 |
| McAnulty, GB | 1 |
| Kidron, R | 1 |
| DeNigris, Y | 1 |
| Hurt, S | 1 |
| Chang, SS | 1 |
| Casper, R | 1 |
| Phelps, B | 1 |
| Poland, R | 1 |
| Braun, T | 1 |
| Seidel, DR | 1 |
| Tsuneizumi, T | 1 |
| Walter, K | 1 |
| Wittmann, B | 1 |
| Krueger, R | 1 |
| Trenk, D | 1 |
| Bonomo, V | 1 |
| Parisi, R | 1 |
| Meco, G | 1 |
| Falaschi, P | 1 |
| Rocco, A | 1 |
| Petrini, P | 1 |
| Rosa, M | 1 |
| Agnoli, A | 1 |
| Schlör, KH | 1 |
| Moises, HW | 1 |
| Rieger, H | 1 |
| Yamagami, S | 1 |
| Bütter, HJ | 1 |
| Dutil, C | 1 |
| Gessa, R | 1 |
| Tagliamonte, A | 1 |
| Hartley, R | 1 |
| Padwick, D | 1 |
| Smith, JA | 1 |
| Máthé, V | 1 |
| Kassay, G | 1 |
| Tüske, M | 1 |
| Kaz'mina, SA | 1 |
| Snyder, S | 1 |
| Greenberg, D | 2 |
| Yamamura, HI | 1 |
| Koppelhus, P | 1 |
| Helweg, E | 1 |
| Monrad, A | 1 |
| Niturad, A | 1 |
| Ciurezu, T | 1 |
| Cucu, I | 1 |
| de Groot, MH | 1 |
| Stevens, J | 1 |
| Wilson, K | 1 |
| Foote, W | 1 |
| Gurovich, IIa | 2 |
| Prokhorova, IS | 1 |
| Tirkel'taub, IuA | 1 |
| Romanov, IuD | 1 |
| Yamumura, HI | 1 |
| Serrano, PM | 1 |
| Tetreault, L | 1 |
| Sathanathan, GL | 1 |
| Angrist, BM | 1 |
| Phillips, N | 1 |
| Matthysse, S | 1 |
| Man, PL | 1 |
| Gannon, P | 1 |
| Hsu, W | 1 |
| Klingenberg, H | 1 |
| Franzén, G | 3 |
| Luckey, WT | 1 |
| Schiele, BC | 2 |
| Semanovskaia, EI | 1 |
| Petrova, ES | 1 |
| Stille, G | 2 |
| Marhold, J | 1 |
| Zimanová, J | 1 |
| Lachman, M | 1 |
| Král, J | 1 |
| Vojtĕchovský, M | 1 |
| Almazov, BN | 1 |
| Aherwadkar, SJ | 1 |
| Efendigil, MC | 1 |
| Coulshed, N | 1 |
| van Lommel, R | 3 |
| Dom, R | 3 |
| Baro, F | 3 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Fyrö, B | 1 |
| Nybäck, H | 1 |
| Wode-Helgodt, B | 1 |
| Serafetinides, EA | 5 |
| Collins, S | 1 |
| Clark, ML | 3 |
| Di Scipio, WJ | 1 |
| Willis, D | 2 |
| Smith, JM | 2 |
| Weston, MJ | 1 |
| Bentley, R | 1 |
| Unwin, A | 1 |
| Harper, MA | 1 |
| Gang, RG | 1 |
| Gowardman, M | 1 |
| Barrer, B | 1 |
| Brown, RA | 1 |
| Spirtes, MA | 1 |
| Swanson, WC | 1 |
| Bost, R | 1 |
| Schmocker, A | 1 |
| Woodrow, KM | 1 |
| Vandecasteele, AJ | 1 |
| Vereecken, JL | 1 |
| Marley, E | 1 |
| Crane, GE | 1 |
| Spensley, J | 1 |
| Bürki, HR | 1 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Baggiolini, M | 1 |
| Fann, WE | 1 |
| Payk, TR | 1 |
| Bazhin, EF | 1 |
| Rafalovich, EG | 1 |
| Overo, K | 1 |
| Kirk, L | 1 |
| Rees, WL | 1 |
| Guerrero-Figueroa, R | 1 |
| Towler, ML | 1 |
| Wick, PH | 1 |
| Dunlop, E | 1 |
| Michaux, L | 1 |
| Gallot, HM | 1 |
| Schneider, JJ | 1 |
| Kammerer, M | 1 |
| Wartel, R | 1 |
| Gurfein, L | 1 |
| Weil, J | 1 |
| Wysoki, V | 1 |
| Gelb, F | 1 |
| Hall, WB | 1 |
| Vestre, ND | 1 |
| Zimmermann, R | 1 |
| Winslow, WW | 1 |
| Stone, WN | 1 |
| Hofling, CK | 1 |
| Soyka, D | 1 |
| Saarma, J | 1 |
| Marjerrison, G | 2 |
| Keogh, RP | 2 |
| Stewart, A | 1 |
| Lafave, HG | 1 |
| Segovia, G | 1 |
| Holden, JM | 1 |
| Keskiner, A | 1 |
| Cocito, E | 1 |
| Ambrosini, G | 1 |
| Arata, A | 1 |
| Bevilacqua, P | 1 |
| Tortora, E | 1 |
| Szafranek, J | 1 |
| Szafranek, K | 1 |
| Bowman, R | 1 |
| Angus, JW | 1 |
| Villeneuve, C | 1 |
| Ananth, JV | 1 |
| De Mesmaecker, L | 1 |
| Demers, RG | 1 |
| Harder, A | 1 |
| Steiner, H | 1 |
| Saletu, M | 1 |
| Itil, T | 1 |
| Knopp, W | 1 |
| Horn, AS | 1 |
| Persson, T | 1 |
| Roos, BE | 1 |
| Madalena, JC | 1 |
| Araujo, MB | 1 |
| Maroja, PR | 1 |
| Mattos, HG | 1 |
| Bruno, A | 2 |
| Bruno, SC | 1 |
| Nash, LR | 1 |
| Radzuweit, H | 1 |
| Zolotnitskii, RI | 1 |
| Kutsenok, BM | 1 |
| Gastev, MD | 1 |
| Fleĭs, EP | 1 |
| Dally, P | 1 |
| Perlson, P | 1 |
| Tobin, JM | 1 |
| Malm, U | 1 |
| Ozola, MIa | 1 |
| Jeri, FR | 1 |
| Ryndina, MG | 1 |
| Novikov, VP | 1 |
| Arushanian, EB | 1 |
| Tolpyshev, BA | 1 |
| Immich, H | 1 |
| Eckmann, F | 1 |
| Schäpperle, O | 1 |
| Tempel, H | 1 |
| Schipper, JA | 1 |
| Lichko, AE | 1 |
| Marchenko, BV | 1 |
| Prakhov, VI | 1 |
| Radavichius, LI | 1 |
| Khaliavin, AV | 1 |
| Flügel, KA | 1 |
| Pfeiffer, WM | 1 |
| Blinder, MG | 1 |
| Golovan', LI | 1 |
| Sokolova, ED | 1 |
| Tsutsul'kovskaia, MIa | 1 |
| Yun, BS | 1 |
| Banner, L | 1 |
| Overbey, CB | 1 |
| Greger, J | 1 |
| Glitschka, A | 1 |
| Müller, K | 1 |
| Brophy, JJ | 1 |
| Blum, RA | 1 |
| Livingston, PB | 1 |
| Holstein, AP | 1 |
| Allegranza, A | 1 |
| Vinar, O | 1 |
| Taussigová, D | 1 |
| Popkowska, N | 1 |
| Prasad, L | 1 |
| Townley, MC | 1 |
| Ekdawi, MY | 1 |
| Fowke, R | 1 |
| Buffa, B | 1 |
| Cotta Ramusino, M | 1 |
| Muti, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up[NCT02526030] | Phase 4 | 203 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Clozapine and Olanzapine in the Treatment of Violence in Schizophrenic Patients[NCT01123408] | 110 participants (Actual) | Interventional | 1999-06-30 | Completed | |||
| An Observational Study of Anti-Psychotic Medication for the Treatment of Agitation in the Emergency Department[NCT02877108] | 100 participants (Anticipated) | Observational | 2016-04-30 | Recruiting | |||
| A Comparison of Long-Acting Injectable Medications for Schizophrenia[NCT01136772] | Phase 4 | 311 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation[NCT02935998] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia[NCT00723606] | Phase 3 | 376 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial.[NCT00395915] | Phase 4 | 106 participants (Actual) | Interventional | 2006-09-30 | Active, not recruiting | ||
| A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness[NCT01152697] | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | |||
| Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in First Episode Untreated Schizophrenia: A Randomized, Open Label, Active Controlled Study[NCT03304457] | Phase 4 | 100 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156117] | Phase 3 | 417 participants (Actual) | Interventional | 2005-05-12 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156104] | Phase 3 | 460 participants (Actual) | Interventional | 2005-07-01 | Completed | ||
| An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277] | Phase 3 | 67 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia[NCT01164059] | Phase 4 | 149 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825] | 100 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence - A Prospective Randomized Evaluation of Response and Toxicity[NCT03303365] | 203 participants (Actual) | Interventional | 2018-02-01 | Completed | |||
| Is Flunarizine a Cheap, Well-Tolerated and Long-Acting Atypical Antipsychotic? A Randomized Double-Blind Flexible-Dose Clinical Trial Versus Haloperidol for the Treatment of Schizophrenia[NCT00740259] | Phase 4 | 70 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder[NCT01198353] | Phase 4 | 67 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741] | 180 participants (Anticipated) | Observational | 2023-01-09 | Recruiting | |||
| A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia[NCT02704962] | Phase 4 | 94 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| GiSAS Trial: Aripiprazole, Olanzapine, and Haloperidol in the Long Term Treatment of Schizophrenia.[NCT01052389] | Phase 4 | 300 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Effectiveness of Switching Antipsychotic Medications[NCT00044655] | Phase 4 | 219 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia[NCT00088478] | Phase 3 | 402 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Effectiveness of the RemedRugby Program, a Program of Ecological Cognitive Remediation of Social Cognition Disorders in Schizophrenia[NCT03775564] | 60 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| Transdermal Nicotine in Female Patients at High Risk for PONV[NCT00775749] | 0 participants (Actual) | Interventional | 2009-04-30 | Withdrawn (stopped due to The study is not feasible with the number of subjects needed to complete it.) | |||
| A Pathophysiological Study to Determine if Enhancing Glutamate Transporter Function Produces Antidepressant Effects in Patients With Major Depressive Disorder[NCT02049385] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2014-01-03 | Terminated (stopped due to Severe side effects & lack of target engagement) | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder[NCT00998608] | Phase 4 | 88 participants (Actual) | Interventional | 2007-08-31 | Terminated (stopped due to terminated) | ||
| MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia[NCT00505076] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Six Month, Double Blind, Placebo-controlled Trial of the Efficacy of Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women[NCT01573637] | Phase 3 | 78 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia[NCT00007774] | Phase 4 | 600 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| The Cognitive Effects of Risperidone and Olanzapine[NCT00108368] | Phase 4 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia[NCT00159081] | Phase 4 | 159 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Metabolic Profile and Anthropometric Changes in Schizophrenia[NCT00534183] | 2,006 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Multimodal Neural Investigation of Reward Processing in Mental Illness[NCT03068793] | 80 participants (Actual) | Observational | 2013-10-01 | Completed | |||
| An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance[NCT01929889] | Phase 4 | 19 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Low recruitment) | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis[NCT05282277] | Phase 4 | 103 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | ||
| Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132] | Phase 3 | 523 participants (Actual) | Interventional | Completed | |||
| Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)[NCT02487966] | 132 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | |||
| Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.[NCT00249119] | Phase 3 | 1,579 participants (Actual) | Interventional | Completed | |||
| Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580] | 15 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| Clozapine Response and Biogenic Amines in Schizophrenia[NCT00169039] | Phase 4 | 66 participants | Interventional | 1994-12-31 | Terminated | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Differences in Voxel-based Morphometry of Different Brain Structures in Patients With Mood Disorder Bipolar Mania in Comparison to Morphometry of Nrmal Controls[NCT03181698] | 45 participants (Actual) | Observational | 2017-09-22 | Completed | |||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva[NCT00395499] | 19 participants | Observational | 2001-05-31 | Completed | |||
| Clinical Trial of Dipyridamole in Schizophrenia[NCT00349973] | 29 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
| Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking[NCT00621777] | Phase 4 | 247 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Double-blind and Randomized Trial of Ginkgo Biloba Extract Added to Risperidone in Treatment-naive First-episode Schizophrenia[NCT01524380] | 124 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures[NCT00409201] | Phase 1 | 30 participants | Interventional | 2006-03-31 | Recruiting | ||
| A Survey of Sexual Function in Schizophrenic Patients[NCT01835522] | 0 participants (Actual) | Observational | 2009-07-31 | Withdrawn | |||
| Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia[NCT03075657] | Phase 4 | 120 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Brain Changes in Pediatric Obstructive Sleep Apnea[NCT05368077] | 70 participants (Anticipated) | Interventional | 2022-05-14 | Recruiting | |||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)[NCT01138618] | 85 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| Thermoregulation Among Individuals With First-episode Psychosis[NCT04369677] | 20 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement. (NCT01136772)
Timeframe: Baseline to 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Paliperidone Palmitate | -6.87 |
| Haloperidol Decanoate | -6.40 |
Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication. (NCT01136772)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Paliperidone Palmitate | 49 |
| Haloperidol Decanoate | 47 |
BARS measures the degree of agitated behavior using a 7-point scale describing increasing levels of activity (1 =difficult or unable to rouse; 2 = asleep but responds normally to verbal or physical contact; 3 = drowsy, appears sedated; 4 = quiet and awake [normal level of activity]; 5 = signs of overt [physical or verbal] activity, calms down with instructions; 6 = extremely or continuously active, not requiring restraint; 7 = violent, requires restraint. (NCT00723606)
Timeframe: Baseline, 72 hours
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Ziprasidone | -0.93 |
| Haloperidol | -1.06 |
The BPRS agitation subscale score was composed of 4 questions (questions 2, 6, 10, 17). The BPRS agitation subscale score was obtained by summing the relevant individual items. Total possible score range=4 to 28. Change: score at final visit minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Ziprasidone | -6.97 |
| Haloperidol | -7.45 |
BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. Change: score at final visit minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Ziprasidone | -17.32 |
| Haloperidol | -18.44 |
CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Ziprasidone | -1.18 |
| Haloperidol | -1.21 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. (NCT00723606)
Timeframe: 72 hours
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Ziprasidone | 2.52 |
| Haloperidol | 2.55 |
The BPRS agitation subscale score was composed of 4 questions (questions 2, 6, 10, 17). The BPRS agitation subscale score was obtained by summing the relevant individual items. Total possible score range=4 to 28. A response was defined as a > 30 percent reduction from baseline in BPRS agitation subscale score. (NCT00723606)
Timeframe: 72 hours
| Intervention | participants (Number) | |
|---|---|---|
| Response | No Response | |
| Haloperidol | 155 | 29 |
| Ziprasidone | 149 | 39 |
Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 2.43 |
Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 7.00 |
Subjects will be asked how many days they have been homeless (NCT01152697)
Timeframe: 12 months
| Intervention | days (Mean) |
|---|---|
| Patient Noncompliance | 35 |
The frequency of health resource use will be measured through interview of the participant. (NCT01152697)
Timeframe: 25 weeks
| Intervention | days (Mean) |
|---|---|
| Patient Noncompliance | 20.18 |
Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate better outcomes. (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 1.33 |
"Satisfaction will be measured by a seven item inventory taken by the participant.~Scale ranges from 1 (Strongly Agree) to 5 (Strongly Disagree). Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The highest possible score is 35." (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 12.33 |
"Satisfaction will be measured by a seven item inventory taken by the participant.~Scale ranges from 1 (Strongly Agree) to 5 (Strongly Disagree). Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The highest possible score is 35." (NCT01152697)
Timeframe: 25 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Patient Noncompliance | 12.12 |
Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 6.63 | 4.47 |
Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 7.47 | 8.07 |
Subjects will be asked how many days they have been homeless (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | days (Mean) | |
|---|---|---|
| Baseline | 25 Weeks | |
| Patient Noncompliance | 6.50 | 9.85 |
Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 2.31 | 1.19 |
A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | Percentage of doses (Mean) | |
|---|---|---|
| Past week | Past month | |
| Patient Noncompliance | 30.91 | 10.10 |
"Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976) Lower scores indicate improved outcomes. Higher scores indicate worse outcomes.~Illness scale: 1 - 7 (1 = Normal/not at all ill ; 7 = Among the most extremely ill patients) Global improvement scale: 1 - 7 (1 = Very much improved ; 7 = Very much worse)" (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline - Severity | Week 25 - Severity | Baseline - Global Improvement | Week 25 - Global Improvement | |
| Patient Noncompliance | 4.76 | 3.24 | 3.43 | 2.14 |
"The PANSS (Kay, Fiszbein, & Opler 1987) was created to assess both the positive and negative symptoms of schizophrenia such as hallucinations and emotional withdrawal, respectively. The scale rates 30 symptoms on a scale from 1 (absent) to 7 (extreme) and has been shown to limit bias between the assessment of positive and negative symptoms, providing a broad but balanced spectrum of the illness.~There are three subscales: positive symptoms, negative symptoms, general psychopathology. Potential responses to Items on all subscales range from 1 (absent) to 7 (extreme). Lower scores indicate lower symptoms and, therefore, better outcomes. Higher scores indicate more presence of symptoms and, therefore, worse outcomes.~Subscales are combined to produce a total score, which is summed from all of the subscales. Lower total scores indicate lower symptoms and, therefore, better outcomes. Higher total scores indicate more presence of symptoms and, therefore, worse outcomes." (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 46.37 | 32.84 |
"The BPRS, developed by Overall and Gorham (1962), is a widely used, relatively brief scale that measures major psychotic and non-psychotic symptoms in individuals with SMI. The 18-item BPRS is well-validated and is perhaps the most researched instrument in psychiatry. Reliability coefficients are reported to be in the range of 0.56-0.87.~Scale Range: 18-126 Lower scores represent improved outcomes." (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 46.37 | 32.84 |
Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF. The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Patient Noncompliance | 45.33 | 63.83 |
Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF (Global Assessment of Functioning). The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 25 | |
| Patient Noncompliance | 47.35 | 58.65 |
The frequency of health resource use will be measured through interview of the participant. (NCT01152697)
Timeframe: Month 1-3, Month 10-12
| Intervention | days (Mean) | |
|---|---|---|
| 3 Month | 12 Month | |
| Patient Noncompliance | 19.33 | 15.50 |
"Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976) Lower scores indicate improved outcomes. Higher scores indicate worse outcomes.~Illness scale: 1 - 7 (1 = Normal/not at all ill ; 7 = Among the most extremely ill patients) Global improvement scale: 1 - 7 (1 = Very much improved ; 7 = Very much worse)" (NCT01152697)
Timeframe: 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Severity | Global Improvement | |
| Patient Noncompliance | 3.17 | 2.42 |
A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections. (NCT01152697)
Timeframe: 12 months
| Intervention | Percentage of doses (Mean) | |
|---|---|---|
| Past Week | Past Month | |
| Patient Noncompliance | 28.65 | 6 |
Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | 2.14 |
| 2. IM Haloperidol Pus Lorazepam | 2.23 |
The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | -10.2 |
| 2. IM Haloperidol Plus Lorazepam | -9.9 |
(NCT00044655)
Timeframe: Measured at Six Months
| Intervention | participants (Number) |
|---|---|
| Stay | 11 |
| Switch | 23 |
Change in Montgomery Asberg Depression Rating Scale (MADRS) from baseline to 7 days post-treatment. The range of values is from 0 - 60, with a higher score indicating increased depressive symptoms. A score of 7-19 indicates mild depression; 20-34 indicates moderate depression; >34 indicates severe depression. (NCT02049385)
Timeframe: 7 days
| Intervention | percentage of change in units of scale (Median) |
|---|---|
| Diazoxide | 0 |
| Placebo | 10 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
The primary outcome measure is the composite score on the Matrics Consensus Cognitive Battery (MCCB). The MCCB composite score is a standardized mean of the seven domain scores. T-scores are standardized to normative data, and have an estimated mean of 50 and SD of 10 in the general healthy population. Data reduction for analysis of neurocognitive testing used the following steps: i) individual neurocognitive test scores at baseline and follow-up were converted to t-scores; ii) t-scores within the pre-specified cognitive domains measured by more than one test were averaged to obtain a domain-specific t-score; and iii) domain-specific t-scores were averaged to create the MCCB composite score. (NCT00505076)
Timeframe: 4 weeks
| Intervention | composite score (Mean) |
|---|---|
| MK-077 8 mg BID | 27.9 |
| MK-0777 3 mg BID | 31.3 |
| Placebo BID | 32.5 |
The Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity. The SCoRS Interviewer Global Rating of function has a range 1 to 10. Higher ratings indicate greater impairment. (NCT00505076)
Timeframe: 4 Weeks (Baseline to End of Treatment)
| Intervention | SCoRS Score (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| MK-077 8 mg BID | 4.1 | 4.0 |
| MK-0777 3 mg BID | 4.8 | 4.6 |
| Placebo BID | 3.8 | 3.6 |
The UCSD Performance-Based Skills Assessment assessed functional capacity. The UPSA Summary Score has a range from 0 to 120. A higher score indicates less impairment. (NCT00505076)
Timeframe: Baseline and end of treatment, a total of four weeks.
| Intervention | UPSA Summary Score (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| MK-077 8 mg BID | 91.7 | 90.4 |
| MK-0777 3 mg BID | 85.0 | 86.3 |
| Placebo BID | 95.0 | 96.5 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
"Facial Affect Perception Test that assesses the ability to accurately recognize facially expressed emotions as published by Smith et al 2014; Derntl et al., 2009. This scale ranges from 0-100 percent with a total of 30 trials. We examined the percent correct as the total number of correct responses divided by the total number of completed trials. There were no subscales. 100% accurate is the best outcome and 0% accurate is the worst outcome.~Cognitive Empathy Test that assesses the ability to accurately determine the emotional expression of another person as depicted in a static image of a social interaction as published by Smith et al 2014; Derntl et al., 2009. This scale ranges from 0-100 percent with a total of 60 trials. We examined the percent correct as the total number of correct responses divided by the total number of completed trials. There were no subscales. 100% accurate is the best outcome and 0% accurate is the worst outcome." (NCT01929889)
Timeframe: baseline and twelve weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Facial Affect Perception Test | Cognitive Empathy Test | |
| Iloperidone | 0 | -3.333 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
The primary endpoint will be the severity of pain measured by changes in PLP from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS pain scale is a simple 10- point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -2.84 |
| Active tDCS and Sham Mirror Therapy | -3.35 |
| Sham tDCS and Active Mirror Therapy | -1.78 |
| Sham tDCS and Sham Mirrory Therapy | -2.58 |
The endpoint will be the severity of pain measured by changes in Phantom Limb Sensation from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Sensation scale is a simple 10- point scale (0 = ''no Phantom Limb Sensation'', 10 = ''Phantom Limb Sensation as much as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.86 |
| Active tDCS and Sham Mirror Therapy | -2.55 |
| Sham tDCS and Active Mirror Therapy | -1.35 |
| Sham tDCS and Sham Mirrory Therapy | -2.83 |
The endpoint will be the severity of pain measured by changes in Stump Pain from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Stump Pain scale is a simple 10- point scale (0 = ''no Phantom Limb Stump Pain'', 10 = ''Phantom Limb Stump Pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.31 |
| Active tDCS and Sham Mirror Therapy | -1.9 |
| Sham tDCS and Active Mirror Therapy | -0.91 |
| Sham tDCS and Sham Mirrory Therapy | -0.96 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
The Scale for the Assessment of Negative Symptoms (SANS) total score, minus the global items, inappropriate affect, poverty of content of speech, and attention items, used to measure negative symptoms. Mean SANS total score by treatment and week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms. (NCT00349973)
Timeframe: Baseline and Follow-Up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (Phase 1/Week 1) | Follow-Up (Phase 4/Week 1) | |
| Dipyridamole | 23.3 | 25.8 |
| Olanzapine | 25.6 | 27.0 |
"The Brief Psychiatric Rating Scale (BPRS) consists of 20 items, with 6 of these items used to assess positive symptom change. The BPRS positive symptom items are: somatic concern, conceptual disorganization, hostility, suspiciousness, hallucinatory behavior, and unusual thought content. Each scale ranges from 1=Not Present to 7=Very Severe. A higher score indicates a more severe positive symptom rating." (NCT00349973)
Timeframe: Baseline and follow-up
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - Somatic Concern | Follow-Up - Somatic Concern | Baseline - Conceptual Disorganization | Follow-Up - Conceptual Disorganization | Baseline - Hostility | Follow-Up - Hostility | Baseline - Suspiciousness | Follow-Up - Suspiciousness | Baseline - Hallucination | Follow-Up - Hallucination | Baseline - Unusual Thought Content | Follow-Up - Unusual Thought Content | |
| Dipyridamole | 2.222 | 1.60 | 2.667 | 2.00 | 1.222 | 1.00 | 4.11 | 3.000 | 2.67 | 2.600 | 3.111 | 2.800 |
| Olanzapine | 1.400 | 1.00 | 2.600 | 2.00 | 1.200 | 2.00 | 3.40 | 1.500 | 3.80 | 2.500 | 3.400 | 1.500 |
The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160. (NCT00349973)
Timeframe: Baseline and Follow-Up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (Phase 1/Week 1) | Follow-Up (Phase 3/Week 6) | |
| Dipyridamole | 73.00 | 77.40 |
| Olanzapine | 59.00 | 65.00 |
The 12-Item Short Form Health Survey (SF-12) is a 12-item measure of perceived health status with good reliability, validity and correlation with other health measures. It is scored via a standard algorithm, with higher scores indicating better patient self perception of health, with a mean score of 50 and a standard deviation of 10 in a representative sample of the US population. The score is computed using the scores of the twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health. This was administered at baseline and end of study. (NCT00621777)
Timeframe: at week 52
| Intervention | units on a scale (Mean) |
|---|---|
| Varenicline | 47.59 |
| Placebo | 48.39 |
Brief Psychiatric Rating Scale is a 24 item scale that is designed to assess positive and negative symptoms, and general psychopathology in people with serious mental illness. Each item is rated on a 7-point scale from not present to extremely severe; higher scores in a range of 24 to 168, indicate more severe symptoms Ratings are based on observation and patient report. The validity of the BPRS is generally high when compared with other measures of general psychopathology. It was administered at baseline, study weeks 12, 18, 26, 38, 52 (NCT00621777)
Timeframe: at week 52
| Intervention | units on a scale (Mean) |
|---|---|
| Varenicline | 50.43 |
| Placebo | 47.88 |
(NCT00621777)
Timeframe: 76 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| 7-day, point-prevalence abstinence at week 52 | Continuous abstinence, weeks 12-64 | Continuous abstinence, weeks 12-76 | |
| Placebo | 9 | 7 | 5 |
| Varenicline | 24 | 18 | 12 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
170 reviews available for haloperidol and Dementia Praecox
| Article | Year |
|---|---|
Clinical characteristics and treatment outcomes of patients with newly diagnosed schizophrenia: A 4-year single-center experience in Saudi Arabia.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Saudi Arabia; Schizophrenia; Treatme | 2022 |
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lur | 2022 |
Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.
Topics: Antipsychotic Agents; Drug Tapering; Haloperidol; Humans; Randomized Controlled Trials as Topic; Rec | 2023 |
The Mini-TRH Test.
Topics: Dopamine; Haloperidol; Humans; Male; Prolactin; Schizophrenia; Thyrotropin-Releasing Hormone | 2023 |
The Mini-TRH Test.
Topics: Dopamine; Haloperidol; Humans; Male; Prolactin; Schizophrenia; Thyrotropin-Releasing Hormone | 2023 |
The Mini-TRH Test.
Topics: Dopamine; Haloperidol; Humans; Male; Prolactin; Schizophrenia; Thyrotropin-Releasing Hormone | 2023 |
The Mini-TRH Test.
Topics: Dopamine; Haloperidol; Humans; Male; Prolactin; Schizophrenia; Thyrotropin-Releasing Hormone | 2023 |
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetia | 2023 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action P | 2020 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network M | 2021 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphen | 2021 |
Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Network Meta- | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressio | 2021 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistan | 2017 |
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Diabetic Ketoaci | 2017 |
Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia.
Topics: Antipsychotic Agents; Drug Substitution; Fluphenazine; Haloperidol; Humans; Schizophrenia; Treatment | 2018 |
Dealing with missing outcome data in meta-analysis.
Topics: Bias; Data Collection; Data Interpretation, Statistical; Depression; Haloperidol; Humans; Meta-Analy | 2020 |
Haloperidol discontinuation for people with schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; R | 2019 |
Current use of atypical antipsychotics.
Topics: Antipsychotic Agents; Autoreceptors; Brain; Dose-Response Relationship, Drug; Flupenthixol; Haloperi | 2002 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
Haloperidol dose for the acute phase of schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Haloperidol; Humans; Randomized Controlled Trials as Topic; Sch | 2013 |
Haloperidol versus placebo for schizophrenia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Parkinsonian Disorders | 2013 |
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Haloperidol; Heterocyclic Compounds, 4 | 2014 |
A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes.
Topics: Adult; Antipsychotic Agents; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; Schizo | 2014 |
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Patient Dropouts; Randomized Co | 2014 |
The ‘snake’ man: ophidianthropy in a case of schizophrenia, along with literature review.
Topics: Antipsychotic Agents; Delusions; Haloperidol; Humans; Male; Schizophrenia; Treatment Outcome; Young | 2014 |
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
Topics: Administration, Oral; Antipsychotic Agents; Haloperidol; Humans; Loxapine; Psychotic Disorders; Rand | 2015 |
[The neurotoxicity of pyridinium metabolites of haloperidol].
Topics: Antipsychotic Agents; Biotransformation; Brain; Delirium; Haloperidol; Humans; Nausea; Neurodegenera | 2015 |
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Clozapine; Double-Blind Method; Drug Re | 2016 |
Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials.
Topics: Antipsychotic Agents; Benzamides; Haloperidol; Humans; Publication Bias; Randomized Controlled Trial | 2016 |
Haloperidol for long-term aggression in psychosis.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; H | 2016 |
Depot antipsychotics: Where do we stand?
Topics: Antipsychotic Agents; Haloperidol; Hospitalization; Humans; Medication Adherence; Paliperidone Palmi | 2016 |
Aripiprazole vs. Placebo or Haloperidol for Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Haloperidol; Humans; Schizophrenia; Treatment Outcome | 2016 |
Are second generation antipsychotics a distinct class?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cognition Disorders; Haloperidol; Humans; Q | 2008 |
[Clinical and therapeutic aspects of agitation].
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as Topi | 2007 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evi | 2009 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperi | 2010 |
[Action of amygdala dopamine and effect of antipsychotics].
Topics: Amygdala; Animals; Antipsychotic Agents; Aripiprazole; Catecholamines; Conditioning, Classical; Dopa | 2010 |
Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials.
Topics: Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Olan | 2011 |
The role of the cerebellum in schizophrenia: from cognition to molecular pathways.
Topics: Animals; Antipsychotic Agents; Cerebellum; Cognition Disorders; Glutamic Acid; Haloperidol; Humans; | 2011 |
Bromperidol decanoate (depot) for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Randomized Controlled Trials | 2011 |
A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Bayes Theorem; Haloperidol; Humans; Randomized Control | 2011 |
Is rational antipsychotic polytherapy feasible? A selective review.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Piper | 2012 |
The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)?
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Disease M | 2012 |
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Dibenzothiazepines; | 2012 |
[The long-term treatment of schizophrenia].
Topics: Activities of Daily Living; Administration, Oral; Antipsychotic Agents; Cognitive Behavioral Therapy | 2012 |
The differences between typical and atypical antipsychotics: the effects on neurogenesis.
Topics: Antipsychotic Agents; Apoptosis; Brain; Brain-Derived Neurotrophic Factor; Haloperidol; Humans; Nerv | 2012 |
[Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature].
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Methotrimeprazine; | 2012 |
Bromperidol decanoate (depot) for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Randomized Controlled Trials | 2012 |
Haloperidol dose for the acute phase of schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Haloperidol; Humans; Randomized Controlled Trials as Topic; Sch | 2002 |
Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness.
Topics: Animals; Antipsychotic Agents; Behavior; Behavior, Animal; Brain; Dizocilpine Maleate; Dopamine Anta | 2002 |
Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Drinking Behavior; Drug Administration Schedule; Dr | 2003 |
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; | 2003 |
The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dibenzothiazepines; Haloperidol; Humans; Psychiatric | 2003 |
A meta-analysis of the efficacy of second-generation antipsychotics.
Topics: Algorithms; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperido | 2003 |
Pharmacogenetics in psychosis.
Topics: Antipsychotic Agents; Clozapine; Cytochrome P-450 Enzyme System; Drug Resistance; Dyskinesia, Drug-I | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
[Late schizophrenia].
Topics: Adult; Age of Onset; Aged; Antipsychotic Agents; Chlorpromazine; Clozapine; Diagnostic and Statistic | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant | 2003 |
[Problems with the treatment of schizophrenics in the doctor's office].
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Diazepam; Drug Therapy, Combination | 2003 |
New generation antipsychotics for first episode schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
[Effect of antipsychotics on glutaminergic neural transmission in the animal model].
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Disease Models, Animal; Haloperidol; Humans; Long-T | 2004 |
[Paralytic ileus during haloperidol therapy].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Fatal Outcome; Haloperidol; Humans; Intestinal Pseudo | 2004 |
[Effect of smoking on pharmacokinetics of antipsychotics].
Topics: Antipsychotic Agents; Body Weight; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Halope | 2004 |
Depot bromperidol decanoate for schizophrenia.
Topics: Antipsychotic Agents; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Haloperidol; | 2004 |
[The features of atypical neuroleptic amisulpride action].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Clinical | 2004 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral | 2003 |
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase III as Topic; Haloperidol; Humans; Meta-A | 2004 |
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Depression; Female; Haloper | 2005 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; | 2004 |
Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review.
Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Dystonia; Female; Haloperidol; Humans; Larynge | 2005 |
Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Computer Simulation; Decision Making; Haloperi | 2006 |
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double- | 2005 |
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Brief Psychi | 2006 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzot | 2005 |
Risks versus benefits of different types of long-acting injectable antipsychotics.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Haloperidol; Health Care Costs; Humans; In | 2006 |
Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Humans; Randomized Controlled T | 2006 |
[Two cases of tardive Tourette syndrome].
Topics: Adult; Akathisia, Drug-Induced; Alcoholism; Amantadine; Antipsychotic Agents; Cholinergic Antagonist | 2006 |
Neuroleptic-induced dysphagia: case report and literature review.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Deglutition; Deglutition Disorders; Haloperidol; Human | 2007 |
Haloperidol versus placebo for schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Placebo Effect; Randomized Controlled Trials as Topic; Sc | 2006 |
A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects.
Topics: Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Ha | 2007 |
Delusional denial of pregnancy as a special form of Cotard's syndrome: case report and review of the literature.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Delusions; Denial, Psychological; Doxepin; Femal | 2007 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chlorproma | 2007 |
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Halo | 2007 |
Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Clozapine; Dopamine Agonists; Dopamine Antagonists; Drug | 2008 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Bl | 2008 |
Haloperidol versus chlorpromazine for schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Randomized Controlled Trials as Topic; Sc | 2008 |
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 2008 |
Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bias; Bupropion; Data Interpretation | 2008 |
Central nervous system dopamine receptors.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Brain; Dopamine; Guanine Nucleotides; Haloperidol; | 1980 |
The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations.
Topics: Animals; Antipsychotic Agents; Blood-Brain Barrier; Cerebral Cortex; Chlorpromazine; Dopamine; Drug | 1980 |
[Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
Topics: Adenylyl Cyclase Inhibitors; Animals; Antipsychotic Agents; Apomorphine; Blood Platelets; Brain; Bro | 1980 |
Interictal schizophrenia-like psychoses in temporal lobe epilepsy.
Topics: Anticonvulsants; Brain; Carbamazepine; Electroencephalography; Epilepsy, Temporal Lobe; Functional L | 1983 |
Prolactin levels and effects of neuroleptics.
Topics: Antipsychotic Agents; Biological Availability; Chlorpromazine; Drug Tolerance; Dyskinesia, Drug-Indu | 1983 |
[Schizophrenia as a dopamine excess syndrome].
Topics: Aged; Amphetamines; Animals; Brain; Dopamine; Haloperidol; Humans; Male; Psychoses, Substance-Induce | 1983 |
Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Clozapine; Dibenzazepines; Dose-Response | 1983 |
[Recent advances in clinical psychopharmacology].
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Benzamides; Carbamazepine; Dyskine | 1984 |
Dopamine autoreceptor stimulation: clinical significance.
Topics: Apomorphine; Dopamine; Haloperidol; Humans; Huntington Disease; Mental Disorders; Neurons; Parkinson | 1982 |
Cerebellar pathology in schizophrenia--cause or consequence?
Topics: Animals; Apomorphine; Atrophy; Behavior, Animal; Brain Stem; Cats; Cerebellar Diseases; Cerebellum; | 1982 |
Haloperidol plasma level monitoring in neuropsychiatric patients.
Topics: Chronic Disease; Drug Resistance; Haloperidol; Humans; Kinetics; Mental Disorders; Nervous System Di | 1982 |
Pharmacological profile of risperidone.
Topics: Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Haloperidol; Humans; Isoxazoles; Meta | 1993 |
Extrapyramidal side effects and tolerability of risperidone: a review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; D | 1994 |
Clinical use of the newer antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Female; Formularies as Topic; Halo | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric | 1995 |
Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Cyclic AMP; Dopamine; Haloperidol; Neurotensin; Pyr | 1995 |
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Topics: Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Fluphenazine; Haloperidol; Humans; Pl | 1994 |
Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy.
Topics: Animals; Brain; Clozapine; Haloperidol; Humans; Norepinephrine; Rats; Receptors, Adrenergic; Schizop | 1994 |
The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Clozapine; Haloperidol; Humans; Neurotensin; Nucleus | 1994 |
A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
Topics: Antipsychotic Agents; Biological Availability; Biotransformation; Brain; Dose-Response Relationship, | 1993 |
Prediction of outcome in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Growth Hormo | 1993 |
Dose response of prophylactic antipsychotics.
Topics: Administration, Oral; Aftercare; Antipsychotic Agents; Combined Modality Therapy; Delayed-Action Pre | 1993 |
CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
Topics: Animals; Anxiety; Brain; Cholecystokinin; Dopamine; Haloperidol; Humans; Neurons; Pyrazoles; Recepto | 1994 |
Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Humans; Schizophrenia; Treatmen | 1995 |
[The "neuroleptic threshold"--a review of the literature].
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; H | 1996 |
The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches.
Topics: Animals; Antipsychotic Agents; Dopamine Antagonists; Haloperidol; Humans; Locomotion; Naphthalenes; | 1995 |
Antipsychotic dosing strategies in acute schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administratio | 1996 |
Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis.
Topics: Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Humans; P | 1996 |
Mechanisms of action of atypical antipsychotic drugs: a critical analysis.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Biogenic Amines; Brain; Clo | 1996 |
Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.
Topics: Antiparkinson Agents; Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Efficacy of olanzapine: an overview of pivotal clinical trials.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Male | 1997 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
Dosing the antipsychotic medication olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Respons | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collect | 1997 |
The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Haloperidol; Humans; Schizophrenia | 1998 |
Facilitating compliance with antipsychotic medication.
Topics: Antipsychotic Agents; Clozapine; Cognition; Drug Monitoring; Haloperidol; Health Care Costs; Humans; | 1998 |
Sertindole: a review of clinical efficacy.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Depression; Haloperidol; Humans; Imidazoles; Indoles | 1998 |
Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review.
Topics: Adult; Autoimmune Diseases; Chorea; Comorbidity; Haloperidol; Humans; Mental Disorders; Obsessive-Co | 1996 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Meth | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; H | 1999 |
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Topics: Amoxapine; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Haloperi | 1999 |
[Clinical efficacy of olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Binding Sites; Clinical Trials as Topic; Clozapine; Dopamine | 1999 |
Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Dibenzothiazepines; Haloperidol; Humans; Male; Mod | 1999 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relations | 2000 |
Depot haloperidol decanoate for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Schizophrenia | 2000 |
Depot bromperidol decanoate for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Schizophrenia | 2000 |
Neuroleptic malignant syndrome and severe thrombocytopenia: case report and literature review.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malig | 2000 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc | 2000 |
Focus on risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Risperidone | 2000 |
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dose-Response Relationship, Drug; Haloper | 2000 |
Effects of risperidone on affective symptoms in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as T | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid | 2001 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
Haloperidol versus placebo for schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Placebo Effect; Randomized Controlled Trials as Topic; Sc | 2001 |
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; Haloperi | 2001 |
Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Metho | 2001 |
Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.
Topics: Antipsychotic Agents; Brain; Corpus Striatum; Haloperidol; Humans; Neuronal Plasticity; Nucleus Accu | 2001 |
Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Topics: Antipsychotic Agents; Chlorpromazine; Clozapine; Cost-Benefit Analysis; Decision Support Techniques; | 2001 |
The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Factor Analysis, Statistical; Female; | 2001 |
[Effects of anti-psychotic agents on brain glucose metabolism and regional cerebral circulation in patients with schizophrenia-- study by functional brain imaging of SPECT and PET].
Topics: Antipsychotic Agents; Brain; Cerebrovascular Circulation; Glucose; Haloperidol; Humans; Schizophreni | 2002 |
Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Chlorpromazine; Dibenzoxazepines; Drug Interacti | 1978 |
Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol.
Topics: Acute Disease; Administration, Oral; Basal Ganglia Diseases; Bipolar Disorder; Clinical Trials as To | 1979 |
Haloperidol in the therapy of severe behavior disorders.
Topics: Benperidol; Bipolar Disorder; Child Behavior; Dementia; Droperidol; Haloperidol; Humans; Neurocognit | 1976 |
Biological psychiatry: on the relationship of schizophrenia and dopaminergic hyperactivity.
Topics: Amphetamine; Animals; Chlorpromazine; Corpus Striatum; Dopamine; Environment; Hallucinogens; Haloper | 1975 |
Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?
Topics: Animals; Haloperidol; Humans; Schizophrenia | 1992 |
Neuroleptic plasma levels.
Topics: Antipsychotic Agents; Biological Availability; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Pe | 1991 |
Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury.
Topics: Adult; Cerebellar Diseases; Cerebellum; Chronic Disease; Dose-Response Relationship, Drug; Fever; Ha | 1989 |
On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics.
Topics: Animals; Antipsychotic Agents; Binding Sites; Chromatography, Gas; Corpus Striatum; Ethnicity; Follo | 1985 |
The strategy and value of neuroleptic drug monitoring.
Topics: Antipsychotic Agents; Chlorpromazine; Chromatography, Gas; Chromatography, Liquid; Fluphenazine; For | 1985 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum.
Topics: Adult; Corpus Striatum; Haloperidol; Humans; National Institute of Mental Health (U.S.); Raclopride; | 1988 |
Review of haloperidol blood level and clinical response: looking through the window.
Topics: Dose-Response Relationship, Drug; Haloperidol; Humans; Schizophrenia | 1987 |
Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.
Topics: Animals; Antipsychotic Agents; Butyrophenones; Chemical Phenomena; Chemistry; Chlorpromazine; Dibenz | 1974 |
Gilles de la Tourette's disease--a review.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Corpus Striatum; Diagnosis, Differential; Female; | 1974 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
Results and trends of conditioning studies in schizophrenia.
Topics: Chlorpromazine; Conditioning, Classical; Haloperidol; Higher Nervous Activity; Humans; Insulin; Reac | 1968 |
[Tryptophan and its metabolism in schizophrenia].
Topics: Chlorpromazine; Drug Synergism; Haloperidol; Humans; Monoamine Oxidase Inhibitors; Neurologic Manife | 1970 |
796 trials available for haloperidol and Dementia Praecox
| Article | Year |
|---|---|
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fum | 2023 |
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Glucose; Haloperidol; Humans; Inflammation; Olanzapine; Perph | 2024 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Human | 2020 |
Glutamatergic Contribution to Probabilistic Reasoning and Jumping to Conclusions in Schizophrenia: A Double-Blind, Randomized Experimental Trial.
Topics: Decision Making; Delusions; Double-Blind Method; Haloperidol; Healthy Volunteers; Humans; Schizophre | 2020 |
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.
Topics: Adult; Antipsychotic Agents; Clozapine; Conduct Disorder; Double-Blind Method; Female; Haloperidol; | 2021 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloper | 2017 |
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Interpersonal Relatio | 2019 |
Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Age Factors; Aged; Antipsychotic Agents; Delayed- | 2018 |
Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Tolerance; Female; Haloperidol; Humans; Male; | 2019 |
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper | 2013 |
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper | 2013 |
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper | 2013 |
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper | 2013 |
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Follow-Up St | 2013 |
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Female; Haloperidol; Humans | 2014 |
Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study.
Topics: Adult; Cognition; Cross-Over Studies; Decision Making; Delusions; Dopamine Agonists; Dopamine Antago | 2014 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Disease-Free Survival; Drug Resistance; Drug Therapy, | 2013 |
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Depression; Double-Blind Method | 2014 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostilit | 2014 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; | 2014 |
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Inje | 2014 |
Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperid | 2013 |
Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Bli | 2014 |
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 2014 |
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Hosp | 2014 |
Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol.
Topics: Administration, Oral; Adult; Antioxidants; Antipsychotic Agents; Biomarkers; Combined Modality Thera | 2016 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocyclohe | 2015 |
The effectiveness of psychoeducational family intervention for patients with schizophrenia in a 14-year follow-up study in a Chinese rural area.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; China; Family; Female; Follow-Up Studies; H | 2015 |
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Haloperidol; Humans | 2015 |
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Haloper | 2015 |
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; | 2016 |
Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Bone Remodeling; Bone Resorption; Female; Halo | 2015 |
Intractability of Deficit Syndrome of Schizophrenia Against Adjunctive Modafinil.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Double-Blind Method; Drug Therapy, Combination; F | 2016 |
Antipsychotics decrease response confidence.
Topics: Adult; Antipsychotic Agents; Cross-Over Studies; Delusions; Dopamine Agents; Double-Blind Method; Fe | 2016 |
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; D | 2016 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep | 2016 |
Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Antipsychotic Agents; Case-Control Studies; Femal | 2008 |
Decreased serum neurotrophin 3 in chronically medicated schizophrenic males.
Topics: Adult; Antipsychotic Agents; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Enzym | 2008 |
Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists | 2008 |
[The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics].
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male; Nifedipine; | 2008 |
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Double-Bli | 2008 |
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Double-Blind Method; Drug-Related Side Effects | 2009 |
Time-lapse mapping of cortical changes in schizophrenia with different treatments.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Brain Mapping; Disease Progression; Female; Hal | 2009 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis | 2010 |
Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Genotype; Haloperidol; Humans; Male; Pharm | 2009 |
Neuropsychological impairments predict the clinical course in schizophrenia.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Cognition Disorders; Double-Blind Method; Female; | 2008 |
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, H | 2009 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male | 2008 |
Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans | 2009 |
Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Cognition Disorders; Double-Blind Method; Fema | 2009 |
Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
Topics: Administration, Oral; Adult; Analysis of Variance; Antipsychotic Agents; Dopamine Antagonists; Doubl | 2008 |
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazin | 2009 |
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Topics: Adult; Aggression; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body | 2009 |
Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Haloperidol; Humans; International Classificati | 2009 |
The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation.
Topics: Antipsychotic Agents; Black or African American; Carrier Proteins; Clozapine; Double Bind Interactio | 2009 |
Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2009 |
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Protocols; Clozapine; Drug Resistance; Drug Therapy, Co | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperido | 2009 |
Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Clozapine; Drug Administration Schedule; Female; Halope | 2009 |
The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Dru | 2009 |
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow-Up Studies; Halope | 2009 |
Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cerebrovascular Circulation; Female; Haloperido | 2009 |
FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brain Mapping; Female; Fluorodeoxyglucose F18; Fr | 2009 |
Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Haloperidol; Humans; Male; | 2009 |
Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Black People; Double-Blind Method; Dyskinesia, Drug-I | 2009 |
Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Electrocardiogr | 2010 |
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; | 2010 |
Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiogr | 2010 |
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Dibenzocycloheptenes; Double-Blind Method; Female; Ha | 2010 |
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Dis | 2010 |
Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Im | 2011 |
A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Halo | 2010 |
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug-Related Side Effects and Adv | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2011 |
A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; | 2010 |
Aripiprazole versus haloperidol treatment in early-stage schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Femal | 2011 |
The different trajectories of antipsychotic response: antipsychotics versus placebo.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Halope | 2011 |
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Mal | 2011 |
[A randomized double-blinded controlled study on treatment of schizophrenia by in vitro fostered bezoar combined with haloperidol].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Femal | 2010 |
Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial.
Topics: Adenosine; Adenosine Deaminase; Adult; Chronic Disease; Clozapine; Double-Blind Method; Female; Halo | 2011 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Drug Resistanc | 2011 |
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body | 2011 |
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Italy; Logistic Models; Ol | 2011 |
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Double-Blind Method; Female; Follow-Up St | 2012 |
Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study.
Topics: Adult; Antipsychotic Agents; Cognition; Cognition Disorders; Female; Haloperidol; Humans; Inpatients | 2011 |
Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Body Mass Index; | 2011 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperid | 2011 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; F | 2011 |
Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Haloperidol | 2012 |
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Executive Function; Female; Hal | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Dru | 2012 |
Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Ni | 2012 |
Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; China; Clonazepam; Diagn | 2012 |
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Awareness; Benzodiazepines; Case-Control Studies; C | 2012 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenaz | 2012 |
Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Cerebellum; Cerebral Cortex; Female; Haloperidol; Humans | 2012 |
Sertindole in the long-term treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Imidazoles; Indoles; Mai | 2012 |
The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Female; Halo | 2012 |
Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 2012 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzot | 2013 |
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; D | 2012 |
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cerebral Corte | 2012 |
Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; DNA Mutational Analysis; Double-Blind Method; Fem | 2013 |
Akathisia and suicidal ideation in first-episode schizophrenia.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; | 2012 |
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2012 |
Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?
Topics: Adult; Antipsychotic Agents; Disease Progression; Double-Blind Method; Female; Haloperidol; Humans; | 2013 |
The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Diagnosis, Comp | 2012 |
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Caudate Nucleus; Double-Blind Method; Female; Haloperi | 2013 |
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Educational Status; Female; Haloperidol; Humans; Logis | 2013 |
Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Corpus Striatum; Dibenzoxazepines; Dopamine D2 Receptor Antagon | 2002 |
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; H | 2002 |
Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Female; Haloperidol; | 2002 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl | 2002 |
Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia.
Topics: Administration, Cutaneous; Adult; Anti-Dyskinesia Agents; Brain; Female; Haloperidol; Humans; Hypoki | 2002 |
Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol.
Topics: Adult; Antipsychotic Agents; Blood Pressure; Cross-Over Studies; Double-Blind Method; Electroencepha | 2002 |
Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depression; Double-Blind Metho | 2002 |
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Antipsychotic Agents; Atenolol; Blood Gluc | 2003 |
A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Cross-Over Studies; Female; Haloperidol; Heart Conduction S | 2003 |
Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study.
Topics: Adult; Antipsychotic Agents; Australia; Austria; Canada; Clinical Trials as Topic; Cognition Disorde | 2003 |
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bone Density; Clopenthixol; Cloz | 2002 |
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; M | 2002 |
Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halo | 2002 |
Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Diazoxide; Double-Blind Method; Drug | 2002 |
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Re | 2003 |
19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate.
Topics: Adult; Antipsychotic Agents; Female; Fluorine; Haloperidol; Humans; Injections, Intramuscular; Isoto | 2002 |
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagnosis, Differential; Femal | 2003 |
Augmentation of clozapine partial responders with conventional antipsychotics.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Synergism; Fluphenazine; Haloperidol; Humans; Middle Ag | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Corpus Striatum; D | 2003 |
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Cyclizine; Dose-Response Relationship, Drug; Drug Interactions; D | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Cross-Cultural Comparison; Female; Haloperi | 2003 |
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Disease | 2003 |
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Doubl | 2003 |
Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study.
Topics: Adult; Antipsychotic Agents; Automobile Driving; Dopamine Antagonists; Female; Haloperidol; Humans; | 2003 |
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Double-Blin | 2003 |
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug; | 2003 |
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 2003 |
Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Dibenzothiazepines; Double- | 2003 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho | 2003 |
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Behavior Therapy; Brief Psychiatric Rating | 2003 |
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Brief Psychiatric Rating Scale; Caudate Nucleus; Cloza | 2003 |
Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Clozapine; Cost-Benefit Analysis; Female; Haloperidol; Humans; Male; Sc | 2003 |
The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Chronic Disease; Clozapine; Diagnostic and Stat | 2003 |
Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluvoxamine; | 2004 |
Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Circadian Rhythm; Cros | 2003 |
Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial.
Topics: Adult; Analysis of Variance; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Ethiny | 2003 |
Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Emotions; Eye Movements; Facial Expression; | 2003 |
Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Brain Mapping; Clozapine; Fe | 2004 |
Olanzapine effects on auditory sensory gating in schizophrenia.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; | 2003 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Rel | 2003 |
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; | 2003 |
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists | 2003 |
Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia.
Topics: Chromatography, Gas; Cytokines; Enzyme-Linked Immunosorbent Assay; Erythrocyte Membrane; Fatty Acids | 2003 |
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Dopamine; Female; Fingers; Functional | 2003 |
Optimal treatment project for schizophrenia: results from a randomized, controlled, longitudinal study.
Topics: Adaptation, Psychological; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case Management | 2003 |
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Benztropine; Double-Blind Met | 2003 |
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatr | 2003 |
Discrete state analysis for interpretation of data from clinical trials.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cluster Analysis; Cross-Sectional Studies | 2004 |
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2004 |
Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Topics: Adult; Blood Pressure; Case-Control Studies; Dopamine Antagonists; Dose-Response Relationship, Drug; | 2004 |
Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Case-Control Studies | 2004 |
A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Interactions; Dyskinesia, Drug-In | 2004 |
Correlates of cognitive deficits in first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Diagnostic and Statistical Manual of M | 2004 |
The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Double-Blind Method; Factor Analy | 2004 |
Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Drug | 2004 |
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.
Topics: Adolescent; Adult; Benzodiazepines; Comorbidity; Diagnostic and Statistical Manual of Mental Disorde | 2004 |
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dibenzothiazepines; Double-Blind Method; Drug Ad | 2004 |
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Factor Analysis, Stati | 2004 |
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepin | 2004 |
Effect of preoperative discontinuation of antipsychotics in schizophrenic patients on outcome during and after anaesthesia.
Topics: Adult; Analysis of Variance; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Antip | 2004 |
A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Dyskinesia, Drug-Indu | 2004 |
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Autoanalysis; Cross Reactions; Drug Monitoring | 2004 |
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigati | 2004 |
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorder | 2004 |
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Huma | 2004 |
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; | 2004 |
Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Hyperprolactinemia; M | 2005 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloper | 2004 |
Long-term olanzapine treatment and p300 parameters in schizophrenia.
Topics: Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Electroencephalography; Event-Rel | 2004 |
Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Ma | 2003 |
Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
Topics: Adult; Confidence Intervals; Cross-Over Studies; Electrocardiography; Female; Haloperidol; Humans; I | 2004 |
Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; D | 2004 |
Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
Topics: Adult; Antipsychotic Agents; Attention; Automobile Driving; Case-Control Studies; Female; Haloperido | 2005 |
Haloperidol half-life after chronic dosing.
Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind | 2004 |
[Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Exercise Test; Femal | 2004 |
Olanzapine treatment of residual positive and negative symptoms.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; | 2005 |
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 2005 |
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Topics: Acute Disease; Administration, Oral; Adult; Affective Disorders, Psychotic; Brief Psychiatric Rating | 2005 |
Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Brain Stem; Female; Fixation, Ocular; Follow-Up Studies; Hal | 2005 |
Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Topics: Adult; Allopurinol; Antipsychotic Agents; Case-Control Studies; Dopamine Antagonists; Double-Blind M | 2005 |
Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Estrogens; | 2005 |
Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Body Mass Index; Dibenzothiazep | 2005 |
Antipsychotic drug effects on brain morphology in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Caudate Nucleus; Cognition Disorders; Female; H | 2005 |
Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
Topics: Adult; Antibodies, Monoclonal; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Dis | 2005 |
Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
Topics: Adult; Antibodies, Monoclonal; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Dis | 2005 |
Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
Topics: Adult; Antibodies, Monoclonal; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Dis | 2005 |
Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
Topics: Adult; Antibodies, Monoclonal; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Dis | 2005 |
Evidence for onset of antipsychotic effects within the first 24 hours of treatment.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rat | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Double-Blind Method; Drug Resistance; Female; Hal | 2005 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Femal | 2005 |
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Addictive; Benzodiazepines; Cocaine-Related | 2005 |
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Nursing | 2005 |
Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Demography; Dose-Response Rela | 2005 |
Does clozapine decrease smoking?
Topics: Adult; Antipsychotic Agents; Biomarkers; Clozapine; Cotinine; Double-Blind Method; Female; Haloperid | 2005 |
Performance of diadochokinetic movements in schizophrenic patients.
Topics: Analysis of Variance; Antipsychotic Agents; Biomechanical Phenomena; Case-Control Studies; Dose-Resp | 2005 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studie | 2005 |
Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.
Topics: Algorithms; Antipsychotic Agents; Biometry; Clozapine; Computer Simulation; Data Interpretation, Sta | 2005 |
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Dibenzothiazepi | 2005 |
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Cultural Comparison; Dibenzothi | 2005 |
Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Brain Chemistry; Corpus Striatum; Dopamine | 2005 |
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Dose-Respo | 2005 |
The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
Topics: Adult; Antipsychotic Agents; Brain; Cognition; Cognition Disorders; Double-Blind Method; Female; Fol | 2005 |
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperi | 2005 |
Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Female; Haloperidol; Humans; | 2005 |
Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
Topics: Adult; Antipsychotic Agents; Biperiden; Cholinergic Antagonists; Cytochrome P-450 CYP2D6; Drug Thera | 2005 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administra | 2005 |
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Benzodiazepines; Double-Blind Method; Female; Ha | 2006 |
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chlorpromazine; Double-Blind Method; Dr | 2006 |
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Double-Blind Method; Fem | 2005 |
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.
Topics: Adult; Antipsychotic Agents; Behavior, Addictive; Benzodiazepines; Cocaine-Related Disorders; Cues; | 2006 |
The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
Topics: Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Prolactin; Psychiatric Status Rating | 2006 |
Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Female; Haloperidol; Humans; | 2006 |
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Behavioral Symptoms; Brief Psychiat | 2006 |
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Halo | 2006 |
Time course for antipsychotic treatment response in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 2006 |
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitaliz | 2006 |
Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Cognition; Dopamine D2 Receptor Antagonists; Dose-R | 2006 |
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Ha | 2006 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; F | 2007 |
Premorbid functioning and treatment response in recent-onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Female; Haloperidol; Humans | 2006 |
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Diabetes | 2005 |
[Clinical observations with aripiprazole in schizophrenia].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Femal | 2006 |
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Human | 2006 |
The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
Topics: Adult; Antioxidants; Antipsychotic Agents; Brief Psychiatric Rating Scale; CD3 Complex; CD4 Lymphocy | 2006 |
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents | 2006 |
Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Diagnostic and Statistical Manual of | 2006 |
Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; Benzodiazepines; Double-Blind Method; F | 2006 |
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Halope | 2006 |
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Schizophrenia; Treatm | 2006 |
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Chronic Disease; Cognition Disorders; Donepe | 2007 |
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2007 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Sc | 2006 |
Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Corpus Striatum; Female; Flupenthixol; Frontal Lobe; Haloperidol; Human | 2007 |
Remission in first-episode psychosis: predictor variables and symptom improvement patterns.
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Humans; Male; Predictive Value | 2006 |
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; Cognition Disorders; Com | 2007 |
Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; Cerebrovascular Circulation; Double-Blind Method; Fema | 2008 |
Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia.
Topics: Adult; Affect; Affective Symptoms; Antipsychotic Agents; Cerebral Cortex; Double-Blind Method; Femal | 2007 |
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Neur | 2007 |
Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Electron Transport; Electron Transp | 2007 |
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Do | 2007 |
Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 2007 |
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.
Topics: Acoustic Stimulation; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Electromyography; | 2007 |
The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antioxidants; Antipsychotic Agents; Ascorbic Acid; Eryth | 2007 |
Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cost of Illness; | 2007 |
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Anta | 2007 |
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Topics: Activities of Daily Living; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cogn | 2008 |
Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study.
Topics: Acute Disease; Adolescent; Adult; Affect; Antipsychotic Agents; Diagnostic and Statistical Manual of | 2009 |
Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Chlorpromazine; Dose-Response Rela | 1974 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
Amoxapine as an antipsychotic: comparative study versus haloperidol.
Topics: Adolescent; Adult; Age Factors; Amoxapine; Antidepressive Agents, Second-Generation; Antipsychotic A | 2007 |
Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Discrimination, Psychological; Double- | 2007 |
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Algorithms; Antipsychotic Agents; Biomedical Research; Cooperative Behavior; D | 2007 |
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnosti | 2007 |
Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Attention; Behavioral Symptoms; Case-Control Stud | 2008 |
Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Brain; Brain Chemistry; Brain Mapping; Choli | 2008 |
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Haloperi | 2008 |
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dose-Response Relationship, Drug; D | 2008 |
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Follow-Up Studies; Haloperidol; H | 2008 |
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; H | 2008 |
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass I | 2008 |
Lithium response and psychoses: a double-blind, placebo-controlled study.
Topics: Affective Disorders, Psychotic; Chlorides; Clinical Trials as Topic; Double-Blind Method; Drug Thera | 1984 |
A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Evaluation; Haloperidol; Humans; Psychiatric Status | 1981 |
Dysphoric response to neuroleptics as a predictor of treatment outcome with schizophrenics. A comparative study of haloperidol versus mesoridazine.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Emotions; Female; Halope | 1981 |
Initial improvement as predictor of outcome of neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Benperidol; Female; Haloperidol; Humans; Male; Prognosis; Schizophrenia | 1981 |
Prophylactic effect of neuroleptics in symptom-free schizophrenics.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Diazepam; Female; Haloperidol; Humans; Imipramine; Male | 1982 |
A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
Topics: Adolescent; Adult; Antipsychotic Agents; Butyrophenones; Clinical Trials as Topic; Double-Blind Meth | 1983 |
Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Clozapine; Dibenzazepines; Dose-Response | 1983 |
A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Haloperidol; | 1983 |
Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine.
Topics: Adult; Analysis of Variance; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blin | 1984 |
Rapid tranquilization: a comparative study of thiothixene and haloperidol.
Topics: Adult; Bipolar Disorder; Brief Psychiatric Rating Scale; Female; Haloperidol; Humans; Injections, In | 1984 |
Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trial | 1984 |
Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens.
Topics: Acute Disease; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; F | 1983 |
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Metho | 1984 |
Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Th | 1984 |
Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report.
Topics: Adult; Autonomic Nervous System; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; | 1984 |
A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Schi | 1984 |
The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol.
Topics: Acute Disease; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Huma | 1984 |
Clinical response and plasma haloperidol levels in schizophrenia.
Topics: Haloperidol; Humans; Schizophrenia | 1983 |
Differential improvements from haloperidol in two types of schizophrenics.
Topics: Haloperidol; Humans; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology | 1984 |
Akathisia with haloperidol and thiothixene.
Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, | 1984 |
Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Topics: Adult; Chromatography, Gas; Female; Haloperidol; Humans; Male; Prolactin; Psychiatric Status Rating | 1984 |
Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder.
Topics: Hallucinations; Haloperidol; Hostility; Humans; Hypochondriasis; Schizophrenia; Schizophrenia, Paran | 1984 |
Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients.
Topics: Adult; Brain; Drug Therapy, Combination; Drug Tolerance; Female; Haloperidol; Homovanillic Acid; Hum | 1983 |
Electric convulsive therapy (ECT) increases plasma and red blood cell haloperidol neuroleptic activities.
Topics: Adult; Brain; Electroconvulsive Therapy; Erythrocytes; Female; Haloperidol; Humans; Male; Schizophre | 1983 |
Haloperidol plasma and red blood cell levels and clinical antipsychotic response.
Topics: Erythrocytes; Haloperidol; Humans; Plasma; Schizophrenia | 1984 |
[Controlled comparison of nalorphine with haloperidol in acute psychoses of the schizophrenic group ].
Topics: Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Nalorphine; Psychot | 1982 |
High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Haloperidol; Humans; Male; Mi | 1980 |
A clinical and pharmacodynamic evaluation of sulpiride.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Middle | 1981 |
Flupenthixol versus haloperidol in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anxiety Disorders; Bipolar Disorder; Female; Flupenthixol; H | 1983 |
Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations.
Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Drug Administration Schedule; Haloperido | 1981 |
Viloxazine and the depressed schizophrenic--methodological issues.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Comb | 1981 |
Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Halop | 1982 |
Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients--a double-blind clinical multicentre investigation.
Topics: Adult; Clinical Trials as Topic; Clopenthixol; Double-Blind Method; Female; Haloperidol; Humans; Mal | 1981 |
Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study.
Topics: Acute Disease; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Ma | 1982 |
Effects of supidimide in schizophrenic inpatients undergoing neuroleptic maintenance therapy with haloperidol.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric | 1982 |
Behavioral prediction of response to haloperidol: a test dose strategy.
Topics: Acute Disease; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Male; Par | 1982 |
Bromperidol maintenance in schizophrenia.
Topics: Double-Blind Method; Haloperidol; Humans; Psychiatric Status Rating Scales; Schizophrenia; Schizophr | 1982 |
Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
Topics: Administration, Oral; Adult; Female; Haloperidol; Humans; Injections, Intravenous; Male; Prolactin; | 1982 |
[Flupenthixol versus haloperidol in acute psychotic episodes].
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Flupenthixol; Haloper | 1982 |
A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient.
Topics: Acute Disease; Adult; Crisis Intervention; Double-Blind Method; Female; Haloperidol; Humans; Indoles | 1981 |
Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Female; Ha | 1980 |
Language comprehension in schizophrenia: trait or state indicator?
Topics: Adult; Concept Formation; Double-Blind Method; Haloperidol; Humans; Luria-Nebraska Neuropsychologica | 1995 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Fe | 1994 |
Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations.
Topics: Adult; Age Factors; Age of Onset; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; | 1994 |
Negative symptoms in schizophrenia: assessment of the effect of risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Isoxazoles; Male; Middle | 1994 |
Efficacy of risperidone on positive features of schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; | 1994 |
Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.
Topics: Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Desmopressin for risperidone-induced enuresis.
Topics: Administration, Intranasal; Adult; Antipsychotic Agents; Deamino Arginine Vasopressin; Double-Blind | 1994 |
Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperid | 1994 |
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Fe | 1995 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Hum | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric | 1995 |
Critique of the Canadian Multicenter Placebo-Controlled Study of Risperidone and Haloperidol.
Topics: Canada; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Research Design; Risperid | 1995 |
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; | 1995 |
Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 1995 |
Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors.
Topics: Adult; Agranulocytosis; Clozapine; Female; Haloperidol; Humans; Male; Prospective Studies; Receptors | 1995 |
Effect of risperidone on hostility in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Haloperidol; Hostility; Humans; | 1995 |
A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Fluphenazine; Haloperidol; Human | 1995 |
Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
Topics: Acute Disease; Adult; Biogenic Monoamines; Female; Haloperidol; Humans; Hydrocortisone; Male; Prolac | 1995 |
Clozapine decreases smoking in patients with chronic schizophrenia.
Topics: Adult; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status Rating | 1995 |
Further evidence of a dose-response threshold for haloperidol in psychosis.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 1995 |
Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study.
Topics: Adult; Chronic Disease; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Female; Foll | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 1993 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Ma | 1993 |
Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dominance, Cerebral; Dose-Response Relationship, Drug | 1993 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Fema | 1993 |
Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
Topics: Adult; Chromatography, Gas; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; Schizop | 1995 |
Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
Topics: Adult; Carbolines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Schizophreni | 1995 |
Orthostatic challenge during neuroleptic test dose: a possible predictor of short-term outcome.
Topics: Adult; Arousal; Autonomic Nervous System; Blood Pressure; Brain; Female; Haloperidol; Heart Rate; Hu | 1994 |
Haloperidol: therapeutic window in schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male | 1994 |
Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Topics: Adult; Benztropine; Chronic Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 1994 |
Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine.
Topics: Adrenocorticotropic Hormone; Adult; Clozapine; Haloperidol; Humans; Male; Middle Aged; Piperazines; | 1993 |
A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Actio | 1994 |
An exploratory evaluation of ECT in haloperidol-treated DSM-IIIR schizophreniform disorder.
Topics: Adolescent; Adult; Double-Blind Method; Electroconvulsive Therapy; Haloperidol; Humans; Male; Middle | 1994 |
The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.
Topics: Adult; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Neuropsychological Tests; | 1994 |
Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.
Topics: Adolescent; Adult; Aged; Blood Proteins; Chronic Disease; Cytosol; Erythrocytes; Female; Haloperidol | 1994 |
Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Ha | 1993 |
A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Arousal; Clopenthixol; | 1994 |
Prolactin and TSH responses to TRH and to haloperidol in schizophrenic patients before and after treatment.
Topics: Adult; Haloperidol; Humans; Injections, Intramuscular; Male; Prolactin; Psychiatric Status Rating Sc | 1994 |
Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Resistance; Haloperidol; Humans; Midd | 1994 |
Attentional predictors of clinical change during neuroleptic treatment in schizophrenia.
Topics: Adult; Attention; Female; Follow-Up Studies; Haloperidol; Humans; Male; Mental Recall; Middle Aged; | 1994 |
ERPs in schizophrenia: effects of antipsychotic medication.
Topics: Adult; Antipsychotic Agents; Arousal; Cerebral Cortex; Dopamine; Dose-Response Relationship, Drug; D | 1994 |
Stability of neurological signs with clozapine treatment.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedul | 1994 |
Clozapine in tardive dyskinesia: observations from human and animal model studies.
Topics: Adult; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dyskinesia, Drug-Induced; F | 1994 |
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.
Topics: Adolescent; Age of Onset; Child; Clozapine; Drug Administration Schedule; Female; Haloperidol; Human | 1994 |
Predictors of acute dystonia in first-episode psychotic patients.
Topics: Adolescent; Adult; Age Factors; Biperiden; Delusions; Double-Blind Method; Dystonia; Female; Haloper | 1994 |
Clinical action of remoxipride.
Topics: Double-Blind Method; Haloperidol; Humans; Psychiatric Status Rating Scales; Remoxipride; Schizophren | 1994 |
Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
Topics: Administration, Oral; Chromatography, Liquid; Delayed-Action Preparations; Drug Resistance; Electroc | 1994 |
A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses.
Topics: Adult; Biogenic Amines; Chromatography, High Pressure Liquid; Chronic Disease; Dopamine; Double-Blin | 1994 |
A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: II. Correlations with psychopathology.
Topics: Adult; Biogenic Amines; Dopamine; Double-Blind Method; Female; Haloperidol; Humans; Kynurenine; Male | 1994 |
Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
Topics: Adult; Chronic Disease; Corticotropin-Releasing Hormone; Double-Blind Method; Haloperidol; Humans; M | 1994 |
Blood levels of haloperidol and clinical outcome in schizophrenia.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Erythrocytes; Female; Halo | 1994 |
The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Cognition; Double-Blind Method; Drug Tolerance; Emotions; | 1994 |
Initial improvement as a criterion for drug choice in acute schizophrenia.
Topics: Adult; Brief Psychiatric Rating Scale; Double-Blind Method; Haloperidol; Humans; Perazine; Schizophr | 1993 |
Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.
Topics: Adult; Antipsychotic Agents; Brain; Debrisoquin; Dopamine; Haloperidol; Homovanillic Acid; Humans; M | 1993 |
Positive versus negative symptoms in schizophrenia: response to haloperidol.
Topics: Acute Disease; Adult; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status Rat | 1994 |
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns.
Topics: Adult; Ambulatory Care; Chronic Disease; Clozapine; Double-Blind Method; Female; Follow-Up Studies; | 1993 |
Memory and plasma HVA changes in schizophrenia: are they episode markers?
Topics: Adult; Biomarkers; Cognition Disorders; Double-Blind Method; Haloperidol; Homovanillic Acid; Humans; | 1994 |
The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenocorticotropic Hormone; Adult; Analysis of Variance; Clozapine; | 1994 |
Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flupenthi | 1993 |
Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; | 1993 |
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.
Topics: Adult; Ambulatory Care; Chronic Disease; Clozapine; Double-Blind Method; Female; Haloperidol; Humans | 1994 |
Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
Topics: Adult; Cohort Studies; Comorbidity; Confounding Factors, Epidemiologic; Double-Blind Method; Female; | 1994 |
CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
Topics: Adult; Arousal; Brain; Carrier Proteins; Diazepam Binding Inhibitor; Dopamine; gamma-Aminobutyric Ac | 1993 |
Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
Topics: Adult; Analysis of Variance; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloper | 1993 |
Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Saccades; Schizophr | 1993 |
Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid.
Topics: Adolescent; Adult; Affect; Arousal; Attention; Brain; Dose-Response Relationship, Drug; Double-Blind | 1993 |
Studies of catecholamine metabolism in schizophrenia/psychosis--II.
Topics: Adult; Aged; Analysis of Variance; Catecholamines; Circadian Rhythm; Haloperidol; Homovanillic Acid; | 1993 |
Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glutamic Acid; Haloperidol; Hu | 1995 |
Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brief Psychiatric Rating Scale; Female; Fluphenaz | 1995 |
Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
Topics: Adult; Amphetamines; Brain; Corpus Striatum; Glucose; Haloperidol; Humans; Male; Psychiatric Status | 1996 |
Differential effect of clozapine on weight: a controlled study.
Topics: Ambulatory Care; Clozapine; Double-Blind Method; Follow-Up Studies; Haloperidol; Humans; Psychiatric | 1996 |
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
Topics: Adult; Brain; Carbon Radioisotopes; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; M | 1996 |
A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Fe | 1996 |
Facial affect recognition in the course of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Emotions; Facia | 1996 |
[Efficacy and tolerance of risperidone in various doses (report of a study)].
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Perphenazine; R | 1996 |
Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Erythrocytes; Female; Haloperidol; Homo | 1995 |
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Respon | 1996 |
Clonidine plus haloperidol in the treatment of schizophrenia/psychosis.
Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Clonidine; Double-Blind Method; Drug Therapy | 1995 |
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Double-Blind Method; Drug The | 1996 |
Prediction of haloperidol steady-state levels in plasma after a single test dose.
Topics: Adult; Antipsychotic Agents; Biotransformation; Chromatography, Gas; Double-Blind Method; Female; Ha | 1996 |
Predicting haloperidol treatment response in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyh | 1996 |
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
Topics: Adult; Antipsychotic Agents; Cognition; Drug Synergism; Female; Haloperidol; Humans; Male; Memory; M | 1996 |
Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, C | 1996 |
Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Psychiatric Statu | 1996 |
A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dibenzothiepins; Double-Blind Method; F | 1996 |
Does eosinophilia predict clozapine induced neutropenia?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biomarkers; Clozapine; Eosinophilia; Female; Haloperi | 1996 |
No interaction between desipramine and bromperidol.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 1996 |
Positive and negative symptoms: is their change related?
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Halop | 1996 |
Weight gain induced by clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Schizophrenia; Weight Gai | 1995 |
Predictive value of eosinophilia for neutropenia during clozapine treatment.
Topics: Adult; Clozapine; Double-Blind Method; Eosinophilia; Female; Haloperidol; Humans; Incidence; Male; N | 1996 |
The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Topics: Adult; Antipsychotic Agents; Brain; Bromocriptine; Chronic Disease; Dopamine Agonists; Dose-Response | 1997 |
Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzothiazoles; Dopamine Agonists; Drug Therap | 1997 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response | 1997 |
First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Biogenic Monoamines; Dopamine; Female; Haloperidol; Humans; | 1997 |
No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.
Topics: Adult; Biperiden; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia; | 1997 |
Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Disease Prog | 1997 |
Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Eye Movements; Female; Haloperidol; Humans; Male; Prospective Studies; | 1997 |
A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; D | 1997 |
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Chro | 1997 |
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
Topics: Adult; Benztropine; Double-Blind Method; Female; Haloperidol; Humans; Male; Memory; Neuropsychologic | 1997 |
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 1997 |
Extrapyramidal symptoms in patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Double-Blind Method; Fema | 1997 |
D2-dopamine-receptor occupancy during treatment with haloperidol decanoate.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Mi | 1997 |
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 1997 |
Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Haloperidol; Humans; M | 1997 |
Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskine | 1997 |
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Canada; Chronic Disease; Cost-Benefit Analysis; Doubl | 1997 |
Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Female; Haloperidol; Humans; Male; | 1997 |
Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Mal | 1997 |
Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Drug Interactions; Female; Fl | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collect | 1997 |
Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Chroni | 1997 |
Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal.
Topics: Adolescent; Adult; Antipsychotic Agents; Arousal; Catalepsy; Enzyme-Linked Immunosorbent Assay; Halo | 1997 |
Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Rela | 1997 |
Short and long-term immunosuppressive effects of clozapine and haloperidol.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Immunosuppressiv | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration | 1997 |
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Costs and Cost Analysis; Cross-Over Studies; Double-Blind Me | 1997 |
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.
Topics: Adult; Akathisia, Drug-Induced; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; D | 1997 |
Effects of risperidone on polydipsia in chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Chronic Disease; Combined Modality Therapy; Double-Bl | 1997 |
Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Clozapine; Haloperidol; Homovanillic Acid; Humans; | 1997 |
Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Heterozygote; H | 1997 |
IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Female | 1997 |
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Cross-Sectional Studies; Dopa | 1997 |
Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Double-Blind Method; Haloperidol; Hippocampus; Humans; Male; | 1997 |
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloper | 1998 |
Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Haloperidol; Humans; Neuropsychologi | 1997 |
Haloperidol plasma levels and dose optimization.
Topics: Adolescent; Adult; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Drug Administra | 1998 |
Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Female; Haloperi | 1998 |
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Meth | 1997 |
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.
Topics: Adult; Antipsychotic Agents; Austria; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; | 1997 |
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; | 1998 |
Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.
Topics: Adolescent; Adult; Aged; Aging; Anti-Anxiety Agents; Antipsychotic Agents; Biotransformation; Cytoch | 1998 |
Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brief Psychiatric Rating Scale; Female; Fenfluram | 1998 |
Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Imi | 1998 |
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Haloperidol; Humans; Mal | 1998 |
Topographic analysis of EEG photic driving in patients with schizophrenia following clozapine treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Over Studies; Double-Blind Method; Electroencephalogra | 1998 |
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Dose-Response Relationship, Drug; | 1998 |
Naltrexone augmentation of neuroleptics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Therapy, Comb | 1998 |
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
Topics: Adult; Age of Onset; Antipsychotic Agents; Clozapine; Double-Blind Method; Employment; Female; Follo | 1998 |
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; | 1998 |
Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Topics: Adult; Antipsychotic Agents; Case Management; Clozapine; Cross-Over Studies; Double-Blind Method; Fe | 1998 |
Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Emotions; F | 1998 |
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug | 1998 |
Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Bl | 1998 |
Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short-term outcome?
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Autonomic Nervous System; Blood Pressure; Cardiov | 1998 |
Combined treatment of schizophrenic psychoses with haloperidol and valproate.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Brief Psychiatric Rating Scale; Chlo | 1998 |
Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Topics: Adult; Age Factors; Antipsychotic Agents; Clozapine; Double-Blind Method; Drug Resistance; Female; H | 1998 |
A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.
Topics: Adult; Affect; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Dr | 1998 |
Effects of clozapine on auditory event-related potentials in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Double-Blind Method; Event-Related Potentials, P300; Evoked | 1998 |
Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
Topics: Adult; Brief Psychiatric Rating Scale; Dopamine; Dopamine Antagonists; Female; Haloperidol; Humans; | 1998 |
Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Drug Monitoring; Female; Haloperidol; Humans; Male; Middle Aged; Patien | 1998 |
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Topics: Clozapine; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Haloperidol; Hospital Costs; Hosp | 1998 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin | 1999 |
Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Topics: Analysis of Variance; Clozapine; Cross-Over Studies; Double-Blind Method; Drug Administration Schedu | 1999 |
Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients.
Topics: Adult; Antipsychotic Agents; Glutamic Acid; Haloperidol; Humans; Male; Middle Aged; Psychiatric Stat | 1999 |
Co-administration of sertraline and haloperidol.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Drug Interactions; Drug Therapy, Combinati | 1998 |
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Contrast | 1999 |
Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Fenfluramine; Haloperidol; Humans; Male; Prolact | 1999 |
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Ben | 1999 |
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Topics: Antipsychotic Agents; Anxiety; Benzodiazepines; Brief Psychiatric Rating Scale; Depression; Double-B | 1999 |
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; H | 1999 |
The treatment of negative symptoms: a clinical and methodological study.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiat | 1999 |
Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Female; | 1999 |
Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Cost-Benefit Analysis; Cross-Over Studies; Drug Costs; Femal | 1999 |
Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Sch | 1999 |
Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 1999 |
Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response.
Topics: Adult; Aging; Alcohol Drinking; Algorithms; Antipsychotic Agents; Atrophy; Brain; Cerebral Ventricle | 1999 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Bene | 1999 |
Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combi | 1999 |
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug | 1999 |
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Europe; Fem | 1999 |
Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Cell Membrane; Dopamine Antagonists; Female; Haloperidol; H | 1999 |
Risperidone in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Cholinergic Ant | 1999 |
Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia?
Topics: Adult; Antipsychotic Agents; Drug Synergism; Excitatory Amino Acid Antagonists; Female; Haloperidol; | 1999 |
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Drug Costs | 1999 |
The schizophrenia ketamine challenge study debate.
Topics: Anesthetics, Dissociative; Anxiety; Bioethics; Brief Psychiatric Rating Scale; Consumer Product Safe | 1999 |
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; | 1999 |
The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Haloperidol; Hospital Costs; Humans; O | 1999 |
Double-blind study of clozapine dose response in chronic schizophrenia.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Cross-Sectional Studies; Dose-Respo | 1999 |
Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Co | 1999 |
[Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Automobile Driving; Cognitio | 1999 |
Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade.
Topics: Adult; Carbon Radioisotopes; Cerebellum; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor | 2000 |
How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Over Studies; Double-Blind Method; Female; Haloperidol | 1999 |
Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Double-Blind Method; Female; Haloperidol; Humans; Male; Neur | 2000 |
Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes.
Topics: Adult; Antipsychotic Agents; Benztropine; Cross-Over Studies; Double-Blind Method; Frontal Lobe; Hal | 2000 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Me | 2000 |
A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Relationship, Drug; Double-Blind Meth | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Carbon Radioisotopes; Corpus Striat | 2000 |
Quantitative EEG in schizophrenic patients before and during pharmacotherapy.
Topics: Adult; Antipsychotic Agents; Beta Rhythm; Delta Rhythm; Electroencephalography; Female; Fluphenazine | 2000 |
Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Topics: Adult; Antipsychotic Agents; Biotransformation; Dose-Response Relationship, Drug; Drug Administratio | 2000 |
High-dose treatment with haloperidol: the effect of dose reduction.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 2000 |
Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Female; Haloperidol; Humans; Male; Predictive Val | 2000 |
Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Comb | 2000 |
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induce | 2000 |
Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Black or African American; Clozapine; Double-Blind Method; Drug Adminis | 2000 |
Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions.
Topics: Adult; Antipsychotic Agents; Dipyridamole; Drug Therapy, Combination; Female; Haloperidol; Humans; M | 2000 |
A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Female; Halo | 2000 |
No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study.
Topics: Acute Disease; Alleles; Antipsychotic Agents; Benzamides; Dopamine Antagonists; Dopamine D2 Receptor | 2000 |
Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Compulsive Behavior; Female; | 2000 |
A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Double-Blind Method; Female; Haloperidol; Humans; Male; P | 1998 |
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Femal | 2000 |
Intravenous biperiden in akathisia: an open pilot study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Biperiden; Cholinergic Antagoni | 2000 |
Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
Topics: Adult; Antipsychotic Agents; Clozapine; Connecticut; Cost-Benefit Analysis; Drug Costs; Economics, P | 2000 |
Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Family Health; Female; Haloperidol; Health Status; Humans; I | 2000 |
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind M | 2000 |
Acute antipsychotic drug administration lowers body temperature in drug-free male schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Temperature; Haloperidol; Humans; Longitudinal Studies | 2000 |
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relation | 2000 |
Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Therapy, Combination; Female; Haloperidol; Hospi | 2001 |
The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Female; | 2001 |
No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study.
Topics: Adult; Benzamides; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Polymorphism, Genetic; R | 2001 |
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double- | 2001 |
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric | 2001 |
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Haloperidol; H | 2001 |
Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Double-Blind Method; Drug The | 2001 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Decision Making; Dibenzothiazepines; Double-Blind | 2001 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent | 2001 |
Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cerebrovascular Circulation; Female; Haloperidol; Humans; Magnet | 2001 |
Detecting improvement in quality of life and symptomatology in schizophrenia.
Topics: Adult; Clozapine; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Hospitalization; Huma | 2001 |
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Length of | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Pr | 2001 |
Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Polymorphism, | 2001 |
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 2001 |
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, | 2001 |
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind | 2001 |
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperi | 2001 |
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Benzodiazepines; Contrast Media; Corpus Stri | 2001 |
Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.
Topics: Adult; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Drug Therapy, Combin | 2001 |
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; DNA; Dose-Response Relationship, Drug | 2001 |
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
Topics: Adult; Anorexia; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Dizziness; Dose-Re | 2001 |
Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Clozapine; Cognition; Cognition Disorders; Cross- | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2001 |
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Dose-Response Relatio | 2001 |
Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
Topics: Adult; Antipsychotic Agents; Asian People; Chronic Disease; Double-Blind Method; Female; Haloperidol | 2001 |
The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Ginkgo biloba; Haloperidol; Humans; | 1999 |
Does cognitive function improve with quetiapine in comparison to haloperidol?
Topics: Antipsychotic Agents; Cognition Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Ne | 2002 |
Determining the optimal dose of haloperidol in first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male; | 2001 |
A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Therapy, Combination | 2001 |
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Disease-Free Survival; Female; Haloperidol; Humans; Male; Middle Aged; | 2002 |
Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Double-Blind Method; Female; Haloperidol; Humans; Male | 2001 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; | 2001 |
Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Patient Compliance; Psy | 2002 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 2002 |
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relatio | 2002 |
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 2002 |
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relatio | 2002 |
Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia.
Topics: Activities of Daily Living; Adult; Ambulatory Care; Antipsychotic Agents; Behavior Therapy; Clinical | 2002 |
Sex differences in clinical response to olanzapine compared with haloperidol.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; H | 2002 |
Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal | 2002 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Inta | 2002 |
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone.
Topics: Adult; Antipsychotic Agents; Cognition; Dose-Response Relationship, Drug; Female; Haloperidol; Human | 2002 |
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Nausea; Pip | 2002 |
A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aggression; Brief Psychiatric Rating Scale; Clinical Trials as Top | 1977 |
Sulpiride--an antipsychotic agent: comparative trial vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; | 1977 |
Neuroleptic-potentiating effect of metyrosine.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Synergism; Haloperi | 1979 |
Benztropine prophylaxis of dystonic reactions.
Topics: Adult; Aged; Antipsychotic Agents; Benztropine; Clinical Trials as Topic; Dystonia; Female; Haloperi | 1979 |
Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Drug Sy | 1979 |
Parkinsonism by haloperidol and piribedil.
Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Parkinson Disease, S | 1978 |
Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. A Veterans Administration cooperative study.
Topics: Adult; Aftercare; Attitude; Chlorpromazine; Chronic Disease; Cost-Benefit Analysis; Day Care, Medica | 1979 |
Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Delayed-Action Preparat | 1975 |
Hemispheric dysfunction in schizophrenia: assessment by visual perception tasks.
Topics: Acute Disease; Adult; Cerebral Cortex; Dominance, Cerebral; Double-Blind Method; Female; Haloperidol | 1979 |
Droperidol in acutely agitated patients. A double-blind placebo-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Clinical Trials as Topic; Droperidol; Drug | 1977 |
High dosage haloperidol in chronic schizophrenia.
Topics: Adult; Alkaline Phosphatase; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Double-Blind | 1977 |
Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study.
Topics: Acute Disease; Adult; Aged; Aggression; Biperiden; Clinical Trials as Topic; Dibenzoxazepines; Doubl | 1977 |
A comparison of the relative efficacy of Serenace and chlorpromazine in the treatment of chronic schizophrenics.
Topics: Adult; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Haloperidol; Huma | 1978 |
Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study.
Topics: Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Administration | 1978 |
Haloperidol dose, plasma levels, and clinical response: a double-blind study [proceedings].
Topics: Clinical Trials as Topic; Double-Blind Method; Haloperidol; Humans; Schizophrenia; Time Factors | 1978 |
Double-blind comparison of bromperidol and perphenazine.
Topics: Adult; Aged; Behavior; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; M | 1978 |
Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol.
Topics: Acute Disease; Administration, Oral; Basal Ganglia Diseases; Bipolar Disorder; Clinical Trials as To | 1979 |
Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; F | 1979 |
Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Carbidopa; Chlorpromazine; Chronic Disease; Clinical Trials | 1979 |
Paroxysmal EEG activity and psychopathology during the treatment with clozapine.
Topics: Adolescent; Adult; Clinical Trials as Topic; Clozapine; Dibenzazepines; Electroencephalography; Fema | 1979 |
Acute high-dose parenteral haloperidol treatment of psychosis.
Topics: Acute Disease; Adult; Bipolar Disorder; Blood Pressure; Clinical Trials as Topic; Diazepam; Dose-Res | 1979 |
[Extrapyamidal side-effects with 1-day dosage of haloperidol (author's transl)].
Topics: Adolescent; Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Ha | 1978 |
The effects of selected antipsychotic drugs of human judgment.
Topics: Adult; Clinical Trials as Topic; Cognition; Female; Haloperidol; Humans; Judgment; Male; Middle Aged | 1977 |
[Therapy of acute schizophrenic attacks. High dosage haloperidol therapy compared with a two component treatment].
Topics: Anxiety; Attention; Basal Ganglia Diseases; Drug Therapy, Combination; Haloperidol; Humans; Memory; | 1979 |
Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment.
Topics: Adolescent; Adult; Ambulatory Care; Chronic Disease; Double-Blind Method; Drug Evaluation; Employmen | 1978 |
Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.
Topics: Adult; Anxiety; Chlorpromazine; Clinical Trials as Topic; Female; Haloperidol; Humans; Longitudinal | 1976 |
A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients.
Topics: Acute Disease; Clinical Trials as Topic; Dibenzoxazepines; Haloperidol; Humans; Loxapine; Schizophre | 1976 |
Clinical observations of the treatment of tardive dyskinesia with haloperidol.
Topics: Adult; Antiparkinson Agents; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Age | 1975 |
[The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research (author's transl)].
Topics: Adult; Basal Ganglia Diseases; Clinical Trials as Topic; Dibenzoxazepines; Female; Haloperidol; Huma | 1975 |
Rehabilitation of the chronic patient: experience in the USA.
Topics: Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Mental Disorders; Midd | 1976 |
Higher than usual dosage of haloperidol: a pilot study in 'back ward' schizophrenics.
Topics: Antiparkinson Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Haloperi | 1976 |
Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
Topics: Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; Psychiatric Status Rating Scales; Sc | 1976 |
A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients.
Topics: Adolescent; Clinical Trials as Topic; Dibenzoxazepines; Drug Evaluation; Female; Haloperidol; Humans | 1976 |
Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics.
Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Dibenzoxazepines; Female; Haloperidol; H | 1976 |
Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol.
Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Female; Fluphenazine; Haloperidol; Human | 1976 |
Some methodological considerations for the clinical evaluation of neuroleptics--comparative effects of clozapine and haloperidol on schizophrenics.
Topics: Clozapine; Dibenzazepines; Drug Evaluation; Haloperidol; Humans; Methods; Psychiatric Status Rating | 1977 |
Computerized EEG: predictor of outcome in schizophrenia.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Computers; Drug Resistance; Electroencephalography | 1975 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
Therapeutic reversal with benxtropine in schizophrenics. Practical and theoretical significance.
Topics: Adult; Affect; Attention; Benztropine; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; Dr | 1975 |
A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.
Topics: Adult; Affect; Anxiety; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Clinical Trials as Topi | 1975 |
A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences.
Topics: Adult; Affect; Antiparkinson Agents; Arousal; Chlorpromazine; Clinical Trials as Topic; Dose-Respons | 1975 |
The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
Topics: Antipsychotic Agents; Chronic Disease; Cross-Cultural Comparison; Double-Blind Method; Haloperidol; | 1992 |
[A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin].
Topics: Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Female; Haloperidol; Humans; Male; M | 1992 |
Effects of antipsychotic drugs on memory functions of schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Humans; Male; Mental Recall; Middl | 1992 |
Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia.
Topics: Adult; Alprazolam; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Emergencies | 1992 |
Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method; Female; Haloperi | 1992 |
Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.
Topics: Administration, Oral; Antipsychotic Agents; Bipolar Disorder; Creatine Kinase; Female; Follow-Up Stu | 1992 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospit | 1992 |
Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebral Ventricles; Chronic Disease; Dilatation, Patholog | 1992 |
Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group.
Topics: Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric | 1992 |
Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
Topics: Adult; Arousal; Double-Blind Method; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; | 1992 |
Striatal metabolic rate and clinical response to neuroleptics in schizophrenia.
Topics: Adult; Basal Ganglia; Caudate Nucleus; Cerebral Cortex; Deoxyglucose; Double-Blind Method; Female; F | 1992 |
Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
Topics: Acute Disease; Haloperidol; Homovanillic Acid; Humans; Placebos; Psychiatric Status Rating Scales; S | 1992 |
A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1992 |
A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. The British Isles Raclopride Study Group.
Topics: Adolescent; Adult; Aged; Dopamine D2 Receptor Antagonists; Double-Blind Method; Female; Haloperidol; | 1992 |
Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
Topics: Adult; Aged; Chronic Disease; Depression; Double-Blind Method; Female; Fluphenazine; Haloperidol; Hu | 1992 |
Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
Topics: Acute Disease; Adult; Drug Therapy, Combination; Female; Haloperidol; Humans; Lorazepam; Male; Middl | 1992 |
Haloperidol in schizophrenic children: early findings from a study in progress.
Topics: Child; Child, Preschool; Double-Blind Method; Female; Haloperidol; Humans; Male; Schizophrenia | 1992 |
Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio.
Topics: Adult; Biotransformation; Haloperidol; Humans; Male; Mathematics; Metabolic Clearance Rate; Models, | 1992 |
Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Hospitalization; | 1992 |
Plasma drug level and clinical response.
Topics: Chronic Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychiatric Status Rating Sc | 1992 |
Haloperidol blood levels and clinical effects.
Topics: Acute Disease; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Placebos; Psy | 1992 |
Evaluating the effects of drugs on behavior and quality of life: an alternative strategy for clinical trials.
Topics: Administration, Oral; Clinical Trials as Topic; Haloperidol; Humans; Psychiatric Status Rating Scale | 1992 |
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Topics: Adult; Aged; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Ind | 1992 |
Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.
Topics: Adolescent; Adult; Anxiety Disorders; Chlorpromazine; Depressive Disorder; Female; Haloperidol; Huma | 1992 |
Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve.
Topics: Adult; Biological Availability; Brain; Electroencephalography; Follow-Up Studies; Haloperidol; Human | 1992 |
Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status R | 1992 |
Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.
Topics: Age Factors; Ambulatory Care; Antipsychotic Agents; Double-Blind Method; Follow-Up Studies; Haloperi | 1991 |
Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperido | 1991 |
Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
Topics: Antipsychotic Agents; Benzazepines; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male; M | 1991 |
Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Follow-Up S | 1991 |
[Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, | 1991 |
[Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method; Dyskinesia, Drug | 1991 |
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Dys | 1991 |
A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Delayed-Action Preparat | 1991 |
Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Haloperidol; Human | 1991 |
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; | 1991 |
Serum prolactin as a correlate of clinical response to haloperidol.
Topics: Adult; Dose-Response Relationship, Drug; Haloperidol; Hospitalization; Humans; Male; Prolactin; Psyc | 1991 |
A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia.
Topics: Adult; Brain; Chlorprothixene; Chronic Disease; Female; Haloperidol; Humans; Male; Middle Aged; Rece | 1991 |
Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.
Topics: Adult; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Longitudinal Studies; Psychiatric St | 1991 |
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Double-Blind Method; Drug Administration S | 1991 |
Predictors of therapeutic response to haloperidol in acute schizophrenia.
Topics: Acute Disease; Haloperidol; Humans; Prognosis; Psychiatric Status Rating Scales; Schizophrenia; Schi | 1991 |
Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study.
Topics: Adult; Chronic Disease; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1991 |
Treatment of positive and negative symptoms: pharmacologic approaches.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1990 |
Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Hal | 1990 |
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Halop | 1990 |
Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Delayed-Action Preparations; Dou | 1990 |
A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug; Double-Blind | 1990 |
A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Hal | 1990 |
Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship | 1990 |
A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship | 1990 |
A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug | 1990 |
A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Double-Blind Method; Female; | 1990 |
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; De | 1990 |
Experiences of long-term treatment with remoxipride: efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Chronic Disease; Double-Blind Method; Dys | 1990 |
Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Dose-Response Relationship, Drug; D | 1990 |
Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. The Canadian Remoxipride Study Group.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug; Double-Blind | 1990 |
Cognitive disturbances in neuroleptic therapy.
Topics: Adult; Antipsychotic Agents; Benzamides; Cognition Disorders; Double-Blind Method; Haloperidol; Huma | 1990 |
A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Canada; Dose-Response Relationsh | 1990 |
A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug; Double- | 1990 |
Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Double-Blind Method; Female; Haloperidol; | 1990 |
Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Dose-Response Relationship, Drug; Double- | 1990 |
[Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Fluphenazine; Haloperidol; Humans; Remission Induction; | 1990 |
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
Topics: Adult; Affect; Blinking; Cerebral Ventricles; Chronic Disease; Cognition; Concept Formation; Dextroa | 1991 |
Dosage of haloperidol for schizophrenia.
Topics: Acute Disease; Administration, Oral; Adult; Drug Administration Schedule; Female; Haloperidol; Hospi | 1991 |
An open trial of buspirone added to neuroleptics in schizophrenic patients.
Topics: Adult; Buspirone; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Psychia | 1991 |
The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia.
Topics: Adult; Cerebrovascular Circulation; Cognition; Dextroamphetamine; Female; Frontal Lobe; Haloperidol; | 1991 |
Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia.
Topics: Carbamazepine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Hal | 1990 |
Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group.
Topics: Adult; Benzamides; Double-Blind Method; Female; Haloperidol; Humans; Male; Prolactin; Receptors, Dop | 1990 |
The effects of haloperidol on thought disorder and IQ in schizophrenia.
Topics: Adult; Female; Haloperidol; Humans; Intelligence; Longitudinal Studies; Male; Psychometrics; Randomi | 1990 |
Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide.
Topics: Anticonvulsants; Chlorprothixene; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therap | 1990 |
Cholecystokinin, dopamine and schizophrenia.
Topics: Adult; Cholecystokinin; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Male; Neurons; Sch | 1990 |
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.
Topics: Administration, Oral; Basal Ganglia Diseases; Double-Blind Method; Drug Evaluation; Evaluation Studi | 1990 |
Haloperidol plasma levels and acute clinical change in schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric | 1990 |
Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.
Topics: Adult; Biotransformation; China; Half-Life; Haloperidol; Humans; Male; Middle Aged; Oxidation-Reduct | 1990 |
Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Topics: Adult; Aged; Biological Availability; Double-Blind Method; Female; Fluphenazine; Half-Life; Haloperi | 1990 |
The use of midazolam in acutely agitated psychiatric patients.
Topics: Adult; Amobarbital; Haloperidol; Humans; Male; Midazolam; Middle Aged; Schizophrenia | 1990 |
Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Topics: Adult; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Sch | 1990 |
A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Hospitalization; | 1990 |
Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Clinical Trials as Topic; Drug Th | 1990 |
A pilot study of the role of prophylactic antiparkinson treatment during neuroleptic therapy.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Hu | 1989 |
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Ac | 1989 |
Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Dibenzothiepins; Double-Blind Method; Female; | 1989 |
Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Middle Aged; Rand | 1989 |
Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Cognition; Double-Blind Method; Female; Halo | 1989 |
Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
Topics: Adult; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Metho | 1989 |
Treatment of chronic schizophrenia with cyproheptadine.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Cyproheptadine; Drug Therapy, Combination; Female; | 1989 |
Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Erythrocytes; Fem | 1989 |
Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol.
Topics: Adult; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1989 |
Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 1989 |
Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.
Topics: Adolescent; Adult; Amitriptyline; Benztropine; Clinical Trials as Topic; Depressive Disorder; Desipr | 1989 |
Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
Topics: Adult; Biological Availability; Brain; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male | 1989 |
Experimental examination of trazodone.
Topics: Adult; Amitriptyline; Anxiety; Depression; Depressive Disorder; Double-Blind Method; Female; Haloper | 1989 |
Molindone and haloperidol in tardive dyskinesia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Dy | 1985 |
Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
Topics: Adult; Brief Psychiatric Rating Scale; Erythrocytes; Haloperidol; Humans; Psychiatric Status Rating | 1985 |
Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Sch | 1986 |
[Chronic treatment of schizophrenia with injectable bromperidol decanoate].
Topics: Adult; Brief Psychiatric Rating Scale; Chronic Disease; Clinical Trials as Topic; Female; Haloperido | 1985 |
A randomised controlled trial of prophylactic neuroleptic treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Female; Flu | 1986 |
Low-dose treatment strategies.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, | 1986 |
Fluperlapine vs haloperidol: a comparison of their neuroendocrinological profiles and the influence on serum lipids.
Topics: Adrenocorticotropic Hormone; Adult; Antipsychotic Agents; Dibenzazepines; Haloperidol; Hormones; Hum | 1986 |
The AMDP system in international clinical trials: a double-blind comparison of fluperlapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Dibenzazepines; Double-Blind Method; Female; | 1986 |
Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Haloperidol; | 1986 |
Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy.
Topics: Adult; Antipsychotic Agents; Attention; Brain; Dibenzazepines; Electroencephalography; Eye Movements | 1986 |
Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Depression; Dibenzazepines; F | 1987 |
Neuroleptic treatment and prediction of response.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Schizophren | 1988 |
The use of benzodiazepines in the treatment of manic-depressive illness.
Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Basal Ga | 1988 |
Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Flupenthixol; Haloperidol; Humans; Male; P | 1988 |
[Treatment with bromperidol in schizophrenic patients].
Topics: Brief Psychiatric Rating Scale; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Schizop | 1988 |
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Clozapine; Dibenzazepines; Double-Blind Method; Fem | 1988 |
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Clozapine; Dibenzazepines; Double-Blind Method; Fem | 1988 |
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Clozapine; Dibenzazepines; Double-Blind Method; Fem | 1988 |
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Clozapine; Dibenzazepines; Double-Blind Method; Fem | 1988 |
Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Apomorphine; Chronic Disease; Clinical Trials as Topic; Diben | 1988 |
[Clinical experience with bromperidol in chronic psychoses].
Topics: Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Inp | 1988 |
Lithium combined with haloperidol in schizophrenic patients.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Combinat | 1988 |
Patterns of response to amitriptyline and haloperidol among borderline patients.
Topics: Amitriptyline; Haloperidol; Humans; Schizophrenia; Schizophrenic Psychology | 1988 |
Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
Topics: Acute Disease; Adult; Female; Haloperidol; Humans; Male; Prognosis; Prolactin; Psychiatric Status Ra | 1988 |
Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia.
Topics: Adult; Analysis of Variance; Body Temperature; Clozapine; Dibenzazepines; Haloperidol; Humans; Hypot | 1988 |
Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Flupenthixol; Haloper | 1987 |
[Comparison of the therapeutic effects between haloperidol and insulin coma in schizophrenia and optimal blood levels of haloperidol].
Topics: Adolescent; Adult; Clinical Trials as Topic; Convulsive Therapy; Double-Blind Method; Female; Halope | 1987 |
Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; H | 1987 |
Antipsychotic effects of verapamil in schizophrenia.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged | 1987 |
Carbamazepine as an adjunct of antipsychotic therapy.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adult; Biperiden; Carbamazepine; Chlorprothixene; Clinical Tria | 1987 |
High potency neuroleptics and violence in schizophrenics.
Topics: Adult; Akathisia, Drug-Induced; Chlorpromazine; Clozapine; Haloperidol; Humans; Schizophrenia; Schiz | 1988 |
Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol.
Topics: Acute Disease; Adult; Double-Blind Method; Haloperidol; Humans; Middle Aged; Psychiatric Status Rati | 1987 |
A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aggression; Clinical Trials as Topic; | 1986 |
A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
Topics: Administration, Oral; Adult; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; | 1986 |
Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures.
Topics: Adult; Brain; Cerebral Ventricles; Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; M | 1986 |
Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Topics: Adult; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Fema | 1986 |
A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; | 1986 |
The therapeutic index of haloperidol in newly admitted schizophrenic patients.
Topics: Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Patient Compl | 1987 |
Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia.
Topics: Adolescent; Adult; Alpha Rhythm; Benztropine; Beta Rhythm; Brain Mapping; Chlorpromazine; Clozapine; | 1987 |
Use of verapamil to treat negative symptoms in schizophrenia.
Topics: Adult; Double-Blind Method; Haloperidol; Humans; Male; Middle Aged; Schizophrenia; Verapamil | 1987 |
Plasma haloperidol levels and clinical response.
Topics: Chromatography, Gas; Haloperidol; Humans; Psychiatric Status Rating Scales; Research Design; Schizop | 1987 |
Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
Topics: Adult; Double-Blind Method; Female; Flupenthixol; Haloperidol; Humans; Male; Middle Aged; Schizophre | 1986 |
A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
Topics: Clinical Trials as Topic; Double-Blind Method; Haloperidol; Humans; Schizophrenia | 1985 |
Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics.
Topics: Acute Disease; Administration, Oral; Adult; Clinical Trials as Topic; Double-Blind Method; Female; H | 1985 |
Review of clinical and laboratory experiences with molindone hydrochloride.
Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationshi | 1985 |
Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; | 1985 |
Plasma levels of haloperidol and clinical response.
Topics: Dose-Response Relationship, Drug; Haloperidol; Humans; Long-Term Care; Schizophrenia; Schizophrenic | 1985 |
Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data.
Topics: Adolescent; Adult; China; Haloperidol; Humans; Middle Aged; Psychotic Disorders; Schizophrenia | 1985 |
Plasma haloperidol levels and clinical response: confounding variables.
Topics: Haloperidol; Humans; Psychotic Disorders; Schizophrenia | 1985 |
Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Topics: Adult; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Schizophre | 1985 |
A crossover study of clocapramine and haloperidol in chronic schizophrenia.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Basal Ganglia Diseases; Chronic Disease; D | 1985 |
Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzazepi | 1974 |
Assessment of antipsychotic activity of a butyrophenone analogue, lenperone (AHR 2277).
Topics: Benzoates; Butyrophenones; Clinical Trials as Topic; Haloperidol; Humans; Piperidines; Placebos; Psy | 1974 |
A comparison of haloperidol and Trifluoperazine. (A double-blind, controlled study on chronic schizophrenic outpatients).
Topics: Clinical Trials as Topic; Depression; Extrapyramidal Tracts; Haloperidol; Humans; Male; Middle Aged; | 1967 |
Efficacy of haloperidol in drug refractory patients.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Female; Fluphenazine; Haloperidol; Humans; M | 1967 |
Butaperazine (Repoise).
Topics: Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; Perphenazine; Phenothiazines; Pipera | 1968 |
Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Analysis of Variance; Bilirubin; Blood Cell Count | 1972 |
Changes in staff anxiety and attitudes during a double blind study of haloperidol in acute schizophrenics within a structured milieu.
Topics: Antiparkinson Agents; Anxiety; Attitude of Health Personnel; Benztropine; Clinical Trials as Topic; | 1972 |
Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia.
Topics: Adult; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Clopenthixol; Electroencephalograp | 1972 |
Sleeplessness in acute and chronic schizophrenia--response to haloperidol and anti-parkinsonism agents.
Topics: Acute Disease; Adult; Antiparkinson Agents; Arousal; Benztropine; Chronic Disease; Clinical Trials a | 1973 |
A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Pl | 1973 |
Psychological effects of single-dose antipsychotic medication.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Clopenthixol; Dose-Response Relationship, Drug; Fem | 1973 |
Critical study of the Organic Integrity Test as a diagnostic and therapeutic index in schizophrenia.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Cognition; Color Perception; Female; Form Perceptio | 1973 |
Pimozide (R6238) in chronic schizophrenia: double blind trial.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Blo | 1973 |
Psychopharmacological study of schizophrenia--some ways out of an impasse. A case study with haloperidol.
Topics: Acute Disease; Benztropine; Clinical Trials as Topic; Cognition Disorders; Dose-Response Relationshi | 1973 |
Penfluridol: an efficacious long-acting oral antipsychotic compound.
Topics: Acute Disease; Administration, Oral; Chromatography, Gas; Clinical Trials as Topic; Cooperative Beha | 1974 |
[Assessment of the severity of psychiatric states].
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Drug Evaluation; Haloperidol; Humans; Interview | 1974 |
The influence of haloperidol and penfluridol on the learning capacity of the schizophrenic.
Topics: Adult; Clinical Trials as Topic; Haloperidol; Humans; Hydrocarbons, Halogenated; Learning; Male; Mid | 1974 |
A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia.
Topics: Adult; Aged; Antiparkinson Agents; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Drug | 1974 |
A method of quantifying EEG for psychopharmacological research.
Topics: Alpha Rhythm; Chlorpromazine; Clopenthixol; Electroencephalography; Haloperidol; Humans; Methods; Mo | 1973 |
European experiences with haloperidol.
Topics: Bipolar Disorder; Clinical Trials as Topic; Haloperidol; Humans; Schizophrenia | 1967 |
Prospective clinical applications of haloperidol.
Topics: Bipolar Disorder; Clinical Trials as Topic; Haloperidol; Humans; Lithium; Phenothiazines; Schizophre | 1967 |
Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action.
Topics: Acute Disease; Antidepressive Agents; Chlorpromazine; Clinical Trials as Topic; Haloperidol; Humans; | 1967 |
Treatment of acute exacerbations in chronic schizophrenic patients.
Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middl | 1967 |
Long term haloperidol therapy in outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Bipolar Disorder; Clinical Trials as Topic; Depressive Dis | 1967 |
[Clinical experimentation with desipramine with statistical control].
Topics: Adult; Aged; Anorexia Nervosa; Barbiturates; Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Cli | 1968 |
A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics.
Topics: Adult; Aged; Behavior; Chronic Disease; Clinical Trials as Topic; Fluphenazine; Haloperidol; Humans; | 1968 |
A pilot investigation in neuroleptic therapy.
Topics: Adult; Autonomic Nervous System; Clinical Trials as Topic; Female; Haloperidol; Handwriting; Humans; | 1968 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
[The effect of psychopharmacological drugs and other central nervous system effecting drugs on experimental nystagmus].
Topics: Amitriptyline; Apomorphine; Aporphines; Barbiturates; Chlordiazepoxide; Chlorpromazine; Clinical Tri | 1968 |
Integrated EEG. variability: drug effects in acute schizophrenics.
Topics: Adolescent; Adult; Brain; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Electroencephal | 1969 |
Haloperidol--new addition to the drug treatment of schizophrenia.
Topics: Adult; Clinical Trials as Topic; Emotions; Female; Haloperidol; Humans; Male; Middle Aged; Placebos; | 1969 |
Assessment and significance of changes in laboratory values with haloperidol and fluphenazine hydrochloride therapy.
Topics: Adult; Clinical Trials as Topic; Computers; Female; Fluphenazine; Haloperidol; Humans; Male; Middle | 1970 |
Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol.
Topics: Adult; Asthenia; Benperidol; Catatonia; Clinical Trials as Topic; Depression; Haloperidol; Humans; H | 1970 |
A comparison of chlorprothixene and haloperidol in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Chlorprothixene; Clinical Trials as Topic; Electroencephalography; | 1971 |
A controlled study of haloperidol in chronic schizophrenia.
Topics: Adult; Clinical Trials as Topic; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1967 |
Further studies on the effect of butyrophenones on cholesterol synthesis in humans.
Topics: Cholesterol; Clinical Trials as Topic; Haloperidol; Humans; Male; Schizophrenia | 1967 |
Treatment of chronic schizophrenic patients with haloperidol and chlorpromazine combined.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Drug Synergism; Female; Haloperidol; Humans; Male; | 1968 |
Further studies of the butyrophenone, CI-601, in chronic schizophrenic patients.
Topics: Adult; Butyrophenones; Clinical Trials as Topic; Haloperidol; Humans; Male; Middle Aged; Placebos; P | 1968 |
Treatment of acute and chronic psychoses with haloperidol: review of clinical results.
Topics: Acute Disease; Chlorpromazine; Chlorprothixene; Chronic Disease; Haloperidol; Humans; Schizophrenia | 1969 |
CI-601, a butyrophenone derivative, in the treatment of chronically withdrawn schizophrenic patients.
Topics: Adult; Butyrophenones; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; | 1970 |
Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Evaluation; Electroencephalography; E | 1971 |
Effects of L-DOPA on pharmacological parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Haloper | 1966 |
A butyrophenone (haloperidol) for the treatment of institutionalized patients.
Topics: Adolescent; Adult; Aged; Antisocial Personality Disorder; Brain Damage, Chronic; Child; Clinical Tri | 1966 |
Clinical evaluation of neuroleptic drug action, particularly considering butyrophenones.
Topics: Aged; Butyrophenones; Chlorpromazine; Clinical Trials as Topic; Electrocardiography; Female; Haloper | 1966 |
[Depot-neuroleptics in the treatment of schizophrenia].
Topics: Adult; Chlorpromazine; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Middl | 1971 |
Changes in cognition, attention and language in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Attention; Cognition; Female; Haloperidol; Humans; Intelligence Te | 1969 |
1553 other studies available for haloperidol and Dementia Praecox
| Article | Year |
|---|---|
3-[4-[1-(6-Fluorobenzo[b]thiophen-3-yl)-4-piperazinyl]butyl]- 2,5,5-trimethyl-4-thiazolidinone: a new atypical antipsychotic agent for the treatment of schizophrenia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Mice; Rats; Receptors, Dopami | 1992 |
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Topics: Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cloning, Molecular; Clozapine; Dibenzoc | 2009 |
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.
Topics: Animals; Carbazoles; Disease Models, Animal; Dopamine Agonists; Rats; Receptor, Serotonin, 5-HT1A; R | 2009 |
Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Topics: Animals; Antipsychotic Agents; Blood-Brain Barrier; CHO Cells; Cricetinae; Cricetulus; Humans; Quina | 2009 |
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Cell Line; Humans; Ligands; Male; Mice; Piperaz | 2010 |
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Agonists; Quinolones; Receptor, Sero | 2010 |
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Topics: Administration, Oral; Animals; Cyclic GMP; Dose-Response Relationship, Drug; Drug Discovery; Humans; | 2012 |
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Topics: Animals; Antipsychotic Agents; Berberine; Berberine Alkaloids; CHO Cells; Cricetinae; Cricetulus; Do | 2013 |
Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chemistry Techniques, Synthetic; Dose-Response Rela | 2013 |
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biological Availability; Drug Discovery; El | 2014 |
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine Antagonists; | 2014 |
Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.
Topics: Animals; Antipsychotic Agents; Ether-A-Go-Go Potassium Channels; Humans; Mice; Oxazoles; Patch-Clamp | 2015 |
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
Topics: Animals; Brain; Catalepsy; Central Nervous System Stimulants; Cognition; Dextroamphetamine; Drug Des | 2016 |
Potent haloperidol derivatives covalently binding to the dopamine D2 receptor.
Topics: Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Ligands; Molecular Dock | 2017 |
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
Topics: Animals; Antipsychotic Agents; Body Weight; Chemistry Techniques, Synthetic; Drug Design; Ether-A-Go | 2018 |
Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics.
Topics: Amides; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Cha | 2020 |
Therapeutic potential of TAK-071, a muscarinic M
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; CHO Cells; Cognition; Cognitive Dysfunction; C | 2021 |
Efficacy and safety of intranasal haloperidol in an acute Psychiatry Unit: a pilot study on schizophrenic patients with mild-modedate agitation.
Topics: Administration, Intranasal; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Pilot Projec | 2021 |
The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiepins; Female; Haloperidol; Humans; Hyperglycemia; | 2022 |
[Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone].
Topics: Adipokines; Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2021 |
Improved response to electroconvulsive therapy after switching from haloperidol to blonanserin in a patient with treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Electroconvulsive Therapy; Haloperidol; Humans; Piperazines; Piperidines; Schi | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cl | 2022 |
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; | 2022 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Topics: Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Polymorphism, | 2023 |
Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study.
Topics: Antipsychotic Agents; Child; Female; Haloperidol; Humans; Male; Schizophrenia; Sleep | 2023 |
Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive-compulsive disorder by integrated bioinformatics analysis.
Topics: Haloperidol; Humans; MicroRNAs; Obsessive-Compulsive Disorder; Psychotic Disorders; Schizophrenia; S | 2023 |
Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; | 2023 |
Ketamine disrupts locomotion and electrolocation in a novel model of schizophrenia, Gnathonemus petersii fish.
Topics: Animals; Electric Fish; Haloperidol; Ketamine; Locomotion; Schizophrenia | 2023 |
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.
Topics: Aged; Aged, 80 and over; Aging; Animals; Antipsychotic Agents; Autopsy; Datasets as Topic; Disease M | 2023 |
Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Risperidone; Schizoph | 2022 |
Rho kinase inhibitors ameliorate cognitive impairment in a male mouse model of methamphetamine-induced schizophrenia.
Topics: Animals; Clozapine; Cognitive Dysfunction; Haloperidol; Male; Methamphetamine; Mice; Monomeric GTP-B | 2023 |
Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Epigenesis, Genetic; Glial Cell | 2023 |
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).
Topics: Antipsychotic Agents; Delayed-Action Preparations; Haloperidol; Humans; Olanzapine; Psychotic Disord | 2023 |
Pharmacological and proteomic analyses of neonatal polyI:C-treated adult mice.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Animals, Newborn; Antipsychotic Agents; Clozapine; Disease | 2019 |
Risk Factors for Noncompliance with Antipsychotic Medication in Long-Term Treated Chronic Schizophrenia Patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Olanzapine; Patient Compliance; Risk Factors; | 2019 |
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Polymorphism, Genetic; Receptor | 2020 |
Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment.
Topics: Amphetamine; Animals; Attention; Central Nervous System Stimulants; Choice Behavior; Dopamine Antago | 2020 |
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment.
Topics: Animals; Antipsychotic Agents; Brain; Cannabidiol; Cerebrovascular Circulation; Disease Models, Anim | 2020 |
Neuroleptic malignant syndrome in a COVID-19 patient.
Topics: Acute Kidney Injury; Antipsychotic Agents; Betacoronavirus; Bromocriptine; C-Reactive Protein; Coron | 2020 |
SARS-CoV-2
Topics: Animals; Antiviral Agents; Base Sequence; Betacoronavirus; Chromosomes, Human, Pair 1; Coronavirus I | 2020 |
Haloperidol Discontinuation for People with Schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2020 |
Ubiquitin-proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia.
Topics: Antipsychotic Agents; Cells, Cultured; Clozapine; DNA Damage; DNA Repair; Haloperidol; Humans; Lipid | 2020 |
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Lipid Metabolism; Male; | 2020 |
Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Arginine; Behavior, Animal; Catalepsy; Disease Models, Animal; Di | 2021 |
Effects of various antipsychotics on driving-related cognitive performance in adults with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cognition; Cross-Sectional Studies; Halo | 2020 |
Characterization hiPSC-derived neural progenitor cells and neurons to investigate the role of NOS1AP isoforms in human neuron dendritogenesis.
Topics: Adaptor Proteins, Signal Transducing; Cells, Cultured; Clozapine; Dendrites; Drug Evaluation, Precli | 2020 |
Evaluation of NDEL1 oligopeptidase activity in blood and brain in an animal model of schizophrenia: effects of psychostimulants and antipsychotics.
Topics: Animals; Antipsychotic Agents; Brain; Central Nervous System Stimulants; Clozapine; Cysteine Endopep | 2020 |
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Intra-Ab | 2021 |
Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Corpus Striatum; Dopamine; Glycogen S | 2021 |
Haloperidol elicits oxidative damage in the brain of rats submitted to the ketamine-induced model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Haloperidol; Ketamine; Male; Oxidative Stress; Rats; Rats, Wis | 2021 |
Risk and Prevention of Aggression in Patients With Psychotic Disorders.
Topics: Aggression; Clozapine; Conduct Disorder; Haloperidol; Humans; Olanzapine; Psychotic Disorders; Schiz | 2021 |
Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Nicotine; Olanzapine; Practice Gu | 2022 |
Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Haloperidol; Phenotype; Rats; Rotenone; Schizophr | 2021 |
Identifying therapeutic targets for schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Drug Discovery; Haloperidol; Humans; Molecular Targeted Therap | 2021 |
A drug-drug conditioning paradigm reveals multiple antipsychotic-nicotine interactions.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Conditioning, Classical; Conditioning, | 2017 |
The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; CREB-Binding Protein; Drug | 2017 |
Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs.
Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzodiazepines; Case-Control S | 2017 |
On the Magical Thinking Related to Mental Health in Chad.
Topics: Antipsychotic Agents; Chad; Culture; Haloperidol; Health Knowledge, Attitudes, Practice; Humans; Men | 2017 |
Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects.
Topics: Animals; Antipsychotic Agents; Brain; Corpus Striatum; Gene Expression Regulation; Genetic Predispos | 2018 |
Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.
Topics: Anesthetics, Dissociative; Animals; Antioxidants; Antipsychotic Agents; Benzodiazepines; Brain; Drug | 2017 |
Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
Topics: Adult; Antipsychotic Agents; Belgium; Benzodiazepines; Delayed-Action Preparations; Drug Administrat | 2017 |
An acute oral intoxication with haloperidol decanoate.
Topics: Administration, Oral; Antipsychotic Agents; Arrhythmias, Cardiac; Charcoal; Electrocardiography; Fem | 2017 |
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2017 |
Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits.
Topics: Animals; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; CA1 Region, Hippocampal | 2018 |
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Disease Mod | 2017 |
Assessing the critical issues of atypical antipsychotics in schizophrenic inpatients.
Topics: Antipsychotic Agents; Haloperidol; Humans; Inpatients; Schizophrenia | 2017 |
Periodic catatonia with long-term treatment: a case report.
Topics: Antipsychotic Agents; Catatonia; Clozapine; Drug Therapy, Combination; Female; Haloperidol; Humans; | 2017 |
Persistent oromandibular dystonia and angioedema secondary to haloperidol.
Topics: Adult; Angioedema; Antipsychotic Agents; Diagnosis, Differential; Dystonia; Haloperidol; Humans; Mal | 2017 |
Haloperidol affects bones while clozapine alters metabolic parameters - sex specific effects in rats perinatally treated with phencyclidine.
Topics: Animals; Antipsychotic Agents; Bone and Bones; Bone Density; Clozapine; Corticosterone; Female; Halo | 2017 |
Two unusual cases of protracted inter-ictal delirium following electroconvulsive therapy.
Topics: Adult; Antipsychotic Agents; Delirium; Electroconvulsive Therapy; Haloperidol; Humans; Lorazepam; Ma | 2017 |
Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Drug Therapy, Com | 2018 |
Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Biological Products; D | 2018 |
Understanding the influence of antipsychotic drugs on global methylation events and its relevance in treatment response.
Topics: 5-Methylcytosine; Adult; Antipsychotic Agents; Case-Control Studies; Clozapine; Cytosine; DNA; DNA ( | 2018 |
Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Cardiovascular Diseases; Chronic Disease; Clozapine; Cross-Sectional St | 2018 |
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance.
Topics: Animals; Brain; Caffeine; Central Nervous System Agents; Cytoskeletal Proteins; Drug Interactions; D | 2018 |
Cell-subtype-specific changes in adenosine pathways in schizophrenia.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Kinase; Adenosine Triphosphatases; Adult; Aged; Animals; Antip | 2018 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Topics: Administration, Oral; Adult; Algorithms; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill | 2019 |
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Brain-Derived Neurotrophic Factor; Catalase; Dise | 2018 |
Sensorimotor gating deficits and effects of antipsychotics on the hyperactivity in VGF-overexpressing mice.
Topics: Animals; Antipsychotic Agents; Haloperidol; Male; Mice; Mice, Transgenic; Nerve Growth Factors; Neur | 2018 |
Trends in pharmacological emergency treatment of patients suffering from schizophrenia over a 16-year observation period.
Topics: Adult; Antipsychotic Agents; Austria; Benzodiazepines; Emergency Treatment; Female; Haloperidol; Hos | 2018 |
Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.
Topics: Antipsychotic Agents; Autonomic Nervous System; Cardiovascular Diseases; Diagnosis, Differential; Do | 2018 |
[The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: affinity linked mechanism].
Topics: Antipsychotic Agents; Cytokines; Haloperidol; Humans; Leukocytes, Mononuclear; Olanzapine; Receptors | 2018 |
Clozapine toxicity in a CYP2D6 poor metaboliser: Additive effects of haloperidol and valproate on clozapine metabolism.
Topics: Adult; Antipsychotic Agents; Clozapine; Cytochrome P-450 CYP2D6; Drug Synergism; Haloperidol; Humans | 2018 |
[In process].
Topics: Antipsychotic Agents; Atrophy; Brain; Cerebral Cortex; Dopamine; Dose-Response Relationship, Drug; G | 2016 |
Albizia zygia root extract exhibits antipsychotic-like properties in murine models of schizophrenia.
Topics: Albizzia; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Cognition; Disease Models, Ani | 2018 |
A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference.
Topics: Antipsychotic Agents; Bayes Theorem; Biomarkers; Causality; Endpoint Determination; Entropy; Haloper | 2018 |
Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Dose-Re | 2018 |
Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Emergency Service, Hospital; Ethics, Research; Female | 2019 |
Impact of nuclear distribution element genes in the typical and atypical antipsychotics effects on nematode Caenorhabditis elegans: Putative animal model for studying the pathways correlated to schizophrenia.
Topics: Animals; Animals, Genetically Modified; Antipsychotic Agents; Behavior, Animal; Caenorhabditis elega | 2019 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Fe | 2019 |
Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Brain; Case-Control Studies; Female; Gas Chromatog | 2019 |
Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration.
Topics: Animals; Antipsychotic Agents; Cell Count; Clozapine; Corpus Striatum; Female; Gyrus Cinguli; Halope | 2019 |
Adverse Events in a Breastfed Infant Exposed to Risperidone and Haloperidol.
Topics: Antipsychotic Agents; Dietary Exposure; Drug Therapy, Combination; Female; Haloperidol; Humans; Infa | 2019 |
Effects of haloperidol on cognitive function and behavioural flexibility in the IntelliCage social home cage environment.
Topics: Animals; Behavior, Animal; Cognition; Discrimination Learning; Disease Models, Animal; Exploratory B | 2019 |
Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France
.
Topics: Antipsychotic Agents; Delayed-Action Preparations; France; Haloperidol; Humans; Injections; Paliperi | 2019 |
Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; Erectile Dysfuncti | 2019 |
Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Delta Rhythm; Dibenzocycloheptenes; Disease Models, | 2019 |
Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, Combin | 2019 |
Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof.
Topics: Adult; Algorithms; Antipsychotic Agents; Biotransformation; Brain; Chlorpromazine; Diagnostic and St | 2013 |
Expression and differential response to haloperidol treatment of Cyclon/CCDC86 mRNA in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Leukocytes; Male; Middle Aged; Nuclear Pro | 2013 |
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Map | 2013 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia | 2013 |
Length of mechanical restraint following haloperidol injections versus oral atypical antipsychotics for the initial treatment of acute schizophrenia: a propensity-matched analysis from the Japanese diagnosis procedure combination database.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Case-Control Studies; Databases, Bibliographic; Fema | 2013 |
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fluphenazine; Haloperidol; Human | 2013 |
Unique pharmacological actions of atypical neuroleptic quetiapine: possible role in cell cycle/fate control.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Astrocytes; Cell Cycle; Dibenzothiazepines; Dis | 2013 |
Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Animals; Antipsychotic Agents; Benzodiazepines; Berberine; Calcium C | 2013 |
Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antipsychotic Agents; Female; Gene Expressio | 2013 |
Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Case-Control Studies; Endosomal Sorting Complexes Required for Tra | 2013 |
Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Brain; Cohort Studies; Haloperidol; Humans; Neocortex; Rats; Risperid | 2014 |
Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain.
Topics: Animals; Antipsychotic Agents; Astrocytes; Chromatography, High Pressure Liquid; gamma-Aminobutyric | 2013 |
Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia.
Topics: Animals; Antipsychotic Agents; Clozapine; Dopamine Antagonists; Haloperidol; Inhibition, Psychologic | 2013 |
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Combinations; Female; Fluphenazine; H | 2013 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
Conserved chromosome 2q31 conformations are associated with transcriptional regulation of GAD1 GABA synthesis enzyme and altered in prefrontal cortex of subjects with schizophrenia.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Chromosomes, Human, Pair 2; Clozapine; DNA Methylati | 2013 |
Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Dizocilpine Maleate; Excitatory Amino Acid Antagonis | 2013 |
Conservative approach to tardive dyskinesia-induced neck and upper back pain.
Topics: Adult; Antipsychotic Agents; Back Pain; Female; Haloperidol; Humans; Manipulation, Osteopathic; Move | 2013 |
The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Catechol O-Methyltransferase; Ch | 2013 |
Antipsychotics promote the differentiation of oligodendrocyte progenitor cells by regulating oligodendrocyte lineage transcription factors 1 and 2.
Topics: 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; Animals; Antipsychotic Agents; Basic Helix-Loop-Helix | 2013 |
Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate.
Topics: Adult; Antioxidants; Antipsychotic Agents; Basal Ganglia Diseases; Catalase; Female; Glutathione; Gl | 2013 |
ΔFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Avoidance Learning; Gene Expression Regulation; Haloperi | 2014 |
Cerebellar motor learning deficits in medicated and medication-free men with recent-onset schizophrenia.
Topics: Adaptation, Psychological; Adolescent; Adult; Antipsychotic Agents; Blinking; Cerebellum; Clozapine; | 2014 |
Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Model | 2013 |
Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.
Topics: Adult; Animals; Antigens, Differentiation; Antipsychotic Agents; Benzodiazepines; Female; GABAergic | 2014 |
Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Pali | 2013 |
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost of Illness; Cost-Benefit Analysis; Del | 2014 |
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Diazepam; Disea | 2014 |
Should remission in schizophrenia data be combined from different studies?
Topics: Activities of Daily Living; Behavioral Symptoms; Female; Haloperidol; Humans; Male; Remission Induct | 2014 |
Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia.
Topics: Administration, Intranasal; Animals; Catalepsy; Corpus Striatum; Drug Carriers; Drug Compounding; Dr | 2014 |
Alterations of the myristoylated, alanine-rich C kinase substrate (MARCKS) in prefrontal cortex in schizophrenia.
Topics: Aged; Animals; Antipsychotic Agents; Blotting, Western; Down-Regulation; Female; Haloperidol; Humans | 2014 |
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Female; | 2014 |
Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged | 2014 |
[Antipsychotic-induced priapism and management challenges: a case report].
Topics: Antipsychotic Agents; Benzodiazepines; Drug Substitution; Follow-Up Studies; Haloperidol; Hospitals, | 2014 |
Gamma power and cognition in patients with schizophrenia and their first-degree relatives.
Topics: Adult; Antipsychotic Agents; Brain; Cognition; Electroencephalography; Evoked Potentials; Family; Fe | 2014 |
Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Female; Haloperidol; Humans; Male; Middle A | 2014 |
Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment.
Topics: Adult; Alleles; Antipsychotic Agents; Female; Genome-Wide Association Study; Genotype; Haloperidol; | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; | 2014 |
Death due to fulminant neuroleptic malignant syndrome induced by low doses of haloperidol: a rare case.
Topics: Adult; Antipsychotic Agents; Creatinine; Dose-Response Relationship, Drug; Haloperidol; Humans; Leuk | 2014 |
Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; DNA Methylation; Gene Expression; | 2014 |
Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia.
Topics: Animals; Benzazepines; Brain; Carrier Proteins; Disks Large Homolog 4 Protein; Dopamine; Dopamine Ag | 2014 |
Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia.
Topics: Animals; Antipsychotic Agents; Endocytosis; Female; Gene Expression Regulation; Genetic Association | 2015 |
Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antipsychotic Agents; Female; G-Protein-Coup | 2014 |
Antipsychotic haloperidol binding to the human dopamine D3 receptor: beyond docking through QM/MM refinement toward the design of improved schizophrenia medicines.
Topics: Antipsychotic Agents; Dopamine Antagonists; Haloperidol; Humans; Models, Chemical; Molecular Docking | 2014 |
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders; Disease Model | 2014 |
Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.
Topics: Animals; Atrophy; Bipolar Disorder; Case-Control Studies; Clozapine; Dendritic Spines; Female; Front | 2014 |
Haloperidol treatment at pre-exposure phase reduces the disturbance of latent inhibition in rats with neonatal ventral hippocampus lesions.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Dise | 2014 |
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine | 2015 |
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol | 2015 |
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Female; Haloperidol; | 2015 |
[Alcohol hallucinosis].
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Antipsychotic Agents; Diagnosis, Differential; Hallu | 2015 |
A Bayesian framework to account for uncertainty due to missing binary outcome data in pairwise meta-analysis.
Topics: Antipsychotic Agents; Bayes Theorem; Bias; Data Interpretation, Statistical; Dose-Response Relations | 2015 |
Inhibition of 14-3-3 Proteins Leads to Schizophrenia-Related Behavioral Phenotypes and Synaptic Defects in Mice.
Topics: 14-3-3 Proteins; Animals; Antipsychotic Agents; Behavior, Animal; Catenins; Cerebral Cortex; Clozapi | 2015 |
The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
Topics: Adolescent; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome | 2015 |
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; | 2015 |
Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Benzodiazepines; cdc42 GTP-Binding Protein; Cytoskeletal Prote | 2015 |
A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Depression; Disease Models, Animal; Ha | 2015 |
Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Antipsychotic Agents; | 2015 |
Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; CA1 Region, Hippocampal; Carrier Proteins; Chlorprom | 2015 |
Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Brain; Case-Control Studies; Excitatory Amin | 2015 |
Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia.
Topics: Aged; Animals; Antipsychotic Agents; Blotting, Western; Female; Gray Matter; Haloperidol; Humans; Ma | 2015 |
Haloperidol vs. Low-Potency Antipsychotic Drugs for Schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Schizophrenia | 2015 |
Stress induced by the socially evaluated cold-pressor test cause equivalent deficiencies of sensory gating in male subjects with schizophrenia and healthy controls.
Topics: Adult; Anticipation, Psychological; Antipsychotic Agents; Case-Control Studies; Cold Temperature; Co | 2015 |
Protein Expression of Proteasome Subunits in Elderly Patients with Schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Blotting, Western; Female; Haloperidol; Huma | 2016 |
AMIGO-Kv2.1 Potassium Channel Complex Is Associated With Schizophrenia-Related Phenotypes.
Topics: Adult; Animals; Antipsychotic Agents; Behavior, Animal; Blotting, Western; Brain; Cell Membrane; Clo | 2016 |
SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; Chlorpromazine; Depressive Di | 2015 |
Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Gene Expression; Glycine Plasma Me | 2015 |
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Follow | 2015 |
A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study.
Topics: Adult; Antipsychotic Agents; Drug Delivery Systems; Female; Flupenthixol; Haloperidol; Humans; Male; | 2015 |
LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Ketamine; Male; Memor | 2016 |
Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study.
Topics: Antipsychotic Agents; Haloperidol; Humans; Paliperidone Palmitate; Psychotic Disorders; Randomized C | 2016 |
Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics.
Topics: Adult; Amino Acids; Antipsychotic Agents; Chromatography, Ion Exchange; Clopenthixol; Clozapine; Coh | 2015 |
Tyrosine hydroxylase localization in the nucleus accumbens in schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Benzodiazepines; Dopamine; Female; Haloperidol; Humans; Male; | 2016 |
Haloperidol Suppresses NF-kappaB to Inhibit Lipopolysaccharide-Induced Pro-Inflammatory Response in RAW 264 Cells.
Topics: Animals; B7-1 Antigen; B7-2 Antigen; Cytokines; Female; Haloperidol; Inflammation; Interleukins; Lip | 2016 |
Decreased protein S-palmitoylation in dorsolateral prefrontal cortex in schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Brain Chemistry; Female; Haloperidol; Humans | 2016 |
Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cell Line, Tumor; Cell Survival; Clozapine; Gene | 2016 |
Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect.
Topics: Animals; Antipsychotic Agents; Cardiovascular Diseases; Clozapine; Comorbidity; Genetic Predispositi | 2016 |
Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia.
Topics: Animals; Antipsychotic Agents; Clozapine; Corpus Striatum; Female; Haloperidol; Humans; Immunoprecip | 2016 |
Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Disease Models, Animal; Female; Gene Expression; Hal | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapi | 2015 |
Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Studies as Topic; Flupenthixol; Halope | 2016 |
Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Drug Therapy, Combination | 2016 |
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.
Topics: Amino Acids; Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic | 2016 |
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2016 |
Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Autoradiography; Binding Sites; Brain | 2016 |
The glial phosphorylase of glycogen isoform is reduced in the dorsolateral prefrontal cortex in chronic schizophrenia.
Topics: Aged; Animals; Antipsychotic Agents; Astrocytes; Cells, Cultured; Chronic Disease; Cohort Studies; D | 2016 |
Treatment of agitation in the acute psychiatric setting. An observational study of the effectiveness of intramuscular psychotropic medication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Female; Haloperidol; Humans; Injec | 2016 |
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; H | 2016 |
The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Benzofurans; Brain-Derived Neurotrophic Factor; | 2016 |
Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Drug Resistance; Gene Expression; Haloperidol; Homer | 2017 |
Clinical and biological outcomes of prolonged treatment with haloperidol in schizophrenia.
Topics: Aged; Animals; Demography; Haloperidol; Humans; Male; Rats, Wistar; Schizophrenia; Time Factors; Tom | 2016 |
Potential drug-drug interaction in Mexican patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Biperiden; Cross-Sectional Studies; Drug Incompatibility; D | 2016 |
First and second generation antipsychotics differentially affect structural and functional properties of rat hippocampal neuron synapses.
Topics: Animals; Antipsychotic Agents; Astrocytes; Benzodiazepines; Cells, Cultured; Coculture Techniques; F | 2016 |
Assessing a surrogate predictive value: a causal inference approach.
Topics: Antipsychotic Agents; Biomarkers; Causality; Data Interpretation, Statistical; Endpoint Determinatio | 2017 |
Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia: A Naturalistic, Comparative Study.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Medication Adherence; Ret | 2017 |
Postsynaptic Density-95 Isoform Abnormalities in Schizophrenia.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Disease Models, Animal; Disks Large Homolog 4 Protein; F | 2017 |
Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.
Topics: Amphetamines; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Clozapine; Dizocilpine | 2017 |
Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics.
Topics: Adenine; Adult; Algeria; Antipsychotic Agents; Clozapine; Diagnostic and Statistical Manual of Menta | 2008 |
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle | 2008 |
Imputation methods for missing outcome data in meta-analysis of clinical trials.
Topics: Haloperidol; Humans; Meta-Analysis as Topic; Models, Statistical; Outcome Assessment, Health Care; R | 2008 |
Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Electrocardiography; Female; Haloperid | 2009 |
Attitudes of patients and family members towards implantable psychiatric medication.
Topics: Adult; Attitude to Health; Clozapine; Cross-Cultural Comparison; Data Collection; Drug Implants; Fam | 2008 |
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Topics: Adult; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genetic Markers; Genotype; H | 2008 |
Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.
Topics: Adult; Age of Onset; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Cohort Studies; Dis | 2008 |
Are all antipsychotics equal?
Topics: Antipsychotic Agents; Attitude of Health Personnel; Haloperidol; Humans; Patient Readmission; Schizo | 2008 |
Haloperidol versus chlorpromazine for treatment of schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Psychotic Disorders; Randomized Controlle | 2008 |
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Attention; Cholinergic Antagonists; Clozapine; Cognition Disorders; C | 2009 |
Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Benzamides; Central Nervous Sys | 2009 |
Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Haloperidol; Hu | 2008 |
An autoregressive linear mixed effects model for the analysis of longitudinal data which include dropouts and show profiles approaching asymptotes.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Haloperidol; Humans; Linear Models; Longitudinal Stu | 2008 |
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Clozapine; DNA Primer | 2008 |
Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Electric Stimul | 2009 |
Fluctuation of latent inhibition along the estrous cycle in the rat: modeling the cyclicity of symptoms in schizophrenic women?
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Conditioning, Psychological; Data Inte | 2008 |
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Antip | 2010 |
Zotepine-induced spontaneous ejaculation.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Ejaculation; Genital Diseases, Male; Haloperidol; Huma | 2008 |
Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost of Illness; Dibe | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous | 2009 |
Exacerbation of tics secondary to clozapine therapy.
Topics: Agranulocytosis; Antipsychotic Agents; Clozapine; Disease Progression; Dose-Response Relationship, D | 2008 |
Differential brain activation during facial emotion discrimination in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Brain Mapping; Cues; Discrimination, Psychological; | 2009 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rat | 2009 |
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze | 2009 |
[The possibility of high-quality remission in the long chronic course of schizophrenia].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Disease Progression; Drug Therapy, Co | 2008 |
[Depression in schizophrenia].
Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Chi-S | 2008 |
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-B | 2008 |
Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine | 2009 |
The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Belgium; Butyrophenones; Drug Industry; Haloperid | 2009 |
Combination of electroconvulsive therapy with skin graft surgery for a schizophrenic patient with burns.
Topics: Anesthesia; Antipsychotic Agents; Burns; Drug Resistance; Electroconvulsive Therapy; Hallucinations; | 2009 |
Internal capsule size associated with outcome in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Hippocampus; Humans | 2009 |
Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Cell Line, Tumor; Chronic Disease; Down-Regulation; Fema | 2009 |
Cathepsin K generates enkephalin from beta-endorphin: a new mechanism with possible relevance for schizophrenia.
Topics: Adult; Antipsychotic Agents; Arcuate Nucleus of Hypothalamus; beta-Endorphin; Brain Chemistry; Cathe | 2009 |
Targeting cognition in schizophrenia research: from etiology to treatment.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dibenzothiazepin | 2009 |
Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
Topics: Animals; Antipsychotic Agents; Blotting, Western; Brain; Disease Models, Animal; Haloperidol; Humans | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Io | 2009 |
2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease.
Topics: Adult; Analysis of Variance; Animals; Bipolar Disorder; Brain; Case-Control Studies; Chromatography, | 2009 |
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Topics: Antipsychotic Agents; Benzodiazepines; Brazil; Cost-Benefit Analysis; Drug Costs; Haloperidol; Human | 2009 |
[Complex therapy of schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Art Therapy; Benzodiazepines; Clinical Trials as Topic; Clo | 2009 |
[Effect of nifedipine on the effectiveness of antipsychotic therapy in schizophrenia].
Topics: Adult; Antipsychotic Agents; Calcium Channel Blockers; Cognition; Dibenzothiazepines; Dose-Response | 2009 |
Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia.
Topics: Adult; Aged; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; | 2009 |
The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats.
Topics: Aging; Analysis of Variance; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dopam | 2010 |
Haloperidol-induced neuroleptic malignant syndrome complicated by hyperosmolar hyperglycemic state.
Topics: Adult; Antipsychotic Agents; Fatal Outcome; Haloperidol; Humans; Hyperglycemia; Male; Malignant Hype | 2009 |
Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Female; Haloperidol; Humans; Kaplan-Meier Est | 2010 |
Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions.
Topics: Animals; Antipsychotic Agents; Astrocytes; Brain Chemistry; Cell Line; Glutamate-Ammonia Ligase; Glu | 2010 |
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Female; Finland; Haloperidol; Humans; Ma | 2010 |
A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Clozapine; Corpus Striatum; Female; H | 2010 |
Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Cholinesterase Inhibitors; Dyskinesia, Drug-Induced; Female; Genetic | 2010 |
Expression changes of serotonin receptor gene subtype 5HT3a in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and Olanzapin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Leukocytes, Mononuclear; Olanzapi | 2009 |
Psychiatrist accused of dishonesty for prescribing drugs to a patient under a false name.
Topics: Antipsychotic Agents; Deception; England; Female; Haloperidol; Humans; Lorazepam; Prescription Drugs | 2010 |
The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Cells, Cultured; Clozapine; Dopamine; Drug The | 2011 |
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Case-C | 2010 |
A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process.
Topics: Animals; Antipsychotic Agents; Drug Implants; Haloperidol; Rats; Schizophrenia | 2010 |
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Halo | 2011 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relati | 2010 |
Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Cadherins; Carrier Proteins; Cerebral Cortex | 2010 |
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Cerebellar Cortex; Cerebral Cort | 2010 |
Haloperidol normalized prenatal vitamin D depletion-induced reduction of hippocampal cell proliferation in adult rats.
Topics: Animals; Antipsychotic Agents; Cell Proliferation; Disease Models, Animal; Female; Haloperidol; Hipp | 2010 |
Treatment of a tardive dyskinesia patient with temporomandibular disorder: a case report.
Topics: Aged; Antipsychotic Agents; Botulinum Toxins, Type A; Bruxism; Clozapine; Dyskinesia, Drug-Induced; | 2010 |
Acute respiratory distress due to antipsychotic drugs.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Drug Therapy, Co | 2010 |
An early improvement threshold to predict response and remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Germany; Ha | 2010 |
Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism.
Topics: Adult; Alleles; Analysis of Variance; Animals; Antipsychotic Agents; Case-Control Studies; Chronic D | 2010 |
Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.
Topics: Adult; Aged; Analysis of Variance; Animals; Antipsychotic Agents; Case-Control Studies; Cohort Studi | 2010 |
Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.
Topics: Adult; Antioxidants; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Glutathione Peroxida | 2010 |
Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.
Topics: Adult; Animals; Antipsychotic Agents; Carrier Proteins; Female; Gene Expression Regulation; Gene Fre | 2011 |
Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; | 2010 |
The effects of clozapine on quinpirole-induced non-regulatory drinking and prepulse inhibition disruption in rats.
Topics: Animals; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic Factor; Clozapine; Disease Models, | 2010 |
Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain Mapping; Clozapine; Female; Haloperidol; Humans; | 2010 |
Neonatal ventral hippocampus lesion induces increase in nitric oxide [NO] levels which is attenuated by subchronic haloperidol treatment.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Drug Administration Schedule; Female; Haloperidol | 2010 |
Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationsh | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
Topics: Adrenergic Agents; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopamine Agents; Dopamine Pla | 2011 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagoni | 2011 |
Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model.
Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Benzhydryl Compounds; Discrimination, Ps | 2010 |
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; | 2011 |
Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects.
Topics: Adult; Antipsychotic Agents; Demography; Drug Administration Schedule; Female; Haloperidol; Humans; | 2011 |
Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Lipoprotein Lipase; Mac | 2010 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines | 2011 |
Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Chemical Phenomena; Disease Models, Animal; Dyskinesia, | 2011 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Emergencies; Emergency Medicine; Emergency Ser | 2011 |
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Fe | 2011 |
Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures.
Topics: Antipsychotic Agents; Cell Line; Clozapine; Fibroblasts; Fluphenazine; Haloperidol; Humans; Schizoph | 2011 |
Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dopa | 2012 |
Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; beta-Glucans; Female; Haloperidol; H | 2011 |
[Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia].
Topics: Adult; Antipsychotic Agents; Autoantibodies; Biomarkers; Brain-Derived Neurotrophic Factor; Female; | 2011 |
Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients.
Topics: Adolescent; Adult; Aged; Haloperidol; Humans; Middle Aged; Molecular Structure; Saliva; Schizophreni | 2011 |
Alpha1,6-fucosyltransferase-deficient mice exhibit multiple behavioral abnormalities associated with a schizophrenia-like phenotype: importance of the balance between the dopamine and serotonin systems.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain; Dopamine; Fucosyltransferases; Haloperidol; | 2011 |
[The effect of serotonin on the cytotoxic activity of natural killer lymphocytes in patients with the first episode of endogenous psychosis].
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Cytotoxicity, Immunologic; Haloperidol; Humans; | 2011 |
An importance of dose in antipsychotic combination therapy for schizophrenia.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Haloperidol; Humans; Randomized Controlled Trials a | 2011 |
Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Blotting, Western; Clathrin; Electrophoresis | 2011 |
Inhibition of ketamine-induced hyperlocomotion in mice by the essential oil of Alpinia zerumbet: possible involvement of an antioxidant effect.
Topics: Alpinia; Animals; Antioxidants; Antipsychotic Agents; Glutathione; Haloperidol; Hypnotics and Sedati | 2011 |
Does the association with diabetes say more about schizophrenia and its treatment?--the GLUT hypothesis.
Topics: Animals; Clozapine; Diabetes Complications; Dopamine; Glucose; Glucose Transporter Type 1; Glucose T | 2011 |
Abnormally rapid reversal learning and reduced response to antipsychotic drugs following ovariectomy in female rats.
Topics: Animals; Antipsychotic Agents; Attention; Clozapine; Discrimination Learning; Estradiol; Estrogens; | 2012 |
[A fatal laryngeal lesion].
Topics: Angioedema; Antipsychotic Agents; Asphyxia; Autopsy; Drug Hypersensitivity; Drug Therapy, Combinatio | 2011 |
Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets.
Topics: Antipsychotic Agents; CD4-Positive T-Lymphocytes; Cell Differentiation; Cells, Cultured; Clozapine; | 2011 |
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharma | 2011 |
Cortical opioid markers in schizophrenia and across postnatal development.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Enkephalins; Female; Haloperidol; Humans; Macaca fas | 2012 |
Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia.
Topics: Adiponectin; Adult; Antipsychotic Agents; Blood Pressure; Body Mass Index; Clozapine; Female; Halope | 2011 |
Do elevated glucocorticoids contribute to reduced cerebral expression of insulin-degrading enzyme in schizophrenia?
Topics: Animals; Antipsychotic Agents; Down-Regulation; Female; Haloperidol; Humans; Insulysin; Male; Prefro | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diben | 2011 |
Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes.
Topics: Animals; Antipsychotic Agents; Astrocytes; Cells, Cultured; Citrates; Clozapine; Glutamic Acid; Halo | 2012 |
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic study.
Topics: Antipsychotic Agents; Follow-Up Studies; Haloperidol; Humans; Kaplan-Meier Estimate; Schizophrenia; | 2011 |
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain | 2011 |
Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia.
Topics: Alleles; Animals; Ankyrins; Case-Control Studies; Cohort Studies; Executive Function; Female; Genoty | 2012 |
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Fe | 2011 |
Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Case-Control Studies; Cognition; Dose-Response Relati | 2011 |
Case report: increased patient response to intramuscular haloperidol decanoate following a change in needle length.
Topics: Antipsychotic Agents; Biological Availability; Dose-Response Relationship, Drug; Female; Haloperidol | 2011 |
Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients.
Topics: Adolescent; Adult; Analysis of Variance; Benzamides; Corpus Striatum; Dopamine Antagonists; Dopamine | 2012 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperido | 2011 |
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzot | 2012 |
Effects of microinjections of apomorphine and haloperidol into the inferior colliculus on prepulse inhibition of the acoustic startle reflex in rat.
Topics: Acoustic Stimulation; Animals; Apomorphine; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopam | 2012 |
Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Brain; Haloperidol; Lithium Compounds; Magnetic Res | 2012 |
Effectiveness of sulpiride in adult patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Female; Haloperidol; | 2013 |
Reversal of oxidative stress by histamine H₃ receptor-ligands in experimental models of schizophrenia.
Topics: Amphetamine; Animals; Antioxidants; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain Chemi | 2012 |
Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperidol; Humans; Male; M | 2011 |
Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment.
Topics: Aged; Alleles; Animals; Antipsychotic Agents; Cerebellum; Clozapine; Disease Models, Animal; Excitat | 2013 |
Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Biomarkers; Catechol O-Methyltransferase; DNA | 2012 |
Improvement in QTc prolongation induced by zotepine following a switch to perospirone.
Topics: Antipsychotic Agents; Dibenzothiepins; Electrocardiography; Female; Haloperidol; Heart Rate; Humans; | 2012 |
Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Diabetes Complications; Dibenzothiepins; Dopamine; Drug Interact | 2012 |
Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzodiazepines; Brain; Catalepsy; Cel | 2012 |
Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis.
Topics: Animals; Antigens, Nuclear; Apoptosis; Cell Nucleus; Cell Proliferation; Cells, Cultured; Disease Mo | 2012 |
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Ratin | 2012 |
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperi | 2012 |
Reduced glutamate decarboxylase 65 protein within primary auditory cortex inhibitory boutons in schizophrenia.
Topics: Adult; Aged; Animals; Auditory Cortex; Case-Control Studies; Dendritic Spines; Female; Glutamate Dec | 2012 |
Differential effects of antipsychotics on hippocampal presynaptic protein expressions and recognition memory in a schizophrenia model in mice.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Frontal Lobe; | 2012 |
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Benzodiazepines; Body Weight; Cocain | 2013 |
Blood cells show differences in DNA methylation in schizophrenia patients.
Topics: Age of Onset; Antipsychotic Agents; Biomarkers; DNA Methylation; Epigenesis, Genetic; Epigenomics; G | 2012 |
Increased density of prohibitin-immunoreactive oligodendrocytes in the dorsolateral prefrontal white matter of subjects with schizophrenia suggests extraneuronal roles for the protein in the disease.
Topics: Adult; Animals; Antipsychotic Agents; Cell Compartmentation; Cell Count; Cell Cycle; Cell Line, Tran | 2012 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Halo | 2012 |
Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antineoplastic Agents; Antipsychotic Agents; Cell D | 2013 |
A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Cell Cycle Proteins; Clozapine; Disease Models, Animal; Gene E | 2012 |
Antipsychotic response in the first week predicts later efficacy.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Prognosis; Schizophreni | 2012 |
13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients.
Topics: Adult; Animals; Antipsychotic Agents; Breath Tests; Carbon Isotopes; Chronic Disease; Dopamine; Halo | 2012 |
Visual perception during mirror gazing at one's own face in schizophrenia.
Topics: Adult; Aged; Analysis of Variance; Attention; Body Dysmorphic Disorders; Dopamine Antagonists; Elect | 2012 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Citalopram; Conditioning, Psycho | 2012 |
Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Halope | 2012 |
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Conditioning, Classic | 2013 |
Upregulation of cornichon transcripts in the dorsolateral prefrontal cortex in schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Egg Proteins; Female; Frontal Lobe; Gene Exp | 2012 |
[Severe hypotension and ventricular fibrillation during combined general and epidural anesthesia in a patient on major tranquilizers].
Topics: Anesthesia, Epidural; Anesthesia, General; Antipsychotic Agents; Haloperidol; Humans; Hypotension; I | 2012 |
[Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Dose-Response Rel | 2013 |
RNA-binding protein QKI regulates Glial fibrillary acidic protein expression in human astrocytes.
Topics: Amino Acid Sequence; Antipsychotic Agents; Astrocytes; Cells, Cultured; Gene Expression; Gene Expres | 2013 |
History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia.
Topics: Antipsychotic Agents; Drug Discovery; Haloperidol; History, 20th Century; Humans; Neurobiology; Rece | 2013 |
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotic | 2013 |
Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Disease Models, Animal; Excitatory Amino Aci | 2013 |
Atypical neuroleptic malignant syndrome in H1N1 pneumonia.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Haloperidol; Humans; Influ | 2013 |
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind M | 2002 |
Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients.
Topics: Adult; Animals; Antipsychotic Agents; Blood Platelets; Brain-Derived Neurotrophic Factor; Chronic Di | 2002 |
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Fem | 2002 |
Schizophrenia. Management issues that complicate care of older persons.
Topics: Age Factors; Aged; Antipsychotic Agents; Cognition Disorders; Comorbidity; Haloperidol; Health Servi | 2002 |
Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Dopamine; Dose-Response Relationship, Drug; Drug In | 2002 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulatio | 2001 |
The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Topics: Adult; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Female; Genotype; Haloperidol; Hum | 2002 |
Delayed mesolimbic system alteration in a developmental animal model of schizophrenia.
Topics: Administration, Oral; Age Factors; Animals; Animals, Newborn; Corpus Striatum; Disease Models, Anima | 2002 |
The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dose | 2002 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity | 2002 |
Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; | 2002 |
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.
Topics: Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Clozapine; Cohort Studies; Confidence Inter | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenze | 2002 |
An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics.
Topics: Adult; Antipsychotic Agents; Costs and Cost Analysis; Dibenzothiazepines; Haloperidol; Humans; Marko | 2002 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Hal | 2002 |
Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Carbon Dioxide; Female; Haloperidol; Humans; Male; Matched-Pair Analysi | 2003 |
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Menta | 2003 |
Atypical antipsychotic drugs improve cognition in schizophrenia.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Follow-Up Studies; Haloperidol; Huma | 2003 |
The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro.
Topics: Amitriptyline; Antidepressive Agents; Antipsychotic Agents; Clozapine; Haloperidol; Humans; In Vitro | 2002 |
Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Conditioning, Psychological; Disease Mod | 2003 |
In-vitro immunomodulatory effects of haloperidol and perazine in schizophrenia.
Topics: Adjuvants, Immunologic; Adult; CD4 Antigens; CD8 Antigens; Cells, Cultured; Dopamine Antagonists; Fe | 2000 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Cohort Effect; Cohort Studies; Haloperidol; Humans | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Cohort Effect; Dose-Response Relationship, Drug; Drug Adminis | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Met | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat | 2003 |
Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Blotting, Western; Cell Count; Contractile Proteins | 2003 |
Atypical neuroleptic malignant syndrome with clozapine and subsequent haloperidol treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; S | 2003 |
Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Benzodiazep | 2003 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens | 2003 |
Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo.
Topics: Adult; Brain; Dopamine; Down-Regulation; Haloperidol; Humans; Male; Middle Aged; Patients; Schizophr | 2003 |
Role of ethnicity in predicting antipsychotic medication adherence.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Ethnicity; Female; Haloper | 2003 |
Cerebral metabolic patterns in chronic and recent-onset schizophrenia.
Topics: Acute Disease; Adult; Basal Ganglia; Brain; Brain Mapping; Cerebellum; Cerebral Cortex; Chronic Dise | 2003 |
Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome.
Topics: Administration, Cutaneous; Animals; Antipsychotic Agents; Area Under Curve; Drug Delivery Systems; F | 2003 |
Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Brain-Derived Neurotrophic Factor; Dizocilpin | 2003 |
A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Data Collection; Dibenzothiazep | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepin | 2003 |
Elevated cerebrospinal fluid SNAP-25 in schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Case-Control Studies; Dopamine Antagonists; Exocytosis; Hal | 2003 |
Limitations of brain imaging in forensic psychiatry.
Topics: Antipsychotic Agents; Brain; Electroencephalography; Forensic Psychiatry; gamma-Aminobutyric Acid; H | 2003 |
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug Utilization; Fem | 2003 |
Rehospitalization risk with second-generation and depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Data Collection; Delayed-Action Preparation | 2003 |
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, Animal; Cebus; Clozapine; Disease Mod | 2003 |
Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia.
Topics: Aging; Amphetamine; Animals; Central Nervous System Stimulants; Clozapine; Corpus Striatum; Disease | 2003 |
Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia.
Topics: Adult; Aged; Animals; Autoradiography; Benztropine; Calbindin 2; Cell Count; Female; gamma-Aminobuty | 2003 |
Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain; Clozapine; Dopamine; Enkephalins; gamma-Amin | 2003 |
Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cost-Benefit Analysis; Drug Administration Schedul | 2003 |
Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine.
Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Dopamine Agents; Haloperidol; Humans; Least-Squares A | 2003 |
Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Case-Control Studies; Clozapine; Corpus Striatum; Dissoc | 2003 |
Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea.
Topics: Adult; Amenorrhea; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Female; Haloperid | 2003 |
Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Animals; Antipsychotic Agents; Apolipoproteins E; Autopsy; | 2003 |
A controlled trial of haloperidol in chronic schizophrenics.
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Schizophrenia | 1960 |
[Clinical tests with haldol in long-term schizophrenia and acute manic states].
Topics: Anesthesia; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psycho | 1961 |
[Therapy with Haloperidol (R-1625) and psychodiagnostic examinations in a group of chronic schizophrenics].
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Physical Examination; Schizophrenia | 1962 |
Haloperidol: a controlled trial in chronic schizophrenia.
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Schizophrenia | 1962 |
[Therapeutic trials of thioproperazine in moderate doses and in combination with Haloperidol on a group of schizophrenics].
Topics: Haloperidol; Humans; Phenothiazines; Schizophrenia | 1962 |
[Modifications in the Rorschach test in patients treated with haloperidol].
Topics: Haloperidol; Humans; Paranoid Disorders; Rorschach Test; Schizophrenia | 1961 |
[Haloperidol in psychiatry].
Topics: Haloperidol; Humans; Psychiatry; Schizophrenia | 1962 |
Controlled comparison of Haloperidol with thiopropazate in newly admitted schizophrenics.
Topics: Haloperidol; Hospitalization; Humans; Phenothiazines; Schizophrenia; Tranquilizing Agents | 1962 |
[Treatment of schizophrenia with haloperidol].
Topics: Haloperidol; Humans; Schizophrenia | 1963 |
PSYCHOMOTOR ASSESSMENT OF THE EFFECTS OF HALOPERIDOL.
Topics: Bipolar Disorder; Haloperidol; Kinesthesis; Motor Skills; Parkinsonian Disorders; Psychotic Disorder | 1963 |
HALOPERIDOL IN SCHIZOPHRENIC REACTIONS.
Topics: Haloperidol; Humans; Schizophrenia | 1963 |
[SPIROPERIDOL].
Topics: Catatonia; Geriatrics; Hallucinations; Haloperidol; Humans; Hypnotics and Sedatives; Paranoid Disord | 1963 |
POTENTIATION OF PHARMACOLOGICAL AND THERAPEUTIC ACTION OF PHENOTHIAZINES BY NYLIDRIN (ARLIDIN).
Topics: Bipolar Disorder; Brain; Brain Damage, Chronic; Chlorprothixene; Depressive Disorder, Major; Dextran | 1964 |
[CLINICAL ASPECTS OF HALOPERIDOL].
Topics: Dementia; Geriatrics; Haloperidol; Injections, Intramuscular; Mental Disorders; Neurotic Disorders; | 1964 |
[ON THE TREATMENT OF PARANOID SCHIZOPHRENIA WITH HALOPERIDOL].
Topics: Haloperidol; Humans; Schizophrenia; Schizophrenia, Paranoid | 1964 |
[CLINICAL EXPERIENCES WITH HALOPERIDOL (SERENASE)].
Topics: Bipolar Disorder; Chlorpromazine; Chorea; Dementia; Depressive Disorder, Major; Epilepsy; Haloperido | 1964 |
[A PSYCHIATRIC EMERGENCY SITUATION: THE START OF THE SCHIZOPHRENIC ATTACK].
Topics: Chlorprothixene; Diagnosis; Haloperidol; Humans; Promazine; Schizophrenia; Tranquilizing Agents | 1964 |
THE BUTYROPHENONES IN THE TREATMENT OF THE PSYCHOTIC PATIENT.
Topics: Biomedical Research; Butyrophenones; Catatonia; Haloperidol; Humans; Meperidine; Paranoid Disorders; | 1964 |
[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Delirium; Depression; Hallucinations; Halope | 1964 |
[CLINICO-THERAPEUTIC TRIALS WITH DIPIPERON, A NEW BUTYROPHENONE SERIES DERIVATIVE].
Topics: Butyrophenones; Depression; Haloperidol; Humans; Hypnotics and Sedatives; Mental Disorders; Psychoti | 1964 |
[CONTRIBUTION TO THE STUDY OF A NEURODYSLEPTIC SYNDROME IN THE COURSE OF HALOPERIDOL THERAPY].
Topics: Antisocial Personality Disorder; Drug Therapy; Extrapyramidal Tracts; Haloperidol; Mental Disorders; | 1964 |
[TREATMENT OF CHRONIC PSYCHOSES WITH HALOPERIDOL (R 1625)].
Topics: Bipolar Disorder; Drug Therapy; Haloperidol; Humans; Mental Disorders; Movement Disorders; Psychotic | 1964 |
A CLINICAL COMPARISON OF TRIFLUPERIDOL, HALOPERIDOL, AND CHLORPROMAZINE.
Topics: Biomedical Research; Chlorpromazine; Haloperidol; Parasympatholytics; Placebos; Schizophrenia; Toxic | 1964 |
COMPARISON OF HALOPERIDOL, TRIFLUPERIDOL, AND CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
Topics: Biomedical Research; Chlorpromazine; Haloperidol; Humans; Hypnotics and Sedatives; Schizophrenia; Tr | 1964 |
CHANGES IN SERUM PROTEINS AND CEREBROSPINAL FLUID PROTEINS DURING PHARMACOTHERAPY OF PSYCHOSES.
Topics: Alcoholism; Bipolar Disorder; Blood Proteins; Cerebrospinal Fluid Proteins; Chlorpromazine; Drug The | 1964 |
[CLINICO-ELECTROENCEPHALOGRAPHIC STUDY OF THE EFFECT OF HALOPERIDOL ON SCHIZOPHRENICS].
Topics: Catatonia; Depression; Depressive Disorder; Drug Therapy; Electroencephalography; Haloperidol; Human | 1964 |
TRIFLUPERIDOL AND HALOPERIDOL IN THE TREATMENT OF ACUTE SCHIZOPHRENIA.
Topics: Chlorpromazine; Drug Therapy; Haloperidol; Psychological Tests; Schizophrenia; Tranquilizing Agents; | 1964 |
[SOMATOTHERAPY OF ENDOGENOUS PSYCHOSES AT MARBURG UNIVERSITY NEUROLOGIC CLINIC].
Topics: Bipolar Disorder; Chlordiazepoxide; Chlorpromazine; Chlorprothixene; Convulsive Therapy; Depression; | 1964 |
[THE HALOPERIDOL-THIORIDAZINE THERAPEUTIC COMBINATION].
Topics: Drug Therapy; Haloperidol; Humans; Schizophrenia; Thioridazine | 1964 |
[PROBLEMS OF SIMULTANEOUS PSYCHO- AND PHARMACOTHERAPY OF SCHIZOPHRENICS].
Topics: Haloperidol; Humans; Psychotherapy; Schizophrenia; Tranquilizing Agents | 1963 |
[ON THERAPEUTIC EFFICACY OF SUDDEN SUSPENSION OF PROLONGED THERAPY WITH ASSOCIATED RESERPINE AND CHLORPROMAZINE IN SCHIZOPHRENIC SUBJECTS].
Topics: Chlorpromazine; Drug Therapy; Haloperidol; Humans; Phenothiazines; Reserpine; Schizophrenia; Substan | 1965 |
[THERAPEUTIC RESULTS AND PRELIMINARY CONSIDERATIONS OF A BUTYRROPHENONE TREATMENT (HALOPERIDOL AND TRIPERIDOL) COMBINED WITH THIORIDAZINE IN CHRONIC SCHIZOPHRENIC SUBJECTS].
Topics: Haloperidol; Humans; Hypnotics and Sedatives; Schizophrenia; Thioridazine; Trifluperidol | 1965 |
Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Antipsychotic Agents; Arousal; Attention; Benzodi | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combinat | 2003 |
Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects.
Topics: Adult; Antipsychotic Agents; Carrier Proteins; Female; Haloperidol; Humans; Intracellular Signaling | 2003 |
Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
Topics: Adult; Aged; Analysis of Variance; Brief Psychiatric Rating Scale; Carbamazepine; Dose-Response Rela | 2003 |
Fluoxetine augmentation of haloperidol in chronic schizophrenia.
Topics: Adult; Chi-Square Distribution; Chronic Disease; Drug Synergism; Female; Fluoxetine; Haloperidol; Hu | 2003 |
Risk adjustment in studies using administrative data.
Topics: Adult; Antipsychotic Agents; Clozapine; Costs and Cost Analysis; Female; Forecasting; Haloperidol; H | 2003 |
Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Hum | 2003 |
Excitability of the motor cortex in schizophrenia following typical and atypical antipsychotics: two serial case reports.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Electromagnetic Fields; Electromyography; Evoked | 2003 |
Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation.
Topics: Aged; Antipsychotic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cas | 2004 |
The role of psychodynamic understanding in the treatment of the medication-refusing schizophrenic patient: a clinical report.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Comprehension; Fe | 2003 |
Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia.
Topics: Antipsychotic Agents; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Hapl | 2004 |
Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; | 2004 |
Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug | 2004 |
Antipsychotic medications can induce transient psychotic episodes without oculogyric crises.
Topics: Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine; | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine; | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Endocrine System; Haloperidol; Humans; | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Drug Resistance; Haloperidol; Humans | 2004 |
Olanzapine vs haloperidol for treatment of schizophrenia.
Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine; | 2004 |
Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression.
Topics: Animals; Antipsychotic Agents; Binding Sites; Clozapine; Disease Models, Animal; Drug Administration | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Clozapine maintenance therapy in schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Clozapine; Female; Haloperidol; Hu | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
COMT158 polymorphism and hostility.
Topics: Antipsychotic Agents; Benzodiazepines; Catechol O-Methyltransferase; Clozapine; Genotype; Haloperido | 2004 |
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
Topics: Antipsychotic Agents; Attitude of Health Personnel; Drug Administration Schedule; Drug Costs; Drug U | 2004 |
Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Biomechanical Phenomena; Butyrophenones; Case-C | 2004 |
Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice.
Topics: Adrenalectomy; Amphetamine; Animals; Corticosterone; Dose-Response Relationship, Drug; Haloperidol; | 2004 |
Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.
Topics: Adult; Benztropine; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interacti | 2004 |
A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses.
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chromosomes, Human, Pair 12; Comorbidity; Ge | 2004 |
Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
Topics: Antipsychotic Agents; Catechol O-Methyltransferase; Codon; DNA Primers; Dopamine; Dyskinesia, Drug-I | 2004 |
Covariate adjustment in clinical trials with non-ignorable missing data and non-compliance.
Topics: Antipsychotic Agents; Clozapine; Empirical Research; Haloperidol; Humans; Outcome Assessment, Health | 2004 |
The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition.
Topics: Animals; Autistic Disorder; Behavior, Animal; Cognition; Dizocilpine Maleate; Dopamine Antagonists; | 2004 |
Two cases of deep vein thrombosis associated with antipsychotic drug use.
Topics: Aged; Antipsychotic Agents; Chlorpromazine; Depressive Disorder, Major; Dose-Response Relationship, | 2004 |
Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.
Topics: Antipsychotic Agents; Computer Simulation; Haloperidol; Humans; Longitudinal Studies; Models, Statis | 2004 |
Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Animals; Blotting, Western; Calcium-Bind | 2004 |
Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement.
Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Female; Haloperidol; Humans; Male; Positron-Emission | 2005 |
Effects of typical and atypical antipsychotics on human glycine transporters.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlori | 2004 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complicati | 2004 |
Aripiprazole: novelty, adherence and understatement.
Topics: Antipsychotic Agents; Aripiprazole; Haloperidol; Humans; Patient Compliance; Piperazines; Psychiatri | 2005 |
Chronic antidopaminergic medication might affect amygdala structure in patients with schizophrenia.
Topics: Amygdala; Antipsychotic Agents; Brain; Clopenthixol; Dose-Response Relationship, Drug; Epilepsy, Tem | 2004 |
Stable deficits in gray matter volumes following a first episode of schizophrenia.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; Clozapine; Haloperidol; Humans; Schizophrenia | 2004 |
Reply to Dr. J-C Shim and colleagues regarding "Fluoxetine augmentation of haloperidol in chronic schizophrenia" [J Clin Psychopharmacol 2003;23:520-521].
Topics: Drug Synergism; Drug Therapy, Combination; Fluoxetine; Haloperidol; Humans; Schizophrenia | 2004 |
EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dose-Response Re | 2004 |
Heat shock protein 12A shows reduced expression in the prefrontal cortex of subjects with schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Blotting, Northern; Case-Control Studies; Depressive Disorder, | 2004 |
Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia.
Topics: Adult; Aged; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Benztropine; Brain-Derived Neuro | 2005 |
Decreased expression of a 40-kDa catecholamine-regulated protein in the ventral striatum of schizophrenic brain specimens from the Stanley Foundation Neuropathology Consortium.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia; Clozapine; Diagnostic and Statistical Manual of Me | 2005 |
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
Topics: Adaptor Proteins, Vesicular Transport; Aged; Animals; Antipsychotic Agents; Behavior, Animal; Cognit | 2005 |
A putative animal model of the "prodromal" state of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Anim | 2005 |
[Anesthesia for cesarean section in a parturient taking risperidone and haloperidol].
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antipsychotic Agents; Cesarean Section; Female; | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Mod | 2005 |
Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol.
Topics: Amygdala; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Drinking Behavior; Halop | 2006 |
Cortical gene expression in the neonatal ventral-hippocampal lesion rat model.
Topics: Analysis of Variance; Animals; Animals, Newborn; Disease Models, Animal; Doublecortin Protein; Front | 2005 |
Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
Topics: Animals; Antipsychotic Agents; Biogenic Monoamines; Bupropion; Disease Models, Animal; Dopamine Upta | 2005 |
Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Benzofurans; Brain Chemistry; Cataplexy; Cytochrome P-450 Enzyme Syst | 2005 |
Possible malignant neuroleptic syndrome that associated with hypothyroidism.
Topics: Adrenal Insufficiency; Antipsychotic Agents; Body Temperature; Clozapine; Female; Haloperidol; Human | 2005 |
Infanticide.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Depression, Postpartum; Expert Testimony; Female; For | 2005 |
Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Cerebrovascular Circulation; Cor | 2005 |
Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Diet; Exercise; Female; Haloperidol; H | 2005 |
Excellent review of psychotropic drug-induced torsade de pointes.
Topics: Chronobiology Disorders; Haloperidol; Humans; Long QT Syndrome; Schizophrenia; Torsades de Pointes | 2005 |
Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Clozapine; Cognition Disorders; Depressive Disorder, Ma | 2005 |
Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia.
Topics: Athetosis; Chorea; Clopenthixol; Delayed-Action Preparations; Dominance, Cerebral; Drug Therapy, Com | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials | 2005 |
Olanzapine and haloperidol for residual symptoms.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Haloperido | 2005 |
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Haloperidol; Humans; Male; Nervous System D | 2005 |
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
Topics: Antipsychotic Agents; Cell Line, Tumor; Cholesterol; Clozapine; Fatty Acid Synthases; Fatty Acids; G | 2005 |
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzod | 2005 |
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Human | 2005 |
Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Bromocriptine; Clozapine; Cr | 2005 |
Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clopenthixol; Female; Haloperidol; Humans; Imid | 2005 |
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Haloperidol; H | 2005 |
The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Haloperidol; Hum | 2005 |
A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Diazepam; Disease Models, Animal; Dopamine; Electrophysio | 2005 |
Aripiprazole: new drug. Just another neuroleptic.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drugs, Investigational; Halo | 2005 |
Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain.
Topics: Actins; Amino Acid Transport System X-AG; Animals; Antipsychotic Agents; Excitatory Amino Acid Trans | 2006 |
[Should we discontinue the use of Serenase?].
Topics: Antipsychotic Agents; Brain; Haloperidol; Humans; Schizophrenia | 2005 |
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Inj | 2005 |
Models of treatment with antipsychotics of the schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Bosnia and Herzegovina; Clozapine; Drug Utilization; Female; Halo | 2005 |
Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
Topics: Adult; Antipsychotic Agents; Female; Genes, MDR; Genotype; Haloperidol; Humans; Male; Middle Aged; P | 2006 |
Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Longitudinal Studies; Male; Mi | 2006 |
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; | 2005 |
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
Topics: Antipsychotic Agents; Belgium; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Decision Tre | 2005 |
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Topics: Administration, Oral; Antipsychotic Agents; Canada; Cost of Illness; Cost-Benefit Analysis; Delayed- | 2005 |
Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Clozapine; Cytokines; Drug Interactio | 2006 |
Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Clozapine; COP9 Signalosome Complex; Female; | 2006 |
[Neuroleptic malignant syndrome].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Coma; Combined Modality Therapy; Cryotherapy; Drug The | 2006 |
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Chronic Disease; Double-Blind Meth | 2006 |
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; | 2005 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies | 2007 |
Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate.
Topics: Administration, Oral; Antipsychotic Agents; Dibenzothiazepines; Drug Administration Schedule; Halope | 2006 |
Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dizoc | 2006 |
Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine.
Topics: Amphetamine; Animals; Antipsychotic Agents; Brain; Brain Chemistry; Chromosome Mapping; Clozapine; D | 2006 |
[123I]TPCNE--a novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge.
Topics: Adult; Binding, Competitive; Brain; Dopamine Antagonists; Drug Interactions; Female; Gyrus Cinguli; | 2006 |
Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients.
Topics: Acoustic Stimulation; Amphetamine; Animals; Auditory Threshold; Brain Stem; Central Nervous System S | 2006 |
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; H | 2005 |
Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dose-Response Relationship, Drug | 2006 |
Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Mal | 2006 |
Neuroleptic malignant syndrome: a case report.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Schizophre | 2006 |
Is the superior efficacy of new generation antipsychotics an artifact of LOCF?
Topics: Amisulpride; Artifacts; Benzodiazepines; Bias; Flupenthixol; Haloperidol; Humans; Olanzapine; Patien | 2007 |
Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Genotype; Haloperidol; Humans; Interleukin 1 R | 2006 |
Effects of (-)stepholidine in animal models for schizophrenia.
Topics: Animals; Antipsychotic Agents; Berberine; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; | 2006 |
Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction.
Topics: Boron Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Fluorescence; Halope | 2006 |
Remission of positive and negative symptoms in refractory schizophrenia with a combination of haloperidol and quetiapine: Two case studies.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Female; Haloperidol; Hum | 2006 |
Constructing an Index for the Subjective Well-being Under Neuroleptics scale (SWN), short form: applying structural equation modeling for testing reliability and validity of the index.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Germany; Haloperidol; Humans; Models, Statistical; Ola | 2006 |
Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Dose-Response Rela | 2006 |
Anatomical evidence of impaired feedforward auditory processing in schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Auditory Pathways; Female; Haloperidol; Humans; Immunohistoche | 2007 |
AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Clozapine; Female; Gene Expression; H | 2007 |
Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol.
Topics: Benzodiazepines; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Trees; Haloperidol; Health | 1998 |
The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Flunitrazepam; GABA Agonists; | 2007 |
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines | 2007 |
Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cocaine; Dextroamphetamine; Dopamine Ago | 2007 |
Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Drug Combinat | 2007 |
Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Eating; Hallucinogens; Haloperidol | 2007 |
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Benzodiazepines; Cerebral Cortex; Child; Cognition | 2007 |
Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study.
Topics: Adult; Antipsychotic Agents; Cell Count; Corpus Striatum; Diagnostic and Statistical Manual of Menta | 2007 |
Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia.
Topics: Animals; Brain Diseases, Metabolic; Cognition Disorders; Disease Models, Animal; Dopamine; Dopamine | 2007 |
Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.
Topics: Animals; Antipsychotic Agents; Clozapine; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Ex | 2007 |
Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Dopamine Antagonists; Dose-Response Relationship, Drug; Fem | 2007 |
Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cell Line; Disease Models, Animal; Enzyme-Linked I | 2007 |
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Topics: Administration, Oral; Adult; Alcoholism; Antipsychotic Agents; Black People; Cohort Studies; Comorbi | 2007 |
Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Depression; Dopamine; Female; Hallucinations; Haloperidol; | 2007 |
Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Europe; Haloperidol; Humans; | 2007 |
Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; | 2007 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose- | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzoth | 2007 |
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Drug Cost | 2007 |
Intramuscular aripiprazole in the control of agitation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Dr | 2007 |
Relation of neurological soft signs to psychiatric symptoms in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Brief Psychiatric Rating Scale; Female; Haloperidol; Humans; Mal | 2007 |
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Arginine Vasopressin; Clozapine; Deamino Argini | 2007 |
(+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics.
Topics: Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid An | 2007 |
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid; | 2007 |
Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice.
Topics: Animals; Antipsychotic Agents; Autoradiography; Baclofen; Brain; Clozapine; Disease Models, Animal; | 2007 |
Status epilepticus associated with sertindole.
Topics: Anticonvulsants; Antipsychotic Agents; Brain; Brain Chemistry; Dose-Response Relationship, Drug; Ele | 2007 |
Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Topics: Adult; Alleles; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; | 2007 |
Antipsychotic medication for childhood-onset schizophrenia.
Topics: Age Factors; Antipsychotic Agents; Child; Clozapine; Haloperidol; Humans; Neutropenia; Randomized Co | 2007 |
Pretrial medication bias in randomized antipsychotic drug trials.
Topics: Antipsychotic Agents; Bias; Drug Administration Schedule; Haloperidol; Humans; Randomized Controlled | 2007 |
Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia.
Topics: Adult; Animals; Arrestins; Autopsy; beta-Arrestins; Bipolar Disorder; Case-Control Studies; Cell Lin | 2008 |
Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1.
Topics: Animals; Antipsychotic Agents; Arousal; Attention; Behavior, Animal; Disease Models, Animal; Genes, | 2008 |
Pisa syndrome: acute and tardive forms.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Humans; Male; Schizoph | 2007 |
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinem | 2007 |
Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Databases, Factua | 2007 |
Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
Topics: Antipsychotic Agents; Computer Simulation; Controlled Clinical Trials as Topic; Data Interpretation, | 2007 |
Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 2007 |
Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Fem | 2007 |
Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report.
Topics: Aged; Antipsychotic Agents; Constipation; Dementia; Dose-Response Relationship, Drug; Drug Therapy, | 2007 |
d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Blotting, Western; Brain; D-Amino-Aci | 2007 |
Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine.
Topics: Adult; Age of Onset; Antipsychotic Agents; Brazil; Clozapine; Epidemiologic Methods; Female; Haloper | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Fa | 2007 |
Treatment of clozapine-associated tardive dyskinesia.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Clozapine; Cross-Over Studies; Dibenzothiepins; | 2008 |
Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Behavior, Animal; Clozapine; Dopamin | 2008 |
Myocarditis after overdose of conventional antipsychotics.
Topics: Aged; Antipsychotic Agents; Blood Pressure; Chlorpromazine; Creatine Kinase; Dopamine; Drug Overdose | 2009 |
Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Densitometry; Flunitrazepam; Halope | 2008 |
Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, An | 2008 |
Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Binding Sites; Brain; Diazepam; Dis | 2008 |
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Magnet | 2007 |
Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Hu | 2007 |
Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia.
Topics: Animals; Attention; Clozapine; Cognition; Cognition Disorders; Disease Models, Animal; Haloperidol; | 2008 |
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dopamine D2 Receptor Antagonists | 2008 |
Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Blotting, Western; Dominance, Cerebral; Fema | 2008 |
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-I | 2007 |
The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Conditioning, Psychological; Disease | 2008 |
Increased lactate levels and reduced pH in postmortem brains of schizophrenics: medication confounds.
Topics: Animals; Antipsychotic Agents; Artifacts; Brain; Brain Chemistry; Brain Diseases, Metabolic; Cerebel | 2008 |
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
Topics: Benzodiazepines; Case-Control Studies; Ethics, Clinical; Feasibility Studies; Haloperidol; Humans; O | 2008 |
Beacon-like/ubiquitin-5-like immunoreactivity is highly expressed in human hypothalamus and increased in haloperidol-treated schizophrenics and a rat model of schizophrenia.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Astrocytes; Cell Line, Tumor; Eye Proteins; Female; | 2008 |
Gabapentin for ultra resistant schizophrenia with aggressive behavior.
Topics: Adult; Aggression; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Drug | 2008 |
Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Brain; Cerebrovascular Disorders; Clozapine; Cognition; Drug Resistance | 2008 |
Longterm maintenance therapy with depot haloperidol in schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Electroencephalography; Employment; Haloperidol; | 1991 |
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Diagnostic and Statistical | 2008 |
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug C | 2008 |
Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 Enzyme System; Drug Therapy, Combination | 2008 |
Pharmacotherapy of first-episode schizophrenia.
Topics: Antipsychotic Agents; Drug Industry; Haloperidol; Humans; Randomized Controlled Trials as Topic; Res | 2008 |
Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Topics: Administration, Oral; Adult; Age Factors; Ambulatory Care; Antipsychotic Agents; Clozapine; Cross-Se | 2008 |
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Prescriptions; Female | 2007 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzo | 2007 |
Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Patient Compliance; Randomized Contr | 2008 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Hum | 2008 |
What CATIE did: some thoughts on implications deep and wide.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Drug Administrati | 2008 |
Reduced dendritic spine density in auditory cortex of subjects with schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Auditory Cortex; Dendritic Spines; Female; Haloperidol; Humans | 2009 |
A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Cohort Studies; Cost Savings; Drug Costs; Drug Therapy | 2008 |
Absorption and excretion of tritiated haloperidol in man. (A preliminary report).
Topics: Haloperidol; Humans; Parkinson Disease, Secondary; Schizophrenia; Tritium | 1967 |
Clinical efficacy of haloperidol in chronic psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Female; Haloperidol; Humans; Male; Middle A | 1967 |
Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brain; Butyrophenones; Caudate Nucleus; Haloperidol; | 1980 |
Human leukocyte antigen A2 and psychopathology in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Haloperidol; HLA Antigens; Humans; Lymphocytes; Recept | 1980 |
Abnormal neuroleptic/dopamine receptors in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Brain; Caudate Nucleus; Haloperidol; Humans; Middle | 1980 |
[Sensory disorders arising during neuroleptic therapy].
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Female; Haloperidol | 1980 |
Distal colon motility in schizophrenic patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Colon; Dopamine; Female; Gastrointestinal Mot | 1980 |
Does neuroleptic blocking of dopamine receptors continue after chronic treatment?
Topics: Adolescent; Adult; Animals; Antipsychotic Agents; Corpus Striatum; Cyclic AMP; Cyclic GMP; Female; H | 1980 |
Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Female; Fluphenazine; Haloperidol; Humans; Male; | 1981 |
Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Dextroamphetamine; Dopamine; Female; Haloperidol; Humans; Male; | 1980 |
[Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chlorpromazine; Chronic Disease; Dose-Response Relations | 1980 |
Dopamine receptors, neuroleptics, and schizophrenia.
Topics: Adenylyl Cyclases; Antipsychotic Agents; Apomorphine; Brain; Brain Chemistry; Caudate Nucleus; Dopam | 1981 |
A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Chronic Disease; Depression, Chemical; Female; Fluphen | 1981 |
Neuroleptic-induced decrease in platelet MAO activity of schizophrenic patients.
Topics: Blood Platelets; Depression, Chemical; Female; Haloperidol; Humans; Male; Monoamine Oxidase; Phenoth | 1981 |
[Neuroleptic large dose therapy of schizophrenias].
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1981 |
Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Homovanillic Acid; Humans; Male; P | 1981 |
Tolerance to the prolactin-elevating effect of neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Dopamine; Drug Tolerance; Haloperidol; Humans; Ma | 1981 |
Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma prolactin response to haloperidol challenge.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Tolerance; Haloperidol; Humans; | 1981 |
Neuroendocrine tests during treatment with neuroleptic drugs. II. The TRH test.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Flupenthixol; Fluphenazine; | 1981 |
[Predicting the effect of psychopharmacotherapy in schizophrenic patients].
Topics: Adolescent; Adult; Antipsychotic Agents; Autonomic Nervous System; Chlorpromazine; Convulsive Therap | 1982 |
Neuroleptic-associated dysphagia confirmed by esophageal manometry.
Topics: Antipsychotic Agents; Deglutition Disorders; Esophagus; Gastrointestinal Motility; Haloperidol; Huma | 1982 |
[Dynamics of integral parameters of the background EEG during treatment with neuroleptics].
Topics: Antipsychotic Agents; Automatism; Brain; Chlorpromazine; Clozapine; Electroencephalography; Haloperi | 1982 |
Lithium-haloperidol combination and brain damage.
Topics: Brain; Drug Interactions; Haloperidol; Humans; Lithium; Schizophrenia | 1982 |
[The role of high-dosage neuroleptic therapy and electroshock in the treatment of the acute phase of schizophrenia].
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Electroconvul | 1981 |
[Status of microhemodynamics and features of capillary permeability in schizophrenia].
Topics: Adult; Capillary Permeability; Diphenhydramine; Ethinyl Estradiol; Female; Haloperidol; Histamine H1 | 1982 |
The long-term treatment of schizophrenia in the community.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperidol; | 1982 |
Low serum neuroleptic levels predict relapse in schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Male; Middle A | 1982 |
Effects of neuroleptics on platelet monoamine oxidase activity.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Haloperidol; Humans; Monoamine Oxidase; Phenothiazines | 1982 |
Mania: diagnosis and treatment.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Antiparkinson Agents; Antipsychotic Agents; Bipol | 1982 |
[Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; H | 1982 |
Neuroleptic drug effect on platelet monoamine oxidase and plasma amine oxidase in schizophrenia.
Topics: Adult; Amine Oxidase (Copper-Containing); Antipsychotic Agents; Blood Platelets; Chlorpromazine; Fem | 1982 |
"Tardive" Tourette syndrome in relation to long-term neuroleptic treatment of multiple tics.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Phenothiazines; Schizophrenia; | 1982 |
Neuroleptic drugs and erythrocyte catechol-O-methyltransferase in schizophrenia.
Topics: Adult; Antipsychotic Agents; Catechol O-Methyltransferase; Chlorpromazine; Chronic Disease; Erythroc | 1982 |
Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Dopamine beta-Hydroxylase; Female; Flu | 1982 |
Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
Topics: Acute Disease; Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Radioligand Assa | 1983 |
[Malignant neuroleptic syndrome].
Topics: Adult; Antipsychotic Agents; Blood Pressure; Body Temperature; Consciousness; Female; Haloperidol; H | 1983 |
Haloperidol decanoate: a depot neuroleptic.
Topics: Antipsychotic Agents; Haloperidol; Humans; Kinetics; Schizophrenia | 1983 |
Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Dopamine beta-Hydroxylase; Fluphenazine; Haloperidol; Humans; | 1983 |
[Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Haloper | 1984 |
[Long-term use of 200 mg Dogmatil. Apropos of 13 cases].
Topics: Adult; Amitriptyline; Antipsychotic Agents; Bipolar Disorder; Borderline Personality Disorder; Drug | 1984 |
Imaging CNS receptors: the dopaminergic system.
Topics: Animals; Antipsychotic Agents; Apomorphine; Binding Sites; Brain; Carbon Radioisotopes; Deoxyglucose | 1984 |
The effect of neuroleptic treatment and of high dosage diazepam therapy on beta-endorphin immunoreactivity in plasma of schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; beta-Endorphin; Diazepam; Dose-Response Relationship, Drug; | 1984 |
Dissimilar dosing with high-potency and low-potency neuroleptics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Drug Utilization; F | 1984 |
Within-individual variation in steady state plasma levels of different neuroleptics and prolactin.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Flupenthixol; Fluphenazine; Haloperidol; Hu | 1984 |
No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia.
Topics: Adult; Antipsychotic Agents; beta-Endorphin; Endorphins; Female; Haloperidol; Humans; Male; Penfluri | 1984 |
The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Drug Interactions; Electroencephalography; Female; Half | 1984 |
Information processing and neuroleptic response in acute and stabilized schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cognition; Fluphenazine; Haloperidol; Humans; Male; Pattern Recognition | 1984 |
Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations.
Topics: Adult; Biperiden; Brief Psychiatric Rating Scale; Drug Therapy, Combination; Dyskinesia, Drug-Induce | 1984 |
Intramuscular haloperidol decanoate for neuroleptic maintenance therapy.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Female; Haloperidol; Hum | 1984 |
Effects of short- and long-term neuroleptic treatment on brain serotonin synthesis and turnover: focus on the serotonin hypothesis of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Chlorpromazine; Haloperidol; Humans; Hydroxyindoleacetic Acid; | 1981 |
Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
Topics: Adult; Aged; Amantadine; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Drug Ther | 1982 |
beta-Endorphin and beta-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders.
Topics: Adrenocorticotropic Hormone; Adult; beta-Endorphin; beta-Lipotropin; Chronic Disease; Endorphins; Fe | 1981 |
TSH-response patterns to TRH stimulation may indicate therapeutic mechanisms of antidepressant and neuroleptic drugs.
Topics: Adult; Clomipramine; Depressive Disorder; Female; Haloperidol; Humans; Prognosis; Psychiatric Status | 1984 |
Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
Topics: Erythrocytes; Haloperidol; Humans; Outpatients; Patient Compliance; Schizophrenia; Thioridazine; Tim | 1984 |
Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Bipolar Disorder; Dose-Response Relationship, Drug; Female; | 1984 |
Differential drug effects identified by 3-way configural frequency analysis.
Topics: Acute Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Prognosis; Schizophrenia; Schi | 1984 |
Amantadine in the neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome | 1984 |
Possible interference by the reduced haloperidol metabolite with the radioimmunoassay and radioreceptor assay of blood haloperidol.
Topics: Chromatography, High Pressure Liquid; Haloperidol; Humans; Oxidation-Reduction; Radioimmunoassay; Ra | 1984 |
Combination of phenobarbital and haloperidol in resistant schizophrenia.
Topics: Adult; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Male; Phenobarbital; Prolact | 1984 |
[Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
Topics: Adult; Delusions; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; | 1984 |
The relationship between haloperidol blood levels and clinical responses.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Radioimmuno | 1984 |
Chronic haloperidol administration enhances the gamma-aminobutyric acid level in the rat striatum without altering the glutamate level.
Topics: Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamates; Haloperidol; Humans; Male; | 1984 |
[The effects of chronic methamphetamine and single haloperidol injections on thiamine and its phosphate ester levels in the rat brain].
Topics: Animals; Brain; Disease Models, Animal; Haloperidol; Humans; Male; Methamphetamine; Rats; Rats, Inbr | 1984 |
Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation.
Topics: Adult; Bromocriptine; Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans | 1983 |
Prolactin response to single and multiple doses of haloperidol in schizophrenic patients.
Topics: Adolescent; Adult; Chromatography, Gas; Dose-Response Relationship, Drug; Female; Haloperidol; Human | 1984 |
Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.
Topics: Adult; Animals; Brain Chemistry; Cerebellum; Chemical Phenomena; Chemistry; Chromatography, High Pre | 1984 |
Haloperidol concentrations elevated in Chinese patients.
Topics: Adult; Asian People; China; Haloperidol; Humans; Schizophrenia; United States; White People | 1984 |
Total and free plasma neuroleptic levels in schizophrenic patients.
Topics: Adult; Chlorpromazine; Haloperidol; Humans; Kinetics; Male; Psychiatric Status Rating Scales; Radiol | 1984 |
Eye tracking dysfunction unrelated to clinical state and treatment with haloperidol.
Topics: Adult; Double-Blind Method; Eye Movements; Female; Haloperidol; Humans; Male; Motion Perception; Sch | 1983 |
[Clinical approach to therapy-resistant schizophrenia by quantitative EEG analysis].
Topics: Drug Resistance; Electroencephalography; Haloperidol; Humans; Imipramine; Prognosis; Schizophrenia | 1983 |
Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Dantrolene; Fever; Haloperidol; Humans; Male; Muscle Rigi | 1983 |
Response to intracerebral dopamine injection as a model of schizophrenic symptomatology.
Topics: Animals; Brain Mapping; Corpus Striatum; Disease Models, Animal; Dopamine; Grooming; Haloperidol; Hu | 1983 |
Response to antipsychotic medication: the doctor's and the consumer's view.
Topics: Adult; Akathisia, Drug-Induced; Attitude of Health Personnel; Attitude to Health; Basal Ganglia Dise | 1984 |
The use of depot neuroleptic haloperidol decanoate.
Topics: Bipolar Disorder; Depressive Disorder; Haloperidol; Humans; Prognosis; Psychotic Disorders; Schizoph | 1984 |
Tremor of the eyelids.
Topics: Adult; Eyelid Diseases; Female; Haloperidol; Humans; Schizophrenia; Tremor | 1984 |
Beyond the therapeutic window: a case presentation.
Topics: Adult; Ambulatory Care; Drug Administration Schedule; Haloperidol; Hospitalization; Humans; Male; Ps | 1984 |
Plasma catecholamine metabolites and early response to haloperidol.
Topics: Acute Disease; Adolescent; Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Hospitalization; | 1984 |
Bromperidol radioimmunoassay: human plasma levels.
Topics: Antibody Specificity; Biological Availability; Biotransformation; Cross Reactions; Haloperidol; Huma | 1984 |
[Complex use of phenazepam, lithium and haloperidol in the treatment of several forms of schizophrenia].
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Caudate Nucleus; D | 1984 |
Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Oxidation-Reduction; Plasma; Schizophrenia | 1984 |
Case report: psychomotor status-like episodes under haloperidol treatment.
Topics: Adult; Diazepam; Epilepsy; Haloperidol; Humans; Male; Schizophrenia | 1984 |
High-performance liquid chromatography of haloperidol in serum at the concentrations achieved during chronic therapy.
Topics: Bipolar Disorder; Chromatography, High Pressure Liquid; Chronic Disease; Haloperidol; Humans; Kineti | 1984 |
Platelet monoamine oxidase activity in schizophrenia: relationship to family history of the illness and neuroleptic treatment.
Topics: Adolescent; Adult; Blood Platelets; Female; Haloperidol; Humans; Male; Middle Aged; Monoamine Oxidas | 1984 |
Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies.
Topics: Adult; Baclofen; Chronic Disease; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Halop | 1980 |
Abnormal growth hormone response to LRH and TRH in adolescent schizophrenic boys.
Topics: Adolescent; Chlorpromazine; Gonadotropin-Releasing Hormone; Growth Hormone; Haloperidol; Humans; Mal | 1981 |
Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
Topics: Drug Resistance; Haloperidol; Humans; Radioimmunoassay; Radioligand Assay; Schizophrenia | 1981 |
Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
Topics: Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Schizophren | 1982 |
The active uptake of serotonin by platelets of schizophrenic patients and their families: possibility of a genetic marker.
Topics: Adult; Blood Platelets; Chlorpromazine; Female; Genetic Markers; Haloperidol; Humans; Kinetics; Male | 1982 |
High-dose haloperidol increases CSF opioid activity in patients with chronic schizophrenia.
Topics: Adult; Chronic Disease; Endorphins; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1983 |
Blood levels of haloperidol in schizophrenic patients.
Topics: Adolescent; Adult; Aging; Drug Interactions; Erythrocytes; Female; Half-Life; Haloperidol; Humans; M | 1983 |
Haloperidol-induced neuroleptic malignant syndrome.
Topics: Adult; Catatonia; Fever; Haloperidol; Humans; Male; Psychoses, Substance-Induced; Schizophrenia; Syn | 1983 |
Bilateral asymmetry in striatal dopamine metabolism: implications for pharmacotherapy of schizophrenia.
Topics: Animals; Dopamine; Female; Haloperidol; Humans; Rats; Rats, Inbred Strains; Schizophrenia; Substanti | 1982 |
Computerized EEG study on drug-induced extrapyramidalism in schizophrenic patients.
Topics: Adolescent; Amantadine; Brain; Computers; Electroencephalography; Female; Glycolates; Haloperidol; H | 1982 |
Relapse in patients with shifting RDC diagnoses treated with lithium alone.
Topics: Adult; Bipolar Disorder; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Ha | 1982 |
Prolactin response in tardive dyskinesia.
Topics: Adult; Affective Disorders, Psychotic; Chronic Disease; Dyskinesia, Drug-Induced; Haloperidol; Human | 1982 |
RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Topics: Adolescent; Adult; Drug Administration Schedule; Erythrocytes; Haloperidol; Humans; Middle Aged; Psy | 1982 |
[Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Topics: Adult; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic | 1982 |
Radioimmunoassay of haloperidol.
Topics: Chromatography, Gas; Cross Reactions; Haloperidol; Humans; Kinetics; Male; Radioimmunoassay; Schizop | 1982 |
Predictive indices for chlorpromazine therapy in schizophrenics.
Topics: Adult; Biotransformation; Chlorpromazine; Electroconvulsive Therapy; Haloperidol; Humans; Kinetics; | 1982 |
Haloperidol-induced changes in blink rates correlate with changes in BPRS score.
Topics: Adult; Blinking; Chronic Disease; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scale | 1982 |
Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients.
Topics: Absorption; Administration, Oral; Adult; Biological Availability; Haloperidol; Humans; Injections, I | 1982 |
Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia.
Topics: Adult; Blood Pressure; Chlorpromazine; Dopamine beta-Hydroxylase; Haloperidol; Humans; Hypotension, | 1982 |
Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Drug Administration Schedule; Haloperidol; Humans; Male; Middle Aged; Psychi | 1982 |
Pain insensitivity in psychosis.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Diagnosis, Differential; Duodenal Ulcer; Female; Haloperido | 1982 |
Plasma haloperidol levels and clinical response in acute schizophrenia.
Topics: Acute Disease; Adult; Haloperidol; Humans; Schizophrenia | 1982 |
Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
Topics: Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Kinetics; Male; Schi | 1982 |
12-month study of haloperidol decanoate in chronic schizophrenic patients.
Topics: Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; M | 1982 |
Interchangeability of stress and amphetamine in sensitization.
Topics: Animals; Behavior, Animal; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; Haloperido | 1980 |
Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
Topics: Animals; Behavior, Animal; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Moto | 1980 |
Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder.
Topics: Animals; Attention; Avoidance Learning; Chlorpromazine; Dextroamphetamine; Dopamine; Dose-Response R | 1981 |
Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
Topics: Basal Ganglia Diseases; Chronic Disease; Female; Haloperidol; Humans; Middle Aged; Prolactin; Schizo | 1980 |
A comparison of dopamine receptor blocking assay with plasma drug levels of haloperidol in schizophrenic patients.
Topics: Adult; Chromatography, Gas; Female; Haloperidol; Humans; Male; Mass Spectrometry; Middle Aged; Recep | 1981 |
Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Haloperidol; | 1980 |
Mobilization of refractory chronic schizophrenics with haloperidol.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperi | 1980 |
Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro.
Topics: Adult; Aged; Aging; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Oleic Acids; | 1981 |
Cognitive changes in acute schizophrenia with brief neuroleptic treatment.
Topics: Adolescent; Adult; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; P | 1981 |
Haloperidol levels and clinical response.
Topics: Dose-Response Relationship, Drug; Haloperidol; Humans; Schizophrenia | 1981 |
Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs.
Topics: Chromatography, Gas; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1980 |
[Depressive states in schizophrenic in-patients on admission and at discharge (author's transl)].
Topics: Acute Disease; Depressive Disorder; Haloperidol; Hospitals, Psychiatric; Humans; Motivation; Schizop | 1981 |
Radioimmunoassay of haloperidol in human serum: correlation of serum haloperidol with serum prolactin.
Topics: Animals; Chromatography, Gas; Female; Haloperidol; Humans; Male; Prolactin; Rabbits; Radioimmunoassa | 1981 |
Haloperidol blood levels during dosage reduction in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Sc | 1981 |
Neuroleptic drug effects on average evoked response augmentation-reduction in rats.
Topics: Animals; Chlorpromazine; Depression, Chemical; Endorphins; Evoked Potentials, Visual; Haloperidol; H | 1981 |
Effect of haloperidol administration on serum MHPG-SO4 levels in chronic schizophrenics.
Topics: Adult; Biotransformation; Brain; Chronic Disease; Glycols; Haloperidol; Humans; Male; Methoxyhydroxy | 1981 |
[An integrated program for psychosis].
Topics: Adult; Chlorpromazine; Cognition; Female; Haloperidol; Humans; Male; Methods; Pilot Projects; Progno | 1980 |
[Treatment of outpatients with high doses of haloperidol].
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antiparkinson Agents; Basal Ganglia Diseases; Bipolar Diso | 1981 |
Receptor supersensitivity: relationships to cerebral anatomy and histopathology of schizophrenia.
Topics: Afferent Pathways; Apomorphine; Brain; Corpus Striatum; Gliosis; Haloperidol; Humans; Receptors, Dop | 1981 |
Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment.
Topics: Adult; Ambulatory Care; Chronic Disease; Employment; Female; Haloperidol; Humans; Male; Middle Aged; | 1980 |
Serum level of haloperidol and its clinical significance.
Topics: Adult; Aged; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Radioimmu | 1980 |
Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients.
Topics: Adolescent; Adult; Chlorpromazine; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Ma | 1980 |
Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.
Topics: Chromatography, Gas; Chronic Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Prolact | 1980 |
Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, | 1980 |
Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Topics: Acute Disease; Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status | 1981 |
Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia.
Topics: Animals; Biomarkers; Female; Gene Expression; Haloperidol; Histocytochemistry; Humans; In Situ Hybri | 1995 |
Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Erythrocytes; Female; Haloperidol; Hu | 1995 |
Distractibility in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Attention; Chronic Disease; Cognition Disord | 1995 |
No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone.
Topics: Adult; Carbon Radioisotopes; Cerebellum; Dopamine Agonists; Female; Frontal Lobe; Haloperidol; Human | 1995 |
Schizophrenia: gender, family risk, and plasma homovanillic acid.
Topics: Adolescent; Adult; Family; Female; Haloperidol; Homovanillic Acid; Humans; Male; Risk Factors; Schiz | 1995 |
The gonadal axis in men with schizophrenia.
Topics: Adult; Circadian Rhythm; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Haloperidol; Huma | 1995 |
Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
Topics: Adult; Chromogranin A; Chromogranins; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1994 |
Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Butyrophenones; Dogs; Dopamine D2 Receptor | 1994 |
CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
Topics: Adult; Female; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydrox | 1994 |
Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 1994 |
Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hal | 1994 |
Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
Topics: Adult; Age of Onset; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Logistic Mode | 1995 |
Effects of haloperidol on CSF glutamate levels in drug-naive schizophrenic patients.
Topics: Adolescent; Adult; Dopamine Antagonists; Female; Glutamic Acid; Haloperidol; Humans; Male; Schizophr | 1995 |
Antipsychotic effect of cannabidiol.
Topics: Adult; Cannabidiol; Diazepam; Drug Therapy, Combination; Female; Haloperidol; Humans; Psychiatric St | 1995 |
Genetic variation of the 5-HT2A receptor and response to clozapine.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Polymorphism, Genetic; Rats; Receptor | 1995 |
Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Arousal; Autonomic Nervous System; Female; Galvanic Skin Re | 1995 |
Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy.
Topics: Acute Kidney Injury; Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant S | 1995 |
Clozapine in tardive Tourette syndrome.
Topics: Adult; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Injections, I | 1995 |
Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
Plasma clozapine levels and clinical benefit.
Topics: Adolescent; Clinical Trials as Topic; Clozapine; Dose-Response Relationship, Drug; Drug Administrati | 1995 |
Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.
Topics: Blood Platelets; Dose-Response Relationship, Drug; Haloperidol; Humans; Kinetics; Monoamine Oxidase; | 1995 |
Canny cases. Case 5: the dextral dodder.
Topics: Adult; Auditory Perception; Female; Hallucinations; Haloperidol; Humans; Schizophrenia | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
Topics: Adult; Haloperidol; Humans; Interleukin-1; Interleukin-2; Male; Middle Aged; Probability; Recurrence | 1995 |
Course of patients diagnosed as having schizophrenia during first episode occurring under age 18 years.
Topics: Adolescent; Adult; Age of Onset; Female; Haloperidol; Hospitalization; Hospitals, Psychiatric; Human | 1995 |
Haloperidol increases smoking in patients with schizophrenia.
Topics: Adult; Carbon Monoxide; Female; Haloperidol; Humans; Male; Middle Aged; Nicotine; Schizophrenia; Smo | 1995 |
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
Topics: Adult; Dopamine; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Psychiatric | 1993 |
Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats.
Topics: Analysis of Variance; Anesthesia; Animals; Disease Models, Animal; Dopamine; Haloperidol; Male; Micr | 1994 |
Platelet aggregation and dense granule secretion in schizophrenia.
Topics: Adenosine Triphosphate; Adult; Age of Onset; Arachidonic Acid; Collagen; Haloperidol; Humans; Male; | 1994 |
Haloperidol blocks the uptake of [18F]N-methylspiroperidol by extrastriatal dopamine receptors in schizophrenic patients.
Topics: Adult; Brain; Fluorine Radioisotopes; Haloperidol; Humans; Receptors, Dopamine; Schizophrenia; Spipe | 1995 |
Intra- and interethnic variability in reduced haloperidol to haloperidol ratios.
Topics: Adult; Analysis of Variance; Asian People; Black People; Ethnicity; Female; Haloperidol; Humans; Mal | 1995 |
Increased levels of GAP-43 protein in schizophrenic brain tissues demonstrated by a novel immunodetection method.
Topics: Adult; Aged; Animals; Blotting, Western; Brain; Brain Chemistry; Cell Membrane; Electrophoresis, Gel | 1995 |
Depression in schizophrenia: clinical and pharmacological variables.
Topics: Adolescent; Adult; Age Factors; Aged; Depressive Disorder; Dexamethasone; Female; Fluphenazine; Halo | 1995 |
In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.
Topics: Adult; Bipolar Disorder; Brain; Carbon Radioisotopes; Caudate Nucleus; Female; Haloperidol; Humans; | 1995 |
Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Apomorphine; Dopamine Agonist | 1995 |
An open-label study of famotidine as a treatment for schizophrenia.
Topics: Adult; Famotidine; Haloperidol; Humans; Middle Aged; Schizophrenia; Treatment Outcome | 1995 |
Diurnal variation in tardive dyskinesia.
Topics: Adult; Chronic Disease; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Mal | 1995 |
[Drug treatment of schizophrenic psychoses in puerperium].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chronic Disease; Clozapine; Dose-Response Relationship, | 1994 |
Seasonal variation in the dexamethasone suppression test: a longitudinal study in chronic schizophrenics and in healthy subjects.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dexamethasone; F | 1994 |
Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Fluoxetine; Haloperidol; Humans; Male; Middle Ag | 1994 |
Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Base Sequence; Brain Chemistry; Citalopram; Cl | 1994 |
D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.
Topics: Adult; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced | 1994 |
Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics.
Topics: Adult; Clozapine; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; Humans; Middle Age | 1994 |
[Accelerated breakdown of membrane phospholipids in schizophrenia--implications for the hypofrontality hypothesis].
Topics: Adult; Animals; Blood Platelets; Dominance, Cerebral; Dopamine; Female; Frontal Lobe; Haloperidol; H | 1994 |
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia; Chromatography, High Pressure Liquid; D | 1995 |
Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition.
Topics: Adult; Chromatography, Gas; Erythrocyte Membrane; Fatty Acids; Fatty Acids, Unsaturated; Haloperidol | 1994 |
Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures.
Topics: Adult; Erythrocyte Deformability; Erythrocyte Membrane; Fatty Acids; Fatty Acids, Unsaturated; Halop | 1994 |
[Brain antibodies in schizophrenia].
Topics: Autoantibodies; Autoimmune Diseases; Brain; Brain Mapping; Haloperidol; Humans; Schizophrenia | 1994 |
Do enzyme inducers modify haloperidol decanoate rate of release?
Topics: Antipsychotic Agents; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Haloperido | 1994 |
Ten-year course of schizophrenia--the Madras longitudinal study.
Topics: Adult; Chlorpromazine; Cohort Studies; Developing Countries; Female; Haloperidol; Humans; India; Lon | 1994 |
CSF levels of diazepam-binding inhibitor correlate with REM latency in schizophrenia, a pilot study.
Topics: Adult; Carrier Proteins; Diazepam Binding Inhibitor; Haloperidol; Humans; Male; Middle Aged; Pilot P | 1994 |
Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Benzazepines; Cerebral Cortex; Clozapine; Corpus Striatum; Dopamine; | 1995 |
A schizophrenic patient who developed extreme hypothermia after an increase in the dose of haloperidol: a case report.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloperidol; Huma | 1994 |
Selegiline for neuroleptic-induced parkinsonism.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Schizoph | 1993 |
Subjective response to neuroleptics in schizophrenia.
Topics: Adult; Affective Symptoms; Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Female; H | 1993 |
Three cases of alopecia areata induced by zotepine.
Topics: Adult; Alopecia; Alopecia Areata; Antipsychotic Agents; Autoimmune Diseases; Carbamazepine; Clomipra | 1993 |
Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationshi | 1993 |
Neuroleptic effects on serine and glycine metabolism.
Topics: Adult; Animals; Antipsychotic Agents; Brain; Cytosol; Female; Fluphenazine; Glycine; Glycine Hydroxy | 1993 |
Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Schizophr | 1993 |
A loading-dose strategy for converting from oral to depot haloperidol.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Dos | 1993 |
Single photon emission computed tomography with 123I-IMP in three cases of the neuroleptic malignant syndrome.
Topics: Adult; Amphetamines; Antipsychotic Agents; Basal Ganglia; Brain; Dantrolene; Dose-Response Relations | 1994 |
Recurrent sinus arrest in association with neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Cardiac Pacing, Artificial; Catatonia; Chlorpromazine; Clopenthixol; Dr | 1994 |
Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
Topics: Adult; Aged; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relation | 1994 |
Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Haloperidol; Humans; Male; Middle Aged; Pyridin | 1994 |
[Emergency caesarean section for a patient with chronic schizophrenia].
Topics: Adult; Anesthesia, Obstetrical; Cesarean Section; Chronic Disease; Emergencies; Female; Fetal Blood; | 1994 |
Correct titration of non-drugs and some other methodological issues.
Topics: Administration, Oral; Amitriptyline; Anxiety Disorders; Benperidol; Depressive Disorder; Dose-Respon | 1994 |
Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
Topics: Adult; Haloperidol; Hospitalization; Hospitals, Psychiatric; Humans; Length of Stay; Placebo Effect; | 1994 |
A fulminant case of neuroleptic malignant syndrome.
Topics: Adult; Drug Therapy, Combination; Fatal Outcome; Haloperidol; Humans; Male; Neuroleptic Malignant Sy | 1994 |
QEEG alpha 1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients.
Topics: Adolescent; Adult; Brain; Clopenthixol; Dose-Response Relationship, Drug; Electroencephalography; Fe | 1994 |
Overflow movements may predict neuroleptic-induced dystonia.
Topics: Adolescent; Adult; Bipolar Disorder; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Humans; Male; | 1994 |
Clinical correlates of body weight changes in schizophrenia.
Topics: Adult; Atrophy; Brain; Cerebral Ventricles; Energy Intake; Female; Haloperidol; Humans; Male; Psychi | 1994 |
Vitamin C in the treatment of schizophrenia.
Topics: Adult; Ascorbic Acid; Chronic Disease; Drug Therapy, Combination; Haloperidol; Humans; Male; Schizop | 1993 |
More on obsessive-compulsive symptoms and clozapine.
Topics: Adult; Clozapine; Haloperidol; Humans; Male; Obsessive-Compulsive Disorder; Schizophrenia; Schizophr | 1994 |
[Intraindividual comparison of haloperidol decanoate and oxyprothepine in maintenance therapy in schizophrenic psychoses].
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Female; Haloperidol; Humans; Male; Schizophrenia | 1993 |
Haloperidol decanoate (Janssen) in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Schizophrenia | 1993 |
Long-term high-dose neuroleptic treatment: who gets it and why?
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halo | 1993 |
EEG- and EP-mapping--possible indicators for disturbed information processing in schizophrenia?
Topics: Adult; Antipsychotic Agents; Brain Mapping; Electroencephalography; Evoked Potentials, Auditory; Hal | 1993 |
[Clozapine and priapism: an association to consider].
Topics: Adult; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Libido; Male; Penile Erection; Pri | 1994 |
Optimal drug and behavior therapy for treatment-refractory schizophrenic patients.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administr | 1994 |
Basal ganglia iron in tardive dyskinesia: an MRI study.
Topics: Adult; Basal Ganglia; Dominance, Cerebral; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Ir | 1994 |
A pilot study of a structured interview addressing sexual function in men with schizophrenia.
Topics: Adult; Basal Ganglia Diseases; Fluphenazine; Haloperidol; Hospitalization; Humans; Libido; Male; Mas | 1994 |
A preliminary prospective study on natural autoantibodies and the response of untreated schizophrenic patients to neuroleptics.
Topics: Adult; Autoantibodies; Autoantigens; DNA; Dopamine; Female; Haloperidol; Humans; Immunoglobulin G; I | 1994 |
A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.
Topics: Analysis of Variance; Animals; Autoradiography; Benzamides; Benzazepines; Cerebral Cortex; Clozapine | 1994 |
Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity.
Topics: Adult; Anisotropy; Dose-Response Relationship, Drug; Erythrocyte Deformability; Erythrocyte Membrane | 1994 |
Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
Topics: Adolescent; Adult; Anxiety Disorders; Brain; Cerebral Ventricles; Depressive Disorder; Dexamethasone | 1994 |
Determination of some butyrophenones in body fluids by gas chromatography with surface ionization detection.
Topics: Butyrophenones; Chromatography, Gas; Haloperidol; Humans; Schizophrenia; Sensitivity and Specificity | 1993 |
Acute dystonia due to clozapine.
Topics: Acute Disease; Biperiden; Clozapine; Dystonia; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1994 |
Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
Topics: Acute Disease; Adolescent; Adult; Cross-Cultural Comparison; Dose-Response Relationship, Drug; Femal | 1993 |
Auditory evoked potentials in schizophrenic patients before and during neuroleptic treatment. Relationship to psychopathological state.
Topics: Adult; Electrooculography; Evoked Potentials, Auditory; Female; Haloperidol; Humans; Male; Prognosis | 1993 |
Reduced total complement haemolytic activity in schizophrenic patients.
Topics: Autoimmune Diseases; Bipolar Disorder; Chronic Disease; Complement Activation; Complement C3; Comple | 1993 |
Effects of single dose haloperidol administration on plasma homovanillic acid levels in normal subjects.
Topics: Adolescent; Adult; Circadian Rhythm; Dopamine; Haloperidol; Homovanillic Acid; Humans; Male; Schizop | 1993 |
Prediction of response to haloperidol dose reduction by Span of Apprehension measures for treatment-refractory schizophrenic patients.
Topics: Adult; Dose-Response Relationship, Drug; Female; Form Perception; Haloperidol; Humans; Male; Psychia | 1993 |
3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects.
Topics: Adult; Binding, Competitive; Clozapine; Dose-Response Relationship, Drug; Female; Haloperidol; Human | 1993 |
Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdala.
Topics: Adult; Aged; Amygdala; Analysis of Variance; Animals; Autopsy; Female; Haloperidol; Hippocampus; Hum | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Disease Models, Animal; Dopamine D2 Receptor Antago | 1993 |
Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Hippocamp | 1993 |
Early response to haloperidol treatment in chronic schizophrenia.
Topics: Adult; Chronic Disease; Cohort Studies; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Psy | 1993 |
Acutely administered haloperidol has little effect on steady-state visual evoked potentials from pattern-reversal stimulations in treated schizophrenics.
Topics: Adult; Evoked Potentials, Visual; Female; Form Perception; Haloperidol; Humans; Male; Occipital Lobe | 1993 |
Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Female; Haloperidol; Humans; Male | 1993 |
Alprazolam in the emergency treatment of schizophrenia.
Topics: Alprazolam; Drug Therapy, Combination; Emergencies; Haloperidol; Humans; Schizophrenia | 1993 |
Schizophrenia, obsessive-compulsive disorder, and Tourette's syndrome: a case of triple comorbidity.
Topics: Adult; Basal Ganglia Diseases; Brain; Clomipramine; Comorbidity; Female; Haloperidol; Humans; Obsess | 1993 |
Monitoring plasma level of haloperidol in schizophrenia.
Topics: Drug Interactions; Drug Monitoring; Haloperidol; Humans; Schizophrenia; Schizophrenic Psychology | 1993 |
Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
Topics: Adult; Ambulatory Care; Chronic Disease; Cocaine; Combined Modality Therapy; Comorbidity; Delayed-Ac | 1993 |
Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
Topics: Adult; Female; Half-Life; Haloperidol; Humans; Injections, Intramuscular; Male; Metabolic Clearance | 1993 |
The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Mon | 1993 |
Acutely psychotic patients receiving high-dose haloperidol therapy.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Crisis Intervention; Dose-Response Relationship, | 1993 |
Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
Topics: Adult; Dose-Response Relationship, Drug; Female; Half-Life; Haloperidol; Humans; Male; Metabolic Cle | 1993 |
Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients.
Topics: Adult; Brain; Chronic Disease; Delayed-Action Preparations; Female; Haloperidol; Homovanillic Acid; | 1993 |
Cardiac effects of haloperidol and carbamazepine treatment.
Topics: Carbamazepine; Electrocardiography; Haloperidol; Humans; Long QT Syndrome; Prevalence; Retrospective | 1996 |
Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.
Topics: Adult; Age of Onset; Basal Ganglia; Brain; Cerebral Cortex; Deoxyglucose; Female; Fluorodeoxyglucose | 1996 |
Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Homovanillic Acid; Humans; Male; Prola | 1995 |
D1 receptor antagonists in schizophrenia.
Topics: Animals; Dopamine Antagonists; Haloperidol; Raclopride; Receptors, Dopamine D1; Salicylamides; Schiz | 1995 |
The drug-drug interaction effects of haloperidol on plasma carbamazepine levels.
Topics: Anticonvulsants; Antipsychotic Agents; Binding, Competitive; Carbamazepine; Cytochrome P-450 CYP2D6; | 1995 |
Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Clozapine; Female; Haloperidol; H | 1996 |
In vivo study of the mutagenicity of biperidine, pipotiazine, chlorpromazine, and haloperidol.
Topics: Adult; Antipsychotic Agents; Biperiden; Case-Control Studies; Cells, Cultured; Chlorpromazine; Drug | 1996 |
Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Drug Therapy, Combination; Electr | 1996 |
Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.
Topics: Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Glutamic Acid; Glycine; | 1995 |
Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Prolactin; Psychiatric Status Rating Scales; | 1995 |
3H-spiperone binding to peripheral mononuclear cells in psychiatric in-patients.
Topics: Adult; Binding, Competitive; Clozapine; Female; Haloperidol; Hospitalization; Humans; Lymphocytes; M | 1996 |
Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Recurrence; | 1995 |
Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Drug Interactions; Drug Therapy, Combinati | 1996 |
Comments on "Clozapine treatment after agranulocytosis induced by classic neuroleptics".
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Haloperidol; Humans; Male; Risperidone; Schizophrenia; | 1996 |
Managing the first episode of schizophrenia: the role of new therapies.
Topics: Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.
Topics: Clozapine; Cognition; Fluphenazine; Haloperidol; Humans; Maze Learning; Risperidone; Schizophrenia | 1996 |
Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies.
Topics: Adult; Dopamine; Haloperidol; Homovanillic Acid; Humans; Male; Schizophrenia | 1996 |
Cost-benefits of risperidone.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Dementia; Dose- | 1996 |
Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Biological Availability; Chronic Disease; Dose-Re | 1995 |
Effects of haloperidol and SCH 23390 on acoustic startle in animals depleted of dopamine as neonates: implications for neuropsychiatric syndromes.
Topics: Animals; Animals, Newborn; Benzazepines; Dopamine; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Re | 1996 |
Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Binding, Competitive; Carrier Protein | 1996 |
Assessing a drug's cost-benefits.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Haloperidol; Humans; | 1996 |
Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Dopamine D2 Receptor Antagonists; Double-Blind Me | 1996 |
Antinuclear autoantibodies in chronic schizophrenia.
Topics: Adult; Antibodies, Antinuclear; Antipsychotic Agents; Autoantibodies; Autoimmunity; Chronic Disease; | 1995 |
Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Arachidonic Acid; Blood Platelets; Chromatography, High Pressure Liquid | 1996 |
Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1996 |
Tardive lingual dystonia treated with clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Dystonia; Haloperidol; Humans; Male; Schizophrenia; Tongue | 1996 |
Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia.
Topics: Adenosine Diphosphate; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; | 1996 |
Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Clozapine; Corpus Striatum; Frontal Lobe; Gene Expre | 1996 |
Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Discrimination Learning; Dopamine D2 Receptor Antagonists; F | 1996 |
Acute effects of haloperidol on cerebral cortex blood flow in normal and schizophrenic subjects.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Blood Flow Velocity; Cerebral Cortex; Female; Hal | 1996 |
Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Creatine Kinase; Female; Haloperidol; Humans; Male; Schizoph | 1996 |
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Topics: Adult; Antipsychotic Agents; Factor Analysis, Statistical; Haloperidol; Humans; Male; Middle Aged; P | 1996 |
Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients.
Topics: Adult; Antipsychotic Agents; Binding Sites; Cerebellum; Corpus Striatum; Haloperidol; Humans; Middle | 1996 |
5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adult; Aged; Animals; Antipsychotic Agents; Autoradiography; | 1996 |
Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dipeptidy | 1996 |
Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.
Topics: Adult; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schi | 1996 |
[Bromperidol decanoate in the residual phase of schizophrenia].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Psych | 1996 |
A longitudinal study of EEG sleep in schizophrenia.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delta Rhythm; Drug Therapy, Combinati | 1996 |
Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Anti-Anxiety Agents; Antipsychotic Agents; Buspirone; Chromatography, H | 1996 |
Large variations of plasma levels during maintenance treatment with depot neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Drug Monitoring; Female; Flupenthixo | 1996 |
Pattern-mixture models for multivariate incomplete data with covariates.
Topics: Algorithms; Bayes Theorem; Biometry; Data Interpretation, Statistical; Haloperidol; Humans; Likeliho | 1996 |
Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Topics: Adult; Aged; Antipsychotic Agents; Depression; Dopamine D2 Receptor Antagonists; Dose-Response Relat | 1996 |
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Corpus Striatum; Haloperidol; Humans; Midd | 1996 |
[Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
Topics: Acute Disease; Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Prognosis; Prolactin; Psychia | 1996 |
The relationship between plasma haloperidol concentrations and clinical results.
Topics: Chronic Disease; Drug Administration Schedule; Haloperidol; Humans; Psychiatric Status Rating Scales | 1996 |
Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Dose | 1997 |
Regulation of [3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors.
Topics: Analgesics; Analysis of Variance; Animals; Cyclohexylamines; Dopamine; Dopamine Antagonists; Guinea | 1996 |
Phenelzine as a possible treatment for depression in schizophrenic patients.
Topics: Adult; Depressive Disorder; Drug Therapy, Combination; Haloperidol; Humans; Male; Monoamine Oxidase | 1996 |
[Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride].
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Prol | 1996 |
Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Brain; Cerebellum; Dopamine Antagonists; Dop | 1997 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamin | 1996 |
The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Brain; Brain Mapping; Cerebellum; Cerebral Cortex; Chron | 1997 |
Possible interaction between cisapride and bromperidol.
Topics: Adult; Cisapride; Drug Interactions; Haloperidol; Humans; Male; Piperidines; Schizophrenia; Sympatho | 1997 |
Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients.
Topics: Adult; Asian People; Basal Ganglia Diseases; Dextromethorphan; Female; Haloperidol; Humans; Male; Ph | 1997 |
Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cocaine; Comorbidity; Delayed-Action Preparations; Flu | 1997 |
Quantification of neuroreceptors in the living human brain: III. D2-like dopamine receptors: theory, validation, and changes during normal aging.
Topics: Aging; Algorithms; Animals; Brain; Brain Chemistry; Computer Simulation; Corpus Striatum; Dopamine A | 1997 |
SPECT studies of D2 occupancy in low-dose haloperidol treatment.
Topics: Adult; Basal Ganglia; Benzamides; Cerebellum; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats.
Topics: Animals; Antipsychotic Agents; Cocaine; Discrimination, Psychological; Dopamine; Dopamine Antagonist | 1997 |
Chronic haloperidol treatment does not affect structure of attention in schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Haloperidol; Humans; Male; Middle Aged; Neuropsychological T | 1997 |
A longitudinal study of cerebrospinal fluid angiotensin-converting enzyme in neuroleptic-treated schizophrenia.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Humans; Longitudinal Studies; Male | 1997 |
[Zotepin--its value and potentials for further development].
Topics: Animals; Antipsychotic Agents; Clozapine; Dibenzothiepins; Disease Models, Animal; Haloperidol; Huma | 1994 |
Interaction between carbamazepine and bromperidol.
Topics: Adult; Analgesics, Non-Narcotic; Antipsychotic Agents; Carbamazepine; Chromatography, High Pressure | 1997 |
Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Dys | 1997 |
Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
Topics: Adult; Algorithms; Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Female; H | 1997 |
Prefrontal cortical and hippocampal modulation of dopamine-mediated effects.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Apomorphine; Disease Models, Animal; Dopamine; Halope | 1998 |
Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Dyskinesia, | 1997 |
Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Brain; Delayed-Action Preparations; Dopamine Antagonists | 1997 |
Evaluation of a complex case: the value of a drug washout period.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Schizophreni | 1997 |
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.
Topics: Adult; Body Temperature; Cytokines; Depressive Disorder; Female; Haloperidol; Humans; Leukocyte Coun | 1997 |
A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Psyc | 1997 |
Selective effects on prefrontal cortex serotonin by dopamine D3 receptor agonism: interaction with low-dose haloperidol.
Topics: Animals; Antipsychotic Agents; Dopamine Agonists; Drug Interactions; Haloperidol; Male; Prefrontal C | 1997 |
Olanzapine on trial.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Haloperidol; Humans; Olanzapi | 1998 |
Clozapine compared with haloperidol for refractory schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Schizophrenia | 1998 |
A schizophrenic patient with an arrhythmic circadian rest-activity cycle.
Topics: Adult; Antipsychotic Agents; Bed Rest; Body Temperature; Catatonia; Chronic Disease; Circadian Rhyth | 1997 |
Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Female; Haloperidol; Hum | 1997 |
Neuroleptic-induced laryngeal dystonia can mimic anaphylaxis.
Topics: Acute Disease; Adult; Anaphylaxis; Antipsychotic Agents; Diagnosis, Differential; Dystonia; Haloperi | 1997 |
Kainic acid lesions in adult rats as a model of schizophrenia: changes in auditory information processing.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Auditory Perception; Disease Models, Animal; El | 1998 |
Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
Topics: Adult; Algorithms; Antipsychotic Agents; Brain; Brief Psychiatric Rating Scale; Cerebellum; Corpus S | 1998 |
Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients.
Topics: Animals; Antipsychotic Agents; Binding Sites; Case-Control Studies; Caudate Nucleus; Haloperidol; Hu | 1998 |
A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Dextroamphetamine; Disease Models, Anima | 1998 |
Prolactin response to bromperidol treatment in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Schizophreni | 1998 |
MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients.
Topics: Antipsychotic Agents; Blood Platelets; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Is | 1998 |
Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; beta-Endorphin; | 1998 |
Partial inhibition of reverse tolerance by a high dose of ritanserin or low dose of haloperidol in methamphetamine-sensitized rat.
Topics: Animals; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Drug Tolerance; Haloperidol; Loc | 1998 |
[Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP3A; Cytochrome P-450 | 1998 |
Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles | 1998 |
Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1998 |
Dopamine D2-receptor density in humans as assessed with SPET and the new high-affinity ligand 123I-NCQ298: a pilot study.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebrovascular Circulation; Dopamine Agonists; Female; Ha | 1998 |
Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Dextroamphetamine; Disease Mod | 1998 |
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Haloperidol; Hu | 1998 |
Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Clozapine; Contrast Media; D | 1998 |
Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, | 1998 |
Reduced status of plasma total antioxidant capacity in schizophrenia.
Topics: Adult; Antioxidants; Antipsychotic Agents; Free Radicals; Haloperidol; Humans; Male; Middle Aged; Ps | 1998 |
Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Electr | 1998 |
Olanzapine for primary negative symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as | 1998 |
Olanzapine for the treatment of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Biperiden; Dyskinesia, Drug-Induced; Female; Haloperido | 1998 |
Reduced level of plasma antioxidant uric acid in schizophrenia.
Topics: Adult; Antioxidants; Antipsychotic Agents; Cotinine; Haloperidol; Humans; Male; Schizophrenia; Smoki | 1998 |
APA Practice Guideline for schizophrenia: risperidone equivalents. American Psychiatric Association.
Topics: Drug Administration Schedule; Haloperidol; Humans; Practice Guidelines as Topic; Psychiatry; Risperi | 1998 |
Sertindole versus haloperidol for schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Imidazoles; Indoles; Patient Dropouts; Randomized Control | 1998 |
Sertindole versus haloperidol for schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Imidazoles; Indoles; Randomized Controlled Trials as Topi | 1998 |
Does clozapine treatment cause brain disease?
Topics: Adult; Age Factors; Brain Diseases; Child; Clozapine; Drug Therapy, Combination; Haloperidol; Humans | 1998 |
[A study of neuroleptic malignant syndrome in the presenium and senium].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Haloperidol; Humans; Male | 1998 |
Research and treatment strategies in first-episode psychoses. The Pittsburgh experience.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Diseases; Developmental Disabilities; Episode of Care | 1998 |
Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension.
Topics: Adolescent; Adult; Electroencephalography; Female; Haloperidol; Humans; Male; Middle Aged; Polysomno | 1998 |
Treatment of tardive dystonia with an antispastic agent.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Dystonia; Female; Haloperidol; Humans; Propiophenones; | 1998 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 1998 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival | 1998 |
An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.
Topics: Adult; Antipsychotic Agents; Asian; Cross-Cultural Comparison; Dose-Response Relationship, Drug; Dys | 1998 |
Schizophrenia: do we really need placebo-controlled studies?
Topics: Antipsychotic Agents; Double-Blind Method; Evaluation Studies as Topic; Haloperidol; Humans; Placebo | 1998 |
Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Drug Monitoring; Fem | 1999 |
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Mood Disorders; Prospective Studies; Risperid | 1999 |
Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Basal Ganglia Diseases; Depressive Dis | 1999 |
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Asian People; Cytochrome P-450 CYP2D6; Drug Administration Sch | 1999 |
A cost-effectiveness clinical decision analysis model for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Decision Support Systems, C | 1998 |
Atypical antipsychotics and formulary decisions.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Costs; Efficiency; Formularies as | 1998 |
Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Monitoring; Female; H | 1999 |
Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Haloperidol; Humans; Itracona | 1999 |
Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
Topics: Adult; Aged; Beverages; Citrus; Female; Food-Drug Interactions; Haloperidol; Humans; Middle Aged; Ps | 1999 |
[Decompensated "anorexia" at age 52--diagnosis of schizophrenia 30 years later].
Topics: Adult; Anorexia; Anti-Anxiety Agents; Antipsychotic Agents; Diazepam; Female; Haloperidol; Humans; M | 1999 |
Spontaneous slow and fast MEG activity in male schizophrenics treated with clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Electroencephalography; Haloperidol; Humans; Magnetoencephal | 1999 |
Modulation of language processing in schizophrenia: effects of context and haloperidol on the event-related potential.
Topics: Acoustic Stimulation; Adult; Attention; Discrimination, Psychological; Electroencephalography; Event | 1999 |
Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone.
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Haloperidol; Humans; Male; Middle Aged; Pituitary | 1999 |
Human plasma glutathione peroxidase and symptom severity in schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Case-Control Studies; Chronic Disease; Enzyme-Linked Immuno | 1999 |
Persistence of haloperidol in human brain tissue.
Topics: Antipsychotic Agents; Brain; Brain Chemistry; Caudate Nucleus; Cerebellar Nuclei; Chromatography, Hi | 1999 |
Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Hu | 1999 |
Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; No | 1999 |
Neuroleptic influences on a lateralized behavioral bias in unoperated rats.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Female; Functional Laterality; Haloper | 1999 |
Trace analysis of haloperidol and its chiral metabolite in plasma by capillary electrophoresis.
Topics: Electrophoresis, Capillary; Haloperidol; Humans; Reference Standards; Reproducibility of Results; Sc | 1999 |
Alcohol dependence and hospitalization in schizophrenia.
Topics: Adult; Alcoholism; Antipsychotic Agents; Cocaine-Related Disorders; Comorbidity; Female; Fluphenazin | 1999 |
Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; GABA Antagonists; GABA-A Receptor Antagonists | 1999 |
In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Cerebral Cortex; Clozapine; Corpus Striatum; Do | 1999 |
Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients.
Topics: Adult; Aged; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme I | 1999 |
Economic grand rounds: direct cost of care for patients with schizophrenia treated with haloperidol in an emergency unit.
Topics: Adult; Aged; Antipsychotic Agents; Canada; Combined Modality Therapy; Emergency Service, Hospital; E | 1999 |
Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects.
Topics: Adult; Aged; Animals; Axons; Carrier Proteins; Delayed-Action Preparations; Dopamine; Dopamine Plasm | 1999 |
Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Drug I | 1999 |
[Leukopenia associated with butyrophenones. A successful treatment of psychoses with pulsed administration of neuroleptics].
Topics: Antipsychotic Agents; Benperidol; Female; Haloperidol; Humans; Leukopenia; Middle Aged; Pulse Therap | 1999 |
Some behavioural effects of risperidone in rats: comparison with haloperidol.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Drug Evaluation, Preclini | 1999 |
Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics.
Topics: Adult; Antipsychotic Agents; Asian People; Cytochrome P-450 CYP2D6; DNA; Exons; Female; Haloperidol; | 1999 |
Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects.
Topics: Animals; Antipsychotic Agents; Axons; Carrier Proteins; Female; GABA Plasma Membrane Transport Prote | 1999 |
Recommended haloperidol and risperidone doses in first-episode psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; H | 1999 |
The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Topics: Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Genotype; Haloperidol; Humans; Male; Mid | 1999 |
[Neuro-cognition and schizophrenia. 11th World Congress for Psychiatry. Hamburg, 8 August 1999].
Topics: Antipsychotic Agents; Cognition Disorders; Haloperidol; Humans; Risperidone; Schizophrenia | 1999 |
Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Prolactin | 1999 |
Propranolol: a treatment for pseudoakathisia.
Topics: Adult; Agnosia; Akathisia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Perphenazine; Propr | 1994 |
PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Haloperidol; Indoles; Male; Meglumine; Rats; Rat | 2000 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonist | 2000 |
[Effect of activation tasks on acute neuroleptic-induced akathisia].
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Arousal; Attention; Benperidol; Diagnosis, Dif | 2000 |
Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients.
Topics: Acute Disease; Adult; Angiotensin I; Antipsychotic Agents; Chlorpromazine; Cross-Sectional Studies; | 2000 |
Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects.
Topics: Adult; Animals; Antipsychotic Agents; Autopsy; Axons; Case-Control Studies; Dopamine; Entorhinal Cor | 2000 |
["More is less": a retrospective study of haloperidol dosages in acute schizophrenia].
Topics: Acute Disease; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Dos | 2000 |
Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Immunosuppressive Agents; Inter | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Dose-Response Relationship, Drug; Halo | 2000 |
[Selection and dosages of therapeutic agents for the early stage of schizophrenia].
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Humans; Male; Schizophrenia | 1999 |
Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biotransformation; Dose-Response Relationship, Drug; | 2000 |
Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine.
Topics: Animals; Antipsychotic Agents; Clozapine; DNA-Binding Proteins; Drug Administration Schedule; Halope | 2000 |
Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory.
Topics: Animals; Antipsychotic Agents; Benzazepines; Brain; Excitatory Amino Acid Antagonists; Glutamic Acid | 2000 |
Need for a new framework to understand the mechanism of all antipsychotics.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Resistance; Hal | 2000 |
Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Topics: Alleles; Antipsychotic Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Enzyme Induction; F | 2000 |
Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats.
Topics: Amygdala; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Antagonists; Exci | 2000 |
Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Autoradiography; Dominance, Cerebral; Female; Haloperidol; | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilizat | 2000 |
Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients.
Topics: Adult; Aged; Animals; Autopsy; Brain-Derived Neurotrophic Factor; Cause of Death; Female; Gene Expre | 2000 |
Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients.
Topics: Activating Transcription Factor 2; Adult; Aged; Animals; Cerebellum; Cyclic AMP Receptor Protein; Cy | 2000 |
Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia.
Topics: Acute Disease; Akathisia, Drug-Induced; Amino Acid Substitution; Antipsychotic Agents; Dyskinesias; | 2000 |
Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose- | 2000 |
Antipsychotics and working memory in schizophrenia.
Topics: Animals; Antipsychotic Agents; Haloperidol; Haplorhini; Humans; Memory; Receptors, Dopamine D1; Schi | 2000 |
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Costs and Cost Analysis; Haloperido | 2000 |
Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics.
Topics: Adult; Antipsychotic Agents; Dopamine; Enzyme-Linked Immunosorbent Assay; Haloperidol; Homovanillic | 2000 |
Prevalence and characteristics of patients with pseudoakathisia.
Topics: Adult; Akathisia, Drug-Induced; Antiparkinson Agents; Antipsychotic Agents; Chlorpromazine; Chronic | 2000 |
Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.
Topics: Aconitine; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Animals; Antipsychotic | 2000 |
Comment on 'reduced haloperidol does not interfere with antipsychotic activity of halperidol in the treatment of acute schizophrenia'.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Haloperidol; Humans; Reproducibility of Results; Res | 2000 |
Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Brief Psychia | 2000 |
Severe self-injurious behavior associated with treatment-resistant schizophrenia: treatment with maintenance electroconvulsive therapy.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Electroconvulsive Therapy; Haloperidol; Hum | 2000 |
Treatment of patients with delirium.
Topics: Delirium; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Haloperidol; Humans; Pract | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2000 |
Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Bipolar Disorder; Brain; Depressive Disorder | 2000 |
Effect of chlorpromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Clozapine; Drug Interactions; Drug Therapy, Combination | 2000 |
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behav | 2000 |
[Pancytopenia].
Topics: Chemical and Drug Induced Liver Injury; Chronic Disease; Diagnosis, Differential; Female; Haloperido | 2000 |
Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Confidence Intervals; Dose-Response Relationship, Dru | 2000 |
Insomnia related to biperiden withdrawal in two schizophrenic patients.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Female; Haloperidol; Humans; Middle Ag | 2000 |
Neuroleptic therapy influences basal ganglia activation: a functional magnetic resonance imaging study comparing controls to haloperidol- and olanzapine-treated inpatients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Haloperidol; Hospitalization; Hu | 2000 |
Drug review "surprises" reader.
Topics: Aged; Alanine Transaminase; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug In | 2000 |
GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons.
Topics: Adult; Animals; Carrier Proteins; Cell Count; Female; GABA Plasma Membrane Transport Proteins; gamma | 2001 |
Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Corpus Striatum; Drug Therapy, Combi | 2001 |
Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.
Topics: Acoustic Stimulation; Adamantane; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Conditioni | 2001 |
The effect of nicotine and haloperidol co-treatment on nicotinic receptor levels in the rat brain.
Topics: Aconitine; Animals; Brain Chemistry; Bridged Bicyclo Compounds, Heterocyclic; Dopamine Antagonists; | 2001 |
Haloperidol and clozapine increase neural activity in the rat prefrontal cortex.
Topics: Action Potentials; Animals; Antipsychotic Agents; Clozapine; Electrophysiology; Haloperidol; Male; N | 2001 |
Abnormal age-related changes of plasma antioxidant proteins in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aging; Albumins; Antipsychotic Agents; Anxiety; Bilirubin; Depressio | 2000 |
FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration.
Topics: Animals; Cell Count; Clozapine; Drug Administration Schedule; Gene Expression Regulation; Haloperido | 2001 |
Reversal of rabbit syndrome with olanzapine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; M | 2000 |
Neurosyphilis presenting as schizophrenialike psychosis.
Topics: Acute Disease; Adult; Diagnosis, Differential; Female; Frontal Lobe; Haloperidol; Humans; Neurosyphi | 2000 |
Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Hallucinogens; Haloperidol; Male; Mice; | 2001 |
Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.
Topics: Adult; Female; Haloperidol; Humans; Panic Disorder; Remission, Spontaneous; Risperidone; Schizophren | 2001 |
Hyperactivity and disruption of prepulse inhibition induced by N-methyl-D-aspartate stimulation of the ventral hippocampus and the effects of pretreatment with haloperidol and clozapine.
Topics: Animals; Clozapine; Dopamine Antagonists; Excitatory Amino Acid Agonists; Haloperidol; Hippocampus; | 2001 |
Acute phase of schizophrenia: impact of atypical antipsychotics.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risper | 2000 |
Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses.
Topics: Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Chi-Square Distribution; Cl | 2001 |
Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; | 2001 |
Haloperidol downregulates phospholipase A(2) signaling in rat basal ganglia circuits.
Topics: Animals; Antipsychotic Agents; Arachidonic Acid; Autoradiography; Basal Ganglia; Brain Chemistry; Do | 2001 |
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Se | 2001 |
The changes of biological markers and treatment efficacy in schizophrenia.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Brain; Cognition; Dexamethasone | 2001 |
Relapse prevention in schizophrenia: attitudes of neurologists-psychiatrists.
Topics: Adult; Antipsychotic Agents; Attitude of Health Personnel; Female; Greece; Haloperidol; Humans; Male | 2001 |
Atypical antipsychotic effects of quetiapine fumarate in animal models.
Topics: Amphetamine; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Disease Models, Anima | 2000 |
Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Chromosomes, Human, Pair 1; Depressive Disorder, Major; Family | 2001 |
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Humans; | 2001 |
Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone.
Topics: Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Sexu | 2001 |
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.
Topics: Adult; Alleles; Deoxyribonucleases, Type II Site-Specific; Dopamine Antagonists; Female; Genotype; H | 2001 |
Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Ra | 2001 |
No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.
Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Corpus Striatum; Female; Haloperidol; Humans; Male; M | 2001 |
Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepinones; Central Nervous System Stimulants; Cl | 2001 |
Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Risper | 2001 |
A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dat | 2001 |
Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia.
Topics: Adult; Antipsychotic Agents; Enzyme-Linked Immunosorbent Assay; Female; Haloperidol; Humans; Interle | 2001 |
An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response.
Topics: Animals; Antipsychotic Agents; Brain; Caffeine; Cerebrovascular Circulation; Disease Models, Animal; | 2001 |
Asymmetrical hand force persistence and neuroleptic treatment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studi | 2001 |
Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Cytochrome P-450 CYP2D6; Drug Interactions; Drug | 2001 |
Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy.
Topics: Adult; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Co | 2001 |
Hippocampal and cortical sensory gating in rats: effects of quinpirole microinjections in nucleus accumbens core and shell.
Topics: Acoustic Stimulation; Animals; Auditory Perception; Cerebral Cortex; Dopamine; Dopamine Agonists; Do | 2001 |
BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Axotomy; Brain-Derived Neurotrophic Factor; Clozapi | 2001 |
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzamides; Depression; Dopamine Antagonists; Female; Haloperi | 2001 |
Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Topics: Adult; Antipsychotic Agents; Clomipramine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; H | 2001 |
Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus.
Topics: Adult; Age Factors; Aged; Animals; Cause of Death; Cell Count; Depressive Disorder; Female; Haloperi | 2001 |
Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Caudate Nucleus; Clozapine; Fem | 2001 |
Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism.
Topics: Adult; Antipsychotic Agents; Chromatography, Liquid; Female; Haloperidol; Humans; Parkinsonian Disor | 2001 |
Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol.
Topics: Adult; Aged; Cytochrome P-450 CYP2D6; Female; Genotype; Haloperidol; Humans; Male; Middle Aged; Prol | 2001 |
Increased cortical kynurenate content in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Female; Frontal Lobe; Haloperidol; Hu | 2001 |
Global index of safety (GIS): a new instrument to assess drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Benzodiazepines; Consumer Product Saf | 2001 |
Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Cell Membrane; Female; Haloperidol; Humans; Male; Phos | 2001 |
Outcome comparison of patients receiving oral or depot neuroleptic medication.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Cohort Studies; Delayed-Action P | 2001 |
Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Anta | 2001 |
Probing the human hippocampus using rCBF: contrasts in schizophrenia.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Cerebrovascular Circulation; Excitatory Amino Aci | 2001 |
[Manic syndrome: diagnostic trends and principles of treatment].
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Chl | 1998 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Compliance; Research Support as Topic; Risperidon | 2002 |
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].
Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Female; Haloperidol; | 2001 |
Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia.
Topics: 5' Flanking Region; Adenine; Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP1A2; Cytosine; E | 2002 |
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Female; Ha | 2001 |
Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.
Topics: Adult; Aged; Alanine; Animals; Antipsychotic Agents; Aspartic Acid; Biogenic Polyamines; Female; Gen | 2002 |
Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Polysomnography; Psychi | 2002 |
Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study.
Topics: Adult; Aged; Antipsychotic Agents; Binding Sites; Binding, Competitive; Butaclamol; Down-Regulation; | 2002 |
Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Female; Fingers; | 2002 |
The characteristics of side-effects of bromperidol in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dystonia; Female; Haloperidol; Humans; Hypokinesia; Male; Schizophrenia | 2002 |
Functional brain asymmetry and attentional modulation in young and stabilised schizophrenic patients: a dichotic listening study.
Topics: Adult; Antipsychotic Agents; Attention; Cerebral Cortex; Dichotic Listening Tests; Dominance, Cerebr | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Dropouts; Risperidone; Schizophrenia; Secondary P | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Hyperkinesis; Psychomotor Agitation; Risperidone; Schizop | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Compliance; Risperidone; Schizophrenia; Secondary | 2002 |
Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Clozapine; Dopamine; Dopamine Agents; Dose-Response | 2002 |
Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study.
Topics: Adult; Basal Ganglia; Benzodiazepines; Cerebellum; Cerebral Cortex; Female; Haloperidol; Humans; Lin | 2002 |
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Schizophrenia; Statistics, Nonpara | 2002 |
Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Catheters, Indwelling; Corpus Striatum; Delayed-Action Preparations; | 2002 |
Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Brain Chemistry; Clozapine; Dopamine; Dopamine Ag | 2001 |
Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
Topics: Antipsychotic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Adminis | 2002 |
Switching to amisulpride due to hepatic complications.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Flupenthixol; Halo | 2002 |
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Models, Animal; Haloperidol; Hipp | 2002 |
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clomipramine; Clozapine; Haloperidol; | 2002 |
Sexual side effects of novel antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Clozapine; Erectile Dysfunction; Fluphenazine; Haloperidol; Humans; Mal | 2002 |
Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Clozapine; Disease Models, Animal; Dose-Response Rel | 2002 |
Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Clozapine; DNA-Binding Proteins; Drug Administration Schedule; Gene E | 2002 |
Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Topics: Adult; Aged; Female; Haloperidol; Humans; Middle Aged; Prolactin; Risperidone; Schizophrenia; Statis | 2002 |
[The contribution of drug research to the understanding of schizophrenia].
Topics: Adult; Amphetamines; Animals; Antipsychotic Agents; Baclofen; Chlorpromazine; Corpus Striatum; Dopam | 1975 |
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Binding, Competitive; Butyrophenones; Corpus Stria | 1976 |
Letter: Dosage of antipsychotic drugs.
Topics: Antipsychotic Agents; Haloperidol; Humans; Schizophrenia | 1976 |
Somatic profiles in chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Folic Acid Deficiency; Haloperidol; Humans; Hypoglycemia; Hyp | 1976 |
Drugs for psychiatric disorders.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; | 1976 |
Sedative, hypnotic, and antipsychotic effects of low doses of apomorphine in man.
Topics: Adolescent; Adult; Antipsychotic Agents; Apomorphine; Bipolar Disorder; Drug Interactions; Female; H | 1977 |
Prolactin responses to neuroleptics in normal and schizophrenic subjects.
Topics: Chlorpromazine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Tolerance; Haloperidol; | 1978 |
Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Clozapine; Conditioning, Operant; De | 1977 |
Acutely disturbed psychotic patients treated with parenteral haloperidol.
Topics: Acute Disease; Adult; Aged; Female; Haloperidol; Humans; Infusions, Parenteral; Male; Middle Aged; P | 1978 |
The treatment of severely depressed schizophrenic patients.
Topics: Acute Disease; Antipsychotic Agents; Delayed-Action Preparations; Depression; Electroconvulsive Ther | 1978 |
Long term treatment of tardive dyskinesia.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesi | 1979 |
Do anticholinergic antagonize antipsychotic drug action?
Topics: Antipsychotic Agents; Brain; Chlorpromazine; Choline O-Acetyltransferase; Dopamine; Factor Analysis, | 1978 |
Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptics in schizophrenia. Implications for a neuropharmacological model.
Topics: Antiparkinson Agents; Antipsychotic Agents; Benztropine; Chlorpromazine; Drug Therapy, Combination; | 1979 |
Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Biopharmaceutics; Chronic Disease; Dose-Response Relationship, Drug; Er | 1979 |
Urinary incontinence in patients receiving neuroleptics.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Brain; Chlorpromazine; Female; Fluphenazine; | 1979 |
[Norepinephrine turnover under neuroleptic treatment of schizophrenic syndromes (author's transl)].
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Haloperidol; Humans; Methoxyhydroxyp | 1978 |
Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
Topics: Adult; Antipsychotic Agents; Anxiety; Arousal; Autonomic Nervous System; Basal Ganglia Diseases; Chl | 1979 |
The effect of antipsychotic drugs on body weight: a retrospective review.
Topics: Antipsychotic Agents; Body Weight; Fluphenazine; Haloperidol; Humans; Loxapine; Schizophrenia; Thior | 1979 |
Normal prolactin responses in tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Prola | 1979 |
Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Drug Therapy, Combination | 1979 |
[The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients].
Topics: Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; | 1979 |
Dopamine and schizophrenia. A therapy revisited and revised.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Astrocytes; Cattle; Caudate Nucleus; Cyclic | 1978 |
Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man.
Topics: Adult; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Neurosecretory Systems | 1979 |
Neuroendocrine effects of haloperidol therapy in chronic schizophrenia.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adrenocorticotropic Hormone; Adult; Blood Gl | 1975 |
Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency.
Topics: Chlorpromazine; Dopamine; Dose-Response Relationship, Drug; Fluphenazine; Haloperidol; Humans; Male; | 1977 |
A peptide-containing fraction in the urine of schizophrenic patients which stimulates opiate receptors and inhibits dopamine uptake.
Topics: Adult; Animals; Brain; Chromatography, Gel; Dopamine; Dopamine Antagonists; Drug Tolerance; Female; | 1979 |
Clinical significance of monitoring plasma levels of psychotropic drugs.
Topics: Adult; Child; Chronic Disease; Clomipramine; Haloperidol; Humans; Mental Disorders; Parasympatholyti | 1979 |
Haloperidol in normals.
Topics: Cognition; Emotions; Haloperidol; Humans; Schizophrenia | 1977 |
Effect of neuroleptic treatment in schizophrenia on the electroretinogram, electrooculogram, and color vision.
Topics: Adenylyl Cyclase Inhibitors; Haloperidol; Humans; Retina; Schizophrenia | 1979 |
[The effects of thioridazine, flupenthixol and haloperidol on serum catalase activity in schizophrenia].
Topics: Adult; Catalase; Female; Flupenthixol; Haloperidol; Humans; Male; Middle Aged; Schizophrenia; Statis | 1977 |
Tardive dyskinesia in young adults.
Topics: Adult; Age Factors; Dyskinesia, Drug-Induced; Haloperidol; Humans; Long-Term Care; Male; Schizophren | 1977 |
Drug-induced EEG changes studied on two-dimensional rectangular coordinates using principal component analysis.
Topics: Adult; Amitriptyline; Chlorpromazine; Computers; Diazepam; Electroencephalography; Haloperidol; Huma | 1979 |
Cognitive abnormality in schizophrenia: a dual-process model.
Topics: Adolescent; Adult; Arousal; Attention; Chlorpromazine; Cognition Disorders; Color Perception; Concep | 1979 |
Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
Topics: Aged; Ambulatory Care; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Injec | 1979 |
Benzodiazepines in chronic schizophrenia.
Topics: Adult; Diazepam; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; | 1979 |
Schizophrenia: glutens and neuroleptics.
Topics: Glutens; Haloperidol; Humans; Intestinal Absorption; Schizophrenia | 1979 |
Emergency use of intravenous haloperidol.
Topics: Adult; Bipolar Disorder; Emergency Services, Psychiatric; Female; Hallucinations; Haloperidol; Human | 1979 |
Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: growth hormone and prolactin response to stimuli.
Topics: Adult; Female; Growth Hormone; Haloperidol; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Prola | 1979 |
Pathophysiological studies on schizophrenia with special reference to homovanillic acid concentration in cerebrospin fluid.
Topics: Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Phenylacetates; Schizophren | 1979 |
Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
Topics: Adult; Apomorphine; Cyproheptadine; Growth Hormone; Haloperidol; Humans; Male; Pituitary Gland, Ante | 1979 |
[Influence of extrapyramidal disorders induced by haloperidol on phenamine stereotypy and the effects of schizophrenic patients' serum (experimental study)].
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Behavior; Behavior, Animal; Haloperidol; Humans; Immun | 1977 |
Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia?
Topics: Animals; Behavior; Dextroamphetamine; Disease Models, Animal; Haloperidol; Humans; Male; Phenethylam | 1977 |
[Pathogenesis of stereotyped behavior].
Topics: Animals; Behavior; Caudate Nucleus; Diazepam; Disease Models, Animal; gamma-Aminobutyric Acid; Halop | 1979 |
Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Chemical Phenomena; Chemistry; Drug Evaluation; Fem | 1978 |
Protracted vomiting following abrupt cessation of psychotropics: a case report.
Topics: Adult; Benztropine; Depression; Drug Therapy, Combination; Haloperidol; Humans; Imipramine; Male; Sc | 1978 |
Serum dopamine-beta-hydroxylase in schizophrenic patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Chlorpromazine; Dopamine beta-Hydroxylase; Haloperidol; | 1978 |
Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains.
Topics: Adult; Aged; Apomorphine; Brain; Butyrophenones; Caudate Nucleus; Cerebral Cortex; Female; Haloperid | 1978 |
Thrombocytopenia in the absence of leukopenia associated with the use of neuroleptics.
Topics: Adult; Benztropine; Chlorpromazine; Haloperidol; Humans; Male; Perphenazine; Schizophrenia; Thalasse | 1978 |
[Updating haloperidol: 1975].
Topics: Chlorpromazine; Haloperidol; Humans; Schizophrenia | 1978 |
Serum prolactin and clinical state during neuroleptic treatment and withdrawal.
Topics: Adult; Alcoholism; Haloperidol; Humans; Hysteria; Male; Middle Aged; Prolactin; Psychiatric Status R | 1979 |
Cardiovascular safety of rapid treatment with intramuscular haloperidol.
Topics: Adult; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; H | 1979 |
The computer diagnosis in a multicenter study of psychoactive agents.
Topics: Adult; Aged; Diagnosis, Computer-Assisted; Haloperidol; Humans; Middle Aged; Schizophrenia; Sulpirid | 1976 |
Serum dopamine-beta-hydroxylase in psychiatric patients and normals. Effect of d-amphetamine and haloperidol.
Topics: Depression; Dextroamphetamine; Dopamine beta-Hydroxylase; Haloperidol; Humans; Mental Disorders; Sch | 1976 |
Patterns of violent behavior among schizophrenic inpatients.
Topics: Adult; Age Factors; Chlordiazepoxide; Chlorpromazine; Electroshock; Female; Haloperidol; Humans; Len | 1977 |
A positive response to rapid treatment.
Topics: Adult; Chronic Disease; Haloperidol; Humans; Male; Schizophrenia | 1977 |
Questions about rapid treatment.
Topics: Acute Disease; Bipolar Disorder; Emergency Service, Hospital; Female; Haloperidol; Humans; Psychotic | 1977 |
Psychotolysis with haloperidol. Rapid control of the acutely disturbed psychotic patient.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Conflict, Psychological; Female; Hallucina | 1977 |
Acute hypertension after abrupt withdrawal of antipsychotic medication.
Topics: Adolescent; Benztropine; Fluphenazine; Haloperidol; Humans; Hypertension; Male; Schizophrenia; Subst | 1977 |
Influence of the antiparkinsonian drugs on the plasma level of neuroleptics.
Topics: Adult; Antiparkinson Agents; Chlorpromazine; Drug Therapy, Combination; Female; Haloperidol; Humans; | 1977 |
Schizophrenia in a 46,XY male with the Noonan syndrome.
Topics: Adult; Electroencephalography; Haloperidol; Humans; Male; Phenotype; Psychological Tests; Schizophre | 1977 |
Clinical study with bromperidol, a new butyrophenone derivative.
Topics: Adult; Bromine; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1977 |
Evidence for dopamine receptors in the human brain mediating sedation and sleep.
Topics: Adult; Apomorphine; Brain; Female; Haloperidol; Humans; Hypnotics and Sedatives; Male; Receptors, Do | 1977 |
[Long-term treatment with neuroleptics in schizophrenic and paraphrenic psychoses].
Topics: Delayed-Action Preparations; Depressive Disorder, Major; Fluphenazine; Haloperidol; Humans; Schizoph | 1977 |
Catatonic reactions to high-potency neuroleptic drugs.
Topics: Adolescent; Adult; Amantadine; Catatonia; Dose-Response Relationship, Drug; Female; Fluphenazine; Ha | 1977 |
Inappropriate ADH secretion.
Topics: Haloperidol; Humans; Schizophrenia; Syndrome; Thioridazine; Vasopressins | 1977 |
A possible subgroup of the schizophrenic syndrome and implications for treatment.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Diazepam; Dominance, Cerebral; Dys | 1976 |
[Usefulness for differential diagnosis of the distribution of extrapyramidal symptoms resulting from neuroleptic therapy in psychiatric practice].
Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Diagnosis, Differential; Female; Functional Lateral | 1976 |
[Significance and advantages of Orap in the ambulatory care of schizophrenic psychoses].
Topics: Adolescent; Adult; Aged; Ambulatory Care; Cyclothymic Disorder; Depression; Depressive Disorder, Maj | 1976 |
Antipsychotic drug doses and neuroleptic/dopamine receptors.
Topics: Animals; Binding, Competitive; Cattle; Caudate Nucleus; Dopamine; Haloperidol; Humans; Rats; Recepto | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
Topics: Adult; Female; Hallucinations; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1976 |
[Use of haloperidol at very high doses].
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; | 1976 |
On some mechanisms of haloperidol and chlorpromazine effect [proceedings].
Topics: Cell Nucleus; Chlorpromazine; Haloperidol; Humans; Leukocytes; Schizophrenia | 1976 |
Diazepam in the treatment of tardive dyskinesia. Preliminary observations.
Topics: Adult; Chlorpromazine; Diazepam; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Schizo | 1976 |
Haloperidol update: 1975.
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Mental Disorders; Parkinson D | 1976 |
[Clinical study of Haldol at high doses in chronic schizophrenia].
Topics: Adult; Affect; Aged; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Age | 1976 |
[Biochemical studies of schizophrenia].
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Brain; Dopamine; Haloperidol; Humans; Parkinson Disease; S | 1976 |
Adverse reactions in treatment with lithium carbonate and haloperidol.
Topics: Affective Symptoms; Bipolar Disorder; Drug Synergism; Female; Fever; Haloperidol; Humans; Lithium; M | 1976 |
Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
Topics: Animals; Binding Sites; Corpus Striatum; Dopamine; Haloperidol; Humans; Male; Rats; Receptors, Drug; | 1975 |
Letter: Aspiration pneumonia.
Topics: Adult; Foreign-Body Reaction; Haloperidol; Humans; Male; Pneumonia, Aspiration; Schizophrenia | 1976 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Atypical tardive dyskinesia.
Topics: Adult; Age Factors; Benztropine; Haloperidol; Humans; Male; Movement Disorders; Remission, Spontaneo | 1975 |
Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Electric Stimul | 1975 |
Dopamine-sensitive adenylyl cyclase in human caudate nucleus. A study in control subjects and schizophrenic patients.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Animals; Autopsy; Carbon Radioisotopes; Caudate Nucleus; | 1975 |
Platelet monoamine oxidase activity during the course of a schizophreniform psychosis.
Topics: Blood Platelets; Cognition Disorders; Delusions; Emotions; Hallucinations; Haloperidol; Humans; Male | 1975 |
Technique of fluphenazine decanoate therapy in acute schizophrenic illnesses.
Topics: Acute Disease; Ambulatory Care; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluphen | 1975 |
Glucose-insulin metabolism in chronic schizophrenia.
Topics: Adult; Chronic Disease; Diabetes Complications; Female; Glucose; Glucose Tolerance Test; Haloperidol | 1975 |
Growth hormone secretion in chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Female; Growth Hormone; Haloperidol; Humans; Insulin; Male; Midd | 1975 |
Glucose-insulin metabolism in chronic schizophrenia.
Topics: Adult; Blood Glucose; Diabetes Complications; Glucose; Glucose Tolerance Test; Haloperidol; Humans; | 1976 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloper | 1976 |
[Predicting the effects of haloperidol on schizophrenics by quantitative pharmaco-EEG].
Topics: Adolescent; Adult; Electroencephalography; Female; Haloperidol; Humans; Male; Prognosis; Schizophren | 1992 |
Use of pimozide in the Pisa syndrome.
Topics: Adult; Dystonia; Haloperidol; Humans; Male; Pimozide; Receptors, Opioid; Receptors, sigma; Schizophr | 1992 |
Lowest effective dose of depot neuroleptics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationsh | 1992 |
Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Combined Modality Therapy; Dose-Response Relationship | 1992 |
Increased turnover of platelet phosphatidylinositol in schizophrenia.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Haloperidol; Humans; Hydrolysis; Inositol; Male; Middl | 1992 |
EEG-brain mapping. A method to optimize therapy in schizophrenics using absolute power and center frequency values.
Topics: Adult; Alpha Rhythm; Antipsychotic Agents; Brain Mapping; Cerebral Cortex; Dominance, Cerebral; Dose | 1992 |
Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
Topics: Adult; Antipsychotic Agents; Benztropine; Chlorpromazine; Dose-Response Relationship, Drug; Dyskines | 1992 |
Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Dopamine; Haloperidol; Humans; Huntington Disease | 1992 |
Coping style and cognitive dysfunction in schizophrenic patients.
Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Arousal; Attention; Chronic Disease; D | 1992 |
Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
Topics: Adult; Chromatography, High Pressure Liquid; Haloperidol; Humans; Middle Aged; Psychiatric Status Ra | 1992 |
Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Female; Hair; Haloperidol; | 1992 |
5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Buspirone; Dose-Response Rela | 1992 |
Shifts in covert visual attention in schizophrenic patients and normal controls.
Topics: Arousal; Attention; Clozapine; Haloperidol; Humans; Orientation; Psychiatric Status Rating Scales; P | 1992 |
Acutely administered haloperidol-induced pattern changes of regional cerebral blood flow in schizophrenics. Observation from subtraction of brain imaging with single photon emission computed tomography using technetium-99m hexamethyl-propyleneamine oxime.
Topics: Acute Disease; Adult; Brain; Cerebral Cortex; Dose-Response Relationship, Drug; Female; Haloperidol; | 1992 |
Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment.
Topics: Adult; Brain Mapping; Electroencephalography; Female; Haloperidol; Humans; Male; Schizophrenia; Sign | 1992 |
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Topics: Administration, Oral; Adult; Brain; Dopamine; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Ps | 1992 |
The effect of haloperidol on aldosterone secretion.
Topics: Adult; Aldosterone; Haloperidol; Humans; Infusions, Intravenous; Male; Middle Aged; Prolactin; Schiz | 1992 |
Alopecia and mood stabilizers: two case reports.
Topics: Adult; Alopecia; Carbamazepine; Clorazepate Dipotassium; Depressive Disorder; Female; Fluvoxamine; H | 1992 |
Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients.
Topics: Adult; Diagnosis, Differential; Haloperidol; Hospitalization; Hospitals, Psychiatric; Humans; Inject | 1992 |
CSF noradrenergic activity and sleep EEG in clinically stable schizophrenic patients after haloperidol withdrawal.
Topics: Adult; Dopamine beta-Hydroxylase; Electroencephalography; Haloperidol; Humans; Methoxyhydroxyphenylg | 1992 |
Seizure with low doses of clozapine.
Topics: Basal Ganglia Diseases; Clozapine; Haloperidol; Schizophrenia; Schizophrenic Psychology; Seizures | 1992 |
NMS complicated by diazepam.
Topics: Aged; Coma; Diazepam; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Risk Factors; Schiz | 1992 |
Cycloid psychosis: regional cerebral blood flow correlates of a psychotic episode.
Topics: Adult; Aged; Bipolar Disorder; Blood Flow Velocity; Cerebral Cortex; Chlorpromazine; Dominance, Cere | 1992 |
Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.
Topics: Chromatography, High Pressure Liquid; Delayed-Action Preparations; Erythrocytes; Haloperidol; Humans | 1992 |
Fluid intake patterns in schizophrenia and normal controls.
Topics: Adult; Creatinine; Drinking Behavior; Female; Haloperidol; Humans; Male; Schizophrenia; Schizophreni | 1992 |
Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol-treated schizophrenic patients.
Topics: Adolescent; Adult; beta-Endorphin; Cholecystokinin; Female; Haloperidol; Humans; Male; Monocytes; Ps | 1992 |
The "social chemistry" of pharmacological discovery: the haloperidol story. An interview with Dr. Paul Janssen, January 21, 1986. Interview by Stanley Einstein.
Topics: Animals; Female; Hallucinations; Haloperidol; Humans; Male; Rats; Schizophrenia; Schizophrenic Psych | 1992 |
Drug-responsive symptoms during early neuroleptic treatment.
Topics: Adult; Benztropine; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Th | 1992 |
Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
Topics: Administration, Oral; Adult; Biological Availability; China; Chromatography, High Pressure Liquid; H | 1992 |
Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
Topics: Black or African American; Black People; China; Chromatography, Liquid; Ethnicity; Haloperidol; Hisp | 1992 |
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Topics: Adult; Aged; Apomorphine; Brain; Dyskinesia, Drug-Induced; Haloperidol; Homovanillic Acid; Humans; M | 1992 |
Prolactin bioassay in schizophrenia before and after neuroleptics.
Topics: Adult; Biological Assay; Dose-Response Relationship, Drug; Fluphenazine; Haloperidol; Humans; Male; | 1992 |
Haloperidol induced CSF protein variations in schizophrenic patients: as studied by two-dimensional electrophoresis.
Topics: Adult; Cerebrospinal Fluid Proteins; Electrophoresis, Gel, Two-Dimensional; Haloperidol; Humans; Mal | 1992 |
Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F]haloperidol.
Topics: Adult; Animals; Brain; Fluorine Radioisotopes; Haloperidol; Humans; Male; Mice; Schizophrenia; Spipe | 1992 |
[A feverish psychotic].
Topics: Adult; Chlorpromazine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Schizophrenia | 1992 |
Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
Topics: Adult; Delta Rhythm; Electroencephalography; Female; Haloperidol; Humans; Male; Middle Aged; Recurre | 1992 |
Somatostatin-like immunoreactivity in CSF in schizophrenic patients during haloperidol treatment.
Topics: Adult; Aged; Female; Haloperidol; Humans; Male; Middle Aged; Peptides; Reference Values; Schizophren | 1992 |
Evidence of glutamatergic deficiency in schizophrenia.
Topics: Aged; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Glutamate De | 1991 |
[Drug treatment of schizophrenic patients].
Topics: Antipsychotic Agents; Depression; Haloperidol; Humans; Patient Compliance; Psychotherapy; Schizophre | 1991 |
Reduced lymphocyte response to PHA and OKT3 in drug-free and neuroleptic-treated chronic schizophrenics.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Electroconvulsive | 1991 |
Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese.
Topics: Adult; Asian People; China; Female; Haloperidol; Humans; Male; Oxidation-Reduction; Schizophrenia; T | 1991 |
Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Topics: Antipsychotic Agents; Chronic Disease; Female; Follow-Up Studies; Haloperidol; Humans; Ireland; Male | 1991 |
Effect of haloperidol decanoate on the cardiovascular system.
Topics: Adult; Antipsychotic Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiography; | 1991 |
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.
Topics: Antipsychotic Agents; Chronic Disease; Cohort Studies; Haloperidol; Humans; Male; Risk Factors; Schi | 1991 |
Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
Topics: Acute Disease; Adult; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methox | 1990 |
The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness.
Topics: Adult; Antigens, Differentiation; Antipsychotic Agents; CD5 Antigens; Clozapine; Female; Fluphenazin | 1991 |
CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
Topics: Adult; Arousal; Atrophy; Brain; Chromogranin A; Chromogranins; Haloperidol; Homovanillic Acid; Human | 1991 |
Pretreatment EEG predicts short-term response to haloperidol treatment.
Topics: Adult; Electroencephalography; Haloperidol; Humans; Psychiatric Status Rating Scales; Psychometrics; | 1991 |
An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia.
Topics: Age Factors; Animals; Apomorphine; Catalepsy; Estradiol; Female; Haloperidol; Male; Rats; Receptors, | 1991 |
Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients.
Topics: Adolescent; Adult; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Halop | 1991 |
Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia.
Topics: Adult; Arousal; Chlorpromazine; Delusions; Female; Hallucinations; Haloperidol; Humans; Male; Psychi | 1991 |
Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Haloperidol; Humans; Male; Mass Spectrometry; M | 1991 |
Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.
Topics: Adult; Basal Ganglia; Blood Glucose; Brain; Brain Mapping; Chronic Disease; Dose-Response Relationsh | 1991 |
Switching haloperidol from oral to im depot formulation.
Topics: Administration, Oral; Biological Availability; Chronic Disease; Dosage Forms; Dose-Response Relation | 1991 |
CEEG mapping in drug-free schizophrenics. Differences from healthy subjects and changes induced by haloperidol treatment.
Topics: Adult; Brain Mapping; Cerebral Cortex; Chronic Disease; Dose-Response Relationship, Drug; Electroenc | 1991 |
[Clinical study of intractable mental diseases].
Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder; Electroencephalography; Epilepsy; Fem | 1991 |
Visual dysfunction in treated schizophrenia suggested by visual evoked potentials from pattern-reversal stimulation.
Topics: Adult; Biperiden; Drug Therapy, Combination; Electroencephalography; Evoked Potentials, Visual; Fema | 1991 |
A new approach to dose reduction in chronic schizophrenia.
Topics: Adult; Aged; Bromocriptine; Chronic Disease; Dose-Response Relationship, Drug; Growth Hormone; Halop | 1991 |
Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol.
Topics: Adult; Aged; Brain Chemistry; Clozapine; Female; Fluorine Radioisotopes; Glucose; Haloperidol; Human | 1991 |
Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance.
Topics: Adult; Arousal; Attention; Auditory Perception; Benztropine; Female; Haloperidol; Humans; Male; Neur | 1991 |
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study.
Topics: Acute Disease; Adult; Ambulatory Care; Clozapine; Haloperidol; Hospitalization; Humans; Male; Psychi | 1991 |
Haloperidol reductase activity in red blood cells from oriental patients on haloperidol.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Erythrocytes; Female; Haloperidol; Humans; Male; Middle | 1991 |
Abnormal growth of skin fibroblasts from schizophrenic patients.
Topics: Adolescent; Adult; Biopsy; Cell Division; Cells, Cultured; Female; Fibroblasts; Haloperidol; Humans; | 1991 |
Cold agglutinin autoantibodies in psychiatric patients: their relation to diagnosis and pharmacological treatment.
Topics: Adult; Age Factors; Agglutinins; Autoantibodies; Bipolar Disorder; Cryoglobulins; Depressive Disorde | 1991 |
Sleep onset REM periods in schizophrenic patients.
Topics: Adult; Cerebral Cortex; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Sc | 1991 |
Ethnicity and family involvement in the treatment of schizophrenic patients.
Topics: Asia; Caregivers; Cross-Cultural Comparison; Emigration and Immigration; Ethnicity; Family; Female; | 1991 |
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Topics: Administration, Oral; Adult; Chronic Disease; Depression, Chemical; Dopamine; Dopamine Antagonists; | 1991 |
Time course and clinical predictors of treatment response in schizophrenia.
Topics: Adult; Analysis of Variance; Haloperidol; Humans; Male; Middle Aged; Prognosis; Schizophrenia; Schiz | 1991 |
Tc-99m HMPAO SPECT analysis of neuroleptic effects on regional brain function.
Topics: Adult; Brain; Female; Haloperidol; Humans; Male; Organotechnetium Compounds; Oximes; Schizophrenia; | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Haloperidol and lithium carbonate treatment did not influence serum immunoglobulin levels in schizophrenic and affective patients.
Topics: Adolescent; Adult; Bipolar Disorder; Chronic Disease; Depressive Disorder; Female; Haloperidol; Huma | 1991 |
Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response.
Topics: Adult; Cholecystokinin; Female; Haloperidol; Humans; Lithium; Male; Psychiatric Status Rating Scales | 1991 |
Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Mi | 1990 |
A role for high-dose antipsychotics.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Antipsychotic drug action associated with synthesis of a lymphocyte protein.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Humans; Lymphocytes; Male; Peptide | 1990 |
Neuroleptic malignant syndrome with renal and respiratory complications--a case report.
Topics: Acute Kidney Injury; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndro | 1990 |
Prevalence of neuroleptic-induced dystonia in mania and schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug | 1990 |
The rabbit syndrome.
Topics: Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Movement Disorders; Schizophre | 1990 |
Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients.
Topics: Activities of Daily Living; Acute Disease; Adult; Antipsychotic Agents; Dopamine beta-Hydroxylase; D | 1990 |
EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol.
Topics: Adult; Antipsychotic Agents; Behavior; Benzamides; Brain Mapping; Electroencephalography; Female; Ha | 1990 |
Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
Topics: Adult; Female; Haloperidol; Homovanillic Acid; Humans; Lithium; Male; Middle Aged; Neurotensin; Psyc | 1991 |
Prolactin responses to haloperidol in drug-free and treated schizophrenic patients.
Topics: Adult; Haloperidol; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Prolactin; Receptors, | 1991 |
Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
Topics: Adult; Aged; Basal Ganglia Diseases; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetin | 1991 |
Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Topics: Adult; Animals; Biotransformation; Corpus Striatum; Dose-Response Relationship, Drug; Guinea Pigs; H | 1991 |
[3H]ditolylguanidine binding to human brain sigma sites is diminished after haloperidol treatment.
Topics: Binding Sites; Brain; Guanidines; Haloperidol; Humans; Schizophrenia; Tritium | 1991 |
Effect of clozapine on psychogenic polydipsia in chronic schizophrenia.
Topics: Adult; Clozapine; Drinking; Haloperidol; Humans; Loxapine; Male; Psychiatric Status Rating Scales; S | 1991 |
High-performance liquid chromatography of droperidol in whole blood.
Topics: Adult; Chromatography, High Pressure Liquid; Droperidol; Haloperidol; Humans; Hydrogen-Ion Concentra | 1990 |
Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Mal | 1990 |
Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism.
Topics: Adult; Bipolar Disorder; Blood Pressure; Depressive Disorder; Down-Regulation; Feedback; Female; Hal | 1990 |
Association of high prolactin levels and neuroleptics immediately postpartum.
Topics: Adult; Female; Haloperidol; Humans; Hyperplasia; Hyperprolactinemia; Pituitary Gland; Prolactin; Pue | 1990 |
C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment.
Topics: Adult; Brain Mapping; Electroencephalography; Female; Haloperidol; Humans; Male; Psychiatric Status | 1990 |
D2 receptor occupancy and plasma concentration of antipsychotics.
Topics: Brain; Haloperidol; Humans; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia | 1990 |
Drug-induced pneumonitis associated with haloperidol. A case report.
Topics: Adult; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Pulmonary | 1990 |
The influence of cigarette smoking on haloperidol pharmacokinetics.
Topics: Adult; Female; Half-Life; Haloperidol; Humans; Male; Prospective Studies; Schizophrenia; Schizophren | 1990 |
Correlates of rapid neuroleptic response in male patients with schizophrenia.
Topics: Adult; Haloperidol; Homovanillic Acid; Humans; Male; Neuropsychological Tests; Psychiatric Status Ra | 1990 |
Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
Topics: Adult; Affective Disorders, Psychotic; Female; Haloperidol; Humans; Prolactin; Psychiatric Status Ra | 1990 |
Increase of spontaneous blink associated with extrapyramidal side effects: a case report.
Topics: Blinking; Chronic Disease; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Schiz | 1990 |
Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.
Topics: Adult; Bipolar Disorder; Haloperidol; Humans; Male; Prolactin; Psychiatric Status Rating Scales; Psy | 1990 |
Measurement of haloperidol reductase activity in red blood cells and reduced haloperidol/haloperidol ratios in plasma in oriental psychiatric patients.
Topics: Adult; Alcohol Oxidoreductases; Delusions; Erythrocytes; Female; Haloperidol; Humans; Kinetics; Male | 1990 |
Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics.
Topics: Adult; Affective Disorders, Psychotic; Age Factors; Cerebral Ventricles; Cerebral Ventriculography; | 1990 |
Blink rate response to haloperidol as possible predictor of therapeutic outcome.
Topics: Adult; Blinking; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Prognosi | 1990 |
Length of psychiatric hospitalization and prediction of antipsychotic response.
Topics: Fluphenazine; Hallucinations; Haloperidol; Hospitalization; Humans; Length of Stay; Prognosis; Schiz | 1990 |
Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
Topics: Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Mi | 1990 |
A case study: schizophrenia and tactile hallucinations, treated with electroconvulsive therapy.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Delusions; Electroconvulsive Therapy; Hallucinati | 1990 |
Slower theta activity over the midfrontal cortex in schizophrenic patients.
Topics: Adult; Biperiden; Chronic Disease; Drug Therapy, Combination; Electroencephalography; Female; Fronta | 1990 |
HLA antigens in schizophrenia.
Topics: Dominance, Cerebral; Female; Gene Frequency; Genetic Linkage; Haloperidol; HLA-A Antigens; HLA-B Ant | 1990 |
Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.
Topics: Acute Disease; Adolescent; Adult; Brain; Haloperidol; Humans; Infusions, Intravenous; Male; Neurocog | 1990 |
[Possible involvement of phospholipase A2 in the pathogenesis of schizophrenia].
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Pancreas; Phospholipases; Phospholipases A; P | 1990 |
Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia.
Topics: Adult; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Psychometrics; Schizophr | 1990 |
Haloperidol-induced torsades de pointes.
Topics: Adult; Electrocardiography; Haloperidol; Humans; Male; Schizophrenia; Tachycardia | 1990 |
Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
Topics: Dose-Response Relationship, Drug; Half-Life; Haloperidol; Humans; Prospective Studies; Psychiatric S | 1990 |
Factors affecting the clinical response to haloperidol therapy in schizophrenia.
Topics: Adult; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Haloperidol; | 1990 |
Medication may be required for the development of automatic information processing in schizophrenia.
Topics: Adult; Attention; Benztropine; Discrimination Learning; Drug Therapy, Combination; Form Perception; | 1990 |
Longisectional interaction structure analysis (LISA) in psychopharmacology and developmental psychopathology.
Topics: Adolescent; Child; Developmental Disabilities; Drug Evaluation; Haloperidol; Humans; Longitudinal St | 1985 |
Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia.
Topics: Adult; Chronic Disease; Circadian Rhythm; Dopamine; Female; Haloperidol; Hospitalization; Humans; Hy | 1987 |
Neuroleptic malignant syndrome.
Topics: Amylases; Haloperidol; Humans; Lipase; Male; Middle Aged; Neuroleptic Malignant Syndrome; Schizophre | 1988 |
CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
Topics: Adult; Chromatography, High Pressure Liquid; Chronic Disease; Haloperidol; Homovanillic Acid; Humans | 1989 |
Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients.
Topics: Acute Disease; Adult; Dose-Response Relationship, Drug; Haloperidol; Humans; Luteinizing Hormone; Ma | 1989 |
[Severe late dyskinesia caused by neuroleptics in a young female. Follow-up and treatment].
Topics: Adolescent; Carbamazepine; Clozapine; Diagnosis, Differential; Dose-Response Relationship, Drug; Dru | 1989 |
Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers.
Topics: Adult; Carbon Radioisotopes; Clozapine; Corpus Striatum; Dibenzazepines; Frontal Lobe; Haloperidol; | 1989 |
Fluphenazine decanoate: a clinical problem?
Topics: Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Fluphenazine; Haloperidol; H | 1989 |
Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Topics: Adult; Alprazolam; Antipsychotic Agents; Basal Ganglia Diseases; Drug Synergism; Drug Therapy, Combi | 1989 |
Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
Topics: Adult; Antipsychotic Agents; Brain; Chronic Disease; Dyskinesia, Drug-Induced; Electroencephalograph | 1989 |
Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid.
Topics: Ascorbic Acid; Haloperidol; Humans; Male; Neurotransmitter Agents; Oxidation-Reduction; Psychiatric | 1989 |
Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Topics: Adult; Antipsychotic Agents; Brain; Female; Fluphenazine; Haloperidol; Humans; Male; Prolactin; Psyc | 1989 |
R-R interval during neuroleptic treatment.
Topics: Antipsychotic Agents; Chlorpromazine; Electrocardiography; Haloperidol; Humans; Methotrimeprazine; S | 1989 |
Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.
Topics: Adolescent; Adult; Cerebellum; Corpus Striatum; Dopamine Agents; Dopamine Antagonists; Fluorine Radi | 1989 |
Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; F | 1989 |
Electroencephalographic changes and other indices of neurotoxicity with haloperidol-lithium therapy.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Brain; Dyskinesia, Drug-Induced; Electroencephalograp | 1989 |
RBC and plasma choline in neuroleptic-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Brain; Choline; Chronic Disease; Erythrocytes; Female; Haloperidol; Hum | 1989 |
Pharmacokinetic properties of haloperidol decanoate.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Humans; Schizophrenia | 1989 |
Haloperidol decanoate in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Sc | 1989 |
Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Blood-Brain Barrier; Brain; Chlorpromazine; Fluphenazine; Haloper | 1989 |
Clinical predictors of schizophrenic patient response to neuroleptics.
Topics: Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, Drug; Double-Blind Method; Halope | 1989 |
Incisive neuroleptic drugs in child psychiatry.
Topics: Antipsychotic Agents; Child; Child Psychiatry; Haloperidol; Humans; Obsessive-Compulsive Disorder; P | 1989 |
HLA antigens and neuroleptic response in clinical subtypes of schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Chromosome Mapping; Female; Gene Frequency; Haloperidol; HLA-A | 1989 |
Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antipsychotic Agents; Chronic Disease; Dopamine; Female; Halo | 1985 |
Hydroxyhaloperidol and clinical outcome in schizophrenia.
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; | 1989 |
Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients.
Topics: Adult; Asian People; Basal Ganglia Diseases; China; Female; Haloperidol; Humans; Male; Middle Aged; | 1989 |
Comparison of untreated and treated schizophrenic patients, normals, and neuroleptic-treated normals: "hypofrontality" and different EEG spectra before and during voluntary movement.
Topics: Alpha Rhythm; Biperiden; Electroencephalography; Frontal Lobe; Haloperidol; Humans; Motor Activity; | 1989 |
Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Basal Ganglia Diseases; Benztropine; Chronic Disease; Cognitio | 1989 |
Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
Topics: Adult; Aged; Female; Haloperidol; Humans; Male; Middle Aged; Orphenadrine; Parkinson Disease, Second | 1989 |
Longitudinal study of the effect, tolerance and undesired side effects of injection haloperidol decanoate applied in different psychiatric indications.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Longitudinal Studi | 1989 |
Substantial rise in sparteine metabolic ratio during haloperidol treatment.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia; Sparteine | 1989 |
Rebound psychoses following the discontinuation of a high potency neuroleptic.
Topics: Adult; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Psychoses, Substance-Induced; | 1989 |
Clinical implications of determination of plasma haloperidol levels.
Topics: Adult; Haloperidol; Humans; Psychiatric Status Rating Scales; Psychometrics; Schizophrenia; Schizoph | 1989 |
Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Infant; Infant, Newborn; Male; Neonata | 1989 |
Findings significant with respect to short- and medium-term outcome in schizophrenia--a preliminary report.
Topics: Emotions; Haloperidol; Humans; Prognosis; Psychological Tests; Schizophrenia; Schizophrenic Psycholo | 1989 |
[Sulpiride in psychiatric practice].
Topics: Anorexia Nervosa; Bulimia; Haloperidol; Humans; Schizophrenia; Sulpiride | 1989 |
Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance.
Topics: Adult; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Dyskinesia, Drug-Induced; Female; | 1989 |
A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
Topics: Adult; Asian People; Basal Ganglia Diseases; Drug Administration Schedule; Female; Haloperidol; Huma | 1989 |
Dopamine receptor occupancy and plasma haloperidol levels.
Topics: Brain; Haloperidol; Humans; Receptors, Dopamine; Schizophrenia; Tomography, Emission-Computed | 1989 |
Manners of arginine vasopressin secretion in schizophrenic patients--with reference to the mechanism of water intoxication.
Topics: Adult; Animals; Arginine Vasopressin; Chlorpromazine; Female; Haloperidol; Humans; Hyponatremia; Mal | 1989 |
Haloperidol decanoate.
Topics: Adult; Bipolar Disorder; Female; Haloperidol; Humans; Patient Compliance; Schizophrenia; Schizophren | 1989 |
Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Topics: Adolescent; Adult; Haloperidol; Humans; Male; Prolactin; Psychiatric Status Rating Scales; Radioimmu | 1989 |
Lack of effect of 28 days of neuroleptic treatment on platelet benzodiazepine binding sites in schizophrenics.
Topics: Adolescent; Adult; Blood Platelets; Female; Haloperidol; Humans; Isoquinolines; Male; Psychiatric St | 1987 |
Initial identification and characterization of sigma receptors on human peripheral blood leukocytes.
Topics: Animals; Guanidines; Haloperidol; Leukocytes; Lymphocyte Activation; Male; Phencyclidine; Rats; Rats | 1988 |
[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring].
Topics: Adult; Antipsychotic Agents; Drug Interactions; Female; Flupenthixol; Haloperidol; Humans; Kinetics; | 1985 |
The psychiatric intensive care unit.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Australia; Critical Care; Female; Halop | 1985 |
Acutely psychotic patients: a treatment approach.
Topics: Acute Disease; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Combined Modality Therapy; Do | 1985 |
Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Prognosis; Psychiatric Status Rating Scal | 1985 |
Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Tolerance; Female; Haloperidol; Humans; Male; Mid | 1985 |
Heatstroke in a chronic schizophrenic patient treated with high-potency neuroleptics.
Topics: Antipsychotic Agents; Benztropine; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, | 1985 |
[Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients].
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Haloperid | 1985 |
Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Topics: Administration, Oral; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response | 1985 |
[Psychopathometric study of the prognostic significance of psychopathologic findings and premorbid personality for discharge of neuroleptic treated patients with schizophrenic psychoses].
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Length of Stay; Paranoid Disorders; Personality Te | 1985 |
Early treatment events and prediction of response to neuroleptics in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Haloperidol; Humans; Middle Aged; Psychiatric Status Rating | 1985 |
Radio receptor assay of serum neuroleptic levels in psychiatric patients.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Halo | 1986 |
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Child; Chlorp | 1986 |
[Structure of the anxious-delusional syndrome of schizophrenic patients during treatment with anxiolytics].
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Benzodiazepinones; Clozapine | 1986 |
[Changes in the health state of schizophrenic patients in neuroleptic therapy].
Topics: Adolescent; Adult; Antipsychotic Agents; Attitude to Health; Clozapine; Dyskinesia, Drug-Induced; Ha | 1986 |
Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
Topics: Adult; Antipsychotic Agents; Caudate Nucleus; Haloperidol; Humans; Kinetics; Receptors, Dopamine; Re | 1986 |
Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study.
Topics: Antipsychotic Agents; Eye Movements; Haloperidol; Humans; Interviews as Topic; Nonverbal Communicati | 1986 |
Neuroleptic bioavailability, psychosocial factors, and clinical status: a 1-year study of schizophrenic outpatients after dose reduction.
Topics: Adult; Aged; Antipsychotic Agents; Biological Availability; Dose-Response Relationship, Drug; Halope | 1986 |
Haloperidol metabolism and antipsychotic effect in schizophrenia.
Topics: Adult; Haloperidol; Humans; Schizophrenia | 1987 |
Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Delayed-Action | 1986 |
Evaluation of optimal doses of a neuroleptic: preliminary results.
Topics: Analysis of Variance; Antipsychotic Agents; Haloperidol; Humans; Middle Aged; Schizophrenia | 1986 |
Cortical atrophy and white matter density in the brains of schizophrenics and clinical response to neuroleptics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Female; Haloperidol; Humans; Male; Middle Age | 1987 |
[Neuroleptic modification of basic schizophrenic disorders].
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Haloperidol; Humans; M | 1987 |
Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Schizophreni | 1987 |
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Brain; Carbon Radioisotopes; Dopamine Antagonists; Female; Haloperidol; | 1988 |
Comparative study of schizophrenic patients relapsed on and off medication.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Clozapine; Delayed-Action Preparations; Female; Haloper | 1987 |
Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Delayed-Action Preparations; Flupenthixol; | 1987 |
Effects of neuroleptic treatments on peripheral opioid secretion.
Topics: Adult; Antipsychotic Agents; beta-Endorphin; beta-Lipotropin; Chlorpromazine; Chronic Disease; Diben | 1987 |
Pisa syndrome. Report of a case.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Schiz | 1988 |
Certain neuroleptics reduce bone mineralization in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Bone and Bones; Calcium; Chlorpromazine; Chronic Disease; D | 1987 |
[A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
Topics: Acute Disease; Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Haloperidol; Humans; | 1988 |
Dyscognitive syndromes in neuroleptic therapy.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Haloperidol; Humans; Male; Psychiatric Sta | 1988 |
Outcome of treatment with haloperidol decanoate in a patient with schizophrenia, chronic undifferentiated type, and end stage renal disease.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Kidney Failure, Chronic; Male; Schizophrenia | 1988 |
Premorbid sociosexual functioning and long-term outcome in schizophrenia.
Topics: Adult; Aged; Brain; Cerebral Ventricles; Chronic Disease; Haloperidol; Humans; Longitudinal Studies; | 1989 |
Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Hospitalization; Humans; Male; | 1989 |
Visual contrast sensitivity in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Female; Fluspir | 1989 |
Positron tomographic quantitation of neuroreceptors in human brain in vivo--with special reference to the D2 dopamine receptors in caudate nucleus.
Topics: Adult; Caudate Nucleus; Cerebellum; Haloperidol; Humans; Male; Middle Aged; Models, Neurological; Re | 1987 |
Elevated D2 dopamine receptors in drug-naïve schizophrenics.
Topics: Brain; Haloperidol; Humans; Kinetics; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia | 1988 |
Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.
Topics: Adult; Binding, Competitive; Chlorpromazine; Corpus Striatum; Haloperidol; Humans; Male; Middle Aged | 1988 |
[Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia].
Topics: Adolescent; Adult; Aged; alpha-Tocopherol; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; | 1988 |
Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.
Topics: Adult; Female; Haloperidol; Humans; Male; Metabolic Clearance Rate; Middle Aged; Oxidation-Reduction | 1986 |
[A preliminary study on the measurements of microelements in the serum of schizophrenics].
Topics: Adult; Chlorpromazine; Copper; Haloperidol; Humans; Iron; Lithium; Lithium Carbonate; Male; Middle A | 1987 |
Serum lipids and lipoproteins in schizophrenic patients receiving major tranquilizers.
Topics: Adult; Chlorpromazine; Cholesterol; Drug Therapy, Combination; Female; Haloperidol; Humans; Hypercho | 1988 |
No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia.
Topics: Acetylcholinesterase; Adult; Corpus Striatum; Haloperidol; Humans; Male; Middle Aged; Receptors, Cho | 1988 |
Clonazepam-haloperidol therapy in schizophrenia.
Topics: Clonazepam; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Schizophrenia | 1988 |
[Use of evoked potentials in psychiatry. III. Evoked potentials and prediction of the effectiveness of psychopharmaceuticals].
Topics: Adolescent; Adult; Evoked Potentials, Auditory; Evoked Potentials, Visual; Haloperidol; Humans; Reac | 1988 |
Serum haloperidol concentration and clinical response in schizophrenia.
Topics: Adult; Female; Haloperidol; Humans; Male; Pilot Projects; Psychiatric Status Rating Scales; Schizoph | 1988 |
Urinary retention in the course of neuroleptic therapy with haloperidol.
Topics: Female; Haloperidol; Humans; Middle Aged; Schizophrenia; Urination Disorders | 1988 |
Treatment of chronic schizophrenic patients.
Topics: Chronic Disease; Haloperidol; Humans; Schizophrenia | 1988 |
CT scans and neuroleptic response in schizophrenia: a multidimensional approach.
Topics: Adult; Bromocriptine; Cerebral Cortex; Cerebral Ventricles; Drug Therapy, Combination; Female; Halop | 1988 |
Coprophagia in a schizophrenic patient: case report.
Topics: Adult; Combined Modality Therapy; Delusions; Electroconvulsive Therapy; Female; Hallucinations; Halo | 1988 |
Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences.
Topics: Adult; Female; Haloperidol; Humans; Male; Mass Spectrometry; Middle Aged; Prognosis; Schizophrenia | 1988 |
Resolution of chlorpromazine-induced pigmentation with haloperidol substitution.
Topics: Adult; Chlorpromazine; Female; Haloperidol; Humans; Male; Middle Aged; Pigmentation Disorders; Schiz | 1988 |
Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias).
Topics: Haloperidol; Humans; Lithium; Schizophrenia; Time Factors | 1988 |
The relationship of haloperidol concentrations to therapeutic response.
Topics: Adolescent; Adult; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; | 1988 |
Plasma homovanillic acid as a predictor of response to neuroleptics.
Topics: Adult; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Male; Probability; Psychiatric Stat | 1988 |
Plasma homovanillic acid levels and subtyping of schizophrenia.
Topics: Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; Prognosis; Sch | 1988 |
Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Topics: Dose-Response Relationship, Drug; Haloperidol; Humans; Schizophrenia | 1988 |
[Evoked potentials and the prediction of the efficacy of psychopharmaceutical agents].
Topics: Adolescent; Adult; Brain Stem; Drug Evaluation; Evoked Potentials, Auditory; Haloperidol; Humans; Mi | 1988 |
Changes in proton T1 in dog brains due to the administration of haloperidol.
Topics: Animals; Brain; Corpus Striatum; Dogs; Haloperidol; Magnetic Resonance Imaging; Schizophrenia; Thala | 1987 |
[Priapism in neuroleptic therapy].
Topics: Drug Therapy, Combination; Haloperidol; Humans; Male; Methotrimeprazine; Middle Aged; Priapism; Schi | 1987 |
Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
Topics: Adult; Debrisoquin; Drug Therapy, Combination; Haloperidol; Homovanillic Acid; Humans; Isoquinolines | 1987 |
Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
Topics: Animals; Delayed-Action Preparations; Dogs; Haloperidol; Humans; Schizophrenia | 1986 |
The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Female; Haloperidol; Humans; Male; Schizophreni | 1986 |
Schizophrenia, panic anxiety, and alprazolam.
Topics: Adult; Alprazolam; Anxiety Disorders; Drug Therapy, Combination; Fear; Haloperidol; Humans; Male; Pa | 1987 |
Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy.
Topics: Adult; Female; Haloperidol; Humans; Male; Neurocognitive Disorders; Phospholipases; Phospholipases A | 1987 |
Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients.
Topics: Adult; Chlorpromazine; Female; Haloperidol; Humans; Male; Schizophrenia; Vasopressins | 1987 |
Thrombocytopenia associated with chlorpromazine, haloperidol and thiothixene: a case report.
Topics: Chlorpromazine; Drug Therapy, Combination; Female; Haloperidol; Humans; Middle Aged; Platelet Count; | 1987 |
[Depressive syndromes within the scope of schizophrenic diseases].
Topics: Clozapine; Depressive Disorder; Haloperidol; Humans; Risk; Schizophrenia; Schizophrenic Psychology | 1986 |
Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping.
Topics: Adolescent; Adult; Benztropine; Chlorpromazine; Drug Therapy, Combination; Female; Haloperidol; Huma | 1987 |
Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
Topics: Adolescent; Adult; Haloperidol; Humans; Male; Middle Aged; Radioligand Assay; Schizophrenia | 1987 |
The neuroleptic malignant syndrome (N.M.S.) in a West Indian of African descent.
Topics: Adult; Africa; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Schizophrenia; Trinidad | 1987 |
Pharmaco-epidemiology in 136 hospitalized schizophrenic patients.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Utilization; Female; Haloperidol; Hospital | 1987 |
Rapid normalization of the dexamethasone suppression test with mianserin.
Topics: Chlorpromazine; Depressive Disorder; Dexamethasone; Haloperidol; Humans; Hydrocortisone; Mianserin; | 1987 |
Animal models for schizophrenia: the hippocampally lesioned animal.
Topics: Animals; Attention; Disease Models, Animal; Dopamine Antagonists; Galvanic Skin Response; Haloperido | 1987 |
[Computerized analysis of spontaneous EEG in schizophrenics].
Topics: Adolescent; Adult; Electroencephalography; Electronic Data Processing; Female; Haloperidol; Humans; | 1987 |
Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.
Topics: Adult; Female; Haloperidol; Hospitalization; Humans; Outcome and Process Assessment, Health Care; Pr | 1987 |
Verapamil in refractory schizophrenia: a case report.
Topics: Adult; Chronic Disease; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Male; Schiz | 1987 |
Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Prolact | 1987 |
Familial schizophrenia and treatment response.
Topics: Adolescent; Adult; Brain; Cerebral Ventricles; Chronic Disease; Haloperidol; Hospitalization; Humans | 1987 |
Abnormal prolactin response to haloperidol challenge in men with schizophrenia.
Topics: Adult; Dopamine; Haloperidol; Humans; Male; Prolactin; Schizophrenia | 1987 |
Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
Topics: China; Ethnicity; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia | 1987 |
In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol.
Topics: Adult; Chlorpromazine; Electrocardiography; Haloperidol; Heart; Heart Rate; Humans; Male; Middle Age | 1987 |
Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients. Short note.
Topics: Autoantibodies; Binding, Competitive; Haloperidol; Humans; Immunoglobulin G; Receptors, Dopamine; Sc | 1987 |
The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.
Topics: Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Haloperidol; Humans; Inj | 1987 |
Differential therapeutic response by history during treatment with neuroleptic threshold haloperidol doses.
Topics: Adult; Haloperidol; Humans; Middle Aged; Schizophrenia | 1987 |
[Value of neuroleptic therapy in the self assessment of schizophrenic patients].
Topics: Clozapine; Depressive Disorder; Dibenzazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Psych | 1987 |
Increase in human urine homovanillic acid concentration after neuroleptic treatment is the same with or without debrisoquin administration.
Topics: Brain; Debrisoquin; Dopamine; Haloperidol; Homovanillic Acid; Humans; Isoquinolines; Male; Schizophr | 1987 |
Lithium and haloperidol.
Topics: Adult; Drug Therapy, Combination; Erythrocytes; Haloperidol; Humans; Lithium; Psychotic Disorders; S | 1986 |
Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Female; Haloperidol; Hu | 1986 |
Drug holidays and serum haloperidol levels in schizophrenic patients.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Haloperidol; Hospitalization; Humans; Ki | 1986 |
Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis.
Topics: Adult; Drug Interactions; Haloperidol; Humans; Isoniazid; Metabolic Clearance Rate; Middle Aged; Rif | 1986 |
Auditory brain stem responses in schizophrenic patients.
Topics: Adult; Brain Stem; Evoked Potentials, Auditory; Female; Haloperidol; Humans; Male; Middle Aged; Reac | 1986 |
[Successful combined neuroleptic and lithium treatment of a chronic schizophrenic patient with recurrent aggressive behavior].
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Haloperidol; Humans; Lithium; Male; Recurrence; S | 1986 |
Computed tomography and pattern reversal visual evoked potentials in chronic schizophrenic patients.
Topics: Adult; Brain; Chronic Disease; Evoked Potentials, Visual; Haloperidol; Humans; Male; Middle Aged; Sc | 1986 |
[Results of treatment with clozapine in schizophrenic adolescents].
Topics: Adolescent; Clozapine; Dibenzazepines; Follow-Up Studies; Haloperidol; Humans; Residential Treatment | 1986 |
Haloperidol pharmacokinetics following gastric bypass surgery.
Topics: Female; Haloperidol; Humans; Middle Aged; Obesity; Schizophrenia; Stomach | 1986 |
Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration.
Topics: Brain; Dopamine; Haloperidol; Homovanillic Acid; Humans; Schizophrenia; Time Factors | 1987 |
Lateral ventricular enlargement and clinical response in schizophrenia.
Topics: Brain; Cerebral Ventricles; Haloperidol; Humans; Hypertrophy; Psychiatric Status Rating Scales; Schi | 1985 |
Increased urine volume in chronic schizophrenic patients.
Topics: Adult; Benztropine; Chronic Disease; Drinking; Female; Haloperidol; Humans; Hyponatremia; Male; Poly | 1985 |
Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Topics: Adult; Apomorphine; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; Psychotic Disorders; | 1985 |
Endocrinological function in schizophrenic patients under haloperidol treatment: plasma PRL, HGH and 5HT levels after L-5HTP loading.
Topics: 5-Hydroxytryptophan; Adult; Growth Hormone; Haloperidol; Humans; Hypothalamic Diseases; Hypothalamo- | 1985 |
In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone.
Topics: Adult; Aged; Biological Transport, Active; Brain; Butyrophenones; Cerebellum; Cerebral Cortex; Corpu | 1985 |
Variable dose studies provide misleading therapeutic windows.
Topics: Haloperidol; Humans; Schizophrenia | 1986 |
Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Female; Haloperidol; Humans; Male; Middle Aged; Orphenadr | 1986 |
Structure and function: brain electrical activity mapping and computed tomography in schizophrenia.
Topics: Adult; Atrophy; Brain; Brain Mapping; Cerebral Ventricles; Delta Rhythm; Electroencephalography; Evo | 1985 |
Elimination half-life and bioavailability of haloperidol in schizophrenic patients.
Topics: Administration, Oral; Adult; Biological Availability; Chronic Disease; Half-Life; Haloperidol; Human | 1985 |
Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.
Topics: Adult; Carbamazepine; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Schizophren | 1985 |
Plasma homovanillic acid concentration and the severity of schizophrenic illness.
Topics: Adult; Haloperidol; Homovanillic Acid; Humans; Male; Phenylacetates; Schizophrenia | 1985 |
Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays.
Topics: Chromatography, Gas; Haloperidol; Humans; Radioligand Assay; Schizophrenia; Thioridazine | 1985 |
Haloperidol plasma levels and clinical response: basic concepts and clinical data.
Topics: Acute Disease; Haloperidol; Humans; Kinetics; Schizophrenia | 1985 |
Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Schizop | 1985 |
Effects of carbamazepine on plasma haloperidol levels.
Topics: Carbamazepine; Drug Interactions; Drug Therapy, Combination; Epilepsy, Temporal Lobe; Haloperidol; H | 1985 |
Absence of age effect on plasma haloperidol neuroleptic levels in psychiatric patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aging; Female; Haloperidol; Humans; Male; Middle Aged | 1985 |
Plasma haloperidol levels: clinical response and fancy mathematics.
Topics: Drug Administration Schedule; Haloperidol; Hospitalization; Humans; Psychiatric Status Rating Scales | 1985 |
The interpretation of plasma haloperidol concentrations.
Topics: Drug Administration Schedule; Haloperidol; Humans; Psychiatric Status Rating Scales; Research Design | 1985 |
Quantification of reduced haloperidol and haloperidol by radioimmunoassay.
Topics: Chromatography, Liquid; Cross Reactions; Haloperidol; Humans; Radioimmunoassay; Schizophrenia | 1985 |
Long-acting therapy of schizophrenia.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzodiazepines; Biofeedback, Psychology; Bromocriptine; Dy | 1985 |
Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Drug Tolerance; Erectile Dysfunction; Female; Haloperidol; Human | 1985 |
Schizophrenia, psychoticism, neuroleptics, and auditory evoked potentials.
Topics: Adult; Arousal; Evoked Potentials, Auditory; Female; Hallucinations; Haloperidol; Humans; Male; Pers | 1985 |
[Schizophrenically disordered time perception and its modification by neuroleptics].
Topics: Adolescent; Adult; Clozapine; Dibenzazepines; Haloperidol; Humans; Middle Aged; Schizophrenia; Schiz | 1985 |
[Determination of blood haloperidol levels by radioimmunoassay--a methodological study].
Topics: Haloperidol; Humans; Radioimmunoassay; Schizophrenia | 1985 |
The assessment of a psychosocial treatment with chronic schizophrenic patients using neuropsychopharmacological indices.
Topics: Chronic Disease; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Psychopharmaco | 1985 |
Blockade by apomorphine of haloperidol-induced dyskinesia in schizophrenic patients.
Topics: Adult; Apomorphine; Haloperidol; Humans; Male; Movement Disorders; Schizophrenia | 1972 |
The inhibition of pineal hydroxyindole-O-methyltransferase by haloperidol and fluphenazine.
Topics: Aminobutyrates; Animals; Cattle; Fluphenazine; Haloperidol; Humans; Indoles; Methyltransferases; Pin | 1972 |
[Results of glucose tolerance tests and changes in inorganic serum phosphate and potassium levels in schizophrenic patients responding to treatment with psychotropic drugs].
Topics: Adolescent; Adult; Amitriptyline; Chlorpromazine; Diazepam; Glucose Tolerance Test; Haloperidol; Hum | 1971 |
[The properdin system in patients with schizophrenia during the process of active therapy].
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Complement System Proteins; Diet Therapy; D | 1973 |
Clinical differences among phenothiazines in schizophrenics. Introduction: specific indications for antipsychotics: elusive end of the rainbow.
Topics: Antipsychotic Agents; Depression; Haloperidol; Humans; Kinetics; Perphenazine; Phenothiazines; Piper | 1974 |
Maintenance treatment of schizophrenia with long-acting fluphenazine.
Topics: Adult; Chlorpromazine; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Movem | 1974 |
The clinical use of psychotherapeutic drugs in the elderly.
Topics: Aged; Aging; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Benzodiazepi | 1974 |
Psychopharmacology in the aged. Use of psychotropic drugs in geriatric patients.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Depression; Dih | 1974 |
GABA blockade, dopamine and schizophrenia: experimental studies in the cat.
Topics: Alkaloids; Aminobutyrates; Amitriptyline; Animals; Atropine; Behavior, Animal; Cats; Dextroamphetami | 1974 |
[Sudden cessation of psychotropic drugs].
Topics: Adolescent; Adult; Amitriptyline; Antidepressive Agents; Bipolar Disorder; Blood Pressure; Chlorprom | 1974 |
Antipsychotic drugs and catecholamine synapses.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Brain; Catecholamines; Chlorprom | 1974 |
Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Brain; Chlorpromazine; | 1974 |
Potentiation of haloperidol by -methyldopa in the treatment of schizophrenic patients.
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Blood Pressure; Body Weight; Drug Synergism; Fe | 1973 |
Dopamine and the pharmacology of schizophrenia: the state of the evidence.
Topics: Amphetamine; Animals; Brain; Cats; Caudate Nucleus; Chlorpromazine; Dogs; Dopamine; Haloperidol; Hap | 1974 |
Long-term effects of haloperidol.
Topics: Adolescent; Adult; Back Pain; Basal Ganglia Diseases; Bipolar Disorder; Depression; Depressive Disor | 1973 |
Digital computer analyzed sleep and resting EEG during haloperidol treatment.
Topics: Adult; Analysis of Variance; Animals; Arousal; Computers; Diagnosis, Computer-Assisted; Electroencep | 1970 |
Serum cortisol in chronic schizophrenia. Changes in the response to intravenously administered insulin and ACTH on withdrawal of drugs.
Topics: Adrenocorticotropic Hormone; Aged; Amitriptyline; Blood Glucose; Chronic Disease; Female; Haloperido | 1971 |
Serum cortisol in chronic schizophrenia. A study of the adrenocortical response to intravenously administered insulin and ACTH.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Age Factors; Aged; Amitriptyline; Blood Glucose; Chlorp | 1971 |
[Affective disorders in the course of treatment with neuroleptics of children and adolescents with schizophrenia].
Topics: Adolescent; Affect; Child; Child, Preschool; Chlorpromazine; Depression; Haloperidol; Humans; Moveme | 1967 |
[Hallucinatory paraphrenic syndrome in the course of schizophrenia].
Topics: Adult; Automatism; Azo Compounds; Delirium; Hallucinations; Haloperidol; Humans; Illusions; Paranoid | 1967 |
[Neuroleptic therapy of schizophrenia from pharmacological viewpoint].
Topics: Animals; Apomorphine; Arousal; Caudate Nucleus; Chlorpromazine; Chlorprothixene; Electroencephalogra | 1969 |
To the incompatibility of haloperidol with lithium salts.
Topics: Adolescent; Bipolar Disorder; Drug Incompatibility; Drug Therapy, Combination; Female; Haloperidol; | 1974 |
[Comparative results of pharmacologic loading with aminazine and heloperidol in the treatment of the simple form of schizophrenia (according to pain sensography findings)].
Topics: Adolescent; Adult; Chlorpromazine; Female; Haloperidol; Humans; Hypesthesia; Male; Pain; Schizophren | 1974 |
Letter: Reversible dyskinesis caused by haloperidol.
Topics: Adolescent; Female; Haloperidol; Humans; Movement Disorders; Schizophrenia | 1974 |
Chlorpromazine therapy, and associated acute disturbances of cardiac rhythm.
Topics: Adult; Blood Glucose; Chlorpromazine; Electrocardiography; Female; Haloperidol; Heart Block; Humans; | 1974 |
Interaction between neuroleptic therapy and sociotherapeutic approach an investigation with penfluorid and haloperidol.
Topics: Haloperidol; Humans; Hydrocarbons, Halogenated; Intelligence; Interpersonal Relations; Occupational | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Bipolar Disorder; Brain; Chlorpromazine; Chromatography, Gas; Deuterium; Dopamin | 1974 |
Pharmacology and psychiatry.
Topics: Animals; Brain Chemistry; Cats; Chlorpromazine; Dogs; Dopamine; Haloperidol; Humans; Mice; Models, C | 1972 |
Haloperidol: fifteen years of clinical experience.
Topics: Antiemetics; Basal Ganglia Diseases; Bipolar Disorder; Female; Haloperidol; Humans; Mental Disorders | 1972 |
Reversal of some therapeutic effects of an antipsychotic agent by an antiparkinsonism drug.
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Drug Antagonism; Female; Haloperid | 1973 |
Voltage laterality in the EEG of psychiatric patients.
Topics: Adult; Brain; Chlorpromazine; Clopenthixol; Dominance, Cerebral; Dose-Response Relationship, Drug; E | 1973 |
Rapid reversal of tardive dyskinesia.
Topics: Adult; Chlorpromazine; Dibenzoxepins; Female; Haloperidol; Humans; Movement Disorders; Neurologic Ma | 1973 |
Ataractic drugs versus ECT in schizophrenia.
Topics: Chlorpromazine; Dose-Response Relationship, Drug; Electroconvulsive Therapy; Follow-Up Studies; Halo | 1973 |
[Pharmacological and neurochemical effects of clozapine (Leponex): new aspects in the drug therapy of schizophrenia].
Topics: Animals; Brain Stem; Caudate Nucleus; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; Dopamine; E | 1973 |
Possible potentiation of haloperidol neurotoxicity in acute hyperthyroidism.
Topics: Haloperidol; Humans; Hyperthyroidism; Male; Middle Aged; Propranolol; Schizophrenia; Spasm; Thyroid | 1973 |
[Course of a schizophrenic process during a traumatic brain injury caused by cerebral fat emboli].
Topics: Adult; Brain Injuries; Embolism, Fat; Female; Haloperidol; Humans; Intracranial Embolism and Thrombo | 1973 |
[Treatment of hallucinatory disorders in schizophrenia with atropine comas].
Topics: Amitriptyline; Atropine; Chlorpromazine; Coma; Drug Therapy, Combination; Epinephrine; Hallucination | 1973 |
Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.
Topics: Animals; Antidepressive Agents; Carbon Radioisotopes; Chlordiazepoxide; Diazepam; Dose-Response Rela | 1974 |
[Drawings of a schizophrenic during a Sakel cure].
Topics: Adult; Chlorpromazine; Convulsive Therapy; Diazepam; Haloperidol; Humans; Male; Methotrimeprazine; P | 1967 |
Schneiderian first-rank symptoms and clinical prognostic features in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Auditory Perception; Delusions; Diagnosis, Differential; Hallucinati | 1972 |
Comparative trial of low dose haloperidol and fluphenazine in office patients.
Topics: Adult; Affect; Aged; Depression; Evaluation Studies as Topic; Female; Fluphenazine; Haloperidol; Hum | 1972 |
Optimum use of antipsychotic drugs.
Topics: Dosage Forms; Haloperidol; Humans; Schizophrenia; Thiothixene; Tranquilizing Agents; Xanthenes | 1972 |
Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment. A multidisciplinary approach.
Topics: Adult; Attention; Benzimidazoles; Chronic Disease; Haloperidol; Humans; Hydrocarbons, Halogenated; K | 1972 |
Psychosocial profiles and efficacy of lithium treatment.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Human | 1971 |
Serum cortisol in chronic schizophrenia. Changes in the diurnal rhythm and psychiatric mental status on withdrawal of drugs.
Topics: Aged; Amitriptyline; Chronic Disease; Circadian Rhythm; Cognition; Female; Haloperidol; Humans; Hydr | 1971 |
[Course of body temperature during injection therapy with neuroleptics. Statistical evaluation of data from a retrospective study].
Topics: Body Temperature; Chlorpromazine; Chlorprothixene; Clopenthixol; Dibenzothiazepines; Electroconvulsi | 1971 |
Haloperidol.
Topics: Depression; Haloperidol; Humans; Schizophrenia; Tourette Syndrome | 1967 |
Man's tripartite brain and psychosomatic medicine.
Topics: Acute Disease; Adolescent; Brain; Emotions; Evaluation Studies as Topic; Haloperidol; Humans; Male; | 1970 |
Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs.
Topics: Binding Sites; Chlorpromazine; Dibenzoxepins; Dopamine; Haloperidol; Humans; Isomerism; Models, Stru | 1971 |
Clinical and pharmacological effects of monoamine precursors or haloperidol in chronic schizophrenia.
Topics: 5-Hydroxytryptophan; Dihydroxyphenylalanine; Haloperidol; Humans; Hydroxyindoleacetic Acid; Phenylac | 1968 |
[Clothiapine in chronic schizophrenia].
Topics: Adult; Aged; Dibenzothiazepines; Haloperidol; Humans; Middle Aged; Schizophrenia | 1969 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |
[On the results of treatment and complications during the use of haloperidol in patients with long-term schizophrenia].
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Catatonia; Chlorpromazine; Cognition Disorders; Hall | 1969 |
[Specific distribution of extrapyramidal symptoms due to neuroleptic treatment of schizophrenics (denoting the increased sensitivity of the subdominant lobe)].
Topics: Electromyography; Extrapyramidal Tracts; Functional Laterality; Haloperidol; Humans; Schizophrenia | 1969 |
[A chronic extrapyramidal syndrome as a complication of neuroleptic therapy].
Topics: Aged; Bipolar Disorder; Chlorpromazine; Chronic Disease; Extrapyramidal Tracts; Female; Haloperidol; | 1969 |
The present status of psychotropic drugs.
Topics: Antidepressive Agents; Chlormethiazole; Diazepam; Dibenzazepines; Fluphenazine; Haloperidol; Humans; | 1970 |
Treatment of psychic masochism in schizophrenic patients.
Topics: Adolescent; Adult; Amitriptyline; Behavior Therapy; Chlordiazepoxide; Diazepam; Female; Haloperidol; | 1970 |
Intramuscular long-acting fluphenazine in the treatment of schizophrenia.
Topics: Administration, Oral; Adult; Aged; Chlorpromazine; Chronic Disease; Fluphenazine; Haloperidol; Human | 1970 |
[A therapeutic pathomorphosis of schizophrenia proceeding with paranoid disorders].
Topics: Adult; Chlorpromazine; Convulsive Therapy; Female; Haloperidol; Humans; Male; Paranoid Disorders; Pr | 1970 |
[Use of haloperidol in residual schizophrenia and in the paranoid states].
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Paranoid Disorders; Schizophrenia | 1970 |
[Appearance of the symptoms of diabetes insipidus during haloperidol treatment].
Topics: Adult; Diabetes Insipidus; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1970 |
[The effect of phenamine on medicinal parkinsonism and retardation of movement upon stimulation of the caudate nucleus (a clinico-experimental study)].
Topics: Amphetamine; Caudate Nucleus; Female; Haloperidol; Humans; Male; Parkinson Disease; Parkinson Diseas | 1970 |
[Joint clinical study of a long term neuroleptic drug fluspirilene].
Topics: Affective Symptoms; Delayed-Action Preparations; Haloperidol; Humans; Injections, Intramuscular; Par | 1970 |
[Features of a reaction to intravenous haloperidol administration].
Topics: Adult; Aggression; Alcoholism; Anxiety; Depression; Hallucinations; Haloperidol; Humans; Injections, | 1971 |
[Clinical experiences with butyrophenone benperidol].
Topics: Benperidol; Bipolar Disorder; Electroencephalography; Epilepsy; Female; Haloperidol; Humans; Male; P | 1967 |
Some observations on the use of lithium carbonate.
Topics: Acute Disease; Bipolar Disorder; Haloperidol; Humans; Imipramine; Lithium; Phenothiazines; Schizophr | 1968 |
[On the problem of the general and elective action of psycholeptics in the therapy of schizophrenia].
Topics: Catatonia; Chlordiazepoxide; Chlorpromazine; Haloperidol; Humans; Paranoid Disorders; Perphenazine; | 1968 |
Evaluation of a new antipsychotic agent--haloperidol (haldol).
Topics: Bipolar Disorder; Haloperidol; Humans; Mental Disorders; Schizophrenia | 1968 |
Clinical experience with haldol (haloperidol) in chronic schizophrenics.
Topics: Adult; Chronic Disease; Female; Haloperidol; Humans; Middle Aged; Schizophrenia | 1968 |
[Clinical use of butyrophenones].
Topics: Butyrophenones; Chlorpromazine; Depression; Haloperidol; Humans; Hypnotics and Sedatives; Schizophre | 1968 |
[On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
Topics: Adult; Aged; Bipolar Disorder; Catatonia; Child; Depression; Depressive Disorder, Major; Extrapyrami | 1968 |
Single daily doses of neuroleptic drugs.
Topics: Chlorpromazine; Chlorprothixene; Chronic Disease; Dosage Forms; Fluphenazine; Haloperidol; Humans; M | 1969 |
Haloperidol--a preliminary clinical study.
Topics: Depressive Disorder, Major; Extrapyramidal Tracts; Haloperidol; Humans; Paranoid Disorders; Schizoph | 1965 |
The effect of haloperidol on the urinary excretion of dopamine, homovanillic and vanilmandelic acids in schizophrenics.
Topics: Adolescent; Adult; Dihydroxyphenylalanine; Dopamine; Haloperidol; Humans; Male; Mandelic Acids; Phen | 1965 |
Clinical experience with methylperidol.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1965 |
[Studies on the pupillary reaction in the course of a psychotropic treatment].
Topics: Adolescent; Adult; Chlorpromazine; Female; Haloperidol; Humans; Male; Middle Aged; Pupil; Schizophre | 1966 |
Haloperidol and thioridazine in treatment of chronic schizophrenics.
Topics: Female; Haloperidol; Humans; Male; Parkinson Disease, Secondary; Schizophrenia; Thioridazine | 1966 |
A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Haloperidol; Humans; Middle Aged; Orphenadrine; Parasympatholytic | 1966 |
[Haloperidol in states of psychomotor excitation and in anxiety states secondary to acute cardiocirculatory insufficiency].
Topics: Aged; Anxiety Disorders; Coronary Disease; Dementia; Female; Haloperidol; Heart Diseases; Humans; Hy | 1966 |